<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC3004943/results/search/disease/results.xml">
   <result pre=": Biophysics: Biophysics Simulations : Computational Biology : Population Modeling:" exact="Infectious" post="Disease Modeling : Microbiology : Virology: Viral Transmission and"/>
   <result pre="Biophysics: Biophysics Simulations : Computational Biology : Population Modeling: Infectious" exact="Disease" post="Modeling : Microbiology : Virology: Viral Transmission and Infection:"/>
   <result pre=": Population Modeling: Infectious Disease Modeling : Microbiology : Virology:" exact="Viral" post="Transmission and Infection: Host-Pathogen Interaction : Population Biology :"/>
   <result pre="Transmission and Infection: Host-Pathogen Interaction : Population Biology : Epidemiology:" exact="Infectious" post="Disease EpidemiologySpatial Epidemiology: Population Modeling : Mathematics: Applied Mathematics"/>
   <result pre="and Infection: Host-Pathogen Interaction : Population Biology : Epidemiology: Infectious" exact="Disease" post="EpidemiologySpatial Epidemiology: Population Modeling : Mathematics: Applied Mathematics :"/>
   <result pre="Population Modeling : Mathematics: Applied Mathematics : Medicine : Epidemiology:" exact="Infectious" post="Disease Epidemiology : Infectious Diseases: Infectious Disease Modeling Viral"/>
   <result pre="Modeling : Mathematics: Applied Mathematics : Medicine : Epidemiology: Infectious" exact="Disease" post="Epidemiology : Infectious Diseases: Infectious Disease Modeling Viral Epidemics"/>
   <result pre="Applied Mathematics : Medicine : Epidemiology: Infectious Disease Epidemiology :" exact="Infectious" post="Diseases: Infectious Disease Modeling Viral Epidemics in a Cell"/>
   <result pre=": Medicine : Epidemiology: Infectious Disease Epidemiology : Infectious Diseases:" exact="Infectious" post="Disease Modeling Viral Epidemics in a Cell Culture: Novel"/>
   <result pre="Medicine : Epidemiology: Infectious Disease Epidemiology : Infectious Diseases: Infectious" exact="Disease" post="Modeling Viral Epidemics in a Cell Culture: Novel High"/>
   <result pre="Epidemiology: Infectious Disease Epidemiology : Infectious Diseases: Infectious Disease Modeling" exact="Viral" post="Epidemics in a Cell Culture: Novel High Resolution Data"/>
   <result pre="Data and Their Interpretation by a Percolation Theory Based Model" exact="Viral" post="Epidemics in a Cell Culture GönciBalázs1NémethValéria1BaloghEmeric123SzabóBálint1DénesÁdám45KörnyeiZsuzsanna4VicsekTamás16*[1], Department of Biological"/>
   <result pre="Because of its relevance to everyday life, the spreading of" exact="viral" post="infections has been of central interest in a variety"/>
   <result pre="of its relevance to everyday life, the spreading of viral" exact="infections" post="has been of central interest in a variety of"/>
   <result pre="units, but virtually no data are available about observations of" exact="infection" post="spreading for a very large number of immobile units."/>
   <result pre="Here we present the first detailed quantitative documentation of percolation-type" exact="viral" post="epidemics in a highly reproducible in vitro system consisting"/>
   <result pre="confluent astroglial monolayer in a Petri dish and induce productive" exact="infection" post="in a limited number of cells with a genetically"/>
   <result pre="in a Petri dish and induce productive infection in a" exact="limited" post="number of cells with a genetically modified herpesvirus strain."/>
   <result pre="systems, which are difficult to study in isolation. page-count: Introduction" exact="Epidemic" post="is a common phenomenon in a wide variety of"/>
   <result pre="the statistics of the dynamics and spatial aspects of spreading" exact="infection" post="could be crucial in its containment [1]–[4]. Appropriate predictions"/>
   <result pre="is known about the details of the spreading of a" exact="disease" post="in a natural environment. In particular, observations of epidemics"/>
   <result pre="(involving tens of thousands of organisms) are extremely scarce and" exact="incomplete" post="[1], [2], [9], [10]. There are obvious reasons for"/>
   <result pre="remained limited. In general, there are two major types of" exact="infection" post="spreading: i) the position of the infected units does"/>
   <result pre="in time, e.g., in cells in a tissue exposed to" exact="viral" post="or bacterial infection [14] or trees in a forest"/>
   <result pre="e.g., in cells in a tissue exposed to viral or" exact="bacterial infection" post="[14] or trees in a forest [15] ii) the"/>
   <result pre="in cells in a tissue exposed to viral or bacterial" exact="infection" post="[14] or trees in a forest [15] ii) the"/>
   <result pre="trees in a forest [15] ii) the organisms carrying the" exact="infection" post="are moving around and thus are acquiring new sets"/>
   <result pre="birds or people, they can make huge distances in a" exact="short" post="time so that the spatial aspect is less relevant"/>
   <result pre="to serious diseases caused by microorganisms such as Burkholderia spp.," exact="Listeria" post="monocytogenes [18], Mycobacterium marinum [19], Shigella spp. [20], and"/>
   <result pre="marinum [19], Shigella spp. [20], and Rickettsia spp [21]. These" exact="bacterial" post="pathogens enter host cells and spread through tissues by"/>
   <result pre="propelling them inside the cytoplasm. The in vitro spreading of" exact="Listeria" post="[14] and Shigella [22] in 2D cell cultures was"/>
   <result pre="more complex plaques. Finally, a standard paradigm used to explain" exact="infection" post="spreading through a percolation-like process involves a forest in"/>
   <result pre="study in detail the outbreak dynamics and the patterns of" exact="infection" post="spreading in a system containing tens of thousand of"/>
   <result pre="making video recordings and high resolution photos (i.e., tracking the" exact="infection" post="by both GFP expression and making preparations with various"/>
   <result pre="in preliminary experiments, as these cells show restricted release of" exact="infectious" post="viral particles whereas the spread of infection among interconnected"/>
   <result pre="preliminary experiments, as these cells show restricted release of infectious" exact="viral" post="particles whereas the spread of infection among interconnected cells"/>
   <result pre="restricted release of infectious viral particles whereas the spread of" exact="infection" post="among interconnected cells is not compromised [24]. Figure 1"/>
   <result pre="well as in Materials and Methods. First, we initiated productive" exact="infection" post="provoking GFP expression in a limited number of cells"/>
   <result pre="First, we initiated productive infection provoking GFP expression in a" exact="limited" post="number of cells (see Materials and Methods). After removing"/>
   <result pre="number of cells (see Materials and Methods). After removing the" exact="infective" post="viral particles from the culture medium (Table S1) we"/>
   <result pre="of cells (see Materials and Methods). After removing the infective" exact="viral" post="particles from the culture medium (Table S1) we obtained"/>
   <result pre="h (A), 30 h (B) and 42 hours (C) after" exact="infection" post="with the BDG-PRV virus. In the bottom row (D)"/>
   <result pre="scaling behaviour at 42 hours and the spreading of the" exact="infection" post="before that are well characterized by the model. A"/>
   <result pre="exponential drop. Model time was scaled to fit to the" exact="infection" post="spreading rate of high titer experiments. Figure 5 Determination"/>
   <result pre="static configurations, we have also investigated the dynamics of the" exact="infection" post="spreading in our tissue cultures (Fig. 7 and supplementary"/>
   <result pre="all of them had been exposed to a uniformly distributed" exact="infection" post="for a short (as compared to the experiments' time"/>
   <result pre="had been exposed to a uniformly distributed infection for a" exact="short" post="(as compared to the experiments' time scale) time interval."/>
   <result pre="representative microscopic field. Formation of cell clusters with more advanced" exact="infection" post="can be seen in image series F) and Video"/>
   <result pre="have determined the rate by which cells acquire a &quot;primary&quot;" exact="infection" post="(directly related to the initial exposure), and also the"/>
   <result pre="number of infected cells grows as a result of &quot;secondary&quot;" exact="infections" post="(infection due to being a neighbour of an already"/>
   <result pre="infections (infection due to being a neighbour of an already" exact="infectious" post="cell; Table S2, Fig. S2). The motion picture recordings"/>
   <result pre="(Fig. 8). Figure 8 Visualization of the spreading of the" exact="infection" post="around a single infected seed. The upper picture (A)"/>
   <result pre="spreading of the infection around a single infected seed. The" exact="upper" post="picture (A) demonstrates the progression of the infection around"/>
   <result pre="seed. The upper picture (A) demonstrates the progression of the" exact="infection" post="around a single infected cell (see Videos S4, S5,"/>
   <result pre="isolated cell (playing the role of a seed for the" exact="infection" post="spreading) to become infected. Fitted is a log-normal function"/>
   <result pre="a probability taken from an algebraic (non-linear) distribution, ii) a" exact="secondary" post="wave of infection was represented by the gradual introduction"/>
   <result pre="from an algebraic (non-linear) distribution, ii) a secondary wave of" exact="infection" post="was represented by the gradual introduction of new infectious"/>
   <result pre="of infection was represented by the gradual introduction of new" exact="infectious" post="sites (see Table S2 and MATERIALS AND METHODS for"/>
   <result pre="model can be seen in supplementary Video S7. Discussion Our" exact="infection" post="spreading experiments have been possible because the viral particles"/>
   <result pre="Discussion Our infection spreading experiments have been possible because the" exact="viral" post="particles are able to spread within the compromised cell"/>
   <result pre="progeny virions to infect their surroundings and to initiate a" exact="focal" post="spread of infection over time. Compromised (but viable) as"/>
   <result pre="infect their surroundings and to initiate a focal spread of" exact="infection" post="over time. Compromised (but viable) as well as dying"/>
   <result pre="as well as dying cells are also capable of releasing" exact="infectious" post="virus particles into the media, which may attach to"/>
   <result pre="from a large distance to the place of the original" exact="infection" post="[26]–[31]. Detailed documentation of the spreading of viral infection"/>
   <result pre="the original infection [26]–[31]. Detailed documentation of the spreading of" exact="viral infection" post="in a layer of many thousands of cells has"/>
   <result pre="original infection [26]–[31]. Detailed documentation of the spreading of viral" exact="infection" post="in a layer of many thousands of cells has"/>
   <result pre="thousands of cells has been carried out in a very" exact="limited" post="number of papers only [32], [33]. These prior investigations"/>
   <result pre="infected cells introduced back to the medium significant amounts of" exact="viral" post="particles. Under these conditions the infected regions of the"/>
   <result pre="of infection. We observed such convection current-induced disturbance of the" exact="infection" post="spread in the case of some cell types used"/>
   <result pre="of the PRV virus versus astrocytes system, however, neither the" exact="infection" post="of all of the neighbours nor the secondary infection"/>
   <result pre="neither the infection of all of the neighbours nor the" exact="secondary" post="infection of the medium played a dominant role and,"/>
   <result pre="the infection of all of the neighbours nor the secondary" exact="infection" post="of the medium played a dominant role and, in"/>
   <result pre="rapid cell lysis - released a very high titer of" exact="infectious" post="viral particles into the culture medium (data not shown),"/>
   <result pre="cell lysis - released a very high titer of infectious" exact="viral" post="particles into the culture medium (data not shown), low"/>
   <result pre="astrocytes did not lead to convection current-induced disturbance of the" exact="infection" post="spread and, in line with simulation data, the growth"/>
   <result pre="the growth of newly formed clusters after 18 hours of" exact="infection" post="did not have a relevant impact on the percolation-type"/>
   <result pre="impact on the percolation-type growth. Another possible advantage of using" exact="primary" post="astrocytes over cell lines may be that due to"/>
   <result pre="due to cell to cell contact inhibition, the proliferation of" exact="primary" post="astrocytes is much slower than that of cell lines."/>
   <result pre="biological and physical parameters are known to affect the cells'" exact="susceptibility to" post="infection and/or lead to inhomogeneous spreading of infection in"/>
   <result pre="physical parameters are known to affect the cells' susceptibility to" exact="infection" post="and/or lead to inhomogeneous spreading of infection in both"/>
   <result pre="cells' susceptibility to infection and/or lead to inhomogeneous spreading of" exact="infection" post="in both in vivo and cell cultures. Variability in"/>
   <result pre="cultures. Variability in cell cycle (both in cell lines and" exact="primary" post="cells), expression levels and availability of different virus receptors,"/>
   <result pre="in a highly variable number of contacts (through which the" exact="infection" post="can take place) between them. The non-linear term (power"/>
   <result pre="of the individual cells as well as their log-normally distributed" exact="susceptibility to" post="become infected after a sudden initial exposure to infection."/>
   <result pre="However, the plaques themselves have a complex geometry since the" exact="infection" post="rate of a cell is highly varying from cell"/>
   <result pre="designed to account for the above experimental details. Both the" exact="visual" post="appearance and the quantitative statistical features of the simulated"/>
   <result pre="very wide variety of experimental situations being dominated by the" exact="infection" post="taking place at spatially scattered points and spreading to"/>
   <result pre="to consider cell populations in which the migration of the" exact="infectious" post="cells cannot be ignored. In principle, even the network"/>
   <result pre="cannot be ignored. In principle, even the network aspects of" exact="infection" post="spreading could be studied in a similar setup with"/>
   <result pre="and anti-mouse-Alexa488 fluorescent dyes were obtained from Invitrogen Co., Hungary." exact="Primary" post="antibody to PRV virion proteins was a kind gift"/>
   <result pre="1. Astroglial cultures Astrocytes were isolated from whole brains of" exact="neonatal" post="(P0-P3) mice, as described earlier [42]. In brief, meninges"/>
   <result pre="onto poly-L-lysine coated plastic surfaces and were grown in Minimal" exact="Essential" post="Medium supplemented with 10% foetal calf serum, 4 mM"/>
   <result pre="two days and every second or third day afterwards. Confluent" exact="primary" post="cultures were harvested by trypsinization and re-plated onto pLL"/>
   <result pre="or into petri dishes, according to the actual experimental design." exact="Secondary" post="astrocytic cultures reaching confluency and displaying mosaic-like pattern were"/>
   <result pre="mosaic-like pattern were infected with PRV viruses, as it follows." exact="Viral" post="infection We aimed to choose a virus strain for"/>
   <result pre="pattern were infected with PRV viruses, as it follows. Viral" exact="infection" post="We aimed to choose a virus strain for the"/>
   <result pre="cassette to the putative antisense promoter (ASP) located at the" exact="inverted" post="repeat region of the virus [43]. Due to this"/>
   <result pre="[43]. Due to this modification, BDG multiplicates with a significantly" exact="lower" post="rate in vitro and infects fewer numbers of cells"/>
   <result pre="Therefore, GFP was expressed at a very early stage of" exact="infection" post="in the compromised cells that made possible to precisely"/>
   <result pre="cells that made possible to precisely follow the spread of" exact="infection" post="over time. The detailed explanation of the mechanisms underlying"/>
   <result pre="and stored at −80°C. Aliquots were thawed immediately prior to" exact="infection" post="of astrocyte cultures. During preliminary experiments, the appropriate virus"/>
   <result pre="medium, for 1 h, at room temperature. The multiplicity of" exact="infection" post="(MOI) was ∼0,17 or 0,017 PFU/cell, respectively. Removal of"/>
   <result pre="infection (MOI) was ∼0,17 or 0,017 PFU/cell, respectively. Removal of" exact="infective" post="viral particles from the culture medium In order to"/>
   <result pre="(MOI) was ∼0,17 or 0,017 PFU/cell, respectively. Removal of infective" exact="viral" post="particles from the culture medium In order to remove"/>
   <result pre="viral particles from the culture medium In order to remove" exact="infective" post="virus particles from the culture medium we washed all"/>
   <result pre="the cultures at least three times after the 1 h" exact="viral" post="exposure. To check whether three changes of medium was"/>
   <result pre="indicated that 3 washes were sufficient to remove the &quot;original&quot;" exact="viral" post="particles from the infected cultures (see supplementary Table S1)."/>
   <result pre="from the infected cultures (see supplementary Table S1). Release of" exact="infective" post="viral particles to the culture medium by astrocytes To"/>
   <result pre="the infected cultures (see supplementary Table S1). Release of infective" exact="viral" post="particles to the culture medium by astrocytes To determine,"/>
   <result pre="medium by astrocytes To determine, whether the virus-treated cells released" exact="infective" post="virus particles into the medium during culture maintenance we"/>
   <result pre="particles into the medium during culture maintenance we analyzed the" exact="infective" post="capacity of the culture media removed after 1, 5,"/>
   <result pre="coverslip (duplicates). The data indicate that ∼24 hrs after the" exact="infection" post="astrocytes began to release infective viral particles to the"/>
   <result pre="that ∼24 hrs after the infection astrocytes began to release" exact="infective" post="viral particles to the culture medium (Table S2). Determination"/>
   <result pre="∼24 hrs after the infection astrocytes began to release infective" exact="viral" post="particles to the culture medium (Table S2). Determination of"/>
   <result pre="were performed as described earlier [42]. In the present work," exact="primary" post="antibodies to structural virus proteins (PRV, rabbit, kind gift"/>
   <result pre="(mouse) were used in 1∶1000 and 1∶2000 dilutions, respectively. As" exact="secondary" post="antibodies anti-rabbit-Alexa594 and anti-mouse-Alexa488 fluorescent dyes were used in"/>
   <result pre="13000*10000 pixels (8,5*6,5 mm) containing approx. 100–150 000 astrocytes. Virus" exact="infection" post="of single cells monitored by GFP expression develops in"/>
   <result pre="whether a cell is already infected. On the basis of" exact="visual" post="image analysis we tuned the threshold to find all"/>
   <result pre="all infected cells even in a very early state of" exact="infection" post="appearing brighter than the background noise. As a result"/>
   <result pre="and white image. (See Fig. 3) Real time monitoring of" exact="infection" post="spreading Dynamics of virus propagation was monitored in astroglial"/>
   <result pre="Time-lapse recordings were performed on a computer-controlled Leica DM IRB" exact="inverted" post="microscope equipped with 10x and 20x objectives and an"/>
   <result pre="the CellMovie control software (http://cellmovie.eu). Phase-contrast and fluorescent images were" exact="acquired" post="every 10–20 min for 2–5 days. We scanned 3×3"/>
   <result pre="increasing or decreasing the threshold in the range of early" exact="infection" post="results only in a time shift of virus spreading."/>
   <result pre="were tagged manually one by one on the basis of" exact="visual" post="detection resulting in the xy position of infected cells"/>
   <result pre="and S6. Simulations, modeling The model we designed to simulate" exact="infection" post="spreading is based on the combination of the well"/>
   <result pre="models [1–2.] or, in other words, it is a simple" exact="infection" post="spreading model in an inhomogeneous environment with a simple"/>
   <result pre="individual cells. Our goal was to reproduce the dynamics of" exact="infection" post="spreading and the structure and shape of the resulting"/>
   <result pre="are two stages when infected cells appear because of the" exact="infection" post="from the surrounding medium. At the beginning of the"/>
   <result pre="of the experiment the whole system is exposed to the" exact="infection" post="uniformly, thus, infected cells appear randomly in time and"/>
   <result pre="cells became infected due to the initial exposure to the" exact="infection" post="was approximated from Fig. 8B: the frequency with which"/>
   <result pre="with a lognormal distribution. This is the dominant mechanism for" exact="infection" post="from the medium. At later stages cells (primarily during"/>
   <result pre="but relatively low titer, leading to a second stage of" exact="infection" post="beginning at around 18 hours (See also the increase"/>
   <result pre="in a hexagonal lattice Double of the size of the" exact="partial" post="system captured by the images Number of particles appearing"/>
   <result pre="images Number of particles appearing during the first stage of" exact="infection" post="500 Approximated from Fig. 8 Number of particles appearing"/>
   <result pre="no overlap for the standard model. Fig. S5 shows the" exact="visual" post="result gained using the standard percolation model. Visual observation"/>
   <result pre="one depends on several factors and is modelled with allowing" exact="infection" post="between two trees with a given probability p. In"/>
   <result pre="p is smaller than a given, lattice dependent pc, the" exact="infection" post="cannot spread, above this critical probability a finite proportion"/>
   <result pre="GFP expressing infected cells, 48 hours after the onset of" exact="infection" post="with &quot;high&quot; virus titer. High resolution file can be"/>
   <result pre="and clusters developed in the model (D,E,F). Time elapsed after" exact="infection" post="was 18 h (A,D), 30 h (B,E) and 42"/>
   <result pre="of a simplified model. The clusters generated with seeds of" exact="infection" post="appearing at a rate corresponding to the experiment, but"/>
   <result pre="appearing at a rate corresponding to the experiment, but the" exact="infection" post="spreading according to the p=0.7 simple percolation rule leads"/>
   <result pre="Click here for additional data file. Table S1 Removal of" exact="infective" post="viral particles from the culture medium. Percentage of infected"/>
   <result pre="here for additional data file. Table S1 Removal of infective" exact="viral" post="particles from the culture medium. Percentage of infected (GFP"/>
   <result pre="Click here for additional data file. Table S2 Release of" exact="infective" post="viral particles to the culture medium by astrocytes. Percentage"/>
   <result pre="here for additional data file. Table S2 Release of infective" exact="viral" post="particles to the culture medium by astrocytes. Percentage of"/>
   <result pre="2DaleyDJGaniJ1999Epidemic Modelling: an Introduction.CambridgeCambridge University Press 3RileyS2007Large-Scale Spatial-Transmission Models of" exact="Infectious" post="Disease.Science3161298130117540894 4Alain BarratABarthelemyMVespignaniA2008Dynamical processes on complex networks.New YorkCambridge University"/>
   <result pre="emerging influenza pandemic in Southeast Asia.Nature43720921416079797 9LaiPCSoFMChanK-W2009Spatial Epidemiological Approaches in" exact="Disease" post="Mapping and Analysis.Boca RatonCRC Press, Taylor &amp;amp; Francis Group"/>
   <result pre="viruses. Nat. Biotechnol.14491493 14MarquisH2006Tissue Culture Cell Assays Used to Analyze" exact="Listeria" post="monocytogenes.Curr Prot in Microbiol.Unit 9B.4 15RhodesCJAndersonRM1998Forest-fire as a model"/>
   <result pre="Microbiol.Unit 9B.4 15RhodesCJAndersonRM1998Forest-fire as a model for the dynamics of" exact="disease" post="epidemics.J Franklin Inst335199211 16HuHMyersSColizzaVVespignaniA2009WiFi networks and malware epidemiology.Proc Natl"/>
   <result pre="filaments and the growth, movement, and spread of the intracellular" exact="bacterial" post="parasite, Listeria monocytogenes.J Cell Biol109159716082507553 19StammLMMorisakiJHGaoLYJengRLMcDonaldKLet al.2003Mycobacterium marinum escapes"/>
   <result pre="the growth, movement, and spread of the intracellular bacterial parasite," exact="Listeria" post="monocytogenes.J Cell Biol109159716082507553 19StammLMMorisakiJHGaoLYJengRLMcDonaldKLet al.2003Mycobacterium marinum escapes from phagosomes"/>
   <result pre="infection.Infect Immun66134213489529051 23StaufferDAharonyA1991Introduction to Percolation Theory.LondonTaylor and Francis 24CardJPRinamanLLynnRBLeeBHMeadeRPet al.1993Pseudorabies" exact="virus infection" post="of the rat central nervous system: ultrastructural characterization of"/>
   <result pre="Immun66134213489529051 23StaufferDAharonyA1991Introduction to Percolation Theory.LondonTaylor and Francis 24CardJPRinamanLLynnRBLeeBHMeadeRPet al.1993Pseudorabies virus" exact="infection" post="of the rat central nervous system: ultrastructural characterization of"/>
   <result pre="infection of the rat central nervous system: ultrastructural characterization of" exact="viral" post="replication, transport, and pathogenesis.J Neurosci132515398388923 25VicsekT1992Fractal Growth Phenomena.SingaporeWorld Scientific"/>
   <result pre="vivo and across junctions of cultured cells.J Virol688348458289387 28DucaKALamVKerenIEndlerEELetchworthGJet al.2001Quantifying" exact="viral" post="propagation in vitro: toward a method for characterization of"/>
   <result pre="Prog171156116511735454 29KatsumotoTHiranoAKurimuraTTakagiA1981In situ electron microscopical observation of cells infected with" exact="herpes" post="simplex virus.J Gen Virol522672786270236 30PriceRWRubensteinRKhanA1982Herpes simplex virus infection of"/>
   <result pre="cells infected with herpes simplex virus.J Gen Virol522672786270236 30PriceRWRubensteinRKhanA1982Herpes simplex" exact="virus infection" post="of isolated autonomic neurons in culture: viral replication and"/>
   <result pre="infected with herpes simplex virus.J Gen Virol522672786270236 30PriceRWRubensteinRKhanA1982Herpes simplex virus" exact="infection" post="of isolated autonomic neurons in culture: viral replication and"/>
   <result pre="30PriceRWRubensteinRKhanA1982Herpes simplex virus infection of isolated autonomic neurons in culture:" exact="viral" post="replication and spread in a neuronal network.Arch Virol711271406279059 31GarnerJA2003Herpes"/>
   <result pre="autonomic neurons in culture: viral replication and spread in a" exact="neuronal" post="network.Arch Virol711271406279059 31GarnerJA2003Herpes simplex virion entry into and intracellular"/>
   <result pre="within mammalian cells.Adv Drug Deliv Rev1414971513 32LamVDucaKAYinJ2005Arrested spread of vesicular" exact="stomatitis" post="virus infections in vitro depends on interferon-mediated antiviral activity.Biotechnol"/>
   <result pre="cells.Adv Drug Deliv Rev1414971513 32LamVDucaKAYinJ2005Arrested spread of vesicular stomatitis virus" exact="infections" post="in vitro depends on interferon-mediated antiviral activity.Biotechnol Bioeng90779380415834946 33DucaKALamVKerenIEndlerEELetchworthGJet"/>
   <result pre="in vitro depends on interferon-mediated antiviral activity.Biotechnol Bioeng90779380415834946 33DucaKALamVKerenIEndlerEELetchworthGJet al.2001Quantifying" exact="viral" post="propagation in vitro: toward a method for characterization of"/>
   <result pre="rabbitpox virus.J Gen Virol1319174108676 35LawMHollinsheadRSmithGL2002Antibody-sensitive and antibody-resistant cell-to-cell spread by" exact="vaccinia" post="virus: role of the A33R protein in antibody-resistant spread.J"/>
   <result pre="by multiplex analysis.J Proteome Res94179580420121167 38van der MeulenKMNauwynckHJPensaertMB2002Increased susceptibility of" exact="peripheral" post="blood mononuclear cells to equine herpes virus type 1"/>
   <result pre="der MeulenKMNauwynckHJPensaertMB2002Increased susceptibility of peripheral blood mononuclear cells to equine" exact="herpes" post="virus type 1 infection upon mitogen stimulation: a role"/>
   <result pre="susceptibility of peripheral blood mononuclear cells to equine herpes virus" exact="type 1" post="infection upon mitogen stimulation: a role of the cell"/>
   <result pre="peripheral blood mononuclear cells to equine herpes virus type 1" exact="infection" post="upon mitogen stimulation: a role of the cell cycle"/>
   <result pre="cell receptors are necessary, but not sufficient, to confer cell" exact="susceptibility to" post="African swine fever virus.Arch Virol144713092110481739 40LiDDuanLFreimuthPO'MalleyBWJr1999Variability of adenovirus receptor"/>
   <result pre="are necessary, but not sufficient, to confer cell susceptibility to" exact="African" post="swine fever virus.Arch Virol144713092110481739 40LiDDuanLFreimuthPO'MalleyBWJr1999Variability of adenovirus receptor density"/>
   <result pre="density influences gene transfer efficiency and therapeutic response in head" exact="and neck" post="cancer.Clin Cancer Res51241758110632357 41KhélifaRMenezesJ1982Epstein-Barr virus-lymphoid cell interactions. III. Effect"/>
   <result pre="transfer efficiency and therapeutic response in head and neck cancer.Clin" exact="Cancer" post="Res51241758110632357 41KhélifaRMenezesJ1982Epstein-Barr virus-lymphoid cell interactions. III. Effect of concanavalin"/>
   <result pre="viruses optimized for labelling and neurochemical characterization of neural circuitry.Mol" exact="Brain" post="Res10910511812531520 44BoldogkőiZSíkADénesÁReichartAToldiJet al.2004Novel tracing paradigms-genetically engineered herpesviruses as tools"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC3561042/results/search/disease/results.xml">
   <result pre="Genetics: Effective Population Size : Population Biology : Population Dynamics:" exact="Disease" post="Dynamics : Medicine : Epidemiology: Epidemiological MethodsInfectious Disease Epidemiology"/>
   <result pre="Population Dynamics: Disease Dynamics : Medicine : Epidemiology: Epidemiological MethodsInfectious" exact="Disease" post="Epidemiology : Infectious diseases : Viral diseases : Hepatitis:"/>
   <result pre="Dynamics : Medicine : Epidemiology: Epidemiological MethodsInfectious Disease Epidemiology :" exact="Infectious" post="diseases : Viral diseases : Hepatitis: Hepatitis C Integrating"/>
   <result pre=": Epidemiology: Epidemiological MethodsInfectious Disease Epidemiology : Infectious diseases :" exact="Viral" post="diseases : Hepatitis: Hepatitis C Integrating Phylodynamics and Epidemiology"/>
   <result pre="Disease Epidemiology : Infectious diseases : Viral diseases : Hepatitis:" exact="Hepatitis" post="C Integrating Phylodynamics and Epidemiology to Estimate Transmission Diversity"/>
   <result pre="C Integrating Phylodynamics and Epidemiology to Estimate Transmission Diversity in" exact="Viral" post="Epidemics Variation of Transmissibility in Viral Pathogens MagiorkinisGkikas12*SypsaVana1MagiorkinisEmmanouil1ParaskevisDimitrios1KatsoulidouAntigoni1BelshawRobert2FraserChristophe3PybusOliver George2HatzakisAngelos1*[1],"/>
   <result pre="Estimate Transmission Diversity in Viral Epidemics Variation of Transmissibility in" exact="Viral" post="Pathogens MagiorkinisGkikas12*SypsaVana1MagiorkinisEmmanouil1ParaskevisDimitrios1KatsoulidouAntigoni1BelshawRobert2FraserChristophe3PybusOliver George2HatzakisAngelos1*[1], Department of Hygiene, Epidemiology and Medical"/>
   <result pre="author and source are properly credited. Abstract The epidemiology of" exact="chronic" post="viral infections, such as those caused by Hepatitis C"/>
   <result pre="and source are properly credited. Abstract The epidemiology of chronic" exact="viral" post="infections, such as those caused by Hepatitis C Virus"/>
   <result pre="epidemiology of chronic viral infections, such as those caused by" exact="Hepatitis" post="C Virus (HCV) and Human Immunodeficiency Virus (HIV), is"/>
   <result pre="as those caused by Hepatitis C Virus (HCV) and Human" exact="Immunodeficiency" post="Virus (HIV), is affected by the risk group structure"/>
   <result pre="Risk groups are defined by each of their members having" exact="acquired" post="infection through a specific behavior. However, risk group definitions"/>
   <result pre="groups are defined by each of their members having acquired" exact="infection" post="through a specific behavior. However, risk group definitions say"/>
   <result pre="potential of each infected individual. Variation in the number of" exact="secondary" post="infections is extremely difficult to estimate for HCV and"/>
   <result pre="of each infected individual. Variation in the number of secondary" exact="infections" post="is extremely difficult to estimate for HCV and HIV"/>
   <result pre="genetic approaches to estimate the variation in transmissibility of rapidly-evolving" exact="viral" post="epidemics. We evaluate this method using a nationwide HCV"/>
   <result pre="a nationwide HCV epidemic and for the first time co-estimate" exact="viral" post="generation times and superspreading events from a combination of"/>
   <result pre="basis of powerful tools for describing the transmission dynamics of" exact="chronic" post="viral diseases, and for evaluating control strategies directed against"/>
   <result pre="of powerful tools for describing the transmission dynamics of chronic" exact="viral" post="diseases, and for evaluating control strategies directed against them."/>
   <result pre="place. The disciplines of epidemiology and population genetics independently provide" exact="partial" post="answers to these questions by analysing surveillance data and"/>
   <result pre="design of effective public health interventions targeting the spread of" exact="viral" post="pathogens. Funding GM is supported by the Wellcome Trust"/>
   <result pre="the manuscript. page-count: Introduction Mathematical epidemiology describes the spread of" exact="infectious diseases" post="and aims to aid in the design of effective"/>
   <result pre="aid in the design of effective public health interventions [1]–[3]." exact="Central" post="to this endeavour is the basic reproductive number (R0)"/>
   <result pre="this endeavour is the basic reproductive number (R0) of an" exact="infectious disease," post="the mean number of secondary infections per primary infection"/>
   <result pre="number (R0) of an infectious disease, the mean number of" exact="secondary" post="infections per primary infection in a completely susceptible population"/>
   <result pre="(R0) of an infectious disease, the mean number of secondary" exact="infections" post="per primary infection in a completely susceptible population [4]"/>
   <result pre="an infectious disease, the mean number of secondary infections per" exact="primary" post="infection in a completely susceptible population [4] (for notations"/>
   <result pre="infectious disease, the mean number of secondary infections per primary" exact="infection" post="in a completely susceptible population [4] (for notations see"/>
   <result pre="[2], [4], [5]. However, studies on sexually transmitted and vector-borne" exact="infections" post="indicate that infected individuals behave far from identically and"/>
   <result pre="far from identically and that variation in the number of" exact="secondary" post="infections per infected individual can play a major role"/>
   <result pre="from identically and that variation in the number of secondary" exact="infections" post="per infected individual can play a major role in"/>
   <result pre="Units R0 Basic reproductive number or ratio Mean number of" exact="secondary" post="infections Number of infections R0,a Basic reproductive number or"/>
   <result pre="R0 Basic reproductive number or ratio Mean number of secondary" exact="infections" post="Number of infections R0,a Basic reproductive number or ratio"/>
   <result pre="number or ratio Mean number of secondary infections Number of" exact="infections" post="R0,a Basic reproductive number or ratio of the transmitter"/>
   <result pre="or ratio of the transmitter group assuming a transmitter, non-transmitter" exact="secondary" post="infections model Mean number of secondary infections Number of"/>
   <result pre="ratio of the transmitter group assuming a transmitter, non-transmitter secondary" exact="infections" post="model Mean number of secondary infections Number of infections"/>
   <result pre="assuming a transmitter, non-transmitter secondary infections model Mean number of" exact="secondary" post="infections Number of infections Z Number of secondary infections"/>
   <result pre="a transmitter, non-transmitter secondary infections model Mean number of secondary" exact="infections" post="Number of infections Z Number of secondary infections per"/>
   <result pre="secondary infections model Mean number of secondary infections Number of" exact="infections" post="Z Number of secondary infections per infected individual Random"/>
   <result pre="number of secondary infections Number of infections Z Number of" exact="secondary" post="infections per infected individual Random variable Number of infections"/>
   <result pre="of secondary infections Number of infections Z Number of secondary" exact="infections" post="per infected individual Random variable Number of infections Za"/>
   <result pre="of secondary infections per infected individual Random variable Number of" exact="infections" post="Za Number of secondary infections of the transmitter group"/>
   <result pre="infected individual Random variable Number of infections Za Number of" exact="secondary" post="infections of the transmitter group assuming a transmitter, non-transmitter"/>
   <result pre="individual Random variable Number of infections Za Number of secondary" exact="infections" post="of the transmitter group assuming a transmitter, non-transmitter secondary"/>
   <result pre="secondary infections of the transmitter group assuming a transmitter, non-transmitter" exact="secondary" post="infections model Random variable Number of infections N Number"/>
   <result pre="infections of the transmitter group assuming a transmitter, non-transmitter secondary" exact="infections" post="model Random variable Number of infections N Number of"/>
   <result pre="a transmitter, non-transmitter secondary infections model Random variable Number of" exact="infections" post="N Number of prevalent cases - Number of infected"/>
   <result pre="cases - Number of infected people Ne Effective number of" exact="infections" post="- Number of infected people PTP Phylodynamic transmission parameter"/>
   <result pre="of infected people PTP Phylodynamic transmission parameter - Number of" exact="infections" post="per year T Generation time Average length of time"/>
   <result pre="per year T Generation time Average length of time between" exact="primary" post="and secondary infections Years γ Recovery rate from the"/>
   <result pre="T Generation time Average length of time between primary and" exact="secondary" post="infections Years γ Recovery rate from the disease -"/>
   <result pre="Generation time Average length of time between primary and secondary" exact="infections" post="Years γ Recovery rate from the disease - Number"/>
   <result pre="primary and secondary infections Years γ Recovery rate from the" exact="disease" post="- Number of persons per year μ Death rate"/>
   <result pre="persons per year SSE Superspreading Events Minimum expected number of" exact="secondary" post="infections from a superspreader Number of secondary infections k"/>
   <result pre="per year SSE Superspreading Events Minimum expected number of secondary" exact="infections" post="from a superspreader Number of secondary infections k Dispersion"/>
   <result pre="expected number of secondary infections from a superspreader Number of" exact="secondary" post="infections k Dispersion parameter of the negative binomial distribution"/>
   <result pre="number of secondary infections from a superspreader Number of secondary" exact="infections" post="k Dispersion parameter of the negative binomial distribution -"/>
   <result pre="of infected individuals when we rank them by their attributed" exact="secondary" post="infections - - In previous work, variation in the"/>
   <result pre="infected individuals when we rank them by their attributed secondary" exact="infections" post="- - In previous work, variation in the number"/>
   <result pre="- - In previous work, variation in the number of" exact="secondary" post="infections per infected individual, Z, has been represented by"/>
   <result pre="- In previous work, variation in the number of secondary" exact="infections" post="per infected individual, Z, has been represented by a"/>
   <result pre="that is described by two parameters, (i) mean R0 among" exact="infections" post="and (ii) the dispersion parameter k[8], [9]. A small"/>
   <result pre="top 1% of hosts when ranked by the number of" exact="secondary" post="infections they create [8]. Although superspreading events (SSE) (i.e."/>
   <result pre="1% of hosts when ranked by the number of secondary" exact="infections" post="they create [8]. Although superspreading events (SSE) (i.e. the"/>
   <result pre="[8]. Although superspreading events (SSE) (i.e. the minimum number of" exact="secondary" post="infections generated by a superspreader) have been estimated for"/>
   <result pre="Although superspreading events (SSE) (i.e. the minimum number of secondary" exact="infections" post="generated by a superspreader) have been estimated for directly-transmitted"/>
   <result pre="infections generated by a superspreader) have been estimated for directly-transmitted" exact="acute" post="infections [8], they have never been described for chronic"/>
   <result pre="generated by a superspreader) have been estimated for directly-transmitted acute" exact="infections" post="[8], they have never been described for chronic viral"/>
   <result pre="directly-transmitted acute infections [8], they have never been described for" exact="chronic" post="viral infections. The indolent and subclinical nature of chronic"/>
   <result pre="acute infections [8], they have never been described for chronic" exact="viral" post="infections. The indolent and subclinical nature of chronic infections"/>
   <result pre="for chronic viral infections. The indolent and subclinical nature of" exact="chronic" post="infections makes it difficult to track primary and secondary"/>
   <result pre="chronic viral infections. The indolent and subclinical nature of chronic" exact="infections" post="makes it difficult to track primary and secondary infections"/>
   <result pre="subclinical nature of chronic infections makes it difficult to track" exact="primary" post="and secondary infections of the multiple strains that concurrently"/>
   <result pre="of chronic infections makes it difficult to track primary and" exact="secondary" post="infections of the multiple strains that concurrently transmit in"/>
   <result pre="chronic infections makes it difficult to track primary and secondary" exact="infections" post="of the multiple strains that concurrently transmit in a"/>
   <result pre="population. The problem is further compounded for HIV and the" exact="hepatitis C" post="virus (HCV) that circulate in socially-marginalised groups such as"/>
   <result pre="transmission, another epidemiologically-important parameter is the average time between the" exact="primary" post="and secondary infections, typically termed the infection generation time"/>
   <result pre="epidemiologically-important parameter is the average time between the primary and" exact="secondary" post="infections, typically termed the infection generation time (T; several"/>
   <result pre="time between the primary and secondary infections, typically termed the" exact="infection" post="generation time (T; several other definitions are used in"/>
   <result pre="(T; several other definitions are used in the literature). A" exact="short" post="T indicates rapid transmission, whilst a longer T suggests"/>
   <result pre="and thus it is reasonable to conclude that directly transmitted" exact="acute" post="infections have T&amp;lt;1 month whilst chronic infections have T"/>
   <result pre="thus it is reasonable to conclude that directly transmitted acute" exact="infections" post="have T&amp;lt;1 month whilst chronic infections have T values"/>
   <result pre="conclude that directly transmitted acute infections have T&amp;lt;1 month whilst" exact="chronic" post="infections have T values on the order of months"/>
   <result pre="that directly transmitted acute infections have T&amp;lt;1 month whilst chronic" exact="infections" post="have T values on the order of months or"/>
   <result pre="months or years. Here we show how transmission variability and" exact="infection" post="generation time can be estimated by combining viral genomic"/>
   <result pre="variability and infection generation time can be estimated by combining" exact="viral" post="genomic data with surveillance data and mathematical epidemiology. Results/Discussion"/>
   <result pre="as the studied population at time t. Ne(t) is typically" exact="lower" post="than N(t), the population's actual size at time t."/>
   <result pre="individuals [15], [16]. If the population in question is a" exact="viral" post="epidemic, then N(t) is the number of infections at"/>
   <result pre="is a viral epidemic, then N(t) is the number of" exact="infections" post="at time t (or number of prevalent cases) and"/>
   <result pre="of prevalent cases) and Ne(t) represents the effective number of" exact="infections" post="(i.e. the number of infections of an idealised epidemic"/>
   <result pre="represents the effective number of infections (i.e. the number of" exact="infections" post="of an idealised epidemic that experiences the same level"/>
   <result pre="formally equal to var(Z), the variance in the number of" exact="secondary" post="infections [17], [18]: (1)N(t) can be directly observed or"/>
   <result pre="equal to var(Z), the variance in the number of secondary" exact="infections" post="[17], [18]: (1)N(t) can be directly observed or estimated"/>
   <result pre="the pattern of genetic diversity in a sample of the" exact="viral" post="population. Specifically, methods based on coalescent theory, such as"/>
   <result pre="intensity of transmission within a population, (i) the variance of" exact="secondary" post="infections among infections, and (ii) time between infections. Equation"/>
   <result pre="of transmission within a population, (i) the variance of secondary" exact="infections" post="among infections, and (ii) time between infections. Equation 2"/>
   <result pre="sections we consider practical aspects of inferring these two variables." exact="Infection" post="generation time Volz and Frost [21], [22] incorporated mathematical"/>
   <result pre="can assume that T remains constant. Distributions of numbers of" exact="secondary" post="infections for epidemics with active and inactive transmitters To"/>
   <result pre="assume that T remains constant. Distributions of numbers of secondary" exact="infections" post="for epidemics with active and inactive transmitters To describe"/>
   <result pre="density function of the random variable Z, the number of" exact="secondary" post="infections per infected individual. Previous work has modeled variation"/>
   <result pre="function of the random variable Z, the number of secondary" exact="infections" post="per infected individual. Previous work has modeled variation in"/>
   <result pre="two parameters, mean R0 and a dispersion parameter k[8], [9]." exact="Chronic" post="viral infections, such as those caused by HIV and"/>
   <result pre="parameters, mean R0 and a dispersion parameter k[8], [9]. Chronic" exact="viral" post="infections, such as those caused by HIV and HCV,"/>
   <result pre="these epidemics a significant proportion of transmissions result in inactive" exact="infections" post="that transmit the virus no further and thus a"/>
   <result pre="representation. In our study we define a sub-population of &quot;inactive&quot;" exact="infections" post="whose expected number of secondary infections is equal to"/>
   <result pre="define a sub-population of &quot;inactive&quot; infections whose expected number of" exact="secondary" post="infections is equal to 0. The rest of the"/>
   <result pre="a sub-population of &quot;inactive&quot; infections whose expected number of secondary" exact="infections" post="is equal to 0. The rest of the population"/>
   <result pre="The rest of the population is defined as &quot;active&quot;. Active" exact="infections" post="comprise a proportion u of all infections and their"/>
   <result pre="as &quot;active&quot;. Active infections comprise a proportion u of all" exact="infections" post="and their expected number of secondary infections are assumed"/>
   <result pre="proportion u of all infections and their expected number of" exact="secondary" post="infections are assumed to be Poisson distributed with mean"/>
   <result pre="u of all infections and their expected number of secondary" exact="infections" post="are assumed to be Poisson distributed with mean R0,a."/>
   <result pre="distributed with mean R0,a. The distribution of the number of" exact="secondary" post="infections Z in the whole population (active and inactive"/>
   <result pre="with mean R0,a. The distribution of the number of secondary" exact="infections" post="Z in the whole population (active and inactive combined)"/>
   <result pre="and 4 can be used to estimate the number of" exact="secondary" post="infections of active infections (R0,a) provided that estimates of"/>
   <result pre="4 can be used to estimate the number of secondary" exact="infections" post="of active infections (R0,a) provided that estimates of E(Z),"/>
   <result pre="used to estimate the number of secondary infections of active" exact="infections" post="(R0,a) provided that estimates of E(Z), u and var(Z)"/>
   <result pre="concept: Concurrent nationwide epidemics of HCV Well-described cohorts of HCV" exact="infections" post="(of subtypes 1a, 1b, 3a and 4a) have been"/>
   <result pre="epidemics we have both surveillance information and concurrent samples of" exact="viral" post="genome sequences from the same population. First, we used"/>
   <result pre="to estimate the value Ne(t)T for each subtype from the" exact="viral" post="genome sequences sampled concurrently from the same populations (see"/>
   <result pre="chronically infected with HCV. The majority of patients with HCV" exact="infection" post="develop persistent or chronic infection (60–92%) whilst a minority"/>
   <result pre="HCV. The majority of patients with HCV infection develop persistent" exact="or chronic" post="infection (60–92%) whilst a minority clears HCV-RNA (8–40%); viral"/>
   <result pre="The majority of patients with HCV infection develop persistent or" exact="chronic" post="infection (60–92%) whilst a minority clears HCV-RNA (8–40%); viral"/>
   <result pre="majority of patients with HCV infection develop persistent or chronic" exact="infection" post="(60–92%) whilst a minority clears HCV-RNA (8–40%); viral clearance"/>
   <result pre="or chronic infection (60–92%) whilst a minority clears HCV-RNA (8–40%);" exact="viral" post="clearance is much faster within the first 2 years"/>
   <result pre="clearance is much faster within the first 2 years of" exact="infection" post="and slower thereafter (≪1% per year), while increased rates"/>
   <result pre="and slower thereafter (≪1% per year), while increased rates of" exact="viral" post="clearance are associated with younger age, female gender, lack"/>
   <result pre="increased rates of viral clearance are associated with younger age," exact="female" post="gender, lack of HIV co-infection, chronic HBV infection and"/>
   <result pre="associated with younger age, female gender, lack of HIV co-infection," exact="chronic" post="HBV infection and genetic variation in IL28B [29]–[42]. HCV"/>
   <result pre="younger age, female gender, lack of HIV co-infection, chronic HBV" exact="infection" post="and genetic variation in IL28B [29]–[42]. HCV phylodynamic analysis"/>
   <result pre="respectively (Table S1). The majority of subtype 1a and 3a" exact="infections" post="were associated with injecting drug use, while for subtype"/>
   <result pre="with injecting drug use, while for subtype 1b and 4a" exact="infections" post="the source of infection was usually unknown. These distributions"/>
   <result pre="while for subtype 1b and 4a infections the source of" exact="infection" post="was usually unknown. These distributions are consistent with previous"/>
   <result pre="Since the outbreaks were not monophyletic we can only provide" exact="upper" post="limits of the date of introduction of each subtype"/>
   <result pre="subtype (B) have been scaled between maximum and minimum values." exact="Epidemic" post="and phylodynamic estimates are correlated For each HCV subtype,"/>
   <result pre="maximum lag between the cross-correlated data to correct statistical significance." exact="Linear" post="regressions of N(t) against Ne(t)T for each HCV subtype"/>
   <result pre="IDUs within each subtype. 4Upper 1% of the distribution of" exact="secondary" post="infections including transmitters and non-transmitters. Subtype-specific R0 estimates The"/>
   <result pre="within each subtype. 4Upper 1% of the distribution of secondary" exact="infections" post="including transmitters and non-transmitters. Subtype-specific R0 estimates The subtype-specific"/>
   <result pre="value for that subtype, which suggests an average of &amp;gt;10" exact="secondary" post="infections per primary infection. Model of secondary infections in"/>
   <result pre="for that subtype, which suggests an average of &amp;gt;10 secondary" exact="infections" post="per primary infection. Model of secondary infections in the"/>
   <result pre="subtype, which suggests an average of &amp;gt;10 secondary infections per" exact="primary" post="infection. Model of secondary infections in the Greek HCV"/>
   <result pre="average of &amp;gt;10 secondary infections per primary infection. Model of" exact="secondary" post="infections in the Greek HCV epidemics Historically, HCV epidemics"/>
   <result pre="of &amp;gt;10 secondary infections per primary infection. Model of secondary" exact="infections" post="in the Greek HCV epidemics Historically, HCV epidemics have"/>
   <result pre="we suggest a bimodal distribution model for the number of" exact="secondary" post="infections (see Eq.3–5) that can represent both types of"/>
   <result pre="suggest a bimodal distribution model for the number of secondary" exact="infections" post="(see Eq.3–5) that can represent both types of transmission"/>
   <result pre="this study). Regression of PTP against the percentage of IDU" exact="infections" post="for each HCV subtype is strongly significant (Figure 2)"/>
   <result pre="for the generation time (T) of HCV since tracking of" exact="secondary" post="infections is very difficult and date of infection is"/>
   <result pre="the generation time (T) of HCV since tracking of secondary" exact="infections" post="is very difficult and date of infection is in"/>
   <result pre="tracking of secondary infections is very difficult and date of" exact="infection" post="is in most cases unknown. Some workers have suggested"/>
   <result pre="years and 1/μ = 70 years) (Table S3). If we assume that" exact="secondary" post="infections follow a Poisson process within the duration of"/>
   <result pre="and 1/μ = 70 years) (Table S3). If we assume that secondary" exact="infections" post="follow a Poisson process within the duration of infectiousness"/>
   <result pre="infectiousness (1/(γ+μ)) (i.e. if we perform a simulation of random" exact="secondary" post="infections within 25 years of infectiousness), then the mean"/>
   <result pre="(1/(γ+μ)) (i.e. if we perform a simulation of random secondary" exact="infections" post="within 25 years of infectiousness), then the mean average"/>
   <result pre="25 years of infectiousness), then the mean average time between" exact="primary" post="and the subtending secondary infections is similarly high (∼12.5"/>
   <result pre="then the mean average time between primary and the subtending" exact="secondary" post="infections is similarly high (∼12.5 years) regardless of the"/>
   <result pre="the mean average time between primary and the subtending secondary" exact="infections" post="is similarly high (∼12.5 years) regardless of the average"/>
   <result pre="similarly high (∼12.5 years) regardless of the average number of" exact="secondary" post="infections. Such values are epidemiologically and empirically unrealistic for"/>
   <result pre="generation times (T) using the two-group (transmitter, non-transmitter) model of" exact="secondary" post="infections (Eq.1). R0 T var(Z) u R0,a 1a 3.4"/>
   <result pre="times (T) using the two-group (transmitter, non-transmitter) model of secondary" exact="infections" post="(Eq.1). R0 T var(Z) u R0,a 1a 3.4 1"/>
   <result pre="3). Using Greek surveillance data on the proportion of HCV" exact="infections" post="of each subtype associated with IDU [24] we estimate"/>
   <result pre="4a are more compatible with the natural history of the" exact="disease" post="than those based on the duration of infectiousness (∼12.5"/>
   <result pre="on the duration of infectiousness (∼12.5 years). The probability of" exact="secondary" post="infection per contact is expected to be higher during"/>
   <result pre="the duration of infectiousness (∼12.5 years). The probability of secondary" exact="infection" post="per contact is expected to be higher during the"/>
   <result pre="to be higher during the first year of infection, when" exact="viral" post="load is 10 times greater than later in infection"/>
   <result pre="when viral load is 10 times greater than later in" exact="infection" post="[55], [56]. Also, in the first year patients are"/>
   <result pre="led them to be infected. Taken together, this suggests that" exact="secondary" post="infections are more likely during the first year of"/>
   <result pre="them to be infected. Taken together, this suggests that secondary" exact="infections" post="are more likely during the first year of infection."/>
   <result pre="74 and the 99th percentile SSE from 18 to 83" exact="secondary" post="infections (Table 2, Figure 4, Figure S4). Compared to"/>
   <result pre="and the 99th percentile SSE from 18 to 83 secondary" exact="infections" post="(Table 2, Figure 4, Figure S4). Compared to directly-transmitted"/>
   <result pre="and 4a investigated here, we estimate that 80% of the" exact="infections" post="are caused by approximately 20%, 5%, 35% and 15%"/>
   <result pre="by approximately 20%, 5%, 35% and 15% of the most" exact="infectious" post="individuals, respectively (Figure 5). Figure 4 Estimated distributions of"/>
   <result pre="(Figure 5). Figure 4 Estimated distributions of the number of" exact="secondary" post="infections per primary infection for each HCV subtype. Figure"/>
   <result pre="5). Figure 4 Estimated distributions of the number of secondary" exact="infections" post="per primary infection for each HCV subtype. Figure 5"/>
   <result pre="4 Estimated distributions of the number of secondary infections per" exact="primary" post="infection for each HCV subtype. Figure 5 Cumulative proportion"/>
   <result pre="Estimated distributions of the number of secondary infections per primary" exact="infection" post="for each HCV subtype. Figure 5 Cumulative proportion of"/>
   <result pre="for each HCV subtype. Figure 5 Cumulative proportion of onward" exact="infection" post="versus the infected population ranked by the number of"/>
   <result pre="infection versus the infected population ranked by the number of" exact="secondary" post="infections they create. 20% of onward infections is indicated"/>
   <result pre="versus the infected population ranked by the number of secondary" exact="infections" post="they create. 20% of onward infections is indicated with"/>
   <result pre="the number of secondary infections they create. 20% of onward" exact="infections" post="is indicated with a grey horizontal line. The proportion"/>
   <result pre="create. 20% of onward infections is indicated with a grey" exact="horizontal" post="line. The proportion of the population that generates 80%"/>
   <result pre="The proportion of the population that generates 80% of onward" exact="infections" post="is shown by a vertical dashed line. HCV subtype"/>
   <result pre="is close to the 80-20 rule (i.e. 80% of the" exact="infections" post="are caused by the most infectious 18%). The subtype"/>
   <result pre="(i.e. 80% of the infections are caused by the most" exact="infectious" post="18%). The subtype 1b epidemic is the oldest and"/>
   <result pre="contaminated blood and blood products. The very large number of" exact="secondary" post="infections for each member of the transmitter population (R0,a = 75),"/>
   <result pre="blood and blood products. The very large number of secondary" exact="infections" post="for each member of the transmitter population (R0,a = 75), the"/>
   <result pre="blood transfusions in the 1960s and 1970s. Historically, subtype 1b" exact="infections" post="in Greece are attributed to the use of imported"/>
   <result pre="almost proportionally higher mean and variance in the number of" exact="secondary" post="infections. The dynamics of these epidemics are still operating"/>
   <result pre="overestimated – our estimate of PTP can be considered a" exact="lower" post="bound and that variation in onward transmission might be"/>
   <result pre="to incorporate both sources of uncertainty and provide a proper" exact="posterior" post="distribution for PTP. Our approach provides information about superspreading"/>
   <result pre="superspreading from analytical relationships between the rate of coalescence (Ne)," exact="viral" post="generation time (T), and prevalence (N) and thus is"/>
   <result pre="approach is required. For example a zero-inflated Poisson distribution of" exact="secondary" post="infections does not fit most of the HIV-1 epidemics."/>
   <result pre="is required. For example a zero-inflated Poisson distribution of secondary" exact="infections" post="does not fit most of the HIV-1 epidemics. A"/>
   <result pre="data to estimate the variability in ongoing transmission of a" exact="chronic" post="viral epidemic, and to investigate its generation time. Both"/>
   <result pre="to estimate the variability in ongoing transmission of a chronic" exact="viral" post="epidemic, and to investigate its generation time. Both parameters"/>
   <result pre="expect our approach to be most readily adapted to other" exact="chronic" post="viral diseases such as HIV, but could also be"/>
   <result pre="our approach to be most readily adapted to other chronic" exact="viral" post="diseases such as HIV, but could also be applied"/>
   <result pre="applied to directly transmitted (e.g. Influenza) or vector-borne (e.g. Dengue)" exact="viral" post="epidemics, for which superspreading events and generation times are"/>
   <result pre="by the IRB of Athens University Medical School. Estimation of" exact="chronic" post="HCV incidence and prevalence through time The overall and"/>
   <result pre="and prevalence through time The overall and genotype-specific incidence of" exact="chronic" post="HCV infection has been estimated in previous studies using"/>
   <result pre="through time The overall and genotype-specific incidence of chronic HCV" exact="infection" post="has been estimated in previous studies using back-calculation [24],"/>
   <result pre="were adults (18–70 years old) with a histological diagnosis of" exact="chronic hepatitis." post="Injecting drug use, transfusion, other and sporadic transmissions were"/>
   <result pre="of the patients, respectively. The distribution of the dates of" exact="infection" post="within each transmission group was determined using data from"/>
   <result pre="We extended the back-calculation approach to estimate subtype-specific incidence of" exact="chronic" post="HCV [25] in Greece as follows: a) we estimated"/>
   <result pre="incidence according to transmission group using the number of new" exact="infections" post="in the past for each transmission group and the"/>
   <result pre="exponential growth phase, γ is the recovery rate of the" exact="disease" post="and μ is the death rate in the general"/>
   <result pre="Click here for additional data file. Figure S2 Upper and" exact="lower" post="limits of the 95% Higher Posterior Density (HPD) of"/>
   <result pre="for additional data file. Figure S4 Cumulative distribution of the" exact="secondary" post="infections for the Greek HCV epidemics (solid lines) and"/>
   <result pre="additional data file. Figure S4 Cumulative distribution of the secondary" exact="infections" post="for the Greek HCV epidemics (solid lines) and directly"/>
   <result pre="useful comments. References References 1GrasslyNC, FraserC (2008) Mathematical models of" exact="infectious disease" post="transmission. Nat Rev Microbiol6: 477–487.18533288 2Anderson RM, May RM"/>
   <result pre="comments. References References 1GrasslyNC, FraserC (2008) Mathematical models of infectious" exact="disease" post="transmission. Nat Rev Microbiol6: 477–487.18533288 2Anderson RM, May RM"/>
   <result pre="transmission. Nat Rev Microbiol6: 477–487.18533288 2Anderson RM, May RM (1992)" exact="Infectious" post="Diseases of Humans: Dynamics and Control. Oxford: Oxford University"/>
   <result pre="Nat Rev Microbiol6: 477–487.18533288 2Anderson RM, May RM (1992) Infectious" exact="Diseases" post="of Humans: Dynamics and Control. Oxford: Oxford University Press."/>
   <result pre="Oxford: Oxford University Press. 3Keeling MJ, Rohani P (2008) Modeling" exact="Infectious" post="Diseases in Humans and Animals. Princeton, New Jersey: Princeton"/>
   <result pre="Oxford University Press. 3Keeling MJ, Rohani P (2008) Modeling Infectious" exact="Diseases" post="in Humans and Animals. Princeton, New Jersey: Princeton University"/>
   <result pre="Soc Lond A115: 700–721. 5AndersonRM, MayRM (1979) Population biology of" exact="infectious" post="diseases: Part I. Nature280: 361–367.460412 6MayRM, AndersonRM (1987) Transmission"/>
   <result pre="Part I. Nature280: 361–367.460412 6MayRM, AndersonRM (1987) Transmission dynamics of" exact="HIV infection." post="Nature326: 137–142.3821890 7WoolhouseME, DyeC, EtardJF, SmithT, CharlwoodJD, et al."/>
   <result pre="SmithT, CharlwoodJD, et al. (1997) Heterogeneities in the transmission of" exact="infectious" post="agents: implications for the design of control programs. Proc"/>
   <result pre="GetzWM (2005) Superspreading and the effect of individual variation on" exact="disease" post="emergence. Nature438: 355–359.16292310 9Lloyd-SmithJO (2007) Maximum likelihood estimation of"/>
   <result pre="binomial dispersion parameter for highly overdispersed data, with applications to" exact="infectious diseases." post="PloS one2: e180.17299582 10GarskeT, RhodesCJ (2008) The effect of"/>
   <result pre="how contact networks shape parasite evolutionary trees. Interdisciplinary perspectives on" exact="infectious" post="diseases2011: 238743.21151699 15KimuraM, CrowJF (1963) The measurement of effective"/>
   <result pre="App Prob19A: 27–43. 19DeufficS, BuffatL, PoynardT, ValleronAJ (1999) Modeling the" exact="hepatitis C" post="virus epidemic in France. Hepatology29: 1596–1601.10216148 20StrimmerK, PybusOG (2001)"/>
   <result pre="generalized skyline plot. Mol Biol Evol18: 2298–2305.11719579 21FrostSD, VolzEM (2010)" exact="Viral" post="phylodynamics and the search for an ‘effective number of"/>
   <result pre="22VolzEM, Kosakovsky PondSL, WardMJ, Leigh BrownAJ, FrostSD (2009) Phylodynamics of" exact="infectious disease" post="epidemics. Genetics183: 1421–1430.19797047 23KoelleK, RasmussenDA (2012) Rates of coalescence"/>
   <result pre="Kosakovsky PondSL, WardMJ, Leigh BrownAJ, FrostSD (2009) Phylodynamics of infectious" exact="disease" post="epidemics. Genetics183: 1421–1430.19797047 23KoelleK, RasmussenDA (2012) Rates of coalescence"/>
   <result pre="SypsaV, TassopoulosNC, BoletisJ, KarafoulidouA, et al. (2006) Molecular epidemiology of" exact="hepatitis C" post="virus (HCV) in Greece: temporal trends in HCV genotype-specific"/>
   <result pre="genotype-specific incidence and molecular characterization of genotype 4 isolates. J" exact="Viral" post="Hepat13: 19–27.16364078 25SypsaV, TouloumiG, TassopoulosNC, KetikoglouI, VafiadisI, et al."/>
   <result pre="TassopoulosNC, KetikoglouI, VafiadisI, et al. (2004) Reconstructing and predicting the" exact="hepatitis C" post="virus epidemic in Greece: increasing trends of cirrhosis and"/>
   <result pre="the hepatitis C virus epidemic in Greece: increasing trends of" exact="cirrhosis" post="and hepatocellular carcinoma despite the decline in incidence of"/>
   <result pre="C virus epidemic in Greece: increasing trends of cirrhosis and" exact="hepatocellular carcinoma" post="despite the decline in incidence of HCV infection. J"/>
   <result pre="virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular" exact="carcinoma" post="despite the decline in incidence of HCV infection. J"/>
   <result pre="carcinoma despite the decline in incidence of HCV infection. J" exact="Viral" post="Hepat11: 366–374.15230860 26MagiorkinisG, MagiorkinisE, ParaskevisD, HoSY, ShapiroB, et al."/>
   <result pre="ParaskevisD, HoSY, ShapiroB, et al. (2009) The global spread of" exact="hepatitis C" post="virus 1a and 1b: a phylodynamic and phylogeographic analysis."/>
   <result pre="PreissL, KonkleBA, et al. (2006) Correlates of spontaneous clearance of" exact="hepatitis C" post="virus among people with hemophilia. Blood107: 892–897.16204310 30VogtM, LangT,"/>
   <result pre="KlinglerC, SendlAF, et al. (1999) Prevalence and clinical outcome of" exact="hepatitis C" post="infection in children who underwent cardiac surgery before the"/>
   <result pre="et al. (1999) Prevalence and clinical outcome of hepatitis C" exact="infection" post="in children who underwent cardiac surgery before the implementation"/>
   <result pre="A polymorphism near IL28B is associated with spontaneous clearance of" exact="acute" post="hepatitis C virus and jaundice. Gastroenterology139: 1586–1592.20637200 32ThomasDL, ThioCL,"/>
   <result pre="polymorphism near IL28B is associated with spontaneous clearance of acute" exact="hepatitis C" post="virus and jaundice. Gastroenterology139: 1586–1592.20637200 32ThomasDL, ThioCL, MartinMP, QiY,"/>
   <result pre="al. (2009) Genetic variation in IL28B and spontaneous clearance of" exact="hepatitis C" post="virus. Nature461: 798–801.19759533 33ThomasDL, AstemborskiJ, RaiRM, AnaniaFA, SchaefferM, et"/>
   <result pre="RaiRM, AnaniaFA, SchaefferM, et al. (2000) The natural history of" exact="hepatitis C" post="virus infection: host, viral, and environmental factors. JAMA284: 450–456.10904508"/>
   <result pre="MillerRN, RabkinCS, Buskell-BalesZ, Straley-EasonKD, et al. (2000) 45-year follow-up of" exact="hepatitis C" post="virus infection in healthy young adults. Ann Intern Med132:"/>
   <result pre="Buskell-BalesZ, Straley-EasonKD, et al. (2000) 45-year follow-up of hepatitis C" exact="virus infection" post="in healthy young adults. Ann Intern Med132: 105–111.10644270 35SantantonioT,"/>
   <result pre="Straley-EasonKD, et al. (2000) 45-year follow-up of hepatitis C virus" exact="infection" post="in healthy young adults. Ann Intern Med132: 105–111.10644270 35SantantonioT,"/>
   <result pre="factors and outcome among a large patient cohort with community-acquired" exact="acute" post="hepatitis C in Italy. Clin Infect Dis43: 1154–1159.17029134 36Kenny-WalshE"/>
   <result pre="and outcome among a large patient cohort with community-acquired acute" exact="hepatitis C" post="in Italy. Clin Infect Dis43: 1154–1159.17029134 36Kenny-WalshE (1999) Clinical"/>
   <result pre="Italy. Clin Infect Dis43: 1154–1159.17029134 36Kenny-WalshE (1999) Clinical outcomes after" exact="hepatitis C" post="infection from contaminated anti-D immune globulin. Irish Hepatology Research"/>
   <result pre="Infect Dis43: 1154–1159.17029134 36Kenny-WalshE (1999) Clinical outcomes after hepatitis C" exact="infection" post="from contaminated anti-D immune globulin. Irish Hepatology Research Group."/>
   <result pre="WongD, MillerRH, ShihJW, et al. (1991) A long-term study of" exact="hepatitis C" post="virus replication in non-A, non-B hepatitis. N Engl J"/>
   <result pre="MelpolderJ, ShakilAO, et al. (1996) Routes of infection, viremia, and" exact="liver disease" post="in blood donors found to have hepatitis C virus"/>
   <result pre="ShakilAO, et al. (1996) Routes of infection, viremia, and liver" exact="disease" post="in blood donors found to have hepatitis C virus"/>
   <result pre="viremia, and liver disease in blood donors found to have" exact="hepatitis C" post="virus infection. N Engl J Med334: 1691–1696.8637513 39BortolottiF, VerucchiG,"/>
   <result pre="liver disease in blood donors found to have hepatitis C" exact="virus infection." post="N Engl J Med334: 1691–1696.8637513 39BortolottiF, VerucchiG, CammaC, CabibboG,"/>
   <result pre="VerucchiG, CammaC, CabibboG, ZancanL, et al. (2008) Long-term course of" exact="chronic hepatitis C" post="in children: from viral clearance to end-stage liver disease."/>
   <result pre="CammaC, CabibboG, ZancanL, et al. (2008) Long-term course of chronic" exact="hepatitis C" post="in children: from viral clearance to end-stage liver disease."/>
   <result pre="(2008) Long-term course of chronic hepatitis C in children: from" exact="viral" post="clearance to end-stage liver disease. Gastroenterology134: 1900–1907.18439604 40AlterMJ, MargolisHS,"/>
   <result pre="of chronic hepatitis C in children: from viral clearance to" exact="end-stage liver disease." post="Gastroenterology134: 1900–1907.18439604 40AlterMJ, MargolisHS, KrawczynskiK, JudsonFN, MaresA, et al."/>
   <result pre="chronic hepatitis C in children: from viral clearance to end-stage" exact="liver disease." post="Gastroenterology134: 1900–1907.18439604 40AlterMJ, MargolisHS, KrawczynskiK, JudsonFN, MaresA, et al."/>
   <result pre="JudsonFN, MaresA, et al. (1992) The natural history of community-acquired" exact="hepatitis C" post="in the United States. The Sentinel Counties Chronic non-A,"/>
   <result pre="community-acquired hepatitis C in the United States. The Sentinel Counties" exact="Chronic" post="non-A, non-B Hepatitis Study Team. N Engl J Med327:"/>
   <result pre="in the United States. The Sentinel Counties Chronic non-A, non-B" exact="Hepatitis" post="Study Team. N Engl J Med327: 1899–1905.1280771 41AlterMJ, Kruszon-MoranD,"/>
   <result pre="Kruszon-MoranD, NainanOV, McQuillanGM, GaoF, et al. (1999) The prevalence of" exact="hepatitis C" post="virus infection in the United States, 1988 through 1994."/>
   <result pre="McQuillanGM, GaoF, et al. (1999) The prevalence of hepatitis C" exact="virus infection" post="in the United States, 1988 through 1994. N Engl"/>
   <result pre="GaoF, et al. (1999) The prevalence of hepatitis C virus" exact="infection" post="in the United States, 1988 through 1994. N Engl"/>
   <result pre="Med341: 556–562.10451460 42AlterHJ, SeeffLB (2000) Recovery, persistence, and sequelae in" exact="hepatitis C" post="virus infection: a perspective on long-term outcome. Semin Liver"/>
   <result pre="RambautA, HolmesEC, et al. (2001) The epidemic behavior of the" exact="hepatitis C" post="virus. Science292: 2323–2325.11423661 45NelsonPK, MathersBM, CowieB, HaganH, Des JarlaisD,"/>
   <result pre="CowieB, HaganH, Des JarlaisD, et al. (2011) Global epidemiology of" exact="hepatitis" post="B and hepatitis C in people who inject drugs:"/>
   <result pre="JarlaisD, et al. (2011) Global epidemiology of hepatitis B and" exact="hepatitis C" post="in people who inject drugs: results of systematic reviews."/>
   <result pre="HadlerSC, JudsonFN, MaresA, AlexanderWJ, et al. (1990) Risk factors for" exact="acute" post="non-A, non-B hepatitis in the United States and association"/>
   <result pre="AlexanderWJ, et al. (1990) Risk factors for acute non-A, non-B" exact="hepatitis" post="in the United States and association with hepatitis C"/>
   <result pre="non-A, non-B hepatitis in the United States and association with" exact="hepatitis C" post="virus infection. JAMA264: 2231–2235.2170702 48WallingaJ, LipsitchM (2007) How generation"/>
   <result pre="hepatitis in the United States and association with hepatitis C" exact="virus infection." post="JAMA264: 2231–2235.2170702 48WallingaJ, LipsitchM (2007) How generation intervals shape"/>
   <result pre="Sci274: 599–604.17476782 49HaganH, PougetER, Des JarlaisDC, Lelutiu-WeinbergerC (2008) Meta-regression of" exact="hepatitis C" post="virus infection in relation to time since onset of"/>
   <result pre="49HaganH, PougetER, Des JarlaisDC, Lelutiu-WeinbergerC (2008) Meta-regression of hepatitis C" exact="virus infection" post="in relation to time since onset of illicit drug"/>
   <result pre="PougetER, Des JarlaisDC, Lelutiu-WeinbergerC (2008) Meta-regression of hepatitis C virus" exact="infection" post="in relation to time since onset of illicit drug"/>
   <result pre="Epidemiol168: 1099–1109.18849303 50Raptopoulou-GigiM, OrphanouE, LallaTH, LitaA, GarifallosA (2001) Prevalence of" exact="hepatitis C" post="virus infection in a cohort of pregnant women in"/>
   <result pre="50Raptopoulou-GigiM, OrphanouE, LallaTH, LitaA, GarifallosA (2001) Prevalence of hepatitis C" exact="virus infection" post="in a cohort of pregnant women in northern Greece"/>
   <result pre="OrphanouE, LallaTH, LitaA, GarifallosA (2001) Prevalence of hepatitis C virus" exact="infection" post="in a cohort of pregnant women in northern Greece"/>
   <result pre="Prevalence, risk factors and evaluation of a screening strategy for" exact="chronic hepatitis C" post="and B virus infections in healthy company employees. Eur"/>
   <result pre="risk factors and evaluation of a screening strategy for chronic" exact="hepatitis C" post="and B virus infections in healthy company employees. Eur"/>
   <result pre="a screening strategy for chronic hepatitis C and B virus" exact="infections" post="in healthy company employees. Eur J Epidemiol17: 721–728.12086089 52GoritsasC,"/>
   <result pre="721–728.12086089 52GoritsasC, PlerouI, AgaliotisS, SpinthakiR, MimidisK, et al. (2000) HCV" exact="infection" post="in the general population of a Greek island: prevalence"/>
   <result pre="AlbertiA, BernasconiE, ButiM, et al. (2011) A systematic review of" exact="hepatitis C" post="virus epidemiology in Europe, Canada and Israel. Liver Int31"/>
   <result pre="Int31 Suppl 2: 30–60.21651702 54NelsonKE, VlahovD, MargolickJ, BernalM, TaylorE (1990)" exact="Blood" post="and plasma donations among a cohort of intravenous drug"/>
   <result pre="JAMA263: 2194–2197.1969502 55PageK, HahnJA, EvansJ, ShiboskiS, LumP, et al. (2009)" exact="Acute" post="hepatitis C virus infection in young adult injection drug"/>
   <result pre="2194–2197.1969502 55PageK, HahnJA, EvansJ, ShiboskiS, LumP, et al. (2009) Acute" exact="hepatitis C" post="virus infection in young adult injection drug users: a"/>
   <result pre="HahnJA, EvansJ, ShiboskiS, LumP, et al. (2009) Acute hepatitis C" exact="virus infection" post="in young adult injection drug users: a prospective study"/>
   <result pre="EvansJ, ShiboskiS, LumP, et al. (2009) Acute hepatitis C virus" exact="infection" post="in young adult injection drug users: a prospective study"/>
   <result pre="et al. (2009) Acute hepatitis C virus infection in young" exact="adult" post="injection drug users: a prospective study of incident infection,"/>
   <result pre="ShermanSG, StrathdeeS, et al. (2005) Prospective evaluation of community-acquired acute-phase" exact="hepatitis C" post="virus infection. Clin Infect Dis40: 951–958.15824985 57ArmstrongGL, AlterMJ, McQuillanGM,"/>
   <result pre="et al. (2005) Prospective evaluation of community-acquired acute-phase hepatitis C" exact="virus infection." post="Clin Infect Dis40: 951–958.15824985 57ArmstrongGL, AlterMJ, McQuillanGM, MargolisHS (2000)"/>
   <result pre="951–958.15824985 57ArmstrongGL, AlterMJ, McQuillanGM, MargolisHS (2000) The past incidence of" exact="hepatitis C" post="virus infection: implications for the future burden of chronic"/>
   <result pre="hepatitis C virus infection: implications for the future burden of" exact="chronic" post="liver disease in the United States. Hepatology31: 777–782.10706572 58WilliamsIT,"/>
   <result pre="C virus infection: implications for the future burden of chronic" exact="liver disease" post="in the United States. Hepatology31: 777–782.10706572 58WilliamsIT, BellBP, KuhnertW,"/>
   <result pre="virus infection: implications for the future burden of chronic liver" exact="disease" post="in the United States. Hepatology31: 777–782.10706572 58WilliamsIT, BellBP, KuhnertW,"/>
   <result pre="58WilliamsIT, BellBP, KuhnertW, AlterMJ (2011) Incidence and transmission patterns of" exact="acute" post="hepatitis C in the United States, 1982–2006. Arch Intern"/>
   <result pre="BellBP, KuhnertW, AlterMJ (2011) Incidence and transmission patterns of acute" exact="hepatitis C" post="in the United States, 1982–2006. Arch Intern Med171: 242–248.21325115"/>
   <result pre="perspective. Blood112: 2617–2626.18809775 60ChungH, UedaT, KudoM (2010) Changing trends in" exact="hepatitis C" post="infection over the past 50 years in Japan. Intervirology53:"/>
   <result pre="2617–2626.18809775 60ChungH, UedaT, KudoM (2010) Changing trends in hepatitis C" exact="infection" post="over the past 50 years in Japan. Intervirology53: 39–43.20068339"/>
   <result pre="e1002413.22412361 62StackJC, WelchJD, FerrariMJ, ShapiroBU, GrenfellBT (2010) Protocols for sampling" exact="viral" post="sequences to study epidemic dynamics. J R Soc Interface7:"/>
   <result pre="al. (2008) Impact of HIV on Host-Virus Interactions during Early" exact="Hepatitis" post="C Virus Infection. J Infect Dis11: 1558–1566. 64TichopadA, DilgerM,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC6695746/results/search/disease/results.xml">
   <result pre="Drep—A Retrospective Study Evaluating the Influence of Weather Conditions and" exact="Viral" post="Epidemics on Vaso-Occlusive Crises in Patients with Sickle Cell"/>
   <result pre="Conditions and Viral Epidemics on Vaso-Occlusive Crises in Patients with" exact="Sickle Cell Disease" post="Living in French Guiana ParriaultMarie-Claire1*CropetClaire1FahrasmaneAniza1RogierStéphanie1https://orcid.org/0000-0003-1221-6960ParisotMichaël2NacherMathieu13https://orcid.org/0000-0003-0624-4180ElengaNarcisse234[1], [2], [3], [4], *Correspondence:"/>
   <result pre="Viral Epidemics on Vaso-Occlusive Crises in Patients with Sickle Cell" exact="Disease" post="Living in French Guiana ParriaultMarie-Claire1*CropetClaire1FahrasmaneAniza1RogierStéphanie1https://orcid.org/0000-0003-1221-6960ParisotMichaël2NacherMathieu13https://orcid.org/0000-0003-0624-4180ElengaNarcisse234[1], [2], [3], [4], *Correspondence:"/>
   <result pre="Objectives: French Guiana is the French territory most affected by" exact="sickle cell disease" post="(SCD). This study investigates the associations between different environmental"/>
   <result pre="Guiana is the French territory most affected by sickle cell" exact="disease" post="(SCD). This study investigates the associations between different environmental"/>
   <result pre="investigates the associations between different environmental factors relative to climate," exact="infectious" post="outbreaks, and emergency visits or weekly hospital admissions for"/>
   <result pre="the medicalized information system and emergency medical records of Cayenne" exact="General" post="Hospital, between 1 January 2010 and 31 December 2016."/>
   <result pre="should encourage patients to get immunized for influenza every year." exact="sickle cell disease" post="vaso-occlusive crisis (VOC) climate flu outbreak French Guiana 1."/>
   <result pre="patients to get immunized for influenza every year. sickle cell" exact="disease" post="vaso-occlusive crisis (VOC) climate flu outbreak French Guiana 1."/>
   <result pre="(VOC) climate flu outbreak French Guiana 1. Introduction Sickle cell" exact="disease" post="(SCD) is one of the most common genetic disorders"/>
   <result pre="person to person and change over time, include intermittent and" exact="recurrent" post="acute severe pain episodes, as a result of vaso-occlusion."/>
   <result pre="to person and change over time, include intermittent and recurrent" exact="acute" post="severe pain episodes, as a result of vaso-occlusion. These"/>
   <result pre="VOC [5]. Indeed, several studies have already identified climate and" exact="infectious diseases" post="as factors associated with painful crises [3,5,6,7]. French Guiana"/>
   <result pre="[3,5,6,7]. French Guiana is the French territory most affected by" exact="sickle cell disease." post="The population, of African ancestry, consists mainly of three"/>
   <result pre="territory most affected by sickle cell disease. The population, of" exact="African" post="ancestry, consists mainly of three groups: Guianese Creoles, Maroons"/>
   <result pre="main genetic forms that combine different structural hemoglobin variants or" exact="thalassemia" post="syndromes (hemoglobin S HbS, hemoglobin C HbC, β-thalassemia): HbSS"/>
   <result pre="different structural hemoglobin variants or thalassemia syndromes (hemoglobin S HbS," exact="hemoglobin C" post="HbC, β-thalassemia): HbSS (68%), HbSC (25%), and Sβ thalassemia"/>
   <result pre="hemoglobin C HbC, β-thalassemia): HbSS (68%), HbSC (25%), and Sβ" exact="thalassemia" post="(7%) [10]. Identifying a link between environmental factors and"/>
   <result pre="investigates the associations between different environmental factors, such as: climate," exact="infectious" post="outbreaks, and weekly emergency visits and hospital admissions for"/>
   <result pre="VOC. Ethical Approval: This study was presented at the Cayenne" exact="General" post="Hospital Ethical Committee (Number 1-2017-V2) and the database was"/>
   <result pre="with an informative poster in the medical units concerned with" exact="sickle cell disease." post="2. Materials and Methods This study was performed using"/>
   <result pre="system program (MISP) and Emergency Medical Records (EMR) of Cayenne" exact="General" post="Hospital. Hospital admissions and emergency visits for VOC in"/>
   <result pre="models allow time series modelling, which takes into account potential" exact="residual" post="autocorrelations, under the hypothesis that each measure may be"/>
   <result pre="of VOC, and of the series’ autocorrelation function (ACF), and" exact="partial" post="autocorrelation functions (PACF), different ARIMA models were tested. Estimation"/>
   <result pre="with significant parameters at the 10% level and where the" exact="residual" post="series was Gaussian white noise were retained. The Ljung"/>
   <result pre="and the normality plot were used to confirm that the" exact="residual" post="series of the final model were Gaussian white noise."/>
   <result pre="June, is marked by heavy rainfall, high humidity and slightly" exact="lower" post="temperatures. The rainy season is usually interrupted in March"/>
   <result pre="series of influenza outbreaks clearly showed the occurrence of several" exact="infectious" post="episodes during the period of interest. Data showed that"/>
   <result pre="and frequent complications among SCD patients (severe pain crisis, pneumonia," exact="acute" post="chest syndrome, etc.) explains, in part, the increase in"/>
   <result pre="frequent complications among SCD patients (severe pain crisis, pneumonia, acute" exact="chest" post="syndrome, etc.) explains, in part, the increase in hospitalizations"/>
   <result pre="[16]. The question of vaccination also arises here. Protection against" exact="infections" post="is a major goal of any care program for"/>
   <result pre="physicians. A study in the UK showed an immunization against" exact="viral" post="influenza of 12% in adults and 8% in children"/>
   <result pre="the bronchial mucosa, often paves the way for subsequent pneumococcal" exact="infections" post="[18]. Patients with sickle cell disease are normally vaccinated,"/>
   <result pre="paves the way for subsequent pneumococcal infections [18]. Patients with" exact="sickle cell disease" post="are normally vaccinated, but vaccine valences do no cover"/>
   <result pre="way for subsequent pneumococcal infections [18]. Patients with sickle cell" exact="disease" post="are normally vaccinated, but vaccine valences do no cover"/>
   <result pre="from the year 2010 because the data collection was more" exact="complete" post="thereafter. The study period was correct for this type"/>
   <result pre="device or to defective measures was substantial. The integration of" exact="chikungunya" post="and Zika epidemics as explanatory series of VOC would"/>
   <result pre="quite clear, but so far there has been only one" exact="chikungunya" post="epidemic and one Zika epidemic in French Guiana, which"/>
   <result pre="does not allow a time series analysis. The impact of" exact="dengue fever" post="should also be tested, but so far the two"/>
   <result pre="seemed, however, that graphically there were no correlations between the" exact="dengue fever" post="series and the two VOC series. In conclusion, patients"/>
   <result pre="their entourage and to physicians, to improve knowledge about the" exact="sickle cell disease" post="and its management. Acknowledgments We would like to thank"/>
   <result pre="and to physicians, to improve knowledge about the sickle cell" exact="disease" post="and its management. Acknowledgments We would like to thank"/>
   <result pre="like to thank the medical information unit of the Cayenne" exact="General" post="Hospital, especially Ward Schrooten and Milko Sobesky, the regional"/>
   <result pre="S.R., M.P., M.N. and N.E. Funding This research received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
   <result pre="between air quality and the number of hospital admissions for" exact="acute" post="pain and sickle-cell disease in an urban environmentBr. J."/>
   <result pre="and the number of hospital admissions for acute pain and" exact="sickle-cell disease" post="in an urban environmentBr. J. Haematol.200713684484810.1111/j.1365-2141.2007.06493.x17341271 4.PlattO.S.ThoringtonB.D.BrambillaD.J.MilnerP.F.RosseW.F.VichinskyE.KinneyT.R.Pain in sickle"/>
   <result pre="the number of hospital admissions for acute pain and sickle-cell" exact="disease" post="in an urban environmentBr. J. Haematol.200713684484810.1111/j.1365-2141.2007.06493.x17341271 4.PlattO.S.ThoringtonB.D.BrambillaD.J.MilnerP.F.RosseW.F.VichinskyE.KinneyT.R.Pain in sickle"/>
   <result pre="sickle cell diseaseHaematologica201710266667510.3324/haematol.2016.15424527909222 6.DessapA.M.ContouD.Dandine-RoullandC.HemeryF.HabibiA.Charles-NelsonA.KatsahianS.Environmental influences on daily emergency admissions in" exact="sickle-cell disease" post="patientsMedicine201493e28010.1097/MD.000000000000028025546672 7.RogovikA.L.PersaudJ.FriedmanJ.N.KirbyM.A.GoldmanR.D.Pediatric vaso occlusive crisis and weather conditionsJ. Emerg."/>
   <result pre="cell diseaseHaematologica201710266667510.3324/haematol.2016.15424527909222 6.DessapA.M.ContouD.Dandine-RoullandC.HemeryF.HabibiA.Charles-NelsonA.KatsahianS.Environmental influences on daily emergency admissions in sickle-cell" exact="disease" post="patientsMedicine201493e28010.1097/MD.000000000000028025546672 7.RogovikA.L.PersaudJ.FriedmanJ.N.KirbyM.A.GoldmanR.D.Pediatric vaso occlusive crisis and weather conditionsJ. Emerg."/>
   <result pre="occlusive crisis and weather conditionsJ. Emerg. Med.20114155956510.1016/j.jemermed.2010.05.00620576392 8.SimonnetC.ElangaN.JolyP.VazT.NacherM.Genetic modulators of" exact="sickle cell disease" post="in French Guiana: Markers of the slave tradeAm. J."/>
   <result pre="and weather conditionsJ. Emerg. Med.20114155956510.1016/j.jemermed.2010.05.00620576392 8.SimonnetC.ElangaN.JolyP.VazT.NacherM.Genetic modulators of sickle cell" exact="disease" post="in French Guiana: Markers of the slave tradeAm. J."/>
   <result pre="de la prise en chargeBull. Épidémiologique Hebd.201227–28322325 10.ElengaN.CuadroE.MartinÉ.Cohen-AddadN.BassetT.Associated factors of" exact="acute" post="chest syndrome in children with sickle cell disease in"/>
   <result pre="la prise en chargeBull. Épidémiologique Hebd.201227–28322325 10.ElengaN.CuadroE.MartinÉ.Cohen-AddadN.BassetT.Associated factors of acute" exact="chest" post="syndrome in children with sickle cell disease in French"/>
   <result pre="prise en chargeBull. Épidémiologique Hebd.201227–28322325 10.ElengaN.CuadroE.MartinÉ.Cohen-AddadN.BassetT.Associated factors of acute chest" exact="syndrome" post="in children with sickle cell disease in French GuianaInt."/>
   <result pre="Hebd.201227–28322325 10.ElengaN.CuadroE.MartinÉ.Cohen-AddadN.BassetT.Associated factors of acute chest syndrome in children with" exact="sickle cell disease" post="in French GuianaInt. J. Pediatrics.2014201410.1155/2014/21368124678322 11.BoxG.E.JenkinsG.M.Time Series Analysis: Forecasting"/>
   <result pre="factors of acute chest syndrome in children with sickle cell" exact="disease" post="in French GuianaInt. J. Pediatrics.2014201410.1155/2014/21368124678322 11.BoxG.E.JenkinsG.M.Time Series Analysis: Forecasting"/>
   <result pre="are associated with an increased number of hospital admissions for" exact="acute" post="pain and sickle cell disease in an urban environment"/>
   <result pre="an increased number of hospital admissions for acute pain and" exact="sickle cell disease" post="in an urban environment with a maritime temperate climateBr."/>
   <result pre="number of hospital admissions for acute pain and sickle cell" exact="disease" post="in an urban environment with a maritime temperate climateBr."/>
   <result pre="maritime temperate climateBr. J. Haematol.200513153053310.1111/j.1365-2141.2005.05799.x16281945 13.AhmedS.KaguM.AbjahU.BukarA.Seasonal variations in frequencies of" exact="acute" post="vaso-occlusive morbidities among sickle cell anaemia patients in northern"/>
   <result pre="variations in frequencies of acute vaso-occlusive morbidities among sickle cell" exact="anaemia" post="patients in northern NigeriaJ. Blood Disord Transfus20123210.4172/2155-9864.1000120 14.RedwoodA.M.WilliamsE.M.DesalP.SerjeantG.R.Climate and"/>
   <result pre="vaso-occlusive morbidities among sickle cell anaemia patients in northern NigeriaJ." exact="Blood" post="Disord Transfus20123210.4172/2155-9864.1000120 14.RedwoodA.M.WilliamsE.M.DesalP.SerjeantG.R.Climate and painful crisis of sickle-cell disease"/>
   <result pre="northern NigeriaJ. Blood Disord Transfus20123210.4172/2155-9864.1000120 14.RedwoodA.M.WilliamsE.M.DesalP.SerjeantG.R.Climate and painful crisis of" exact="sickle-cell disease" post="in JamaicaBr. Med J.19761666810.1136/bmj.1.6001.661244937 15.AwaH.M.DongmoF.UmS.N.FonkwoV.M.YandaA.A.NlendA.E.N.TchokoteuP.F.Aspects Épidémiologiques, Cliniques et Thérapeutiques"/>
   <result pre="NigeriaJ. Blood Disord Transfus20123210.4172/2155-9864.1000120 14.RedwoodA.M.WilliamsE.M.DesalP.SerjeantG.R.Climate and painful crisis of sickle-cell" exact="disease" post="in JamaicaBr. Med J.19761666810.1136/bmj.1.6001.661244937 15.AwaH.M.DongmoF.UmS.N.FonkwoV.M.YandaA.A.NlendA.E.N.TchokoteuP.F.Aspects Épidémiologiques, Cliniques et Thérapeutiques"/>
   <result pre="Pathol.200962424510.1136/jcp.2008.05898219103859 18.NacherM.Using pathogen interactions: Challenges and opportunitiesEcology and Evolution of" exact="Infectious" post="Disease: Pathogen Control and Public Health Management in Low-Income"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC6964091/results/search/disease/results.xml">
   <result pre="540 doi: 10.1186/s12992-019-0540-4 : Research Spatial and temporal distribution of" exact="infectious disease" post="epidemics, disasters and other potential public health emergencies in"/>
   <result pre="doi: 10.1186/s12992-019-0540-4 : Research Spatial and temporal distribution of infectious" exact="disease" post="epidemics, disasters and other potential public health emergencies in"/>
   <result pre="disasters and other potential public health emergencies in the WHO" exact="African" post="region between 2016 and 2018. Methods We abstracted data"/>
   <result pre="Methods We abstracted data from several sources, including: the WHO" exact="African" post="Region’s weekly bulletins on epidemics and emergencies, the WHO-Disease"/>
   <result pre="Disasters (CRED). Other sources were: the Program for Monitoring Emerging" exact="Diseases" post="(ProMED) and the Global Infectious Disease and Epidemiology Network"/>
   <result pre="the Program for Monitoring Emerging Diseases (ProMED) and the Global" exact="Infectious" post="Disease and Epidemiology Network (GIDEON). We included information on"/>
   <result pre="Program for Monitoring Emerging Diseases (ProMED) and the Global Infectious" exact="Disease" post="and Epidemiology Network (GIDEON). We included information on the"/>
   <result pre="epicentres) experienced over 10 events and all of them had" exact="limited" post="or developing IHR capacities. The top five causes of"/>
   <result pre="capacities. The top five causes of epidemics were: Cholera, Measles," exact="Viral" post="Haemorrhagic Diseases, Malaria and Meningitis. Conclusions The frequent and"/>
   <result pre="five causes of epidemics were: Cholera, Measles, Viral Haemorrhagic Diseases," exact="Malaria" post="and Meningitis. Conclusions The frequent and widespread occurrence of"/>
   <result pre="government to finance country specific needs. We call upon all" exact="African" post="countries to establish governance and predictable financing mechanisms for"/>
   <result pre="IHR implementation and to build resilient health systems everywhere. Keywords" exact="African" post="region Disaster Epidemic Event International health regulations Public health"/>
   <result pre="to build resilient health systems everywhere. Keywords African region Disaster" exact="Epidemic" post="Event International health regulations Public health emergency Public health"/>
   <result pre="of the 47 countries in the World Health Organization (WHO)" exact="African" post="Region is at risk of health security threats [1,"/>
   <result pre="risk of health security threats [1, 2]. Emerging and re-emerging" exact="infectious diseases" post="with a potential to spread internationally continue to challenge"/>
   <result pre="significant harm to humans, while &quot;event&quot; means a manifestation of" exact="disease" post="or an occurrence that creates a potential for disease"/>
   <result pre="of disease or an occurrence that creates a potential for" exact="disease" post="[3]. Epidemic refers to an increase, often sudden, in"/>
   <result pre="or an occurrence that creates a potential for disease [3]." exact="Epidemic" post="refers to an increase, often sudden, in the number"/>
   <result pre="increase, often sudden, in the number of cases of a" exact="disease" post="above what is normally expected in a given population"/>
   <result pre="definition of epidemic, it is often used for a more" exact="limited" post="geographic area. Pandemic refers to an epidemic that has"/>
   <result pre="event, which overwhelms local capacity, necessitating national or international level" exact="external" post="assistance [6]. A public health emergency on the other"/>
   <result pre="health risk to other States through the international spread of" exact="disease" post="and to potentially require a coordinated international response [3]."/>
   <result pre="require a coordinated international response [3]. Every year, the WHO" exact="African" post="Region records more epidemics, disasters and potential public health"/>
   <result pre="temporal analysis indicates that the risk of emerging and re-emerging" exact="infectious disease" post="epidemics has risen [1, 8]. This could partly be"/>
   <result pre="analysis indicates that the risk of emerging and re-emerging infectious" exact="disease" post="epidemics has risen [1, 8]. This could partly be"/>
   <result pre="international travel, increasing human population density, rapid and unplanned urbanisation," exact="recurrent" post="political and other social conflicts and growth of informal"/>
   <result pre="The recent devastating effects of the cyclone in the southern" exact="African" post="region, the current Ebola virus disease (EVD) epidemic in"/>
   <result pre="cyclone in the southern African region, the current Ebola virus" exact="disease" post="(EVD) epidemic in the Democratic Republic of Congo (DRC),"/>
   <result pre="and the humanitarian crisis in Northern Nigeria, South Sudan, DRC," exact="Central" post="African Republic(CAR) and Mali are poignant reminders of the"/>
   <result pre="the humanitarian crisis in Northern Nigeria, South Sudan, DRC, Central" exact="African" post="Republic(CAR) and Mali are poignant reminders of the local"/>
   <result pre="disasters and other potential public health emergencies in the WHO" exact="African" post="Region for the period 2016 to 2018. This led"/>
   <result pre="2018. This led to a comprehensive compilation of data on" exact="disease" post="epidemics, disasters and other potential health emergencies and where"/>
   <result pre="Data sources The key data sources used were: the WHO" exact="African" post="Region’s Weekly bulletins on epidemics and other emergencies, and"/>
   <result pre="Disasters (CRED). Additional sources included: the Program for Monitoring Emerging" exact="Diseases" post="(ProMED) and the Global Infectious Diseases and Epidemiology Online"/>
   <result pre="the Program for Monitoring Emerging Diseases (ProMED) and the Global" exact="Infectious" post="Diseases and Epidemiology Online Network (GIDEON). As part of"/>
   <result pre="Program for Monitoring Emerging Diseases (ProMED) and the Global Infectious" exact="Diseases" post="and Epidemiology Online Network (GIDEON). As part of the"/>
   <result pre="WHO Health Emergencies Programme from the website https://www.afro.who.int/health-topics/disease-outbreaks/outbreaks-and-other-emergencies-updates. Data on" exact="infectious disease" post="epidemics, disasters and other emergencies were compiled from the"/>
   <result pre="Health Emergencies Programme from the website https://www.afro.who.int/health-topics/disease-outbreaks/outbreaks-and-other-emergencies-updates. Data on infectious" exact="disease" post="epidemics, disasters and other emergencies were compiled from the"/>
   <result pre="based on notifications of public health events caused by various" exact="infectious" post="pathogens and other hazardous substances submitted to the WHO"/>
   <result pre="are published weekly in the DON website (https://www.who.int/csr/don/archive/year/2016/en/). Data on" exact="infectious disease" post="epidemics and other health emergencies were compiled from the"/>
   <result pre="published weekly in the DON website (https://www.who.int/csr/don/archive/year/2016/en/). Data on infectious" exact="disease" post="epidemics and other health emergencies were compiled from the"/>
   <result pre="online reporting system established in 1994 by the Federation of" exact="American" post="Scientists and the United Kingdom Space Agency-SATELLIFE, to provide"/>
   <result pre="by the Federation of American Scientists and the United Kingdom" exact="Space" post="Agency-SATELLIFE, to provide up-to-date information on outbreaks of diseases"/>
   <result pre="from ProMED contained 42 epidemics/events. The GIDEON is a Global" exact="Infectious" post="disease knowledge management tool that maintains up to date"/>
   <result pre="ProMED contained 42 epidemics/events. The GIDEON is a Global Infectious" exact="disease" post="knowledge management tool that maintains up to date information"/>
   <result pre="are standard publications of WHO and the US Centres for" exact="Disease" post="Prevention and Control (US CDC). Additionally, relevant peer-reviewed publications"/>
   <result pre="the period 2016 to 2018. Assembly of the data for" exact="infectious disease" post="epidemics and other public health emergencies Most of the"/>
   <result pre="period 2016 to 2018. Assembly of the data for infectious" exact="disease" post="epidemics and other public health emergencies Most of the"/>
   <result pre="location of the epidemic, the number of cases and deaths." exact="Epidemic" post="data from each data source were counter-checked with data"/>
   <result pre="the record from the data source that had reported the" exact="disease" post="causing the epidemic, the exact location of the epidemic,"/>
   <result pre="bubble plots to show temporal trends of all epidemics and" exact="disease" post="specific epidemics due to Cholera, Measles, Meningitis and Viral"/>
   <result pre="all epidemics and disease specific epidemics due to Cholera, Measles," exact="Meningitis" post="and Viral Haemorrhagic Diseases (Crimean Congo, Dengue Fever, Ebola"/>
   <result pre="and disease specific epidemics due to Cholera, Measles, Meningitis and" exact="Viral" post="Haemorrhagic Diseases (Crimean Congo, Dengue Fever, Ebola Virus Disease,"/>
   <result pre="specific epidemics due to Cholera, Measles, Meningitis and Viral Haemorrhagic" exact="Diseases" post="(Crimean Congo, Dengue Fever, Ebola Virus Disease, Lassa Fever,"/>
   <result pre="to Cholera, Measles, Meningitis and Viral Haemorrhagic Diseases (Crimean Congo," exact="Dengue" post="Fever, Ebola Virus Disease, Lassa Fever, Marburg Virus Disease,"/>
   <result pre="Meningitis and Viral Haemorrhagic Diseases (Crimean Congo, Dengue Fever, Ebola" exact="Virus Disease," post="Lassa Fever, Marburg Virus Disease, Rift Valley Fever, Yellow"/>
   <result pre="(Crimean Congo, Dengue Fever, Ebola Virus Disease, Lassa Fever, Marburg" exact="Virus Disease," post="Rift Valley Fever, Yellow Fever and Viral Haemorrhagic Fevers"/>
   <result pre="Disease, Lassa Fever, Marburg Virus Disease, Rift Valley Fever, Yellow" exact="Fever" post="and Viral Haemorrhagic Fevers of unknown or unspecified origin."/>
   <result pre="Fever, Marburg Virus Disease, Rift Valley Fever, Yellow Fever and" exact="Viral" post="Haemorrhagic Fevers of unknown or unspecified origin. We computed"/>
   <result pre="Virus Disease, Rift Valley Fever, Yellow Fever and Viral Haemorrhagic" exact="Fevers" post="of unknown or unspecified origin. We computed the frequencies"/>
   <result pre="Fever, Yellow Fever and Viral Haemorrhagic Fevers of unknown or" exact="unspecified" post="origin. We computed the frequencies of each event and"/>
   <result pre="events by country for the period 2016–2018. Results Over 260" exact="infectious disease" post="epidemics, disasters and other potential public health emergencies were"/>
   <result pre="by country for the period 2016–2018. Results Over 260 infectious" exact="disease" post="epidemics, disasters and other potential public health emergencies were"/>
   <result pre="WHO Africa Region, Cholera being the most geographically widespread. Ebola" exact="Virus Disease," post="Lassa Fever and Marburg Virus Disease were focal and"/>
   <result pre="Cholera being the most geographically widespread. Ebola Virus Disease, Lassa" exact="Fever" post="and Marburg Virus Disease were focal and mostly impacted"/>
   <result pre="most geographically widespread. Ebola Virus Disease, Lassa Fever and Marburg" exact="Virus Disease" post="were focal and mostly impacted specific areas in the"/>
   <result pre="geographically widespread. Ebola Virus Disease, Lassa Fever and Marburg Virus" exact="Disease" post="were focal and mostly impacted specific areas in the"/>
   <result pre="Ebola Virus Disease, Lassa Fever and Marburg Virus Disease were" exact="focal" post="and mostly impacted specific areas in the region. Cholera"/>
   <result pre="and Measles caused outbreaks in many parts of the WHO" exact="African" post="Region, while outbreaks of Meningitis and Crimean-Congo Haemorrhagic Fever"/>
   <result pre="many parts of the WHO African Region, while outbreaks of" exact="Meningitis" post="and Crimean-Congo Haemorrhagic Fever primarily occurred in a few"/>
   <result pre="WHO African Region, while outbreaks of Meningitis and Crimean-Congo Haemorrhagic" exact="Fever" post="primarily occurred in a few areas. Fig. 1 Bubble"/>
   <result pre="from all diseases (Left Panel); Epidemics caused by Cholera, Measles," exact="Meningitis" post="and Viral Haemorrhagic Diseases (Crimean Congo, Dengue, Ebola, Lassa,"/>
   <result pre="diseases (Left Panel); Epidemics caused by Cholera, Measles, Meningitis and" exact="Viral" post="Haemorrhagic Diseases (Crimean Congo, Dengue, Ebola, Lassa, Marburg, Rift"/>
   <result pre="Panel); Epidemics caused by Cholera, Measles, Meningitis and Viral Haemorrhagic" exact="Diseases" post="(Crimean Congo, Dengue, Ebola, Lassa, Marburg, Rift Valley Fever,"/>
   <result pre="(Crimean Congo, Dengue, Ebola, Lassa, Marburg, Rift Valley Fever, Yellow" exact="Fever" post="and Viral Haemorrhagic Fever of unknown or unspecified origin)"/>
   <result pre="Dengue, Ebola, Lassa, Marburg, Rift Valley Fever, Yellow Fever and" exact="Viral" post="Haemorrhagic Fever of unknown or unspecified origin) (Middle Panel);"/>
   <result pre="Lassa, Marburg, Rift Valley Fever, Yellow Fever and Viral Haemorrhagic" exact="Fever" post="of unknown or unspecified origin) (Middle Panel); and epidemics"/>
   <result pre="Fever, Yellow Fever and Viral Haemorrhagic Fever of unknown or" exact="unspecified" post="origin) (Middle Panel); and epidemics caused by Viral Haemorrhagic"/>
   <result pre="unknown or unspecified origin) (Middle Panel); and epidemics caused by" exact="Viral" post="Haemorrhagic Diseases (Right Panel) that occurred between 2016 and"/>
   <result pre="unspecified origin) (Middle Panel); and epidemics caused by Viral Haemorrhagic" exact="Diseases" post="(Right Panel) that occurred between 2016 and 2018 in"/>
   <result pre="Panel) that occurred between 2016 and 2018 in the WHO" exact="African" post="Region The top five causes of outbreaks during the"/>
   <result pre="of outbreaks during the period 2016–2018 were: Cholera, Measles and" exact="Viral" post="Haemorrhagic Diseases, such as Ebola Virus Disease, Yellow Fever,"/>
   <result pre="were: Cholera, Measles and Viral Haemorrhagic Diseases, such as Ebola" exact="Virus Disease," post="Yellow Fever, Dengue Fever, Lassa Fever, and Rift Valley"/>
   <result pre="Viral Haemorrhagic Diseases, such as Ebola Virus Disease, Yellow Fever," exact="Dengue" post="Fever, Lassa Fever, and Rift Valley Fever. Other causes"/>
   <result pre="Fever, Lassa Fever, and Rift Valley Fever. Other causes were" exact="Malaria" post="and Meningitis. Figure 2 illustrates the frequency and spatial"/>
   <result pre="and spatial distribution, while Fig. 3 are maps showing the" exact="infectious" post="disease-causing agent responsible for the epidemic or the public"/>
   <result pre="4 is a stacked chart of all the epidemics by" exact="disease" post="for each country where an epidemic was reported, and"/>
   <result pre="that occurred during 2016–2018 in the countries of the WHO" exact="African" post="region. Fig. 2 Map showing the number of epidemics"/>
   <result pre="of epidemics and other public health emergencies in the WHO" exact="African" post="region, 2016–2018 Fig. 3 Map showing the spatial distribution"/>
   <result pre="of epidemics and other public health emergencies in the WHO" exact="African" post="region, 2016–2018 Fig. 4 A stacked bar graph of"/>
   <result pre="A stacked bar graph of all the epidemic events by" exact="disease" post="in the countries of the WHO African region, 2016–2018"/>
   <result pre="epidemic events by disease in the countries of the WHO" exact="African" post="region, 2016–2018 Fig. 5 A stacked bar graph of"/>
   <result pre="the other public health emergencies by countries of the WHO" exact="African" post="region, 2016–2018 Forty-one countries (87%) had at least one"/>
   <result pre="one epidemic per year (Fig. 1). These data demonstrate that" exact="infectious disease" post="epidemics continue to emerge and re-emerge predictably in certain"/>
   <result pre="epidemic per year (Fig. 1). These data demonstrate that infectious" exact="disease" post="epidemics continue to emerge and re-emerge predictably in certain"/>
   <result pre="of them are in the Central, West and the East" exact="African" post="regions. These countries could be categorized as the epicentres"/>
   <result pre="more epidemics during the period 2016–2018. These countries also had" exact="limited" post="or developing IHR capacities, based on the 2018 IHR"/>
   <result pre="1). Table 1 Prioritization of countries, based on frequency of" exact="infectious disease" post="epidemics, 2016–2018 Discussion This analysis demonstrates that the entire"/>
   <result pre="Table 1 Prioritization of countries, based on frequency of infectious" exact="disease" post="epidemics, 2016–2018 Discussion This analysis demonstrates that the entire"/>
   <result pre="epidemics, 2016–2018 Discussion This analysis demonstrates that the entire WHO" exact="African" post="region continues to be at risk of health security"/>
   <result pre="suggests that there is an increase in the frequency of" exact="infectious disease" post="epidemics, disasters and other potential public health emergencies in"/>
   <result pre="that there is an increase in the frequency of infectious" exact="disease" post="epidemics, disasters and other potential public health emergencies in"/>
   <result pre="disasters and other potential public health emergencies in the WHO" exact="African" post="region. This observation is similar to what was reported"/>
   <result pre="is similar to what was reported in a 2016 WHO" exact="African" post="region review of the occurrence of epidemics for the"/>
   <result pre="period 1970–2016 [1]. There were fewer epidemics of Measles and" exact="Viral" post="Haemorrhagic Diseases in the 2016 review compared to this"/>
   <result pre="[1]. There were fewer epidemics of Measles and Viral Haemorrhagic" exact="Diseases" post="in the 2016 review compared to this review. However,"/>
   <result pre="review and is still very common in this review, while" exact="Polio" post="and Malaria are less common in this review. A"/>
   <result pre="is still very common in this review, while Polio and" exact="Malaria" post="are less common in this review. A caveat to"/>
   <result pre="greater scale of epidemics. Some of the changes in the" exact="infectious disease" post="transmission patterns are likely a consequence of climate change,"/>
   <result pre="scale of epidemics. Some of the changes in the infectious" exact="disease" post="transmission patterns are likely a consequence of climate change,"/>
   <result pre="example, the time taken to control outbreaks in the WHO" exact="African" post="Region, has reduced from an average of 418 days (well"/>
   <result pre="epidemics are being detected and responded to faster [19]. Moreover," exact="African" post="countries are commended for their willingness to assess and"/>
   <result pre="to emergencies [20]. To date, forty-six countries in the WHO" exact="African" post="region have had their IHR capacities assessed through joint"/>
   <result pre="African region have had their IHR capacities assessed through joint" exact="external" post="evaluation (JEE) [11, 18]. This is the highest number"/>
   <result pre="have been shown to substantially improve the response time for" exact="Viral" post="Haemorrhagic Disease epidemics, thus reducing the scale and length"/>
   <result pre="shown to substantially improve the response time for Viral Haemorrhagic" exact="Disease" post="epidemics, thus reducing the scale and length of epidemics"/>
   <result pre="implementation of the IHR. In 2016, the Nigeria Centre for" exact="Disease" post="Control (NCDC) was established and has been instrumental in"/>
   <result pre="last recorded case [22]. Surveillance for the early detection of" exact="viral" post="spillovers and advanced genetic characterization for determination of the"/>
   <result pre="There are several worrying trends. First, there is evidence that" exact="Viral" post="Haemorrhagic Disease epidemics that were previously rare have recently"/>
   <result pre="several worrying trends. First, there is evidence that Viral Haemorrhagic" exact="Disease" post="epidemics that were previously rare have recently caused devastating"/>
   <result pre="in the region [26, 27]. For instance, Ebola and Marburg" exact="Virus Diseases" post="(MVD), previously known to be rare, have recently caused"/>
   <result pre="the region [26, 27]. For instance, Ebola and Marburg Virus" exact="Diseases" post="(MVD), previously known to be rare, have recently caused"/>
   <result pre="and 2016 revealed that the epicentres for the Ebola virus" exact="disease" post="and Marburg virus disease epidemics were mainly in East"/>
   <result pre="revealed that the epicentres for the Ebola virus disease and" exact="Marburg virus disease" post="epidemics were mainly in East and Central Africa, except"/>
   <result pre="the epicentres for the Ebola virus disease and Marburg virus" exact="disease" post="epidemics were mainly in East and Central Africa, except"/>
   <result pre="and Marburg virus disease epidemics were mainly in East and" exact="Central" post="Africa, except for the West Africa Ebola virus disease"/>
   <result pre="and Central Africa, except for the West Africa Ebola virus" exact="disease" post="epidemic [1]). Second, several epidemics of meningococcal meningitis recently"/>
   <result pre="Africa Ebola virus disease epidemic [1]). Second, several epidemics of" exact="meningococcal meningitis" post="recently occurred outside the meningitis belt, showing a high"/>
   <result pre="Ebola virus disease epidemic [1]). Second, several epidemics of meningococcal" exact="meningitis" post="recently occurred outside the meningitis belt, showing a high"/>
   <result pre="Second, several epidemics of meningococcal meningitis recently occurred outside the" exact="meningitis" post="belt, showing a high likelihood that the areas at"/>
   <result pre="over 3000 deaths were reported from 17 countries in the" exact="African" post="region and countries, such as Chad and Zambia, where"/>
   <result pre="constituting a dual threat. We explored the dual occurrence of" exact="infectious disease" post="epidemics, disasters and humanitarian crises. A comparison of data"/>
   <result pre="a dual threat. We explored the dual occurrence of infectious" exact="disease" post="epidemics, disasters and humanitarian crises. A comparison of data"/>
   <result pre="epidemics, disasters and humanitarian crises. A comparison of data on" exact="infectious disease" post="epidemics, disasters and other potential public health emergencies suggest"/>
   <result pre="disasters and humanitarian crises. A comparison of data on infectious" exact="disease" post="epidemics, disasters and other potential public health emergencies suggest"/>
   <result pre="emergencies suggest that certain countries have a high frequency of" exact="infectious disease" post="epidemics, as well as, a high frequency of other"/>
   <result pre="suggest that certain countries have a high frequency of infectious" exact="disease" post="epidemics, as well as, a high frequency of other"/>
   <result pre="or tropical rain forests, which are ecologically prone to numerous" exact="infectious diseases." post="Secondly, most of these countries have had recurrent civil,"/>
   <result pre="numerous infectious diseases. Secondly, most of these countries have had" exact="recurrent" post="civil, social and political strife, which has often resulted"/>
   <result pre="them have had challenges with governance and leadership and consequently" exact="limited" post="political and financial commitment for building resilient health systems."/>
   <result pre="Africa highlight the negative compounding effects of humanitarian crisis and" exact="infectious disease" post="epidemics, suggesting obvious benefits of cross linkages and the"/>
   <result pre="highlight the negative compounding effects of humanitarian crisis and infectious" exact="disease" post="epidemics, suggesting obvious benefits of cross linkages and the"/>
   <result pre="to UHC and health security. All countries in the WHO" exact="African" post="region have embraced the revised IHR monitoring and evaluation"/>
   <result pre="to implement the IHRs fully. In the early 2000s, HIV/AIDS," exact="Tuberculosis" post="and Malaria were affecting millions of vulnerable populations. In"/>
   <result pre="the IHRs fully. In the early 2000s, HIV/AIDS, Tuberculosis and" exact="Malaria" post="were affecting millions of vulnerable populations. In 2002, the"/>
   <result pre="partnership to accelerate the end of the &quot;epidemics&quot; of AIDS," exact="Tuberculosis" post="and Malaria. The Global Fund mobilizes and invests more"/>
   <result pre="requires similar bold partnerships with governments, civil society, technical agencies," exact="bilateral" post="and multilateral funding agencies, the private sector and the"/>
   <result pre="to leverage on the opportunities provided by funding for vertical" exact="disease" post="programmes, climate change, the Global Fund, and private sector"/>
   <result pre="public health interventions for health systems strengthening, implementation of integrated" exact="disease" post="surveillance and response (IDSR) and IHR. However, the institutionalisation"/>
   <result pre="a focus on prioritization within priorities. We call upon all" exact="African" post="governments to establish governance and predictable sustainable financing mechanisms"/>
   <result pre="to build resilient health systems everywhere. Abbreviations CDC Centres for" exact="Disease" post="Prevention and Control (United States) CRED Centre for Research"/>
   <result pre="of Disasters DFID Department for International Development (United Kingdom) DON" exact="Disease" post="Outbreak News DRC Democratic Republic of the Congo EM-DAT"/>
   <result pre="Republic of the Congo EM-DAT Emergency Events Database EVD Ebola" exact="Virus Disease" post="GIDEON Global Infectious Disease and Epidemiology Online Network IDSR"/>
   <result pre="of the Congo EM-DAT Emergency Events Database EVD Ebola Virus" exact="Disease" post="GIDEON Global Infectious Disease and Epidemiology Online Network IDSR"/>
   <result pre="EM-DAT Emergency Events Database EVD Ebola Virus Disease GIDEON Global" exact="Infectious" post="Disease and Epidemiology Online Network IDSR Integrated Disease Surveillance"/>
   <result pre="Emergency Events Database EVD Ebola Virus Disease GIDEON Global Infectious" exact="Disease" post="and Epidemiology Online Network IDSR Integrated Disease Surveillance and"/>
   <result pre="GIDEON Global Infectious Disease and Epidemiology Online Network IDSR Integrated" exact="Disease" post="Surveillance and Response IHR NFP International Health Regulations National"/>
   <result pre="Regulations IHRMEF International Health Regulations Monitoring and Evaluation Framework JEE" exact="Joint" post="External Evaluation NAPHS National Action Plan for Health Security"/>
   <result pre="Public Health Emergency Operation Centre PROMED Program for Monitoring Emerging" exact="Diseases" post="SATELLIFE SatelLife (United Kingdom Space Agency) TDDAP Tackling Deadly"/>
   <result pre="PROMED Program for Monitoring Emerging Diseases SATELLIFE SatelLife (United Kingdom" exact="Space" post="Agency) TDDAP Tackling Deadly Diseases in Africa Programme (United"/>
   <result pre="Diseases SATELLIFE SatelLife (United Kingdom Space Agency) TDDAP Tackling Deadly" exact="Diseases" post="in Africa Programme (United Kingdom) VHDs Viral Haemorrhagic Diseases"/>
   <result pre="TDDAP Tackling Deadly Diseases in Africa Programme (United Kingdom) VHDs" exact="Viral" post="Haemorrhagic Diseases WHO World Health Organisation Publisher’s Note Springer"/>
   <result pre="Deadly Diseases in Africa Programme (United Kingdom) VHDs Viral Haemorrhagic" exact="Diseases" post="WHO World Health Organisation Publisher’s Note Springer Nature remains"/>
   <result pre="Kingdom’s Department for International Development (DFID), under the &quot;Tackling Deadly" exact="Diseases" post="in Africa Programme (TDDAP). E.A.O is funded through a"/>
   <result pre="Not applicable as this was a review and analysis of" exact="secondary" post="data. Consent for publication Not applicable. Competing interests The"/>
   <result pre="Mapping risks and the distribution of epidemics in the WHO" exact="African" post="region, a technical report for the Regional Office for"/>
   <result pre="Office for Africa (2018). The Work of WHO in the" exact="African" post="Region - Report of the Regional Director: 2017–2018. Brazzaville."/>
   <result pre="Organisation. International Health Regulations (2005), Third Edition. http://apps.who.int/iris/bitstream/10665/246107/1/9789241580496-eng.pdf?ua=1. 4.Centres for" exact="Disease" post="Control (CDC), United States. www.cdc.gov/csels/dsepd/ss1978/lesson1/section11.html. Accessed 9 Dec 2019."/>
   <result pre="www.who.int/hac/about/definitions/en/. Accessed 10 Dec 2019. 8.JonesKEPatelNGLevyMAet al.Global trends in emerging" exact="infectious" post="diseasesNature200845199099310.1038/nature0653618288193 9.McMichael AJ, Campbell-Lendrum DH, Corvalán CF et al."/>
   <result pre="Accessed 27 Feb 2019. 10.McMichaelAJEnvironmental and social influences on emerging" exact="infectious" post="diseases: past, present and futurePhilos Trans R Soc Lond"/>
   <result pre="Trans R Soc Lond Series B Biol Sci20043591049105810.1098/rstb.2004.1480 11.TalisunaAYahayaAARajatonirinaSCStephenMOkeAet al.Joint" exact="external" post="evaluation of the International Health Regulation (2005) capacities: current"/>
   <result pre="(2005) capacities: current status and lessons learnt in the WHO" exact="African" post="regionBMJ Glob Health20194e00131210.1136/bmjgh-2018-001312 12.WHO (2017). Report on one health"/>
   <result pre="crisesN Engl J Med20163741281128710.1056/NEJMsr160023626761419 15.UNDP. Socio-economic Impact of Ebola virus" exact="disease" post="in West African countries: a call for national and"/>
   <result pre="Med20163741281128710.1056/NEJMsr160023626761419 15.UNDP. Socio-economic Impact of Ebola virus disease in West" exact="African" post="countries: a call for national and regional containment recovery"/>
   <result pre="recovery and prevention. United Nations Development Group – Western and" exact="Central" post="Africa. Nairobi, 2015;. (www.africa.undp.org/content/dam/rba/docs/Reports/ebola-west-africa.pdf. Accessed 26 Feb 2019. 16.World"/>
   <result pre="16.World Bank. The Economic Impact of the 2014 Ebola Epidemic:" exact="short" post="and medium-term estimates for West Africa. Washington DC, 2015."/>
   <result pre="2015. http://www.worldbank.org/en/region/afr/publication/the-economic-impact-of-the-2014-ebola-epidemic-short-and-medium-term-estimates-for-west-africa. Accessed 1 Mar 2019. 17.World Bank. Ebola: most" exact="African" post="countries avoid major economic loss but impact on Guinea,"/>
   <result pre="be curtailed. http://venturesafrica.com/how-the-monkeypox-outbreak-can-be-curtailed-in-nigeria/. Accessed 22 Feb 2019. 23.Nigeria Centers for" exact="Disease" post="Control (NCDC). Nigeria monkey pox outbreak report 027: November"/>
   <result pre="pox outbreak report 027: November 13, 2018. Nigeria Centre for" exact="disease" post="control. Abuja, Nigeria. Retrieved February 26, 2019 at: https://ncdc.gov.ng/themes/common/files/sitreps/30abb20fe681f2c54122a307e305fb51.pdf."/>
   <result pre="outbreaks in previously unaffected areas?Microbiol Immunol20145848349110.1111/1348-0421.1218125040642 27.MbonyeAWamalaJWinyi-Kaboyoet al.Repeated outbreaks of" exact="viral" post="haemorrhagic fevers in UgandaAfr Health Sci20121257958323516123 28.BremanJGHeymannDLLloydGet al.Discovery and"/>
   <result pre="Ebola Zaire virus in 1976 and relevance to the west" exact="African" post="epidemic during 2013-2016J Infect Dis2016214S93S10110.1093/infdis/jiw20727357339 29.UndurragaEACariasCMeltzerMIKahnEBPotential for broad-scale transmission"/>
   <result pre="2013-2016J Infect Dis2016214S93S10110.1093/infdis/jiw20727357339 29.UndurragaEACariasCMeltzerMIKahnEBPotential for broad-scale transmission of Ebola virus" exact="disease" post="during the West Africa crisis: lessons for the Global"/>
   <result pre="security agendaInfect Dis Poverty201716159 30.SpenglerJRErvinEDTownerJSRollinPENicholSTPerspectives on West Africa Ebola virus" exact="disease" post="outbreak, 2013-2016Emerg Infect Dis20162295696310.3201/eid2206.16002127070842 31.collab: PREVAIL III Study GroupSnellerMCReillyCBadioMBishopRJet"/>
   <result pre="for Filoviruses: A risk map for ebola and marburg virus" exact="disease" post="outbreaks in uganda. PLoS Curr. 2017;5:9. 33.NyakarahukaLShoemakerTRBalinandiSChemosGKwesigaBet al.Marburg virus"/>
   <result pre="disease outbreaks in uganda. PLoS Curr. 2017;5:9. 33.NyakarahukaLShoemakerTRBalinandiSChemosGKwesigaBet al.Marburg virus" exact="disease" post="outbreak in Kween District Uganda, 2017: Epidemiological and laboratory"/>
   <result pre="2017: Epidemiological and laboratory findingsPLoS Negl Trop Dis201913e000725710.1371/journal.pntd.000725730883555 34.WHO. Ebola" exact="Virus Disease," post="2018; (https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease). Accessed 6 Mar 2019. 35.WHO. Ebola strikes"/>
   <result pre="(https://www.who.int/news-room/detail/26-02-2019-ebola-response-in-democratic-republic-of-the-congo-risks-slowdown). Accessed 27 Feb 2019. 37.Ilunga KalengaOlyMoetiMatshidisoSparrowAnnieNguyenVinh-KimLuceyDanielGhebreyesusTedros A.The Ongoing Ebola" exact="Epidemic" post="in the Democratic Republic of Congo, 2018–2019New England Journal"/>
   <result pre="Conceptual Framework for Strengthening Public Health Disaster Risk Management: An" exact="African" post="ViewpointFront Public Health2017526310.3389/fpubh.2017.0026329034230 40.KlugeHet al.Strengthening global health security by"/>
   <result pre="44.Global Fund. Accelerating the end to the AIDs, Tuberculsos and" exact="Malaria" post="Epidemics. https://www.theglobalfund.org/en/. Accessed 9 Dec 2019."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7098263/results/search/disease/results.xml">
   <result pre="32187328 doi: 10.1590/0074-0276019046100850 : Perspectives Phylogenetics applied to the human" exact="immunodeficiency" post="virus type 1 (HIV-1): from the cross-species transmissions to"/>
   <result pre="10.1590/0074-0276019046100850 : Perspectives Phylogenetics applied to the human immunodeficiency virus" exact="type 1" post="(HIV-1): from the cross-species transmissions to the contact network"/>
   <result pre="to elucidate the origin and spread of the pandemic human" exact="immunodeficiency" post="virus type 1 (HIV-1) group M virus, both during"/>
   <result pre="the origin and spread of the pandemic human immunodeficiency virus" exact="type 1" post="(HIV-1) group M virus, both during the pre-epidemic period"/>
   <result pre="dynamics in concentrated and generalised epidemics. Significant efforts to obtain" exact="viral" post="sequences from newly HIV-infected individuals could certainly contribute to"/>
   <result pre="Phylogenetics and the pre-epidemic phase of HIV-1 spread The human" exact="immunodeficiency" post="virus type 1 (HIV-1) has been spreading in human"/>
   <result pre="the pre-epidemic phase of HIV-1 spread The human immunodeficiency virus" exact="type 1" post="(HIV-1) has been spreading in human populations over the"/>
   <result pre="100 years and is responsible for most of the global" exact="HIV/AIDS" post="pandemic. Phylogenetic analyses of simian immunodeficiency viruses (SIV) sequences"/>
   <result pre="most of the global HIV/AIDS pandemic. Phylogenetic analyses of simian" exact="immunodeficiency" post="viruses (SIV) sequences from different species of non-human primates"/>
   <result pre="different species of non-human primates and of HIV-1 sequences from" exact="Central" post="African countries were decisive to elucidate the origin of"/>
   <result pre="species of non-human primates and of HIV-1 sequences from Central" exact="African" post="countries were decisive to elucidate the origin of this"/>
   <result pre="Cameroon and neighboring countries, the group M spread out of" exact="Central" post="Africa and currently infects around 40 million people worldwide."/>
   <result pre="supports that during the pre-epidemic phase the HIV-1 group M" exact="primary" post="spread from Kinshasa, reaching the neighboring city of Brazzaville"/>
   <result pre="slow growth, until about 1960.5 Phylogenetics applied to the human" exact="immunodeficiency" post="virus type 1 (HIV-1) molecular epidemiology investigation revealed the"/>
   <result pre="until about 1960.5 Phylogenetics applied to the human immunodeficiency virus" exact="type 1" post="(HIV-1) molecular epidemiology investigation revealed the history of the"/>
   <result pre="among humans. (A) Phylogenetic tree of HIV-1 and related simian" exact="immunodeficiency" post="viruses (SIV) sequences reveals the multiple virus cross-species transmission"/>
   <result pre="Congo basin to neighboring regions in southern, eastern, and west" exact="African" post="regions, before being disseminated outside Africa.5 The subtype B"/>
   <result pre="not go through a phase of wide dissemination within the" exact="African" post="continent, but moved directly from Central Africa to the"/>
   <result pre="wide dissemination within the African continent, but moved directly from" exact="Central" post="Africa to the Americas or Southeast Asia, respectively, from"/>
   <result pre="et al.12 revealed that the BCAR epidemic resulted from early" exact="viral" post="transmissions from Hispaniola to Trinidad and Tobago and to"/>
   <result pre="detected in Brazil that mostly circulate in West (CRF02_AG) and" exact="Central" post="(CRF45_cpx) Africa.13,14 The estimated onset dates of the CRF02_AG"/>
   <result pre="surveillance system. Those studies revealed that the CRF02_AG and CRF45_cpx" exact="Brazilian" post="epidemics did not resulted from rapid expansion of recently"/>
   <result pre="of recently introduced viruses, but from slow dissemination of ancient" exact="viral" post="introductions combined with delayed detection by the public health"/>
   <result pre="the CRF02_AG outbreak affecting Libyan children arose from a single" exact="viral" post="introduction from West Africa before March 1998 and that"/>
   <result pre="Africa before March 1998 and that many of the HIV" exact="infections" post="already occurred before the foreign medical staff arrived, excluding"/>
   <result pre="initial transmissions. Another example was the characterisation of a spatially" exact="localised" post="iatrogenic outbreak occurred in rural Cambodia in 2014-2015, suspected"/>
   <result pre="that the transmission reached a peak of 15 new HIV" exact="infections" post="per day one year later, declining thereafter, coinciding with"/>
   <result pre="to elucidate the impact of preventive or therapeutic strategies on" exact="localised" post="HIV epidemics. A recent study dated back the origin"/>
   <result pre="heterosexual population from southern Brazil support that major changes in" exact="viral" post="transmission dynamics (transient epidemic stabilisation and resume epidemic increase)"/>
   <result pre="and perception of risk for HIV transmission.19 Phylodynamics analyses of" exact="viral" post="sequences recovered from newly HIV-infected individuals will certainly contribute"/>
   <result pre="and to assess the impact of public health interventions on" exact="localised" post="and country-wide epidemics on real time. Phylogenetics and the"/>
   <result pre="time. Phylogenetics and the study of HIV-1 transmission networks The" exact="absence of" post="proofreading activity of the viral reverse transcriptase and fast"/>
   <result pre="HIV-1 transmission networks The absence of proofreading activity of the" exact="viral" post="reverse transcriptase and fast replication rate make mutations to"/>
   <result pre="that the genetic diversity accumulates faster enough to reconstruct the" exact="viral" post="transmission network, which describes the history of infections at"/>
   <result pre="reconstruct the viral transmission network, which describes the history of" exact="infections" post="at the resolution of individual cases. The basic assumption"/>
   <result pre="are connected by a common source, a direct or a" exact="short" post="chain of transmissions [Figure (D)]. In the recent years,"/>
   <result pre="services for screening of drug-resistance mutations (genotyping), which generate HIV" exact="partial" post="genome sequences for virtually every individual entering/failing therapy. Focusing"/>
   <result pre="clustering rates and the number of transmissions happening in the" exact="acute" post="phase were much smaller among heterosexual then in the"/>
   <result pre="analysing factors correlated with cluster membership, typical features like high" exact="viral" post="load and CD4+ T cell counts, not on ART"/>
   <result pre="about the HIV serostatus were found, underscoring the importance of" exact="acute" post="phase of infection in the HIV transmission dynamics. Despite"/>
   <result pre="serostatus were found, underscoring the importance of acute phase of" exact="infection" post="in the HIV transmission dynamics. Despite the high HIV"/>
   <result pre="the HIV transmission dynamics. Despite the high HIV transmissibility during" exact="acute" post="phase, Volz et al.24 revealed that time since infection"/>
   <result pre="during acute phase, Volz et al.24 revealed that time since" exact="infection" post="is the main explanatory variable driving clustering in a"/>
   <result pre="genetic distance, might better represent individuals highly engaged in accessing" exact="primary" post="care, instead of vulnerable subpopulations burdened by high transmission"/>
   <result pre="This highlights that the prevention potential of immediate ART is" exact="limited" post="without an approach that includes intensification of HIV testing"/>
   <result pre="HIV transmission dynamics in developed countries with concentrated epidemics, where" exact="viral" post="sequences are routinely sampled, few studies were able to"/>
   <result pre="of a good sampling coverage of these locations, for example," exact="African" post="countries has more than 60% of the HIV infection"/>
   <result pre="for example, African countries has more than 60% of the" exact="HIV infection" post="cases in the world, but less than 30% of"/>
   <result pre="example, African countries has more than 60% of the HIV" exact="infection" post="cases in the world, but less than 30% of"/>
   <result pre="HIV transmissions among several communities, with constant introduction of new" exact="viral" post="lineages. In the concept of treatment as prevention (TasP),"/>
   <result pre="HIV transmission networks where the epidemic is worst. In an" exact="intermediate" post="position, middle income countries might find in the phylogenetic"/>
   <result pre="goal is to improve strategies of HIV prevention in the" exact="Brazilian" post="population, identifying key populations and understanding what interventions should"/>
   <result pre="of a T-lymphotropic retrovirus from a patient at risk for" exact="acquired immune deficiency syndrome" post="(AIDS)Science198322045998688716189183 4WorobeyMGemmelMTeuwenDEHaselkornTKunstmanKBunceMDirect evidence of extensive diversity of HIV-1 in"/>
   <result pre="T-lymphotropic retrovirus from a patient at risk for acquired immune" exact="deficiency" post="syndrome (AIDS)Science198322045998688716189183 4WorobeyMGemmelMTeuwenDEHaselkornTKunstmanKBunceMDirect evidence of extensive diversity of HIV-1"/>
   <result pre="retrovirus from a patient at risk for acquired immune deficiency" exact="syndrome" post="(AIDS)Science198322045998688716189183 4WorobeyMGemmelMTeuwenDEHaselkornTKunstmanKBunceMDirect evidence of extensive diversity of HIV-1 in"/>
   <result pre="HCV sequences from Libyan outbreakNature2006444712183683717171825 16RouetFNouhinJZhengDPRocheBBlackAPrakSMassive iatrogenic outbreak of human" exact="immunodeficiency" post="virus type 1 in rural Cambodia, 2014-2015Clin Infect Dis201866111733174129211835"/>
   <result pre="from Libyan outbreakNature2006444712183683717171825 16RouetFNouhinJZhengDPRocheBBlackAPrakSMassive iatrogenic outbreak of human immunodeficiency virus" exact="type 1" post="in rural Cambodia, 2014-2015Clin Infect Dis201866111733174129211835 17VinkenLFransenKCuypersLAlexievIBalottaCDebaisieuxLEarlier initiation of"/>
   <result pre="KingdomPLoS Pathog200959e100059019779560 22KouyosRDvon WylVYerlySBöniJTafféPShahCMolecular epidemiology reveals long-term changes in HIV" exact="type 1" post="subtype B transmission in SwitzerlandJ Infect Dis2010201101488149720384495 23HassanASPybusOGSandersEJAlbertJEsbjörnssonJDefining HIV-1"/>
   <result pre="Comput Biol201286e100255222761556 25PoonAFYImpacts and shortcomings of genetic clustering methods for" exact="infectious disease" post="outbreaksVirus Evol201622vew031vew03128058111 26RatmannOvan SighemABezemerDGavryushkinaAJurriaansSWensingASources of HIV infection among men"/>
   <result pre="Biol201286e100255222761556 25PoonAFYImpacts and shortcomings of genetic clustering methods for infectious" exact="disease" post="outbreaksVirus Evol201622vew031vew03128058111 26RatmannOvan SighemABezemerDGavryushkinaAJurriaansSWensingASources of HIV infection among men"/>
   <result pre="clustering methods for infectious disease outbreaksVirus Evol201622vew031vew03128058111 26RatmannOvan SighemABezemerDGavryushkinaAJurriaansSWensingASources of" exact="HIV infection" post="among men having sex with men and implications for"/>
   <result pre="methods for infectious disease outbreaksVirus Evol201622vew031vew03128058111 26RatmannOvan SighemABezemerDGavryushkinaAJurriaansSWensingASources of HIV" exact="infection" post="among men having sex with men and implications for"/>
   <result pre="implementation case studyLancet HIV201635e231e23827126490 28de OliveiraTKharsanyABMGräfTCawoodCKhanyileDGroblerATransmission networks and risk of" exact="HIV infection" post="in KwaZulu-Natal, South Africa a community-wide phylogenetic studyLancet HIV201741e41e5027914874"/>
   <result pre="case studyLancet HIV201635e231e23827126490 28de OliveiraTKharsanyABMGräfTCawoodCKhanyileDGroblerATransmission networks and risk of HIV" exact="infection" post="in KwaZulu-Natal, South Africa a community-wide phylogenetic studyLancet HIV201741e41e5027914874"/>
   <result pre="South Africa a community-wide phylogenetic studyLancet HIV201741e41e5027914874 29GrabowskiMKLesslerJReddADKagaayiJLaeyendeckerONdyanaboAThe role of" exact="viral" post="introductions in sustaining community-based HIV epidemics in rural Uganda"/>
   <result pre="30JunqueiraDMde MedeirosRMGräfTAlmeidaSEMShort-term dynamic and local epidemiological trends in the South" exact="American" post="HIV-1B epidemicPLoS One2016116e015671227258369"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7102705/results/search/disease/results.xml">
   <result pre=": italic;} J Infect Public HealthJ Infect Public HealthJournal of" exact="Infection" post="and Public Health1876-03411876-035XKing Saud Bin Abdulaziz University for Health"/>
   <result pre="S1876-0341(16)30002-8 doi: 10.1016/j.jiph.2016.02.005 : Article Deciphering emerging Zika and dengue" exact="viral" post="epidemics: Implications for global maternal–child health burden TamboErnesttambo0711@gmail.comab⁎ChuisseuPascal D.aNgogangJeanne"/>
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="in Aedes endemic and epidemic-prone countries. The current unprecedented Zika" exact="viral" post="epidemics and rapid spread in the Western hemisphere pose"/>
   <result pre="the Western hemisphere pose a substantial global threat, with associated" exact="anxiety" post="and consequences. The lack of safe and effective drugs"/>
   <result pre="examines knowledge gaps in both emerging and neglected arthropod-borne flavivirus" exact="infectious diseases" post="associated with poverty and their implications for fostering local,"/>
   <result pre="and their implications for fostering local, national and regional emerging" exact="disease" post="preparedness, effective and robust surveillance–response systems, sustained control and"/>
   <result pre="affected to date, with multiple health and socio-economic consequences. This" exact="infectious disease" post="of poverty was first discovered in Uganda in 1947;"/>
   <result pre="to date, with multiple health and socio-economic consequences. This infectious" exact="disease" post="of poverty was first discovered in Uganda in 1947;"/>
   <result pre="only 15 cases were documented prior to 2007, and the" exact="disease" post="remained in a state of dormancy until now [1]."/>
   <result pre="been identified in more than 20 countries in South and" exact="Central" post="America, the Caribbean, Asia-Pacific and Africa and some Pacific"/>
   <result pre="Micronesia) have also reported sporadic outbreaks [2], [3], [4]. Arbovirus" exact="disease" post="epidemics have the potential to worsen the global maternal–child"/>
   <result pre="1 ). Figure 1 Reported and active transmission of Zika" exact="viral" post="disease countries. Zika is caused by an arthropod-borne virus"/>
   <result pre="). Figure 1 Reported and active transmission of Zika viral" exact="disease" post="countries. Zika is caused by an arthropod-borne virus &quot;arbovirus&quot;"/>
   <result pre="the flavivirus family that also includes dengue, West Nile and" exact="yellow fever." post="Zika virus (ZIKV) can be transmitted through blood and"/>
   <result pre="during sexual intercourse or mother-to-fetus transmission throughout pregnancy [2]. ZIKV" exact="disease" post="outbreaks have been linked with pregnancy syndrome, newborn and"/>
   <result pre="economic impacts. In comparison, Brazil reported 4000 cases of fetal" exact="microcephaly" post="during pregnancy yet had only 150 cases total in"/>
   <result pre="of fetal microcephaly during pregnancy yet had only 150 cases" exact="total" post="in 2015 and 2014, respectively. In addition, of the"/>
   <result pre="and tools for early detection and rapid confirmation of ZIKV-linked" exact="microcephaly" post="and early warning systems to provide timely evidence-based information"/>
   <result pre="paper examines the knowledge gaps of these emerging and neglected" exact="infectious diseases" post="of poverty epidemics (Zika and dengue) implications in fostering"/>
   <result pre="or dengue arthropod-borne flaviviruses vector threat and epidemics surveillance, Zika" exact="viral" post="outbreak response, Aedes mosquito control, dengue control programs and"/>
   <result pre="guidelines for outbreak surveillance and response in humanitarian emergencies, global" exact="infectious disease" post="surveillance, epidemic preparedness and response, Global Alert and Response"/>
   <result pre="for outbreak surveillance and response in humanitarian emergencies, global infectious" exact="disease" post="surveillance, epidemic preparedness and response, Global Alert and Response"/>
   <result pre="studies focusing on programs and emergency response. The Centers for" exact="Disease" post="Control and Prevention's National Notifiable Dengue Surveillance databases and"/>
   <result pre="response. The Centers for Disease Control and Prevention's National Notifiable" exact="Dengue" post="Surveillance databases and World Health Global Outbreak Emergency Response"/>
   <result pre="public health burdens of ZIKV and DENV diseases. Results A" exact="total" post="of 174 papers were analyzed; 31 were selected based"/>
   <result pre="fully assessed and analyzed, with respect to the prevention of" exact="disease" post="co-infection burden and maternity and pediatric care delivery services."/>
   <result pre="services. Chronological trend and general characteristics of Zika and dengue" exact="viral" post="diseases epidemics From its discovery in Uganda in 1947"/>
   <result pre="and 2016, Brazil recorded the highest number of cases of" exact="microcephaly" post="(more than 3800), which was over 30 times more"/>
   <result pre="in any year since 2010 (Fig. 1). Zika and dengue" exact="viral" post="disease impact implications on global maternal–child health burden Both"/>
   <result pre="any year since 2010 (Fig. 1). Zika and dengue viral" exact="disease" post="impact implications on global maternal–child health burden Both Zika"/>
   <result pre="health burden Both Zika and dengue are emerging or re-emerging" exact="viral" post="diseases that are both caused by the arbovirus &quot;Aedes"/>
   <result pre="caused by the arbovirus &quot;Aedes species&quot;. Both Zika and dengue" exact="infections" post="appear to have similar early signs and symptoms including"/>
   <result pre="in their late stage or complication symptoms, such as hemorrhagic" exact="bleeding" post="in dengue. Previous dengue epidemics have been documented but"/>
   <result pre="Previous dengue epidemics have been documented but less virulent and" exact="localized" post="than the ongoing widespread ZIKV epidemics. Nevertheless, there is"/>
   <result pre="sexual intercourse with an infected individual and perhaps breastfeeding. More" exact="short" post="and long-term operational research is needed to further establish"/>
   <result pre="determinants and to confirm the association between Zika virus infections," exact="microcephaly" post="and related neurological aberrations suspected in fetal and childhood"/>
   <result pre="infections, microcephaly and related neurological aberrations suspected in fetal and" exact="childhood" post="development (Table 1 ). Table 1 Key comparative characteristics"/>
   <result pre="). Table 1 Key comparative characteristics between Zika and dengue" exact="viral" post="disease threats and epidemics. Table 1 Characteristics Zika Dengue"/>
   <result pre="Table 1 Key comparative characteristics between Zika and dengue viral" exact="disease" post="threats and epidemics. Table 1 Characteristics Zika Dengue References"/>
   <result pre="dengue viral disease threats and epidemics. Table 1 Characteristics Zika" exact="Dengue" post="References Discovery year 1947 UgandaZika virus isolation in monkey"/>
   <result pre="in Nigeria, respectively 265–420 ADAedes confirmation in 1906 [1], [4]" exact="Disease" post="type Viral arthropod-borne flavivirus Viral arthropod-borne flavivirus Vector mosquito"/>
   <result pre="respectively 265–420 ADAedes confirmation in 1906 [1], [4] Disease type" exact="Viral" post="arthropod-borne flavivirus Viral arthropod-borne flavivirus Vector mosquito Aedes aegypti,"/>
   <result pre="confirmation in 1906 [1], [4] Disease type Viral arthropod-borne flavivirus" exact="Viral" post="arthropod-borne flavivirus Vector mosquito Aedes aegypti, Aedes albopictus Aedes"/>
   <result pre="fluids: blood, semen, rectal fluids, vaginal fluids, mother-to-child transmission via" exact="breast" post="milk. Blood transfusion or needle exchange Mosquito Aedes biteUnprotected"/>
   <result pre="semen, rectal fluids, vaginal fluids, mother-to-child transmission via breast milk." exact="Blood" post="transfusion or needle exchange Mosquito Aedes biteUnprotected sexual intercourseInfected"/>
   <result pre="fluids: blood, semen, rectal fluids, vaginal fluids, mother-to-child transmission via" exact="breast" post="milk or blood transfusion suspected [11], [13], [23] Route"/>
   <result pre="infected human and animal including blood, urine, sweat, semen and" exact="breast" post="milk (sweat, semen, saliva) Human-to-human transmissionWildlife-to-human by infected Aedes"/>
   <result pre="infected human and animal including blood, urine, sweat, semen and" exact="breast" post="milk (sweat, semen, saliva) [1], [12], [13], [15], [16],"/>
   <result pre="chimpanzees Human and animals Susceptible countries &amp;gt;50 Africa (Cape Verde," exact="Central" post="African Republic, Egypt, Gabon, Sierra Leone, Tanzania, Nigeria and"/>
   <result pre="Human and animals Susceptible countries &amp;gt;50 Africa (Cape Verde, Central" exact="African" post="Republic, Egypt, Gabon, Sierra Leone, Tanzania, Nigeria and Uganda),"/>
   <result pre="Indonesia, Malaysia, the Philippines, Thailand and Vietnam, Samoa), South and" exact="Central" post="America (Brazil, Colombia, Mexico, Venezuela, Ecuador, Jamaica, El Salvador,"/>
   <result pre="the Pacific Islands and middle East including (Uganda, South and" exact="Central" post="America, Brazil, Colombia, Mexico, Venezuela, El Salvador, Haiti, Honduras,"/>
   <result pre="Poverty and insecurityUnsafe sexual behavior, probably from patients’ body fluids," exact="breast" post="milk, unsterilized virus infected needles and materials [3], [6],"/>
   <result pre="needles and materials [3], [6], [22], [23] Signs and symptoms" exact="Fever" post="and arthralgiaJoints pain and conjunctivitis, Rash, headaches, Guillain–Barre syndrome,"/>
   <result pre="and arthralgiaJoints pain and conjunctivitis, Rash, headaches, Guillain–Barre syndrome, increasing" exact="congenital" post="microcephaly or birth defects or neurological disorders in babies/newborns,"/>
   <result pre="arthralgiaJoints pain and conjunctivitis, Rash, headaches, Guillain–Barre syndrome, increasing congenital" exact="microcephaly" post="or birth defects or neurological disorders in babies/newborns, stillbirths"/>
   <result pre="joint painSwollen glands or rash nausea, vomitingComplications include fluid accumulation," exact="respiratory" post="distress, severe bleeding,Restlessness and blood in vomit or organ"/>
   <result pre="[4], [7], [14], [25] Global incidence – NA &amp;lt;284–528 million" exact="infections" post="annually [1], [2] Global cumulative cases &amp;gt;2 million &amp;gt;652,212"/>
   <result pre="&amp;gt;2 million &amp;gt;652,212 cases of dengue hemorrhagic fever67–136 million cases" exact="dengue fever" post="Global cumulative deaths – NA 22,000 deaths mainly among"/>
   <result pre="deaths – NA 22,000 deaths mainly among children Diagnostic methods" exact="Syndromic" post="screening in most cases.Travel and work history exposure to"/>
   <result pre="work history exposure to wildlife PrognosisDifferential diagnosis by detecting of" exact="viral" post="RNA by PCR/RT-PCR and proteins antibodies against the virus"/>
   <result pre="in infected patient's blood by ELISA or Serum neutralization test." exact="Syndromic" post="screening in most cases.Travel and work history exposure to"/>
   <result pre="work history exposure to wildlife prognosisDifferential diagnosis by detecting of" exact="viral" post="RNA by PCR/RT-PCR and proteins antibodies against the virus"/>
   <result pre="oral rehydration therapy– Integration of active and comprehensive threat and" exact="disease" post="surveillance and actions systems (1) Integration of a comprehensive"/>
   <result pre="and actions systems (1) Integration of a comprehensive threat and" exact="disease" post="surveillance and actions systems (2) Increasing community awareness education"/>
   <result pre="and care (4) Partnership and cooperation among stakeholders in emerging" exact="infectious" post="prevention and control programs and measures [15], [23], [26],"/>
   <result pre="not available data. Treatment or vaccination against ZIKV and DENV" exact="disease" post="prevention and control In the absence of safe and"/>
   <result pre="against ZIKV and DENV disease prevention and control In the" exact="absence of" post="safe and effective Zika or dengue drugs and vaccines,"/>
   <result pre="social, ecological and contextual risk factors and determinants of emerging" exact="disease" post="outbreaks. Currently, only palliative treatments including anti-inflammatory and antiviral"/>
   <result pre="changes, urbanization and globalization approaches to reducing mother-to-child transmission, comprehensive" exact="antenatal" post="and postnatal programs for women, sexual education and use"/>
   <result pre="is needed to strengthen health systems, nurture safe motherhood and" exact="childhood" post="practices and foster evidence-driven community project ownership to accelerate"/>
   <result pre="accelerate recovery programs and activities in affected communities. Strengthening vector-borne" exact="disease" post="preparedness and surveillance–response in maternal and neonatal child health"/>
   <result pre="communities. Strengthening vector-borne disease preparedness and surveillance–response in maternal and" exact="neonatal" post="child health Weak or lack of health system preparedness"/>
   <result pre="and reporting tools and resources in Zika and other emerging" exact="infectious diseases" post="are major challenges in most affected countries. The poor"/>
   <result pre="Improving the health system capacity to respond to maternal and" exact="neonatal" post="health challenges can be accomplished by timely, credible and"/>
   <result pre="and optimal resilient culture and integrated quality packages, including mosquito-borne" exact="disease" post="awareness and health education campaigns, mitigation and recovery measures."/>
   <result pre="other diseases with similar symptoms could be misleading due to" exact="acquired" post="immunity to other tropical infections in ZIKV human reservoirs,"/>
   <result pre="could be misleading due to acquired immunity to other tropical" exact="infections" post="in ZIKV human reservoirs, which might also complicate the"/>
   <result pre="national preparedness as well as surveillance–response system implementation in maternal," exact="neonatal" post="and child health. Accelerating the process of local/national ZIKV"/>
   <result pre="and poverty alleviation programs, programs and services linking communities and" exact="primary" post="health facilities and referral hospitals. Moreover, effective and sustainable"/>
   <result pre="inequities, poverty and the maternal–child health burden in most emerging" exact="infectious disease" post="epidemic-prone countries. Discussion Zika and dengue viral diseases have"/>
   <result pre="poverty and the maternal–child health burden in most emerging infectious" exact="disease" post="epidemic-prone countries. Discussion Zika and dengue viral diseases have"/>
   <result pre="most emerging infectious disease epidemic-prone countries. Discussion Zika and dengue" exact="viral" post="diseases have posed great challenges to the most affected"/>
   <result pre="communication approaches require more research in the future. Tackling persistent" exact="disease" post="resurgence by intensifying information dissemination and innovative actions requires"/>
   <result pre="reforms at all levels, faith-based and community-based interventions for emerging" exact="disease" post="outbreak preparedness, prevention and emergency response are all vital."/>
   <result pre="prevention and emergency response are all vital. ZIKV and DENV" exact="infections" post="have important health consequences; geographical, structural and biological risk"/>
   <result pre="biological risk factors, including poor community engagement and lack of" exact="viral" post="disease surveillance–response systems, have several related implications [6], [8]."/>
   <result pre="risk factors, including poor community engagement and lack of viral" exact="disease" post="surveillance–response systems, have several related implications [6], [8]. Table"/>
   <result pre="of person-to-person transmission [12], [21]. The incubation period of both" exact="viral" post="diseases is short and varies between 2 and 23"/>
   <result pre="[12], [21]. The incubation period of both viral diseases is" exact="short" post="and varies between 2 and 23 days; progression to"/>
   <result pre="days [21]. Blood-fed Zika mosquito screening and monitoring of emerging" exact="viral" post="diseases, especially in maternal and child populations, are needed."/>
   <result pre="transmission dynamics of ZIKV and DENV to plan for future" exact="infection" post="resurgence, especially in vulnerable regions. Because most African countries"/>
   <result pre="for future infection resurgence, especially in vulnerable regions. Because most" exact="African" post="countries have limited surveillance indicators to assess the threat"/>
   <result pre="resurgence, especially in vulnerable regions. Because most African countries have" exact="limited" post="surveillance indicators to assess the threat of re-emergence, early"/>
   <result pre="surveillance indicators to assess the threat of re-emergence, early warning" exact="disease" post="alerts, community awareness outreach and education are essential. Both"/>
   <result pre="do not have an effective antiretroviral cure [8], [15], [21]." exact="Infections" post="caused by Ebola hemorrhagic fever have killed 50–70% of"/>
   <result pre="currently most affected by Zika include forest fringes and unstable" exact="African" post="countries [20], [28], [29]. These areas have very weak"/>
   <result pre="weak health systems, which accounts for the re-emergence of these" exact="infectious diseases" post="[15], [20]. Therefore, strengthening community health systems and fostering"/>
   <result pre="practices and behavioral changes (e.g., promotion of condom usage. abstinence," exact="antenatal" post="counseling) among ZIKV victims offer new opportunities to eliminate"/>
   <result pre="is highly practiced in West Africa, is associated with a" exact="lower" post="risk of ZIKV and other sexually transmitted diseases compared"/>
   <result pre="to other countries with low/no male circumcision rates [27], [28]." exact="Local" post="and international partnerships with sustainable commitment and support are"/>
   <result pre="efforts. Similar to Ebola outbreaks in West Africa, re-emerging vector-borne" exact="infections" post="could have severe impacts on maternal–child healthcare and worsening"/>
   <result pre="socio-economic challenges in sub-Saharan Africa. Tackling emerging or re-emerging vector-borne" exact="viral" post="disease requires more proactive and concrete efforts and commitment"/>
   <result pre="challenges in sub-Saharan Africa. Tackling emerging or re-emerging vector-borne viral" exact="disease" post="requires more proactive and concrete efforts and commitment in"/>
   <result pre="with MERS-CoV and dengue in Saudi Arabia, H1N1 and H7N9" exact="avian influenza" post="in China [2], [5], [9], [17], [26], [28]. Additionally,"/>
   <result pre="vector-virus genetic evolution and flow as well as population immunity," exact="viral" post="competence and virulence advantages will require further research. Currently,"/>
   <result pre="infected individuals were able to silently and unknowingly spread the" exact="infection" post="for years [32]. In contrast, Ebola and HIV infections"/>
   <result pre="the infection for years [32]. In contrast, Ebola and HIV" exact="infections" post="and related deaths are rapid and therefore more terrifying;"/>
   <result pre="Ebola virus requires more sophisticated isolation measures to contain the" exact="disease" post="[21], [29] than does Zika or dengue. There is"/>
   <result pre="and children [28], [29], [31], [32]. Addressing mosquito vector and" exact="viral" post="surveillance challenges in the context of limited resources or"/>
   <result pre="mosquito vector and viral surveillance challenges in the context of" exact="limited" post="resources or urbanized settings is necessary for effective treatment"/>
   <result pre="urgent need to improve investment in Zika, dengue and other" exact="infectious disease" post="research and development on evidence-informed and sustainable policies making"/>
   <result pre="need to improve investment in Zika, dengue and other infectious" exact="disease" post="research and development on evidence-informed and sustainable policies making"/>
   <result pre="aggressive and strategic innovative interventions to prevent or control these" exact="viral" post="diseases will be tantamount to directly or indirectly in"/>
   <result pre="idea and built the conceptual framework. ET screened the synthetic" exact="primary" post="information, analyzed and wrote the primary draft of the"/>
   <result pre="ET screened the synthetic primary information, analyzed and wrote the" exact="primary" post="draft of the manuscript. ET, HAK and EIMK provided"/>
   <result pre="to pregnant womenBMJ352January2016i30610.1136/bmj.i30626783242 4Oliveira MeloA.S.MalingerG.XimenesR.SzejnfeldP.O.Alves SampaioS.Bispo de FilippisA.M.Zika virus intrauterine" exact="infection" post="causes fetal brain abnormality and microcephaly: tip of the"/>
   <result pre="4Oliveira MeloA.S.MalingerG.XimenesR.SzejnfeldP.O.Alves SampaioS.Bispo de FilippisA.M.Zika virus intrauterine infection causes fetal" exact="brain" post="abnormality and microcephaly: tip of the iceberg?Ultrasound Obstet Gynecol47January"/>
   <result pre="surveillance response systems to combat Ebola outbreaks and other emerging" exact="infectious diseases" post="in African countriesInf Dis Poverty3August201429 7VenturaC.V.MaiaM.Bravo-FilhoV.GóisA.L.BelfortR.Jr.Zika virus in Brazil"/>
   <result pre="to combat Ebola outbreaks and other emerging infectious diseases in" exact="African" post="countriesInf Dis Poverty3August201429 7VenturaC.V.MaiaM.Bravo-FilhoV.GóisA.L.BelfortR.Jr.Zika virus in Brazil and macular"/>
   <result pre="African countriesInf Dis Poverty3August201429 7VenturaC.V.MaiaM.Bravo-FilhoV.GóisA.L.BelfortR.Jr.Zika virus in Brazil and macular" exact="atrophy" post="in a child with microcephalyLancetJanuary201610.1016/S0140-6736(16)00006-4pii: S0140-6736(16)00006-4 8Villamil-GómezW.E.González-CamargoO.Rodriguez-AyubiJ.Zapata-SerpaD.Rodriguez-MoralesA.J.Dengue, chikungunya and"/>
   <result pre="and macular atrophy in a child with microcephalyLancetJanuary201610.1016/S0140-6736(16)00006-4pii: S0140-6736(16)00006-4 8Villamil-GómezW.E.González-CamargoO.Rodriguez-AyubiJ.Zapata-SerpaD.Rodriguez-MoralesA.J.Dengue," exact="chikungunya" post="and Zika co-infection in a patient from ColombiaJ Infect"/>
   <result pre="outbreak – United States, 2016Morb Mortal Wkly Rep65January (2)20163033 16KorhonenE.M.HuhtamoE.SmuraT.Kallio-KokkoH.RaassinaM.VapalahtiO.Zika" exact="virus infection" post="in a traveller returning from the Maldives, June 2015Euro"/>
   <result pre="– United States, 2016Morb Mortal Wkly Rep65January (2)20163033 16KorhonenE.M.HuhtamoE.SmuraT.Kallio-KokkoH.RaassinaM.VapalahtiO.Zika virus" exact="infection" post="in a traveller returning from the Maldives, June 2015Euro"/>
   <result pre="mosquitoes (Diptera: Culicidae) to transmit Zika virusBMC Infect Dis15November201549226527535 19MorensD.M.FauciA.S.Emerging" exact="infectious" post="diseases: threats to human health and global stabilityPLoS Pathog972013e100346723853589"/>
   <result pre="human health and global stabilityPLoS Pathog972013e100346723853589 20FauciA.S.MorensD.M.The perpetual challenge of" exact="infectious" post="diseasesN Engl J Med366201245446110.1056/nejmra110829622296079 21TamboE.ChidiebereE.U.OlowasogoA.O.IsattaW.JeannettaK.J.Values and hopes of Ebola"/>
   <result pre="policies and programsJ Prev Infect Control1120152 27RothA.MercierA.LepersC.HoyD.DuituturagaS.BenyonE.Concurrent outbreaks of dengue," exact="chikungunya" post="and Zika virus infections – an unprecedented epidemic wave"/>
   <result pre="Infect Control1120152 27RothA.MercierA.LepersC.HoyD.DuituturagaS.BenyonE.Concurrent outbreaks of dengue, chikungunya and Zika virus" exact="infections" post="– an unprecedented epidemic wave of mosquito-borne viruses in"/>
   <result pre="Trop Dis7August (8)2013e234823936579 31TappeD.Pérez-GirónJ.V.ZammarchiL.RisslandJ.FerreiraD.F.JaenischT.Cytokine kinetics of Zika virus-infected patients from" exact="acute" post="to reconvalescent phaseMed Microbiol ImmunolDecember2015 32GrardG.CaronM.MomboI.M.NkogheD.Mboui OndoS.JiolleD.Zika virus in"/>
   <result pre="(1)2016162026876061 34GoorhuisA.von EijeK.J.DoumaR.A.RijnbergN.van VugtM.StijnisC.Zika virus and the risk of imported" exact="infection" post="in returned travelers: implications for clinical careTravel Med Infect"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7119083/results/search/disease/results.xml">
   <result pre="A critical care perspective informed by lessons learnt from other" exact="viral" post="epidemics LingLowellaJoyntGavin M.gavinmjoynt@cuhk.edu.hka⁎LipmanJeffbcdConstantinJean-MichelefJoannes-BoyauOlivierg[a], [b], [c], [d], [e], [f], [g],"/>
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="as long as the COVID-19 resource centre remains active. Keywords" exact="Infection" post="control Outbreak SARS-CoV-2 1 Introduction The world is closely"/>
   <result pre="1 Introduction The world is closely watching the outbreak of" exact="respiratory" post="illness associated with the novel beta coronavirus SARS-CoV-2. The"/>
   <result pre="now officially named SARS-CoV-2 is 80–89% similar to bat severe" exact="acute" post="respiratory syndrome related coronaviruses found in Chinese horseshoe bats"/>
   <result pre="officially named SARS-CoV-2 is 80–89% similar to bat severe acute" exact="respiratory" post="syndrome related coronaviruses found in Chinese horseshoe bats [2],"/>
   <result pre="named SARS-CoV-2 is 80–89% similar to bat severe acute respiratory" exact="syndrome" post="related coronaviruses found in Chinese horseshoe bats [2], [3]."/>
   <result pre="[3]. In addition, it is about 79% akin to severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) and 50% related to Middle"/>
   <result pre="In addition, it is about 79% akin to severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) and 50% related to Middle East"/>
   <result pre="addition, it is about 79% akin to severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) and 50% related to Middle East respiratory"/>
   <result pre="respiratory syndrome coronavirus (SARS-CoV) and 50% related to Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV). The latter two coronaviruses have their"/>
   <result pre="syndrome coronavirus (SARS-CoV) and 50% related to Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV). The latter two coronaviruses have their immediate"/>
   <result pre="and gastrointestinal tract [10], [11], [12]. 3 Natural history and" exact="disease" post="progression Initial symptoms are non-specific and include fever, cough,"/>
   <result pre="one week after symptom onset, and some progress to develop" exact="acute" post="respiratory distress syndrome. The median time from presentation to"/>
   <result pre="week after symptom onset, and some progress to develop acute" exact="respiratory" post="distress syndrome. The median time from presentation to mechanical"/>
   <result pre="observation LL/GMJ). Other organ dysfunctions reported in these cohorts include" exact="acute" post="kidney injury (3%) and septic shock (4–8.7%). Patients requiring"/>
   <result pre="LL/GMJ). Other organ dysfunctions reported in these cohorts include acute" exact="kidney injury" post="(3%) and septic shock (4–8.7%). Patients requiring ICU care"/>
   <result pre="reported in these cohorts include acute kidney injury (3%) and" exact="septic shock" post="(4–8.7%). Patients requiring ICU care were older and had"/>
   <result pre="who may not seek hospital care. 4 Diagnosis and treatment" exact="Infection" post="is confirmed by positive test to SARS-CoV-2 by real-time"/>
   <result pre="criteria such as those advocated by the US Centers for" exact="Disease" post="Control and Prevention (CDC) may be used (https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fclinical-criteria.html). Based"/>
   <result pre="use of high-dose corticosteroids (&amp;gt; 3 g methylprednisolone in the" exact="acute" post="phase of disease) used to modulate the immune response"/>
   <result pre="outcomes, but resulted in devastating steroid induced complications [14]. As" exact="respiratory" post="failure is the predominant complication of COVID-19, attention to"/>
   <result pre="lung protective strategies during mechanical ventilation and prevention of hospital" exact="acquired" post="infections is likely to contribute to improved outcomes in"/>
   <result pre="protective strategies during mechanical ventilation and prevention of hospital acquired" exact="infections" post="is likely to contribute to improved outcomes in critically"/>
   <result pre="to contribute to improved outcomes in critically ill patients. 5" exact="Infection" post="control Lack of clear knowledge of the mechanisms of"/>
   <result pre="mechanisms of COVID-19 transmission makes it difficult to develop evidence-based" exact="infection" post="control protocols to prevent transmission to healthcare workers (HCW)"/>
   <result pre="risk of nosocomial transmission because of potential exposure to aerosolised" exact="respiratory" post="secretions during intubation, tracheal suctioning, bronchoscopy and respiratory circuit"/>
   <result pre="to aerosolised respiratory secretions during intubation, tracheal suctioning, bronchoscopy and" exact="respiratory" post="circuit disconnection, as well as environmental contamination [15], [16],"/>
   <result pre="cases should ideally be isolated in a negative pressure airborne" exact="infection" post="isolation room (AIIR) with sufficient air changes (&amp;gt; 12/h)"/>
   <result pre="sanitary staff, often forgotten, should also receive appropriate PPE and" exact="infection" post="control training, particularly as there may be a risk"/>
   <result pre="[9]. If full airborne precautions are not possible due to" exact="limited" post="facilities or overwhelming numbers of cases, other measures that"/>
   <result pre="one ICU was low, despite suboptimal physical space, ventilation and" exact="complete" post="absence of AIIR facilities [22]. 6 High-risk procedures 6.1"/>
   <result pre="ICU was low, despite suboptimal physical space, ventilation and complete" exact="absence of" post="AIIR facilities [22]. 6 High-risk procedures 6.1 Use of"/>
   <result pre="[22]. 6 High-risk procedures 6.1 Use of NIV and HFNO" exact="Limited" post="data suggests that the use of high-flow nasal oxygen"/>
   <result pre="high-flow nasal oxygen (HFNO) may prevent intubation in severe hypoxemic" exact="respiratory" post="failure [23]. Within the ICU, and with HCW protected"/>
   <result pre="meta-analysis demonstrated that there may be an increased risk of" exact="viral" post="transmission to HCW who treated patients receiving NIV [18]."/>
   <result pre="unclear and mortality benefit of HFNO and NIV in severe" exact="pneumonia" post="is unproven, we do not currently recommend their use"/>
   <result pre="closely monitored in ICU or high care areas, and airborne" exact="respiratory" post="precautions strictly adhered to. 6.2 Intubation The timing and"/>
   <result pre="on a case-by-case basis. The threshold for intubation may be" exact="lower" post="in COVID-19 since use of high-flow nasal oxygen (HFNO)"/>
   <result pre="may potentially increase the risk of transmission to HCW [18]." exact="Disease" post="transmission risk of viral respiratory infections during intubation has"/>
   <result pre="risk of transmission to HCW [18]. Disease transmission risk of" exact="viral" post="respiratory infections during intubation has been shown to be"/>
   <result pre="of transmission to HCW [18]. Disease transmission risk of viral" exact="respiratory" post="infections during intubation has been shown to be high"/>
   <result pre="transmission to HCW [18]. Disease transmission risk of viral respiratory" exact="infections" post="during intubation has been shown to be high [18],"/>
   <result pre="(BVM) resuscitator during manual mask ventilation may serve to reduce" exact="viral" post="particle dispersion into the atsmopshere [27]. Intubation in COVID-19"/>
   <result pre="may be preferable as BVM was previously associated with SARS-CoV" exact="nosocomial infection" post="[31]. Pre-oxygenation under these conditions using a well-sealed BVM"/>
   <result pre="be preferable as BVM was previously associated with SARS-CoV nosocomial" exact="infection" post="[31]. Pre-oxygenation under these conditions using a well-sealed BVM"/>
   <result pre="under these conditions using a well-sealed BVM with appropriately placed" exact="viral" post="filter is recommended. Directly connecting the ventilator circuit to"/>
   <result pre="their own minute ventilation, thus potentially reducing the risk of" exact="disease" post="transmission. For patients already receiving mechanical ventilation in ICU,"/>
   <result pre="mistrust during the crisis [32]. Staff morale is vulnerable and" exact="emotional" post="support should be proactively made available. Frontline staff must"/>
   <result pre="rapid and excessive expansion may overwhelm staff, lead to excess" exact="infections" post="in HCW, and compromise care [33]. Thus, expansion should"/>
   <result pre="with first-hand experience of outbreak expansion that this is realistically" exact="limited" post="to a maximum of 50-100% of baseline capacity [34]."/>
   <result pre="provisions, may allow greater expansion and more patients to have" exact="limited" post="life sustaining interventions under conditions of limited resources [35]."/>
   <result pre="patients to have limited life sustaining interventions under conditions of" exact="limited" post="resources [35]. Should these measures be overwhelmed, individual patient"/>
   <result pre="days. Anyone who develops symptoms that could suggest a coronavirus" exact="infection" post="are encouraged to call a single emergency number and"/>
   <result pre="by a specialised medical team equipped with PPE to prevent" exact="viral" post="contamination, and when necessary, hospitalised in an intensive care"/>
   <result pre="SARS-CoV-2 to date have not yet shown signs of severe" exact="respiratory" post="failure and some have been discharged from hospital after"/>
   <result pre="are therefore well prepared for the treatment of severe contagious" exact="viral" post="infections. 9 Conclusion Should community outbreaks occur globally, the"/>
   <result pre="occur globally, the management of critically ill patients with COVID-19" exact="infection" post="will be challenging. The lack of specific treatment is"/>
   <result pre="patients infected with 2019 novel coronavirus in Wuhan, ChinaLancet39510223202049750631986264 2ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
   <result pre="2019 novel coronavirus in Wuhan, ChinaLancet39510223202049750631986264 2ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
   <result pre="virus origins and receptor bindingLancet39510224202056557432007145 4LiW.WongS.K.LiF.KuhnJ.H.HuangI.C.ChoeH.Animal origins of the severe" exact="acute" post="respiratory syndrome coronavirus: insight from ACE2-S-protein interactionsJ Virol80920064211421916611880 5El-KafrawyS.A.CormanV.M.TolahA.M.Al"/>
   <result pre="origins and receptor bindingLancet39510224202056557432007145 4LiW.WongS.K.LiF.KuhnJ.H.HuangI.C.ChoeH.Animal origins of the severe acute" exact="respiratory" post="syndrome coronavirus: insight from ACE2-S-protein interactionsJ Virol80920064211421916611880 5El-KafrawyS.A.CormanV.M.TolahA.M.Al MasaudiS.B.HassanA.M.MullerM.A.Enzootic"/>
   <result pre="and receptor bindingLancet39510224202056557432007145 4LiW.WongS.K.LiF.KuhnJ.H.HuangI.C.ChoeH.Animal origins of the severe acute respiratory" exact="syndrome" post="coronavirus: insight from ACE2-S-protein interactionsJ Virol80920064211421916611880 5El-KafrawyS.A.CormanV.M.TolahA.M.Al MasaudiS.B.HassanA.M.MullerM.A.Enzootic patterns"/>
   <result pre="from ACE2-S-protein interactionsJ Virol80920064211421916611880 5El-KafrawyS.A.CormanV.M.TolahA.M.Al MasaudiS.B.HassanA.M.MullerM.A.Enzootic patterns of Middle East" exact="respiratory" post="syndrome coronavirus in imported African and local Arabian dromedary"/>
   <result pre="ACE2-S-protein interactionsJ Virol80920064211421916611880 5El-KafrawyS.A.CormanV.M.TolahA.M.Al MasaudiS.B.HassanA.M.MullerM.A.Enzootic patterns of Middle East respiratory" exact="syndrome" post="coronavirus in imported African and local Arabian dromedary camels:"/>
   <result pre="MasaudiS.B.HassanA.M.MullerM.A.Enzootic patterns of Middle East respiratory syndrome coronavirus in imported" exact="African" post="and local Arabian dromedary camels: a prospective genomic studyLancet"/>
   <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet39510223202050751332007143 7PhanL.T.NguyenT.V.LuongQ.C.NguyenT.V.NguyenH.T.LeH.Q.Importation and human-to-human"/>
   <result pre="2 is a functional receptor for the SARS coronavirusNature4266965200345045414647384 11ZhouP.YangX.L.WangX.G.HuB.ZhangL.ZhangW.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
   <result pre="13WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA202010.1001/jama.2020.1585 14GriffithJ.F.AntonioG.E.KumtaS.M.HuiD.S.WongJ.K.JoyntG.M.Osteonecrosis of hip and knee in"/>
   <result pre="ChinaJAMA202010.1001/jama.2020.1585 14GriffithJ.F.AntonioG.E.KumtaS.M.HuiD.S.WongJ.K.JoyntG.M.Osteonecrosis of hip and knee in patients with severe" exact="acute" post="respiratory syndrome treated with steroidsRadiology2351200516817515703312 15TelemanM.D.BoudvilleI.C.HengB.H.ZhuD.LeoY.S.Factors associated with transmission"/>
   <result pre="14GriffithJ.F.AntonioG.E.KumtaS.M.HuiD.S.WongJ.K.JoyntG.M.Osteonecrosis of hip and knee in patients with severe acute" exact="respiratory" post="syndrome treated with steroidsRadiology2351200516817515703312 15TelemanM.D.BoudvilleI.C.HengB.H.ZhuD.LeoY.S.Factors associated with transmission of"/>
   <result pre="of hip and knee in patients with severe acute respiratory" exact="syndrome" post="treated with steroidsRadiology2351200516817515703312 15TelemanM.D.BoudvilleI.C.HengB.H.ZhuD.LeoY.S.Factors associated with transmission of severe"/>
   <result pre="syndrome treated with steroidsRadiology2351200516817515703312 15TelemanM.D.BoudvilleI.C.HengB.H.ZhuD.LeoY.S.Factors associated with transmission of severe" exact="acute" post="respiratory syndrome among health-care workers in SingaporeEpidemiol Infect1325200479780315473141 16ChenW.Q.LingW.H.LuC.Y.HaoY.T.LinZ.N.LingL.Which"/>
   <result pre="treated with steroidsRadiology2351200516817515703312 15TelemanM.D.BoudvilleI.C.HengB.H.ZhuD.LeoY.S.Factors associated with transmission of severe acute" exact="respiratory" post="syndrome among health-care workers in SingaporeEpidemiol Infect1325200479780315473141 16ChenW.Q.LingW.H.LuC.Y.HaoY.T.LinZ.N.LingL.Which preventive"/>
   <result pre="with steroidsRadiology2351200516817515703312 15TelemanM.D.BoudvilleI.C.HengB.H.ZhuD.LeoY.S.Factors associated with transmission of severe acute respiratory" exact="syndrome" post="among health-care workers in SingaporeEpidemiol Infect1325200479780315473141 16ChenW.Q.LingW.H.LuC.Y.HaoY.T.LinZ.N.LingL.Which preventive measures"/>
   <result pre="care workers from SARS?BMC Public Health920098119284644 17BoothT.F.KournikakisB.BastienN.HoJ.KobasaD.StadnykL.Detection of airborne severe" exact="acute" post="respiratory syndrome (SARS) coronavirus and environmental contamination in SARS"/>
   <result pre="workers from SARS?BMC Public Health920098119284644 17BoothT.F.KournikakisB.BastienN.HoJ.KobasaD.StadnykL.Detection of airborne severe acute" exact="respiratory" post="syndrome (SARS) coronavirus and environmental contamination in SARS outbreak"/>
   <result pre="from SARS?BMC Public Health920098119284644 17BoothT.F.KournikakisB.BastienN.HoJ.KobasaD.StadnykL.Detection of airborne severe acute respiratory" exact="syndrome" post="(SARS) coronavirus and environmental contamination in SARS outbreak unitsJ"/>
   <result pre="Infect Dis191920051472147715809906 18TranK.CimonK.SevernM.Pessoa-SilvaC.L.ConlyJ.Aerosol generating procedures and risk of transmission of" exact="acute" post="respiratory infections to healthcare workers: a systematic reviewPLoS One742012e73579"/>
   <result pre="Dis191920051472147715809906 18TranK.CimonK.SevernM.Pessoa-SilvaC.L.ConlyJ.Aerosol generating procedures and risk of transmission of acute" exact="respiratory" post="infections to healthcare workers: a systematic reviewPLoS One742012e73579 19ChengV.C.ChanJ.F.ToK.K.YuenK.Y.Clinical"/>
   <result pre="18TranK.CimonK.SevernM.Pessoa-SilvaC.L.ConlyJ.Aerosol generating procedures and risk of transmission of acute respiratory" exact="infections" post="to healthcare workers: a systematic reviewPLoS One742012e73579 19ChengV.C.ChanJ.F.ToK.K.YuenK.Y.Clinical management"/>
   <result pre="to healthcare workers: a systematic reviewPLoS One742012e73579 19ChengV.C.ChanJ.F.ToK.K.YuenK.Y.Clinical management and" exact="infection" post="control of SARS: lessons learnedAntiviral Res1002201340741923994190 20JiangS.HuangL.ChenX.WangJ.WuW.YinS.Ventilation of wards"/>
   <result pre="learnedAntiviral Res1002201340741923994190 20JiangS.HuangL.ChenX.WangJ.WuW.YinS.Ventilation of wards and nosocomial outbreak of severe" exact="acute" post="respiratory syndrome among healthcare workersChin Med J (Engl)116920031293129714527351 21VariaM.WilsonS.SarwalS.McGeerA.GournisE.GalanisE.Investigation"/>
   <result pre="Res1002201340741923994190 20JiangS.HuangL.ChenX.WangJ.WuW.YinS.Ventilation of wards and nosocomial outbreak of severe acute" exact="respiratory" post="syndrome among healthcare workersChin Med J (Engl)116920031293129714527351 21VariaM.WilsonS.SarwalS.McGeerA.GournisE.GalanisE.Investigation of"/>
   <result pre="20JiangS.HuangL.ChenX.WangJ.WuW.YinS.Ventilation of wards and nosocomial outbreak of severe acute respiratory" exact="syndrome" post="among healthcare workersChin Med J (Engl)116920031293129714527351 21VariaM.WilsonS.SarwalS.McGeerA.GournisE.GalanisE.Investigation of a"/>
   <result pre="Med J (Engl)116920031293129714527351 21VariaM.WilsonS.SarwalS.McGeerA.GournisE.GalanisE.Investigation of a nosocomial outbreak of severe" exact="acute" post="respiratory syndrome (SARS) in Toronto, CanadaCMAJ1694200328529212925421 22GomersallC.D.JoyntG.M.HoO.M.IpM.YapF.DerrickJ.L.Transmission of SARS"/>
   <result pre="J (Engl)116920031293129714527351 21VariaM.WilsonS.SarwalS.McGeerA.GournisE.GalanisE.Investigation of a nosocomial outbreak of severe acute" exact="respiratory" post="syndrome (SARS) in Toronto, CanadaCMAJ1694200328529212925421 22GomersallC.D.JoyntG.M.HoO.M.IpM.YapF.DerrickJ.L.Transmission of SARS to"/>
   <result pre="(Engl)116920031293129714527351 21VariaM.WilsonS.SarwalS.McGeerA.GournisE.GalanisE.Investigation of a nosocomial outbreak of severe acute respiratory" exact="syndrome" post="(SARS) in Toronto, CanadaCMAJ1694200328529212925421 22GomersallC.D.JoyntG.M.HoO.M.IpM.YapF.DerrickJ.L.Transmission of SARS to healthcare"/>
   <result pre="23OuX.HuaY.LiuJ.GongC.ZhaoW.Effect of high-flow nasal cannula oxygen therapy in adults with" exact="acute" post="hypoxemic respiratory failure: a meta-analysis of randomized controlled trialsCMAJ18972017E260E26728246239"/>
   <result pre="high-flow nasal cannula oxygen therapy in adults with acute hypoxemic" exact="respiratory" post="failure: a meta-analysis of randomized controlled trialsCMAJ18972017E260E26728246239 24FowlerR.A.GuestC.B.LapinskyS.E.SibbaldW.J.LouieM.TangP.Transmission of"/>
   <result pre="failure: a meta-analysis of randomized controlled trialsCMAJ18972017E260E26728246239 24FowlerR.A.GuestC.B.LapinskyS.E.SibbaldW.J.LouieM.TangP.Transmission of severe" exact="acute" post="respiratory syndrome during intubation and mechanical ventilationAm J Respir"/>
   <result pre="a meta-analysis of randomized controlled trialsCMAJ18972017E260E26728246239 24FowlerR.A.GuestC.B.LapinskyS.E.SibbaldW.J.LouieM.TangP.Transmission of severe acute" exact="respiratory" post="syndrome during intubation and mechanical ventilationAm J Respir Crit"/>
   <result pre="meta-analysis of randomized controlled trialsCMAJ18972017E260E26728246239 24FowlerR.A.GuestC.B.LapinskyS.E.SibbaldW.J.LouieM.TangP.Transmission of severe acute respiratory" exact="syndrome" post="during intubation and mechanical ventilationAm J Respir Crit Care"/>
   <result pre="Crit Care Med1691120041198120214990393 25RelloJ.PerezM.RocaO.PoulakouG.SoutoJ.LabordaC.High-flow nasal therapy in adults with severe" exact="acute" post="respiratory infection: a cohort study in patients with 2009"/>
   <result pre="Care Med1691120041198120214990393 25RelloJ.PerezM.RocaO.PoulakouG.SoutoJ.LabordaC.High-flow nasal therapy in adults with severe acute" exact="respiratory" post="infection: a cohort study in patients with 2009 influenza"/>
   <result pre="an airborne epidemicClin Chest Med2922008323328vii18440440 30LewisS.R.ButlerA.R.ParkerJ.CookT.M.SmithA.F.Videolaryngoscopy versus direct laryngoscopy for" exact="adult" post="patients requiring tracheal intubationCochrane Database Syst Rev112016CD01113627844477 31ChristianM.D.LoutfyM.McDonaldL.C.MartinezK.F.OfnerM.WongT.Possible SARS"/>
   <result pre="the Select Committee to inquire into the handling of the" exact="Severe" post="Acute Respiratory Syndrome outbreak by the Government and the"/>
   <result pre="Select Committee to inquire into the handling of the Severe" exact="Acute" post="Respiratory Syndrome outbreak by the Government and the Hospital"/>
   <result pre="Committee to inquire into the handling of the Severe Acute" exact="Respiratory" post="Syndrome outbreak by the Government and the Hospital Authority"/>
   <result pre="to inquire into the handling of the Severe Acute Respiratory" exact="Syndrome" post="outbreak by the Government and the Hospital Authority July"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7120695/results/search/disease/results.xml">
   <result pre="Virology Protocols978-1-60761-816-4978-1-60761-817-1 pmcid: 712069523 doi: 10.1007/978-1-60761-817-1_23 : Article Modelling Emerging" exact="Viral" post="Epidemics for Public Health Protection StephensonJohn R.0207 759 27640207"/>
   <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
   <result pre="as a global pandemic. Abstract Mathematical models when applied to" exact="infectious disease" post="data can provide extremely useful insights into the possible"/>
   <result pre="a global pandemic. Abstract Mathematical models when applied to infectious" exact="disease" post="data can provide extremely useful insights into the possible"/>
   <result pre="those that might be less familiar with them. Key words" exact="Epidemic" post="modelling Emerging infectious diseases Epidemiology Transmission Pandemics Deliberate release"/>
   <result pre="be less familiar with them. Key words Epidemic modelling Emerging" exact="infectious diseases" post="Epidemiology Transmission Pandemics Deliberate release Policy and planning Preparedness"/>
   <result pre="control Public health interventions Isolation/quarantine Vaccination Real-time modelling Background to" exact="Epidemic" post="Modelling The application of mathematics within the sciences has"/>
   <result pre="of mathematical modelling in the context of public health and" exact="infectious diseases," post="with early investigations exemplified by Bernoulli (1) (in relation"/>
   <result pre="with early investigations exemplified by Bernoulli (1) (in relation to" exact="smallpox" post="inoculation), Ross (2) (in relation to malaria transmission), and"/>
   <result pre="(in relation to smallpox inoculation), Ross (2) (in relation to" exact="malaria" post="transmission), and Kermack and McKendrick (3) (in relation to"/>
   <result pre="more familiar areas, mathematical investigations have often been related to" exact="childhood" post="vaccination programmes and combating sexually transmitted infections (4, 5)."/>
   <result pre="been related to childhood vaccination programmes and combating sexually transmitted" exact="infections" post="(4, 5). For the sake of brevity, the extensive"/>
   <result pre="ahead of time for potentially high impact outbreaks of emerging" exact="infectious diseases" post="(for which we have little current or certain knowledge)"/>
   <result pre="these latter areas of application to contingency planning for emerging" exact="infections" post="that this chapter will mainly focus. This chapter is"/>
   <result pre="use mathematical models. Rather, it is intended to provide a" exact="short" post="introduction and pragmatic overview to assist the familiarisation of"/>
   <result pre="not only the mathematics, but also, for example, the epidemiology," exact="disease" post="and public health expertise. It is also often beneficial"/>
   <result pre="assessment, and probably most well developed and articulated in the" exact="infectious diseases" post="field for food-borne infection risk assessments, as per relevant"/>
   <result pre="developed and articulated in the infectious diseases field for food-borne" exact="infection" post="risk assessments, as per relevant guidelines of the World"/>
   <result pre="of the complex biological and epidemiological systems that underlie emerging" exact="infectious disease" post="threats and thus enabling better prospects for their control."/>
   <result pre="the complex biological and epidemiological systems that underlie emerging infectious" exact="disease" post="threats and thus enabling better prospects for their control."/>
   <result pre="degree to which the model is able to be generalised." exact="Complex" post="models can also pose other challenges in terms of"/>
   <result pre="likely to have features that are specific to a particular" exact="disease" post="and set of circumstances, several of which may not"/>
   <result pre="enormously complex model that contains all possibilities in terms of" exact="disease" post="natural history (i.e. all the factors that impact on"/>
   <result pre="all the factors that impact on the progression of the" exact="disease" post="both within individuals and populations, such as incubation period,"/>
   <result pre="disease both within individuals and populations, such as incubation period," exact="viral" post="titres in body fluids, infectivity, etc.), public health interventions,"/>
   <result pre="given what little might be known about a particular emerging" exact="infectious disease" post="problem. A more reasonable approach is to have a"/>
   <result pre="what little might be known about a particular emerging infectious" exact="disease" post="problem. A more reasonable approach is to have a"/>
   <result pre="one cannot generally deliberately infect individuals or communities). Introduction to" exact="Simple" post="Models and Their Uses in Epidemiology At one end"/>
   <result pre="takes. For example, the fitting of a normal, lognormal, or" exact="Gamma" post="probability distribution (i.e. ones that have defined parameters such"/>
   <result pre="describe the observed lengths of, for example, the incubation or" exact="symptomatic" post="periods of infectious diseases, particularly when these have been"/>
   <result pre="lengths of, for example, the incubation or symptomatic periods of" exact="infectious diseases," post="particularly when these have been sampled from a large"/>
   <result pre="route of infection. Incubation periods can vary enormously between different" exact="infectious" post="agents both in terms of average incubation period and"/>
   <result pre="mean (and variances) for influenza, SARS coronavirus (SARS CoV), and" exact="smallpox" post="have been estimated to be about 1.3 days (0.5"/>
   <result pre="dynamics (e.g. the rate and extent of spread) of particular" exact="infections" post="and the potential impact that different public health control"/>
   <result pre="= aX + b), where Y is the observed data" exact="and X" post="the (independent) variable; with a and b the slope"/>
   <result pre="parameters, respectively. A simple example concerns crude analysis of the" exact="smallpox" post="outbreaks that resulted from importations into Europe from abroad"/>
   <result pre="into Europe from abroad between 1959 and 1973, when the" exact="disease" post="had otherwise been eradicated from that continent. With these"/>
   <result pre="possible to derive a reasonable estimate of the transmissibility of" exact="smallpox" post="based on an equivalent regression model (31) (Fig. 1)."/>
   <result pre="(Fig. 1). Fig. 1. Fitting a linear regression model to" exact="infectious disease" post="data showing the strong relationship between the extent to"/>
   <result pre="1). Fig. 1. Fitting a linear regression model to infectious" exact="disease" post="data showing the strong relationship between the extent to"/>
   <result pre="data showing the strong relationship between the extent to which" exact="smallpox" post="outbreaks expanded as delays in the public health response"/>
   <result pre="in virology and bacteriology is that between the dose of" exact="infectious" post="agent received by an individual (often an experimental animal)"/>
   <result pre="individual (often an experimental animal) and their subsequent probability of" exact="infection" post="or death. Usually the probability of becoming infected increases"/>
   <result pre="trend to some extent linearised by expressing the probability of" exact="infection" post="or death as a probit transformation (33) plotted against"/>
   <result pre="useful when developing more complex models. The first is the" exact="infectious" post="dose (ID50) or lethal dose (LD50) that gives a"/>
   <result pre="in the dose of organisms administered (i.e. the slope). The" exact="infectious" post="dose (50%) varies considerably for different microorganisms and can"/>
   <result pre="order of 104 spores, whilst that for Francisella tularensis or" exact="smallpox" post="virus has been estimated to be of the order"/>
   <result pre="of 10 cells/virions or so. Moving on to more complex" exact="infectious disease" post="models, there is an extensive ecological and epidemiological modelling"/>
   <result pre="10 cells/virions or so. Moving on to more complex infectious" exact="disease" post="models, there is an extensive ecological and epidemiological modelling"/>
   <result pre="references therein). The simplest models of practical utility for emerging" exact="infectious diseases" post="are possibly best immediately understood through their schematic descriptions;"/>
   <result pre="models (4, 5). Fig. 2. Three different schematic representations of" exact="disease" post="transmission models, from more a simplistic one (a) to"/>
   <result pre="simplistic one (a) to a more complex one involving more" exact="disease" post="states (b) to one involving a range of public"/>
   <result pre="a range of public health interventions, in this case for" exact="smallpox" post="(c), (see text). To better understand these, first imagine"/>
   <result pre="(see text). To better understand these, first imagine simply a" exact="disease" post="that infects a person for 1 day only and"/>
   <result pre="(γ) gamma (the reciprocal of the number of days between" exact="infection" post="of a case and their recovery [assuming they are"/>
   <result pre="of a case and their recovery [assuming they are equally" exact="infectious" post="throughout] which may be inferred from the generation time"/>
   <result pre="epidemic data at the start of outbreaks, as in the" exact="smallpox" post="example above. However, common sense tells us that epidemics"/>
   <result pre="shared contacts in social groups). Further, in a population of" exact="limited" post="size the steadily increasing number of infectious cases would"/>
   <result pre="a population of limited size the steadily increasing number of" exact="infectious" post="cases would dictate that quite soon some will tend"/>
   <result pre="Consequently, the number of new contacts that result in new" exact="infections" post="at each generation must depend both on a contact"/>
   <result pre="meaning that proportion of the population that is (s)usceptible to" exact="infection" post="and I, that part that is (i)nfected and (i)nfectious"/>
   <result pre="this instance cases are assumed to become susceptible again after" exact="infection" post="wanes) and solved explicitly as in Eq. 3, taking"/>
   <result pre="Whilst mathematically tractable such a model is still a fairly" exact="limited" post="representation for most diseases, particularly for those diseases where"/>
   <result pre="a time period much longer than the timescale of the" exact="disease" post="or a single epidemic. If longer timescales are important"/>
   <result pre="problem under investigation (as with assessing vaccination programmes for vaccine-preventable" exact="childhood" post="diseases such as measles and mumps) then disease mortality"/>
   <result pre="with assessing vaccination programmes for vaccine-preventable childhood diseases such as" exact="measles" post="and mumps) then disease mortality has to be factored"/>
   <result pre="for vaccine-preventable childhood diseases such as measles and mumps) then" exact="disease" post="mortality has to be factored into the schema, along"/>
   <result pre="and health-care systems. Clearly, the severity of diseases such as" exact="smallpox" post="with a case fatality ratio estimated to be in"/>
   <result pre="result in rather different set of consequences compared to a" exact="disease" post="such as pandemic influenza with its usually much lower"/>
   <result pre="a disease such as pandemic influenza with its usually much" exact="lower" post="estimates for the case fatality ratio (only up to"/>
   <result pre="in the main wave of the 1918/9 pandemic and much" exact="lower" post="in the 1957 and 1968 ones). Such simple SIR"/>
   <result pre="also dependent on that part of the population that is" exact="infectious" post="being able to transmit infection (dotted line, Fig. 2a)"/>
   <result pre="of the population that is infectious being able to transmit" exact="infection" post="(dotted line, Fig. 2a) to that part that is"/>
   <result pre="simplest understanding of this parameter is the average number of" exact="secondary" post="cases caused by each primary case within an entirely"/>
   <result pre="is the average number of secondary cases caused by each" exact="primary" post="case within an entirely susceptible population (and in the"/>
   <result pre="primary case within an entirely susceptible population (and in the" exact="absence of" post="public health interventions). The effective reproductive ratio, RE (Eq."/>
   <result pre="hand, has a similar description except that the level of" exact="susceptibility to" post="infection within the population and the effects of public"/>
   <result pre="a similar description except that the level of susceptibility to" exact="infection" post="within the population and the effects of public health"/>
   <result pre="RE changes over time as the relative proportions of the" exact="infectious" post="and susceptible population change over the course of the"/>
   <result pre="that defines the stability of the system (i.e. whether the" exact="disease" post="is likely to become a major public health problem"/>
   <result pre="it is greater than 1, the introduction of cases of" exact="disease" post="into a population will likely cause an epidemic, whereas"/>
   <result pre="size) that might need to be immunised to control an" exact="infection" post="(V, i.e. that proportion that is required to bring"/>
   <result pre="one may derive (4), the likely final size of an" exact="uncontrolled" post="epidemic in a closed population (Eq. 8, Fig. 4),"/>
   <result pre="size. Fig. 4. The simplistic dependence of two basic epidemic" exact="disease" post="features on the fundamental disease parameter R0. 7 \documentclass[12pt]{minimal}"/>
   <result pre="dependence of two basic epidemic disease features on the fundamental" exact="disease" post="parameter R0. 7 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy}"/>
   <result pre="final attack size or R0. Therefore, for diseases such as" exact="smallpox" post="(R0 in the range 3–6), SARS CoV (R0 about"/>
   <result pre="in the range 3–6), SARS CoV (R0 about 3–4) and" exact="measles" post="(with one of the highest estimated R0’s for an"/>
   <result pre="measles (with one of the highest estimated R0’s for an" exact="infectious disease," post="variously reported to be in the range 12 to"/>
   <result pre="such as overcrowding and socio-economic conditions. Even for diseases with" exact="lower" post="R0 such as pandemic influenza, assessments are actually made"/>
   <result pre="and others may well become infected and to some degree" exact="infectious" post="whilst remaining asymptomatic. These individuals do not therefore get"/>
   <result pre="actually develop reportable clinical symptoms, whilst by comparison cases of" exact="smallpox" post="and SARS CoV are rarely, if ever considered, to"/>
   <result pre="immune or susceptible at the point of introduction of the" exact="infectious" post="agent) and we also require a so-called equation of"/>
   <result pre="+ R = 1. Typically, for a new or emerging" exact="infectious disease" post="initial conditions are given such that no people are"/>
   <result pre="R = 1. Typically, for a new or emerging infectious" exact="disease" post="initial conditions are given such that no people are"/>
   <result pre="Runge-Kutta, etc.) can be found elsewhere (35). Some Problems with" exact="Simple" post="Models The mathematical formulation of the SIR schema, based"/>
   <result pre="end of epidemics. For example, although the average number of" exact="secondary" post="cases caused by each primary case (i.e. R0) might"/>
   <result pre="although the average number of secondary cases caused by each" exact="primary" post="case (i.e. R0) might be observed to be around"/>
   <result pre="1 and 3 for diseases such as pandemic influenza, pneumonic" exact="plague" post="or SARS CoV, a one off introduction of a"/>
   <result pre="CoV, a one off introduction of a single case of" exact="disease" post="into a population would have a much greater chance"/>
   <result pre="of one imported case causing at least one further infection." exact="Diseases" post="with low R0 therefore have a greater chance of"/>
   <result pre="later, whilst there might be some concept of an average" exact="infectious" post="period (i.e. length of time in I), the duration"/>
   <result pre="(i.e. length of time in I), the duration of such" exact="disease" post="states will also vary between cases. Individual-level variability in"/>
   <result pre="also vary between cases. Individual-level variability in features such as" exact="infectious" post="and/or incubation period has already been discussed previously and"/>
   <result pre="often be best captured by modelling them with lognormal or" exact="Gamma" post="distributions. Differential equation-based models can be formulated within stochastic"/>
   <result pre="the computational cost of such models. Introducing Better Descriptions of" exact="Disease" post="Natural History: Non-uniform Infectiousness It may be sufficient for"/>
   <result pre="that case; whilst the former is the time between the" exact="infection" post="of a primary case and the infection of each"/>
   <result pre="the former is the time between the infection of a" exact="primary" post="case and the infection of each of its secondary"/>
   <result pre="time between the infection of a primary case and the" exact="infection" post="of each of its secondary cases (36, 37). In"/>
   <result pre="a primary case and the infection of each of its" exact="secondary" post="cases (36, 37). In the models discussed so far"/>
   <result pre="whilst at the same time naively assuming people are equally" exact="infectious" post="throughout this period. This relatively unrealistic assumption of uniform"/>
   <result pre="time can, however, be solved reasonably well by introducing more" exact="infectious" post="compartments into the model schema, each of which can"/>
   <result pre="the first 24 h following symptom onset that is more" exact="infectious" post="with individuals then passing into subsequent I2, I3, etc."/>
   <result pre="decline somewhat more slowly (19, 38). Introducing Better Descriptions of" exact="Disease" post="Stages The simple SIR model structure (Fig. 2a), whether"/>
   <result pre="individuals do not necessarily progress from being susceptible to being" exact="infectious" post="(and symptomatic) without some intervening latent period. Accepting this"/>
   <result pre="(Fig. 2b), it might be important to consider five separate" exact="disease" post="classes and extend the differential equation set accordingly (34);"/>
   <result pre="are many ways in which the following aspects of the" exact="disease" post="natural history might be reasonably represented with fewer or"/>
   <result pre="discussed above (5). Thus, there could be a period between" exact="infection" post="and the first non-specific symptoms (often referred to as"/>
   <result pre="for diseases such as smallpox, which have both prodromal and" exact="infectious" post="periods, since in the case of smallpox both are"/>
   <result pre="both prodromal and infectious periods, since in the case of" exact="smallpox" post="both are infectious (signified by the two dotted lines"/>
   <result pre="infectious periods, since in the case of smallpox both are" exact="infectious" post="(signified by the two dotted lines in the Fig."/>
   <result pre="the former, according to our knowledge and analysis of previous" exact="smallpox" post="outbreaks (30, 40). Some Problems with Data and the"/>
   <result pre="(30, 40). Some Problems with Data and the Parameterisation of" exact="Disease" post="Natural History The specific timings of events at an"/>
   <result pre="can be highly critical, especially the relative infectiousness through the" exact="infectious" post="period, which is rarely, if ever, uniform. This can"/>
   <result pre="impact on the control of the onward spread of an" exact="infection" post="than if applied later. In which case it is"/>
   <result pre="it is important to better understand and appropriately capture the" exact="disease" post="natural history in models (Figs. 5 and 6). Thus,"/>
   <result pre="are to have much impact on the onward transmission of" exact="disease" post="(through minimising viral replication and viral loads in the"/>
   <result pre="much impact on the onward transmission of disease (through minimising" exact="viral" post="replication and viral loads in the secretions, as opposed"/>
   <result pre="the onward transmission of disease (through minimising viral replication and" exact="viral" post="loads in the secretions, as opposed to simply ameliorating"/>
   <result pre="the secretions, as opposed to simply ameliorating the course of" exact="infection" post="and reducing the probability of hospitalisation and death (41)"/>
   <result pre="challenging) 12–24 h of symptom onset because of the extremely" exact="short" post="infectious period of influenza and the rapid rise and"/>
   <result pre="12–24 h of symptom onset because of the extremely short" exact="infectious" post="period of influenza and the rapid rise and fall"/>
   <result pre="period of influenza and the rapid rise and fall of" exact="viral" post="titres and infectiousness (19, 22). Whilst serial interval times"/>
   <result pre="often more easily observed than some other intervals in the" exact="disease" post="process, they are in themselves convolutions of the other"/>
   <result pre="there is usually a period between the initial acquiring of" exact="infection" post="by a case to the onset of symptoms (incubation"/>
   <result pre="be coterminous periods and will vary between persons and the" exact="disease" post="(Fig. 5). This distinction between incubation and latent period"/>
   <result pre="latent period can be extremely important since diseases that become" exact="infectious" post="before the onset of symptoms can make them much"/>
   <result pre="contacts. Thus, diseases that can be asymptomatic at points during" exact="infection" post="or relatively mild overall, or chronic or recurring such"/>
   <result pre="be asymptomatic at points during infection or relatively mild overall," exact="or chronic" post="or recurring such as influenza, HIV, or tuberculosis can"/>
   <result pre="asymptomatic at points during infection or relatively mild overall, or" exact="chronic" post="or recurring such as influenza, HIV, or tuberculosis can"/>
   <result pre="overall, or chronic or recurring such as influenza, HIV, or" exact="tuberculosis" post="can theoretically be much harder to control by these"/>
   <result pre="by these means than diseases such as SARS CoV or" exact="smallpox" post="(18). In this respect, the eradication of SARS CoV"/>
   <result pre="other things, the fact that cases were generally not significantly" exact="infectious" post="before showing symptoms and had a reasonably long incubation"/>
   <result pre="before showing symptoms and had a reasonably long incubation and" exact="infectious" post="periods. Incubation/latent periods can often be followed by other"/>
   <result pre="followed by other defined periods that are relevant to the" exact="disease" post="natural history, including: a symptomatic period, during some part"/>
   <result pre="that are relevant to the disease natural history, including: a" exact="symptomatic" post="period, during some part of which cases are usually"/>
   <result pre="during some part of which cases are usually their most" exact="infectious" post="(infectious period) – though, infectiousness is likely to vary"/>
   <result pre="to a peak and tailing off more gradually. For some" exact="infections" post="there may also be a prodromal period (involving non-specific"/>
   <result pre="infections there may also be a prodromal period (involving non-specific" exact="disease" post="symptoms) between the incubation and symptomatic periods that might"/>
   <result pre="prodromal period (involving non-specific disease symptoms) between the incubation and" exact="symptomatic" post="periods that might also be infectious (Fig. 5). Fig."/>
   <result pre="between the incubation and symptomatic periods that might also be" exact="infectious" post="(Fig. 5). Fig. 5. Timelines of infection for two"/>
   <result pre="might also be infectious (Fig. 5). Fig. 5. Timelines of" exact="infection" post="for two different viral diseases, given roughly to scale."/>
   <result pre="(Fig. 5). Fig. 5. Timelines of infection for two different" exact="viral" post="diseases, given roughly to scale. Fig. 6. Two different"/>
   <result pre="that models sometimes use for representing the duration of the" exact="infectious" post="period, one exponential (dashed line) the other lognormal (solid"/>
   <result pre="example, the serial interval are the incubation period of a" exact="secondary" post="case and some part of the infectious period of"/>
   <result pre="period of a secondary case and some part of the" exact="infectious" post="period of the primary case. The latter being the"/>
   <result pre="case and some part of the infectious period of the" exact="primary" post="case. The latter being the time until a relevant"/>
   <result pre="problematic. For example, quite often the point in time when" exact="infection" post="occurs (necessary for the estimation of generation interval and"/>
   <result pre="time. Even then the precision of such observations is often" exact="limited" post="to being differentiated to the nearest whole day. This"/>
   <result pre="relatively long time in the course of influenza compared to" exact="smallpox" post="(Fig. 5). Depending on the natural history of the"/>
   <result pre="history of the disease, and possibly the prevalence of the" exact="disease" post="in the rest of the community, such observations can"/>
   <result pre="can be more or less feasible. For diseases such as" exact="smallpox" post="or SARS CoV that possibly have a better marked"/>
   <result pre="define the timing of contacts with cases in relation to" exact="disease" post="symptoms, as long as the disease is not so"/>
   <result pre="cases in relation to disease symptoms, as long as the" exact="disease" post="is not so prevalent in the rest of the"/>
   <result pre="case that was responsible for them. Smallpox was also a" exact="disease" post="for which contact tracing and quarantine was an important"/>
   <result pre="relation to their symptoms, and especially when the number of" exact="infections" post="more widely in the community might also be quite"/>
   <result pre="(such as for influenza) so as to potentially &quot;mask&quot; unique" exact="infection" post="events. This problem can sometimes be overcome to some"/>
   <result pre="defined contexts, such as households where the time between subsequent" exact="infections" post="can be more easily inferred (11), or volunteer challenge"/>
   <result pre="(11), or volunteer challenge studies (38) where the time of" exact="infection" post="is known. Further Improvement of Descriptions of Disease Natural"/>
   <result pre="time of infection is known. Further Improvement of Descriptions of" exact="Disease" post="Natural History: Non-exponential Disease Periods The differential equation sets"/>
   <result pre="known. Further Improvement of Descriptions of Disease Natural History: Non-exponential" exact="Disease" post="Periods The differential equation sets described above also hold"/>
   <result pre="of the residence times for the exponential will be unrealistically" exact="short" post="(left hand end of distribution – dashed), and another"/>
   <result pre="distribution for residence time, will overall combine to approximate a" exact="Gamma" post="distribution (more like that in Fig. 6, solid line)"/>
   <result pre="or, as with the residence times in each of the" exact="disease" post="classes mentioned above, as a more realistic distribution based"/>
   <result pre="in Fig. 7, which relates to observational data on pneumonic" exact="plague" post="(31), which is transmissible person to person at relatively"/>
   <result pre="= p(1 − p)x, where x is the number of" exact="secondary" post="cases per primary case, f(x) is the frequency, and"/>
   <result pre="p)x, where x is the number of secondary cases per" exact="primary" post="case, f(x) is the frequency, and p = 0.43"/>
   <result pre="infected case, and a greater probability of 4 or more" exact="secondary" post="cases occurring from a primary case. Fig. 7. Offspring"/>
   <result pre="probability of 4 or more secondary cases occurring from a" exact="primary" post="case. Fig. 7. Offspring distribution for pneumonic plague. Data"/>
   <result pre="4, the higher the estimate of R0 for a particular" exact="infectious disease" post="the higher the proportion of the population that needs"/>
   <result pre="the higher the estimate of R0 for a particular infectious" exact="disease" post="the higher the proportion of the population that needs"/>
   <result pre="little as around 37% of the population (43), but for" exact="smallpox" post="with an R0 value in the range of 3–6"/>
   <result pre="often being higher if transmission is promoted by overcrowding and" exact="lower" post="socio-economic conditions. A similar approach could also be simplistically"/>
   <result pre="2c shows an extension of the earlier SEPIR structure for" exact="smallpox" post="to allow for a whole range of public health"/>
   <result pre="This might be based on previously recorded experiences with the" exact="disease" post="or with a disease of similar natural history. For"/>
   <result pre="on previously recorded experiences with the disease or with a" exact="disease" post="of similar natural history. For diseases such as smallpox,"/>
   <result pre="For diseases such as smallpox, pneumonic plague, SARS CoV, and" exact="bacterial meningitis," post="for example, the finding of potentially infected contacts can"/>
   <result pre="who have had sufficient contact with a case to facilitate" exact="disease" post="transmission. Those predominantly getting infected tending to be those"/>
   <result pre="facilities (see later for a discussion of transmission of pneumonic" exact="plague" post="in different settings and contexts). Alternatively, or more likely"/>
   <result pre="to public health controls, as well as those related to" exact="disease" post="natural history, would be systematically varied within ranges considered"/>
   <result pre="analysis was performed [e.g. as in the case of the" exact="smallpox" post="studies referred to earlier (20, 23)]. Introducing Better Descriptions"/>
   <result pre="an extent on aspects of the natural history of the" exact="disease" post="(e.g. the mode of transmission and the degree of"/>
   <result pre="required; the severity of illness and the degree to which" exact="infectious" post="individuals continue to be able to mix). With caveats,"/>
   <result pre="matrices can be estimated by attempting to fit models to" exact="infectious disease" post="data where this has been stratified by age group"/>
   <result pre="can be estimated by attempting to fit models to infectious" exact="disease" post="data where this has been stratified by age group"/>
   <result pre="developing a better understanding of the dynamics of, for example," exact="childhood" post="vaccine-preventable diseases and informing on optimal vaccination strategies. The"/>
   <result pre="strategies. The derivation and use of such WAIFW (who acquires" exact="infection" post="from whom) and similar matrices is beyond the scope"/>
   <result pre="age group. This potential disproportionate mixing and potential transmission of" exact="disease" post="can have important consequences which are often important to"/>
   <result pre="For example, the initial rise in cases during an emerging" exact="uncontrolled" post="epidemic might be seen first as a rise in"/>
   <result pre="try to limit the disproportionate contribution of children to overall" exact="disease" post="transmission. For pandemic influenza it is thought such effects"/>
   <result pre="do seem to be particularly implicated in transmission (47–49). For" exact="smallpox" post="and SARS CoV on the other hand this is"/>
   <result pre="hand this is much less certain. In the case of" exact="smallpox" post="it would seem from the limited historical observations available"/>
   <result pre="In the case of smallpox it would seem from the" exact="limited" post="historical observations available on populations that had not experienced"/>
   <result pre="limited historical observations available on populations that had not experienced" exact="smallpox" post="for some considerable time (and so no older members"/>
   <result pre="Socially Structured Models Depending on what is known about the" exact="disease" post="and the purpose of a model, the extent or"/>
   <result pre="purpose of a model, the extent or facility with which" exact="disease" post="transmission might occur might also be usefully characterised and"/>
   <result pre="here more simply in terms of metapopulation models. Taking pneumonic" exact="plague" post="again as an example it is clear from historical"/>
   <result pre="Fig. 9. The contexts in which the transmission of pneumonic" exact="plague" post="was observed to occur. The most frequent context for"/>
   <result pre="itself probably accounts for the fact that outbreaks of pneumonic" exact="plague" post="(with a low overall reproductive potential) were readily brought"/>
   <result pre="overall reproductive potential) were readily brought under control since the" exact="infectious" post="contacts of cases were relatively easily identified and quarantined"/>
   <result pre="a significant proportion of all transmission (about 50%) before the" exact="disease" post="was correctly identified and subjected to appropriate local infection"/>
   <result pre="the disease was correctly identified and subjected to appropriate local" exact="infection" post="controls (15, 30). Such contexts as described above clearly"/>
   <result pre="the connections (dotted lines in the figure) and probabilities of" exact="infection" post="between geographic units parameterised by the extent to which"/>
   <result pre="in some geographic region based on there being cases of" exact="disease" post="in that region (23). The concept of transmission between"/>
   <result pre="complexity can be constructed to tackle problems related to (re-)emerging" exact="infectious disease" post="problems and their control. Before embarking on model development"/>
   <result pre="can be constructed to tackle problems related to (re-)emerging infectious" exact="disease" post="problems and their control. Before embarking on model development"/>
   <result pre="measured or indeed can never be measured (e.g. time of" exact="infection" post="for some diseases). Reasonable assumptions about such parameters can"/>
   <result pre="Only in this way can an outbreak of an emerging" exact="infectious disease" post="really be better understood at the time when the"/>
   <result pre="in this way can an outbreak of an emerging infectious" exact="disease" post="really be better understood at the time when the"/>
   <result pre="attempt at a new analysis of the mortality caused by" exact="smallpox" post="and of the advantages of inoculation to prevent it."/>
   <result pre="the mathematical theory of epidemicsProc R Soc Lond A192711570072110.1098/rspa.1927.0118 4AndersonRMMayRMInfectious" exact="Diseases" post="of Humans: Dynamics and Control1991OxfordOxford University Press 5KeelingMJRohaniPModeling Infectious"/>
   <result pre="4AndersonRMMayRMInfectious Diseases of Humans: Dynamics and Control1991OxfordOxford University Press 5KeelingMJRohaniPModeling" exact="Infectious" post="Diseases in Humans and Animals2008PrincetonPrinceton University Press 6BaileyNTJThe Mathematical"/>
   <result pre="Diseases of Humans: Dynamics and Control1991OxfordOxford University Press 5KeelingMJRohaniPModeling Infectious" exact="Diseases" post="in Humans and Animals2008PrincetonPrinceton University Press 6BaileyNTJThe Mathematical Theory"/>
   <result pre="in Humans and Animals2008PrincetonPrinceton University Press 6BaileyNTJThe Mathematical Theory of" exact="Infectious" post="Diseases and Its Applications1975LondonCharles Griffin and Company 7GrenfellBTDobsonAPEcology of"/>
   <result pre="Humans and Animals2008PrincetonPrinceton University Press 6BaileyNTJThe Mathematical Theory of Infectious" exact="Diseases" post="and Its Applications1975LondonCharles Griffin and Company 7GrenfellBTDobsonAPEcology of Infectious"/>
   <result pre="Infectious Diseases and Its Applications1975LondonCharles Griffin and Company 7GrenfellBTDobsonAPEcology of" exact="Infectious" post="Diseases in Natural Populations1995CambridgeCambridge University Press 8DaleyDJGaniJEpidemic Modelling1999CambridgeCambridge University"/>
   <result pre="Diseases and Its Applications1975LondonCharles Griffin and Company 7GrenfellBTDobsonAPEcology of Infectious" exact="Diseases" post="in Natural Populations1995CambridgeCambridge University Press 8DaleyDJGaniJEpidemic Modelling1999CambridgeCambridge University Press"/>
   <result pre="Populations1995CambridgeCambridge University Press 8DaleyDJGaniJEpidemic Modelling1999CambridgeCambridge University Press 9HethcoteHThe mathematics of" exact="infectious" post="diseasesSIAM Rev20004259965310.1137/S0036144500371907 10GrasslyNCFraserCMathematical models of infectious disease transmissionNat Rev"/>
   <result pre="Press 9HethcoteHThe mathematics of infectious diseasesSIAM Rev20004259965310.1137/S0036144500371907 10GrasslyNCFraserCMathematical models of" exact="infectious disease" post="transmissionNat Rev Microbiol2008647748718533288 11CauchemezSCarratFViboudCValleronAJBoëllePYA Bayesian MCMC approach to study"/>
   <result pre="9HethcoteHThe mathematics of infectious diseasesSIAM Rev20004259965310.1137/S0036144500371907 10GrasslyNCFraserCMathematical models of infectious" exact="disease" post="transmissionNat Rev Microbiol2008647748718533288 11CauchemezSCarratFViboudCValleronAJBoëllePYA Bayesian MCMC approach to study"/>
   <result pre="Report. Now-Casting and Short-Term Forecasting During Influenza Pandemics: A Focused" exact="Developmental" post="ECDC Workshop, Stockholm, 29–30 November 2007. ECDC, Stockholm. At"/>
   <result pre="reproduction numbers in an emerging epidemicPLoS ONE20072e75810.1371/journal.pone.000075817712406 15GaniRLeachSTransmission potential of" exact="smallpox" post="in contemporary populationsNature200141474875110.1038/414748a11742399 16FergusonNMKeelingMJEdmundsWJGaniRGrenfellBTAndersonRMLeachSPlanning for smallpox outbreaksNature200342568168510.1038/nature0200714562094 17RileySFraserCDonnellyCAGhaniACAbu-RaddadLJHedleyAJLeungGMHoLMLamTHThachTQChauPChanKPLoSVLeungPYTsangTHoWLeeKHLauEMFergusonNMAndersonRMTransmission dynamics"/>
   <result pre="ONE20072e75810.1371/journal.pone.000075817712406 15GaniRLeachSTransmission potential of smallpox in contemporary populationsNature200141474875110.1038/414748a11742399 16FergusonNMKeelingMJEdmundsWJGaniRGrenfellBTAndersonRMLeachSPlanning for" exact="smallpox" post="outbreaksNature200342568168510.1038/nature0200714562094 17RileySFraserCDonnellyCAGhaniACAbu-RaddadLJHedleyAJLeungGMHoLMLamTHThachTQChauPChanKPLoSVLeungPYTsangTHoWLeeKHLauEMFergusonNMAndersonRMTransmission dynamics of the etiological agent of SARS"/>
   <result pre="Kong: impact of public health interventionsScience20033001961196610.1126/science.108647812766206 18FraserCRileySAndersonRMFergusonNMFactors that make an" exact="infectious disease" post="outbreak controllableProc Natl Acad Sci USA20041016146615110.1073/pnas.030750610115071187 19FergusonNMCummingsDACauchemezSFraserCRileySMeeyaiAIamsirithawornSBurkeDSStrategies for containing"/>
   <result pre="impact of public health interventionsScience20033001961196610.1126/science.108647812766206 18FraserCRileySAndersonRMFergusonNMFactors that make an infectious" exact="disease" post="outbreak controllableProc Natl Acad Sci USA20041016146615110.1073/pnas.030750610115071187 19FergusonNMCummingsDACauchemezSFraserCRileySMeeyaiAIamsirithawornSBurkeDSStrategies for containing"/>
   <result pre="Infect Dis20061211011310.3201/eid1201.05059316494726 22FergusonNMCummingsDAFraserCCajkaJCCooleyPCBurkeDSStrategies for mitigating an influenza pandemicNature200644244845210.1038/nature0479516642006 23HallIMEganJRBarrassIGaniRLeachSComparison of" exact="smallpox" post="outbreak control strategies using a spatial metapopulation modelEpidemiol Infect20071351133114417222358"/>
   <result pre="metapopulation modelEpidemiol Infect20071351133114417222358 24PitzerVELeungGMLipsitchMEstimating variability in the transmission of severe" exact="acute" post="respiratory syndrome to household contacts in Hong Kong, ChinaAm"/>
   <result pre="modelEpidemiol Infect20071351133114417222358 24PitzerVELeungGMLipsitchMEstimating variability in the transmission of severe acute" exact="respiratory" post="syndrome to household contacts in Hong Kong, ChinaAm J"/>
   <result pre="Infect20071351133114417222358 24PitzerVELeungGMLipsitchMEstimating variability in the transmission of severe acute respiratory" exact="syndrome" post="to household contacts in Hong Kong, ChinaAm J Epidemiol200716635536310.1093/aje/kwm08217493952"/>
   <result pre="Inc, Chicago, IL. Accessed June 21, 2009, at http://www.britannica.com/EBchecked/topic/424706/Ockhams-razor. 28StuartAOrdKKendall’s" exact="Advanced" post="Theory of Statistics, Vol. 1: Distribution Theory19946LondonHodder and Arnold"/>
   <result pre="and Its Eradication1988GenevaWorld Health Organization 31GaniRLeachSEpidemiologic determinants for modeling pneumonic" exact="plague" post="outbreaksEmerg Infect Dis20041060861410.3201/eid1004.03050915200849 32StuartAOrdKArnoldSKendall’s Advanced Theory of Statistics, Vol."/>
   <result pre="31GaniRLeachSEpidemiologic determinants for modeling pneumonic plague outbreaksEmerg Infect Dis20041060861410.3201/eid1004.03050915200849 32StuartAOrdKArnoldSKendall’s" exact="Advanced" post="Theory of Statistics, Vol. 2A: Classical Inference and the"/>
   <result pre="Advanced Theory of Statistics, Vol. 2A: Classical Inference and the" exact="Linear" post="Model19996LondonHodder and Arnold 33FinneyDJProbit Analysis19471CambridgeCambridge University Press 34HallIMGaniRHughesHELeachSReal-time epidemic"/>
   <result pre="Biosci200720830031110.1016/j.mbs.2006.10.01017174352 37WallingaJEdmundsWJKretzschmarMPerspective: human contact patterns and the spread of airborne" exact="infectious" post="diseasesTrends Microbiol1999737237710.1016/S0966-842X(99)01546-210470046 38CarratFVerguEFergusonNMLemaitreMCauchemezSLeachSValleronAJTime lines of infection and disease in"/>
   <result pre="the spread of airborne infectious diseasesTrends Microbiol1999737237710.1016/S0966-842X(99)01546-210470046 38CarratFVerguEFergusonNMLemaitreMCauchemezSLeachSValleronAJTime lines of" exact="infection" post="and disease in human influenza: a review of volunteer"/>
   <result pre="of airborne infectious diseasesTrends Microbiol1999737237710.1016/S0966-842X(99)01546-210470046 38CarratFVerguEFergusonNMLemaitreMCauchemezSLeachSValleronAJTime lines of infection and" exact="disease" post="in human influenza: a review of volunteer challenge studiesAm"/>
   <result pre="final size formula for an epidemic of a newly invading" exact="infectious" post="diseaseBull Math Biol200668367970210.1007/s11538-005-9047-716794950 43AndersonRMBugliarelloGPlanning for pandemics of infectious diseasesThe"/>
   <result pre="newly invading infectious diseaseBull Math Biol200668367970210.1007/s11538-005-9047-716794950 43AndersonRMBugliarelloGPlanning for pandemics of" exact="infectious" post="diseasesThe Bridge2006Washington, DCNational Academy of Engineering59 44WallingaJTeunisPKretzschmarMUsing data on"/>
   <result pre="on social contacts to estimate age-specific transmission parameters for respiratory-spread" exact="infectious" post="agentsAm J Epidemiol200616493694410.1093/aje/kwj31716968863 45MossongJHensNJitMBeutelsPAuranenKMikolajczykRMassariMSalmasoSTombaGSWallingaJHeijneJSadkowska-TodysMRosinskaMEdmundsWJSocial contacts and mixing patterns relevant"/>
   <result pre="45MossongJHensNJitMBeutelsPAuranenKMikolajczykRMassariMSalmasoSTombaGSWallingaJHeijneJSadkowska-TodysMRosinskaMEdmundsWJSocial contacts and mixing patterns relevant to the spread of" exact="infectious" post="diseasesPLoS Med200853e7410.1371/journal.pmed.005007418366252 46ReadJMEamesKTEdmundsWJDynamic social networks and the implications for"/>
   <result pre="46ReadJMEamesKTEdmundsWJDynamic social networks and the implications for the spread of" exact="infectious" post="diseaseJ R Soc Interface200851001100710.1098/rsif.2008.001318319209 47VynnyckyEEdmundsWJAnalyses of the 1957 (Asian)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7144339/results/search/disease/results.xml">
   <result pre="in spatio-temporal spread of dengue in Nepal Emerging Microbes &amp;amp;" exact="Infections" post="K. P. Acharya et al. http://orcid.org/0000-0002-4208-7592AcharyaKrishna PrasadabCONTACTChaulagainBhimchttp://orcid.org/0000-0002-9327-0530AcharyaNarayandShresthaKshitizeSubramanyaSupram Hosuruf[a], Department"/>
   <result pre="Dear Editor, Nepal is vulnerable to the outbreak of many" exact="infectious diseases," post="including emerging and re-emerging diseases with significant impacts on"/>
   <result pre="agricultural intensification, and unplanned urbanization contribute to increased outbreaks of" exact="infectious diseases" post="in Nepal. Moreover, low socioeconomic status, improper sanitation, poor"/>
   <result pre="favourable situation for the emergence of and outbreaks of several" exact="infectious diseases" post="including Japanese encephalitis (JE), malaria, and dengue fever in"/>
   <result pre="the emergence of and outbreaks of several infectious diseases including" exact="Japanese encephalitis" post="(JE), malaria, and dengue fever in Nepal [3,4]. These"/>
   <result pre="emergence of and outbreaks of several infectious diseases including Japanese" exact="encephalitis" post="(JE), malaria, and dengue fever in Nepal [3,4]. These"/>
   <result pre="of several infectious diseases including Japanese encephalitis (JE), malaria, and" exact="dengue fever" post="in Nepal [3,4]. These diseases contribute significantly to socioeconomic"/>
   <result pre="to socioeconomic burden in Nepal, with an increasing impact from" exact="dengue fever" post="in recent years. Several studies on spatiotemporal epidemiology of"/>
   <result pre="in recent years. Several studies on spatiotemporal epidemiology of this" exact="disease" post="indicate that the situation is likely to worsen in"/>
   <result pre="likely to worsen in the future due to climate change." exact="Dengue" post="fever is an infectious viral disease from tropical and"/>
   <result pre="the future due to climate change. Dengue fever is an" exact="infectious" post="viral disease from tropical and subtropical regions which is"/>
   <result pre="future due to climate change. Dengue fever is an infectious" exact="viral" post="disease from tropical and subtropical regions which is transmitted"/>
   <result pre="due to climate change. Dengue fever is an infectious viral" exact="disease" post="from tropical and subtropical regions which is transmitted to"/>
   <result pre="and subtropical regions which is transmitted to humans from infected" exact="female" post="mosquitoes, Aedes aegypti and Aedes albopictus [5]. Four dengue"/>
   <result pre="and Aedes albopictus [5]. Four dengue serotypes capable of causing" exact="infection" post="have been identified so far (DENV-1, DENV-2, DENV-3 and"/>
   <result pre="DENV-2, DENV-3 and DENV-4) [6,7]. A dramatic increase in global" exact="dengue fever" post="in recent years has put half of the world’s"/>
   <result pre="each year [5]. Since there is no specific treatment for" exact="dengue fever," post="it is now considered to be one of the"/>
   <result pre="considered to be one of the biggest global health crises." exact="Dengue" post="fever was first reported in Nepal in 2004, and"/>
   <result pre="geographical area and in number of people infected [8]. This" exact="disease" post="is now well established in the tropical and subtropical"/>
   <result pre="2010 and 2016, and DENV-2 in 2013 [2]. All four" exact="infectious" post="serotypes of dengue virus (DENV-1–4) are present within the"/>
   <result pre="symptoms compared to previous years. Figure 1. Map of the" exact="total" post="number of confirmed dengue cases reported from different districts"/>
   <result pre="2014/15 until 2019/20. Data were obtained from the Epidemiology and" exact="Disease" post="Control Division, Ministry of Health and Population, Government of"/>
   <result pre="and Population, Government of Nepal. Figure 2. Graph representing the" exact="total" post="number of confirmed dengue cases in each fiscal year"/>
   <result pre="2014/15 until 2019/20. Data were obtained from the Epidemiology and" exact="Disease" post="Control Division, Ministry of Health and Population, Government of"/>
   <result pre="Health and Population, Government of Nepal. The risk of dengue" exact="infection" post="and outbreak in Nepal is increasing year by year"/>
   <result pre="dengue [2]. It is likely that the official tally of" exact="disease" post="incidence is under-reported due to the complex nature of"/>
   <result pre="incidence is under-reported due to the complex nature of the" exact="disease" post="and inadequate monitoring across the country. The majority of"/>
   <result pre="people are rarely tested due to high medical expenses and" exact="limited" post="access to medical facilities in many regions of Nepal."/>
   <result pre="heavy flooding resulting conducive conditions for vector breeding with increased" exact="disease" post="transmission efficiency is linked with higher morbidity and mortality"/>
   <result pre="cases have been observed since 2010, and spatial and temporal" exact="disease" post="projections are known, the government of Nepal is failing"/>
   <result pre="bulletin for &quot;National Guidelines of Prevention, Control &amp;amp; Management of" exact="Dengue" post="in Nepal 2019&quot; in September 2019 [19]. Central, provincial,"/>
   <result pre="at different governmental levels to help manage the outbreaks of" exact="dengue fever." post="Some independent research has been conducted to evaluate the"/>
   <result pre="been conducted to evaluate the spatial and temporal spread of" exact="dengue fever" post="in Nepal [9,21]. These studies have provided the basis"/>
   <result pre="of disease. This information is very important for devising appropriate" exact="disease" post="control strategies. Among several epidemiological parameters, the pathogen’s dispersal"/>
   <result pre="pathogen’s dispersal kernel most strongly influences the spread of the" exact="disease" post="and the efficacy of control strategies. Since dengue fever"/>
   <result pre="of the disease and the efficacy of control strategies. Since" exact="dengue fever" post="exhibits long-distance dispersal (LDD) through its mosquito vector, the"/>
   <result pre="rapidly spread over large spatial scales is greatly concerning. Traditionally," exact="disease" post="spread was modelled using a travelling wave approach with"/>
   <result pre="pathogen’s reproductive capacity, generation time, dispersal ability, and vectors. However," exact="disease" post="spread for the pathogens exhibiting LDD is better characterized"/>
   <result pre="the efficacy of potential outbreak interventions. Some control measures for" exact="dengue fever" post="have been effective in partially reducing the disease burden,"/>
   <result pre="for dengue fever have been effective in partially reducing the" exact="disease" post="burden, yet these still fall below the level of"/>
   <result pre="of control sought by the government as outlined in their" exact="Dengue" post="Report [3]. This lag in control is due to"/>
   <result pre="should adopt stringent prevention and control measures by strengthening the" exact="disease" post="surveillance system, upgrading the healthcare system with advanced facilities,"/>
   <result pre="dispersal of mosquito vectors with the virus, spatial scaling of" exact="disease" post="outbreak, and other epidemiological factors. Special attention should be"/>
   <result pre="other epidemiological factors. Special attention should be paid to initial" exact="disease" post="prevalence and spatial patterns, basic reproduction number of vector"/>
   <result pre="efficacy of control strategies. Environmental and demographic factors that influence" exact="dengue fever" post="outbreaks should also be thoroughly considered while developing management"/>
   <result pre="work proactively in conjunction with the government during periods of" exact="disease" post="outbreaks at different temporal and spatial scales. Acknowledgements The"/>
   <result pre="Nov 15]. Available from: https://www.cbd.int/doc/world/np/np-nbsap-01-en.pdf 2GuptaBP, TuladharR, KurmiR, et al.Dengue" exact="periodic" post="outbreaks and epidemiological trends in Nepal. Ann Clin Microbiol"/>
   <result pre="2019 Oct 21]. Available from: http://library.nhrc.gov.np:8080/nhrc/handle/123456789/91 4collab: Government of Nepal." exact="Infectious" post="Disease Control Guideline (2016). Recuperat: http://www.edcd.gov.np/public/uploads/attachments/1470737313.pdf. 5collab: WHODengue and"/>
   <result pre="Oct 21]. Available from: http://library.nhrc.gov.np:8080/nhrc/handle/123456789/91 4collab: Government of Nepal. Infectious" exact="Disease" post="Control Guideline (2016). Recuperat: http://www.edcd.gov.np/public/uploads/attachments/1470737313.pdf. 5collab: WHODengue and severe"/>
   <result pre="Infectious Disease Control Guideline (2016). Recuperat: http://www.edcd.gov.np/public/uploads/attachments/1470737313.pdf. 5collab: WHODengue and" exact="severe dengue" post="[Internet]. Who. 2016. Recuperat: http://www.who.int/mediacentre/factsheets/fs117/en/. 6HalsteadSM.Dengue and dengue hemorrhagic"/>
   <result pre="and severe dengue [Internet]. Who. 2016. Recuperat: http://www.who.int/mediacentre/factsheets/fs117/en/. 6HalsteadSM.Dengue and" exact="dengue hemorrhagic fever." post="In Handbook of zoonoses, second edition, section B: viral"/>
   <result pre="hemorrhagic fever. In Handbook of zoonoses, second edition, section B:" exact="viral" post="zoonoses. 2017. doi:10.1201/9780203752463. 7GublerDJ.Dengue and dengue hemorrhagic fever. Clin"/>
   <result pre="second edition, section B: viral zoonoses. 2017. doi:10.1201/9780203752463. 7GublerDJ.Dengue and" exact="dengue hemorrhagic fever." post="Clin Microbiol Rev. 1998. doi: 10.1128/cmr.11.3.480 8PandeyBD, RaiSK, MoritaK,"/>
   <result pre="doi: 10.1128/cmr.11.3.480 8PandeyBD, RaiSK, MoritaK, et al.First case of dengue" exact="virus infection" post="in Nepal. Nepal Med Coll J. 2004;6(2):157–159.16295753 9AcharyaBK, CaoC,"/>
   <result pre="10.1128/cmr.11.3.480 8PandeyBD, RaiSK, MoritaK, et al.First case of dengue virus" exact="infection" post="in Nepal. Nepal Med Coll J. 2004;6(2):157–159.16295753 9AcharyaBK, CaoC,"/>
   <result pre="Coll J. 2004;6(2):157–159.16295753 9AcharyaBK, CaoC, LakesT, et al.Spatiotemporal analysis of" exact="dengue fever" post="in Nepal from 2010 to 2014. BMC Public Health."/>
   <result pre="in Nepal. BMC Res Notes; 2018; doi:10.1186/s13104-018-3514-3. 11collab: EDCDUpdates on" exact="dengue fever." post="Epidemiol Dis Control Div. 2019: 1–2[cited 2019 Dec 3]."/>
   <result pre="Nov 11]. Available from: https://dohs.gov.np/wp-content/uploads/2018/04/Annual_Report_2073-74.pdf 14GuptaBP, AdhikariA, RauniyarR, et al.Dengue" exact="virus infection" post="in a French traveller to the hilly region of"/>
   <result pre="11]. Available from: https://dohs.gov.np/wp-content/uploads/2018/04/Annual_Report_2073-74.pdf 14GuptaBP, AdhikariA, RauniyarR, et al.Dengue virus" exact="infection" post="in a French traveller to the hilly region of"/>
   <result pre="https://reliefweb.int/report/nepal/more-30-people-down-dengue-hetauda 21DhimalM, GautamI, KreßA, et al.Spatio-temporal distribution of dengue and" exact="lymphatic filariasis" post="vectors along an altitudinal transect in central Nepal. PLoS"/>
   <result pre="21DhimalM, GautamI, KreßA, et al.Spatio-temporal distribution of dengue and lymphatic" exact="filariasis" post="vectors along an altitudinal transect in central Nepal. PLoS"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7180007/results/search/disease/results.xml">
   <result pre="used with permission). The emergence of novel coronavirus called severe" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) caused a deadly pneumonia outbreak"/>
   <result pre="with permission). The emergence of novel coronavirus called severe respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) caused a deadly pneumonia outbreak in"/>
   <result pre="called severe respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a deadly" exact="pneumonia" post="outbreak in Wuhan, China [1,2]. It is thought to"/>
   <result pre="be the continuation of serious epidemics caused by Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)"/>
   <result pre="the continuation of serious epidemics caused by Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS) in"/>
   <result pre="caused by Middle East respiratory syndrome coronavirus (MERS-CoV) and severe" exact="acute" post="respiratory syndrome (SARS) in Middle East (2009) and Guangdong,"/>
   <result pre="by Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute" exact="respiratory" post="syndrome (SARS) in Middle East (2009) and Guangdong, China"/>
   <result pre="Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory" exact="syndrome" post="(SARS) in Middle East (2009) and Guangdong, China (2002-03),"/>
   <result pre="and to properly utilize effective therapies (Figure 1). Figure 1" exact="Psychological" post="interventions. Currently, primary importance is given to the physical"/>
   <result pre="utilize effective therapies (Figure 1). Figure 1 Psychological interventions. Currently," exact="primary" post="importance is given to the physical health that includes"/>
   <result pre="ignoring the profound importance of psychological health, ensued by the" exact="viral infection," post="isolation, restricted social activities, troubled sleeping, lockdown and forged"/>
   <result pre="health workers and the public. Then we summarize some facts" exact="acquired" post="in SARS and MERS outbreaks to assist the vulnerable"/>
   <result pre="ON PEOPLE AND THEIR RESPONSES In a broad aspect of" exact="viral" post="outbreaks, it is impossible to predict the extent of"/>
   <result pre="pathogenic virus. Considering the current situation of the world environment," exact="viral" post="outbreaks may affect animals or humans [3,9], without causing"/>
   <result pre="anxiety, insomnia, panic behavior, fear, and hopelessness. In some cases" exact="viral" post="outbreaks infect thousands of people, cause hundreds to thousands"/>
   <result pre="authorities have consisted of equivocal recommendations for the prevention of" exact="viral" post="infections (S4). For instance, some of the infected individuals"/>
   <result pre="have consisted of equivocal recommendations for the prevention of viral" exact="infections" post="(S4). For instance, some of the infected individuals were"/>
   <result pre="general population must be informed by these recommendations; information about" exact="viral" post="outbreak and possible impact, individual risk, outcomes of negative"/>
   <result pre="public awareness regarding necessary actions to prevent the spread of" exact="viral" post="infections. Furthermore, people must be provided with follow-up information"/>
   <result pre="communities. MEASUREMENTS AND RESPONSES Resilience of affected and/or infected individuals" exact="Psychological" post="resilience is generally defined as &quot;the ability to sustain"/>
   <result pre="can be achieved by ending the vulnerability to psychopathology and" exact="mental dysfunction" post="when exposed to the viral infection or at-least living"/>
   <result pre="vulnerability to psychopathology and mental dysfunction when exposed to the" exact="viral infection" post="or at-least living in the regions under threat. People"/>
   <result pre="to psychopathology and mental dysfunction when exposed to the viral" exact="infection" post="or at-least living in the regions under threat. People"/>
   <result pre="distinct molecular adaptations to promote normal behavioral function and the" exact="absence of" post="molecular abnormalities that occur in susceptible individuals that impairs"/>
   <result pre="with increasing resilience (S5-S9). While combating the impact of COVID-19" exact="pneumonia" post="(Figure 1), the health care regulatory authorities should communicate"/>
   <result pre="developing treatment and prevention strategies and improving facilities. Regions under" exact="secondary" post="threat The regions and areas other than the originating"/>
   <result pre="regions and areas other than the originating region of COVID-19" exact="infection" post="will be considered as the regions under secondary threat."/>
   <result pre="of COVID-19 infection will be considered as the regions under" exact="secondary" post="threat. In these regions, the stress and fear of"/>
   <result pre="secondary threat. In these regions, the stress and fear of" exact="infection" post="along with other above-mentioned factors will likely generate moderate"/>
   <result pre="major behavioral and psychological abnormalities (S10-S12). The overall impact of" exact="infection" post="on mental health will be associated with the rate"/>
   <result pre="higher stress or fear; however, such actions may cause the" exact="viral" post="spread in countries with no facilities for combating coronavirus."/>
   <result pre="must be educated or made aware of the development of" exact="clinical depression," post="and suicidality related symptoms followed by the outbreak. Professional"/>
   <result pre="on rumors and forged news from unauthentic sources. Regions under" exact="primary" post="threat The area of novel coronavirus origination (Wuhan) will"/>
   <result pre="origination (Wuhan) will be considered as the region under the" exact="primary" post="threat. The outbreak of COVID-19 pneumonia imposed a serious"/>
   <result pre="the region under the primary threat. The outbreak of COVID-19" exact="pneumonia" post="imposed a serious threat to the residents of the"/>
   <result pre="MERS-CoV, however the transmission rate in those cases was significantly" exact="lower" post="as compared to 2019-nCoV of Wuhan [3,10,11] (S17). MERS"/>
   <result pre="effects on health and can cause serious mental problems including" exact="acute" post="stress, insomnia, severe anxiety, and chronic depression. MERS and"/>
   <result pre="serious mental problems including acute stress, insomnia, severe anxiety, and" exact="chronic" post="depression. MERS and SARS induced serious psychological problems majorly"/>
   <result pre="problems majorly in health care workers (S22), however, the COVID-19" exact="infection" post="may cause such abnormalities in the general public as"/>
   <result pre="we have discussed in the previous section of regions at" exact="secondary" post="risks should be implemented here. Furthermore, the people should"/>
   <result pre="to serious mortality, rapid transmission and higher morbidity are increasing" exact="hysteria" post="and anxiety among people. People in Wuhan are under"/>
   <result pre="mortality, rapid transmission and higher morbidity are increasing hysteria and" exact="anxiety" post="among people. People in Wuhan are under critical conditions"/>
   <result pre="be provided with pharmacological therapies and psychiatric assistance where needed." exact="Psychological" post="counseling based therapies The alleviation of acute distress and"/>
   <result pre="assistance where needed. Psychological counseling based therapies The alleviation of" exact="acute" post="distress and preventing chronic depression, anxiety and posttraumatic stress"/>
   <result pre="counseling based therapies The alleviation of acute distress and preventing" exact="chronic" post="depression, anxiety and posttraumatic stress among people and health"/>
   <result pre="therapies The alleviation of acute distress and preventing chronic depression," exact="anxiety" post="and posttraumatic stress among people and health care workers"/>
   <result pre="and health care workers indirectly exposed to the carnage of" exact="viral infection." post="Psychological resilience will be important in the population who"/>
   <result pre="care workers indirectly exposed to the carnage of viral infection." exact="Psychological" post="resilience will be important in the population who are"/>
   <result pre="or traumatic symptoms irrespective of their severity. Furthermore, people with" exact="acute" post="stress disorder or depressive disorders will also be dealt"/>
   <result pre="education about these disorders related symptoms and techniques to manage" exact="anxiety" post="including relaxation training, guided self-dialogue and cognitive restructuring (S24-S26)."/>
   <result pre="inhibitors (SSRIs). These drugs are effective against several types of" exact="mental disorders" post="specifically depression and anxiety (S28-S30). Agomelatine (a melatonin receptor"/>
   <result pre="drugs are effective against several types of mental disorders specifically" exact="depression" post="and anxiety (S28-S30). Agomelatine (a melatonin receptor agonist) and"/>
   <result pre="effective against several types of mental disorders specifically depression and" exact="anxiety" post="(S28-S30). Agomelatine (a melatonin receptor agonist) and Vilazodone (a"/>
   <result pre="melatonin receptor agonist) and Vilazodone (a serotonin reuptake inhibitor and" exact="partial" post="agonist of serotonin receptors) are also recommended in depression"/>
   <result pre="and partial agonist of serotonin receptors) are also recommended in" exact="depression" post="(S27,S31). Among second-line agents for anxiety and depressive disorders"/>
   <result pre="are also recommended in depression (S27,S31). Among second-line agents for" exact="anxiety" post="and depressive disorders benzodiazepines have been found with good"/>
   <result pre="therapy) is more beneficial and effective in the case of" exact="chronic anxiety" post="and depressive disorders (S27). SUMMARY AND CONCLUSION In the"/>
   <result pre="is more beneficial and effective in the case of chronic" exact="anxiety" post="and depressive disorders (S27). SUMMARY AND CONCLUSION In the"/>
   <result pre="disorders (S27). SUMMARY AND CONCLUSION In the view of continued" exact="viral" post="outbreaks around the world and specifically in China that"/>
   <result pre="from the actions taken by the government against coronavirus epidemic," exact="viral infection," post="and fear of infection. Generally targeting the entire population"/>
   <result pre="properly. In addition to the general population exposed to the" exact="viral" post="outbreak, health care workers need serious attention and psychological"/>
   <result pre="Rev Microbiol. 2019;17:181-92. 10.1038/s41579-018-0118-930531947 4ZhongNSZhengBJLiYMPoonLLMXieZHChanKHet al.Epidemiology and cause of severe" exact="acute" post="respiratory syndrome (SARS) in Guangdong, People’s Republic of China,"/>
   <result pre="Microbiol. 2019;17:181-92. 10.1038/s41579-018-0118-930531947 4ZhongNSZhengBJLiYMPoonLLMXieZHChanKHet al.Epidemiology and cause of severe acute" exact="respiratory" post="syndrome (SARS) in Guangdong, People’s Republic of China, in"/>
   <result pre="2019;17:181-92. 10.1038/s41579-018-0118-930531947 4ZhongNSZhengBJLiYMPoonLLMXieZHChanKHet al.Epidemiology and cause of severe acute respiratory" exact="syndrome" post="(SARS) in Guangdong, People’s Republic of China, in February"/>
   <result pre="6ZakiAMVan BoheemenSBestebroerTMOsterhausADMEFouchierRAMIsolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi Arabia.N Engl J Med. 2012;367:1814-20. 10.1056/NEJMoa121172123075143 7World"/>
   <result pre="Arabia.N Engl J Med. 2012;367:1814-20. 10.1056/NEJMoa121172123075143 7World Health Organization. Coronavirus" exact="disease" post="2019 (COVID-19) situation report. February 28, 2020. Geneva: WHO;"/>
   <result pre="8ZarocostasJHow to fight an infodemic.Lancet. 2020;395:676. 10.1016/S0140-6736(20)30461-X32113495 9ZhouPFanHLanTYangX-LShiW-FZhangWet al.Fatal swine" exact="acute" post="diarrhoea syndrome caused by an HKU2-related coronavirus of bat"/>
   <result pre="fight an infodemic.Lancet. 2020;395:676. 10.1016/S0140-6736(20)30461-X32113495 9ZhouPFanHLanTYangX-LShiW-FZhangWet al.Fatal swine acute diarrhoea" exact="syndrome" post="caused by an HKU2-related coronavirus of bat origin.Nature. 2018;556:255-8."/>
   <result pre="of bat origin.Nature. 2018;556:255-8. 10.1038/s41586-018-0010-929618817 10LiuSChanTCChuYTWuJTSGengXZhaoNet al.Comparative epidemiology of human" exact="infections" post="with middle east respiratory syndrome and severe acute respiratory"/>
   <result pre="10.1038/s41586-018-0010-929618817 10LiuSChanTCChuYTWuJTSGengXZhaoNet al.Comparative epidemiology of human infections with middle east" exact="respiratory" post="syndrome and severe acute respiratory syndrome coronaviruses among healthcare"/>
   <result pre="10LiuSChanTCChuYTWuJTSGengXZhaoNet al.Comparative epidemiology of human infections with middle east respiratory" exact="syndrome" post="and severe acute respiratory syndrome coronaviruses among healthcare personnel.PLoS"/>
   <result pre="of human infections with middle east respiratory syndrome and severe" exact="acute" post="respiratory syndrome coronaviruses among healthcare personnel.PLoS One. 2016;11:e0149988. 10.1371/journal.pone.014998826930074"/>
   <result pre="human infections with middle east respiratory syndrome and severe acute" exact="respiratory" post="syndrome coronaviruses among healthcare personnel.PLoS One. 2016;11:e0149988. 10.1371/journal.pone.014998826930074 11HuiDSIAzharEMadaniTANtoumiFKockRDarOet"/>
   <result pre="infections with middle east respiratory syndrome and severe acute respiratory" exact="syndrome" post="coronaviruses among healthcare personnel.PLoS One. 2016;11:e0149988. 10.1371/journal.pone.014998826930074 11HuiDSIAzharEMadaniTANtoumiFKockRDarOet al.The"/>
   <result pre="systematic review of the evidence on social media use and" exact="depression" post="among lesbian, gay, and bisexual minorities.JMIR Ment Health. 2018;5:e10496."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7182292/results/search/disease/results.xml">
   <result pre="serum samples collected from patients presenting with clinical symptoms of" exact="dengue fever" post="and 152 mosquito pools. RESULTS: We detected the Asian"/>
   <result pre="virus. Keywords: Molecular epidemiology Arbovirus Phylogeny fig-count: table-count: equation-count: ref-count:" exact="Dengue" post="fever is endemic in Brazil, and several epidemics have"/>
   <result pre="during an outbreak. DENV-2 is the most frequent cause of" exact="dengue fever" post="epidemics worldwide and is usually associated with severe disease"/>
   <result pre="dengue fever epidemics worldwide and is usually associated with severe" exact="disease" post="cases. DENV-2 is divided into six genotypes: (i) Asian"/>
   <result pre="from South and Southeast Asia; (iv) American, comprising strains from" exact="Central" post="America; (v) Southeast Asian/American, comprising strains from Southeast Asia"/>
   <result pre="America; (v) Southeast Asian/American, comprising strains from Southeast Asia and" exact="Central" post="and South America; and (vi) Sylvatic, comprising strains from"/>
   <result pre="Sylvatic, comprising strains from West Africa and Southeast Asia1. The" exact="American" post="genotype was the predominant genotype in Latin America until"/>
   <result pre="Sinop, in the state of Mato Grosso, Brazil. (B) The" exact="General" post="Time Reversible (GTR) model with four gamma substitution rate"/>
   <result pre="Likelihood phylogenetic tree (PhyML) based on nonstructural protein 5 (NS5)" exact="partial" post="gene sequences of the six DENV-2 genotypes. The sequences"/>
   <result pre="each genotype. The final tree was edited in FigTree. A" exact="total" post="of 164 serum samples were collected from patients presenting"/>
   <result pre="samples were collected from patients presenting with clinical symptoms of" exact="dengue fever" post="between February 2014 and December 2015. Furthermore, 778 mosquitoes"/>
   <result pre="in Sinop, Brazil. Species May June July August September October" exact="Total" post="Aedeomyia (Ady.) squamipennis 3 (F) 2 (F) 23 (F);"/>
   <result pre="(F) 1 (F); 1 (F); 10 3 (M) 1 (M)" exact="Total" post="106 76 111 201 204 80 778 (F) pools"/>
   <result pre="106 76 111 201 204 80 778 (F) pools containing" exact="female" post="specimens; (M) pools containing male specimens. Viral RNA was"/>
   <result pre="(F) pools containing female specimens; (M) pools containing male specimens." exact="Viral" post="RNA was extracted from serum samples and pools of"/>
   <result pre="serum samples and pools of homogenized mosquitoes using the QIAmp" exact="Viral" post="RNA Mini kit (Qiagen GmbH, Hilden, Germany) and TRIzol"/>
   <result pre="kit (Qiagen GmbH, Hilden, Germany) and TRIzol reagent (Invitrogen; Thermo" exact="Fisher" post="Scientific, Inc., Waltham, MA, USA), respectively. Samples were screened"/>
   <result pre="to multiplex-nested RT-PCR5. PCR products from serum samples, mosquitoes, or" exact="viral" post="isolation were purified using the PCR Clean-Up System kit"/>
   <result pre="primers, using the BigDye Terminator v3.1 Cycle Sequencing kit (Thermo" exact="Fisher" post="Scientific, Inc.) and an ABI377 automatic sequencer (Applied Biosystems)."/>
   <result pre="sequencer (Applied Biosystems). Virus identity was determined using the Basic" exact="Local" post="Alignment Search Tool (https://blast.ncbi.nlm.nih.gov/Blast.cgi). We detected arthropod-borne viruses in"/>
   <result pre="in December 2015, tested positive for DENV-2 through multiplex-nested-PCR and" exact="viral" post="isolation. One of the aforementioned samples (BR/Sinop/H361/2015) was isolated"/>
   <result pre="counts. The other sample (BR/Sinop/H345/2015) was collected from a 47-year-old" exact="female" post="patient presenting with headache, arthritis, itchiness, rash, and normal"/>
   <result pre="The pools (BR/Sinop/Ar23/2014 and BR/Sinop/Ar6/2014) consisted of eight and five" exact="female" post="specimens of Culex sp., respectively. We obtained one NS5"/>
   <result pre="female specimens of Culex sp., respectively. We obtained one NS5" exact="partial" post="gene sequence of DENV-2 from a serum sample (BR/Sinop/H345/2015;"/>
   <result pre="numbers MH939169 and MH939170). Phylogenetic analysis based on the NS5" exact="partial" post="gene sequences of DENV-2 (316 base pairs) indicated that"/>
   <result pre="(Figure 1B). The topology of our phylogenetic tree based on" exact="partial" post="NS5 sequences was similar to DENV-2 phylogeny based on"/>
   <result pre="was similar to DENV-2 phylogeny based on the analysis of" exact="complete" post="genomes6. In the Americas, isolates from Cuba (1981), Venezuela"/>
   <result pre="Venezuela (1994), and Mexico (1995) epidemics, detected in cases of" exact="dengue hemorrhagic fever," post="were closely related to Asian II genotype strains from"/>
   <result pre="An NGC-like strain detected in Jamaica in 2007, causing mild" exact="dengue disease," post="was also grouped within the Asian II genotype8. Interestingly,"/>
   <result pre="the Asian II genotype8. Interestingly, the Asian II genotype caused" exact="meningitis" post="in patients from Minas Gerais, in the southeast region"/>
   <result pre="in addition to the prevalent Asian/American genotype. Successive epidemics of" exact="dengue fever," post="with co-circulation of DENV-1, DENV-2, and DENV-4, have been"/>
   <result pre="in forest-collected mosquitoes raises important questions about the source of" exact="infection" post="in mosquitoes and the presence of viruses in other"/>
   <result pre="followed by nested PCR assays for detection and identification of" exact="Brazilian" post="alphaviruses and flavivirusesJ Clin Micro201543269670210.1128/JCM.43.2.696-702.2005 5FigueiredoLTThe use of Aedes"/>
   <result pre="Bras Med Trop199023113182089478 6WamanVPKolekarPRamtirthkarMRKaleMMKukarni-KaleUAnalysis of genotype diversity and evolution of" exact="Dengue" post="virus serotype 2 using complete genomesPeer J20164e232610.7717/peerj.232627635316 7Rico-HesseRMicroevolution and"/>
   <result pre="genotype diversity and evolution of Dengue virus serotype 2 using" exact="complete" post="genomesPeer J20164e232610.7717/peerj.232627635316 7Rico-HesseRMicroevolution and virulence of dengue virusesAdv Virus"/>
   <result pre="Indian Med J201160212012521942113 9MarinhoPEBretas de OliveiraDCandianiTMSCrispimAPCAlvarengaPPMCastroFCSet al.Meningitis Associated with Simultaneous" exact="Infection" post="by Multiple Dengue Virus Serotypes in Children, BrazilEmerg Infect"/>
   <result pre="J201160212012521942113 9MarinhoPEBretas de OliveiraDCandianiTMSCrispimAPCAlvarengaPPMCastroFCSet al.Meningitis Associated with Simultaneous Infection by" exact="Multiple" post="Dengue Virus Serotypes in Children, BrazilEmerg Infect Dis201723111511810.3201/eid2301.16081727983492 10de"/>
   <result pre="9MarinhoPEBretas de OliveiraDCandianiTMSCrispimAPCAlvarengaPPMCastroFCSet al.Meningitis Associated with Simultaneous Infection by Multiple" exact="Dengue" post="Virus Serotypes in Children, BrazilEmerg Infect Dis201723111511810.3201/eid2301.16081727983492 10de ThoisyBLacosteVGermainAMuñoz-JordánJColónCMauffreyJFet"/>
   <result pre="Virus Serotypes in Children, BrazilEmerg Infect Dis201723111511810.3201/eid2301.16081727983492 10de ThoisyBLacosteVGermainAMuñoz-JordánJColónCMauffreyJFet al.Dengue" exact="infection" post="in neotropical forest mammalsVector Borne Zoonotic Dis20099215717010.1089/vbz.2007.028018945183 11TerzianACBZiniNSacchetoLRochaRFParraMCPDel SartoJLet"/>
   <result pre="mammalsVector Borne Zoonotic Dis20099215717010.1089/vbz.2007.028018945183 11TerzianACBZiniNSacchetoLRochaRFParraMCPDel SartoJLet al.Evidence of natural Zika" exact="virus infection" post="in neotropical non-human primates in BrazilScientific reports201881160341603410.1038/s41598-018-34423-630375482"/>
   <result pre="Borne Zoonotic Dis20099215717010.1089/vbz.2007.028018945183 11TerzianACBZiniNSacchetoLRochaRFParraMCPDel SartoJLet al.Evidence of natural Zika virus" exact="infection" post="in neotropical non-human primates in BrazilScientific reports201881160341603410.1038/s41598-018-34423-630375482"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7197577/results/search/disease/results.xml">
   <result pre="protections.nyaa186.pdfpage-count: To the Editor: We performed a literature review on" exact="viral" post="epidemics and pandemics, including the severe acute respiratory syndrome"/>
   <result pre="literature review on viral epidemics and pandemics, including the severe" exact="acute" post="respiratory syndrome (SARS), the Middle East respiratory syndrome (MERS),"/>
   <result pre="review on viral epidemics and pandemics, including the severe acute" exact="respiratory" post="syndrome (SARS), the Middle East respiratory syndrome (MERS), influenza"/>
   <result pre="on viral epidemics and pandemics, including the severe acute respiratory" exact="syndrome" post="(SARS), the Middle East respiratory syndrome (MERS), influenza H1N1,"/>
   <result pre="including the severe acute respiratory syndrome (SARS), the Middle East" exact="respiratory" post="syndrome (MERS), influenza H1N1, and the novel severe acute"/>
   <result pre="the severe acute respiratory syndrome (SARS), the Middle East respiratory" exact="syndrome" post="(MERS), influenza H1N1, and the novel severe acute respiratory"/>
   <result pre="East respiratory syndrome (MERS), influenza H1N1, and the novel severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) with the goal of"/>
   <result pre="respiratory syndrome (MERS), influenza H1N1, and the novel severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) with the goal of identifying"/>
   <result pre="syndrome (MERS), influenza H1N1, and the novel severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) with the goal of identifying the"/>
   <result pre="of identifying the neurological symptoms, signs, and complications of these" exact="infections" post="within the context of the COVID-19 pandemic (Figure). FIGURE."/>
   <result pre="Seizure: 17, encephalitis: 4, meningitis: 4, encephalopathy: 3, meningismus: 3," exact="focal" post="hemorrhagic brain lesions: 2, brain infarction: 1, sensorineural hearing"/>
   <result pre="encephalitis: 4, meningitis: 4, encephalopathy: 3, meningismus: 3, focal hemorrhagic" exact="brain" post="lesions: 2, brain infarction: 1, sensorineural hearing loss: 1"/>
   <result pre="4, encephalopathy: 3, meningismus: 3, focal hemorrhagic brain lesions: 2," exact="brain" post="infarction: 1, sensorineural hearing loss: 1  Frobert et al,"/>
   <result pre="meningismus: 3, focal hemorrhagic brain lesions: 2, brain infarction: 1," exact="sensorineural" post="hearing loss: 1  Frobert et al, 201119 181 Seizure:"/>
   <result pre="303 Seizure: 12, status epilepticus: 7, encephalopathy: 9, headache: 3," exact="focal" post="neurological findings: 5, myositis: 1, aphasia: 6  Glaser et"/>
   <result pre="et al, 201221 2069 Encephalopathy/encephalitis: 29, seizure: 44, meningitis: 3," exact="Guillain-Barré" post="syndrome: 1  Jain et al, 200922 272 Headache: 92"/>
   <result pre="7  Stein et al, 201032 478 Headache: 51, seizure: 41," exact="meningitis" post="or encephalitis: 5  Khandaker et al, 201233 506 Seizure:"/>
   <result pre=" Noorwali et al, 201535 261 Headache: 59, altered consciousness: 53," exact="focal" post="neurological deficit: 10  Saad et al, 201436 70 Confusion:"/>
   <result pre="48, confusion: 2  Umapathi et al, 20045 206 Large artery" exact="cerebral" post="infarctions: 5  Tsai et al, 200543 664 Polyneuropathy: 3,"/>
   <result pre="al, 202046 214 Dizziness: 36, headache: 28, altered consciousness: 16," exact="acute" post="cerebrovascular disease: 6, ataxia: 1, seizure: 1, hypogeusia: 12,"/>
   <result pre="except Howlett et al, 2018, which was prospective. TABLE 2." exact="Neurologic" post="Complications by Viral Disease Neurologic finding Number of patients"/>
   <result pre="al, 2018, which was prospective. TABLE 2. Neurologic Complications by" exact="Viral" post="Disease Neurologic finding Number of patients Percent H1N1  Headache"/>
   <result pre="2018, which was prospective. TABLE 2. Neurologic Complications by Viral" exact="Disease" post="Neurologic finding Number of patients Percent H1N1  Headache 541"/>
   <result pre="which was prospective. TABLE 2. Neurologic Complications by Viral Disease" exact="Neurologic" post="finding Number of patients Percent H1N1  Headache 541 6.73%"/>
   <result pre="difficulties 6 0.07%  Cognitive and memory issues 5 0.06%  Cranial" exact="nerve" post="or focal deficit 5 0.06%  Neurological long-termcomplications, not specified"/>
   <result pre="0.07%  Cognitive and memory issues 5 0.06%  Cranial nerve or" exact="focal" post="deficit 5 0.06%  Neurological long-termcomplications, not specified 5 0.06%"/>
   <result pre=" Neurological long-termcomplications, not specified 5 0.06%  Stroke 4 0.05%  Guillain-Barré" exact="syndrome" post="3 0.04%  Hearing impairment andtinnitus 1 0.01% MERS  Headache"/>
   <result pre="consciousness 136 12.06%  Cognitive or memory issues 18 1.60%  Cranial" exact="nerve" post="or focal deficit 10 0.89%  Seizure 6 0.53% SARS"/>
   <result pre="12.06%  Cognitive or memory issues 18 1.60%  Cranial nerve or" exact="focal" post="deficit 10 0.89%  Seizure 6 0.53% SARS  Headache 109"/>
   <result pre="increase. Neurological manifestations, including headache, dizziness, altered level of consciousness," exact="focal" post="neurological deficits, cranial nerve involvement,2 seizures, and to a"/>
   <result pre="headache, dizziness, altered level of consciousness, focal neurological deficits, cranial" exact="nerve" post="involvement,2 seizures, and to a lesser extent meningoencephalitis,3 more"/>
   <result pre="and to a lesser extent meningoencephalitis,3 more severe necrotizing encephalopathy,4" exact="cerebral edema," post="and stroke,5 have been reported with the recent viral"/>
   <result pre="cerebral edema, and stroke,5 have been reported with the recent" exact="viral" post="epidemics. Importantly, with prior epidemics (Table 3), there are"/>
   <result pre="developing neurological sequelae months to weeks later, including cerebellitis,6,7 neuropathy,8" exact="Guillain-Barré" post="syndrome,9 postinfluenza myositis,10 and postviral Parkinsonism.11 TABLE 3. Year"/>
   <result pre="syndrome,9 postinfluenza myositis,10 and postviral Parkinsonism.11 TABLE 3. Year Identified," exact="Total" post="Case Numbers, and Case Fatality Rates of SARS, H1N1,"/>
   <result pre="33 509 4.8% Coronaviruses are thought to disseminate to the" exact="central nervous system" post="(CNS) through either hematogenous spread, retrograde neuronal dissemination, or"/>
   <result pre="to the central nervous system (CNS) through either hematogenous spread," exact="retrograde" post="neuronal dissemination, or direct invasion of the olfactory epithelium.12"/>
   <result pre="the central nervous system (CNS) through either hematogenous spread, retrograde" exact="neuronal" post="dissemination, or direct invasion of the olfactory epithelium.12 Furthermore,"/>
   <result pre="speculation that invasion into the CNS and damage to the" exact="medullary" post="cardiorespiratory centers may lead to worsening respiratory symptoms.15 Also,"/>
   <result pre="damage to the medullary cardiorespiratory centers may lead to worsening" exact="respiratory" post="symptoms.15 Also, with the prior SARS epidemic, multiple human"/>
   <result pre="respiratory symptoms.15 Also, with the prior SARS epidemic, multiple human" exact="brain" post="specimens demonstrated direct infection of neuronal cells within the"/>
   <result pre="the prior SARS epidemic, multiple human brain specimens demonstrated direct" exact="infection" post="of neuronal cells within the cerebral cortex and hypothalamus.16"/>
   <result pre="SARS epidemic, multiple human brain specimens demonstrated direct infection of" exact="neuronal" post="cells within the cerebral cortex and hypothalamus.16 Additionally, there"/>
   <result pre="brain specimens demonstrated direct infection of neuronal cells within the" exact="cerebral" post="cortex and hypothalamus.16 Additionally, there are reports of a"/>
   <result pre="a higher risk of stroke, especially in the setting of" exact="acute" post="illness and in the elderly population.17 Given the higher"/>
   <result pre="described in this article. References REFERENCES 1.SunT, GuanJNovel coronavirus and" exact="central nervous system." post="Eur J Neurol. published online: March 26, 2020 (doi:10.1111/ene.14227)."/>
   <result pre="2020 (doi:10.1111/ene.14227). 2.KahleKT, WalcottBP, NahedBVet al..Cerebral edema and a transtentorial" exact="brain" post="herniation syndrome associated with pandemic swine influenza A (H1N1)"/>
   <result pre="2.KahleKT, WalcottBP, NahedBVet al..Cerebral edema and a transtentorial brain herniation" exact="syndrome" post="associated with pandemic swine influenza A (H1N1) virus infection."/>
   <result pre="edema and a transtentorial brain herniation syndrome associated with pandemic" exact="swine influenza" post="A (H1N1) virus infection. J Clin Neurosci. 2011;18(9):1245-1248.21742505 3.AkinsPT,"/>
   <result pre="brain herniation syndrome associated with pandemic swine influenza A (H1N1)" exact="virus infection." post="J Clin Neurosci. 2011;18(9):1245-1248.21742505 3.AkinsPT, BelkoJ, UyekiTM, AxelrodY, LeeKK,"/>
   <result pre="J Clin Neurosci. 2011;18(9):1245-1248.21742505 3.AkinsPT, BelkoJ, UyekiTM, AxelrodY, LeeKK, SilverthornJH1N1" exact="encephalitis" post="with malignant edema and review of neurologic complications from"/>
   <result pre="Neurosci. 2011;18(9):1245-1248.21742505 3.AkinsPT, BelkoJ, UyekiTM, AxelrodY, LeeKK, SilverthornJH1N1 encephalitis with" exact="malignant" post="edema and review of neurologic complications from influenza. Neurocrit"/>
   <result pre="from influenza. Neurocrit Care. 2010;13(3):396-406.20811962 4.LyonJB, RemigioC, MilliganT, DelineCAcute necrotizing" exact="encephalopathy" post="in a child with H1N1 influenza infection. Pediatr Radiol."/>
   <result pre="infection. Pediatr Radiol. 2010;40(2):200-205.20020117 5.UmapathiT, KorAC, VenketasubramanianNet al..Large artery ischaemic" exact="stroke" post="in severe acute respiratory syndrome (SARS). J Neurol. 2004;251(10):1227-1231.15503102"/>
   <result pre="2010;40(2):200-205.20020117 5.UmapathiT, KorAC, VenketasubramanianNet al..Large artery ischaemic stroke in severe" exact="acute" post="respiratory syndrome (SARS). J Neurol. 2004;251(10):1227-1231.15503102 6.IshikawaT, FujioY, MoritaM,"/>
   <result pre="5.UmapathiT, KorAC, VenketasubramanianNet al..Large artery ischaemic stroke in severe acute" exact="respiratory" post="syndrome (SARS). J Neurol. 2004;251(10):1227-1231.15503102 6.IshikawaT, FujioY, MoritaM, TakiyamaY,"/>
   <result pre="KorAC, VenketasubramanianNet al..Large artery ischaemic stroke in severe acute respiratory" exact="syndrome" post="(SARS). J Neurol. 2004;251(10):1227-1231.15503102 6.IshikawaT, FujioY, MoritaM, TakiyamaY, NakanoI[An"/>
   <result pre="syndrome (SARS). J Neurol. 2004;251(10):1227-1231.15503102 6.IshikawaT, FujioY, MoritaM, TakiyamaY, NakanoI[An" exact="adult" post="case of acute cerebellitis after influenza A infection with"/>
   <result pre="Neurol. 2004;251(10):1227-1231.15503102 6.IshikawaT, FujioY, MoritaM, TakiyamaY, NakanoI[An adult case of" exact="acute" post="cerebellitis after influenza A infection with a cerebellar corical"/>
   <result pre="TakiyamaY, NakanoI[An adult case of acute cerebellitis after influenza A" exact="infection" post="with a cerebellar corical lesion on MRI]. Rinsho Shinkeigaku."/>
   <result pre="Intern Med. 1997;36(10):747-749.9372341 8.AlgahtaniH, SubahiA, ShirahBNeurological complications of Middle East" exact="respiratory" post="syndrome coronavirus: a report of two cases and review"/>
   <result pre="Med. 1997;36(10):747-749.9372341 8.AlgahtaniH, SubahiA, ShirahBNeurological complications of Middle East respiratory" exact="syndrome" post="coronavirus: a report of two cases and review of"/>
   <result pre="Case Rep Neurol Med. 2016;2016:3502683. 27239356 9.Sivadon-TardyV, OrlikowskiD, PorcherRet al..Guillain-Barré" exact="syndrome" post="and influenza virus infection. Clin Infect Dis. 2009;48(1):48-56.19025491 10.D'SilvaD,"/>
   <result pre="Med. 2016;2016:3502683. 27239356 9.Sivadon-TardyV, OrlikowskiD, PorcherRet al..Guillain-Barré syndrome and influenza" exact="virus infection." post="Clin Infect Dis. 2009;48(1):48-56.19025491 10.D'SilvaD, HewagamaS, DohertyR, KormanTM, ButteryJMelting"/>
   <result pre="Acta. 2009;1792(7):714-721.18760350 12.DesforgesM, Le CoupanecA, DubeauPet al..Human coronaviruses and other" exact="respiratory" post="viruses: underestimated opportunistic pathogens of the central nervous system?Viruses."/>
   <result pre="neuroinvasive potential of SARS-CoV2 may play a role in the" exact="respiratory" post="failure of COVID-19 patients. J Med Virol. published online:"/>
   <result pre="online: February 27 2020 (doi:10.1002/jmv.25728). 16.GuJ, GongE, ZhangBet al..Multiple organ" exact="infection" post="and the pathogenesis of SARS. J Exp Med. 2005;202(3):415-424.16043521"/>
   <result pre="nervous system manifestations in pediatric patients with influenza A H1N1" exact="infection" post="during the 2009 pandemic. Pediatr Neurol. 2014;51(3):370-376.25160541 19.FrobertE, SarretC,"/>
   <result pre="25.KumarA, ZarychanskiR, PintoRet al..Critically ill patients with 2009 influenza A(H1N1)" exact="infection" post="in Canada. JAMA. 2009;302(17):1872-1879.19822627 26.ArcherBN, TimothyGA, CohenCet al..Introduction of"/>
   <result pre="of the initial cases of 2009 pandemic influenza A (H1N1)" exact="virus infection" post="in China. N Engl J Med. 2009;361(26):2507-2517.20007555 29.LibsterR, BugnaJ,"/>
   <result pre="the initial cases of 2009 pandemic influenza A (H1N1) virus" exact="infection" post="in China. N Engl J Med. 2009;361(26):2507-2517.20007555 29.LibsterR, BugnaJ,"/>
   <result pre="with death or hospitalization due to pandemic 2009 influenza A(H1N1)" exact="infection" post="in California. JAMA. 2009;302(17):1896-1902.19887665 31.KediaS, StroudB, ParsonsJet al..Pediatric neurological"/>
   <result pre="course and outcomes of critically ill patients with Middle East" exact="respiratory" post="syndrome coronavirus infection. Ann Intern Med. 2014;160(6):389-397.24474051 35.NoorwaliAA, TurkistaniAM,"/>
   <result pre="and outcomes of critically ill patients with Middle East respiratory" exact="syndrome" post="coronavirus infection. Ann Intern Med. 2014;160(6):389-397.24474051 35.NoorwaliAA, TurkistaniAM, AsiriSIet"/>
   <result pre="al..Descriptive epidemiology and characteristics of confirmed cases of Middle East" exact="respiratory" post="syndrome coronavirus infection in the Makkah region of Saudi"/>
   <result pre="epidemiology and characteristics of confirmed cases of Middle East respiratory" exact="syndrome" post="coronavirus infection in the Makkah region of Saudi Arabia,"/>
   <result pre="characteristics of confirmed cases of Middle East respiratory syndrome coronavirus" exact="infection" post="in the Makkah region of Saudi Arabia, March to"/>
   <result pre="al..Clinical aspects and outcomes of 70 patients with Middle East" exact="respiratory" post="syndrome coronavirus infection: a single-center experience in Saudi Arabia."/>
   <result pre="aspects and outcomes of 70 patients with Middle East respiratory" exact="syndrome" post="coronavirus infection: a single-center experience in Saudi Arabia. Int"/>
   <result pre="37.ArabiYM, Al-OmariA, MandourahYet al..Critically ill patients with the Middle East" exact="respiratory" post="syndrome: a multicenter retrospective cohort study. Crit Care Med."/>
   <result pre="38.ChoiWS, KangCI, KimYet al..Clinical presentation and outcomes of Middle East" exact="respiratory" post="syndrome in the Republic of Korea. Infect Chemother. 2016;48(2):118-126.27433382"/>
   <result pre="KangCI, KimYet al..Clinical presentation and outcomes of Middle East respiratory" exact="syndrome" post="in the Republic of Korea. Infect Chemother. 2016;48(2):118-126.27433382 39.AssiriA,"/>
   <result pre="demographic, and clinical characteristics of 47 cases of Middle East" exact="respiratory" post="syndrome coronavirus disease from Saudi Arabia: a descriptive study."/>
   <result pre="and clinical characteristics of 47 cases of Middle East respiratory" exact="syndrome" post="coronavirus disease from Saudi Arabia: a descriptive study. Lancet"/>
   <result pre="characteristics of 47 cases of Middle East respiratory syndrome coronavirus" exact="disease" post="from Saudi Arabia: a descriptive study. Lancet Infect Dis."/>
   <result pre="Al-HameedF, MandourahYet al..Critically ill healthcare workers with the Middle East" exact="respiratory" post="syndrome (MERS): a multicenter study. PLoS One. 2018;13(11):e0206831.30439974 41.AleanizyFS,"/>
   <result pre="MandourahYet al..Critically ill healthcare workers with the Middle East respiratory" exact="syndrome" post="(MERS): a multicenter study. PLoS One. 2018;13(11):e0206831.30439974 41.AleanizyFS, MohmedN,"/>
   <result pre="2018;13(11):e0206831.30439974 41.AleanizyFS, MohmedN, AlqahtaniFY, El Hadi MohamedRAOutbreak of Middle East" exact="respiratory" post="syndrome coronavirus in Saudi Arabia: a retrospective study. BMC"/>
   <result pre="41.AleanizyFS, MohmedN, AlqahtaniFY, El Hadi MohamedRAOutbreak of Middle East respiratory" exact="syndrome" post="coronavirus in Saudi Arabia: a retrospective study. BMC Infect"/>
   <result pre="TsangOet al..Outcomes and prognostic factors in 267 patients with severe" exact="acute" post="respiratory syndrome in Hong Kong. Ann Intern Med. 2003;139(9):715-723.14597455"/>
   <result pre="al..Outcomes and prognostic factors in 267 patients with severe acute" exact="respiratory" post="syndrome in Hong Kong. Ann Intern Med. 2003;139(9):715-723.14597455 43.TsaiLK,"/>
   <result pre="and prognostic factors in 267 patients with severe acute respiratory" exact="syndrome" post="in Hong Kong. Ann Intern Med. 2003;139(9):715-723.14597455 43.TsaiLK, HsiehST,"/>
   <result pre="Ann Intern Med. 2003;139(9):715-723.14597455 43.TsaiLK, HsiehST, ChangYCNeurological manifestations in severe" exact="acute" post="respiratory syndrome. Acta Neurol Taiwan. 2005;14(3):113-119. 16252612 44.LeungCW, ChiuWKClinical"/>
   <result pre="Intern Med. 2003;139(9):715-723.14597455 43.TsaiLK, HsiehST, ChangYCNeurological manifestations in severe acute" exact="respiratory" post="syndrome. Acta Neurol Taiwan. 2005;14(3):113-119. 16252612 44.LeungCW, ChiuWKClinical picture,"/>
   <result pre="16252612 44.LeungCW, ChiuWKClinical picture, diagnosis, treatment and outcome of severe" exact="acute" post="respiratory syndrome (SARS) in children. Paediatr Respir Rev. 2004;5(4):275-288.15531251"/>
   <result pre="44.LeungCW, ChiuWKClinical picture, diagnosis, treatment and outcome of severe acute" exact="respiratory" post="syndrome (SARS) in children. Paediatr Respir Rev. 2004;5(4):275-288.15531251 45.LienTC,"/>
   <result pre="ChiuWKClinical picture, diagnosis, treatment and outcome of severe acute respiratory" exact="syndrome" post="(SARS) in children. Paediatr Respir Rev. 2004;5(4):275-288.15531251 45.LienTC, SungCS,"/>
   <result pre="2004;5(4):275-288.15531251 45.LienTC, SungCS, LeeCHet al..Characteristic features and outcomes of severe" exact="acute" post="respiratory syndrome found in severe acute respiratory syndrome intensive"/>
   <result pre="45.LienTC, SungCS, LeeCHet al..Characteristic features and outcomes of severe acute" exact="respiratory" post="syndrome found in severe acute respiratory syndrome intensive care"/>
   <result pre="SungCS, LeeCHet al..Characteristic features and outcomes of severe acute respiratory" exact="syndrome" post="found in severe acute respiratory syndrome intensive care unit"/>
   <result pre="and outcomes of severe acute respiratory syndrome found in severe" exact="acute" post="respiratory syndrome intensive care unit patients. J Crit Care."/>
   <result pre="outcomes of severe acute respiratory syndrome found in severe acute" exact="respiratory" post="syndrome intensive care unit patients. J Crit Care. 2008;23(4):557-564.19056023"/>
   <result pre="of severe acute respiratory syndrome found in severe acute respiratory" exact="syndrome" post="intensive care unit patients. J Crit Care. 2008;23(4):557-564.19056023 46.MaoL,"/>
   <result pre="WuD, ChenHet al..Clinical characteristics of 113 deceased patients with coronavirus" exact="disease" post="2019: retrospective study. BMJ. 2020;368:m1091.32217556 49.WuJ, LiuJ, ZhaoXet al..Clinical"/>
   <result pre="epidemiological and clinical features in older patients with corona virus" exact="disease" post="2019 (COVID-19) out of Wuhan. Clin Infect Dis. published"/>
   <result pre="YangB, LiQ, WenL, ZhangRClinical features of 69 cases with coronavirus" exact="disease" post="2019 in Wuhan, China. Clin Infect Dis. published online:"/>
   <result pre="WangSet al..Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2" exact="infection" post="in Wuhan, China: a retrospective single center analysis. Travel"/>
   <result pre="al..Clinical characteristics and imaging manifestations of the 2019 novel coronavirus" exact="disease" post="(COVID-19): a multi-center study in Wenzhou city, Zhejiang, China."/>
   <result pre="al..Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study. Lancet"/>
   <result pre="24, 2020 (doi:10.1016/S2213-2600(20)30079-5). 59.GuanWJ, NiZY, HuYet al..Clinical characteristics of coronavirus" exact="disease" post="2019 in China. N Engl J Med. published online:"/>
   <result pre="Emergency Response Center, Epidemiology Case Management Team, Korea Centers for" exact="Disease" post="Control PreventionEarly epidemiological and clinical characteristics of 28 cases"/>
   <result pre="PreventionEarly epidemiological and clinical characteristics of 28 cases of coronavirus" exact="disease" post="in South Korea. Osong Public Health Res Perspect. 2020;11(1):8-14.32149037"/>
   <result pre="2020;395(10223):497-506. 62.ZhengF, LiaoC, FanQHet al..Clinical characteristics of children with coronavirus" exact="disease" post="2019 in Hubei, China. Curr Med Sci. published online:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7202122/results/search/disease/results.xml">
   <result pre="Address correspondence to Marvin G. Chang, MD, PhD, Division of" exact="Cardiac" post="Anesthesia and Critical Care, Department of Anesthesia, Critical Care"/>
   <result pre="Care, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts" exact="General" post="Hospital, Boston, MA 02114. Address e-mail to mgchang@mgh.harvard.edu. epub:"/>
   <result pre="and case reports and discusses the unifying findings from coronavirus" exact="disease" post="(COVID-19) patients and from the avian (H7N9) and H1N1"/>
   <result pre="bedside option in the initial evaluation, management, and monitoring of" exact="disease" post="progression in patients with confirmed or suspected COVID-19 infection."/>
   <result pre="with confirmed or suspected COVID-19 infection. Amid the recent coronavirus" exact="disease" post="(COVID-19) outbreak and resulting pandemic, there has been a"/>
   <result pre="are suspected to be infected with the virus. Given the" exact="limited" post="supply, cost, and often slow turnaround time of available"/>
   <result pre="findings before the onset of severe clinical symptoms.1 However, the" exact="American" post="College of Radiology recommends that computed tomography not be"/>
   <result pre="diagnose COVID-19 and that it be used sparingly in hospitalized," exact="symptomatic" post="patients given the risk of infection transmission posed to"/>
   <result pre="used sparingly in hospitalized, symptomatic patients given the risk of" exact="infection" post="transmission posed to staff and subsequent patients.2 There is"/>
   <result pre="evidence that lung point-of-care ultrasound (POCUS) may be comparable to" exact="chest" post="radiography and to computed tomography in terms of its"/>
   <result pre="tomography in terms of its ability to detect parenchymal and" exact="pleural" post="pathology and to monitor response to therapies.3 Historically, ultrasound"/>
   <result pre="an important tool for the rapid evaluation and assessment of" exact="pulmonary" post="status in patients during the 2013 avian influenza A"/>
   <result pre="and assessment of pulmonary status in patients during the 2013" exact="avian influenza" post="A (H7N9) epidemic.4,5 Similarly, lung ultrasound may aid in"/>
   <result pre="COVID-19 infections, perhaps even before the onset or progression of" exact="respiratory" post="symptoms. Here, we review the ultrasound findings reported from"/>
   <result pre="bedside option in the initial evaluation, management, and monitoring of" exact="disease" post="progression in patients with confirmed or suspected COVID-19 infection."/>
   <result pre="y (3 cases &amp;gt;65 y) with fever, radiographic features of" exact="pneumonia" post="by computed tomography, and normal or decreased white blood"/>
   <result pre="(&quot;Waterfall Sign&quot;), at times fused and fixed (&quot;White Lung Sign&quot;)Rough" exact="pleural" post="linesSubpleural pulmonary consolidationsDecreased blood flowAir bronchograms Jin et al1"/>
   <result pre="at times fused and fixed (&quot;White Lung Sign&quot;)Rough pleural linesSubpleural" exact="pulmonary" post="consolidationsDecreased blood flowAir bronchograms Jin et al1 (2020) Xiangya"/>
   <result pre="acuity not mentioned) Not identified 12 Zone Method Thickening of" exact="pleural" post="line and irregularitiesB lines in various patternsMultiple patterns of"/>
   <result pre="fever and flu-like symptoms, found to have perihilar infiltrates on" exact="chest" post="radiograph and lymphopenia Unidentified portable ultrasound 12 Zone Method"/>
   <result pre="symptoms, found to have perihilar infiltrates on chest radiograph and" exact="lymphopenia" post="Unidentified portable ultrasound 12 Zone Method Pleural irregularitiesSubpleural consolidationsAreas"/>
   <result pre="chest radiograph and lymphopenia Unidentified portable ultrasound 12 Zone Method" exact="Pleural" post="irregularitiesSubpleural consolidationsAreas of thick, confluent B lines as well"/>
   <result pre="days 1–9 after COVID-19 diagnosis Butterfly iQ Not reported Small" exact="bilateral" post="pleural effusions with a thickened pleural lineBasal B linesPresence"/>
   <result pre="1–9 after COVID-19 diagnosis Butterfly iQ Not reported Small bilateral" exact="pleural" post="effusions with a thickened pleural lineBasal B linesPresence and"/>
   <result pre="iQ Not reported Small bilateral pleural effusions with a thickened" exact="pleural" post="lineBasal B linesPresence and spread of subpleural consolidationsNormal lung"/>
   <result pre="of subpleural consolidationsNormal lung ultrasound initiallyUltrasound findings occur in the" exact="absence of" post="shortness of breath/dyspnea and occur before malaise Thomas et"/>
   <result pre="breath/dyspnea and occur before malaise Thomas et al8 (2020) Victoria" exact="General" post="Hospital (British Columbia, Canada) 1 Critical COVID-19–confirmed patient, 64-y-old"/>
   <result pre="after symptom onset with fevers, hypoxemia (Sp O2 88%), and" exact="bilateral" post="infiltrates on chest radiograph Not identified Not reported Pleural"/>
   <result pre="with fevers, hypoxemia (Sp O2 88%), and bilateral infiltrates on" exact="chest" post="radiograph Not identified Not reported Pleural thickeningSubpleural consolidations, (&quot;skip"/>
   <result pre="and bilateral infiltrates on chest radiograph Not identified Not reported" exact="Pleural" post="thickeningSubpleural consolidations, (&quot;skip lesions&quot;)Multifocal B lines Abbreviations: COVID-19, coronavirus"/>
   <result pre="Pleural thickeningSubpleural consolidations, (&quot;skip lesions&quot;)Multifocal B lines Abbreviations: COVID-19, coronavirus" exact="disease" post="2019; POCUS, point-of-care ultrasound; SpO2 peripheral oxygen saturation. Huang"/>
   <result pre="lines Abbreviations: COVID-19, coronavirus disease 2019; POCUS, point-of-care ultrasound; SpO2" exact="peripheral" post="oxygen saturation. Huang et al7 utilized lung ultrasound to"/>
   <result pre="in COVID-19 patients. Lung ultrasound in these patients demonstrated (1)" exact="posterior" post="and inferior lung field lesions, (2) B lines, (3)"/>
   <result pre="and inferior lung field lesions, (2) B lines, (3) distorted" exact="pleural" post="lines, (4) subpleural pulmonary consolidations, and (5) air bronchograms.7"/>
   <result pre="lesions, (2) B lines, (3) distorted pleural lines, (4) subpleural" exact="pulmonary" post="consolidations, and (5) air bronchograms.7 While these findings may"/>
   <result pre="findings may not be specific to COVID-19 compared to other" exact="viral" post="pneumonias, identification of these patterns during a pandemic could"/>
   <result pre="of computed tomography and superior results to those of standard" exact="chest" post="radiographs.1 Their findings included (1) thickening of the pleural"/>
   <result pre="standard chest radiographs.1 Their findings included (1) thickening of the" exact="pleural" post="line with irregularity, (2) B lines, (3) consolidation, (4)"/>
   <result pre="the appearance of A lines during recovery, and (5) the" exact="absence of" post="pleural effusions.1 They concluded that ultrasound was an effective"/>
   <result pre="of A lines during recovery, and (5) the absence of" exact="pleural" post="effusions.1 They concluded that ultrasound was an effective way"/>
   <result pre="an effective way to assess the severity of a patient’s" exact="pulmonary" post="disease and to trend their disease progression and guide"/>
   <result pre="effective way to assess the severity of a patient’s pulmonary" exact="disease" post="and to trend their disease progression and guide eventual"/>
   <result pre="severity of a patient’s pulmonary disease and to trend their" exact="disease" post="progression and guide eventual respiratory weaning. Dr Yale Tung"/>
   <result pre="disease and to trend their disease progression and guide eventual" exact="respiratory" post="weaning. Dr Yale Tung Chen,6 an emergency physician from"/>
   <result pre="own lungs and share his findings on Twitter as his" exact="disease" post="progressed.6 His ultrasound findings were (1) small bilateral pleural"/>
   <result pre="as his disease progressed.6 His ultrasound findings were (1) small" exact="bilateral" post="pleural effusions with a thickened pleural line, (2) basal"/>
   <result pre="his disease progressed.6 His ultrasound findings were (1) small bilateral" exact="pleural" post="effusions with a thickened pleural line, (2) basal B"/>
   <result pre="findings were (1) small bilateral pleural effusions with a thickened" exact="pleural" post="line, (2) basal B lines, and (3) the presence"/>
   <result pre="lesions7Confluent and isolated B lines (Figure B and C; Supplemental" exact="Digital" post="Content 2, Video 2, http://links.lww.com/AA/D95; Supplemental Digital Content 3,"/>
   <result pre="and C; Supplemental Digital Content 2, Video 2, http://links.lww.com/AA/D95; Supplemental" exact="Digital" post="Content 3, Video 3, http://links.lww.com/AA/D96; and Supplemental Digital Content"/>
   <result pre="http://links.lww.com/AA/D95; Supplemental Digital Content 3, Video 3, http://links.lww.com/AA/D96; and Supplemental" exact="Digital" post="Content 4, Video 4, http://links.lww.com/AA/D97)1,6–9Thickened and/or irregular pleural lines"/>
   <result pre="and Supplemental Digital Content 4, Video 4, http://links.lww.com/AA/D97)1,6–9Thickened and/or irregular" exact="pleural" post="lines (Figure B, C, and E; Supplemental Digital Content"/>
   <result pre="and/or irregular pleural lines (Figure B, C, and E; Supplemental" exact="Digital" post="Content 2, Video 2, http://links.lww.com/AA/D95; Supplemental Digital Content 3,"/>
   <result pre="and E; Supplemental Digital Content 2, Video 2, http://links.lww.com/AA/D95; Supplemental" exact="Digital" post="Content 3, Video 3, http://links.lww.com/AA/D96; and Supplemental Digital Content"/>
   <result pre="http://links.lww.com/AA/D95; Supplemental Digital Content 3, Video 3, http://links.lww.com/AA/D96; and Supplemental" exact="Digital" post="Content 4, Video 4, http://links.lww.com/AA/D97)1,6–9Presence of subpleural consolidations (Figure"/>
   <result pre="4, http://links.lww.com/AA/D97)1,6–9Presence of subpleural consolidations (Figure D and F; Supplemental" exact="Digital" post="Content 3, Video 3, http://links.lww.com/AA/D96 and Supplemental Digital Content"/>
   <result pre="F; Supplemental Digital Content 3, Video 3, http://links.lww.com/AA/D96 and Supplemental" exact="Digital" post="Content 5, Video 5, http://links.lww.com/AA/D98)1,6–9Air bronchograms (Figure F; Supplemental"/>
   <result pre="Digital Content 5, Video 5, http://links.lww.com/AA/D98)1,6–9Air bronchograms (Figure F; Supplemental" exact="Digital" post="Content 5, Video 5, http://links.lww.com/AA/D98)1,7 Abbreviations: COVID-19, coronavirus disease"/>
   <result pre="Supplemental Digital Content 5, Video 5, http://links.lww.com/AA/D98)1,7 Abbreviations: COVID-19, coronavirus" exact="disease" post="2019; POCUS, point-of-care ultrasound. Figure. Common lung ultrasound findings"/>
   <result pre="patients may reveal normal lungs with A lines (A; Supplemental" exact="Digital" post="Content 1, Video 1, http://links.lww.com/AA/D94) during the earliest stage"/>
   <result pre="earliest stage of the infection, isolated B lines (B; Supplemental" exact="Digital" post="Content 2, Video 2, http://links.lww.com/AA/D95; Supplemental Digital Content 3,"/>
   <result pre="lines (B; Supplemental Digital Content 2, Video 2, http://links.lww.com/AA/D95; Supplemental" exact="Digital" post="Content 3, Video 3, http://links.lww.com/AA/D96; Supplemental Digital Content, Video"/>
   <result pre="2, http://links.lww.com/AA/D95; Supplemental Digital Content 3, Video 3, http://links.lww.com/AA/D96; Supplemental" exact="Digital" post="Content, Video 4, http://links.lww.com/AA/D97), confluent B lines (C; Supplemental"/>
   <result pre="Digital Content, Video 4, http://links.lww.com/AA/D97), confluent B lines (C; Supplemental" exact="Digital" post="Content 2, Video 2, http://links.lww.com/AA/D95), thickened and irregular pleural"/>
   <result pre="Supplemental Digital Content 2, Video 2, http://links.lww.com/AA/D95), thickened and irregular" exact="pleural" post="lines (D; Supplemental Digital Content 2, Video 2, http://links.lww.com/AA/D95;"/>
   <result pre="Video 2, http://links.lww.com/AA/D95), thickened and irregular pleural lines (D; Supplemental" exact="Digital" post="Content 2, Video 2, http://links.lww.com/AA/D95; Supplemental Digital Content 3,"/>
   <result pre="lines (D; Supplemental Digital Content 2, Video 2, http://links.lww.com/AA/D95; Supplemental" exact="Digital" post="Content 3, Video 3, http://links.lww.com/AA/D96; Supplemental Digital Content 4,"/>
   <result pre="2, http://links.lww.com/AA/D95; Supplemental Digital Content 3, Video 3, http://links.lww.com/AA/D96; Supplemental" exact="Digital" post="Content 4, Video 4, http://links.lww.com/AA/D97), thickening and jagged pleural"/>
   <result pre="Supplemental Digital Content 4, Video 4, http://links.lww.com/AA/D97), thickening and jagged" exact="pleural" post="lines (E; Supplemental Digital Content 4, Video 4, http://links.lww.com/AA/D97),"/>
   <result pre="Video 4, http://links.lww.com/AA/D97), thickening and jagged pleural lines (E; Supplemental" exact="Digital" post="Content 4, Video 4, http://links.lww.com/AA/D97), and/or subpleural consolidation with"/>
   <result pre="4, http://links.lww.com/AA/D97), and/or subpleural consolidation with air bronchograms (F; Supplemental" exact="Digital" post="Content 5, Video 5, http://links.lww.com/AA/D98).10 COVID-19 indicates coronavirus disease"/>
   <result pre="Supplemental Digital Content 5, Video 5, http://links.lww.com/AA/D98).10 COVID-19 indicates coronavirus" exact="disease" post="2019. Table 2 summarizes the ultrasound findings from the"/>
   <result pre="above and includes (1) subpleural lesions in the inferior and" exact="posterior" post="regions of the lung, which seems to be highly"/>
   <result pre="which seems to be highly consistent with other cases of" exact="viral pneumonia" post="(Figure D and F; Supplemental Digital Content 3, Video"/>
   <result pre="seems to be highly consistent with other cases of viral" exact="pneumonia" post="(Figure D and F; Supplemental Digital Content 3, Video"/>
   <result pre="other cases of viral pneumonia (Figure D and F; Supplemental" exact="Digital" post="Content 3, Video 3, http://links.lww.com/AA/D96 and Supplemental Digital Content"/>
   <result pre="F; Supplemental Digital Content 3, Video 3, http://links.lww.com/AA/D96 and Supplemental" exact="Digital" post="Content 5, Video 5, http://links.lww.com/AA/D98)1,6,7; (2) individual and confluent"/>
   <result pre="individual and confluent B lines (Figure B and C; Supplemental" exact="Digital" post="Content 2, Video 2, http://links.lww.com/AA/D95; Supplemental Digital Content 3,"/>
   <result pre="and C; Supplemental Digital Content 2, Video 2, http://links.lww.com/AA/D95; Supplemental" exact="Digital" post="Content 3, Video 3, http://links.lww.com/AA/D96; and Supplemental Digital Content"/>
   <result pre="http://links.lww.com/AA/D95; Supplemental Digital Content 3, Video 3, http://links.lww.com/AA/D96; and Supplemental" exact="Digital" post="Content 4, Video 4, http://links.lww.com/AA/D97)1,6–9; (3) signs of air"/>
   <result pre="(3) signs of air bronchograms, especially peripherally (Figure F; Supplemental" exact="Digital" post="Content 5, Video 5, http://links.lww.com/AA/D98)1,7–9; and (4) thickened or"/>
   <result pre="Content 5, Video 5, http://links.lww.com/AA/D98)1,7–9; and (4) thickened or irregular" exact="pleural" post="lines (Figure B, C, and E; Supplemental Digital Content"/>
   <result pre="or irregular pleural lines (Figure B, C, and E; Supplemental" exact="Digital" post="Content 2, Video 2, http://links.lww.com/AA/D95; Supplemental Digital Content 3,"/>
   <result pre="and E; Supplemental Digital Content 2, Video 2, http://links.lww.com/AA/D95; Supplemental" exact="Digital" post="Content 3, Video 3, http://links.lww.com/AA/D96; and Supplemental Digital Content"/>
   <result pre="http://links.lww.com/AA/D95; Supplemental Digital Content 3, Video 3, http://links.lww.com/AA/D96; and Supplemental" exact="Digital" post="Content 4, Video 4, http://links.lww.com/AA/D97).1,6–9 Some of these findings"/>
   <result pre="Video 4, http://links.lww.com/AA/D97).1,6–9 Some of these findings are consistent with" exact="viral" post="pneumonias from prior epidemics, including the subpleural consolidations described"/>
   <result pre="A (H1N1) and subpleural consolidations and B lines described in" exact="avian influenza" post="A (H7N9).5,6,9 In contrast, normal lungs have an A-line"/>
   <result pre="contrast, normal lungs have an A-line pattern (Figure A; Supplemental" exact="Digital" post="Content 1, Video 1, http://links.lww.com/AA/D94). THE USE OF LUNG"/>
   <result pre="rapidly deteriorated from self-limited febrile illness to an aggressive pneumonia," exact="chest" post="radiographs often failed to identify early interstitial lung disease.11"/>
   <result pre="disease.11 A cross-sectional study demonstrated abnormal ultrasound patterns showing interstitial" exact="syndrome" post="in 15 of 16 patients who presented with normal"/>
   <result pre="syndrome in 15 of 16 patients who presented with normal" exact="chest" post="radiographs, 63% of whom were subsequently diagnosed with viral"/>
   <result pre="normal chest radiographs, 63% of whom were subsequently diagnosed with" exact="viral" post="(H1N1) pneumonia and 38% of whom were diagnosed with"/>
   <result pre="radiographs, 63% of whom were subsequently diagnosed with viral (H1N1)" exact="pneumonia" post="and 38% of whom were diagnosed with bacterial pneumonia.9"/>
   <result pre="viral (H1N1) pneumonia and 38% of whom were diagnosed with" exact="bacterial" post="pneumonia.9 Overall, lung ultrasound was found to have 94%"/>
   <result pre="86% and a negative predictive value of 96% and outperformed" exact="chest" post="radiography for the detection of viral pneumonia in symptomatic"/>
   <result pre="of 96% and outperformed chest radiography for the detection of" exact="viral pneumonia" post="in symptomatic patients.5 The avian influenza A (H7N9) epidemics"/>
   <result pre="96% and outperformed chest radiography for the detection of viral" exact="pneumonia" post="in symptomatic patients.5 The avian influenza A (H7N9) epidemics"/>
   <result pre="outperformed chest radiography for the detection of viral pneumonia in" exact="symptomatic" post="patients.5 The avian influenza A (H7N9) epidemics of 2013–2014"/>
   <result pre="for the detection of viral pneumonia in symptomatic patients.5 The" exact="avian influenza" post="A (H7N9) epidemics of 2013–2014 and 2016 saw large"/>
   <result pre="A (H7N9) epidemics of 2013–2014 and 2016 saw large regional" exact="infection" post="in China with a documented 1222 infections and a"/>
   <result pre="saw large regional infection in China with a documented 1222" exact="infections" post="and a death rate of 40%.12 Serial lung ultrasounds"/>
   <result pre="demonstrated the effectiveness of POCUS in the early identification of" exact="pneumonia" post="secondary to the H7N9 virus.4,5 In both patients who"/>
   <result pre="the effectiveness of POCUS in the early identification of pneumonia" exact="secondary" post="to the H7N9 virus.4,5 In both patients who eventually"/>
   <result pre="to the H7N9 virus.4,5 In both patients who eventually developed" exact="acute" post="respiratory distress syndrome (ARDS) as a result of the"/>
   <result pre="the H7N9 virus.4,5 In both patients who eventually developed acute" exact="respiratory" post="distress syndrome (ARDS) as a result of the infection,"/>
   <result pre="virus.4,5 In both patients who eventually developed acute respiratory distress" exact="syndrome" post="(ARDS) as a result of the infection, serial lung"/>
   <result pre="of the infection, serial lung ultrasound examinations showed B lines," exact="pleural" post="effusions, and small subpleural consolidations. These findings are consistent"/>
   <result pre="consolidations. These findings are consistent with previously documented findings in" exact="viral" post="pulmonary infections such as measles and H1N1.4,5 Thus, ultrasonography"/>
   <result pre="These findings are consistent with previously documented findings in viral" exact="pulmonary" post="infections such as measles and H1N1.4,5 Thus, ultrasonography has"/>
   <result pre="findings are consistent with previously documented findings in viral pulmonary" exact="infections" post="such as measles and H1N1.4,5 Thus, ultrasonography has repeatedly"/>
   <result pre="with previously documented findings in viral pulmonary infections such as" exact="measles" post="and H1N1.4,5 Thus, ultrasonography has repeatedly proven to be"/>
   <result pre="to aid in both diagnosing and monitoring the progression of" exact="viral" post="pneumonias. Its safety, in terms of lack of radiation"/>
   <result pre="of radiation exposure, lack of portability, and heightened risk of" exact="infectious" post="spread.4,5 THE USE OF LUNG POCUS IN TODAY’S PANDEMIC:"/>
   <result pre="access to hospitals and care centers that are resource limited.13" exact="Transport" post="of these large devices to remote areas also creates"/>
   <result pre="$2500.14 A single handheld probe can be easily sterilized, while" exact="complete" post="sterilization of the knobs, buttons, screens, and carts of"/>
   <result pre="probe covers can further help to reduce the risk of" exact="infectious" post="spread from portable devices.14 The use of portable ultrasound"/>
   <result pre="skills on demand, allowing for increased adoption among clinicians with" exact="limited" post="ultrasound experience.15 Teleguidance further assists novice users by allowing"/>
   <result pre="and recent case reports, lung ultrasound may be preferred over" exact="chest" post="radiography or computed tomography in the diagnosis and monitoring"/>
   <result pre="of bedside use, low associated cost, and reduced risk of" exact="infectious" post="spread.1,4 Lung ultrasound can help clinicians to differentiate between"/>
   <result pre="Lung ultrasound can help clinicians to differentiate between a possible" exact="pneumonia" post="and alternative causes of dyspnea while awaiting confirmatory testing"/>
   <result pre="helpful to track the clinical trajectory of a seemingly unpredictable" exact="disease" post="course and guide suitable treatment options and timing of"/>
   <result pre="dynamic air bronchograms may suggest the development of a superimposed" exact="bacterial pneumonia." post="In addition to other clinical parameters, such ultrasound findings"/>
   <result pre="support a decision to initiate antibiotics.15 Consolidations that are more" exact="posterior" post="may advocate for early prone positioning in the appropriate"/>
   <result pre="for additional PEEP and recruitment maneuvers. Although less common in" exact="viral pneumonia," post="the size, location, and appearance of any pleural effusions"/>
   <result pre="in viral pneumonia, the size, location, and appearance of any" exact="pleural" post="effusions can be assessed by lung ultrasound to determine"/>
   <result pre="consolidations suggest recovery and would support a decision to wean" exact="respiratory" post="support. Although beyond the scope of this article, it"/>
   <result pre="cardiomyopathy19 and who may have weaning failure that is of" exact="cardiovascular" post="origin.20 CONCLUSIONS The COVID-19 pandemic has presented many new"/>
   <result pre="Material LINK LINK LINK LINK LINK FOOTNOTES GLOSSARY ARDS =" exact="acute" post="respiratory distress syndrome COVID-19 = coronavirus disease 2019 PEEP"/>
   <result pre="LINK LINK LINK LINK LINK FOOTNOTES GLOSSARY ARDS = acute" exact="respiratory" post="distress syndrome COVID-19 = coronavirus disease 2019 PEEP ="/>
   <result pre="LINK LINK LINK FOOTNOTES GLOSSARY ARDS = acute respiratory distress" exact="syndrome" post="COVID-19 = coronavirus disease 2019 PEEP = positive end-expiratory"/>
   <result pre="GLOSSARY ARDS = acute respiratory distress syndrome COVID-19 = coronavirus" exact="disease" post="2019 PEEP = positive end-expiratory pressure POCUS = point-of-care"/>
   <result pre="= point-of-care ultrasound PPOCUS = portable point-of-care ultrasound SpO2 =" exact="peripheral" post="oxygen saturation Published ahead of print 30 April 2020."/>
   <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version).Mil Med Res. 2020;7:4.32029004 2.collab: Radiology ACR. ACR"/>
   <result pre="2020;7:4.32029004 2.collab: Radiology ACR. ACR recommendations for the use of" exact="chest" post="radiography and computed tomography (CT) for suspected COVID-19 infection."/>
   <result pre="ultrasound: present and future.Lung India. 2015;32:250–257.25983411 4.TsaiNWNgaiCWMokKLTsungJWLung ultrasound imaging in" exact="avian influenza" post="A (H7N9) respiratory failure.Crit Ultrasound J. 2014;6:6.24949191 5.Yu-Kun ZhangJLJian-pingYYingZJunCLung"/>
   <result pre="India. 2015;32:250–257.25983411 4.TsaiNWNgaiCWMokKLTsungJWLung ultrasound imaging in avian influenza A (H7N9)" exact="respiratory" post="failure.Crit Ultrasound J. 2014;6:6.24949191 5.Yu-Kun ZhangJLJian-pingYYingZJunCLung ultrasonography for the"/>
   <result pre="5.Yu-Kun ZhangJLJian-pingYYingZJunCLung ultrasonography for the diagnosis of 11 patients with" exact="acute" post="respiratory distress syndrome due to bird flu H7N9 infection.Virol"/>
   <result pre="ZhangJLJian-pingYYingZJunCLung ultrasonography for the diagnosis of 11 patients with acute" exact="respiratory" post="distress syndrome due to bird flu H7N9 infection.Virol J."/>
   <result pre="for the diagnosis of 11 patients with acute respiratory distress" exact="syndrome" post="due to bird flu H7N9 infection.Virol J. 2015;12:176.26503117 6.collab:"/>
   <result pre="of 11 patients with acute respiratory distress syndrome due to" exact="bird flu" post="H7N9 infection.Virol J. 2015;12:176.26503117 6.collab: yaletung. (2020, March 9)."/>
   <result pre="headache (thank God!), still no shortness of breath or pleuritic" exact="chest" post="pain. #POCUS update: small bilateral pleural effusion, thickened pleural"/>
   <result pre="shortness of breath or pleuritic chest pain. #POCUS update: small" exact="bilateral" post="pleural effusion, thickened pleural line &amp;amp; basal b-lines (plaps)."/>
   <result pre="of breath or pleuritic chest pain. #POCUS update: small bilateral" exact="pleural" post="effusion, thickened pleural line &amp;amp; basal b-lines (plaps). #coronavirus"/>
   <result pre="pleuritic chest pain. #POCUS update: small bilateral pleural effusion, thickened" exact="pleural" post="line &amp;amp; basal b-lines (plaps). #coronavirus [Tweet]. https://twitter.com/yaletung/status/1237292028221960193;yaletung. (2020,"/>
   <result pre="Yesterday was cough day, still no shortness of breath/chest pain." exact="Diarrhea" post="started, lucky cough got better. #POCUS update: similar effusion,"/>
   <result pre="cough got better. #POCUS update: similar effusion, seems less thickened" exact="pleural" post="line + no b-lines (PLAPS). #mycoviddiary [Tweet]. https://twitter.com/yaletung/status/1237688008444391425;yaletung. (2020,"/>
   <result pre="update: Right side on resolution, Left side a more thickened" exact="pleural" post="line + 2 subpleural consolidations. #mycoviddiary [Tweet]. https://twitter.com/yaletung/status/1238059289094295552;yaletung. (2020,"/>
   <result pre="update: Effusion resolved, as subpleural consolidations spread bilaterally on both" exact="posterior" post="lower lobes. Started on HCQ yesterday. #mycoviddiary [Tweet]. https://twitter.com/yaletung/status/1238369049039515649;yaletung."/>
   <result pre="Effusion resolved, as subpleural consolidations spread bilaterally on both posterior" exact="lower" post="lobes. Started on HCQ yesterday. #mycoviddiary [Tweet]. https://twitter.com/yaletung/status/1238369049039515649;yaletung. (2020,"/>
   <result pre="no dyspnea. No fever. Oxygen saturation 98%. #POCUS update: thick" exact="pleural" post="line, b-lines and subpleural consolidations tend to resolve. Significant"/>
   <result pre="fever. SpO2 96%. #POCUS update: similar to yesterday - thick" exact="pleural" post="line, b-lines &amp;amp; consolidations tend to resolve. On paracetamol"/>
   <result pre="symptoms. No fever. SpO2 96%. #POCUS update: Right resolved. Left" exact="lower" post="lobe much better. Left lateral appeared new focal B-lines."/>
   <result pre="resolved. Left lower lobe much better. Left lateral appeared new" exact="focal" post="B-lines. On paracetamol + HCQ. #mycoviddiary [Tweet]. https://twitter.com/yaletung/status/1239482409604861952;yaletung. (2020,"/>
   <result pre="No fever. SpO2 97%. #POCUS update: similar to yesterday. Left" exact="lower" post="&amp;amp; lateral with thick pleural line &amp;amp; focal B-lines."/>
   <result pre="update: similar to yesterday. Left lower &amp;amp; lateral with thick" exact="pleural" post="line &amp;amp; focal B-lines. On paracetamol + HCQ. #mycoviddiary"/>
   <result pre="yesterday. Left lower &amp;amp; lateral with thick pleural line &amp;amp;" exact="focal" post="B-lines. On paracetamol + HCQ. #mycoviddiary [Tweet]. https://twitter.com/yaletung/status/1239829327015022593. 7.HuangYWangSLiuYA"/>
   <result pre="the ultrasonic manifestations of peripulmonary lesions of non-critical novel coronavirus" exact="pneumonia" post="(COVID-19).SSRN. 2020 February 26 [Epub ahead of print]. 8.ThomasAHaljanGMitraALung"/>
   <result pre="infection.AJR Am J Roentgenol. 2009;193:1488–1493.19933638 12.collab: World Health Organization. Human" exact="infection" post="with avian influenza A (H7N9) virus – China.2017Available at:"/>
   <result pre="J Roentgenol. 2009;193:1488–1493.19933638 12.collab: World Health Organization. Human infection with" exact="avian influenza" post="A (H7N9) virus – China.2017Available at: www.who.int/csr/don/26-october-2017-ah7n9-china/en/. Accessed May"/>
   <result pre="lung ultrasonography during the 2009 H1N1 influenza A pandemic: distinguishing" exact="viral" post="from bacterial pneumonia.Crit Ultrasound J. 2012;4:16.22862998 16.SoldatiGSmargiassiAInchingoloRet al.Proposal for"/>
   <result pre="during the 2009 H1N1 influenza A pandemic: distinguishing viral from" exact="bacterial" post="pneumonia.Crit Ultrasound J. 2012;4:16.22862998 16.SoldatiGSmargiassiAInchingoloRet al.Proposal for international standardization"/>
   <result pre="print]. 17.PratGGuinardSBizienNet al.Can lung ultrasonography predict prone positioning response in" exact="acute" post="respiratory distress syndrome patients?J Crit Care. 2016;32:36–41.26806842 18.WangXTDingXZhangHMChenHSuLXLiuDWcollab: Chinese"/>
   <result pre="17.PratGGuinardSBizienNet al.Can lung ultrasonography predict prone positioning response in acute" exact="respiratory" post="distress syndrome patients?J Crit Care. 2016;32:36–41.26806842 18.WangXTDingXZhangHMChenHSuLXLiuDWcollab: Chinese Critical"/>
   <result pre="lung ultrasonography predict prone positioning response in acute respiratory distress" exact="syndrome" post="patients?J Crit Care. 2016;32:36–41.26806842 18.WangXTDingXZhangHMChenHSuLXLiuDWcollab: Chinese Critical Ultrasound Study"/>
   <result pre="potential of prone positioning and assess prognosis in patients with" exact="acute" post="respiratory distress syndrome.Crit Care. 2016;20:385.27899151 19.ArentzMYimEKlaffLet al.Characteristics and outcomes"/>
   <result pre="of prone positioning and assess prognosis in patients with acute" exact="respiratory" post="distress syndrome.Crit Care. 2016;20:385.27899151 19.ArentzMYimEKlaffLet al.Characteristics and outcomes of"/>
   <result pre="patients with COVID-19 in Washington State.JAMA. 2020;323:1612–1614. 20.RoutsiCStanopoulosIKokkorisSSiderisAZakynthinosSWeaning failure of" exact="cardiovascular" post="origin: how to suspect, detect and treat-a review of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7203543/results/search/disease/results.xml">
   <result pre=": Notes From The Field Challenges to HIV Care and" exact="Psychological" post="Health During the COVID-19 Pandemic Among People Living with"/>
   <result pre="Brown University Alpert Medical School, [3], grid.414379.cYouAn Hospital, Center for" exact="Infectious" post="Diseases, [4], [5], grid.40263.330000 0004 1936 9094Department of Behavioral"/>
   <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
   <result pre="of COVID-19 as a global pandemic. The pandemic of coronavirus" exact="disease" post="2019 (COVID-19) has led to unprecedented disruption in people’s"/>
   <result pre="in China, 32.9–38.4% PLWH reported depressive symptoms and 27.4% experienced" exact="anxiety" post="symptoms [7, 8]. Among patients who regularly attend clinical"/>
   <result pre="in the past ten years, only 15% of PLWH achieved" exact="viral" post="suppression [6]. The COVID-19 outbreak further intensifies existing challenges"/>
   <result pre="Access to Medication Due to the city-level centralized management of" exact="infectious diseases" post="in China (e.g., PLWH are often assigned to certain"/>
   <result pre="COVID-19 cases and the shortage of medical resources, departments of" exact="infectious diseases" post="in many hospitals in China were designated for COVID-19"/>
   <result pre="designated for COVID-19 and suspended on taking new patients with" exact="HIV/AIDS" post="and other infectious diseases. With the dual epidemics (COVID-19"/>
   <result pre="and suspended on taking new patients with HIV/AIDS and other" exact="infectious diseases." post="With the dual epidemics (COVID-19 and HIV) and increased"/>
   <result pre="health system, it was extremely difficult for PLWH with severe" exact="opportunistic infections" post="or other comorbidities to seek medical help, especially when"/>
   <result pre="system, it was extremely difficult for PLWH with severe opportunistic" exact="infections" post="or other comorbidities to seek medical help, especially when"/>
   <result pre="needed. For PLWH in care, maintaining HIV treatment and achieving" exact="viral" post="suppression were also challenging during the COVID-19 outbreak. For"/>
   <result pre="(data collected in February–March 2020), 60.8% reported depression, 49.8% noted" exact="anxiety" post="symptoms, and 38.5% reported recent insomnia. These psychosocial issues"/>
   <result pre="among PLWH [10], including suboptimal medication adherence, failure to achieve" exact="viral" post="suppression, and HIV transmission risk. Conclusion and Implications Lessons"/>
   <result pre="vulnerable populations such as communities affected by HIV during another" exact="infectious disease" post="epidemic. This may also be an opportunity to engage"/>
   <result pre="populations such as communities affected by HIV during another infectious" exact="disease" post="epidemic. This may also be an opportunity to engage"/>
   <result pre="References 1.LiXWangHWilliamsAHeGStigma reported by people living with HIV in South" exact="Central" post="ChinaJ Assoc Nurses AIDS Care2009201223019118768 2.NiuLLuoDLiuYSilenzioVMBXiaoSThe mental health of"/>
   <result pre="in Guangxi, China: a longitudinal studyAIDS Educ Prev2019311385030742482 4.WangTFuHKamingaACLiZGuoGChenLLiQPrevalence of" exact="depression" post="or depressive symptoms among people living with HIV/AIDS in"/>
   <result pre="4.WangTFuHKamingaACLiZGuoGChenLLiQPrevalence of depression or depressive symptoms among people living with" exact="HIV/AIDS" post="in China: a systematic review and meta-analysisBMC Psychiatry20181816011429304757 5.YuYLuoDChenXHuangZWangMXiaoSMedication"/>
   <result pre="Public Health201818118 6.ZhangNBussellSWangGZhuXYangXHuangTQianYTaoXKangDWangNDisparities in HIV care along the path from" exact="infection" post="to viral suppression: a cross-sectional study of HIV/AIDS patient"/>
   <result pre="6.ZhangNBussellSWangGZhuXYangXHuangTQianYTaoXKangDWangNDisparities in HIV care along the path from infection to" exact="viral" post="suppression: a cross-sectional study of HIV/AIDS patient records in"/>
   <result pre="path from infection to viral suppression: a cross-sectional study of" exact="HIV/AIDS" post="patient records in 2013, Shandong Province ChinaClin Infect Dis201663111512127025832"/>
   <result pre="patients with fully successful immune restoration: a cross-sectional study of" exact="anxiety" post="and depression in ChinaFront Psychiatry20189Aug1829410632 8.ZengCLiLHongYAZhangHBabbittAWLiuCLiLQiaoJGuoYCaiWA structural equation model"/>
   <result pre="fully successful immune restoration: a cross-sectional study of anxiety and" exact="depression" post="in ChinaFront Psychiatry20189Aug1829410632 8.ZengCLiLHongYAZhangHBabbittAWLiuCLiLQiaoJGuoYCaiWA structural equation model of perceived"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7225630/results/search/disease/results.xml">
   <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
   <result pre="glycoprotein might guide a path towards a vaccine. Subject terms" exact="Viral" post="proteins Structural biology Virology As SARS-CoV-2 (the cause of"/>
   <result pre="guide a path towards a vaccine. Subject terms Viral proteins" exact="Structural" post="biology Virology As SARS-CoV-2 (the cause of the COVID-19"/>
   <result pre="reminded of what it is like to live with rampant" exact="infectious disease," post="without effective drugs or vaccines. Researchers have piled in"/>
   <result pre="unprecedented speed. One of their main focuses has been the" exact="viral" post="spike glycoprotein that binds to the receptor angiotensin-converting enzyme"/>
   <result pre="large conformational rearrangement from its pre-fusion to post-fusion state, driving" exact="viral" post="fusion with the cell membrane. Coronavirus spikes have been"/>
   <result pre="and MERS-CoV, two related viruses that have caused epidemics of" exact="respiratory" post="disease. A crucial question was whether SARS-CoV-2 resembled either"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7229974/results/search/disease/results.xml">
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="coronavirus, emerging towards the end of 2019 and subsequently named" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, the virus that"/>
   <result pre="emerging towards the end of 2019 and subsequently named Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, the virus that causes"/>
   <result pre="towards the end of 2019 and subsequently named Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2, the virus that causes Coronavirus"/>
   <result pre="the end of 2019 and subsequently named Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2, the virus that causes Coronavirus Disease"/>
   <result pre="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, the virus that causes Coronavirus" exact="Disease" post="2019 [COVID-19]) has been associated with an epidemic initially"/>
   <result pre="globalize world, it immediately became well clear that this fearsome" exact="infection" post="could not be confined to China only, but soon"/>
   <result pre="the country with the highest number of cases of SARS-CoV-2" exact="infection" post="after USA and this has generated an unprecedented health"/>
   <result pre="been investigated, with reported positive outcomes, in outbreaks of other" exact="viral" post="infections, including the 1918 Spanish H1N1 influenza A pandemic"/>
   <result pre="Spanish H1N1 influenza A pandemic and, more recently, the 2003" exact="Avian" post="H5N1 influenza A epidemic, the 2003 SARS-CoV-1 epidemic, the"/>
   <result pre="epidemic, the 2009-2010 H1N1 influenza pandemic, the 2012 Middle East" exact="Respiratory" post="Syndrome (MERS)-CoV epidemic, and the 2014 Ebola epidemic [5]."/>
   <result pre="the 2009-2010 H1N1 influenza pandemic, the 2012 Middle East Respiratory" exact="Syndrome" post="(MERS)-CoV epidemic, and the 2014 Ebola epidemic [5]. Pertaining"/>
   <result pre="epidemic, and the 2014 Ebola epidemic [5]. Pertaining to the" exact="respiratory" post="CoV infections, a number of studies have been conducted"/>
   <result pre="meta-analysis performed in 2015 identified 32 studies of SARS coronavirus" exact="infection" post="and severe influenza. These studies involved 699 treated patients"/>
   <result pre="Following transfusion, 4 out of 5 patients experienced increases in" exact="viral" post="antibody titers, decreases in SARS-CoV-2 viral loads, and normalization"/>
   <result pre="patients experienced increases in viral antibody titers, decreases in SARS-CoV-2" exact="viral" post="loads, and normalization of temperature and resolution of acute"/>
   <result pre="SARS-CoV-2 viral loads, and normalization of temperature and resolution of" exact="acute" post="respiratory distress syndrome (ARDS) [7]. Duan and colleagues presented"/>
   <result pre="viral loads, and normalization of temperature and resolution of acute" exact="respiratory" post="distress syndrome (ARDS) [7]. Duan and colleagues presented a"/>
   <result pre="and normalization of temperature and resolution of acute respiratory distress" exact="syndrome" post="(ARDS) [7]. Duan and colleagues presented a series of"/>
   <result pre="antibody (&amp;gt;1:640) at a median of 16.5 days [8]. The" exact="primary" post="endpoint was safety, which was demonstrated as all patients"/>
   <result pre="all patients tolerated plasma transfusion without severe adverse events. The" exact="secondary" post="endpoints included improvement of clinical symptoms and of laboratory"/>
   <result pre="saturation and lymphocyte count and decrease in C-reactive protein, SARS-CoV-2" exact="viral" post="load and lung lesions on radiological examination [8]. Zhang"/>
   <result pre="at a median of 21.5 days after first detection of" exact="viral" post="shedding, led to the discontinuation of the SARS-CoV-2 shedding"/>
   <result pre="able to improve the survival in these patients with advanced" exact="disease" post="(5/6 and 14/15 deaths in the convalescent plasma group"/>
   <result pre="plasma should be used in an early phase of the" exact="disease" post="to obtain the best effect [10]. Following these first"/>
   <result pre="and considering the efficacy of this treatment in previous severe" exact="viral" post="epidemics and the absence of standardized treatments, the Food"/>
   <result pre="of this treatment in previous severe viral epidemics and the" exact="absence of" post="standardized treatments, the Food and Drug Administration (FDA) approved"/>
   <result pre="plasma, including donors’ selection (i.e., age, gender, diagnosis of SARS-Cov-2" exact="infection" post="and of recovery, anti-SARS-CoV-2 antibody titer required for plasma"/>
   <result pre="collection and biologic qualification (number, volume and frequency of donations," exact="infectious disease" post="markers and pathogen inactivation) and treatment and disease characteristics"/>
   <result pre="and biologic qualification (number, volume and frequency of donations, infectious" exact="disease" post="markers and pathogen inactivation) and treatment and disease characteristics"/>
   <result pre="donations, infectious disease markers and pathogen inactivation) and treatment and" exact="disease" post="characteristics (i.e., dose and timing of convalescent plasma infused"/>
   <result pre="and timing of convalescent plasma infused and stage of the" exact="disease" post="at which to start convalescent plasma treatment). There is"/>
   <result pre="J EpidemiolFeb 222020[Epub ahead of print] 2World Health Organization. Coronavirus" exact="disease" post="(COVID-19) outbreak. https://www.who.int/emergencies/diseases/novel-coronavirus-2019[accessed 2020-5-4]. 3ZhaiP.DingY.WuX.LongJ.ZhongY.LiY.The epidemiology, diagnosis and treatment"/>
   <result pre="of print] 5WongH.K.LeeC.K.Pivotal role of convalescent plasma in managing emerging" exact="infectious" post="diseasesVox SangApr 2202010.1111/vox.12927 6Mair-JenkinsJ.Saavedra-CamposM.BaillieJ.K.Convalescent plasma study group. The effectiveness"/>
   <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
   <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
   <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysisJ"/>
   <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysisJ Infect Dis2112015809025030060"/>
   <result pre="312020(Epub ahead of print) 10ZengQ.L.YuZ.J.GouJ.J.Effect of convalescent plasma therapy on" exact="viral" post="shedding and survival in COVID-19 patientsJ Infect DisApr 292020(Epub"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7241517/results/search/disease/results.xml">
   <result pre="obvious reasons for this, with student safety and risk of" exact="viral" post="dissemination being major concerns for universities. However, this has"/>
   <result pre="also in future epidemics? The value for appreciating global health" exact="disease" post="is clearly needed and is actively encouraged [1]. Despite"/>
   <result pre="can offer so much more, from actively engaging in combatting" exact="viral" post="misinformation to providing telemedicine for underappreciated illnesses that manifest"/>
   <result pre="for underappreciated illnesses that manifest as a consequence of mass" exact="infection" post="[5]. As such, in the face of rapidly evolving"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7245250/results/search/disease/results.xml">
   <result pre=": Article The novel coronavirus (COVID-19) and the risk of" exact="Kawasaki disease" post="in children AlizargarJavadjaz.tmu@gmail.com[], pmc-release: 2020-5-5epub: 2020-5-5received: 2020-5-14rev-recd: 2020-5-18accepted: 2020-5-18(C)"/>
   <result pre="Article The novel coronavirus (COVID-19) and the risk of Kawasaki" exact="disease" post="in children AlizargarJavadjaz.tmu@gmail.com[], pmc-release: 2020-5-5epub: 2020-5-5received: 2020-5-14rev-recd: 2020-5-18accepted: 2020-5-18(C)"/>
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="as the COVID-19 resource centre remains active. The novel coronavirus" exact="disease" post="(COVID-19) has been identified as a pandemic by the"/>
   <result pre="cough, sore throat, fatigue and low-grade fever as well as" exact="atypical" post="symptoms like cerebral hemorrhage and infarction have been reported"/>
   <result pre="fatigue and low-grade fever as well as atypical symptoms like" exact="cerebral hemorrhage" post="and infarction have been reported in COVID-19 patients. As"/>
   <result pre="are quite abundant, the data about the children getting this" exact="disease" post="are rare. COVID-19 is supposed to affect children less"/>
   <result pre="of the COVID-19. Compared to the adults, children get milder" exact="disease" post="and the mortality among them are not high.1 As"/>
   <result pre="children, presentations of the symptoms in children are quite unknown." exact="Kawasaki disease" post="(KD) is an acute systemic febrile disease that mostly"/>
   <result pre="presentations of the symptoms in children are quite unknown. Kawasaki" exact="disease" post="(KD) is an acute systemic febrile disease that mostly"/>
   <result pre="in children are quite unknown. Kawasaki disease (KD) is an" exact="acute" post="systemic febrile disease that mostly affects children that are"/>
   <result pre="children are quite unknown. Kawasaki disease (KD) is an acute" exact="systemic" post="febrile disease that mostly affects children that are less"/>
   <result pre="quite unknown. Kawasaki disease (KD) is an acute systemic febrile" exact="disease" post="that mostly affects children that are less than 5"/>
   <result pre="than 5 years of age. Cough, vomiting, sterile pyuria and" exact="diarrhea" post="is very common in KD patients. The exact etiology"/>
   <result pre="exact etiology of KD is not fully described, but the" exact="infectious disease," post="especially the ones that are caused by the respiratory"/>
   <result pre="infectious disease, especially the ones that are caused by the" exact="respiratory" post="viruses, such enteroviruses, adenoviruses, rhinoviruses and coronaviruses have been"/>
   <result pre="countries, especial attention is needed in the occurrence of this" exact="disease" post="in the time of viral pandemics in Asian countries.2"/>
   <result pre="in the occurrence of this disease in the time of" exact="viral" post="pandemics in Asian countries.2 After some studies reported KD"/>
   <result pre="COVID-19 patients, the public attention has been drawn to this" exact="disease" post="and whether KD can be considered as the presentation"/>
   <result pre="divided all the patients who were diagnosed with a Kawasaki-like" exact="disease" post="in the past 5 years to two groups. Group"/>
   <result pre="to two groups. Group 1 were the patients with Kawasaki-like" exact="disease" post="before the beginning of the COVID-19 epidemics and group"/>
   <result pre="after the epidemics. They found 30-fold increase in the Kawasaki-like" exact="disease" post="after the COVID-19 epidemics. They also found out that"/>
   <result pre="more signs of cardiac involvement as well as macrophage activation" exact="syndrome" post="features. Thus, the concluded that COVID-19 epidemic is associated"/>
   <result pre="Kawasaki-like symptoms referring to the hospitals and clinics during the" exact="viral" post="epidemics like COVID-19. Declaration of Competing Interest The authors"/>
   <result pre="better prognosis than adults [Internet].Acta Paediatr10962020 Jun 110881095Available from:http://www.10.1111/apa.1527032202343 2ChangL.-Y.LuC.-Y.ShaoP.-L.LeeP.-I.LinM.-T.FanT.-Y.Viral" exact="infections" post="associated with Kawasaki disease[Internet]J Formos Med Assoc11332014148154Available from:http://www.sciencedirect.com/science/article/pii/S092966461400003524495555 3VerdoniL.MazzaA.GervasoniA.MartelliL.RuggeriM.CiuffredaM.An"/>
   <result pre="disease[Internet]J Formos Med Assoc11332014148154Available from:http://www.sciencedirect.com/science/article/pii/S092966461400003524495555 3VerdoniL.MazzaA.GervasoniA.MartelliL.RuggeriM.CiuffredaM.An outbreak of severe Kawasaki-like" exact="disease" post="at the Italian epicentre of the SARS-CoV-2 epidemic: an"/>
   <result pre="the SARS-CoV-2 epidemic: an observational cohort study[Internet]Lancet2020Available from:http://www.sciencedirect.com/science/article/pii/S014067362031103X[In press] 4Rivera-FigueroaE.I.SantosR.SimpsonS.GargP.Incomplete" exact="Kawasaki disease" post="in a child with Covid-192020 MayIndian Pediatr 5JonesV.G.MillsM.SuarezD.HoganC.A.YehD.Bradley SegalJ.COVID-19"/>
   <result pre="SARS-CoV-2 epidemic: an observational cohort study[Internet]Lancet2020Available from:http://www.sciencedirect.com/science/article/pii/S014067362031103X[In press] 4Rivera-FigueroaE.I.SantosR.SimpsonS.GargP.Incomplete Kawasaki" exact="disease" post="in a child with Covid-192020 MayIndian Pediatr 5JonesV.G.MillsM.SuarezD.HoganC.A.YehD.Bradley SegalJ.COVID-19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7256497/results/search/disease/results.xml">
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="the authors summarized the use of medical masks in the" exact="viral" post="outbreaks like the COVID-19. They pointed out that wearing"/>
   <result pre="saliva,2 wearing the medical mask stops the transmission of this" exact="disease" post="in droplets and aerosols. As patients may be asymptomatic"/>
   <result pre="As patients may be asymptomatic and the reactivation of this" exact="disease" post="is possible,3, 4 wearing masks by asymptomatic individuals is"/>
   <result pre="virus, which is the main function of medical masks in" exact="viral" post="infections, the other way that wearing the medical masks"/>
   <result pre="the new cases. In COVID-19 outbreak, the symptoms of the" exact="disease" post="are cough, fever, fatigue, diarrhea, headache, sputum production, haemoptysis,"/>
   <result pre="These symptoms are common among other types of influenza and" exact="bacterial" post="common cold. Wearing masks will also prevent those types"/>
   <result pre="common cold. Wearing masks will also prevent those types of" exact="infections" post="caused by other types of pathogens which are communicable"/>
   <result pre="Association.202010.1016/j.jfma.2020.04.013In press 4AghamohammadiM.AlizargarJ.HsiehN.-C.S-FVWuProphylactic anticoagulant therapy for reducing the risk of" exact="stroke" post="and other thrombotic events in COVID-19 patientsJournal of the"/>
   <result pre="Formosan Medical Association.202010.1016/j.jfma.2020.05.005In press 5RothanH.A.ByrareddyS.N.The epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreakJ Autoimmun.109202010243310.1016/j.jaut.2020.102433 Acknowledgments None."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7257617/results/search/disease/results.xml">
   <result pre="; font-style : italic;} Eur Respir JEur. Respir. JERJerjThe European" exact="Respiratory" post="Journal0903-19361399-3003European Respiratory Society pmcid: 7257617 doi: 10.1183/13993003.01852-2020ERJ-01852-2020 Version of"/>
   <result pre=": italic;} Eur Respir JEur. Respir. JERJerjThe European Respiratory Journal0903-19361399-3003European" exact="Respiratory" post="Society pmcid: 7257617 doi: 10.1183/13993003.01852-2020ERJ-01852-2020 Version of Record :"/>
   <result pre="and A.J. Cunnington assume that the greater burden of coronavirus" exact="disease" post="19 (COVID-19) in adults may be related to the"/>
   <result pre="the absence in the population of prior immunity to severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), as occurred in fully"/>
   <result pre="absence in the population of prior immunity to severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), as occurred in fully susceptible"/>
   <result pre="in the population of prior immunity to severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), as occurred in fully susceptible populations"/>
   <result pre="2 (SARS-CoV-2), as occurred in fully susceptible populations during previous" exact="viral" post="epidemics. In particular, S hankset al. [2] report that"/>
   <result pre="epidemics. In particular, S hankset al. [2] report that the" exact="measles" post="mortality rate in a fully susceptible population during the"/>
   <result pre="mortality rate in a fully susceptible population during the 1846" exact="measles" post="epidemic was higher in adults and in children aged"/>
   <result pre="older than 20 years are still more likely to suffer from" exact="measles" post="complications, despite not being fully susceptible [3]. Moreover, S"/>
   <result pre="case fatality ratio is still high in children aged &amp;lt;1 year," exact="lower" post="in children aged 1–9 years, and then rises again in"/>
   <result pre="mortality in adults is not a unique feature of first-contact" exact="measles" post="epidemics. Other reasons, rather than absence of prior immunity,"/>
   <result pre="unique feature of first-contact measles epidemics. Other reasons, rather than" exact="absence of" post="prior immunity, could play a crucial role in the"/>
   <result pre="and A.J. Cunnington assume that the greater burden of coronavirus" exact="disease" post="19 (COVID-19) in adults may be related to the"/>
   <result pre="the absence in the population of prior immunity to severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), as occurred in fully"/>
   <result pre="absence in the population of prior immunity to severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), as occurred in fully susceptible"/>
   <result pre="in the population of prior immunity to severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), as occurred in fully susceptible populations"/>
   <result pre="2 (SARS-CoV-2), as occurred in fully susceptible populations during previous" exact="viral" post="epidemics. In particular, S hankset al. [2] report that"/>
   <result pre="epidemics. In particular, S hankset al. [2] report that the" exact="measles" post="mortality rate in a fully susceptible population during the"/>
   <result pre="mortality rate in a fully susceptible population during the 1846" exact="measles" post="epidemic was higher in adults and in children aged"/>
   <result pre="older than 20 years are still more likely to suffer from" exact="measles" post="complications, despite not being fully susceptible [3]. Moreover, S"/>
   <result pre="case fatality ratio is still high in children aged &amp;lt;1 year," exact="lower" post="in children aged 1–9 years, and then rises again in"/>
   <result pre="mortality in adults is not a unique feature of first-contact" exact="measles" post="epidemics. As regards West Nile virus infection [5], severe"/>
   <result pre="unique feature of first-contact measles epidemics. As regards West Nile" exact="virus infection" post="[5], severe fever with thrombocytopenia syndrome [6] and Plasmodium"/>
   <result pre="feature of first-contact measles epidemics. As regards West Nile virus" exact="infection" post="[5], severe fever with thrombocytopenia syndrome [6] and Plasmodium"/>
   <result pre="As regards West Nile virus infection [5], severe fever with" exact="thrombocytopenia" post="syndrome [6] and Plasmodium falciparum malaria [7], several factors"/>
   <result pre="regards West Nile virus infection [5], severe fever with thrombocytopenia" exact="syndrome" post="[6] and Plasmodium falciparum malaria [7], several factors such"/>
   <result pre="virus infection [5], severe fever with thrombocytopenia syndrome [6] and" exact="Plasmodium falciparum malaria" post="[7], several factors such as pathogen features, transmission dynamics"/>
   <result pre="[5], severe fever with thrombocytopenia syndrome [6] and Plasmodium falciparum" exact="malaria" post="[7], several factors such as pathogen features, transmission dynamics"/>
   <result pre="can be considered fully susceptible over time. Furthermore, the SARS-CoV-2" exact="viral" post="genome is 75–80% identical to the SARS-CoV virus that"/>
   <result pre="that caused a global pandemic in 2002–2003 [8]. Human coronavirus" exact="infections" post="are very common worldwide [9–11]. Recently, G rifoniet al."/>
   <result pre="view of these overall considerations, we can speculate that SARS-CoV-2" exact="infection" post="may not have spread in a fully susceptible population."/>
   <result pre="are more likely to consider that other reasons, rather than" exact="absence of" post="prior immunity, could play a crucial role in the"/>
   <result pre="Respir J2020; 55: 2000749. doi:10.1183/13993003.00749-2020.32241833 2ShanksGD, WallerM, BriemH, et al.Age-specific" exact="measles" post="mortality during the late 19th–early 20th centuries. Epidemiol Infect2015;"/>
   <result pre="Infect2015; 143: 3434–3441. doi:10.1017/S095026881500063125865777 3collab: National Center for Immunization and" exact="Respiratory" post="Diseases, Division of Viral DiseasesComplications of Measles. Centers for"/>
   <result pre="3collab: National Center for Immunization and Respiratory Diseases, Division of" exact="Viral" post="DiseasesComplications of Measles. Centers for Disease Control and Preventionwww.cdc.gov/measles/symptoms/complications.htmlDate"/>
   <result pre="Respiratory Diseases, Division of Viral DiseasesComplications of Measles. Centers for" exact="Disease" post="Control and Preventionwww.cdc.gov/measles/symptoms/complications.htmlDate last updated: 13 June 2019. 4StrebelPM,"/>
   <result pre="5LindseyNP, StaplesJE, LehmanJA, et al.Surveillance for human West Nile virus" exact="disease" post="– United States, 1999–2008. MMWR Surveill Summ2010; 59: 1–17."/>
   <result pre="et al.Epidemiological and clinical features of laboratory-diagnosed severe fever with" exact="thrombocytopenia" post="syndrome in China, 2011–17: a prospective observational study. Lancet"/>
   <result pre="al.Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia" exact="syndrome" post="in China, 2011–17: a prospective observational study. Lancet Infect"/>
   <result pre="SmithA, SmithV, et al.Risk factors for mortality from imported falciparum" exact="malaria" post="in the United Kingdom over 20 years: an observational"/>
   <result pre="study. BMJ2012; 344: e2116. doi:10.1136/bmj.e211622454091 8ZhouP, YangXL, WangXG, et al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
   <result pre="clinical features of human coronaviruses in the pediatric population. J" exact="Pediatric" post="Infect Dis Soc2018; 7: 151–158. doi:10.1093/jpids/pix02728482105 10GorseGJ, PatelGB, VitaleJN,"/>
   <result pre="VitaleJN, et al.Prevalence of antibodies to four human coronaviruses is" exact="lower" post="in nasal secretions than in serum. Clin Vaccine Immunol2010;"/>
   <result pre="doi:10.1128/CVI.00278-1020943876 11MancinoE, CristianiL, PierangeliA, et al.A single centre study of" exact="viral" post="community-acquired pneumonia in children: no evidence of SARS-CoV-2 from"/>
   <result pre="CristianiL, PierangeliA, et al.A single centre study of viral community-acquired" exact="pneumonia" post="in children: no evidence of SARS-CoV-2 from October 2019"/>
   <result pre="T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19" exact="disease" post="and unexposed individuals. Cell2020; in press [10.1016/j.cell.2020.05.015]. doi:10.1016/j.cell.2020.05.015 13FedsonDSInfluenza,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7265527/results/search/disease/results.xml">
   <result pre="Data Science, University of Texas at Austin, [3], 0000000419368710grid.47100.32Center for" exact="Infectious" post="Disease Modeling and Analysis, Yale School of Public Health,"/>
   <result pre="Science, University of Texas at Austin, [3], 0000000419368710grid.47100.32Center for Infectious" exact="Disease" post="Modeling and Analysis, Yale School of Public Health, [4],"/>
   <result pre="1936 9924grid.89336.37Department of Molecular Biosciences, John Ring LaMontagne Center for" exact="Infectious" post="Disease, Institute for Cellular and Molecular Biology, University of"/>
   <result pre="tolls. Baloxavir, the recently approved influenza antiviral, inhibits initiation of" exact="viral" post="mRNA synthesis, whereas oseltamivir, an older drug, inhibits release"/>
   <result pre="treatment on population-level incidence using a new model that links" exact="viral" post="load dynamics from clinical trial data to between-host transmission."/>
   <result pre="trial data to between-host transmission. We estimate that ~22 million" exact="infections" post="and &amp;gt;6,000 deaths would have been averted in the 2017–2018"/>
   <result pre="avert substantial influenza morbidity and mortality every year. Subject terms" exact="Diseases" post="Health care Funding Models of Infectious Disease Agent Study"/>
   <result pre="every year. Subject terms Diseases Health care Funding Models of" exact="Infectious" post="Disease Agent Study (MIDAS) program grant number U01 GM087719"/>
   <result pre="year. Subject terms Diseases Health care Funding Models of Infectious" exact="Disease" post="Agent Study (MIDAS) program grant number U01 GM087719 Funding"/>
   <result pre="Introduction Influenza A and B viruses cause a highly contagious" exact="respiratory" post="disease in humans that kills 290,000–650,000 people worldwide every"/>
   <result pre="Influenza A and B viruses cause a highly contagious respiratory" exact="disease" post="in humans that kills 290,000–650,000 people worldwide every year1."/>
   <result pre="that kills 290,000–650,000 people worldwide every year1. Vaccination is the" exact="primary" post="means for controlling influenza transmission but is hampered by"/>
   <result pre="influenza transmission but is hampered by the variable efficacy and" exact="incomplete" post="population coverage of annual vaccines, and thus is not"/>
   <result pre="symptoms. Prior to 2018, the only approved influenza antivirals were" exact="viral" post="neuraminidase inhibitors2,3. Of these, only oseltamivir (Tamiflu) can be"/>
   <result pre="surface, which is the last step in the production of" exact="infectious" post="virus. Multiple oseltamivir treatments over 5 consecutive days are"/>
   <result pre="is the last step in the production of infectious virus." exact="Multiple" post="oseltamivir treatments over 5 consecutive days are required to"/>
   <result pre="inhibits an early step in virus replication, the initiation of" exact="viral" post="mRNA synthesis5–7. This initiation step requires cap-snatching, a mechanism"/>
   <result pre="This initiation step requires cap-snatching, a mechanism in which the" exact="viral" post="polymerase binds to the cap structure (m7GpppNm) at the"/>
   <result pre="the capped RNA fragments that serve as primers to initiate" exact="viral" post="mRNA synthesis. Because baloxavir almost completely inhibits the cap-dependent"/>
   <result pre="completely inhibits the cap-dependent endonuclease, little or no initiation of" exact="viral" post="mRNA synthesis occurs, and little or no virus is"/>
   <result pre="and a hierarchical mathematical model that links within-host dynamics of" exact="viral" post="load to between-host transmission. Our results indicate that scaling"/>
   <result pre="We estimated the efficacy with which oseltamivir and baloxavir inhibit" exact="viral" post="replication by fitting the model to the results of"/>
   <result pre="the results of a recent clinical trial8 that measured the" exact="viral" post="loads of 1014 influenza virus-infected patients after treatment with"/>
   <result pre="oseltamivir, baloxavir, or a placebo (Table 1). Our model produces" exact="viral" post="titer estimates similar to the clinical data, and, like"/>
   <result pre="within-host and between-host models to data. Parameter Median 95% CI" exact="lower" post="95% CI upper Antiviral efficacy \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts}"/>
   <result pre="models to data. Parameter Median 95% CI lower 95% CI" exact="upper" post="Antiviral efficacy \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs}"/>
   <result pre="\setlength{\oddsidemargin}{-69pt} \begin{document}$$\epsilon$$\end{document} ϵ for oseltamivir 0.89 0.88 0.90 Initial sensitive" exact="viral" post="load V0 (TCID50/ml) 258.2 3.3a 2268.9a Basic reproduction number"/>
   <result pre="G0–24 (hours after symptom onset, truncated at 24 h) G(4.0, 6.3)/2" exact="Delayed" post="distribution of treatment initiation times, G24–48 (hours after symptom"/>
   <result pre="to 24–48 h window) G(4.0, 6.3)/2 + 24 Distribution of time lag between" exact="infection" post="and symptom onset, L (hours) 24aL(0.37,0.41) aFor estimates derived"/>
   <result pre="annealing, we provide 95 percentile range rather than confidence intervals." exact="Viral" post="replication and antiviral efficacy are estimated via simulated annealing46"/>
   <result pre="seasonal influenza incidence data12. Parameters for distributions of time between" exact="infection" post="and symptom onset (lognormal) and from symptom onset to"/>
   <result pre="in Supplementary Tables 2 and 3. Fig. 1 Changes in" exact="viral" post="load following antiviral treatment. The estimated means and standard"/>
   <result pre="treatment on the transmission dynamics of influenza We incorporated this" exact="viral" post="replication model into a stochastic individual-based model of influenza"/>
   <result pre="influenza transmission that tracks the daily evolution of infectiousness with" exact="disease" post="progression. The infectiousness of a case at any given"/>
   <result pre="infectiousness of a case at any given time depends on" exact="viral" post="load, treatment status, and baseline transmission rates estimated from"/>
   <result pre="Consistent with previous studies14,15, we assume a logarithmic relationship between" exact="viral" post="load and infectiousness (Fig. 2). Unless otherwise specified, each"/>
   <result pre="within two days, whereas oseltamivir-treated patients are predicted to remain" exact="infectious" post="for ~4 or 5 days. Fig. 2 Early antiviral"/>
   <result pre="over 900,000 hospitalizations and more than 79,000 deaths16. In the" exact="absence of" post="scaling up antiviral coverage, the timing and magnitude of"/>
   <result pre="48 h after symptoms onset reduces the expected number of influenza" exact="infections" post="throughout the virus season by 38% or 26%, respectively."/>
   <result pre="respectively. We estimate the reduction in the number of overall" exact="infections" post="at other treatment levels, ranging from 10% to 50%"/>
   <result pre="calculated the basic reproduction number (R0), the average number of" exact="secondary" post="infections generated by a typical infectious case at the"/>
   <result pre="the basic reproduction number (R0), the average number of secondary" exact="infections" post="generated by a typical infectious case at the outset"/>
   <result pre="the average number of secondary infections generated by a typical" exact="infectious" post="case at the outset of the epidemic (Supplementary Table"/>
   <result pre="the 80% prediction interval across 1000 stochastic simulations. b Estimated" exact="total" post="attack rates in simulated intervention scenarios ranging from no"/>
   <result pre="stochastic simulation assumes a population of 10,000 individuals, with within-host" exact="viral" post="replication and between-host transmission parameters given in Table 1."/>
   <result pre="after symptoms onset results in a significantly greater reduction in" exact="total" post="incidence than treatment within the second 24 h window following"/>
   <result pre="treatment scenario is expected to avert 3.8 and 5.3 million" exact="infections" post="more than the delayed treatment scenario, respectively. We also"/>
   <result pre="dose after symptom onset. Values are areas between the log" exact="viral" post="titer curves shown in Fig. 2 for untreated and"/>
   <result pre="respectively, across 100 stochastic simulations for each treatment window. b" exact="Total" post="infections averted by treating the indicated percent of cases"/>
   <result pre="across 100 stochastic simulations for each treatment window. b Total" exact="infections" post="averted by treating the indicated percent of cases with"/>
   <result pre="~10,200 lives. Our results indicate that optimal reduction of overall" exact="infection" post="occurs when a significant number of infected cases are"/>
   <result pre="Consequently, efforts to accelerate the diagnosis and treatment of influenza" exact="infections" post="with antivirals such as baloxavir, including potentially cost-saving telemedicine23,"/>
   <result pre="attainable in future influenza epidemics. Influenza A viruses also cause" exact="periodic" post="widespread pandemics usually resulting in higher mortality rates24. The"/>
   <result pre="not modeled possible biases in the data with respect to" exact="disease" post="severity or timing of treatment. Future epidemiological studies and"/>
   <result pre="considered in our models. First, we have not considered that" exact="viral" post="kinetics and the efficacy of treatment may substantially vary"/>
   <result pre="of baloxavir-treated adults8, and in some cases prolonged symptoms and" exact="viral" post="shedding. Combination therapy with baloxavir and a neuraminidase inhibitor"/>
   <result pre="the infectiousness of a case is logarithmically related to their" exact="viral" post="load. Although there is little doubt that infectiousness and"/>
   <result pre="viral load. Although there is little doubt that infectiousness and" exact="viral" post="load are positively correlated, transmission also depends on contact"/>
   <result pre="rates can potentially spare millions of people from influenza virus" exact="infections" post="during epidemics, thereby substantially reducing hospitalizations, morbidity, and deaths."/>
   <result pre="telemedicine and the development of rapid, sensitive assays for influenza" exact="virus infection." post="Methods Our hierarchical method includes three steps (Supplementary Table"/>
   <result pre="A replication dynamics We applied a published model that includes" exact="viral" post="suppression by both the immune response and antiviral treatment10,11,"/>
   <result pre="\usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\epsilon$$\end{document} ϵ denote the" exact="viral" post="replication rate, viral death rate, cell infection rate, growth"/>
   <result pre="\usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\epsilon$$\end{document} ϵ denote the viral replication rate," exact="viral" post="death rate, cell infection rate, growth rate of the"/>
   <result pre="ϵ denote the viral replication rate, viral death rate, cell" exact="infection" post="rate, growth rate of the immune response, and the"/>
   <result pre="estimate all model parameters. We assumed that the time from" exact="infection" post="to symptom onset follows a lognormal distribution, L, and"/>
   <result pre="We do not explicitly consider other sources of heterogeneity in" exact="viral" post="replication or immune response rates. Although most of the"/>
   <result pre="14,15, we assume that infectiousness is a logarithmic function of" exact="viral" post="load, as given by \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb}"/>
   <result pre="where V(t) denotes the virus load at time t since" exact="infection" post="(Supplementary Section 2). To estimate total reduction in infectiousness"/>
   <result pre="at time t since infection (Supplementary Section 2). To estimate" exact="total" post="reduction in infectiousness attributable to treatment, we calculate the"/>
   <result pre="and WHO lab percent positive influenza tests12,13. We then incorporated" exact="viral" post="replication dynamics and antiviral treatment into a stochastic agent-based"/>
   <result pre="model (Supplementary Section 3). We replace the discrete exposed and" exact="symptomatic" post="states with continuously changing infectiousness from the moment of"/>
   <result pre="symptomatic states with continuously changing infectiousness from the moment of" exact="infection" post="that is governed by our within-host model. Exposed individuals"/>
   <result pre="that is governed by our within-host model. Exposed individuals become" exact="symptomatic" post="(and thus eligible for treatment) according to L; treated"/>
   <result pre="within a 48 h window following distribution G0–48 (unless otherwise specified);" exact="symptomatic" post="recover when their virus load falls below zero yielding"/>
   <result pre="recover when their virus load falls below zero yielding average" exact="infectious" post="periods of 9, 4, and 7 days, as infection"/>
   <result pre="average infectious periods of 9, 4, and 7 days, as" exact="infection" post="for untreated, baloxavir-treated, and oseltamivir-treated cases, respectively (assuming treatment"/>
   <result pre="cases, respectively (assuming treatment times follow G0–48). The force of" exact="infection" post="(the probability that a susceptible individual becomes exposed) is"/>
   <result pre="size and βj(t) is the transmission rate of the jth" exact="infectious" post="individual (symptomatic or treated) at time t, which is"/>
   <result pre="the individual’s infectiousness at time t based on the within-host" exact="viral" post="load model. Supplementary Section 6 addresses the assumptions and"/>
   <result pre="of a single simulation, we calculate the average number of" exact="secondary" post="cases produced by all individuals infected during the first"/>
   <result pre="repeatedly run baseline and treatment simulations in tandem, assuming a" exact="total" post="population of 10,000. For each pair i, we record"/>
   <result pre="10,000. For each pair i, we record the difference in" exact="total" post="incidence between the baseline and treatment simulations, di = I0 − It, the"/>
   <result pre="total incidence between the baseline and treatment simulations, di = I0 − It, the" exact="total" post="number of cases treated in the treatment simulation ni."/>
   <result pre="of di/I0 by a CDC reported estimated for number of" exact="infections" post="during the 2017–2018 influenza season12,13. DALYs averted To estimate"/>
   <result pre="treatment, we again pair baseline and treatment simulations. To translate" exact="infections" post="averted into healthy life years gained, we apply a"/>
   <result pre="L.A.M. would like to acknowledge funding from the Models of" exact="Infectious" post="Disease Agent Study (MIDAS) program grant number U01 GM087719."/>
   <result pre="would like to acknowledge funding from the Models of Infectious" exact="Disease" post="Agent Study (MIDAS) program grant number U01 GM087719. R.M.K."/>
   <result pre="2018). 5.PlotchSJBouloyMKrugRMTransfer of 5′-terminal cap of globin mRNA to influenza" exact="viral" post="complementary RNA during transcription in vitroProc. Natl Acad. Sci."/>
   <result pre="endonuclease cleaves capped RNAs to generate the primers that initiate" exact="viral" post="RNA transcriptionCell19812384785810.1016/0092-8674(81)90449-96261960 7.ReichSet al.Structural insight into cap-snatching and RNA"/>
   <result pre="danger of its generation and spreadPLoS Comput. Biol.20073e24010.1371/journal.pcbi.003024018069885 11.SmithAMPerelsonASInfluenza A" exact="virus infection" post="kinetics: quantitative data and modelsWiley Interdiscip. Rev. Syst. Biol."/>
   <result pre="of its generation and spreadPLoS Comput. Biol.20073e24010.1371/journal.pcbi.003024018069885 11.SmithAMPerelsonASInfluenza A virus" exact="infection" post="kinetics: quantitative data and modelsWiley Interdiscip. Rev. Syst. Biol."/>
   <result pre="data and modelsWiley Interdiscip. Rev. Syst. Biol. Med.2011342944510.1002/wsbm.12921197654 12.Centers for" exact="Disease" post="Control and Prevention. Influenza positive tests reported to CDC"/>
   <result pre="laboratories and ILI activity, national summary. CDChttps://gis.cdc.gov/grasp/fluview/fluportaldashboard.html (2018). 13.Centers for" exact="Disease" post="Control and Prevention. Percentage of visits for ILI, national"/>
   <result pre="between and within scales: environmental persistence and within-host fitness of" exact="avian influenza" post="virusesProc. Biol. Sci.20142812013305110.1098/rspb.2013.305124898369 16.Centers for Disease Control and Prevention."/>
   <result pre="within-host fitness of avian influenza virusesProc. Biol. Sci.20142812013305110.1098/rspb.2013.305124898369 16.Centers for" exact="Disease" post="Control and Prevention. Archived estimated influenza illnesses, medical visits,"/>
   <result pre="in the United States—2017–2018 influenza season (CDC, 2019). 17.Centers for" exact="Disease" post="Control and Prevention. Influenza antiviral medications: clinician summary (CDC,"/>
   <result pre="impact of low-efficacy influenza vaccinesProc. Natl Acad. Sci. USA20181155151515610.1073/pnas.180247911529712866 23.GranwehrBPIn" exact="acute" post="uncomplicated influenza, single-dose baloxavir decreased time to symptom relief"/>
   <result pre="23–March 16, 2020MMWR. Morbidity Mortal. Wkly. Rep.20206941141510.15585/mmwr.mm6914e1 33.VegvariCet al.How can" exact="viral" post="dynamics models inform endpoint measures in clinical trials of"/>
   <result pre="models inform endpoint measures in clinical trials of therapies for" exact="acute" post="viral infections?PLoS ONE201611e015823710.1371/journal.pone.015823727367230 34.Hirotsu, N. et al. Baloxavir marboxil"/>
   <result pre="inform endpoint measures in clinical trials of therapies for acute" exact="viral" post="infections?PLoS ONE201611e015823710.1371/journal.pone.015823727367230 34.Hirotsu, N. et al. Baloxavir marboxil in"/>
   <result pre="Bayesian computational methodsStat. Comput.2012221167118010.1007/s11222-011-9288-2 40.JiangHet al.Preliminary epidemiologic assessment of human" exact="infections" post="with highly pathogenic avian influenza A (H5N6) virus, ChinaClin."/>
   <result pre="40.JiangHet al.Preliminary epidemiologic assessment of human infections with highly pathogenic" exact="avian influenza" post="A (H5N6) virus, ChinaClin. Infect. Dis.20176538338810.1093/cid/cix33428407105 41.LesslerJet al.Incubation periods"/>
   <result pre="A (H5N6) virus, ChinaClin. Infect. Dis.20176538338810.1093/cid/cix33428407105 41.LesslerJet al.Incubation periods of" exact="acute" post="respiratory viral infections: a systematic reviewLancet Infect. Dis.2009929130010.1016/S1473-3099(09)70069-619393959 42.KoszalkaPTilmanisDRoeMVijaykrishnaDHurtABaloxavir"/>
   <result pre="(H5N6) virus, ChinaClin. Infect. Dis.20176538338810.1093/cid/cix33428407105 41.LesslerJet al.Incubation periods of acute" exact="respiratory" post="viral infections: a systematic reviewLancet Infect. Dis.2009929130010.1016/S1473-3099(09)70069-619393959 42.KoszalkaPTilmanisDRoeMVijaykrishnaDHurtABaloxavir marboxil"/>
   <result pre="virus, ChinaClin. Infect. Dis.20176538338810.1093/cid/cix33428407105 41.LesslerJet al.Incubation periods of acute respiratory" exact="viral" post="infections: a systematic reviewLancet Infect. Dis.2009929130010.1016/S1473-3099(09)70069-619393959 42.KoszalkaPTilmanisDRoeMVijaykrishnaDHurtABaloxavir marboxil susceptibility"/>
   <result pre="Asia-Pacific, 2012–2018Antiviral Res.2019164919610.1016/j.antiviral.2019.02.00730771405 43.Keeling, M. J. &amp;amp; Rohani, P. Modeling" exact="Infectious" post="Diseases in Humans and Animals (Princeton Univ. Press, 2011)."/>
   <result pre="2012–2018Antiviral Res.2019164919610.1016/j.antiviral.2019.02.00730771405 43.Keeling, M. J. &amp;amp; Rohani, P. Modeling Infectious" exact="Diseases" post="in Humans and Animals (Princeton Univ. Press, 2011). 44.GoldsteinEViboudCCharuVLipsitchMImproving"/>
   <result pre="Biol.201713e100574910.1371/journal.pcbi.100574929049288 46.Xiang, Y., Gubian, S., Suomela, B. &amp;amp; Hoeng, J." exact="Generalized" post="simulated annealing for global optimization: the GenSA package. R"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7279053/results/search/disease/results.xml">
   <result pre="font-style : italic;} Pediatr Infect Dis JPediatr. Infect. Dis. JINFThe" exact="Pediatric" post="Infectious Disease Journal0891-36681532-0987Williams &amp;amp; Wilkins pmcid: 727905300028 doi: 10.1097/INF.0000000000002704"/>
   <result pre=": italic;} Pediatr Infect Dis JPediatr. Infect. Dis. JINFThe Pediatric" exact="Infectious" post="Disease Journal0891-36681532-0987Williams &amp;amp; Wilkins pmcid: 727905300028 doi: 10.1097/INF.0000000000002704 :"/>
   <result pre="italic;} Pediatr Infect Dis JPediatr. Infect. Dis. JINFThe Pediatric Infectious" exact="Disease" post="Journal0891-36681532-0987Williams &amp;amp; Wilkins pmcid: 727905300028 doi: 10.1097/INF.0000000000002704 : Brief"/>
   <result pre="Italy, we have been currently experiencing the effects of severe" exact="acute" post="respiratory syndrome (SARS)-CoV-2 global spread, started at the end"/>
   <result pre="we have been currently experiencing the effects of severe acute" exact="respiratory" post="syndrome (SARS)-CoV-2 global spread, started at the end of"/>
   <result pre="have been currently experiencing the effects of severe acute respiratory" exact="syndrome" post="(SARS)-CoV-2 global spread, started at the end of 2019"/>
   <result pre="than adults, with reported vomiting, abdominal pain and diarrhea.1 Additionally" exact="viral" post="shedding has also been reported in children without gastrointestinal"/>
   <result pre="long-term fecal-oral transmission.2 In March 2020, 2 infants with SARS-CoV-2" exact="infection" post="were admitted to our Pediatrics Department. The first one,"/>
   <result pre="our Pediatrics Department. The first one, a 5-month-old boy, presented" exact="respiratory" post="and gastrointestinal symptoms with diarrhea. Nasopharyngeal and rectal swabs"/>
   <result pre="afebrile and asymptomatic. The second one, 2-months-old, presented only mild" exact="respiratory" post="symptoms. After COVID-19 infection was confirmed with nasopharyngeal swab,"/>
   <result pre="second one, 2-months-old, presented only mild respiratory symptoms. After COVID-19" exact="infection" post="was confirmed with nasopharyngeal swab, despite the absence of"/>
   <result pre="After COVID-19 infection was confirmed with nasopharyngeal swab, despite the" exact="absence of" post="gastrointestinal symptoms and based on the findings of the"/>
   <result pre="Health, the follow-up of these patients, to avoid contagion and" exact="uncontrolled" post="spread of the disease, implies mandatory strict home isolation"/>
   <result pre="SARS outbreak in 2002 to 2003, there were reports of" exact="viral" post="RNA being found in fecal samples, occasionally even after"/>
   <result pre="contamination of airdrops and several environmental surfaces.3 In children, SARS-CoV" exact="infection" post="was associated to gastrointestinal symptoms, but there is no"/>
   <result pre="being performed for diagnosis and further surveillance. In Middle East" exact="Respiratory" post="Syndrome-CoV epidemic in 2012, there was proof of viral"/>
   <result pre="East Respiratory Syndrome-CoV epidemic in 2012, there was proof of" exact="viral" post="RNA detection in fecal specimens in adults, but there"/>
   <result pre="body fluids.4 TABLE 1. Evidence of SARS-CoV-2 Detection in Stools" exact="and Rectal" post="Swabs in Adults and Children Wang et al5 reported"/>
   <result pre="in Adults and Children Wang et al5 reported detection of" exact="viral" post="RNA in respiratory tract swabs and stools, with 44/153"/>
   <result pre="Children Wang et al5 reported detection of viral RNA in" exact="respiratory" post="tract swabs and stools, with 44/153 positive fecal samples."/>
   <result pre="was found in feces of patients without diarrhea, suggesting a" exact="systemic" post="infection. The spread of the virus by also non-respiratory"/>
   <result pre="by also non-respiratory routes might justify the rapid diffusion of" exact="infection" post="and testing of samples from multiple sites may be"/>
   <result pre="sensitivity and decrease false-negative results. Zhang et al6 reported an" exact="adult" post="case that presented after initial negativization positive sputum and"/>
   <result pre="criteria for discharge, requiring 2 consecutive negative samples from the" exact="respiratory" post="tract and stool alike. Holshue et al7 published the"/>
   <result pre="tract and stool alike. Holshue et al7 published the first" exact="adult" post="case in the US, showing high viral loads in"/>
   <result pre="published the first adult case in the US, showing high" exact="viral" post="loads in nasopharyngeal specimens at onset, with a tendency"/>
   <result pre="nasopharyngeal specimens at onset, with a tendency to decrease following" exact="disease" post="course, with increasing Ct values. In addition, viral detection"/>
   <result pre="decrease following disease course, with increasing Ct values. In addition," exact="viral" post="detection in stool samples occurred at 7 days from"/>
   <result pre="pharyngeal swabs, regardless of symptoms and with no correlation to" exact="disease" post="severity.8 Concerning the pediatric population, evidence on the use"/>
   <result pre="pediatric population, evidence on the use of rectal swabs or" exact="viral" post="detection in stools is reported in Table 1. Xu"/>
   <result pre="SARS-CoV-2 infection, all with non-specific symptoms. The children’s pattern of" exact="viral" post="shedding was monitored with subsequent nasopharyngeal and rectal swab"/>
   <result pre="days after discharge, also after nasopharyngeal swabs had turned negative." exact="Viral" post="loads showed that shedding from the gastrointestinal tract may"/>
   <result pre="tract may be higher and more long-lasting compared with the" exact="respiratory" post="tract. As reviewed by He et al,9 a newborn"/>
   <result pre="reviewed by He et al,9 a newborn presenting vomiting and" exact="diarrhea" post="as first symptoms was tested positive for SARS-CoV-2, showing"/>
   <result pre="throat swab samples had turned negative, while on day 17," exact="viral" post="RNA was still found on feces and with weak"/>
   <result pre="since the last exposure, with reported negative samples from the" exact="respiratory" post="tract. Droplets are the main human-to-human mechanism of transmission"/>
   <result pre="shedding with environmental contamination may play an important role in" exact="viral" post="spread. As pointed out by Li et al,12 there"/>
   <result pre="by Li et al,12 there is a great number of" exact="infections" post="not being documented, especially in paucisymptomatic or asymptomatic individuals,"/>
   <result pre="the fast diffusion of the virus.12 The clinical pattern of" exact="disease" post="presentation among children may have facilitated viral dissemination. Moreover,"/>
   <result pre="clinical pattern of disease presentation among children may have facilitated" exact="viral" post="dissemination. Moreover, there is evidence supporting viral viability in"/>
   <result pre="may have facilitated viral dissemination. Moreover, there is evidence supporting" exact="viral" post="viability in environmental settings that may predispose fecal-oral transmission,"/>
   <result pre="requires proper disinfection. Current evidence brings concerns on excluding SARS-CoV-2" exact="infection" post="by single time point nasopharyngeal swabs, with sensitivity being"/>
   <result pre="excretion of SARS-CoV-2 in stools is necessary to confirm fecal" exact="viral" post="loads regardless of enteric symptoms, and to better explore"/>
   <result pre="viral loads regardless of enteric symptoms, and to better explore" exact="viral" post="RNA detection in the early incubation or late convalescence"/>
   <result pre="to disclose. Fecal shedding of human coronavirus was demonstrated with" exact="viral" post="detection in stool samples with RT-polymerase chain reaction (PCR)"/>
   <result pre="(PCR) methods although not routinely for diagnosis.1 References REFERENCES 1.ZimmermannPCurtisNCoronavirus" exact="Infections" post="in Children Including COVID-19 an overview of the epidemiology,"/>
   <result pre="children.Pediatr Infect Dis J. 2020;XX:00–00. 2.XuYLiXZhuBet al.Characteristics of pediatric SARS-CoV-2" exact="infection" post="and potential evidence for persistent fecal viral shedding.Nat Med."/>
   <result pre="of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal" exact="viral" post="shedding.Nat Med. 202010.1038/s41591-020-0817-4 3.YeoCKaushalSYeoDEnteric involvement of coronaviruses: is faecal-oral"/>
   <result pre="[Epub ahead of print] 10.ParkJYHanMSParkKUet al.First pediatric case of Coronavirus" exact="Disease" post="2019 in Korea.J Korean Med Sci. 2020;35:e124.32193905 11.TangATongZ-DWangH-Let al.Detection"/>
   <result pre="from Asymptomatic Child, China.Emerg Infect Dis. 2020;26. 12.LiRPeiSChenBet al.Substantial undocumented" exact="infection" post="facilitates the rapid dissemination of novel coronavirus (SARS-CoV2).Science. 2020"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7283747/results/search/disease/results.xml">
   <result pre="Special Issue: Special Issue How did we get here? A" exact="short" post="history of COVID‐19 and other coronavirus‐related epidemics Lango LangoMiriam"/>
   <result pre="LangoMiriam N.MDhttps://orcid.org/0000-0003-0736-74731mnlango@mdanderson.org[1], Department of Head and Neck SurgeryM. D. Anderson" exact="Cancer" post="Center HoustonTexasUSA *Correspondence Miriam N. Lango, MD, M. D."/>
   <result pre="Center HoustonTexasUSA *Correspondence Miriam N. Lango, MD, M. D. Anderson" exact="Cancer" post="Center, 1515 Holcombe Blvd, Houston, TX 77030, Email: MNLango@mdanderson.org"/>
   <result pre=", This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
   <result pre="closely resembles SARS CoV‐1, which was responsible for the severe" exact="acute" post="respiratory syndrome (SARS) outbreak in 2002. SARS CoV‐1 and"/>
   <result pre="resembles SARS CoV‐1, which was responsible for the severe acute" exact="respiratory" post="syndrome (SARS) outbreak in 2002. SARS CoV‐1 and 2"/>
   <result pre="SARS CoV‐1, which was responsible for the severe acute respiratory" exact="syndrome" post="(SARS) outbreak in 2002. SARS CoV‐1 and 2 share"/>
   <result pre="sequences and use the same host cell receptor to initiate" exact="viral infection." post="However, SARS predominantly affected individuals in close contact with"/>
   <result pre="the current status of vaccine trials. coronavirus COVID‐19 otolaryngology head" exact="and neck" post="surgery review fig-count: table-count: page-count: word-count: LangoMN. How did"/>
   <result pre="table-count: page-count: word-count: LangoMN. How did we get here? A" exact="short" post="history of COVID‐19 and other coronavirus‐related epidemics. Head &amp;amp;"/>
   <result pre="noticed a series of patients showing signs of a severe" exact="acute" post="respiratory syndrome or SARS‐like illness which was subsequently reported"/>
   <result pre="a series of patients showing signs of a severe acute" exact="respiratory" post="syndrome or SARS‐like illness which was subsequently reported to"/>
   <result pre="series of patients showing signs of a severe acute respiratory" exact="syndrome" post="or SARS‐like illness which was subsequently reported to the"/>
   <result pre="Emergency of International Concern (PHEIC). The first case of the" exact="disease" post="due to local person to person spread in the"/>
   <result pre="for the &quot;common cold,&quot; accounting for up to 30% of" exact="upper" post="respiratory tract infections in adults. Coronaviruses, like other RNA"/>
   <result pre="the &quot;common cold,&quot; accounting for up to 30% of upper" exact="respiratory" post="tract infections in adults. Coronaviruses, like other RNA viruses,"/>
   <result pre="cold,&quot; accounting for up to 30% of upper respiratory tract" exact="infections" post="in adults. Coronaviruses, like other RNA viruses, mutate frequently"/>
   <result pre="most significant, growing threat to global health of all emerging" exact="infectious" post="diseases.1 Geographic hotspots, or maps reflecting zoonotic infectious disease"/>
   <result pre="growing threat to global health of all emerging infectious diseases.1" exact="Geographic" post="hotspots, or maps reflecting zoonotic infectious disease risk have"/>
   <result pre="all emerging infectious diseases.1 Geographic hotspots, or maps reflecting zoonotic" exact="infectious disease" post="risk have been identified in South American, Africa and"/>
   <result pre="emerging infectious diseases.1 Geographic hotspots, or maps reflecting zoonotic infectious" exact="disease" post="risk have been identified in South American, Africa and"/>
   <result pre="Heat maps of predicted relative risk distribution of zoonotic emerging" exact="disease" post="threats. The CoV‐2 coronavirus arose in one of these"/>
   <result pre="another outbreak, referred to as MERS for the Middle Eastern" exact="Respiratory" post="Syndrome, and also caused by a coronavirus, resulted in"/>
   <result pre="and also caused by a coronavirus, resulted in over 1000" exact="infections" post="and 400 deaths through 2015. Since SARS and MERS"/>
   <result pre="settings were the most frequent sites of person to person" exact="disease" post="transmission.5, 6 Health care workers and those in close"/>
   <result pre="these outbreaks. In particular, otolaryngologists were at greater risk of" exact="infection" post="due to shedding of virus from nasal and pharyngeal"/>
   <result pre="of virus from nasal and pharyngeal mucosa.7 The implementation of" exact="infection" post="control methods, aggressive contact tracing and isolation limited the"/>
   <result pre="implementation of infection control methods, aggressive contact tracing and isolation" exact="limited" post="the spread of disease in 2003 and 2012. Antiviral"/>
   <result pre="methods, aggressive contact tracing and isolation limited the spread of" exact="disease" post="in 2003 and 2012. Antiviral treatments and vaccines were"/>
   <result pre="SARS‐CoV‐1.8 SARS‐CoV‐2 is more closely related to two bat‐derived severe" exact="acute" post="respiratory syndrome (SARS)‐like coronaviruses, bat‐SL‐CoVZC45 and bat‐SL‐CoVZXC21, collected in"/>
   <result pre="SARS‐CoV‐2 is more closely related to two bat‐derived severe acute" exact="respiratory" post="syndrome (SARS)‐like coronaviruses, bat‐SL‐CoVZC45 and bat‐SL‐CoVZXC21, collected in 2018"/>
   <result pre="is more closely related to two bat‐derived severe acute respiratory" exact="syndrome" post="(SARS)‐like coronaviruses, bat‐SL‐CoVZC45 and bat‐SL‐CoVZXC21, collected in 2018 in"/>
   <result pre="is believed to have occurred from a bat‐CoV to an" exact="intermediate" post="host after which the virus jumped to human hosts"/>
   <result pre="high rates of asymptomatic carriers which promote the spread of" exact="infection" post="to susceptible populations,13 rather than greater stability of virus"/>
   <result pre="than CoV‐1.15 3SARS‐COV2: CONSERVED SEQUENCES AND GENETIC DRIFT While the" exact="viral" post="genome continues to evolve since entering the human population,"/>
   <result pre="on electron micrographs, mediates binding to host cell receptors, determines" exact="viral" post="host range and tissue tropism, and induces host immune"/>
   <result pre="receptor mediates the effects of angiotensin, which affects vasoconstriction and" exact="hypertension" post="in the lungs, heart, kidneys and intestines. An identical"/>
   <result pre="coronaviruses plays an important role in the first step of" exact="viral infection" post="by binding to the host ACE‐2 receptor, and initiating"/>
   <result pre="plays an important role in the first step of viral" exact="infection" post="by binding to the host ACE‐2 receptor, and initiating"/>
   <result pre="are highly conserved, since they are necessary to propagate the" exact="infection" post="in person to person spread. The amino acid sequence"/>
   <result pre="in coronaviruses is uncertain. In general, immune responses to coronavirus" exact="infections" post="confer prolonged immunity. Neutralizing antibodies to SARS CoV‐1, that"/>
   <result pre="confer prolonged immunity. Neutralizing antibodies to SARS CoV‐1, that prevent" exact="viral infection" post="by preventing binding of the S protein to the"/>
   <result pre="prolonged immunity. Neutralizing antibodies to SARS CoV‐1, that prevent viral" exact="infection" post="by preventing binding of the S protein to the"/>
   <result pre="detected in patients with SARS almost 20 years after recovering from" exact="disease" post="suggesting that patients retain protection over long periods after"/>
   <result pre="While the genetic sequences critical to transmission are preserved, noncritical" exact="viral" post="sequences have undergone genetic drift. Compared to CoV‐2 sequences"/>
   <result pre="distinguish European from Asian SARS CoV‐2 coronavirus strains.18 Differences between" exact="viral" post="strains has permitted evaluations of the effectiveness of public"/>
   <result pre="States.19 4 SEROLOGICAL TESTING AND VACCINE DEVELOPMENT The identification of" exact="viral" post="epitopes that stimulate the production of antibodies that serve"/>
   <result pre="that serve as markers of an immune response to CoV‐2" exact="infection" post="are necessary for the development of serologic testing and"/>
   <result pre="design of a SARS‐CoV‐2 vaccine. However, not all antibodies prevent" exact="viral infection," post="despite targeting virus specific epitopes. For example, antibodies raised"/>
   <result pre="example, antibodies raised against SARS CoV‐1 cross‐react with the CoV‐2" exact="viral" post="epitopes, but do not prevent CoV‐2 binding to ACE‐1"/>
   <result pre="these antibodies may provide some clinical protection or attenuate the" exact="disease" post="without actually preventing infection.21, 22 Neutralizing antibodies that prevent"/>
   <result pre="disease without actually preventing infection.21, 22 Neutralizing antibodies that prevent" exact="viral" post="attachment to host cell receptors protect against viral infection."/>
   <result pre="that prevent viral attachment to host cell receptors protect against" exact="viral infection." post="However, subtle amino acid alterations may provide a &quot;back"/>
   <result pre="subtle amino acid alterations may provide a &quot;back door&quot; for" exact="viral" post="escape mutants16. A cocktail of viral epitopes to stimulate"/>
   <result pre="a &quot;back door&quot; for viral escape mutants16. A cocktail of" exact="viral" post="epitopes to stimulate a robust neutralizing immunologic response has"/>
   <result pre="development for SARS. Anecdotal reports of individuals developing more severe" exact="disease" post="after exposure in individuals vaccinated against SARS CoV‐1 raised"/>
   <result pre="Animal models demonstrated an analogous effect. Prior immunization with severe" exact="acute" post="respiratory syndrome (SARS)‐associated coronavirus (SARS‐Cove) nucleocapsid protein caused severe"/>
   <result pre="models demonstrated an analogous effect. Prior immunization with severe acute" exact="respiratory" post="syndrome (SARS)‐associated coronavirus (SARS‐Cove) nucleocapsid protein caused severe pneumonia"/>
   <result pre="demonstrated an analogous effect. Prior immunization with severe acute respiratory" exact="syndrome" post="(SARS)‐associated coronavirus (SARS‐Cove) nucleocapsid protein caused severe pneumonia in"/>
   <result pre="acute respiratory syndrome (SARS)‐associated coronavirus (SARS‐Cove) nucleocapsid protein caused severe" exact="pneumonia" post="in mice infected with SARS‐CoV.27 Demonstrations of safety and"/>
   <result pre="REFERENCES 1JonesKE, PatelNG, LevyMA, et al. Global trends in emerging" exact="infectious diseases." post="Nature. 2008;451(7181):990‐993.18288193 2AllenT, MurrayKA, Zambrana‐TorrelioC, et al. Global hotspots"/>
   <result pre="emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523‐534.27344959 7AlexanderAJ, TanAK, EvansGA, AllenJ." exact="Infection" post="control for the otolaryngologist in the era of severe"/>
   <result pre="Infection control for the otolaryngologist in the era of severe" exact="acute" post="respiratory syndrome. J Otolaryngol. 2003;32(5):281‐287.14974856 8ZhouP, YangXL, WangXG, et"/>
   <result pre="control for the otolaryngologist in the era of severe acute" exact="respiratory" post="syndrome. J Otolaryngol. 2003;32(5):281‐287.14974856 8ZhouP, YangXL, WangXG, et al."/>
   <result pre="syndrome. J Otolaryngol. 2003;32(5):281‐287.14974856 8ZhouP, YangXL, WangXG, et al. A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
   <result pre="10LiJY, YouZ, WangQ, et al. The epidemic of 2019‐novel‐coronavirus (2019‐nCoV)" exact="pneumonia" post="and insights for emerging infectious diseases in the future."/>
   <result pre="The epidemic of 2019‐novel‐coronavirus (2019‐nCoV) pneumonia and insights for emerging" exact="infectious diseases" post="in the future. Microbes Infect. 2020;22(2):80‐85.32087334 11HaoP, ZhongW, SongS,"/>
   <result pre="analysis. Ann Transl Med. 2020;8(4):128.32175421 16RockxB, CortiD, DonaldsonE, et al." exact="Structural" post="basis for potent cross‐neutralizing human monoclonal antibody protection against"/>
   <result pre="human monoclonal antibody protection against lethal human and zoonotic severe" exact="acute" post="respiratory syndrome coronavirus challenge. J Virol. 2008;82(7):3220‐3235.18199635 17PetherickA. Developing"/>
   <result pre="monoclonal antibody protection against lethal human and zoonotic severe acute" exact="respiratory" post="syndrome coronavirus challenge. J Virol. 2008;82(7):3220‐3235.18199635 17PetherickA. Developing antibody"/>
   <result pre="antibody protection against lethal human and zoonotic severe acute respiratory" exact="syndrome" post="coronavirus challenge. J Virol. 2008;82(7):3220‐3235.18199635 17PetherickA. Developing antibody tests"/>
   <result pre="2020. 20ChengMP, PapenburgJ, DesjardinsM, et al. Diagnostic testing for severe" exact="acute" post="respiratory syndrome‐related coronavirus‐2:a narrative review. Ann Intern Med. 202010.7326/M20-1301."/>
   <result pre="20ChengMP, PapenburgJ, DesjardinsM, et al. Diagnostic testing for severe acute" exact="respiratory" post="syndrome‐related coronavirus‐2:a narrative review. Ann Intern Med. 202010.7326/M20-1301. 21HoffmannM,"/>
   <result pre="2020;368:630‐633.32245784 23CoughlinMM, BabcookJ, PrabhakarBS. Human monoclonal antibodies to SARS‐coronavirus inhibit" exact="infection" post="by different mechanisms. Virology. 2009;394(1):39‐46.19748648 24LinJT, ZhangJS, SuN, et"/>
   <result pre="and immunogenicity from a phase I trial of inactivated severe" exact="acute" post="respiratory syndrome coronavirus vaccine. Antivir Ther. 2007;12(7):1107‐1113.18018769 25LurieN, SavilleM,"/>
   <result pre="immunogenicity from a phase I trial of inactivated severe acute" exact="respiratory" post="syndrome coronavirus vaccine. Antivir Ther. 2007;12(7):1107‐1113.18018769 25LurieN, SavilleM, HatchettR,"/>
   <result pre="from a phase I trial of inactivated severe acute respiratory" exact="syndrome" post="coronavirus vaccine. Antivir Ther. 2007;12(7):1107‐1113.18018769 25LurieN, SavilleM, HatchettR, HaltonJ."/>
   <result pre="N Engl J Med. 202010.1056/NEJMp2005630. 26TiradoSM, YoonKJ. Antibody‐dependent enhancement of" exact="virus infection" post="and disease. Viral Immunol. 2003;16(1):69‐86.12725690 27YasuiF, KaiC, KitabatakeM, et"/>
   <result pre="Engl J Med. 202010.1056/NEJMp2005630. 26TiradoSM, YoonKJ. Antibody‐dependent enhancement of virus" exact="infection" post="and disease. Viral Immunol. 2003;16(1):69‐86.12725690 27YasuiF, KaiC, KitabatakeM, et"/>
   <result pre="202010.1056/NEJMp2005630. 26TiradoSM, YoonKJ. Antibody‐dependent enhancement of virus infection and disease." exact="Viral" post="Immunol. 2003;16(1):69‐86.12725690 27YasuiF, KaiC, KitabatakeM, et al. Prior immunization"/>
   <result pre="2003;16(1):69‐86.12725690 27YasuiF, KaiC, KitabatakeM, et al. Prior immunization with severe" exact="acute" post="respiratory syndrome (SARS)‐associated coronavirus (SARS‐CoV) nucleocapsid protein causes severe"/>
   <result pre="27YasuiF, KaiC, KitabatakeM, et al. Prior immunization with severe acute" exact="respiratory" post="syndrome (SARS)‐associated coronavirus (SARS‐CoV) nucleocapsid protein causes severe pneumonia"/>
   <result pre="KaiC, KitabatakeM, et al. Prior immunization with severe acute respiratory" exact="syndrome" post="(SARS)‐associated coronavirus (SARS‐CoV) nucleocapsid protein causes severe pneumonia in"/>
   <result pre="acute respiratory syndrome (SARS)‐associated coronavirus (SARS‐CoV) nucleocapsid protein causes severe" exact="pneumonia" post="in mice infected with SARS‐CoV. J Immunol. 2008;181(9):6337‐6348.18941225 28MitsukiYY,"/>
   <result pre="neutralization affects in vitro and in vivo fitness of severe" exact="acute" post="respiratory syndrome coronavirus. J Infect Dis. 2010;201(6):946–955. 20144042 30ter"/>
   <result pre="affects in vitro and in vivo fitness of severe acute" exact="respiratory" post="syndrome coronavirus. J Infect Dis. 2010;201(6):946–955. 20144042 30ter MeulenJ,"/>
   <result pre="in vitro and in vivo fitness of severe acute respiratory" exact="syndrome" post="coronavirus. J Infect Dis. 2010;201(6):946–955. 20144042 30ter MeulenJ, van"/>
   <result pre="Med. 2006;3(7):e23716796401 31CoughlinMM, PrabhakarBS. Neutralizing human monoclonal antibodies to severe" exact="acute" post="respiratory syndrome coronavirus: target, mechanism of action, and therapeutic"/>
   <result pre="2006;3(7):e23716796401 31CoughlinMM, PrabhakarBS. Neutralizing human monoclonal antibodies to severe acute" exact="respiratory" post="syndrome coronavirus: target, mechanism of action, and therapeutic potential."/>
   <result pre="31CoughlinMM, PrabhakarBS. Neutralizing human monoclonal antibodies to severe acute respiratory" exact="syndrome" post="coronavirus: target, mechanism of action, and therapeutic potential. Rev"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7298473/results/search/disease/results.xml">
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="remains active. As the world is gripped by the Coronavirus" exact="Disease" post="2019 (COVID-19) pandemic, plant epidemics are spreading silently, affecting"/>
   <result pre="plant diseases. While 7.4 million people have been infected by" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus causing"/>
   <result pre="diseases. While 7.4 million people have been infected by Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus causing COVID-19,"/>
   <result pre="While 7.4 million people have been infected by Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2), the virus causing COVID-19, 822"/>
   <result pre="7.4 million people have been infected by Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2), the virus causing COVID-19, 822 million"/>
   <result pre="animal viruses, plant viruses are grouped on the basis of" exact="viral" post="genomic structure. There are 26 families of plant viruses,"/>
   <result pre="the economically important DNA virus family, Geminiviridae, Cassava mosaic begomovirus" exact="infection" post="results in an annual crop loss of 25 million"/>
   <result pre="(CSSV) has become endemic in Ghana, Nigeria, and Togo. West" exact="African" post="cacao production accounts for 70% of the world's cacao"/>
   <result pre="the most economically damaging group of plant viruses. Bromoviruses cause" exact="disease" post="epidemics in fruits, vegetables, and animal feed. Citrus, an"/>
   <result pre="quarantine measures are only effective in areas with a low" exact="infection" post="rate. The most widely distributed viral disease of cereals,"/>
   <result pre="areas with a low infection rate. The most widely distributed" exact="viral" post="disease of cereals, Barley yellow dwarf luteovirus, of the"/>
   <result pre="with a low infection rate. The most widely distributed viral" exact="disease" post="of cereals, Barley yellow dwarf luteovirus, of the Luteoviridae"/>
   <result pre="COVID-19 pandemic, the US government granted USD4.3 billion specifically for" exact="disease" post="control, prevention, and global health programs. With its high"/>
   <result pre="prevention, and global health programs. With its high rate of" exact="infection" post="and severity of symptoms, it is not surprising that"/>
   <result pre="of plant pathogens. Asymptomatic carriers are the leading cause of" exact="infection" post="propagation and disease spread, especially for fruit crops such"/>
   <result pre="Asymptomatic carriers are the leading cause of infection propagation and" exact="disease" post="spread, especially for fruit crops such as citrus, papaya,"/>
   <result pre="environmental conditions, vector proliferation, and viral-genome evolution, could forewarn new" exact="disease" post="emergence. Drone surveillance, self-monitoring, and reporting could control both"/>
   <result pre="diseases. But pandemics occur unexpectedly, and strategies to combat emerging" exact="infectious" post="agents rarely prevent outbreaks. Thus, to prevent future outbreaks,"/>
   <result pre="human and crop diseases. The 2020 US budget for Human" exact="Immunodeficiency" post="Virus (HIV) research (USD2.6 billion) is USD150 million more"/>
   <result pre="that of humans, the expression of weaker related viruses or" exact="viral" post="proteins leads to disease resistance. Innate immunity in plants,"/>
   <result pre="expression of weaker related viruses or viral proteins leads to" exact="disease" post="resistance. Innate immunity in plants, as in humans, protects"/>
   <result pre="immunity in plants, as in humans, protects against pathogens. Antiviral" exact="Resistance" post="(R) genes prevent systemic spread by eliciting programmed cell"/>
   <result pre="in humans, protects against pathogens. Antiviral Resistance (R) genes prevent" exact="systemic" post="spread by eliciting programmed cell death, and RNA silencing"/>
   <result pre="spread by eliciting programmed cell death, and RNA silencing prevents" exact="viral" post="replication (Soosaar et al., 2005). Traditional methods of breeding"/>
   <result pre="the first virus-resistant papaya was obtained through bioengineered expression of" exact="viral" post="protein, successfully demonstrating plant vaccination (Ferreira et al., 2002)."/>
   <result pre="plant pandemics, reduce yield loss, and promote food security; however," exact="limited" post="funding and negative public opinion about genetically modified crops"/>
   <result pre="and subsequent cultivation and consumption. Eradication of emerging or reemerging" exact="infectious diseases" post="requires fast affordable testing and universal vaccination programs. Bioengineered"/>
   <result pre="in fewer investigators and international collaborations and ultimately exacerbating plant" exact="disease" post="and crop loss. The International Year of Plant Health"/>
   <result pre="health. To prevent the negative effects of COVID-19 on plant" exact="disease" post="research, these aims should be adhered to and supported."/>
   <result pre="to protect against and treat crop infection. Funding for crop" exact="disease" post="research continues to decline, partly due to the sporadic"/>
   <result pre="of resistant crops cannot keep up with the number of" exact="infections" post="threatening global food production. References References CapellT.TwymanR.M.Armario-NajeraV.MaJ.K.SchillbergS.ChristouP.Potential applications of"/>
   <result pre="virus in HawaiiPlant Dis.86200210110530823304 KadoC.I.Asymptomatic and Latent Infections. Plant Bacteriology2016The" exact="American" post="Phytopathological SocietySt. Paul, MN221228 KhalidA.ZhangQ.YasirM.LiF.Small RNA based genetic engineering"/>
   <result pre="SocietySt. Paul, MN221228 KhalidA.ZhangQ.YasirM.LiF.Small RNA based genetic engineering for plant" exact="viral" post="resistance: application in crop protectionFront. Microbiol.820174328167936 NicaiseV.Crop immunity against"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7300792/results/search/disease/results.xml">
   <result pre="decades. In this article, he argues that the medicalization of" exact="viral" post="epidemics has distracted us from the importance of their"/>
   <result pre="us. Our cells bring them to life and make them" exact="infectious" post="through our social actions. Confusing viruses with invasive microbes"/>
   <result pre="the face of a foreign threat. Indeed, new work in" exact="viral" post="epidemiology indicates that many viruses have infectious potential long"/>
   <result pre="new work in viral epidemiology indicates that many viruses have" exact="infectious" post="potential long before an epidemic develops. It is not"/>
   <result pre="we behave socially – that ignites the rapid circulation of" exact="viral" post="information. fig-count: table-count: ref-count: page-count: word-count: I would like"/>
   <result pre="for Sonar‐Global, a European Commission social science network responding to" exact="infectious disease" post="outbreaks and antimicrobial resistance. His email is d.napier@ucl.ac.uk. References"/>
   <result pre="Sonar‐Global, a European Commission social science network responding to infectious" exact="disease" post="outbreaks and antimicrobial resistance. His email is d.napier@ucl.ac.uk. References"/>
   <result pre="is d.napier@ucl.ac.uk. References References Anderson, W. &amp;amp; I.R.Mackay2014Intolerant bodies: A" exact="short" post="history of autoimmunity. Baltimore: Johns Hopkins University Press. Cantlupe,"/>
   <result pre="strain correlates with escape from herd immunity. The Journal of" exact="Infectious" post="Diseases208: 1877–1887.23908476 collab: European Commission n.d. Urbanisation worldwide. https://ec.europa.eu/knowledge4policy/foresight/topic/continuing-urbanisation/worldwide-urban-population-growth_en."/>
   <result pre="worldwide. https://ec.europa.eu/knowledge4policy/foresight/topic/continuing-urbanisation/worldwide-urban-population-growth_en. Jooss, K. &amp;amp; N.Chirmule2003Immunity to adenovirus and adeno‐associated" exact="viral" post="vectors: Implications for gene therapy. Gene Therapy10: 955–963.12756416 Kallikourdis,"/>
   <result pre="evolutionary considerations can help identify testable hypotheses for improving immunotherapy." exact="Cancer" post="Immunology, Immunotherapy67(6): 989–998.29335855 Lindesmith, L.C. et al. 2012Immunogenetic mechanisms"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7309422/results/search/disease/results.xml">
   <result pre="temperatures in the Northern hemisphere. We use data from a" exact="primary" post="care registry of almost 15,000 patients over 20 years"/>
   <result pre="almost 15,000 patients over 20 years to retrieve information on" exact="viral" post="respiratory infection outbreaks. Our analysis suggests that the severity"/>
   <result pre="15,000 patients over 20 years to retrieve information on viral" exact="respiratory" post="infection outbreaks. Our analysis suggests that the severity of"/>
   <result pre="patients over 20 years to retrieve information on viral respiratory" exact="infection" post="outbreaks. Our analysis suggests that the severity of the"/>
   <result pre="softened by the seasonal change to summer. Keywords COVID-19 Epidemiology" exact="Respiratory" post="viral infection Influenza Seasonality Pandemic The infection caused by"/>
   <result pre="by the seasonal change to summer. Keywords COVID-19 Epidemiology Respiratory" exact="viral infection" post="Influenza Seasonality Pandemic The infection caused by the human"/>
   <result pre="the seasonal change to summer. Keywords COVID-19 Epidemiology Respiratory viral" exact="infection" post="Influenza Seasonality Pandemic The infection caused by the human"/>
   <result pre="Keywords COVID-19 Epidemiology Respiratory viral infection Influenza Seasonality Pandemic The" exact="infection" post="caused by the human corona virus COVID-19 (SARS-CoV2) resulted"/>
   <result pre="a worldwide pandemic affecting several million people and causing severe" exact="disease" post="and fatality mostly based on virus mediated lung failure"/>
   <result pre="the methods of choice to control the spread of this" exact="infection" post="[3, 4]. However, epidemics with respiratory virus such as"/>
   <result pre="the spread of this infection [3, 4]. However, epidemics with" exact="respiratory" post="virus such as not only influenza but also human"/>
   <result pre="seasons in the Northern hemisphere. To assess local epidemics from" exact="respiratory" post="infections over the course of a season, we retrospectively"/>
   <result pre="in the Northern hemisphere. To assess local epidemics from respiratory" exact="infections" post="over the course of a season, we retrospectively analyzed"/>
   <result pre="15,336 patients (8907 women and 6429 men) who visited a" exact="primary" post="care internal medicine practice in Innsbruck, Austria, between July"/>
   <result pre="dataset included 145,740 diagnoses, of which 16,317 are assigned to" exact="acute" post="respiratory diseases according to the International Classification of Diseases"/>
   <result pre="included 145,740 diagnoses, of which 16,317 are assigned to acute" exact="respiratory" post="diseases according to the International Classification of Diseases (ICD-10;"/>
   <result pre="to acute respiratory diseases according to the International Classification of" exact="Diseases" post="(ICD-10; www.icd.who.int/browse10/2019/en). In particular, we included viral and bacterial"/>
   <result pre="International Classification of Diseases (ICD-10; www.icd.who.int/browse10/2019/en). In particular, we included" exact="viral" post="and bacterial infections classified into diagnostic groups A and"/>
   <result pre="of Diseases (ICD-10; www.icd.who.int/browse10/2019/en). In particular, we included viral and" exact="bacterial infections" post="classified into diagnostic groups A and B as well"/>
   <result pre="Diseases (ICD-10; www.icd.who.int/browse10/2019/en). In particular, we included viral and bacterial" exact="infections" post="classified into diagnostic groups A and B as well"/>
   <result pre="classified into diagnostic groups A and B as well as" exact="infectious diseases" post="of the respiratory tract of groups J (pulmonology), H"/>
   <result pre="A and B as well as infectious diseases of the" exact="respiratory" post="tract of groups J (pulmonology), H (ear, nose and"/>
   <result pre="(ear, nose and throat) and R (general symptoms consistent with" exact="infections" post="such as dyspnea or fatigue). Based on this data,"/>
   <result pre="number of patients who sought medical help because of serious" exact="respiratory" post="infections. Second, we related these counts to the total"/>
   <result pre="serious respiratory infections. Second, we related these counts to the" exact="total" post="number of diagnoses within each month to obtain the"/>
   <result pre="of diagnoses within each month to obtain the share of" exact="viral" post="infections. In the denominator of this ratio, we excluded"/>
   <result pre="of this ratio, we excluded malignancies (group C), neoplasia (D)," exact="diabetes mellitus" post="2 (E-11.9), arterial hypertension (I-10) and ischemic heart diseases"/>
   <result pre="excluded malignancies (group C), neoplasia (D), diabetes mellitus 2 (E-11.9)," exact="arterial hypertension" post="(I-10) and ischemic heart diseases (I-20). As the mentioned"/>
   <result pre="malignancies (group C), neoplasia (D), diabetes mellitus 2 (E-11.9), arterial" exact="hypertension" post="(I-10) and ischemic heart diseases (I-20). As the mentioned"/>
   <result pre="(D), diabetes mellitus 2 (E-11.9), arterial hypertension (I-10) and ischemic" exact="heart" post="diseases (I-20). As the mentioned practice was sometimes closed"/>
   <result pre="was sometimes closed due to holiday breaks, the share of" exact="viral" post="infections might provide a more suitable figure on seasonal"/>
   <result pre="sometimes closed due to holiday breaks, the share of viral" exact="infections" post="might provide a more suitable figure on seasonal patterns"/>
   <result pre="the simple count measure. Figure 1 plots the counts of" exact="respiratory" post="diseases over the course of the years. It shows"/>
   <result pre="2010 and for 2015. Figure 2 depicts the share of" exact="respiratory" post="diseases and pools the information from Fig. 1 into"/>
   <result pre="trend based on year-wise regressions with the relative contributions of" exact="respiratory" post="diseases per month as the dependent variable. In particular,"/>
   <result pre="are carried out with Stata (version 16). Fig. 1 The" exact="total" post="number of infectious respiratory diseases (green line) over a"/>
   <result pre="with Stata (version 16). Fig. 1 The total number of" exact="infectious" post="respiratory diseases (green line) over a time period of"/>
   <result pre="Stata (version 16). Fig. 1 The total number of infectious" exact="respiratory" post="diseases (green line) over a time period of 20"/>
   <result pre="this time period (84.5 ± 41.6), and the shaded area shows the" exact="upper" post="and lower bounds of one standard deviation around this"/>
   <result pre="period (84.5 ± 41.6), and the shaded area shows the upper and" exact="lower" post="bounds of one standard deviation around this mean Fig."/>
   <result pre="deviation around this mean Fig. 2 The relative number of" exact="infectious" post="respiratory diseases over a time period of 20 years"/>
   <result pre="around this mean Fig. 2 The relative number of infectious" exact="respiratory" post="diseases over a time period of 20 years (1999–2020)."/>
   <result pre="time period of 20 years (1999–2020). For each month, the" exact="total" post="number of respiratory diseases is related to the total"/>
   <result pre="20 years (1999–2020). For each month, the total number of" exact="respiratory" post="diseases is related to the total number of diagnoses"/>
   <result pre="the total number of respiratory diseases is related to the" exact="total" post="number of diagnoses in the physician practice (y-axis). The"/>
   <result pre="practice (y-axis). The figure plots the seasons in which previous" exact="respiratory" post="infections have been recorded (02/03 SARS-CoV, purple line; 04/05"/>
   <result pre="(y-axis). The figure plots the seasons in which previous respiratory" exact="infections" post="have been recorded (02/03 SARS-CoV, purple line; 04/05 H5N1,"/>
   <result pre="was not the case (grey lines). Regarding the pattern of" exact="respiratory" post="diagnoses in the season 2019/20, we first used the"/>
   <result pre="to Mar. We further fitted a &quot;potential&quot; seasonal development of" exact="respiratory" post="diseases for three scenarios (dashed red lines): (i) one"/>
   <result pre="scenarios (dashed red lines): (i) one where the share of" exact="respiratory" post="diseases in July 2020 is equal to the average"/>
   <result pre="diseases in July 2020 is equal to the average of" exact="respiratory" post="diseases (indicated by &quot;AVG&quot;) over the month of July"/>
   <result pre="The colored lines plot the seasons in which previous pandemic" exact="respiratory" post="infections have been recorded (02/03 SARS-CoV, purple line; 04/05"/>
   <result pre="colored lines plot the seasons in which previous pandemic respiratory" exact="infections" post="have been recorded (02/03 SARS-CoV, purple line; 04/05 H5N1,"/>
   <result pre="[8] but not showing the absolute contributions of these pandemic" exact="infections" post="to the total number of respiratory infections. The grey"/>
   <result pre="showing the absolute contributions of these pandemic infections to the" exact="total" post="number of respiratory infections. The grey lines indicate seasons"/>
   <result pre="contributions of these pandemic infections to the total number of" exact="respiratory" post="infections. The grey lines indicate seasons where no specific"/>
   <result pre="infections. The grey lines indicate seasons where no specific pandemic" exact="respiratory" post="infections are recorded. In line with Fig. 1, we"/>
   <result pre="The grey lines indicate seasons where no specific pandemic respiratory" exact="infections" post="are recorded. In line with Fig. 1, we can"/>
   <result pre="with Fig. 1, we can see that the peak of" exact="respiratory" post="diseases (including putatively COVID-19) lies between February and April"/>
   <result pre="reduction towards summer. If COVID-19 would behave similar to other" exact="respiratory" post="viruses causing respiratory infections including human corona viruses which"/>
   <result pre="If COVID-19 would behave similar to other respiratory viruses causing" exact="respiratory" post="infections including human corona viruses which peak during winter"/>
   <result pre="COVID-19 would behave similar to other respiratory viruses causing respiratory" exact="infections" post="including human corona viruses which peak during winter time"/>
   <result pre="such as the influenza H1N1v can circulate independent of typical" exact="respiratory" post="viral seasons throughout the whole year [10]. In line"/>
   <result pre="as the influenza H1N1v can circulate independent of typical respiratory" exact="viral" post="seasons throughout the whole year [10]. In line with"/>
   <result pre="which scenario will hold true for the control of COVID-19" exact="infections" post="and how changes of temperature and social behavior will"/>
   <result pre="Ungchusak K, Wieler LH, Strategic WHO, Technical Advisory Group for" exact="Infectious" post="HCOVID-19: towards controlling of a pandemicLancet20203951015101810.1016/S0140-6736(20)30673-532197103 2.PetrosilloNViceconteGErgonulOIppolitoGPetersenECOVID-19, SARS and"/>
   <result pre="ChinaInfection20204815115310.1007/s15010-020-01409-432185635 5.HeraudJMNjouomRRoussetDKadjoHCaroVNdiayeMNVictoirKCollardJMOrelleAYekwaELEkazaERazanajatovoNHAdamouLBiscornetLEnoufVvan der WerfSDiopOMSpatiotemporal circulation of influenza viruses in 5" exact="African" post="countries during 2008–2009: a collaborative study of the Institut"/>
   <result pre="study of the Institut Pasteur International NetworkJ Infect Dis2012206S51310.1093/infdis/jis54123169972 6.MostJWeissGConsecutive" exact="infections" post="with influenza A and B virus in children during"/>
   <result pre="during the 2014–2015 seasonal influenza epidemicJ Infect Dis20162141139114110.1093/infdis/jiw10427095422 7.MoriyamaMHugentoblerWJIwasakiASeasonality of" exact="respiratory" post="viral infectionsAnnu Rev Virol202010.1146/annurev-virology-012420-02244532196426 8.MartinRConseilALongstaffAKodoJSiegertJDuguetAMLobato de FariaPHaringhuizenGEspinJCokerRPandemic influenza control"/>
   <result pre="the 2014–2015 seasonal influenza epidemicJ Infect Dis20162141139114110.1093/infdis/jiw10427095422 7.MoriyamaMHugentoblerWJIwasakiASeasonality of respiratory" exact="viral" post="infectionsAnnu Rev Virol202010.1146/annurev-virology-012420-02244532196426 8.MartinRConseilALongstaffAKodoJSiegertJDuguetAMLobato de FariaPHaringhuizenGEspinJCokerRPandemic influenza control in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7309641/results/search/disease/results.xml">
   <result pre="[b], [c], Correspondence to Nicolas Dauby, MD, PhD, Department of" exact="Infectious" post="Diseases, Centre Hospitalier Universitaire (CHU) Saint-Pierre, Rue Haute 322,"/>
   <result pre="via PMC and Europe PMC, consistent with existing copyright protections.aids-publish-ahead-of-print-10.1097.qad.0000000000002555.pdf" exact="Infection" post="caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),"/>
   <result pre="PMC, consistent with existing copyright protections.aids-publish-ahead-of-print-10.1097.qad.0000000000002555.pdf Infection caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), agent of corona virus"/>
   <result pre="consistent with existing copyright protections.aids-publish-ahead-of-print-10.1097.qad.0000000000002555.pdf Infection caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), agent of corona virus disease"/>
   <result pre="with existing copyright protections.aids-publish-ahead-of-print-10.1097.qad.0000000000002555.pdf Infection caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), agent of corona virus disease 2019"/>
   <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2), agent of corona virus" exact="disease" post="2019 (COVID-19), has emerged in December 2019 in Wuhan,"/>
   <result pre="case on 5 March 2020 [3]. Incidence and severity of" exact="respiratory" post="virus infection, such as influenza, is higher in PLWH"/>
   <result pre="on 5 March 2020 [3]. Incidence and severity of respiratory" exact="virus infection," post="such as influenza, is higher in PLWH as compared"/>
   <result pre="risk of hospitalization, more prolonged hospitalization and death following influenza" exact="infection" post="[4]. Since the beginning of the 21st Century, two"/>
   <result pre="two other coronaviruses have emerged as a cause of severe" exact="respiratory" post="diseases: namely, SARS and Middle East Respiratory Syndrome Coronavirus"/>
   <result pre="cause of severe respiratory diseases: namely, SARS and Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV) [1]. In order to identify previous"/>
   <result pre="of severe respiratory diseases: namely, SARS and Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV) [1]. In order to identify previous clinical"/>
   <result pre="was performed using the MeSH terms ‘Coronavirus’ or ‘Middle East" exact="Respiratory" post="Syndrome Coronavirus’ or ‘SARS Virus’ and ‘HIV’ or ‘Acquired"/>
   <result pre="performed using the MeSH terms ‘Coronavirus’ or ‘Middle East Respiratory" exact="Syndrome" post="Coronavirus’ or ‘SARS Virus’ and ‘HIV’ or ‘Acquired Immunodeficiency"/>
   <result pre="Respiratory Syndrome Coronavirus’ or ‘SARS Virus’ and ‘HIV’ or ‘Acquired" exact="Immunodeficiency" post="Syndrome’. Large cohort studies of SARS-infected and MERS-CoV-infected patients"/>
   <result pre="of SARS and MERS-CoV-infected patients [5–8]. A case of SARS" exact="infection" post="in a 30-year old Chinese man was reported in"/>
   <result pre="tenofovir, had a low CD4+ count (134/μl) and a detectable" exact="viral" post="load (470 copies/ml). The patient was treated with ribavirin and"/>
   <result pre="Chen et al.[13] reported that 19 AIDS patients treated for" exact="opportunistic infections" post="in the same ward of SARS-infected patients did not"/>
   <result pre="et al.[13] reported that 19 AIDS patients treated for opportunistic" exact="infections" post="in the same ward of SARS-infected patients did not"/>
   <result pre="same ward of SARS-infected patients did not develop nosocomial SARS" exact="infection" post="despite long stay. This was in contrast with the"/>
   <result pre="stay. This was in contrast with the high rate of" exact="infection" post="in health-care workers (HCW) working on the same ward"/>
   <result pre="could be hypothesized that distinct immune response might have impacted" exact="susceptibility to" post="SARS infection. However, no definite conclusion regarding the possible"/>
   <result pre="between HIV-infection and SARS can be drawn as exposure to" exact="infective" post="viral particles is probably different between HCW and patients."/>
   <result pre="HIV-infection and SARS can be drawn as exposure to infective" exact="viral" post="particles is probably different between HCW and patients. In"/>
   <result pre="from previous coronaviruses outbreaks on the susceptibility and severity of" exact="disease" post="in PLWH is scarce. International collaborative studies are warranted"/>
   <result pre="Available at: https://bnonews.com/index.php/2020/02/the-latest-coronavirus-cases/. (Accessed 5 March 2020) 4.CohenCMoyesJTempiaSGroomMWalazaSPretoriusMet al.Severe influenza-associated" exact="respiratory" post="infection in high HIV prevalence setting, South Africa, 2009–2011."/>
   <result pre="at: https://bnonews.com/index.php/2020/02/the-latest-coronavirus-cases/. (Accessed 5 March 2020) 4.CohenCMoyesJTempiaSGroomMWalazaSPretoriusMet al.Severe influenza-associated respiratory" exact="infection" post="in high HIV prevalence setting, South Africa, 2009–2011. Emerg"/>
   <result pre="JAMA2003; 289:2801–2809.12734147 6.PeirisJChuCChengVChanKHungIPoonLet al.collab: HKU/UCH SARS Study GroupClinical progression and" exact="viral" post="load in a community outbreak of coronavirus-associated SARS pneumonia:"/>
   <result pre="course and outcomes of critically ill patients with middle east" exact="respiratory" post="syndrome coronavirus infection. Ann Intern Med2014; 160:389–397.24474051 8.AssiriAAl-TawfiqJAAl-RabeeahAAAl-RabiahFAAl-HajjarSAl-BarrakAet al.Epidemiological,"/>
   <result pre="and outcomes of critically ill patients with middle east respiratory" exact="syndrome" post="coronavirus infection. Ann Intern Med2014; 160:389–397.24474051 8.AssiriAAl-TawfiqJAAl-RabeeahAAAl-RabiahFAAl-HajjarSAl-BarrakAet al.Epidemiological, demographic,"/>
   <result pre="demographic, and clinical characteristics of 47 cases of Middle East" exact="respiratory" post="syndrome coronavirus disease from Saudi Arabia: a descriptive study."/>
   <result pre="and clinical characteristics of 47 cases of Middle East respiratory" exact="syndrome" post="coronavirus disease from Saudi Arabia: a descriptive study. Lancet"/>
   <result pre="characteristics of 47 cases of Middle East respiratory syndrome coronavirus" exact="disease" post="from Saudi Arabia: a descriptive study. Lancet Infect Dis2013;"/>
   <result pre="Arabia: a descriptive study. Lancet Infect Dis2013; 13:752–761.23891402 9.WongATYTsangOTYWongMYFLimWLZhengBJLeeSSet al.Coronavirus" exact="infection" post="in an AIDS patient. AIDS Lond Engl2004; 18:829–830. 10.ChuCMChengVCCHungIFNWongMMLChanKHChanKSet"/>
   <result pre="interferon beta against MERS-CoV. Nat Commun2020; 11:222.31924756 13.ChenXPLiGHTangXPXiongYChenXJCaoYLack of severe" exact="acute" post="respiratory syndrome in 19 AIDS patients hospitalized together. J"/>
   <result pre="beta against MERS-CoV. Nat Commun2020; 11:222.31924756 13.ChenXPLiGHTangXPXiongYChenXJCaoYLack of severe acute" exact="respiratory" post="syndrome in 19 AIDS patients hospitalized together. J Acquir"/>
   <result pre="against MERS-CoV. Nat Commun2020; 11:222.31924756 13.ChenXPLiGHTangXPXiongYChenXJCaoYLack of severe acute respiratory" exact="syndrome" post="in 19 AIDS patients hospitalized together. J Acquir Immune"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7316359/results/search/disease/results.xml">
   <result pre="10.1371/journal.pcbi.1007989PCOMPBIOL-D-19-01797 : Research Article : Medicine and Health Sciences :" exact="Infectious" post="Diseases : Viral Diseases: Influenza : Biology and life"/>
   <result pre=": Research Article : Medicine and Health Sciences : Infectious" exact="Diseases" post=": Viral Diseases: Influenza : Biology and life sciences"/>
   <result pre="Article : Medicine and Health Sciences : Infectious Diseases :" exact="Viral" post="Diseases: Influenza : Biology and life sciences : Organisms"/>
   <result pre="Sciences : Microbiology : Medical Microbiology : Microbial Pathogens :" exact="Viral" post="Pathogens : Orthomyxoviruses: Influenza Viruses : Medicine and Health"/>
   <result pre="Pathology and Laboratory Medicine : Pathogens : Microbial Pathogens :" exact="Viral" post="Pathogens : Orthomyxoviruses: Influenza Viruses : Biology and Life"/>
   <result pre=": Biology and Life Sciences : Organisms : Viruses :" exact="Viral" post="Pathogens : Orthomyxoviruses: Influenza Viruses : People and places"/>
   <result pre=": Biology and Life Sciences : Microbiology : Microbial Evolution:" exact="Viral" post="Evolution : Biology and Life Sciences : Evolutionary Biology"/>
   <result pre="Sciences : Evolutionary Biology : Organismal Evolution : Microbial Evolution:" exact="Viral" post="Evolution : Biology and Life Sciences : Microbiology :"/>
   <result pre="Evolution : Biology and Life Sciences : Microbiology : Virology:" exact="Viral" post="Evolution Dynamic interactions of influenza viruses in Hong Kong"/>
   <result pre="New York, United States of America[2], WHO Collaborating Centre for" exact="Infectious" post="Disease Epidemiology and Control, School of Public Health, Li"/>
   <result pre="York, United States of America[2], WHO Collaborating Centre for Infectious" exact="Disease" post="Epidemiology and Control, School of Public Health, Li Ka"/>
   <result pre="worldwide. Currently, two influenza A subtypes, A(H1N1) and A(H3N2), and" exact="type B" post="viruses co-circulate in humans and infection with one type/subtype"/>
   <result pre="and A(H3N2), and type B viruses co-circulate in humans and" exact="infection" post="with one type/subtype could provide cross-protection against the others."/>
   <result pre="importance of simultaneous monitoring of population immunity, incidence rates, and" exact="viral" post="genetic and antigenic changes. Author summary Three influenza viruses,"/>
   <result pre="of the Hong Kong Government, and the National Institute of" exact="General" post="Medical Sciences (grant U54 GM088558 to the Harvard Center"/>
   <result pre="Sciences (grant U54 GM088558 to the Harvard Center for Communicable" exact="Disease" post="Dynamics). The funders had no role in study design,"/>
   <result pre="morbidity and mortality, leading to 3 to 5 million severe" exact="infections" post="and 291,000 to 646,000 deaths worldwide each year [1,2]."/>
   <result pre="and 291,000 to 646,000 deaths worldwide each year [1,2]. These" exact="recurrent" post="epidemics are a combined outcome of viral antigenic changes,"/>
   <result pre="year [1,2]. These recurrent epidemics are a combined outcome of" exact="viral" post="antigenic changes, interactions among co-circulating influenza viruses, transmission and"/>
   <result pre="A(H1N1) and A(H3N2), and influenza B co-circulate in humans; and" exact="infection" post="of a certain type/subtype can result in partial immunity"/>
   <result pre="humans; and infection of a certain type/subtype can result in" exact="partial" post="immunity to influenza strains of the same type/subtype as"/>
   <result pre="cross-immunity—leads to epidemiological interactions among influenza viruses that, along with" exact="viral" post="antigenic changes, shape influenza phylodynamics and epidemic dynamics [19–31]."/>
   <result pre="transmissibility of an infection, defined as the average number of" exact="secondary" post="infections that arise from a primary infection in a"/>
   <result pre="of an infection, defined as the average number of secondary" exact="infections" post="that arise from a primary infection in a naïve"/>
   <result pre="the average number of secondary infections that arise from a" exact="primary" post="infection in a naïve population. We thus first estimate,"/>
   <result pre="average number of secondary infections that arise from a primary" exact="infection" post="in a naïve population. We thus first estimate, for"/>
   <result pre="1F), although to a less extent for A(H1N1); and for" exact="type B," post="it has only one peak in the winter (Fig"/>
   <result pre="1 Seasonality of influenza epidemics in Hong Kong. Upper panel:" exact="infection" post="rate time series for the three influenza viruses (A)."/>
   <result pre="A(H1N1) (B), A(H3N2) (C), and B (D). Color lines show" exact="infection" post="rates for individuals years during Jan 1998 –July 2018;"/>
   <result pre="addition, the model-inference system was able to accurately estimate the" exact="infection" post="rates during both epidemic and non-epidemic periods for all"/>
   <result pre="seasonal cycle as years with epidemics (Fig 3A), the estimated" exact="infection" post="rates remained at near-zero over these extended time-periods when"/>
   <result pre="not in circulation (Fig 2A). Fig 2 Estimates of weekly" exact="infection" post="rate and population susceptibility for the three types/subtypes: A(H1N1)"/>
   <result pre="variables and parameters, as they are intricately linked to the" exact="infection" post="rate. Foremost, overestimation of population susceptibility would lead to"/>
   <result pre="period) replenishes the susceptible pool whereas gaining of cross-immunity from" exact="infection" post="by other types/subtypes (determined by the strength of cross-immunity)"/>
   <result pre="also be accurate in order to achieve accurate estimation of" exact="infection" post="rate. Taken together, the accurate infection rate estimates suggest"/>
   <result pre="achieve accurate estimation of infection rate. Taken together, the accurate" exact="infection" post="rate estimates suggest that the model-inference system was also"/>
   <result pre="accurately estimate key state variables and parameters. Population susceptibility, R0," exact="infectious" post="period, and immunity period Table 1 summarizes the estimates"/>
   <result pre="for B, respectively. These estimates were consistent with the relative" exact="infection" post="rates of individual types/subtypes. Note, however, due to stringent"/>
   <result pre="full range (in parentheses). Strain Strength of cross-immunity (cij) R0" exact="Infectious" post="period (days) Immunity period (years) A(H1N1) A(H3N2) B A(H1N1)"/>
   <result pre="over the 20-year study period for all types/subtypes. The estimated" exact="infectious" post="period was slightly longer for A(H3N2) (3.0; 2.6–4.3 days)"/>
   <result pre="immunity period determines the duration of immune protection from prior" exact="infection" post="and is thus a key epidemiological parameter shaping the"/>
   <result pre="a wide prior range from 1 to 9 years. The" exact="posterior" post="estimate of immunity period (Table 1 and S7 Fig)"/>
   <result pre="A(H3N2) (2.2; 1.8–2.6 years). These estimates accounted for cross-immunity from" exact="infections" post="of other types/subtypes, for which, after conversion based on"/>
   <result pre="and S7 Fig; cij denotes cross-immunity against virus-i gained from" exact="infection" post="of virus-j). Three interesting features seem to characterize the"/>
   <result pre="among all virus-pairs, cross-immunity was the weakest when gained from" exact="infection" post="of A(H3N2) (the mean was 17% of the strength"/>
   <result pre="As estimated here, i.e., setting all cross-immunity terms to the" exact="posterior" post="mean estimates; 2) A(H3N2) outcompeting A(H1N1) via stronger cross-immunity,"/>
   <result pre="and B currently co-circulating in humans and the pattern of" exact="viral" post="interactions. We have also estimated the timing and frequency"/>
   <result pre="higher for A(H3N2) (range: 1.3–2.0). Estimated simultaneously with R0, the" exact="infectious" post="period, or generation time, was slightly longer for A(H3N2)"/>
   <result pre="A(H1N1); these estimates were very close to those based on" exact="viral" post="shedding curves—3.0 vs 3.1 days reported for A(H3N2), 3.1"/>
   <result pre="the higher transmissibility of A(H3N2) (i.e., larger R0 and longer" exact="infectious" post="period) in part explains its larger seasonal epidemics and"/>
   <result pre="period) in part explains its larger seasonal epidemics and resulting" exact="lower" post="average population susceptibility (mean: 60.8% for A(H3N2) vs. 66.6%"/>
   <result pre="the diverse influenza dynamics in other subtropical/tropical regions or other" exact="infections" post="with similar challenges. Cross-immunity and co-circulation pattern Multiple lines"/>
   <result pre="or other infections with similar challenges. Cross-immunity and co-circulation pattern" exact="Multiple" post="lines of evidence have suggested cross protection offered by"/>
   <result pre="Multiple lines of evidence have suggested cross protection offered by" exact="infection" post="of influenza viruses of the same type/subtype as well"/>
   <result pre="estimate that there were relatively strong cross-immunity against A(H3N2) by" exact="infection" post="of A(H1N1) (~40% of the specific-immunity) and moderate level"/>
   <result pre="estimates of weak cross-immunities to A(H1N1) and B conferred by" exact="infection" post="of A(H3N2) appear to contradict the common notion that"/>
   <result pre="key epidemiological features. In particular, A(H3N2) confers shorter immunity following" exact="infection" post="and also undergoes more frequent genetic/antigenic mutations. Based on"/>
   <result pre="whose first exposure was A(H1N1) had long-term protection against subsequent" exact="infection" post="by the same subtype whereas those first exposed to"/>
   <result pre="the product of these two factors is the decrease in" exact="susceptibility to" post="its complement types/subtypes) allows the two less frequently circulating"/>
   <result pre="estimates from phylogenetic analyses. For instance, the two surges in" exact="susceptibility to" post="A(H1N1) during the 2009 pandemic (i.e., around 9/13/09 and"/>
   <result pre="in estimated influenza attack rates. Recent estimates ranged from 3–11%" exact="symptomatic" post="infections among vaccinated and unvaccinated US residents during 2010–2016"/>
   <result pre="estimated influenza attack rates. Recent estimates ranged from 3–11% symptomatic" exact="infections" post="among vaccinated and unvaccinated US residents during 2010–2016 [56]to"/>
   <result pre="vaccinated and unvaccinated US residents during 2010–2016 [56]to 32% confirmed" exact="infection" post="among unvaccinated individuals during 2015 in New Zealand [57]."/>
   <result pre="relatively high but plausible given the longer epidemic duration and" exact="lower" post="vaccination rates in Hong Kong (~10% [58,59] v. ~45%"/>
   <result pre="monitoring population immunity to different influenza viruses, incidence rates, and" exact="viral" post="genetic and antigenic changes. Meanwhile, the model-inference system developed"/>
   <result pre="extended to study influenza epidemic dynamics in other regions with" exact="limited" post="antigenic data. Materials and Methods Influenza surveillance data The"/>
   <result pre="a more specific measure of the incidence of influenza virus" exact="infections" post="in the community, we multiplied the weekly ILI rate"/>
   <result pre="community, we multiplied the weekly ILI rate by the concurrent" exact="viral" post="isolation rate for A(H1N1), A(H3N2) and B, respectively [42,49,65,66]."/>
   <result pre="as A(H1N1)+, A(H3N2)+, and B+. Converting ILI consultation rate to" exact="infection" post="rate The ILI consultation rate is the ratio of"/>
   <result pre="the catchment population. Previously, we showed that conversion to per-capita" exact="infection" post="rate can be made based on Bayes’ rule [65,67]."/>
   <result pre="pandemic ranged from 16% [68] to ~20% [61,69]. Using the" exact="upper" post="end of these estimates and the cumulative pandemic H1N1+"/>
   <result pre="a particle filter with space re-probing. We further smoothed the" exact="posterior" post="estimates of R0 using 3-week moving average and used"/>
   <result pre="chance of reinfection and transmission in any individual with prior" exact="infection" post="by a similar strain (i.e. leaky immunity) or protect"/>
   <result pre="leaky immunity) or protect a portion of individuals with prior" exact="infection" post="(i.e. polarized immunity). In particular, Gog and Grenfell [24]"/>
   <result pre="βi, Di, and Li are, respectively, the transmission rate, mean" exact="infectious" post="period, and mean immunity period, for virus-i; and cij"/>
   <result pre="cij measures the strength of cross-immunity to virus-i conferred by" exact="infection" post="of virus-j (e.g., close to 0 if it is"/>
   <result pre="and cii = 1 for strain-specific immunity). We assumed the" exact="total" post="population size is stable over the study period such"/>
   <result pre="for strain-specific immunity). We assumed the total population size is" exact="stable" post="over the study period such that the birth rate"/>
   <result pre="the SR-IF2 were uniform distributions as follows: Si~U[50%, 90%] of" exact="total" post="population and Di~U[2, 4] days for i = A(H1N1),"/>
   <result pre="interactions. Note, however, with perturbations in the IF2 procedure, the" exact="posterior" post="estimates can go outside the prior range. Together, we"/>
   <result pre="can go outside the prior range. Together, we tested a" exact="total" post="of 736 combinations of Li and cij priors in"/>
   <result pre="(highest likelihood and fewest space re-probing needed) and used their" exact="posterior" post="estimates to compute the prior range for subsequent round"/>
   <result pre="particles. Each run took round 8 to 10 hours to" exact="complete" post="on a high-performance cluster (https://www.mailman.columbia.edu/information-for/information-technology/high-performance-computing-hpc). To account for stochasticity"/>
   <result pre="(highest likelihood and fewest space re-probing needed) and computed the" exact="posterior" post="estimates across those runs per Rubin’s rule [78,79]. Estimating"/>
   <result pre="rate and population susceptibility (A), basic reproductive number R0 (B)," exact="infectious" post="period (C), immunity period (D), and strength of cross-immunity"/>
   <result pre="box plots show the median, 75%, and 95% CIs of" exact="posterior" post="estimates by the model-inference system; orange dashed lines show"/>
   <result pre="rate and population susceptibility (A), basic reproductive number R0 (B)," exact="infectious" post="period (C), immunity period (D), and strength of cross-immunity"/>
   <result pre="box plots show the median, 75%, and 95% CIs of" exact="posterior" post="estimates by the model-inference system; orange dashed lines show"/>
   <result pre="A(H3N2), and (C) B. Black lines are ILI+ observations; red" exact="horizontal" post="lines are baselines; blue vertical lines are the identified"/>
   <result pre="A(H3N2), and (C) B. Black lines are ILI+ observations; red" exact="horizontal" post="lines are baselines; blue vertical lines are the identified"/>
   <result pre="data file. S7 Fig Weekly estimates of key model parameters:" exact="Infectious" post="period for A(H1N1) (A), A(H3N2) (B), and B (C);"/>
   <result pre="six virus-pairs (G-L). Solid lines and surrounding areas show the" exact="posterior" post="mean and 95% CI estimates and dashed lines show"/>
   <result pre="here for additional data file. S8 Fig Simulations using the" exact="posterior" post="mean estimates. Colored lines show simulated weekly infection rates"/>
   <result pre="using the posterior mean estimates. Colored lines show simulated weekly" exact="infection" post="rates from 1000 individual stochastic model runs (A(H1N1) in"/>
   <result pre="B in green); dashed black lines show the weekly mean" exact="infection" post="rates across 1000 simulations and solid black lines show"/>
   <result pre="was set to 0.5 and other parameters set to the" exact="posterior" post="mean estimates. Colored lines show simulated weekly infection rates"/>
   <result pre="to the posterior mean estimates. Colored lines show simulated weekly" exact="infection" post="rates from 1000 individual stochastic model runs (A(H1N1) in"/>
   <result pre="B in green); dashed black lines show the weekly mean" exact="infection" post="rates across 1000 simulations and solid black lines show"/>
   <result pre="were set to 0 and other parameters set to the" exact="posterior" post="mean estimates. Colored lines show simulated weekly infection rates"/>
   <result pre="to the posterior mean estimates. Colored lines show simulated weekly" exact="infection" post="rates from 1000 individual stochastic model runs (A(H1N1) in"/>
   <result pre="B in green); dashed black lines show the weekly mean" exact="infection" post="rates across 1000 simulations and solid black lines show"/>
   <result pre="(TIF) LINK Click here for additional data file. S11 Fig" exact="Epidemic" post="and co-circulation patterns under different strengths of cross-immunity. Box"/>
   <result pre="plots show the distributions across 1000 simulations using the parameter" exact="posterior" post="estimates, stratified by period of time: All weeks from"/>
   <result pre="susceptible (S) individuals can get infected and move to being" exact="infectious" post="(I), who subsequently recover (R) from the infection; due"/>
   <result pre="lose prior immunity and return to being susceptible. While the" exact="infection" post="processes for each virus happen independently (hence the three"/>
   <result pre="three viruses can occur via cross-immune protection, which convert new" exact="infections" post="by other viruses to a loss of susceptibility (thin"/>
   <result pre="MuscatelloDJ, PalekarR, et al. (2018) Estimates of global seasonal influenza-associated" exact="respiratory" post="mortality: a modelling study. Lancet391: 1285–1300. 10.1016/S0140-6736(17)33293-229248255 3MedinaRA, Garcia-SastreA"/>
   <result pre="virus reduces the induction of heterosubtypic immunity against influenza A/H5N1" exact="virus infection" post="in ferrets. J Virol85: 2695–2702. 10.1128/JVI.02371-1021228239 9EkiertDC, BhabhaG, ElsligerMA,"/>
   <result pre="reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus" exact="infection" post="in ferrets. J Virol85: 2695–2702. 10.1128/JVI.02371-1021228239 9EkiertDC, BhabhaG, ElsligerMA,"/>
   <result pre="2695–2702. 10.1128/JVI.02371-1021228239 9EkiertDC, BhabhaG, ElsligerMA, FriesenRH, JongeneelenM, et al. (2009)" exact="Antibody" post="recognition of a highly conserved influenza virus epitope. Science324:"/>
   <result pre="2 influenza A viruses. Science333: 843–850. 10.1126/science.120483921737702 11EpsteinSL (2006) Prior" exact="H1N1 Influenza" post="Infection and Susceptibility of Cleveland Family Study Participants during"/>
   <result pre="A viruses. Science333: 843–850. 10.1126/science.120483921737702 11EpsteinSL (2006) Prior H1N1 Influenza" exact="Infection" post="and Susceptibility of Cleveland Family Study Participants during the"/>
   <result pre="TsibaneT, KrammerF, HaiR, RahmatS, et al. (2012) 1976 and 2009" exact="H1N1 Influenza" post="Virus Vaccines Boost Anti-Hemagglutinin Stalk Antibodies in Humans. J"/>
   <result pre="BoonAC, SmithLR, TreanorJJ, et al. (2007) Cross-reactive neuraminidase antibodies afford" exact="partial" post="protection against H5N1 in mice and are present in"/>
   <result pre="GuarnacciaT, CarolanL, HormanW, YanA, et al. (2016) The time-interval between" exact="infections" post="and viral hierarchies are determinants of viral interference following"/>
   <result pre="HormanW, YanA, et al. (2016) The time-interval between infections and" exact="viral" post="hierarchies are determinants of viral interference following influenza virus"/>
   <result pre="The time-interval between infections and viral hierarchies are determinants of" exact="viral" post="interference following influenza virus infection in a ferret model."/>
   <result pre="and viral hierarchies are determinants of viral interference following influenza" exact="virus infection" post="in a ferret model. Eur J Immunol46: 685–686. 19AndreasenV"/>
   <result pre="viral hierarchies are determinants of viral interference following influenza virus" exact="infection" post="in a ferret model. Eur J Immunol46: 685–686. 19AndreasenV"/>
   <result pre="20BansalS, MeyersLA (2012) The impact of past epidemics on future" exact="disease" post="dynamics. Journal of theoretical biology309: 176–184. 10.1016/j.jtbi.2012.06.01222721993 21BoniMF, GogJR,"/>
   <result pre="closure and mitigation of pandemic (H1N1) 2009, Hong Kong. Emerging" exact="infectious" post="diseases16: 538–541. 10.3201/eid1603.09121620202441 45LiaoQ, CowlingB, LamWT, NgMW, FieldingR (2010)"/>
   <result pre="VerguE, FergusonNM, LemaitreM, CauchemezS, et al. (2008) Time lines of" exact="infection" post="and disease in human influenza: a review of volunteer"/>
   <result pre="LemaitreM, CauchemezS, et al. (2008) Time lines of infection and" exact="disease" post="in human influenza: a review of volunteer challenge studies."/>
   <result pre="FangVJ, ChanKH, WaiW, et al. (2014) Incidence of influenza virus" exact="infections" post="in children in Hong Kong in a 3-year randomized"/>
   <result pre="Kong in a 3-year randomized placebo-controlled vaccine study, 2009–2012. Clinical" exact="infectious" post="diseases: an official publication of the Infectious Diseases Society"/>
   <result pre="study, 2009–2012. Clinical infectious diseases: an official publication of the" exact="Infectious" post="Diseases Society of America59: 517–524.24825868 54BuddAP, BeachamL, SmithCB, GartenRJ,"/>
   <result pre="2009–2012. Clinical infectious diseases: an official publication of the Infectious" exact="Diseases" post="Society of America59: 517–524.24825868 54BuddAP, BeachamL, SmithCB, GartenRJ, ReedC,"/>
   <result pre="Cohort Effects in Influenza Surveillance Data: Evidence That First Influenza" exact="Infection" post="Affects Later Influenza-Associated Illness. The Journal of infectious diseases220:"/>
   <result pre="First Influenza Infection Affects Later Influenza-Associated Illness. The Journal of" exact="infectious" post="diseases220: 820–829. 10.1093/infdis/jiz20131053844 55NextStrain.org (2019) Real-time tracking of influenza"/>
   <result pre="Seasonal Incidence of Symptomatic Influenza in the United States. Clinical" exact="Infectious" post="Diseases66: 1511–1518. 10.1093/cid/cix106029206909 57HuangQS, BandaranayakeD, WoodT, NewbernEC, SeedsR, et"/>
   <result pre="BandaranayakeD, WoodT, NewbernEC, SeedsR, et al. (2019) Risk Factors and" exact="Attack" post="Rates of Seasonal Influenza Infection: Results of the Southern"/>
   <result pre="Effectiveness Research and Surveillance (SHIVERS) Seroepidemiologic Cohort Study. Journal of" exact="Infectious" post="Diseases219: 347–357. 10.1093/infdis/jiy44330016464 58LeeSS, LeungEH, WongNS (2013) Concerns for"/>
   <result pre="Region (2017) Statistics on 2016/17 Vaccination Programmes/Schemes http://www.chp.gov.hk/en/view_content/26734.html 60Centers for" exact="Disease" post="Control and Prevention (2016) National Early-Season Flu Vaccination Coverage,"/>
   <result pre="61WuJT, LeungK, PereraRA, ChuDK, LeeCK, et al. (2014) Inferring influenza" exact="infection" post="attack rate from seroprevalence data. PLoS Pathog10: e100405410.1371/journal.ppat.100405424699693 62LauEHY,"/>
   <result pre="IpDKM, CowlingBJ (2012) Situational Awareness of Influenza Activity Based on" exact="Multiple" post="Streams of Surveillance Data Using Multivariate Dynamic Linear Model."/>
   <result pre="Based on Multiple Streams of Surveillance Data Using Multivariate Dynamic" exact="Linear" post="Model. Plos One7: e3834610.1371/journal.pone.003834622675456 63LauEHY, CowlingBJ, HoLM, LeungGM (2008)"/>
   <result pre="(2008) Optimizing use of multistream influenza sentinel surveillance data. Emerging" exact="infectious" post="diseases14: 1154–1157. 10.3201/eid1407.08006018598647 64CowlingBJ, WongIO, HoLM, RileyS, LeungGM (2006)"/>
   <result pre="Commun4: 283710.1038/ncomms383724302074 66WongJY, WuP, NishiuraH, GoldsteinE, LauEH, et al. (2013)" exact="Infection" post="fatality risk of the pandemic A(H1N1)2009 virus in Hong"/>
   <result pre="MartchevaM, Castillo-ChavezC (2005) Dynamics of Two-Strain Influenza with Isolation and" exact="Partial" post="Cross-Immunity. SIAM Journal on Applied Mathematics65: 964–982. 73KoelleK, KhatriP,"/>
   <result pre="practice and guidelines. BMC Med Res Methodol9: 5710.1186/1471-2288-9-5719638200 79RubinDB (2004)" exact="Multiple" post="imputation for nonresponse in surveys: John Wiley &amp;amp; Sons."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7320681/results/search/disease/results.xml">
   <result pre="10.1016/j.transci.2020.102856102856 : Article Immunomodulation for the management of corona virus" exact="disease" post="(COVID-19) KiprovDobridkiprovcai@aol.com*ConboyMichael J.conboymj@berkeley.eduConboyIrina M.iconboy@berkeley.edu[], ⁎Corresponding author. dkiprovcai@aol.com pmc-release: 2020-6-6ppub:"/>
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="as the COVID-19 resource centre remains active. The corona virus" exact="disease" post="(COVID-19) has caused a global health and economic crisis."/>
   <result pre="convalescent plasma collected from people who have fully recovered from" exact="infection" post="contains antibodies against the infectious agent. Convalescent plasma provides"/>
   <result pre="who have fully recovered from infection contains antibodies against the" exact="infectious" post="agent. Convalescent plasma provides passive immunity and has been"/>
   <result pre="used for the prophylaxis and treatment of a number of" exact="infectious diseases," post="including recent epidemics with SARS-Cov-1, Ebola and Middle Eastern"/>
   <result pre="diseases, including recent epidemics with SARS-Cov-1, Ebola and Middle Eastern" exact="Respiratory" post="Syndrome (MERS) [1]. Small studies from China have demonstrated"/>
   <result pre="including recent epidemics with SARS-Cov-1, Ebola and Middle Eastern Respiratory" exact="Syndrome" post="(MERS) [1]. Small studies from China have demonstrated that"/>
   <result pre="recovered from COVID-19 is safe and results in reduction of" exact="viral" post="load and improved clinical outcome. This prompted the FDA"/>
   <result pre="from COVID-19 and account for the majority of the deaths." exact="Systemic" post="chronic inflammation is believed to be the major cause"/>
   <result pre="COVID-19 and account for the majority of the deaths. Systemic" exact="chronic" post="inflammation is believed to be the major cause of"/>
   <result pre="regulation of the immune response that leads to an increased" exact="susceptibility to" post="viral infections and weakened response to vaccines. Collateral damage"/>
   <result pre="the immune response that leads to an increased susceptibility to" exact="viral" post="infections and weakened response to vaccines. Collateral damage from"/>
   <result pre="immune response that leads to an increased susceptibility to viral" exact="infections" post="and weakened response to vaccines. Collateral damage from chronic"/>
   <result pre="viral infections and weakened response to vaccines. Collateral damage from" exact="chronic" post="inflammation is oxidative stress [2]. Experimental studies in rodents"/>
   <result pre="a beneficial effect in sepsis associated with severe inflammatory response" exact="syndrome" post="(SIRS) [5]. And recently, TPE has been successfully used"/>
   <result pre="been successfully used in the treatment of severe cytokine release" exact="syndrome" post="after Chimera Antigen Receptor T cell (CAR-T) infusion. TPE"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7323437/results/search/disease/results.xml">
   <result pre="and Sons Inc.Hoboken doi: 10.1002/jmv.26194JMV26194 : Short Communication: Short Communications" exact="Dengue" post="and COVID‐19, overlapping epidemics? An Analysis from Colombia CARDONA‐OSPINA"/>
   <result pre="Universitaria Autónoma de las Américas, Sede PereiraPereiraColombia[2], Public Health and" exact="Infection" post="Research Group, Faculty of Health Sciences, Universidad Tecnológica de"/>
   <result pre="Faculty of Medicine, Fundación Universitaria Autónoma de las AméricasPereiraRisaraldaColombia[5], Emerging" exact="Infectious" post="Diseases and Tropical Medicine Research Group, Instituto para la"/>
   <result pre="of Medicine, Fundación Universitaria Autónoma de las AméricasPereiraRisaraldaColombia[5], Emerging Infectious" exact="Diseases" post="and Tropical Medicine Research Group, Instituto para la Investigación"/>
   <result pre="Zoonoses and Travel Medicine, Asociación Colombiana de InfectologíaBogotáDCColombia[7], Coordination, Latin" exact="American" post="Network of Coronavirus Disease 2019‐COVID‐19 Research (LANCOVID‐19)PereiraRisaraldaColombia[8], Facultad de"/>
   <result pre="Asociación Colombiana de InfectologíaBogotáDCColombia[7], Coordination, Latin American Network of Coronavirus" exact="Disease" post="2019‐COVID‐19 Research (LANCOVID‐19)PereiraRisaraldaColombia[8], Facultad de MedicinaUniversidad Nacional Hermilio ValdizánHuánucoPeru[9],"/>
   <result pre="Master in Clinical Epidemiology and Biostatistics, Universidad Científica del SurLimaPeru[10]," exact="Infectious" post="Diseases and Infection Control Research Group, Hospital Universitario de"/>
   <result pre="in Clinical Epidemiology and Biostatistics, Universidad Científica del SurLimaPeru[10], Infectious" exact="Diseases" post="and Infection Control Research Group, Hospital Universitario de SincelejoSincelejoSucreColombia[11],"/>
   <result pre="Epidemiology and Biostatistics, Universidad Científica del SurLimaPeru[10], Infectious Diseases and" exact="Infection" post="Control Research Group, Hospital Universitario de SincelejoSincelejoSucreColombia[11], Programa del"/>
   <result pre="del Doctorado de Medicina Tropical, SUE Caribe, Universidad del AtlánticoBarranquillaColombia[12]," exact="Infectious" post="Diseases DepartmentClinica MarlyBogotáDCColombia[13], Infectious Diseases DepartmentHospital de La SamaritanaDCColombia[14],"/>
   <result pre="Doctorado de Medicina Tropical, SUE Caribe, Universidad del AtlánticoBarranquillaColombia[12], Infectious" exact="Diseases" post="DepartmentClinica MarlyBogotáDCColombia[13], Infectious Diseases DepartmentHospital de La SamaritanaDCColombia[14], Semillero"/>
   <result pre="Tropical, SUE Caribe, Universidad del AtlánticoBarranquillaColombia[12], Infectious Diseases DepartmentClinica MarlyBogotáDCColombia[13]," exact="Infectious" post="Diseases DepartmentHospital de La SamaritanaDCColombia[14], Semillero de Investigación en"/>
   <result pre="SUE Caribe, Universidad del AtlánticoBarranquillaColombia[12], Infectious Diseases DepartmentClinica MarlyBogotáDCColombia[13], Infectious" exact="Diseases" post="DepartmentHospital de La SamaritanaDCColombia[14], Semillero de Investigación en Zoonosis"/>
   <result pre="Departamental de NariñoPastoNariñoColombia[19], Program of Healthcare‐Associated Infections, ESE Pasto SaludPastoNariñoColombia[20]," exact="Infectious" post="Diseases, Department of Internal MedicineUniversidad del ValleSantiago de CaliColombia[21],"/>
   <result pre="Infectious Diseases, Department of Internal MedicineUniversidad del ValleSantiago de CaliColombia[21]," exact="Infectious" post="Diseases DivisionCentro Médico ImbanacoCaliValle del CaucaColombia[22], Pediatric Infectious Diseases,"/>
   <result pre="Diseases, Department of Internal MedicineUniversidad del ValleSantiago de CaliColombia[21], Infectious" exact="Diseases" post="DivisionCentro Médico ImbanacoCaliValle del CaucaColombia[22], Pediatric Infectious Diseases, Centro"/>
   <result pre="ValleSantiago de CaliColombia[21], Infectious Diseases DivisionCentro Médico ImbanacoCaliValle del CaucaColombia[22]," exact="Pediatric" post="Infectious Diseases, Centro de Estudios en Infectología PediátricaCaliValle del"/>
   <result pre="de CaliColombia[21], Infectious Diseases DivisionCentro Médico ImbanacoCaliValle del CaucaColombia[22], Pediatric" exact="Infectious" post="Diseases, Centro de Estudios en Infectología PediátricaCaliValle del CaucaColombia[23],"/>
   <result pre="ValleCaliValle del CaucaColombia[24], Universidad Internacional SEK, Center for Biodiversity, Emerging" exact="Diseases" post="and Environmental Health, Master School of Biomedicine, Natural Sciences"/>
   <result pre=", This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
   <result pre="the duration of the public health emergency.file:JMV-9999-na.pdf Abstract Abstract Coronavirus" exact="Disease" post="2019 (COVID‐19), caused by Severe Acute Respiratory Syndrome Coronavirus"/>
   <result pre="health emergency.file:JMV-9999-na.pdf Abstract Abstract Coronavirus Disease 2019 (COVID‐19), caused by" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), has rapidly spread"/>
   <result pre="emergency.file:JMV-9999-na.pdf Abstract Abstract Coronavirus Disease 2019 (COVID‐19), caused by Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), has rapidly spread throughout"/>
   <result pre="Abstract Abstract Coronavirus Disease 2019 (COVID‐19), caused by Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS‐CoV‐2), has rapidly spread throughout Latin"/>
   <result pre="Abstract Coronavirus Disease 2019 (COVID‐19), caused by Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS‐CoV‐2), has rapidly spread throughout Latin America,"/>
   <result pre="South America. In this report, we analyzed trends for both" exact="viral" post="infections in Colombia during the first 20 epidemiological weeks"/>
   <result pre="America. In this report, we analyzed trends for both viral" exact="infections" post="in Colombia during the first 20 epidemiological weeks of"/>
   <result pre="1st to May 16th, 2020 (epidemiological weeks, EW, 1‐20), a" exact="total" post="of 52,679 cases of dengue and 14,943 cases of"/>
   <result pre="may potentially lead to fatal outcomes, especially in patients with" exact="chronic" post="co‐morbidities, overlapping infections and co‐occurrence may increase the number"/>
   <result pre="to fatal outcomes, especially in patients with chronic co‐morbidities, overlapping" exact="infections" post="and co‐occurrence may increase the number of patients requiring"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7326430/results/search/disease/results.xml">
   <result pre="courier ; font-style : italic;} Infect Dis ModelInfect Dis ModelInfectious" exact="Disease" post="Modelling2468-21522468-0427KeAi Publishing pmcid: 7326430S2468-0427(20)30017-8 doi: 10.1016/j.idm.2020.06.001 : Special issue"/>
   <result pre="Pushing past the tipping points in containment trajectories of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemics: A simple arithmetic"/>
   <result pre="past the tipping points in containment trajectories of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) epidemics: A simple arithmetic rationale"/>
   <result pre="the tipping points in containment trajectories of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) epidemics: A simple arithmetic rationale for"/>
   <result pre="with ambitious national strategies to crush the curve of their" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) epidemic trajectories include"/>
   <result pre="ambitious national strategies to crush the curve of their Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) epidemic trajectories include China,"/>
   <result pre="national strategies to crush the curve of their Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2) epidemic trajectories include China, Korea,"/>
   <result pre="strategies to crush the curve of their Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2) epidemic trajectories include China, Korea, Japan,"/>
   <result pre="for years, decades or even indefinitely. Keywords Coronavirus COVID SARS2" exact="Severe" post="acute respiratory syndrome coronavirus 2 SARS-CoV-2 Model Epidemiology Outbreak"/>
   <result pre="years, decades or even indefinitely. Keywords Coronavirus COVID SARS2 Severe" exact="acute" post="respiratory syndrome coronavirus 2 SARS-CoV-2 Model Epidemiology Outbreak Zoonosis"/>
   <result pre="decades or even indefinitely. Keywords Coronavirus COVID SARS2 Severe acute" exact="respiratory" post="syndrome coronavirus 2 SARS-CoV-2 Model Epidemiology Outbreak Zoonosis Emerging"/>
   <result pre="or even indefinitely. Keywords Coronavirus COVID SARS2 Severe acute respiratory" exact="syndrome" post="coronavirus 2 SARS-CoV-2 Model Epidemiology Outbreak Zoonosis Emerging infection"/>
   <result pre="respiratory syndrome coronavirus 2 SARS-CoV-2 Model Epidemiology Outbreak Zoonosis Emerging" exact="infection" post="Abbreviations SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2 Handling"/>
   <result pre="2 SARS-CoV-2 Model Epidemiology Outbreak Zoonosis Emerging infection Abbreviations SARS-CoV-2," exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 Handling editor: Jianhong Wu"/>
   <result pre="SARS-CoV-2 Model Epidemiology Outbreak Zoonosis Emerging infection Abbreviations SARS-CoV-2, Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 Handling editor: Jianhong Wu Main"/>
   <result pre="Model Epidemiology Outbreak Zoonosis Emerging infection Abbreviations SARS-CoV-2, Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 Handling editor: Jianhong Wu Main text"/>
   <result pre="Epidemiology Outbreak Zoonosis Emerging infection Abbreviations SARS-CoV-2, Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 Handling editor: Jianhong Wu Main text Most"/>
   <result pre="editor: Jianhong Wu Main text Most cases of the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) are relatively mild or"/>
   <result pre="Jianhong Wu Main text Most cases of the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) are relatively mild or even"/>
   <result pre="Wu Main text Most cases of the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) are relatively mild or even asymptomatic"/>
   <result pre="reproductive number of the virus (R) or number of new" exact="infections" post="arising from any initial infection over its full duration."/>
   <result pre="(R) or number of new infections arising from any initial" exact="infection" post="over its full duration. An epidemic curve which has"/>
   <result pre="exactly flattened, so that the rate of incidence of new" exact="infections" post="remains constant (R0 = 1.0), represents the tipping point"/>
   <result pre="the epidemic had reached an incidence rate of 10,000 new" exact="infections" post="per week at the point when a suite of"/>
   <result pre="introduced, with an initial pre-intervention reproductive number of 4 new" exact="infections" post="per existing infection (R0 = 4.0). A and D:"/>
   <result pre="initial pre-intervention reproductive number of 4 new infections per existing" exact="infection" post="(R0 = 4.0). A and D: Controlled reproductive numbers"/>
   <result pre="a plateau, so that the rate of incidence of new" exact="infections" post="remains constant, would have achieved a controlled reproductive number"/>
   <result pre="0.6, Fig. 1A) every 3 weeks (Approximate mean duration of" exact="infection" post="(Killeen &amp;amp; Kiware, 2020)) before petering out after little"/>
   <result pre="reduction, Rc = 0.4, Fig. 1A) and local transmission may" exact="collapse" post="within 30 weeks (Fig. 1B and C). While these"/>
   <result pre="rates for flatten the curve strategies that fall only 5%" exact="short" post="of their targets (Fig. 1B, C, E and F)"/>
   <result pre="may spiral out of control when restrictions are relaxed or" exact="viral" post="reproduction surges for a variety of other reasons (Fig."/>
   <result pre="establishment of zoonotic reservoirs, and rapid evolution of a large" exact="viral" post="population into new forms that could be even more"/>
   <result pre="the various loopholes in intervention coverage and effectiveness that allow" exact="residual" post="transmission to persist through essential workers, goods and services"/>
   <result pre="many encouraging precedents exist for certifying countries as free from" exact="infection" post="with veterinary pathogens like swine fever (Martin, Cameron, Barfod,"/>
   <result pre="Cameron, Barfod, Sergeant, &amp;amp; Greiner, 2007) or human pathogens like" exact="malaria" post="(Feachem et al., 2019). It is also encouraging that"/>
   <result pre="malaria (Feachem et al., 2019). It is also encouraging that" exact="viral" post="outbreaks of Ebola in 2014 and 2018, Severe Acute"/>
   <result pre="encouraging that viral outbreaks of Ebola in 2014 and 2018," exact="Severe" post="Acute Respiratory Syndrome in 2003 and Middle East Respiratory"/>
   <result pre="that viral outbreaks of Ebola in 2014 and 2018, Severe" exact="Acute" post="Respiratory Syndrome in 2003 and Middle East Respiratory Syndrome"/>
   <result pre="viral outbreaks of Ebola in 2014 and 2018, Severe Acute" exact="Respiratory" post="Syndrome in 2003 and Middle East Respiratory Syndrome in"/>
   <result pre="outbreaks of Ebola in 2014 and 2018, Severe Acute Respiratory" exact="Syndrome" post="in 2003 and Middle East Respiratory Syndrome in 2012"/>
   <result pre="2018, Severe Acute Respiratory Syndrome in 2003 and Middle East" exact="Respiratory" post="Syndrome in 2012 all threated to become larger pandemics"/>
   <result pre="Severe Acute Respiratory Syndrome in 2003 and Middle East Respiratory" exact="Syndrome" post="in 2012 all threated to become larger pandemics but"/>
   <result pre="to reduce COVID-19 mortality and healthcare demandWHO collaborating centre for" exact="infectious disease" post="modelling, MRC centre for global infectious disease analysis2020Abdul Latif"/>
   <result pre="reduce COVID-19 mortality and healthcare demandWHO collaborating centre for infectious" exact="disease" post="modelling, MRC centre for global infectious disease analysis2020Abdul Latif"/>
   <result pre="collaborating centre for infectious disease modelling, MRC centre for global" exact="infectious disease" post="analysis2020Abdul Latif Jameel Institute for Disease and Emergency Analytics"/>
   <result pre="centre for infectious disease modelling, MRC centre for global infectious" exact="disease" post="analysis2020Abdul Latif Jameel Institute for Disease and Emergency Analytics"/>
   <result pre="centre for global infectious disease analysis2020Abdul Latif Jameel Institute for" exact="Disease" post="and Emergency Analytics &amp;amp; Imperial College London20 FinebergH.V.Ten weeks"/>
   <result pre="public to explore containment options for the 2019 Novel Coronavirus2020Infectious" exact="Disease" post="Modelling. In press10.1101/2020.04.15.20066845 KisslerS.M.TedijantoC.GoldsteinE.GradY.H.LipsitchM.Projecting the transmission dynamics of SARS-CoV-2"/>
   <result pre="dynamics of SARS-CoV-2 through the postpandemic periodScience368202086086810.1126/science.abb579332291278 MartinP.A.CameronA.R.BarfodK.SergeantE.S.GreinerM.Demonstrating freedom from" exact="disease" post="using multiple complex data sources 2: Case study--classical swine"/>
   <result pre="curve of COVID-19. The case of SpainThe Science of the" exact="Total" post="Environment727202013876110.1016/j.scitotenv.2020.13876132330703 TangB.XiaF.TangS.BragazziN.L.LiQ.SunX.The effectiveness of quarantine and isolation determine the"/>
   <result pre="final phase of the current outbreak in ChinaInternational Journal of" exact="Infectious" post="Diseases95202028829310.1016/j.ijid.2020.03.01832171948 Acknowledgements This study was supported by an AXA"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7332278/results/search/disease/results.xml">
   <result pre="Health2352-46422352-4650Elsevier Ltd. pmcid: 7332278S2352-4642(20)30175-9 doi: 10.1016/S2352-4642(20)30175-9 : Article Emergence of" exact="Kawasaki disease" post="related to SARS-CoV-2 infection in an epicentre of the"/>
   <result pre="Ltd. pmcid: 7332278S2352-4642(20)30175-9 doi: 10.1016/S2352-4642(20)30175-9 : Article Emergence of Kawasaki" exact="disease" post="related to SARS-CoV-2 infection in an epicentre of the"/>
   <result pre="10.1016/S2352-4642(20)30175-9 : Article Emergence of Kawasaki disease related to SARS-CoV-2" exact="infection" post="in an epicentre of the French COVID-19 epidemic: a"/>
   <result pre="[m], [n], [o], *Correspondence to: Dr Ulrich Meinzer, Department of" exact="General" post="Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases, National"/>
   <result pre="Meinzer, Department of General Paediatrics, Paediatric Internal Medicine, Rheumatology and" exact="Infectious" post="Diseases, National Referee Centre for Rheumatic, Autoimmune and Systemic"/>
   <result pre="Medicine, Rheumatology and Infectious Diseases, National Referee Centre for Rheumatic," exact="Autoimmune" post="and Systemic Diseases in Children, Robert Debré University Hospital,"/>
   <result pre="and Infectious Diseases, National Referee Centre for Rheumatic, Autoimmune and" exact="Systemic" post="Diseases in Children, Robert Debré University Hospital, Assistance Publique-Hôpitaux"/>
   <result pre="Infectious Diseases, National Referee Centre for Rheumatic, Autoimmune and Systemic" exact="Diseases" post="in Children, Robert Debré University Hospital, Assistance Publique-Hôpitaux de"/>
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="as the COVID-19 resource centre remains active. Abstract Summary Background" exact="Kawasaki disease" post="is an acute febrile systemic childhood vasculitis, which is"/>
   <result pre="the COVID-19 resource centre remains active. Abstract Summary Background Kawasaki" exact="disease" post="is an acute febrile systemic childhood vasculitis, which is"/>
   <result pre="centre remains active. Abstract Summary Background Kawasaki disease is an" exact="acute" post="febrile systemic childhood vasculitis, which is suspected to be"/>
   <result pre="active. Abstract Summary Background Kawasaki disease is an acute febrile" exact="systemic" post="childhood vasculitis, which is suspected to be triggered by"/>
   <result pre="Abstract Summary Background Kawasaki disease is an acute febrile systemic" exact="childhood" post="vasculitis, which is suspected to be triggered by respiratory"/>
   <result pre="systemic childhood vasculitis, which is suspected to be triggered by" exact="respiratory" post="viral infections. We aimed to examine whether the ongoing"/>
   <result pre="childhood vasculitis, which is suspected to be triggered by respiratory" exact="viral" post="infections. We aimed to examine whether the ongoing COVID-19"/>
   <result pre="to examine whether the ongoing COVID-19 epidemic, caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with an"/>
   <result pre="examine whether the ongoing COVID-19 epidemic, caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), is associated with an increase"/>
   <result pre="whether the ongoing COVID-19 epidemic, caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), is associated with an increase in"/>
   <result pre="(SARS-CoV-2), is associated with an increase in the incidence of" exact="Kawasaki disease." post="Methods We did a quasi-experimental interrupted time series analysis"/>
   <result pre="the COVID-19 outbreak. The main outcome was the number of" exact="Kawasaki disease" post="cases over time, estimated by quasi-Poisson regression. In the"/>
   <result pre="COVID-19 outbreak. The main outcome was the number of Kawasaki" exact="disease" post="cases over time, estimated by quasi-Poisson regression. In the"/>
   <result pre="(2005–2020) and the results of nasopharyngeal multiplex PCR to identify" exact="respiratory" post="pathogens (2017–2020). These data were compared with daily hospital"/>
   <result pre="2005, and May 20, 2020, we included 230 patients with" exact="Kawasaki disease." post="The median number of Kawasaki disease hospitalisations estimated by"/>
   <result pre="included 230 patients with Kawasaki disease. The median number of" exact="Kawasaki disease" post="hospitalisations estimated by the quasi-Poisson model was 1·2 per"/>
   <result pre="230 patients with Kawasaki disease. The median number of Kawasaki" exact="disease" post="hospitalisations estimated by the quasi-Poisson model was 1·2 per"/>
   <result pre="1·1–1·3). In April, 2020, we identified a rapid increase of" exact="Kawasaki disease" post="that was related to SARS-CoV-2 (six cases per month;"/>
   <result pre="In April, 2020, we identified a rapid increase of Kawasaki" exact="disease" post="that was related to SARS-CoV-2 (six cases per month;"/>
   <result pre="and was found in eight (80%) of ten patients with" exact="Kawasaki disease" post="since April 15 (SARS-CoV-2-positive PCR or serology). A second"/>
   <result pre="was found in eight (80%) of ten patients with Kawasaki" exact="disease" post="since April 15 (SARS-CoV-2-positive PCR or serology). A second"/>
   <result pre="or serology). A second peak of hospital admissions due to" exact="Kawasaki disease" post="was observed in December, 2009 (six cases per month;"/>
   <result pre="serology). A second peak of hospital admissions due to Kawasaki" exact="disease" post="was observed in December, 2009 (six cases per month;"/>
   <result pre="influenza A H1N1 pandemic. Interpretation Our study further suggests that" exact="viral" post="respiratory infections, including SAR-CoV-2, could be triggers for Kawasaki"/>
   <result pre="A H1N1 pandemic. Interpretation Our study further suggests that viral" exact="respiratory" post="infections, including SAR-CoV-2, could be triggers for Kawasaki disease"/>
   <result pre="that viral respiratory infections, including SAR-CoV-2, could be triggers for" exact="Kawasaki disease" post="and indicates the potential timing of an increase in"/>
   <result pre="viral respiratory infections, including SAR-CoV-2, could be triggers for Kawasaki" exact="disease" post="and indicates the potential timing of an increase in"/>
   <result pre="the potential timing of an increase in incidence of the" exact="disease" post="in COVID-19 epidemics. Health-care providers should be prepared to"/>
   <result pre="be prepared to manage an influx of patients with severe" exact="Kawasaki disease," post="particularly in countries where the peak of COVID-19 has"/>
   <result pre="Agency. Introduction The rapid spread of COVID-19 caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a"/>
   <result pre="Introduction The rapid spread of COVID-19 caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) has led to a global"/>
   <result pre="The rapid spread of COVID-19 caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) has led to a global pandemic.1"/>
   <result pre="younger than 20 years.1 Available data suggested that compared with" exact="adult" post="patients, paediatric patients have milder symptoms and a better"/>
   <result pre="numbers of children and adolescents with multisystem inflammatory symptoms, including" exact="Kawasaki disease" post="and features of shock with intensive care unit admissions,"/>
   <result pre="of children and adolescents with multisystem inflammatory symptoms, including Kawasaki" exact="disease" post="and features of shock with intensive care unit admissions,"/>
   <result pre="to reports of an increased incidence of paediatric shock and" exact="myocarditis" post="by several health authorities in Europe and North America.5,"/>
   <result pre="Europe and North America.5, 6 A link between COVID-19 and" exact="Kawasaki disease" post="has been suggested by scattered case reports7, 8, 9"/>
   <result pre="and North America.5, 6 A link between COVID-19 and Kawasaki" exact="disease" post="has been suggested by scattered case reports7, 8, 9"/>
   <result pre="an observational cohort study reported an outbreak of severe Kawasaki-like" exact="disease" post="at the Italian epicentre of the SARS-CoV-2 epidemic.10 Acute"/>
   <result pre="Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic.10" exact="Acute" post="heart failure in multisystem inflammatory syndrome in the context"/>
   <result pre="disease at the Italian epicentre of the SARS-CoV-2 epidemic.10 Acute" exact="heart" post="failure in multisystem inflammatory syndrome in the context of"/>
   <result pre="of the SARS-CoV-2 epidemic.10 Acute heart failure in multisystem inflammatory" exact="syndrome" post="in the context of SARS-CoV-2 has also been reported"/>
   <result pre="should be considered as the clinical spectrum of a novel" exact="disease" post="or as an association of various suspected post-infectious diseases"/>
   <result pre="of various suspected post-infectious diseases triggered by SARS-CoV-2 is unknown." exact="Kawasaki disease" post="is an acute febrile systemic childhood vasculitis that affects"/>
   <result pre="various suspected post-infectious diseases triggered by SARS-CoV-2 is unknown. Kawasaki" exact="disease" post="is an acute febrile systemic childhood vasculitis that affects"/>
   <result pre="diseases triggered by SARS-CoV-2 is unknown. Kawasaki disease is an" exact="acute" post="febrile systemic childhood vasculitis that affects medium and small-sized"/>
   <result pre="by SARS-CoV-2 is unknown. Kawasaki disease is an acute febrile" exact="systemic" post="childhood vasculitis that affects medium and small-sized blood vessels"/>
   <result pre="SARS-CoV-2 is unknown. Kawasaki disease is an acute febrile systemic" exact="childhood" post="vasculitis that affects medium and small-sized blood vessels with"/>
   <result pre="is unknown. Kawasaki disease is an acute febrile systemic childhood" exact="vasculitis" post="that affects medium and small-sized blood vessels with a"/>
   <result pre="acute febrile systemic childhood vasculitis that affects medium and small-sized" exact="blood vessels" post="with a coronary artery tropism.12, 13 The disease is"/>
   <result pre="small-sized blood vessels with a coronary artery tropism.12, 13 The" exact="disease" post="is one of the leading causes of acquired heart"/>
   <result pre="13 The disease is one of the leading causes of" exact="acquired" post="heart disease in industrialised countries.12, 13 No specific test"/>
   <result pre="The disease is one of the leading causes of acquired" exact="heart" post="disease in industrialised countries.12, 13 No specific test exists"/>
   <result pre="disease is one of the leading causes of acquired heart" exact="disease" post="in industrialised countries.12, 13 No specific test exists to"/>
   <result pre="specific test exists to confirm the diagnosis. The diagnosis of" exact="Kawasaki disease" post="is based on internationally accepted clinical criteria,14, 15 combining"/>
   <result pre="test exists to confirm the diagnosis. The diagnosis of Kawasaki" exact="disease" post="is based on internationally accepted clinical criteria,14, 15 combining"/>
   <result pre="more with at least four of the following clinical signs:" exact="bilateral" post="conjunctival injection, changes affecting the lips and oral cavity"/>
   <result pre="the oral and pharyngeal mucosa), polymorphic exanthema, changes in the" exact="peripheral" post="extremities or perineal area, and cervical lymphadenopathy of 15"/>
   <result pre="the basis of principal clinical findings are said to have" exact="complete" post="Kawasaki disease. Patients who do not have sufficient principal"/>
   <result pre="basis of principal clinical findings are said to have complete" exact="Kawasaki disease." post="Patients who do not have sufficient principal clinical findings"/>
   <result pre="not have sufficient principal clinical findings might be diagnosed with" exact="incomplete" post="Kawasaki disease. Research in context Evidence before this study"/>
   <result pre="have sufficient principal clinical findings might be diagnosed with incomplete" exact="Kawasaki disease." post="Research in context Evidence before this study The rapid"/>
   <result pre="this study The rapid spread of COVID-19 caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a"/>
   <result pre="study The rapid spread of COVID-19 caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) has led to a global"/>
   <result pre="The rapid spread of COVID-19 caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) has led to a global pandemic."/>
   <result pre="that the numbers of children with multisystem inflammatory symptoms, including" exact="Kawasaki disease," post="were increasing. This suggestion led several health authorities in"/>
   <result pre="study from Italy, indicating a potential link between COVID-19 and" exact="Kawasaki disease." post="Previous studies have suggested that viral infections could be"/>
   <result pre="between COVID-19 and Kawasaki disease. Previous studies have suggested that" exact="viral" post="infections could be the trigger of Kawasaki disease. Thus,"/>
   <result pre="COVID-19 and Kawasaki disease. Previous studies have suggested that viral" exact="infections" post="could be the trigger of Kawasaki disease. Thus, epidemiological"/>
   <result pre="have suggested that viral infections could be the trigger of" exact="Kawasaki disease." post="Thus, epidemiological studies are needed to enlighten the potential"/>
   <result pre="enlighten the potential link between SARS-CoV-2 and the emergence of" exact="Kawasaki disease." post="Added value of this study We did a time-series"/>
   <result pre="time-series analysis that was based on a retrospective review of" exact="Kawasaki disease" post="cases in a French tertiary paediatric centre over the"/>
   <result pre="analysis that was based on a retrospective review of Kawasaki" exact="disease" post="cases in a French tertiary paediatric centre over the"/>
   <result pre="COVID-19 outbreak. We found an increase in the incidence of" exact="Kawasaki disease" post="during the COVID-19 pandemic. During this period, which included"/>
   <result pre="outbreak. We found an increase in the incidence of Kawasaki" exact="disease" post="during the COVID-19 pandemic. During this period, which included"/>
   <result pre="which included the national lockdown, the circulation of all other" exact="respiratory" post="viruses had an unprecedented drop. Our observations further suggest"/>
   <result pre="Our observations further suggest that an association exists between SARS-CoV-2" exact="infection" post="and Kawasaki disease. Interestingly, a second significant peak of"/>
   <result pre="further suggest that an association exists between SARS-CoV-2 infection and" exact="Kawasaki disease." post="Interestingly, a second significant peak of Kawasaki disease was"/>
   <result pre="infection and Kawasaki disease. Interestingly, a second significant peak of" exact="Kawasaki disease" post="was observed in December, 2009, during the influenza A"/>
   <result pre="and Kawasaki disease. Interestingly, a second significant peak of Kawasaki" exact="disease" post="was observed in December, 2009, during the influenza A"/>
   <result pre="series analysis over a 15-year period to assess incidence of" exact="Kawasaki disease" post="and concurrent circulating viruses, including SARS-CoV-2. Implications of all"/>
   <result pre="analysis over a 15-year period to assess incidence of Kawasaki" exact="disease" post="and concurrent circulating viruses, including SARS-CoV-2. Implications of all"/>
   <result pre="SARS-CoV-2 pandemic has been followed by a rapid emergence of" exact="Kawasaki disease," post="suggesting that children can develop severe forms of COVID-19."/>
   <result pre="COVID-19. This increased incidence is similar to the peak of" exact="Kawasaki disease" post="that occurred after the 2009 influenza A H1N1 pandemic,"/>
   <result pre="This increased incidence is similar to the peak of Kawasaki" exact="disease" post="that occurred after the 2009 influenza A H1N1 pandemic,"/>
   <result pre="influenza A H1N1 pandemic, providing evidence of the role of" exact="viral" post="infections in triggering Kawasaki disease. Physicians should prepare to"/>
   <result pre="A H1N1 pandemic, providing evidence of the role of viral" exact="infections" post="in triggering Kawasaki disease. Physicians should prepare to manage"/>
   <result pre="providing evidence of the role of viral infections in triggering" exact="Kawasaki disease." post="Physicians should prepare to manage an increase in the"/>
   <result pre="should prepare to manage an increase in the incidence of" exact="Kawasaki disease," post="depending on the magnitude of their local COVID-19 outbreak."/>
   <result pre="the magnitude of their local COVID-19 outbreak. The cause of" exact="Kawasaki disease" post="is unknown.16 Regions of the extratropical northern hemisphere have"/>
   <result pre="magnitude of their local COVID-19 outbreak. The cause of Kawasaki" exact="disease" post="is unknown.16 Regions of the extratropical northern hemisphere have"/>
   <result pre="between this bimodal seasonality and viruses such as influenza and" exact="respiratory" post="syncytial virus in winter and respiratory enteroviruses in summer"/>
   <result pre="such as influenza and respiratory syncytial virus in winter and" exact="respiratory" post="enteroviruses in summer has been suggested.18, 19, 20, 21"/>
   <result pre="20, 21 This correlation has led to the speculation that" exact="viral" post="infections could be the trigger of Kawasaki disease. To"/>
   <result pre="21 This correlation has led to the speculation that viral" exact="infections" post="could be the trigger of Kawasaki disease. To date,"/>
   <result pre="the speculation that viral infections could be the trigger of" exact="Kawasaki disease." post="To date, whether SARS-CoV-2 can lead to Kawasaki disease"/>
   <result pre="of Kawasaki disease. To date, whether SARS-CoV-2 can lead to" exact="Kawasaki disease" post="is unknown. We aimed to examine whether the outbreak"/>
   <result pre="Kawasaki disease. To date, whether SARS-CoV-2 can lead to Kawasaki" exact="disease" post="is unknown. We aimed to examine whether the outbreak"/>
   <result pre="the outbreak of COVID-19 is associated with an increase of" exact="Kawasaki disease" post="in a tertiary hospital in the French epicentre of"/>
   <result pre="outbreak of COVID-19 is associated with an increase of Kawasaki" exact="disease" post="in a tertiary hospital in the French epicentre of"/>
   <result pre="on a retrospective review of data of all patients with" exact="Kawasaki disease" post="admitted over the past 15 years to a tertiary"/>
   <result pre="a retrospective review of data of all patients with Kawasaki" exact="disease" post="admitted over the past 15 years to a tertiary"/>
   <result pre="20, 2020, we recorded the number of patients diagnosed with" exact="Kawasaki disease" post="using the validated diagnostic criteria15 of the American Heart"/>
   <result pre="2020, we recorded the number of patients diagnosed with Kawasaki" exact="disease" post="using the validated diagnostic criteria15 of the American Heart"/>
   <result pre="with Kawasaki disease using the validated diagnostic criteria15 of the" exact="American" post="Heart Association. Patients for whom another diagnosis was confirmed"/>
   <result pre="Kawasaki disease using the validated diagnostic criteria15 of the American" exact="Heart" post="Association. Patients for whom another diagnosis was confirmed during"/>
   <result pre="same centre in the study period. The results of the" exact="respiratory" post="pathogens identified by multiplex nasopharyngeal PCR from Sept 1,"/>
   <result pre="compared with daily paediatric hospital admissions due to confirmed COVID-19" exact="disease" post="in the same region, recorded by Public Health France."/>
   <result pre="1980120). Outcomes The main outcome was the number of monthly" exact="Kawasaki disease" post="cases over the study period estimated by our model."/>
   <result pre="Outcomes The main outcome was the number of monthly Kawasaki" exact="disease" post="cases over the study period estimated by our model."/>
   <result pre="disease cases over the study period estimated by our model." exact="Secondary" post="outcomes were the number of hospital admissions following paediatric"/>
   <result pre="the past 3 years. Our centre used multiplex PCR (FilmArray" exact="Respiratory" post="Panel 2 plus [Biomérieux, Marcy l'Etoile, France) to test"/>
   <result pre="Panel 2 plus [Biomérieux, Marcy l'Etoile, France) to test for" exact="respiratory" post="pathogens in nasopharyngeal swabs from patients. The tests were"/>
   <result pre="nasopharyngeal swabs from patients. The tests were for the following" exact="respiratory" post="pathogens: adenovirus, coronavirus 229E, coronavirus HKU, coronavirus NL63, coronavirus"/>
   <result pre="rhinovirus or enterovirus, influenza A, influenza B, parainfluenza (types 1–4)," exact="respiratory" post="syncytial virus, Bordetella parapertussis, Bordetella pertussis, Chlamydophila pneumoniae, and"/>
   <result pre="parapertussis, Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. Furthermore, all" exact="Kawasaki disease" post="cases diagnosed since April 1, 2020, were tested with"/>
   <result pre="Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. Furthermore, all Kawasaki" exact="disease" post="cases diagnosed since April 1, 2020, were tested with"/>
   <result pre="Xpress SARS-CoV-2 [Cepheid, Maurens-Scopont, France]). We also analysed the monthly" exact="Kawasaki disease" post="rate per 100 hospital admissions following paediatric emergency department"/>
   <result pre="SARS-CoV-2 [Cepheid, Maurens-Scopont, France]). We also analysed the monthly Kawasaki" exact="disease" post="rate per 100 hospital admissions following paediatric emergency department"/>
   <result pre="was 1 month.24 Because a delay between the onset of" exact="respiratory" post="viral infection and Kawasaki disease is expected on the"/>
   <result pre="1 month.24 Because a delay between the onset of respiratory" exact="viral infection" post="and Kawasaki disease is expected on the basis of"/>
   <result pre="month.24 Because a delay between the onset of respiratory viral" exact="infection" post="and Kawasaki disease is expected on the basis of"/>
   <result pre="a delay between the onset of respiratory viral infection and" exact="Kawasaki disease" post="is expected on the basis of previous studies on"/>
   <result pre="delay between the onset of respiratory viral infection and Kawasaki" exact="disease" post="is expected on the basis of previous studies on"/>
   <result pre="expected on the basis of previous studies on seasonality and" exact="Kawasaki disease," post="we hypothesised that the COVID-19 outbreak would have an"/>
   <result pre="hypothesised that the COVID-19 outbreak would have an effect on" exact="Kawasaki disease" post="cases 1 month (ie, one time unit) after the"/>
   <result pre="that the COVID-19 outbreak would have an effect on Kawasaki" exact="disease" post="cases 1 month (ie, one time unit) after the"/>
   <result pre="immediate post-outbreak change in April, 2020. The only previous major" exact="respiratory" post="virus pandemic identified over the study period was the"/>
   <result pre="The validity of the quasi-Poisson regression model was assessed using" exact="visual" post="inspection of the correlograms (autocorrelation and partial autocorrelation functions)"/>
   <result pre="was assessed using visual inspection of the correlograms (autocorrelation and" exact="partial" post="autocorrelation functions) and analysis of the residuals. All statistical"/>
   <result pre="May 20, 2020, 230 patients were admitted to hospital with" exact="incomplete" post="or complete Kawasaki disease (134 [58%] boys, 96 [42%]"/>
   <result pre="2020, 230 patients were admitted to hospital with incomplete or" exact="complete" post="Kawasaki disease (134 [58%] boys, 96 [42%] girls, aged"/>
   <result pre="230 patients were admitted to hospital with incomplete or complete" exact="Kawasaki disease" post="(134 [58%] boys, 96 [42%] girls, aged 1 month"/>
   <result pre="patients were admitted to hospital with incomplete or complete Kawasaki" exact="disease" post="(134 [58%] boys, 96 [42%] girls, aged 1 month"/>
   <result pre="aged 1 month to 15·5 years). The median number of" exact="Kawasaki disease" post="hospitalisations estimated by the quasi-Poisson model was 1·2 per"/>
   <result pre="1 month to 15·5 years). The median number of Kawasaki" exact="disease" post="hospitalisations estimated by the quasi-Poisson model was 1·2 per"/>
   <result pre="observed a significant increase in the number of patients with" exact="Kawasaki disease" post="admitted to our centre (six patients per month; 497%"/>
   <result pre="a significant increase in the number of patients with Kawasaki" exact="disease" post="admitted to our centre (six patients per month; 497%"/>
   <result pre="[95% CI 72–1082]; p=0.0011). Similar results were obtained when analysing" exact="Kawasaki disease" post="rate per 100 hospitalisations over time (figure 1 ;"/>
   <result pre="CI 72–1082]; p=0.0011). Similar results were obtained when analysing Kawasaki" exact="disease" post="rate per 100 hospitalisations over time (figure 1 ;"/>
   <result pre="April 15 and May 15, 2020. Thus, the increase of" exact="Kawasaki disease" post="hospitalisations started 2 weeks after the first peak of"/>
   <result pre="15 and May 15, 2020. Thus, the increase of Kawasaki" exact="disease" post="hospitalisations started 2 weeks after the first peak of"/>
   <result pre="31 to April 1, 2020 (figure 2 ). Figure 1" exact="Kawasaki disease" post="rate per 100 hospital admissions, 2006 to 2020 230"/>
   <result pre="to April 1, 2020 (figure 2 ). Figure 1 Kawasaki" exact="disease" post="rate per 100 hospital admissions, 2006 to 2020 230"/>
   <result pre="per 100 hospital admissions, 2006 to 2020 230 patients had" exact="Kawasaki disease" post="during this period. The total number of hospital admission"/>
   <result pre="100 hospital admissions, 2006 to 2020 230 patients had Kawasaki" exact="disease" post="during this period. The total number of hospital admission"/>
   <result pre="2020 230 patients had Kawasaki disease during this period. The" exact="total" post="number of hospital admission following paediatric emergency department visits"/>
   <result pre="the Paris region, France. The increase in the rate of" exact="Kawasaki disease" post="observed in April, 2020, was not related to an"/>
   <result pre="Paris region, France. The increase in the rate of Kawasaki" exact="disease" post="observed in April, 2020, was not related to an"/>
   <result pre="coincided with an unprecedented decrease in the proportion of other" exact="respiratory" post="viruses circulating in the Paris region population since March,"/>
   <result pre="between this virus and the increase in the rate of" exact="Kawasaki disease." post="Figure 3 Rate of respiratory pathogens in our centre,"/>
   <result pre="in the rate of Kawasaki disease. Figure 3 Rate of" exact="respiratory" post="pathogens in our centre, 2017 to 2020 The thin"/>
   <result pre="the final quasi-Poisson regression models. The characteristics of patients with" exact="Kawasaki disease" post="during the SARS-CoV-2 epidemic are shown in table 1"/>
   <result pre="final quasi-Poisson regression models. The characteristics of patients with Kawasaki" exact="disease" post="during the SARS-CoV-2 epidemic are shown in table 1"/>
   <result pre="in table 1 . Among the ten children presenting with" exact="Kawasaki disease" post="from April 15 to May 20, 2020, eight (80%)"/>
   <result pre="table 1 . Among the ten children presenting with Kawasaki" exact="disease" post="from April 15 to May 20, 2020, eight (80%)"/>
   <result pre="PCR and serological tests. Among these patients, five (50%) had" exact="complete" post="Kawasaki disease and five (50%) patients had fever with"/>
   <result pre="and serological tests. Among these patients, five (50%) had complete" exact="Kawasaki disease" post="and five (50%) patients had fever with only three"/>
   <result pre="serological tests. Among these patients, five (50%) had complete Kawasaki" exact="disease" post="and five (50%) patients had fever with only three"/>
   <result pre="and five (50%) patients had fever with only three other" exact="Kawasaki disease" post="criteria (incomplete Kawasaki disease). The age of patients with"/>
   <result pre="five (50%) patients had fever with only three other Kawasaki" exact="disease" post="criteria (incomplete Kawasaki disease). The age of patients with"/>
   <result pre="disease criteria (incomplete Kawasaki disease). The age of patients with" exact="Kawasaki disease" post="ranged from 18 months to 15·8 years. Six (60%)"/>
   <result pre="criteria (incomplete Kawasaki disease). The age of patients with Kawasaki" exact="disease" post="ranged from 18 months to 15·8 years. Six (60%)"/>
   <result pre="years. Six (60%) children had cardiac abnormalities, including one major" exact="coronary aneurysm" post="(Z score=12) and five with myocarditis. Six (60%) patients"/>
   <result pre="Six (60%) children had cardiac abnormalities, including one major coronary" exact="aneurysm" post="(Z score=12) and five with myocarditis. Six (60%) patients"/>
   <result pre="fatal outcome was observed. Table 1 Characteristics of patients with" exact="Kawasaki disease" post="who presented during the SARS-CoV-2 epidemic, April 15 to"/>
   <result pre="outcome was observed. Table 1 Characteristics of patients with Kawasaki" exact="disease" post="who presented during the SARS-CoV-2 epidemic, April 15 to"/>
   <result pre="1·8 11·5 1·5 15·5 13·5 9·8 14·5 15·8 6·3 Sex" exact="Female" post="Female Male Male Female Female Female Female Male Male"/>
   <result pre="11·5 1·5 15·5 13·5 9·8 14·5 15·8 6·3 Sex Female" exact="Female" post="Male Male Female Female Female Female Male Male SARS-CoV-2"/>
   <result pre="13·5 9·8 14·5 15·8 6·3 Sex Female Female Male Male" exact="Female" post="Female Female Female Male Male SARS-CoV-2 nasopharyngeal PCR Positive"/>
   <result pre="9·8 14·5 15·8 6·3 Sex Female Female Male Male Female" exact="Female" post="Female Female Male Male SARS-CoV-2 nasopharyngeal PCR Positive NA"/>
   <result pre="14·5 15·8 6·3 Sex Female Female Male Male Female Female" exact="Female" post="Female Male Male SARS-CoV-2 nasopharyngeal PCR Positive NA Positive"/>
   <result pre="15·8 6·3 Sex Female Female Male Male Female Female Female" exact="Female" post="Male Male SARS-CoV-2 nasopharyngeal PCR Positive NA Positive Negative"/>
   <result pre="No Yes Yes Yes Yes Yes No Yes Type of" exact="Kawasaki disease" post="Complete Complete Complete Incomplete Incomplete Complete Incomplete Complete Incomplete"/>
   <result pre="Yes Yes Yes Yes Yes No Yes Type of Kawasaki" exact="disease" post="Complete Complete Complete Incomplete Incomplete Complete Incomplete Complete Incomplete"/>
   <result pre="Yes Yes Yes Yes No Yes Type of Kawasaki disease" exact="Complete" post="Complete Complete Incomplete Incomplete Complete Incomplete Complete Incomplete Incomplete"/>
   <result pre="Yes Yes Yes No Yes Type of Kawasaki disease Complete" exact="Complete" post="Complete Incomplete Incomplete Complete Incomplete Complete Incomplete Incomplete Kobayashi"/>
   <result pre="Yes Yes No Yes Type of Kawasaki disease Complete Complete" exact="Complete" post="Incomplete Incomplete Complete Incomplete Complete Incomplete Incomplete Kobayashi score1"/>
   <result pre="Yes No Yes Type of Kawasaki disease Complete Complete Complete" exact="Incomplete" post="Incomplete Complete Incomplete Complete Incomplete Incomplete Kobayashi score1 8"/>
   <result pre="No Yes Type of Kawasaki disease Complete Complete Complete Incomplete" exact="Incomplete" post="Complete Incomplete Complete Incomplete Incomplete Kobayashi score1 8 1"/>
   <result pre="Yes Type of Kawasaki disease Complete Complete Complete Incomplete Incomplete" exact="Complete" post="Incomplete Complete Incomplete Incomplete Kobayashi score1 8 1 4"/>
   <result pre="Type of Kawasaki disease Complete Complete Complete Incomplete Incomplete Complete" exact="Incomplete" post="Complete Incomplete Incomplete Kobayashi score1 8 1 4 0"/>
   <result pre="of Kawasaki disease Complete Complete Complete Incomplete Incomplete Complete Incomplete" exact="Complete" post="Incomplete Incomplete Kobayashi score1 8 1 4 0 4"/>
   <result pre="Kawasaki disease Complete Complete Complete Incomplete Incomplete Complete Incomplete Complete" exact="Incomplete" post="Incomplete Kobayashi score1 8 1 4 0 4 8"/>
   <result pre="disease Complete Complete Complete Incomplete Incomplete Complete Incomplete Complete Incomplete" exact="Incomplete" post="Kobayashi score1 8 1 4 0 4 8 7"/>
   <result pre="8 1 4 0 4 8 7 6 8 6" exact="Kawasaki disease" post="shock syndrome2 No No No No No Yes Yes"/>
   <result pre="1 4 0 4 8 7 6 8 6 Kawasaki" exact="disease" post="shock syndrome2 No No No No No Yes Yes"/>
   <result pre="No No No No No Yes Yes Yes Yes No" exact="Cardiac" post="involvement Myocarditis No No Coronary dilatation (Z=12) No Myocarditis"/>
   <result pre="Myocarditis No No Coronary dilatation (Z=12) No Myocarditis Myocarditis Myocarditis," exact="pericarditis" post="Myocarditis No First-line treatment IVIg IVIg None IVIg IVIg"/>
   <result pre="5 4 27 5 18 19 13 9 17 SARS-CoV-2=severe" exact="acute" post="respiratory syndrome coronavirus 2. IVIg=intravenous immunoglobulin. PICU=paediatric intensive care"/>
   <result pre="4 27 5 18 19 13 9 17 SARS-CoV-2=severe acute" exact="respiratory" post="syndrome coronavirus 2. IVIg=intravenous immunoglobulin. PICU=paediatric intensive care unit."/>
   <result pre="27 5 18 19 13 9 17 SARS-CoV-2=severe acute respiratory" exact="syndrome" post="coronavirus 2. IVIg=intravenous immunoglobulin. PICU=paediatric intensive care unit. NA=not"/>
   <result pre="PICU=paediatric intensive care unit. NA=not available. A second peak of" exact="Kawasaki disease" post="hospitalisations was detected by the model in December, 2009,"/>
   <result pre="intensive care unit. NA=not available. A second peak of Kawasaki" exact="disease" post="hospitalisations was detected by the model in December, 2009,"/>
   <result pre="1; appendix p 3). The increase in the number of" exact="Kawasaki disease" post="hospitalisations occurred approximately 1–3 weeks after the peak of"/>
   <result pre="appendix p 3). The increase in the number of Kawasaki" exact="disease" post="hospitalisations occurred approximately 1–3 weeks after the peak of"/>
   <result pre="epidemic in the Paris region. A comparison between patients with" exact="Kawasaki disease" post="who were hospitalised in our centre during the SARS-CoV-2"/>
   <result pre="in the Paris region. A comparison between patients with Kawasaki" exact="disease" post="who were hospitalised in our centre during the SARS-CoV-2"/>
   <result pre="patients from another study10 who were hospitalised with a Kawasaki-like" exact="disease" post="during the SARS-CoV-2 epidemic in Bergamo, Italy (table 2)."/>
   <result pre="in Bergamo, Italy (table 2). The characteristics of patients with" exact="Kawasaki disease" post="who were hospitalised during the SARS-CoV-2 epidemic in our"/>
   <result pre="Bergamo, Italy (table 2). The characteristics of patients with Kawasaki" exact="disease" post="who were hospitalised during the SARS-CoV-2 epidemic in our"/>
   <result pre="in Bergamo, with a high proportion of patients with severe" exact="Kawasaki disease" post="with cardiac involvement and the need for a second"/>
   <result pre="Bergamo, with a high proportion of patients with severe Kawasaki" exact="disease" post="with cardiac involvement and the need for a second"/>
   <result pre="line of treatment. By contrast, the characteristics of patients with" exact="Kawasaki disease" post="diagnosed during SARS-COV-2 epidemics appeared to be different from"/>
   <result pre="of treatment. By contrast, the characteristics of patients with Kawasaki" exact="disease" post="diagnosed during SARS-COV-2 epidemics appeared to be different from"/>
   <result pre="3410 × 109 per L; p=0·028). Table 2 Comparison between patients with" exact="Kawasaki disease" post="presenting during the SARS-CoV-2 epidemic in the Paris region,"/>
   <result pre="per L; p=0·028). Table 2 Comparison between patients with Kawasaki" exact="disease" post="presenting during the SARS-CoV-2 epidemic in the Paris region,"/>
   <result pre="during the influenza A H1N1 epidemics and outside of major" exact="viral" post="epidemics SARS-CoV-2 epidemic in Robert Debré Hospital, France* SARS-CoV-2"/>
   <result pre="Italy10 Influenza A H1N1 epidemic in Robert Debré Hospital, France" exact="Kawasaki disease" post="outside of major viral epidemics in Robert Debré Hospital,"/>
   <result pre="Influenza A H1N1 epidemic in Robert Debré Hospital, France Kawasaki" exact="disease" post="outside of major viral epidemics in Robert Debré Hospital,"/>
   <result pre="in Robert Debré Hospital, France Kawasaki disease outside of major" exact="viral" post="epidemics in Robert Debré Hospital, France Time of presentation"/>
   <result pre="214 Incidence per month 6 10 6 1 Rate of" exact="Kawasaki disease" post="per 100 hospital admissions 1·5 NA 1·0 0·2 Sex"/>
   <result pre="Incidence per month 6 10 6 1 Rate of Kawasaki" exact="disease" post="per 100 hospital admissions 1·5 NA 1·0 0·2 Sex"/>
   <result pre="disease per 100 hospital admissions 1·5 NA 1·0 0·2 Sex" exact="Female" post="4/10 (40%) 3/10 (30%) 5/6 (83%) 87/214 (41%) Male"/>
   <result pre="age, years 11·8 (7·4–14·3) 7·2 (5·5–8·1) 2·1 (1·7–3·8) 2·1 (1·1–3·7)" exact="Complete" post="Kawasaki disease 6/10 (60%) 5/10 (50%) 4/6 (67%) 138/214"/>
   <result pre="years 11·8 (7·4–14·3) 7·2 (5·5–8·1) 2·1 (1·7–3·8) 2·1 (1·1–3·7) Complete" exact="Kawasaki disease" post="6/10 (60%) 5/10 (50%) 4/6 (67%) 138/214 (64%) C-reactive"/>
   <result pre="11·8 (7·4–14·3) 7·2 (5·5–8·1) 2·1 (1·7–3·8) 2·1 (1·1–3·7) Complete Kawasaki" exact="disease" post="6/10 (60%) 5/10 (50%) 4/6 (67%) 138/214 (64%) C-reactive"/>
   <result pre="per L 1042 (650–1150) 832 (543–960) 3410 (2010–4590) 3044 (1855–4770)" exact="Platelet" post="count, × 109 per L 274 (192–715) 130 (120–142) 613"/>
   <result pre="Kobayashi score ≥51 7/10 (70%) 7/10 (70%) 0 39/153 (25%)" exact="Kawasaki disease" post="shock syndrome29 4/10 (40%) 5/10 (50%) 0/6 (0%) NA"/>
   <result pre="score ≥51 7/10 (70%) 7/10 (70%) 0 39/153 (25%) Kawasaki" exact="disease" post="shock syndrome29 4/10 (40%) 5/10 (50%) 0/6 (0%) NA"/>
   <result pre="NA Data are n, n (%), or median (IQR). SARS-CoV-2=severe" exact="acute" post="respiratory syndrome coronavirus 2. IVIg=intravenous immunoglobulin. PICU=paediatric intensive care"/>
   <result pre="Data are n, n (%), or median (IQR). SARS-CoV-2=severe acute" exact="respiratory" post="syndrome coronavirus 2. IVIg=intravenous immunoglobulin. PICU=paediatric intensive care unit."/>
   <result pre="are n, n (%), or median (IQR). SARS-CoV-2=severe acute respiratory" exact="syndrome" post="coronavirus 2. IVIg=intravenous immunoglobulin. PICU=paediatric intensive care unit. NA=not"/>
   <result pre="2. IVIg=intravenous immunoglobulin. PICU=paediatric intensive care unit. NA=not available. *The" exact="total" post="number of paediatric patients with COVID-19 who were referred"/>
   <result pre="available. Discussion We found a link between an emergence of" exact="Kawasaki disease" post="and the ongoing COVID-19 pandemic. Several findings support this"/>
   <result pre="Discussion We found a link between an emergence of Kawasaki" exact="disease" post="and the ongoing COVID-19 pandemic. Several findings support this"/>
   <result pre="association. First, we observed that the unexpected high emergence of" exact="Kawasaki disease" post="occurred 2 weeks after the peak of the COVID-19"/>
   <result pre="First, we observed that the unexpected high emergence of Kawasaki" exact="disease" post="occurred 2 weeks after the peak of the COVID-19"/>
   <result pre="the COVID-19 epidemic, in line with the post-infection mechanism of" exact="Kawasaki disease," post="as previously reported.15 Second, following the nationwide lockdown in"/>
   <result pre="the nationwide lockdown in March, 2020, SARS-CoV-2 was the only" exact="respiratory" post="virus with intense circulation in the weeks before the"/>
   <result pre="with intense circulation in the weeks before the emergence of" exact="Kawasaki disease," post="as indicated by our analysis of the results from"/>
   <result pre="disease, as indicated by our analysis of the results from" exact="respiratory" post="multiplex PCR showing a decrease in the proportion of"/>
   <result pre="multiplex PCR showing a decrease in the proportion of other" exact="respiratory" post="viruses in the hospital population at the time. Third,"/>
   <result pre="hospital population at the time. Third, almost all patients with" exact="Kawasaki disease" post="in April, 2020, had a positive nasopharyngeal SARS-CoV-2 PCR,"/>
   <result pre="population at the time. Third, almost all patients with Kawasaki" exact="disease" post="in April, 2020, had a positive nasopharyngeal SARS-CoV-2 PCR,"/>
   <result pre="confirmed COVID-19, or positive serology. The only other peak in" exact="Kawasaki disease" post="observed during the 15-year observation period occurred during the"/>
   <result pre="COVID-19, or positive serology. The only other peak in Kawasaki" exact="disease" post="observed during the 15-year observation period occurred during the"/>
   <result pre="the only virus capable of triggering such an emergence of" exact="Kawasaki disease." post="These findings are in line with previous observations reporting"/>
   <result pre="with previous observations reporting associations between seasonality and outbreaks of" exact="Kawasaki disease," post="especially in Japan, where nationwide epidemics were observed in"/>
   <result pre="in 1979, 1982, and 1986.12, 17, 26 Seasonal patterns of" exact="Kawasaki disease" post="have also been observed in many other countries, including"/>
   <result pre="1979, 1982, and 1986.12, 17, 26 Seasonal patterns of Kawasaki" exact="disease" post="have also been observed in many other countries, including"/>
   <result pre="North America. This finding has led to the speculation that" exact="viral" post="infections might underline Kawasaki disease pathogenesis. However, large outbreaks"/>
   <result pre="America. This finding has led to the speculation that viral" exact="infections" post="might underline Kawasaki disease pathogenesis. However, large outbreaks of"/>
   <result pre="has led to the speculation that viral infections might underline" exact="Kawasaki disease" post="pathogenesis. However, large outbreaks of Kawasaki disease seem to"/>
   <result pre="led to the speculation that viral infections might underline Kawasaki" exact="disease" post="pathogenesis. However, large outbreaks of Kawasaki disease seem to"/>
   <result pre="infections might underline Kawasaki disease pathogenesis. However, large outbreaks of" exact="Kawasaki disease" post="seem to be a rare event. The surges in"/>
   <result pre="might underline Kawasaki disease pathogenesis. However, large outbreaks of Kawasaki" exact="disease" post="seem to be a rare event. The surges in"/>
   <result pre="be a rare event. The surges in the incidence of" exact="Kawasaki disease" post="following two different major epidemic outbreaks observed in our"/>
   <result pre="a rare event. The surges in the incidence of Kawasaki" exact="disease" post="following two different major epidemic outbreaks observed in our"/>
   <result pre="a unique, quasi-experimental condition, further implicating the crucial role of" exact="viral" post="infections in the trigger of Kawasaki disease in susceptible"/>
   <result pre="unique, quasi-experimental condition, further implicating the crucial role of viral" exact="infections" post="in the trigger of Kawasaki disease in susceptible patients."/>
   <result pre="the crucial role of viral infections in the trigger of" exact="Kawasaki disease" post="in susceptible patients. In both observed epidemic peaks the"/>
   <result pre="crucial role of viral infections in the trigger of Kawasaki" exact="disease" post="in susceptible patients. In both observed epidemic peaks the"/>
   <result pre="both observed epidemic peaks the increase in the incidence of" exact="Kawasaki disease" post="was sudden. Further studies will be necessary to understand"/>
   <result pre="observed epidemic peaks the increase in the incidence of Kawasaki" exact="disease" post="was sudden. Further studies will be necessary to understand"/>
   <result pre="context of SARS-CoV-2 and H1N1 epidemics when compared with seasonal" exact="viral" post="infections. The sudden exposure to new antigens might trigger"/>
   <result pre="The sudden exposure to new antigens might trigger a particular" exact="uncontrolled" post="immune response in susceptible children. By contrast, frequent seasonal"/>
   <result pre="precedent seasons, and therefore only a minority of children develop" exact="Kawasaki disease." post="Although our study has shown an emergence of Kawasaki"/>
   <result pre="Kawasaki disease. Although our study has shown an emergence of" exact="Kawasaki disease" post="associated with COVID-19, even in the context of the"/>
   <result pre="disease. Although our study has shown an emergence of Kawasaki" exact="disease" post="associated with COVID-19, even in the context of the"/>
   <result pre="even in the context of the pandemic, this strong inflammatory" exact="disease" post="is very rare. The strength of our study was"/>
   <result pre="done over a long time period (15 years) in a" exact="stable" post="multi-ethnic population, living in a defined area, with stable"/>
   <result pre="a stable multi-ethnic population, living in a defined area, with" exact="stable" post="medical orientation to our tertiary centre. Doing so allowed"/>
   <result pre="centre. Doing so allowed us to observe the rate of" exact="Kawasaki disease" post="over time, enabling the detection of peaks in cases."/>
   <result pre="Doing so allowed us to observe the rate of Kawasaki" exact="disease" post="over time, enabling the detection of peaks in cases."/>
   <result pre="size was sufficient to reach statistical significance, our study is" exact="limited" post="by its single-centre nature and a small number of"/>
   <result pre="increase the sensitivity of assessing the association between SARS-CoV-2 and" exact="Kawasaki disease." post="This approach might have led to an overestimation of"/>
   <result pre="have led to an overestimation of the increased risk for" exact="Kawasaki disease." post="Our study design allowed us to provide a proof"/>
   <result pre="of concept of the link between the COVID-19 pandemic and" exact="Kawasaki disease." post="Larger population-based studies are required to investigate the exact"/>
   <result pre="studies are required to investigate the exact additional risk of" exact="Kawasaki disease" post="associated with SARS-CoV-2 infections. The clinical spectrum of multisystem"/>
   <result pre="are required to investigate the exact additional risk of Kawasaki" exact="disease" post="associated with SARS-CoV-2 infections. The clinical spectrum of multisystem"/>
   <result pre="during the COVID-19 pandemic is believed to include features of" exact="Kawasaki disease" post="(complete or incomplete), toxic shock syndrome, and myocarditis.4, 11,"/>
   <result pre="the COVID-19 pandemic is believed to include features of Kawasaki" exact="disease" post="(complete or incomplete), toxic shock syndrome, and myocarditis.4, 11,"/>
   <result pre="believed to include features of Kawasaki disease (complete or incomplete)," exact="toxic shock syndrome," post="and myocarditis.4, 11, 27 Paediatric and scientific societies in"/>
   <result pre="detailed clinical description30 and suggest new classifications—eg, paediatric multisystem inflammatory" exact="syndrome" post="temporally associated with COVID-19 in Europe and multisystem inflammatory"/>
   <result pre="syndrome temporally associated with COVID-19 in Europe and multisystem inflammatory" exact="syndrome" post="in children in the USA.29, 30 To reduce bias"/>
   <result pre="decided to focus only on patients with clinical presentation of" exact="Kawasaki disease" post="according to established criteria.27 Further studies will be necessary"/>
   <result pre="to focus only on patients with clinical presentation of Kawasaki" exact="disease" post="according to established criteria.27 Further studies will be necessary"/>
   <result pre="understand whether these patients should be classified as having SARS-CoV-2" exact="infection" post="with a Kawasaki disease phenotype or SARS-CoV-2-triggered Kawasaki disease."/>
   <result pre="patients should be classified as having SARS-CoV-2 infection with a" exact="Kawasaki disease" post="phenotype or SARS-CoV-2-triggered Kawasaki disease. Our observations could have"/>
   <result pre="should be classified as having SARS-CoV-2 infection with a Kawasaki" exact="disease" post="phenotype or SARS-CoV-2-triggered Kawasaki disease. Our observations could have"/>
   <result pre="having SARS-CoV-2 infection with a Kawasaki disease phenotype or SARS-CoV-2-triggered" exact="Kawasaki disease." post="Our observations could have practical implications for clinicians and"/>
   <result pre="for clinicians and health-care providers. Indeed, the clinical characteristics of" exact="Kawasaki disease" post="patients hospitalised during the COVID-19 epidemic in our centre"/>
   <result pre="clinicians and health-care providers. Indeed, the clinical characteristics of Kawasaki" exact="disease" post="patients hospitalised during the COVID-19 epidemic in our centre"/>
   <result pre="in Italy,10 with a high proportion of patients with severe" exact="Kawasaki disease" post="with cardiac involvement (abnormal echocardiography, coronary aneurysm, or myocarditis),"/>
   <result pre="Italy,10 with a high proportion of patients with severe Kawasaki" exact="disease" post="with cardiac involvement (abnormal echocardiography, coronary aneurysm, or myocarditis),"/>
   <result pre="patients with severe Kawasaki disease with cardiac involvement (abnormal echocardiography," exact="coronary aneurysm," post="or myocarditis), intensive care unit admissions, inotrope requirement, and"/>
   <result pre="first intravenous immunoglobulin treatment. By contrast, the clinical characteristics of" exact="Kawasaki disease" post="occurring during the only other observed Kawasaki disease peak"/>
   <result pre="intravenous immunoglobulin treatment. By contrast, the clinical characteristics of Kawasaki" exact="disease" post="occurring during the only other observed Kawasaki disease peak"/>
   <result pre="characteristics of Kawasaki disease occurring during the only other observed" exact="Kawasaki disease" post="peak during an H1N1 epidemic resembled those of typical"/>
   <result pre="of Kawasaki disease occurring during the only other observed Kawasaki" exact="disease" post="peak during an H1N1 epidemic resembled those of typical"/>
   <result pre="disease peak during an H1N1 epidemic resembled those of typical" exact="Kawasaki disease" post="cohorts.15, 31, 32 These observations suggest that in the"/>
   <result pre="peak during an H1N1 epidemic resembled those of typical Kawasaki" exact="disease" post="cohorts.15, 31, 32 These observations suggest that in the"/>
   <result pre="context of SARS-CoV-2 circulation a higher proportion of patients with" exact="Kawasaki disease" post="might present a severe phenotype. Furthermore, these observations indicate"/>
   <result pre="of SARS-CoV-2 circulation a higher proportion of patients with Kawasaki" exact="disease" post="might present a severe phenotype. Furthermore, these observations indicate"/>
   <result pre="be prepared to manage an increased influx of patients with" exact="Kawasaki disease" post="and potential severe cardiac involvement, particularly in countries where"/>
   <result pre="prepared to manage an increased influx of patients with Kawasaki" exact="disease" post="and potential severe cardiac involvement, particularly in countries where"/>
   <result pre="reached. Our study provides evidence of a rapid emergence of" exact="Kawasaki disease" post="in children related to SARS-CoV-2, starting approximately 2 weeks"/>
   <result pre="Our study provides evidence of a rapid emergence of Kawasaki" exact="disease" post="in children related to SARS-CoV-2, starting approximately 2 weeks"/>
   <result pre="to manage a potential increased influx of children with severe" exact="Kawasaki disease." post="References References 1WuZMcGooganJMCharacteristics of and important lessons from the"/>
   <result pre="References References 1WuZMcGooganJMCharacteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
   <result pre="a report of 72 314 cases from the Chinese Center for" exact="Disease" post="Control and PreventionJAMA32320201239 2ParriNLengeMBuonsensoDChildren with Covid-19 in pediatric emergency"/>
   <result pre="J Med2020published online May 1.10.1056/NEJMc2007617 3TagarroAEpalzaCSantosMScreening and severity of coronavirus" exact="disease" post="2019 (COVID-19) in children in Madrid, SpainJAMA Pediatr2020published online"/>
   <result pre="pandemicLancet39520201741174332410759 6LoombaRSRaskinAGudauskyTMKirkpatrickERole of the Egami Score in Predicting Intravenous Immunoglobulin" exact="Resistance" post="in Kawasaki Disease Among Different EthnicitiesAm J Ther232016e1293e129925611359 7JonesVGMillsMSuarezDCOVID-19"/>
   <result pre="the Egami Score in Predicting Intravenous Immunoglobulin Resistance in Kawasaki" exact="Disease" post="Among Different EthnicitiesAm J Ther232016e1293e129925611359 7JonesVGMillsMSuarezDCOVID-19 and Kawasaki disease:"/>
   <result pre="and Kawasaki disease: novel virus and novel caseHosp Pediatr10202053754032265235 8Rivera-FigueroaEISantosRSimpsonSGargPIncomplete" exact="Kawasaki disease" post="in a child with Covid-19Indian Pediatr2020S097475591600179. 9SchroederARWilsonKMRalstonSLCOVID-19 and Kawasaki"/>
   <result pre="Kawasaki disease: novel virus and novel caseHosp Pediatr10202053754032265235 8Rivera-FigueroaEISantosRSimpsonSGargPIncomplete Kawasaki" exact="disease" post="in a child with Covid-19Indian Pediatr2020S097475591600179. 9SchroederARWilsonKMRalstonSLCOVID-19 and Kawasaki"/>
   <result pre="noiseHosp Pediatr2020published online May 13.10.1542/hpeds.2020-000356 10VerdoniLMazzaAGervasoniAAn outbreak of severe Kawasaki-like" exact="disease" post="at the Italian epicentre of the SARS-CoV-2 epidemic: an"/>
   <result pre="epicentre of the SARS-CoV-2 epidemic: an observational cohort studyLancet39520201771177832410760 11BelhadjerZMéotMBajolleFAcute" exact="heart" post="failure in multisystem inflammatory syndrome in children (MIS-C) in"/>
   <result pre="an observational cohort studyLancet39520201771177832410760 11BelhadjerZMéotMBajolleFAcute heart failure in multisystem inflammatory" exact="syndrome" post="in children (MIS-C) in the context of global SARS-CoV-2"/>
   <result pre="of global SARS-CoV-2 pandemicCirculation2020published online May 17.10.1161/CIRCULATIONAHA.120.048360 12NakamuraYYashiroMUeharaROkiIWatanabeMYanagawaHEpidemiologic features of" exact="Kawasaki disease" post="in Japan: results from the nationwide survey in 2005–2006J"/>
   <result pre="global SARS-CoV-2 pandemicCirculation2020published online May 17.10.1161/CIRCULATIONAHA.120.048360 12NakamuraYYashiroMUeharaROkiIWatanabeMYanagawaHEpidemiologic features of Kawasaki" exact="disease" post="in Japan: results from the nationwide survey in 2005–2006J"/>
   <result pre="Japan: results from the nationwide survey in 2005–2006J Epidemiol18200816717218635901 13HolmanRCCurnsATBelayEDSteinerCASchonbergerLBKawasaki" exact="syndrome" post="hospitalizations in the United States, 1997 and 2000Pediatrics112200349550112949272 14OzenSRupertoNDillonMJEULAR/PReS"/>
   <result pre="and 2000Pediatrics112200349550112949272 14OzenSRupertoNDillonMJEULAR/PReS endorsed consensus criteria for the classification of" exact="childhood" post="vasculitidesAnn Rheum Dis65200693694116322081 15McCrindleBWRowleyAHNewburgerJWDiagnosis, treatment, and long-term management of"/>
   <result pre="Kawasaki disease: a scientific statement for health professionals from the" exact="American" post="Heart AssociationCirculation1352017e927e99928356445 16NewburgerJWTakahashiMBurnsJCKawasaki DiseaseJ Am Coll Cardiol6720161738174927056781 17BurnsJCHerzogLFabriOSeasonality of"/>
   <result pre="disease: a scientific statement for health professionals from the American" exact="Heart" post="AssociationCirculation1352017e927e99928356445 16NewburgerJWTakahashiMBurnsJCKawasaki DiseaseJ Am Coll Cardiol6720161738174927056781 17BurnsJCHerzogLFabriOSeasonality of Kawasaki"/>
   <result pre="clustering of Kawasaki syndromeEpidemiology16200522022515703537 19KimGBParkSKwonBSHanJWParkYWHongYMEvaluation of the temporal association between" exact="Kawasaki disease" post="and viral infections in South KoreaKorean Circ J44201425025425089137 20Jordan-VillegasAChangMLRamiloOMejíasAConcomitant"/>
   <result pre="of Kawasaki syndromeEpidemiology16200522022515703537 19KimGBParkSKwonBSHanJWParkYWHongYMEvaluation of the temporal association between Kawasaki" exact="disease" post="and viral infections in South KoreaKorean Circ J44201425025425089137 20Jordan-VillegasAChangMLRamiloOMejíasAConcomitant"/>
   <result pre="syndromeEpidemiology16200522022515703537 19KimGBParkSKwonBSHanJWParkYWHongYMEvaluation of the temporal association between Kawasaki disease and" exact="viral" post="infections in South KoreaKorean Circ J44201425025425089137 20Jordan-VillegasAChangMLRamiloOMejíasAConcomitant respiratory viral"/>
   <result pre="19KimGBParkSKwonBSHanJWParkYWHongYMEvaluation of the temporal association between Kawasaki disease and viral" exact="infections" post="in South KoreaKorean Circ J44201425025425089137 20Jordan-VillegasAChangMLRamiloOMejíasAConcomitant respiratory viral infections"/>
   <result pre="disease and viral infections in South KoreaKorean Circ J44201425025425089137 20Jordan-VillegasAChangMLRamiloOMejíasAConcomitant" exact="respiratory" post="viral infections in children with Kawasaki diseasePediatr Infect Dis"/>
   <result pre="and viral infections in South KoreaKorean Circ J44201425025425089137 20Jordan-VillegasAChangMLRamiloOMejíasAConcomitant respiratory" exact="viral" post="infections in children with Kawasaki diseasePediatr Infect Dis J29201077077220354462"/>
   <result pre="viral infections in South KoreaKorean Circ J44201425025425089137 20Jordan-VillegasAChangMLRamiloOMejíasAConcomitant respiratory viral" exact="infections" post="in children with Kawasaki diseasePediatr Infect Dis J29201077077220354462 21TurnierJLAndersonMSHeizerHRJonePNGlodéMPDominguezSRConcurrent"/>
   <result pre="infections in children with Kawasaki diseasePediatr Infect Dis J29201077077220354462 21TurnierJLAndersonMSHeizerHRJonePNGlodéMPDominguezSRConcurrent" exact="respiratory" post="viruses and Kawasaki diseasePediatrics1362015e609e61426304824 22BernalJLCumminsSGasparriniAInterrupted time series regression for"/>
   <result pre="virus circulation: a modelling studyLancet Infect Dis12201268769522738893 26NakamuraYYashiroMUeharaREpidemiologic features of" exact="Kawasaki disease" post="in Japan: results of the 2009–2010 nationwide surveyJ Epidemiol22201221622122447211"/>
   <result pre="circulation: a modelling studyLancet Infect Dis12201268769522738893 26NakamuraYYashiroMUeharaREpidemiologic features of Kawasaki" exact="disease" post="in Japan: results of the 2009–2010 nationwide surveyJ Epidemiol22201221622122447211"/>
   <result pre="results of the 2009–2010 nationwide surveyJ Epidemiol22201221622122447211 27KanegayeJTWilderMSMolkaraDRecognition of a" exact="Kawasaki disease" post="shock syndromePediatrics1232009e783e78919403470 29WhittakerEBamfordAKennyJClinical characteristics of 58 children with a"/>
   <result pre="of the 2009–2010 nationwide surveyJ Epidemiol22201221622122447211 27KanegayeJTWilderMSMolkaraDRecognition of a Kawasaki" exact="disease" post="shock syndromePediatrics1232009e783e78919403470 29WhittakerEBamfordAKennyJClinical characteristics of 58 children with a"/>
   <result pre="syndome temporally associated with SARS-CoV-2JAMA2020published online June 8.10.1001/jama.2020.10369 30KaushikSAydinSIDerespinaKRMultisystem inflammatory" exact="syndrome" post="in children (MIS-C) associated with SARS-CoV-2 infection: a multi-institutional"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7338960/results/search/disease/results.xml">
   <result pre="bold;} span.year {font-family : courier ; font-style : italic;} NeurospineNeurospineNSNeurospine2586-65832586-6591Korean" exact="Spinal" post="Neurosurgery Society pmcid: 7338960 pmid: 32408720 doi: 10.14245/ns.2040248.124ns-2040248-124 :"/>
   <result pre="epidemic in the 5th century BC, known as the Athens" exact="Plague" post="[3], and of which little is known, the first"/>
   <result pre="little is known, the first recorded epidemic was the Justinian" exact="plague" post="which started in 540 AD, lasted for 2 centuries,"/>
   <result pre="Ages [4-6]. which also originated in Asia, and lastly the" exact="bubonic plague" post="pandemic, the third largest recorded, which originated in Yunnan"/>
   <result pre="[4-6]. which also originated in Asia, and lastly the bubonic" exact="plague" post="pandemic, the third largest recorded, which originated in Yunnan"/>
   <result pre="reaction. For example, during the 16th century, the French called" exact="syphilis" post="‘Spanish smallpox,’ the Spanish called it the ‘malady of"/>
   <result pre="a Venetian trading post on the Black Sea [2]. The" exact="plague" post="took advantage of the Genoese galleys' return to Europe"/>
   <result pre="the plague. According to Hippocrates, after 40 days of isolation" exact="acute" post="illness did not manifest itself. In Venice, the ships"/>
   <result pre="court of King Louis XIII, and was developed during the" exact="plague" post="of 1619 which decimated Paris. In the 1890s the"/>
   <result pre="to 100%, was a resurgence of the 1894 Hong Kong" exact="plague" post="which gave the Frenchman Alexandre Yersin an opportunity to"/>
   <result pre="Alexandre Yersin an opportunity to discover the bacillus of the" exact="disease" post="almost concomitantly with the Japanese Kitasato Shibasaburo. Dr. Wu"/>
   <result pre="of masks in Japan. Photos published in the press of" exact="American" post="health corps wearing masks in the streets of San"/>
   <result pre="wearing masks as protection against the Spanish flu, although its" exact="viral" post="origin was not confirmed until 1933. How is an"/>
   <result pre="methods: finding an effective antibiotic treatment when the origin is" exact="bacterial" post="or a vaccine when the origin is viral. In"/>
   <result pre="or a vaccine when the origin is viral. In a" exact="viral" post="epidemic which is not 100% fatal, when 60% or"/>
   <result pre="when 60% or more of the population is infected, the" exact="disease" post="ceases to spread because the vector no longer finds"/>
   <result pre="by a large majority of the countries hit by coronavirus" exact="disease" post="2019 (COVID-19), have brought us back to the times"/>
   <result pre="times when there were no vaccines or antibiotics to fight" exact="infectious diseases" post="[9,10]. Today, faced with coronaviruses, we have no medication."/>
   <result pre="those that are authoritarian. In the 19th century the great" exact="cholera" post="epidemics prompted politicians to take hygiene measures [9]. Great"/>
   <result pre="epidemic will also lead to scientific progress in terms of" exact="viral" post="disease management and that the economic consequences of confinement"/>
   <result pre="will also lead to scientific progress in terms of viral" exact="disease" post="management and that the economic consequences of confinement will"/>
   <result pre="the royal attorney for the commune of Remoulin, during the" exact="plague" post="of Marseille in 1720. Fig. 2. First mask used"/>
   <result pre="Marseille in 1720. Fig. 2. First mask used during the" exact="plague" post="of Paris in 1619. The mask is filled with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7341479/results/search/disease/results.xml">
   <result pre="2019-nCoV. Keywords Coronavirus 2019-nCoV COVID-19 outbreak Epidemics Pathway of spread" exact="Severity of" post="epidemics Geographic location of epidemics The epidemic which started"/>
   <result pre="2019-nCoV COVID-19 outbreak Epidemics Pathway of spread Severity of epidemics" exact="Geographic" post="location of epidemics The epidemic which started in December"/>
   <result pre="Epidemics 2019-nCoV At least &amp;gt; 1000 cases Less than 1000 cases" exact="Total" post="Epidemics in the area 52°-30° Latitude North 65 Panel"/>
   <result pre="other geographic areas 7 Panel B 110 Panel D 117" exact="Total" post="72 176 248 It can be seen that the"/>
   <result pre="those with over 1000 cases, are located in a very" exact="limited" post="area of the globe, where over the last 2–3 months"/>
   <result pre="those which allow to classify the 2019-nCoV as a pandemic" exact="infective" post="agent, are mild and for this reason these widespread"/>
   <result pre="infective agent, are mild and for this reason these widespread" exact="infections" post="represent the best natural form of immunization for the"/>
   <result pre="cases, official notices of local rebound of new cases of" exact="infection" post="in the last several weeks after the end of"/>
   <result pre="strict social measures and behavioural rules that have certainly widely" exact="limited" post="the number of victims. However, it is the very"/>
   <result pre="Not applicable. Competing interests Not applicable. References References 1.WHO. Coronavirus" exact="disease" post="(COVID-2019) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. 2.CDC (US). Coronavirus (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/index.html."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7341712/results/search/disease/results.xml">
   <result pre="initiatives, including an ADB-funded consortium on the double burden of" exact="malnutrition" post="in Asia and a global initiative on agriculture and"/>
   <result pre="interrogate some widely used concepts in framing the interactions between" exact="disease" post="epidemics, food systems and nutrition, with a particular focus"/>
   <result pre="conceptualize vulnerability in such situations – both with regard to" exact="viral" post="exposure and to subsequent nutrition-relevant impacts of epidemics and"/>
   <result pre="impacts of epidemics on food and nutrition security. Keywords COVID-19" exact="Epidemic" post="Food system Nutrition Resilience Transformation Funding A4NH The way"/>
   <result pre="less common notion of resistance (to the initial risk of" exact="viral" post="exposure) may also be helpful in developing preventive responses."/>
   <result pre="time, a conceptual map was developed, highlighting the drivers of" exact="HIV infection," post="and the impacts of AIDS epidemics, from macro (environmental)"/>
   <result pre="association (on which it’s not possible to elaborate in this" exact="short" post="article). Fig. 1 COVID-19: vulnerability, resistance and resilience Reading"/>
   <result pre="the first two columns). The front-line of resistance to any" exact="viral infection" post="is an individual’s immune system (shown at the centre)."/>
   <result pre="first two columns). The front-line of resistance to any viral" exact="infection" post="is an individual’s immune system (shown at the centre)."/>
   <result pre="columns. Important here are a set of individual-level characteristics (including" exact="obesity" post="and undernutrition) that we now know will determine the"/>
   <result pre="that we now know will determine the severity of COVID-19" exact="disease" post="and ultimately the likelihood of dying from it. Beyond"/>
   <result pre="impacts will be significantly greater than the impact of the" exact="viral infection" post="itself (Robertson et al. 2020). Finally, Fig. 1 shows"/>
   <result pre="will be significantly greater than the impact of the viral" exact="infection" post="itself (Robertson et al. 2020). Finally, Fig. 1 shows"/>
   <result pre="Poverty and inequity, for example, can drive upstream vulnerability to" exact="viral" post="exposure, as well as be exacerbated by the downstream"/>
   <result pre="that overlaps and interacts with these three long-wave crises. Take" exact="obesity" post="for example – we know that the obesity epidemic"/>
   <result pre="crises. Take obesity for example – we know that the" exact="obesity" post="epidemic is being driven, in part, by the accessibility"/>
   <result pre="Tan et al. 2020). Evidence is also mounting on how" exact="obesity" post="confers a greater risk of poor outcomes of COVID-19"/>
   <result pre="2020). Compounding this, lockdowns are contributing to a rise in" exact="obesity" post="due to reduced physical activity and difficulties in sourcing"/>
   <result pre="of interest None. References References BarnettTWhitesideAAIDS in the 21st century:" exact="Disease" post="and globalization2002New YorkPalgrave Macmillan BeneCNewshamADaviesMUlrichsMGodfrey-WoodRResilience, poverty and developmentJournal of"/>
   <result pre="Effects of COVID-19 lockdown on lifestyle behaviors in children with" exact="obesity" post="living in Verona, Italy: A Longitudinal Study.Obesity, 2020; 10.1002/oby.22861."/>
   <result pre="in Verona, Italy: A Longitudinal Study.Obesity, 2020; 10.1002/oby.22861. RauberFSteeleEMLouzadaMCMillettCMonteiroCALevyRBUltra-processed food" exact="consumption" post="and indicators of obesity in the United Kingdom population"/>
   <result pre="Longitudinal Study.Obesity, 2020; 10.1002/oby.22861. RauberFSteeleEMLouzadaMCMillettCMonteiroCALevyRBUltra-processed food consumption and indicators of" exact="obesity" post="in the United Kingdom population (2008-2016)PLoS One2020155e023267610.1371/journal.pone.023267632357191 RobertsonTCarterEDChouVBStegmullerARJacksonBDTamYSawadogo-LewisTWalkerNEarly estimates"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7361333/results/search/disease/results.xml">
   <result pre="Virol. 2020;1–3. 10.1002/jmv.2623331502247 1 INTRODUCTION The worldwide spread of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the novel human pathogen,"/>
   <result pre="2020;1–3. 10.1002/jmv.2623331502247 1 INTRODUCTION The worldwide spread of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS‐CoV‐2), the novel human pathogen, first"/>
   <result pre="10.1002/jmv.2623331502247 1 INTRODUCTION The worldwide spread of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS‐CoV‐2), the novel human pathogen, first detected"/>
   <result pre="important epidemics: SARS caused by SARS‐CoV and the Middle East" exact="respiratory" post="syndrome (MERS) caused by MERS‐CoV. SARS‐CoV and MERS‐CoV have"/>
   <result pre="epidemics: SARS caused by SARS‐CoV and the Middle East respiratory" exact="syndrome" post="(MERS) caused by MERS‐CoV. SARS‐CoV and MERS‐CoV have caused"/>
   <result pre="for SARS‐CoV and 37% for MERS‐CoV, respectively.1, 2, 3, 4" exact="Viral" post="fitness of RNA viruses is influenced by their very"/>
   <result pre="very high frequency of mutation, which, in turn, can affect" exact="infection" post="speed and evolution rate.5 However, the resulting genetic variability"/>
   <result pre="information integrity and survival within the host.6, 7, 8 The" exact="viral" post="genome mutagenic process is depended on several factors, including"/>
   <result pre="viral genome mutagenic process is depended on several factors, including" exact="viral" post="enzymes responsible for nucleic acids replication, which may have"/>
   <result pre="as determinants of the template sequence and structure involved in" exact="viral" post="replication.5 In most viruses, RNA polymerase lacks proofreading capability,"/>
   <result pre="In Nidoviruses, complex machinery originated as cleavage products of the" exact="viral" post="ORF1a and ORF1b, composed of a polymerase (RNA‐depended RNA"/>
   <result pre="responsible for virus replication and transcription.9, 10 Biological characterization of" exact="viral" post="mutations provide precious insights for assessing viral drug resistance,"/>
   <result pre="Biological characterization of viral mutations provide precious insights for assessing" exact="viral" post="drug resistance, immune escape, and pathogenesis‐related mechanisms. In addition,"/>
   <result pre="viral drug resistance, immune escape, and pathogenesis‐related mechanisms. In addition," exact="viral" post="mutation studies are crucial for designing new vaccines, antiviral"/>
   <result pre="implications for control of the pandemic and potential emergence of" exact="viral" post="strains with different characteristics, including increased or reduced infectivity"/>
   <result pre="to 20% of the infected people develop rapidly a severe" exact="disease" post="characterized by interstitial pneumonia and acute respiratory distress syndrome"/>
   <result pre="infected people develop rapidly a severe disease characterized by interstitial" exact="pneumonia" post="and acute respiratory distress syndrome that can ultimately lead"/>
   <result pre="develop rapidly a severe disease characterized by interstitial pneumonia and" exact="acute" post="respiratory distress syndrome that can ultimately lead to death."/>
   <result pre="rapidly a severe disease characterized by interstitial pneumonia and acute" exact="respiratory" post="distress syndrome that can ultimately lead to death. This"/>
   <result pre="severe disease characterized by interstitial pneumonia and acute respiratory distress" exact="syndrome" post="that can ultimately lead to death. This is particularly"/>
   <result pre="and dry cough, followed then by breathing difficulties (dyspnea), and" exact="bilateral" post="ground‐glass opacities on chest computed tomography scans, indicating that"/>
   <result pre="then by breathing difficulties (dyspnea), and bilateral ground‐glass opacities on" exact="chest" post="computed tomography scans, indicating that the target cells are"/>
   <result pre="scans, indicating that the target cells are located in the" exact="lower" post="airways.20 Determination of infected subjects and mortality calculations during"/>
   <result pre="period of the epidemic, many patients were diagnosed with coronavirus" exact="disease" post="2019 (COVID‐19) only after developing critical illness or even"/>
   <result pre="in temperatures and humidity,23, 24 like already observed for other" exact="respiratory" post="viruses.25, 26, 27 In addition, several mutated strains of"/>
   <result pre="their host and become endemic, thus allowing spreading in the" exact="absence of" post="a high mortality rate. 2 CONCLUSION Though possible, it"/>
   <result pre="2 CONCLUSION Though possible, it is unlikely that the early" exact="viral" post="mutations observed in Europe and then in the US"/>
   <result pre="the other hand, the early mutations we observed in the" exact="viral" post="polymerase gene could have affected its processivity and fidelity,"/>
   <result pre="fidelity, further increasing its mutation rate and the generation of" exact="viral" post="clades progressively more heterogeneous. The emergence of subsequent specific"/>
   <result pre="in late fall or early winter of 2020, or another" exact="respiratory" post="virus appears in the distant future. Timely viral detection,"/>
   <result pre="or another respiratory virus appears in the distant future. Timely" exact="viral" post="detection, more precise, and reliable tracking methods leading to"/>
   <result pre="social distancing may be complemented with weather pattern analysis and" exact="viral" post="sequence analysis, to help to shape more focused interventions"/>
   <result pre="ErdmanD, GoldsmithCS, et al. A novel coronavirus associated with severe" exact="acute" post="respiratory syndrome. N Engl J Med. 2003;348(20):1953‐1966.12690092 2KuikenT, FouchierRA,"/>
   <result pre="GoldsmithCS, et al. A novel coronavirus associated with severe acute" exact="respiratory" post="syndrome. N Engl J Med. 2003;348(20):1953‐1966.12690092 2KuikenT, FouchierRA, SchuttenM,"/>
   <result pre="2KuikenT, FouchierRA, SchuttenM, et al. Newly discovered coronavirus as the" exact="primary" post="cause of severe acute respiratory syndrome. Lancet. 2003;362(9380):263‐270.12892955 3DrostenC,"/>
   <result pre="al. Newly discovered coronavirus as the primary cause of severe" exact="acute" post="respiratory syndrome. Lancet. 2003;362(9380):263‐270.12892955 3DrostenC, GüntherS, PreiserW, et al."/>
   <result pre="Newly discovered coronavirus as the primary cause of severe acute" exact="respiratory" post="syndrome. Lancet. 2003;362(9380):263‐270.12892955 3DrostenC, GüntherS, PreiserW, et al. Identification"/>
   <result pre="al. Identification of a novel coronavirus in patients with severe" exact="acute" post="respiratory syndrome. N Engl J Med. 2003;348(20):1967‐1976.12690091 4de GrootRJ,"/>
   <result pre="Identification of a novel coronavirus in patients with severe acute" exact="respiratory" post="syndrome. N Engl J Med. 2003;348(20):1967‐1976.12690091 4de GrootRJ, BakerSC,"/>
   <result pre="Med. 2003;348(20):1967‐1976.12690091 4de GrootRJ, BakerSC, BaricRS, et al. Middle East" exact="respiratory" post="syndrome coronavirus (MERS‐CoV): announcement of the Coronavirus Study Group."/>
   <result pre="2003;348(20):1967‐1976.12690091 4de GrootRJ, BakerSC, BaricRS, et al. Middle East respiratory" exact="syndrome" post="coronavirus (MERS‐CoV): announcement of the Coronavirus Study Group. J"/>
   <result pre="10—polymerases of coronaviruses: structure, function, and inhibitors In: GuptaSP, ed." exact="Viral" post="Polymerases. Cambridge, MA: Academic Press; 2019:271‐300. 10GaoY, YanL, HuangY,"/>
   <result pre="Large scale genomic analysis of 3067 SARS‐CoV‐2 genomes reveals a" exact="clonal" post="geo‐distribution and a rich genetic variations of hotspots mutations."/>
   <result pre="DorpL, AcmanM, RichardD, et al. Emergence of genomic diversity and" exact="recurrent" post="mutations in SARS‐CoV‐2. Infect Genet Evol. 2020;83:104351.32387564 15PachettiM, MariniB,"/>
   <result pre="Hospitalization rates and characteristics of patients hospitalized with laboratory‐confirmed coronavirus" exact="disease" post="2019—COVID‐NET, 14 states, March 1–30, 2020. MMWR Morb Mortal"/>
   <result pre="al. Impact of lockdown on Covid‐19 case fatality rate and" exact="viral" post="mutations spread. J Transl Med. 2020. 23BenedettiF, PachettiM, MariniB,"/>
   <result pre="J. 2020. 25AltizerS, OstfeldRS, JohnsonPT, KutzS, HarvellCD. Climate change and" exact="infectious" post="diseases: from evidence to a predictive framework. Science. 2013;341(6145):514‐519.23908230"/>
   <result pre="Attenuation of replication by a 29 nucleotide deletion in SARS‐coronavirus" exact="acquired" post="during the early stages of human‐to‐human transmission. Sci Rep."/>
   <result pre="Yount BLJr, JossetL, et al. Attenuation and restoration of severe" exact="acute" post="respiratory syndrome coronavirus mutant lacking 2′‐o‐methyltransferase activity. J Virol."/>
   <result pre="BLJr, JossetL, et al. Attenuation and restoration of severe acute" exact="respiratory" post="syndrome coronavirus mutant lacking 2′‐o‐methyltransferase activity. J Virol. 2014;88(8):4251‐4264.24478444"/>
   <result pre="JossetL, et al. Attenuation and restoration of severe acute respiratory" exact="syndrome" post="coronavirus mutant lacking 2′‐o‐methyltransferase activity. J Virol. 2014;88(8):4251‐4264.24478444 33ArmengaudJ,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7362058/results/search/disease/results.xml">
   <result pre=", This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7365411/results/search/disease/results.xml">
   <result pre="Public and Occupational Health : Medicine and Health Sciences :" exact="Infectious" post="Diseases: Infectious Disease Modeling : Biology and Life Sciences"/>
   <result pre="Occupational Health : Medicine and Health Sciences : Infectious Diseases:" exact="Infectious" post="Disease Modeling : Biology and Life Sciences : Computational"/>
   <result pre="Health : Medicine and Health Sciences : Infectious Diseases: Infectious" exact="Disease" post="Modeling : Biology and Life Sciences : Computational Biology"/>
   <result pre="Biology and Life Sciences : Computational Biology : Population Modeling:" exact="Infectious" post="Disease Modeling : Biology and Life Sciences : Population"/>
   <result pre="and Life Sciences : Computational Biology : Population Modeling: Infectious" exact="Disease" post="Modeling : Biology and Life Sciences : Population Biology"/>
   <result pre="Biology and Life Sciences : Population Biology : Population Modeling:" exact="Infectious" post="Disease Modeling : Medicine and Health Sciences: Epidemiology :"/>
   <result pre="and Life Sciences : Population Biology : Population Modeling: Infectious" exact="Disease" post="Modeling : Medicine and Health Sciences: Epidemiology : Biology"/>
   <result pre="Sciences : Microbiology : Medical Microbiology : Microbial Pathogens :" exact="Viral" post="Pathogens : Hemorrhagic Fever Viruses: Ebola Virus : Medicine"/>
   <result pre=": Medical Microbiology : Microbial Pathogens : Viral Pathogens :" exact="Hemorrhagic" post="Fever Viruses: Ebola Virus : Medicine and Health Sciences"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Hemorrhagic" exact="Fever" post="Viruses: Ebola Virus : Medicine and Health Sciences :"/>
   <result pre="Pathology and Laboratory Medicine : Pathogens : Microbial Pathogens :" exact="Viral" post="Pathogens : Hemorrhagic Fever Viruses: Ebola Virus : Biology"/>
   <result pre="Medicine : Pathogens : Microbial Pathogens : Viral Pathogens :" exact="Hemorrhagic" post="Fever Viruses: Ebola Virus : Biology and Life Sciences"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Hemorrhagic" exact="Fever" post="Viruses: Ebola Virus : Biology and Life Sciences :"/>
   <result pre=": Biology and Life Sciences : Organisms : Viruses :" exact="Viral" post="Pathogens : Hemorrhagic Fever Viruses: Ebola Virus : Biology"/>
   <result pre="Life Sciences : Organisms : Viruses : Viral Pathogens :" exact="Hemorrhagic" post="Fever Viruses: Ebola Virus : Biology and Life Sciences"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Hemorrhagic" exact="Fever" post="Viruses: Ebola Virus : Biology and Life Sciences :"/>
   <result pre=": Biology and Life Sciences : Organisms : Viruses :" exact="Hemorrhagic" post="Fever Viruses: Ebola Virus : Social Sciences : Sociology:"/>
   <result pre="Biology and Life Sciences : Organisms : Viruses : Hemorrhagic" exact="Fever" post="Viruses: Ebola Virus : Social Sciences : Sociology: Communications"/>
   <result pre="Health Education and Awareness : Medicine and Health Sciences :" exact="Infectious" post="Diseases : Infectious Disease Control: Vaccines : Biology and"/>
   <result pre="Education and Awareness : Medicine and Health Sciences : Infectious" exact="Diseases" post=": Infectious Disease Control: Vaccines : Biology and Life"/>
   <result pre="Awareness : Medicine and Health Sciences : Infectious Diseases :" exact="Infectious" post="Disease Control: Vaccines : Biology and Life Sciences :"/>
   <result pre=": Medicine and Health Sciences : Infectious Diseases : Infectious" exact="Disease" post="Control: Vaccines : Biology and Life Sciences : Neuroscience"/>
   <result pre="Hopkins Center for Health Security, Maryland, United States of America[2]," exact="Viral" post="Diseases Branch, Walter Reed Army Institute of Research, Marlyand,"/>
   <result pre="Center for Health Security, Maryland, United States of America[2], Viral" exact="Diseases" post="Branch, Walter Reed Army Institute of Research, Marlyand, United"/>
   <result pre="Institutes of Health, Maryland, United States of AmericaAkullianAdamEditor[], Institute for" exact="Disease" post="Modeling, UNITED STATES The authors have declared that no"/>
   <result pre="grown during previous outbreaks [1–3]. Despite the informative role that" exact="infectious disease" post="models played in the recent DRC outbreak [4–7], cross-talk"/>
   <result pre="during previous outbreaks [1–3]. Despite the informative role that infectious" exact="disease" post="models played in the recent DRC outbreak [4–7], cross-talk"/>
   <result pre="played in the recent DRC outbreak [4–7], cross-talk within the" exact="infectious disease" post="modeling community and between infectious disease modelers and model"/>
   <result pre="in the recent DRC outbreak [4–7], cross-talk within the infectious" exact="disease" post="modeling community and between infectious disease modelers and model"/>
   <result pre="[4–7], cross-talk within the infectious disease modeling community and between" exact="infectious disease" post="modelers and model stakeholders, such as health agencies, may"/>
   <result pre="cross-talk within the infectious disease modeling community and between infectious" exact="disease" post="modelers and model stakeholders, such as health agencies, may"/>
   <result pre="an informal modeling research coordination group to align efforts around" exact="infectious disease" post="modeling of the outbreak (Fig 1). Each month, two"/>
   <result pre="informal modeling research coordination group to align efforts around infectious" exact="disease" post="modeling of the outbreak (Fig 1). Each month, two"/>
   <result pre="ways this DRC outbreak differed to the prior 2014 West" exact="African" post="outbreak. The impact of violence itself on epidemic growth"/>
   <result pre="[8]. Shifts and development of data sources since 2014 West" exact="African" post="modeling efforts were also conspicuous, particularly in the domain"/>
   <result pre="genomic modeling played a key role in the 2014 West" exact="African" post="epidemic, presentations at this modeling group indicated how these"/>
   <result pre="and use by field epidemiologists [11]. Unlike the prior West" exact="African" post="epidemic, licensed Ebola vaccines were available and were implemented"/>
   <result pre="such as the Global Public Health Intelligence Network or the" exact="Epidemic" post="Intelligence Information System [13,14]. However, we propose that this"/>
   <result pre="stakeholders, with the goal of enabling more efficient and effective" exact="infectious disease" post="modeling relevant to this particular outbreak. Although preprint servers"/>
   <result pre="with the goal of enabling more efficient and effective infectious" exact="disease" post="modeling relevant to this particular outbreak. Although preprint servers"/>
   <result pre="between the generation and reporting of results, making them of" exact="limited" post="use in the field [15,16]. The DRC modeling coordination"/>
   <result pre="transmission and estimation of vaccination impact during an Ebola virus" exact="disease" post="outbreak in Northeastern Democratic Republic of Congo. bioRxiv. 201911;461285."/>
   <result pre="the impact of violent events on transmission in Ebola virus" exact="disease" post="outbreak, Democratic Republic of the Congo, 2018–2019. Epidemics. 2019Sep;28:10035310.1016/j.epidem.2019.10035331378584"/>
   <result pre="9AikenEL, McGoughSF, MajumderMS, WachtelG, NguyenAT, ViboudC, et al.Real-time Estimation of" exact="Disease" post="Activity in Emerging Outbreaks using Internet Search Information [Internet]."/>
   <result pre="13Epidemic intelligence tools and information resources [internet]. European Centre for" exact="Disease" post="Prevention and Control. [cited 2020 Feb 10]. Available from:"/>
   <result pre="Control. [cited 2020 Feb 10]. Available from: https://www.ecdc.europa.eu/en/threats-and-outbreaks/epidemic-intelligence 14WHO |" exact="Epidemic" post="intelligence—systematic event detection [internet]. [cited 2020 Feb 10]. Available"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7365643/results/search/disease/results.xml">
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="that this needs to facilitate ongoing improved coordination for future" exact="infectious disease" post="epidemics and pandemics. Two research funder coordination groups, the"/>
   <result pre="this needs to facilitate ongoing improved coordination for future infectious" exact="disease" post="epidemics and pandemics. Two research funder coordination groups, the"/>
   <result pre="on Development Research (UKCDR) and the Global Research Collaboration for" exact="Infectious" post="Disease Preparedness (GloPID-R), have agreed a set of principles"/>
   <result pre="Development Research (UKCDR) and the Global Research Collaboration for Infectious" exact="Disease" post="Preparedness (GloPID-R), have agreed a set of principles to"/>
   <result pre="are globally applicable, but of particular importance for research in" exact="lower" post="resourced settings. Given the urgency, scale and resource limitations,"/>
   <result pre="accordance with these principles, with a particular focus on resource" exact="limited" post="settings. This will build on the COVID-19 Research Project"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7373336/results/search/disease/results.xml">
   <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
   <result pre="pandemic. Abstract Objectives The outbreak of the 2019 novel coronaviruses" exact="disease" post="(COVID-2019) in areas with epidemics due to imported cases"/>
   <result pre="fluctuations. Moreover, the data demonstrated that the ratio of unexplained" exact="infections" post="to nonimported cases was increasing. Conclusions A two-stage outbreak"/>
   <result pre="epidemic area Outbreak Case time distribution Fujian Province China Introduction" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as"/>
   <result pre="area Outbreak Case time distribution Fujian Province China Introduction Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the"/>
   <result pre="Outbreak Case time distribution Fujian Province China Introduction Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) was identified as the infectious"/>
   <result pre="Case time distribution Fujian Province China Introduction Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) was identified as the infectious agent"/>
   <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the" exact="infectious" post="agent causing an outbreak of viral pneumonia (coronavirus disease"/>
   <result pre="was identified as the infectious agent causing an outbreak of" exact="viral pneumonia" post="(coronavirus disease 2019, COVID-19) in Wuhan, China (Li et"/>
   <result pre="identified as the infectious agent causing an outbreak of viral" exact="pneumonia" post="(coronavirus disease 2019, COVID-19) in Wuhan, China (Li et"/>
   <result pre="the infectious agent causing an outbreak of viral pneumonia (coronavirus" exact="disease" post="2019, COVID-19) in Wuhan, China (Li et al. 2020;"/>
   <result pre="et al. 2020; Special Expert Group for Control of the" exact="Epidemic" post="of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine"/>
   <result pre="Expert Group for Control of the Epidemic of Novel Coronavirus" exact="Pneumonia" post="of the Chinese Preventive Medicine Association 2020). COVID-19, which"/>
   <result pre="Chinese Preventive Medicine Association 2020). COVID-19, which is a new" exact="infectious disease," post="is highly contagious and spread quickly to other provinces"/>
   <result pre="of COVID-19 was reported, and by February 21, 2020, a" exact="total" post="of 293 COVID-19 cases had been confirmed in Fujian."/>
   <result pre="from January 22 to February 3, 2020, during which a" exact="total" post="of 194 cases were confirmed, and the second stage"/>
   <result pre="cases and began on February 4, 2020, during which a" exact="total" post="of 99 cases have been confirmed so far. The"/>
   <result pre="cases in this period accounted for 38% (62/163) of the" exact="total" post="cases in the first stage. However, the longest period"/>
   <result pre="in Fujian Province; b The daily new confirmed of unexplained" exact="infections" post="in Fujian Province; c The ratio of daily new"/>
   <result pre="Province; c The ratio of daily new confirmed of unexplained" exact="infections" post="to daily new confirmed of nonimported cases in Fujian"/>
   <result pre="nonimported cases. Since February 6, 2020, the number of unexplained" exact="infections" post="has increased (Fig. 3b); in particular, the ratio of"/>
   <result pre="has increased (Fig. 3b); in particular, the ratio of unexplained" exact="infections" post="to nonimported cases has shown an obvious increasing trend"/>
   <result pre="increasing trend (Fig. 3c). Discussion The epidemiological data on COVID-19" exact="infections" post="in Fujian Province were collected. The results indicated that"/>
   <result pre="of local transmission already existed. By February 21, 2020, a" exact="total" post="of 293 confirmed cases of COVID-19 (including 14 cases"/>
   <result pre="cumulative number of cases before January 29, 2020. Furthermore, the" exact="total" post="number of imported cases was 81 from January 22"/>
   <result pre="number for COVID-19 was 2.68 (Wu et al. 2020), the" exact="total" post="number of confirmed cases would have been close to"/>
   <result pre="ten thousand on January 29, 2020, in Fujian; however, the" exact="total" post="number of confirmed cases was 101, and the number"/>
   <result pre="the number of nonimported cases was 87, which is even" exact="lower" post="than the number of imported cases (187) on February"/>
   <result pre="that the management strategies implemented to control the source of" exact="infection" post="and prevent transmission as rapidly as possible during the"/>
   <result pre="infections. The data also showed that the ratio of unexplained" exact="infections" post="to nonimported cases has been increasing, and more unexplained"/>
   <result pre="infections to nonimported cases has been increasing, and more unexplained" exact="infections" post="have been detected since February 6, 2020. Currently, there"/>
   <result pre="also thank the staff of the Fujian Provincial Center for" exact="Disease" post="Control and Prevention for their hard work in the"/>
   <result pre="interest. References References BackerJAKlinkenbergDWallingaJIncubation period of 2019 novel coronavirus (2019-nCoV)" exact="infections" post="among travellers from Wuhan, China, 20–28 January 2020Eurosurveillance202025200006210.2807/1560-7917.ES.2020.25.5.2000062 GuanWJNiZYHuYet"/>
   <result pre="20–28 January 2020Eurosurveillance202025200006210.2807/1560-7917.ES.2020.25.5.2000062 GuanWJNiZYHuYet al.Clinical characteristics of 2019 novel coronavirus" exact="infection" post="in ChinaN Engl J Med20203821708172010.1056/NEJMoa200203232109013 LiQGuanXWuPet al.Early transmission dynamics"/>
   <result pre="J Med20203821199120710.1056/NEJMoa20013131995857 collab: Special Expert Group for Control of the" exact="Epidemic" post="of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine"/>
   <result pre="Expert Group for Control of the Epidemic of Novel Coronavirus" exact="Pneumonia" post="of the Chinese Preventive Medicine AssociationAn update on the"/>
   <result pre="Medicine AssociationAn update on the epidemiological characteristics of novel coronavirus" exact="pneumonia" post="(COVID-19)Chin J Epidemiol20204113914410.3760/cma.j.issn.0254-6450.2020.02.002 World Health Organization (2020) Poverty. https://www.who.int/docs/default-source/coronaviruse/situationreports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7376323/results/search/disease/results.xml">
   <result pre="10.1186/s12981-020-00301-3 : Case Report Case report: one case of coronavirus" exact="disease" post="2019 (COVID-19) in a patient co-infected by HIV with"/>
   <result pre="University, [2], grid.24696.3f0000 0004 0369 153XDepartment of Critical care medicine" exact="of liver" post="disease, Beijing You’an Hospital, Capital Medical University, epub: 2020-7-7pmc-release:"/>
   <result pre="[2], grid.24696.3f0000 0004 0369 153XDepartment of Critical care medicine of" exact="liver disease," post="Beijing You’an Hospital, Capital Medical University, epub: 2020-7-7pmc-release: 2020-7-7collection:"/>
   <result pre="case with HIV and SARS-CoV-2 co-infection, which showed a prolonged" exact="viral" post="shedding duration. Case presentation The patient was infected with"/>
   <result pre="during the epidemic. Most importantly, the patient had a prolonged" exact="viral" post="shedding duration of SARS-CoV-2 about 28 days. Conclusion The"/>
   <result pre="viral shedding duration of SARS-CoV-2 about 28 days. Conclusion The" exact="viral" post="shedding duration may be prolonged in people living with"/>
   <result pre="living with HIV RT-PCR Background COVID-19 is a novel virus" exact="disease" post="with over 7250,000 confirmed cases worldwide [1]. And the"/>
   <result pre="al. [5] also reported a maximum 20 days of prolonged" exact="viral" post="clearance period. Here we reported a case of HIV"/>
   <result pre="case of HIV and SARS-CoV-2 co-infection who had a prolonged" exact="viral" post="shedding duration about 28 days. Case report A 49-years"/>
   <result pre="shedding duration about 28 days. Case report A 49-years old" exact="female" post="diagnosed with HIV infection 8 years ago under regular"/>
   <result pre="28 days. Case report A 49-years old female diagnosed with" exact="HIV infection" post="8 years ago under regular ART (anti-retroviral therapy) went"/>
   <result pre="days. Case report A 49-years old female diagnosed with HIV" exact="infection" post="8 years ago under regular ART (anti-retroviral therapy) went"/>
   <result pre="sample was collected for RT-PCR assay of SARS-CoV-2 and the" exact="chest" post="computed tomography (CT) was performed. Previous medical history included"/>
   <result pre="count was 224, a recent test was normal. The HIV" exact="viral" post="load remained undetectable from 2013 (Figs. 1, 2). Fig."/>
   <result pre="2013 (Figs. 1, 2). Fig. 1 a The patient’s COVID-19" exact="disease" post="duration; b the Lymphocyte Count(109/L); c C-reactive protein(mg/L) Fig."/>
   <result pre="2 a The CD4+ T cell count; b the HIV" exact="viral" post="load The CT result showed ground glass dense shadow"/>
   <result pre="segment of the middle lobe and dorsal-base segment of the" exact="lower" post="lobe of the right lung (Fig. 3). Meantime, he"/>
   <result pre="(400 mg QD) was given to the patient for preventing" exact="bacterial infection." post="On day 12, the temperature of the patient returned"/>
   <result pre="for SARS-CoV-2 turned negative on day 44. We confirmed the" exact="viral" post="clearance, and the patient was discharged on day 47."/>
   <result pre="has been a worldwide epidemic disease. As an epidemic disease," exact="viral" post="shedding duration is the key to disease control. Some"/>
   <result pre="an epidemic disease, viral shedding duration is the key to" exact="disease" post="control. Some studies found asymptomatic people who were still"/>
   <result pre="the virus after isolation for 14 days [8]. The prolonged" exact="viral" post="shedding duration in the general population has been reported"/>
   <result pre="population has been reported by several studies and the prolonged" exact="viral" post="shedding duration reported ranges from 21 to 45 days"/>
   <result pre="days [4, 9]. But there are few studies about the" exact="viral" post="shedding duration in suspicious immunocompromised patients. At present, there"/>
   <result pre="kidney transplantation. These two patients finally transferred to ARDS (Acute" exact="respiratory" post="distress syndrome), and eventually died after [10]. Among the"/>
   <result pre="reported a patient with kidney transplantation who had a prolonged" exact="viral" post="shedding duration for 63 days. This is the first"/>
   <result pre="patient co-infected with HIV and SARS-CoV-2 who showed a prolonged" exact="viral" post="shedding duration. Even though not all people living with"/>
   <result pre="are immunocompromised, especially those under ART with an undetectable HIV" exact="viral" post="and normal CD4 count, these people may still be"/>
   <result pre="normal CD4 count, these people may still be vulnerable to" exact="viral infection" post="or subsequent bacterial pneumonia than the general population. Further"/>
   <result pre="CD4 count, these people may still be vulnerable to viral" exact="infection" post="or subsequent bacterial pneumonia than the general population. Further"/>
   <result pre="people may still be vulnerable to viral infection or subsequent" exact="bacterial pneumonia" post="than the general population. Further studies and data collection"/>
   <result pre="may still be vulnerable to viral infection or subsequent bacterial" exact="pneumonia" post="than the general population. Further studies and data collection"/>
   <result pre="had a history of fever and had CT findings of" exact="viral pneumonia." post="COVID-19 was diagnosed by the positive result of RT-PCR."/>
   <result pre="was diagnosed by the positive result of RT-PCR. And the" exact="viral" post="shedding duration lasted about 28 days. Xu et al."/>
   <result pre="Xu et al. [4] concluded the risk factors of prolonged" exact="viral" post="RNA shedding in COVID-19 patients: male sex, delayed admission"/>
   <result pre="in our report. Qin et al. [12] reported that the" exact="total" post="number of B cells, T cells, and NK cells"/>
   <result pre="group dropped more significantly than the moderate group. So, the" exact="infection" post="of SARS-CoV-2 might be dramatically for the people living"/>
   <result pre="one hand, the immune system might be impaired after the" exact="infection" post="of SARS-CoV-2 by the depletion of T lymphocytes [12]."/>
   <result pre="of T lymphocytes [12]. On the other hand, during the" exact="chronic" post="phase of HIV infection, generalized immune activation, and systemic"/>
   <result pre="[12]. On the other hand, during the chronic phase of" exact="HIV infection," post="generalized immune activation, and systemic CD4+ T lymphocyte depletion"/>
   <result pre="the chronic phase of HIV infection, generalized immune activation, and" exact="systemic" post="CD4+ T lymphocyte depletion occur. Fortunately, the CD4+ T"/>
   <result pre="of HIV infection, generalized immune activation, and systemic CD4+ T" exact="lymphocyte depletion" post="occur. Fortunately, the CD4+ T cell count of our"/>
   <result pre="the reason for not causing severe pneumonia. But the prolonged" exact="viral" post="shedding duration. The paradox between the prolonged viral shedding"/>
   <result pre="the prolonged viral shedding duration. The paradox between the prolonged" exact="viral" post="shedding duration and moderate clinical course might be due"/>
   <result pre="with HIV [13]. Lu et al. [5] revealed that prolonged" exact="viral" post="RNA shedding in children was associated with symptomatic infection,"/>
   <result pre="that prolonged viral RNA shedding in children was associated with" exact="symptomatic" post="infection, fever, pneumonia, and lymphocyte count less than 2.0 × 109/L."/>
   <result pre="than 2.0 × 109/L, which might be a co-factor for the prolonged" exact="viral" post="shedding duration. At last, there are no specific antiviral"/>
   <result pre="may not inhibit the replication of SARS-CoV-2 effectively. Conclusion The" exact="viral" post="shedding duration may be prolonged in people living with"/>
   <result pre="that they have no competing interests. References References 1.WHO Coronavirus" exact="disease" post="situation reports. 2020. https://www.who.int/. 2.CiottiMAMinieriSGiovannettiMBenvenutoMPascarellaDSSagnelliCBianchiMBernardiniSCiccozziMCOVID-19 outbreak: an overviewChemotherapy20206419 3.HuangCWangYLiXRenLZhaoJHuYZhangLFanGXuJGuXChengZet"/>
   <result pre="coronavirus in Wuhan, ChinaThe Lancet20203951022349750610.1016/S0140-6736(20)30183-5 4.XuKChenYYuanJYiPDingCWuWet al.Factors associated with prolonged" exact="viral" post="RNA shedding in patients with COVID-19Clin Infect Dis202010.1093/cid/ciaa35132649745 5.LuYLiYDengWLiuMHeYHuangLet"/>
   <result pre="RNA shedding in patients with COVID-19Clin Infect Dis202010.1093/cid/ciaa35132649745 5.LuYLiYDengWLiuMHeYHuangLet al.Symptomatic" exact="infection" post="is associated with prolonged duration of viral shedding in"/>
   <result pre="Dis202010.1093/cid/ciaa35132649745 5.LuYLiYDengWLiuMHeYHuangLet al.Symptomatic infection is associated with prolonged duration of" exact="viral" post="shedding in mild coronavirus disease 2019: a retrospective study"/>
   <result pre="associated with prolonged duration of viral shedding in mild coronavirus" exact="disease" post="2019: a retrospective study of 110 children in WuhanPediatr"/>
   <result pre="of 110 children in WuhanPediatr Infect Dis J2020397e95e9932379191 6.AiTYangZHouHZhanCChenCLvWTaoQSunZXiaLCorrelation of" exact="chest" post="CT and RT-PCR testing in coronavirus disease 2019 (COVID-19)"/>
   <result pre="J2020397e95e9932379191 6.AiTYangZHouHZhanCChenCLvWTaoQSunZXiaLCorrelation of chest CT and RT-PCR testing in coronavirus" exact="disease" post="2019 (COVID-19) in China: a report of 1014 casesRadiology202010.1148/radiol.20202006427233399"/>
   <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(Full version)New Med2020303564 8.MaoZQWanRHeLYHuYCChenWThe enlightenment from two cases of"/>
   <result pre="(Full version)New Med2020303564 8.MaoZQWanRHeLYHuYCChenWThe enlightenment from two cases of asymptomatic" exact="infection" post="with SARS-CoV-2: is it safe after 14 days of"/>
   <result pre="safe after 14 days of isolation?Int J Infect Dis.20209517417510.1016/j.ijid.2020.03.04132251796 9.ZhangWYYuLQHuangJAZengDXProlonged" exact="viral" post="RNA shedding duration in COVID-19Am J Ther.2020101097 10.HuangJLinHWuYFangYKumarRChenGLinSet al.COVID-19"/>
   <result pre="patients with COVID-19 in Wuhan, ChinaClin Infect Dis202010.1093/cid/ciaa24832667972 13.MahnkeYDFletez-BrantKSeretiIRoedererMReconstitution of" exact="peripheral" post="T cells by tissue-derived CCR4 + central memory cells"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7386680/results/search/disease/results.xml">
   <result pre="communities to underresourced areas that render them susceptible to developing" exact="chronic" post="diseases, contracting illnesses like COVID-19, and lacking access to"/>
   <result pre="peers and inquire about ways to be helpful. Ultimately, when" exact="viral" post="and police violence epidemics intersect, remaining silent demonstrates complacency"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7392634/results/search/disease/results.xml">
   <result pre="Health and Nutrition ClusterInstitute of Development StudiesBrightonUK[15], European Commission Directorate" exact="General" post="for Civil Protection and Humanitarian Aid OperationsKinshasaDemocratic Republic of"/>
   <result pre="See: http://creativecommons.org/licenses/by-nc/4.0/.bmjgh-2020-003098.pdf Abstract It is very exceptional that a new" exact="disease" post="becomes a true pandemic. Since its emergence in Wuhan,"/>
   <result pre="Since its emergence in Wuhan, China, in late 2019, severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes"/>
   <result pre="its emergence in Wuhan, China, in late 2019, severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19,"/>
   <result pre="emergence in Wuhan, China, in late 2019, severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, has"/>
   <result pre="these different COVID-19 epidemics; by comparing COVID-19 epidemics with other" exact="respiratory" post="diseases, including other coronaviruses that circulate continuously; and by"/>
   <result pre="COVID-19 and for future waves elsewhere. public health Summary box" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that"/>
   <result pre="and for future waves elsewhere. public health Summary box Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes"/>
   <result pre="for future waves elsewhere. public health Summary box Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19,"/>
   <result pre="future waves elsewhere. public health Summary box Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, has"/>
   <result pre="only a few months. It is unique that an emerging" exact="respiratory" post="virus becomes a pandemic, and can continue human-to-human transmission"/>
   <result pre="affected countries. This is in fact the case with most" exact="infectious diseases." post="Despite limited initial knowledge on COVID-19, most societies have"/>
   <result pre="is in fact the case with most infectious diseases. Despite" exact="limited" post="initial knowledge on COVID-19, most societies have deployed draconian"/>
   <result pre="responses to, COVID-19. Introduction Late in 2019, a cluster of" exact="acute" post="respiratory disease in Wuhan, China, was attributed to a"/>
   <result pre="to, COVID-19. Introduction Late in 2019, a cluster of acute" exact="respiratory" post="disease in Wuhan, China, was attributed to a new"/>
   <result pre="COVID-19. Introduction Late in 2019, a cluster of acute respiratory" exact="disease" post="in Wuhan, China, was attributed to a new coronavirus,1–3"/>
   <result pre="China, was attributed to a new coronavirus,1–3 later named severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2).4 It was soon discovered"/>
   <result pre="was attributed to a new coronavirus,1–3 later named severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2).4 It was soon discovered that"/>
   <result pre="attributed to a new coronavirus,1–3 later named severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2).4 It was soon discovered that the"/>
   <result pre="discovered that the virus is easily transmitted, can cause severe" exact="disease" post="and can be quite lethal especially in the elderly"/>
   <result pre="in the elderly and those with comorbidities.5–8 The new human" exact="disease" post="is called COVID-19.9 Soon it became clear that its"/>
   <result pre="December 2019–May 2020 Month Key events December 2019 Clusters of" exact="pneumonia" post="of unknown origin in Wuhan, China. Human infection probably"/>
   <result pre="Clusters of pneumonia of unknown origin in Wuhan, China. Human" exact="infection" post="probably began sometime between 9 October and 20 December"/>
   <result pre="series of lockdowns across the world. February 2020 The new" exact="disease" post="named COVID-19 on 11 February 2020. Cruise ship Princess"/>
   <result pre="Cruise ship Princess Diamond quarantined near Japan, sparking media attention." exact="Epidemic" post="in China peaked with ~80 000 cases and 2900"/>
   <result pre="2900 deaths (80% of cases restricted to the Hubei Province).73" exact="Local" post="epidemics of varying attack rates and case fatality rates"/>
   <result pre="China partially lifted lockdown while India instituted the world’s biggest" exact="complete" post="lockdown affecting ~1.4 billion people.74 April 2020 COVID-19 cases"/>
   <result pre="Europe. In Africa, the number of cases seemed to fall" exact="short" post="of forecasts. Tremendous socioeconomic fallouts after an estimated 4.5"/>
   <result pre="compare these knowns with what is known of some other" exact="viral" post="respiratory pathogens and identify the critical unknowns. We also"/>
   <result pre="these knowns with what is known of some other viral" exact="respiratory" post="pathogens and identify the critical unknowns. We also discuss"/>
   <result pre="slowly. In contrast, the collateral effects of a lockdown, even" exact="partial" post="in many cases, are mostly felt by the urban"/>
   <result pre="2. Table 2 Contextual variables potentially influencing transmission of severe" exact="acute" post="respiratory syndrome coronavirus 2 Variable Elements Range (variation/extremes) Population"/>
   <result pre="Table 2 Contextual variables potentially influencing transmission of severe acute" exact="respiratory" post="syndrome coronavirus 2 Variable Elements Range (variation/extremes) Population density"/>
   <result pre="2 Contextual variables potentially influencing transmission of severe acute respiratory" exact="syndrome" post="coronavirus 2 Variable Elements Range (variation/extremes) Population density People"/>
   <result pre="from other viruses We do not attempt to give a" exact="complete" post="overview of viruses but select only those viruses that"/>
   <result pre="or that are closely related such as other coronaviruses. Emerging" exact="viral" post="respiratory pathogens Respiratory viruses such as severe acute respiratory"/>
   <result pre="that are closely related such as other coronaviruses. Emerging viral" exact="respiratory" post="pathogens Respiratory viruses such as severe acute respiratory syndrome"/>
   <result pre="closely related such as other coronaviruses. Emerging viral respiratory pathogens" exact="Respiratory" post="viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV),"/>
   <result pre="coronaviruses. Emerging viral respiratory pathogens Respiratory viruses such as severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus"/>
   <result pre="Emerging viral respiratory pathogens Respiratory viruses such as severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV)"/>
   <result pre="viral respiratory pathogens Respiratory viruses such as severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and"/>
   <result pre="such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) and avian influenza A and also"/>
   <result pre="as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) and avian influenza A and also Ebola"/>
   <result pre="syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and" exact="avian influenza" post="A and also Ebola have originated from animal hosts"/>
   <result pre="to another animal host. Table 3 Examples of emerging human" exact="respiratory" post="viral diseases without sustained human-to-human transmission Virus Originating animal"/>
   <result pre="another animal host. Table 3 Examples of emerging human respiratory" exact="viral" post="diseases without sustained human-to-human transmission Virus Originating animal host"/>
   <result pre="Bat First emerged in China in November 2002.76 Causes severe" exact="acute" post="respiratory syndrome (SARS). Transmission through superspreading events in healthcare"/>
   <result pre="First emerged in China in November 2002.76 Causes severe acute" exact="respiratory" post="syndrome (SARS). Transmission through superspreading events in healthcare facilities.77"/>
   <result pre="emerged in China in November 2002.76 Causes severe acute respiratory" exact="syndrome" post="(SARS). Transmission through superspreading events in healthcare facilities.77 8422"/>
   <result pre="emerged in the Middle East in 2012.79 Causes Middle East" exact="respiratory" post="syndrome (MERS). Outbreaks from 2012 to 2019 in Saudi"/>
   <result pre="in the Middle East in 2012.79 Causes Middle East respiratory" exact="syndrome" post="(MERS). Outbreaks from 2012 to 2019 in Saudi Arabia"/>
   <result pre="one outbreak in South Korea (2015). 2502 cases; CFR: 34%79" exact="Avian" post="influenza A (H5N1 and H7N9) Birds/poultry Subtypes of influenza"/>
   <result pre="CFR, case fatality rates. The first human case of a" exact="disease" post="from an emerging viral pathogen, the ‘index case’ or"/>
   <result pre="The first human case of a disease from an emerging" exact="viral" post="pathogen, the ‘index case’ or ‘patient zero’, is invariably"/>
   <result pre="and the outbreak stops. Only very exceptionally can a new" exact="viral" post="pathogen sustain continuous human-to-human transmission. Other viral diseases such"/>
   <result pre="can a new viral pathogen sustain continuous human-to-human transmission. Other" exact="viral" post="diseases such as measles and influenza are ‘old’ diseases;"/>
   <result pre="pathogen sustain continuous human-to-human transmission. Other viral diseases such as" exact="measles" post="and influenza are ‘old’ diseases; they have been studied"/>
   <result pre="and influenza: the importance of context It is thought that" exact="measles" post="emerged thousands of years ago in the Middle East."/>
   <result pre="cross-over occurred from the rinderpest virus,31 to become the human" exact="measles" post="virus. Measles has since spread around the globe in"/>
   <result pre="human-to-human transmission. When measles, along with other viruses such as" exact="smallpox" post="and influenza, was introduced in the Americas by European"/>
   <result pre="High mortality, especially in younger persons (5–15 years; ~25% of" exact="total" post="deaths) in the 1918 pandemic, may have been due"/>
   <result pre="estimated CFR&amp;lt;0.1%.85 86 During the 2009 pandemic, mortality was much" exact="lower" post="than in the 1918 pandemic. Higher mortality in persons"/>
   <result pre="integrated with circulating strains of influenza and continues to cause" exact="localised" post="seasonal influenza outbreaks worldwide.88 A major difference between COVID-19"/>
   <result pre="has triggered an immune response in over 5 million confirmed" exact="infections" post="(and probably in many more), definitely too few to"/>
   <result pre=" A dominant way of studying the transmission dynamics of an" exact="infectious disease" post="such as COVID-19, and predicting the amplitude and peak"/>
   <result pre="dominant way of studying the transmission dynamics of an infectious" exact="disease" post="such as COVID-19, and predicting the amplitude and peak"/>
   <result pre="plausible possibilities, between ‘worst-case’ and ‘best-case’ scenarios.  With a new" exact="disease" post="such as COVID-19, certainly at the start of the"/>
   <result pre="the outbreak, the parameters had to be based on very" exact="limited" post="data from a particular context. However, many variables can"/>
   <result pre="unknowns about COVID-19, as of May 2020 Factor Available information" exact="Disease" post="spectrum Many different estimates: Initially, it was estimated that"/>
   <result pre="for remaining totally asymptomatic (estimated 5%–80%93–96). What determines that an" exact="infection" post="remains asymptomatic? Quasi-absence of disease in children: why? Case"/>
   <result pre="5%–80%93–96). What determines that an infection remains asymptomatic? Quasi-absence of" exact="disease" post="in children: why? Case fatality rate (CFR) Initial estimates"/>
   <result pre="influenza 0.1%; common cold: 0%; SARS: 9%–10%; MERS: 30%.97 Calculated" exact="infection" post="fatality rates (cIFR) and calculated CFR (cCFR) on the"/>
   <result pre="treatment, mainly oxygen therapy.100 101 Also, as in certain other" exact="viral" post="diseases such as measles, possibly influenced by the dose"/>
   <result pre="measles, possibly influenced by the dose of virus in initial" exact="infectious" post="inoculum (see Box 3). CFR and IFR vary depending"/>
   <result pre="ventilation, requiring sophisticated equipment and highly skilled personnel. Like COVID-19," exact="measles" post="and influenza have different epidemic patterns in different contexts."/>
   <result pre="different contexts. This also is the case for cholera, tuberculosis," exact="HIV/AIDS" post="and most infectious diseases. The difference in patterns is"/>
   <result pre="also is the case for cholera, tuberculosis, HIV/AIDS and most" exact="infectious diseases." post="The difference in patterns is most pronounced and so"/>
   <result pre="and so is easily understood with vector-borne and water-borne diseases." exact="Epidemic" post="patterns are also different for air-borne infections, although they"/>
   <result pre="air-borne infections, although they are less easily understood. Transmission of" exact="respiratory" post="viruses is influenced by factors related to the virus"/>
   <result pre="Table 4 Factors related to transmission patterns and severity of" exact="respiratory" post="viruses Factor Variables Virus Infection efficiency, transmissibility. Capacity to"/>
   <result pre="transmission patterns and severity of respiratory viruses Factor Variables Virus" exact="Infection" post="efficiency, transmissibility. Capacity to survive outside the human body"/>
   <result pre="(including in aerosols, in droplets, on surfaces, in stools, in" exact="intermediate" post="animal hosts, etc.) Potential to shed virus from an"/>
   <result pre="Genetic stability or variability (affecting the potential of long-lasting immunity)." exact="Viral" post="load determines the incubation period with the formula high"/>
   <result pre="high load -&amp;gt;short incubation period -&amp;gt;high severity. Human host Human" exact="susceptibility to" post="the virus; transfer of parental immunity to newborns. Route"/>
   <result pre="duration of the disease: proportion symptomatic, lethality (CFR). Pathogenicity and" exact="disease" post="spectrum; disease pattern according to age and comorbidities, and"/>
   <result pre="the disease: proportion symptomatic, lethality (CFR). Pathogenicity and disease spectrum;" exact="disease" post="pattern according to age and comorbidities, and related potential"/>
   <result pre="of vaccines, has been well described. Measles is mostly a" exact="childhood" post="disease, but this is not the case in very"/>
   <result pre="this is not the case in very remote communities, where" exact="measles" post="transmission had been interrupted for extended periods (such as"/>
   <result pre="epidemic’.40 41 The latest stages of the global dissemination of" exact="measles" post="have been well documented, including in Australia, the Fiji"/>
   <result pre="occurred in the 19th and the mid-20th centuries.32 42 Fortunately," exact="measles" post="infection creates robust protective immunity and after a first"/>
   <result pre="in the 19th and the mid-20th centuries.32 42 Fortunately, measles" exact="infection" post="creates robust protective immunity and after a first wave"/>
   <result pre="protective immunity and after a first wave becomes a typical" exact="childhood" post="disease, affecting only those without any prior immunity.43 Human-to-human"/>
   <result pre="affecting only those without any prior immunity.43 Human-to-human transmission of" exact="measles" post="virus in a community stops when the virus cannot"/>
   <result pre="the so-called herd immunity is reached.44 45 But transmission of" exact="measles" post="continues elsewhere on the planet from where it can"/>
   <result pre="enough to allow human-to-human transmission again. The epidemic patterns of" exact="measles" post="are easily understood as measles is highly infectious, creates"/>
   <result pre="again. The epidemic patterns of measles are easily understood as" exact="measles" post="is highly infectious, creates disease in almost every infected"/>
   <result pre="measles are easily understood as measles is highly infectious, creates" exact="disease" post="in almost every infected person and leaves lifelong natural"/>
   <result pre="groups in the Sahel), causing epidemics among all those without" exact="acquired" post="immunity and having lost maternal antibodies.46 These diverse patterns"/>
   <result pre="immunity and having lost maternal antibodies.46 These diverse patterns of" exact="measles" post="epidemics have been fundamentally changed by variable coverage of"/>
   <result pre="measles epidemics have been fundamentally changed by variable coverage of" exact="measles" post="vaccination. They can still help us make sense of"/>
   <result pre="2020. Measles illustrates convincingly that the transmission pattern of a" exact="respiratory" post="virus is strongly influenced by the demographic composition, density"/>
   <result pre="continuous only in some large urban areas. It presents in" exact="short" post="epidemics everywhere else with variable periodicity. This transmission pattern"/>
   <result pre="similar for COVID-19. But it took thousands of years for" exact="measles" post="to reach all human communities while SARS-CoV-2 spread to"/>
   <result pre="spread to all countries in only a few months, despite" exact="measles" post="being much more transmissible than SARS-CoV-2. Factors such as"/>
   <result pre="and continuously circulate and mutate frequently.47 48 They can cause" exact="disease" post="in the same person repeatedly. The typical coronavirus remains"/>
   <result pre="disease in the same person repeatedly. The typical coronavirus remains" exact="localised" post="to the epithelium of the upper respiratory tract, causes"/>
   <result pre="The typical coronavirus remains localised to the epithelium of the" exact="upper" post="respiratory tract, causes mild disease and elicits a poor"/>
   <result pre="typical coronavirus remains localised to the epithelium of the upper" exact="respiratory" post="tract, causes mild disease and elicits a poor immune"/>
   <result pre="to the epithelium of the upper respiratory tract, causes mild" exact="disease" post="and elicits a poor immune response, hence the high"/>
   <result pre="strategies and collective strategies How a virus spreads and its" exact="disease" post="progresses depend not only on the variables described above"/>
   <result pre="the human reactions deployed when people are confronted with a" exact="disease" post="outbreak or the threat of an outbreak. All these"/>
   <result pre="epidemic is not fully characterised by the numbers of known" exact="infections" post="and deaths at the scale of a country. Such"/>
   <result pre="Coping strategies are the actions people and families take when" exact="disease" post="threatens and sickness occurs, including the ways they try"/>
   <result pre="available but also on the understanding and interpretation of the" exact="disease" post="by both the scientific community and the community at"/>
   <result pre="applied and enforced. It clearly had an impact, resulting in" exact="total" post="interruption of transmission locally.54 55 Table 5 Measures recommended"/>
   <result pre="Hand hygiene: handwashing or use of hydroalcoholic solution. Physical distancing." exact="Respiratory" post="etiquette. Masks for infected and symptomatic individuals. Community Mass"/>
   <result pre="hydroalcoholic solution. Physical distancing. Respiratory etiquette. Masks for infected and" exact="symptomatic" post="individuals. Community Mass masking with surgical and/or homemade masks"/>
   <result pre="at first sight seem to reduce transmission opportunities for a" exact="respiratory" post="virus. However, knowledge is lacking about the effectiveness of"/>
   <result pre="consider variable options, public authorities often adopted as ‘blueprint’ with" exact="limited" post="consideration for the socioeconomic context.53 56 The initial lockdown"/>
   <result pre="it became increasingly clear that reaching herd immunity in the" exact="short" post="term was illusive. Most countries thus backed off from"/>
   <result pre="The available information on SARS-CoV-2 and the spectrum of COVID-19" exact="disease" post="is summarised in tables 6 and 7. It is"/>
   <result pre="intensive dissemination. Table 6 Knowns, uncertainties and unknowns about severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), as of May 2020"/>
   <result pre="dissemination. Table 6 Knowns, uncertainties and unknowns about severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), as of May 2020 Factor"/>
   <result pre="Table 6 Knowns, uncertainties and unknowns about severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), as of May 2020 Factor Available"/>
   <result pre="Factor Available information Origin ofSARS-CoV-2 Most probably from bats via" exact="intermediate" post="animal hosts to index case.47 104 All subsequent cases"/>
   <result pre="All subsequent cases resulted from human-to-human transmission. Transmission Mainly through" exact="respiratory" post="droplets from infected persons105; by hands, after contamination at"/>
   <result pre="faecal–oral route108 109; detection in sewage.110–112 Related to peak in" exact="upper" post="respiratory tract viral load prior to symptom onset in"/>
   <result pre="route108 109; detection in sewage.110–112 Related to peak in upper" exact="respiratory" post="tract viral load prior to symptom onset in presymptomatic"/>
   <result pre="detection in sewage.110–112 Related to peak in upper respiratory tract" exact="viral" post="load prior to symptom onset in presymptomatic (paucisymptomatic) persons.106"/>
   <result pre="114 Transmission dynamics in asymptomatic persons not fully elucidated although" exact="viral" post="shedding occurs.115 Influence of climate and/or air pollution on"/>
   <result pre="monoxide, are likely a factor facilitating longevity of virus particles.119" exact="Elevated" post="exposure to common particulate matter can alter host immunity"/>
   <result pre="exposure to common particulate matter can alter host immunity to" exact="respiratory" post="viral infections.119 Immunity—protective antibodies IgM and IgA antibody response"/>
   <result pre="to common particulate matter can alter host immunity to respiratory" exact="viral" post="infections.119 Immunity—protective antibodies IgM and IgA antibody response 5–10"/>
   <result pre="has remained unclear. Rechallenge in rhesus macaques showed immunity post" exact="primary" post="infection.121 How protective immunity after first infection is against"/>
   <result pre="showed immunity post primary infection.121 How protective immunity after first" exact="infection" post="is against subsequent infection with an identical or mutated"/>
   <result pre="infection.121 How protective immunity after first infection is against subsequent" exact="infection" post="with an identical or mutated strain has been uncertain."/>
   <result pre="coronaviruses. Box 3 Relationship between the dose of the initial" exact="infectious" post="inoculum, transmission dynamics and severity of the COVID-19 disease"/>
   <result pre="initial infectious inoculum, transmission dynamics and severity of the COVID-19" exact="disease" post="Hypothesis: The dose of the virus in the initial"/>
   <result pre="the spectrum of the COVID-19 disease. It is plausible that:" exact="Viral" post="dose in inoculum is related to severity of disease."/>
   <result pre="Viral dose in inoculum is related to severity of disease." exact="Severity of" post="disease is related to viral shedding and transmission potential."/>
   <result pre="in inoculum is related to severity of disease. Severity of" exact="disease" post="is related to viral shedding and transmission potential. This"/>
   <result pre="to severity of disease. Severity of disease is related to" exact="viral" post="shedding and transmission potential. This hypothesis plays out potentially"/>
   <result pre="individual level: a person infected with a small dose of" exact="viral" post="inoculum will on average develop milder disease than a"/>
   <result pre="small dose of viral inoculum will on average develop milder" exact="disease" post="than a person infected with a high viral inoculum"/>
   <result pre="develop milder disease than a person infected with a high" exact="viral" post="inoculum and vice versa. At cluster level: a person"/>
   <result pre="and vice versa. At cluster level: a person with asymptomatic" exact="infection" post="or mild disease will on average spread lower doses"/>
   <result pre="At cluster level: a person with asymptomatic infection or mild" exact="disease" post="will on average spread lower doses of virus in"/>
   <result pre="with asymptomatic infection or mild disease will on average spread" exact="lower" post="doses of virus in droplets and aerosols and is"/>
   <result pre="the newly infected person is more likely to have milder" exact="disease" post="than if infected by a severely ill person, who"/>
   <result pre="thing, but how effective it is, is quite another. As" exact="acquired" post="immunity after a natural infection is probably not very"/>
   <result pre="is, is quite another. As acquired immunity after a natural" exact="infection" post="is probably not very robust (table 6), it will"/>
   <result pre="Only once? Or yearly? Will there be any adverse effects?" exact="Acquired" post="immunity is not very strong; hence, what is the"/>
   <result pre="be made mandatory, especially for international travel? LICs/LMICs, low and" exact="lower" post="middle income countries. Regarding the severity of COVID-19, initial"/>
   <result pre="have also lessened. It has progressively become clear that many" exact="infections" post="remain asymptomatic, that severe disease is rare in children"/>
   <result pre="progressively become clear that many infections remain asymptomatic, that severe" exact="disease" post="is rare in children and young adults, and that"/>
   <result pre="of the variables in the transmission of SARS-CoV-2 and the" exact="disease" post="spectrum of COVID-19 could be quantified. This allows for"/>
   <result pre="Predictive models developed by the Imperial College63; the Center for" exact="Disease" post="Dynamics, Economics &amp;amp; Policy and Johns Hopkins University28; the"/>
   <result pre="possible. This will strongly depend on: How strong will the" exact="acquired" post="immunity after a first infection with SARS-CoV-2 be and"/>
   <result pre="on: How strong will the acquired immunity after a first" exact="infection" post="with SARS-CoV-2 be and how long will it last?"/>
   <result pre="SARS-CoV-2 be and how long will it last? Evidence of" exact="acquired" post="immunity against subsequent infections has been limited. Measurable antibodies"/>
   <result pre="long will it last? Evidence of acquired immunity against subsequent" exact="infections" post="has been limited. Measurable antibodies have been observed in"/>
   <result pre="recovered from COVID-19,131 and research in animal models has suggested" exact="limited" post="possibility of reinfection.121 It is still unclear as to"/>
   <result pre="for those recovered from COVID-19 has been ongoing.128 137 How" exact="stable" post="is the virus (mutation) and do the different clades"/>
   <result pre="second and third waves were characterised by a more severe" exact="disease" post="pattern.36 84 What is the role of children in"/>
   <result pre="transmission? Children have quasi-universally presented less severe disease. However, their" exact="susceptibility to" post="infection remains unclear, with large heterogeneity reported between studies.138"/>
   <result pre="have quasi-universally presented less severe disease. However, their susceptibility to" exact="infection" post="remains unclear, with large heterogeneity reported between studies.138 139"/>
   <result pre="where lockdown or more selective measures are equally effective with" exact="lower" post="societal effects. Relationship between the dose of the initial"/>
   <result pre="lower societal effects. Relationship between the dose of the initial" exact="infectious" post="inoculum, transmission dynamics and severity of the COVID-19 disease"/>
   <result pre="initial infectious inoculum, transmission dynamics and severity of the COVID-19" exact="disease" post="New evidence is being discovered rapidly. Some evidence comes"/>
   <result pre="is a relationship between the dose of virus in the" exact="infectious" post="inoculum and the severity of COVID-19 disease. Several intriguing"/>
   <result pre="to create new insight which may influence control strategies. This" exact="viral" post="inoculum theory is consistent with many observations from the"/>
   <result pre="in subsequent waves. In some countries, transmission will continue at" exact="lower" post="levels. In other countries, such as China, the virus"/>
   <result pre="hotter climates the transmission may become continuous, year round at" exact="lower" post="levels. It is increasingly clear that hot climate does"/>
   <result pre="immunity. Individual immunity will dictate how mild or severe the" exact="disease" post="will be in subsequent infections. Herd immunity could be"/>
   <result pre="communities/regions/countries that, in theory, could be fenced off, allowing only" exact="limited" post="interaction with other areas, impacting the spread of the"/>
   <result pre="scale? Conclusion The current first wave is unfolding in the" exact="absence of" post="effective biomedical tools (no vaccine, no effective antiviral or"/>
   <result pre="thankful to Mrs. Ann Byers for editing the manuscript at" exact="short" post="notice. Twitter: @Ingelbeen, @jdossou80, @seyeabimbola, @jarthurk, @@vdbrouwere, @SamehAlawlaqi, @prashanthns"/>
   <result pre="additional data are available. References References 1LuH, StrattonCW, TangYi‐WeiOutbreak of" exact="pneumonia" post="of unknown etiology in Wuhan, China: the mystery and"/>
   <result pre="and the miracle. J Med Virol2020;92:401–2. 10.1002/jmv.2567831950516 2XinhuanetNew-type coronavirus causes" exact="pneumonia" post="in Wuhan: expert; 9 January 2020, 2020 Available: http://www.xinhuanet.com/english/2020-01/09/c_138690570.htm"/>
   <result pre="3ZhuN, ZhangD, WangW, et al.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019. N Engl J Med Overseas Ed2020;382:727–33."/>
   <result pre="of the International Committee on Taxonomy of VirusesThe species severe" exact="acute" post="respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2."/>
   <result pre="the International Committee on Taxonomy of VirusesThe species severe acute" exact="respiratory" post="syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat"/>
   <result pre="5XuZ, ShiL, WangY, et al.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndrome. Lancet Respir Med2020;8:420–2. 10.1016/S2213-2600(20)30076-X32085846 6DingQ, LuP,"/>
   <result pre="ShiL, WangY, et al.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndrome. Lancet Respir Med2020;8:420–2. 10.1016/S2213-2600(20)30076-X32085846 6DingQ, LuP, FanY,"/>
   <result pre="Med2020;8:420–2. 10.1016/S2213-2600(20)30076-X32085846 6DingQ, LuP, FanY, et al.The clinical characteristics of" exact="pneumonia" post="patients coinfected with 2019 novel coronavirus and influenza virus"/>
   <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus–Infected" exact="pneumonia" post="in Wuhan, China. JAMA2020;323:106110.1001/jama.2020.1585 8LiQ, GuanX, WuP, et al.Early"/>
   <result pre="Med Overseas Ed2020;382:1199–207. 10.1056/NEJMoa2001316 9collab: World Health OrganizationNaming the coronavirus" exact="disease" post="(COVID-19) and the virus that causes it, 2020 Available:"/>
   <result pre="https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020 [Accessed 17 Apr 2020]. 11LaiC-C, ShihT-P, KoW-C, et al.Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):"/>
   <result pre="[Accessed 17 Apr 2020]. 11LaiC-C, ShihT-P, KoW-C, et al.Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the"/>
   <result pre="17 Apr 2020]. 11LaiC-C, ShihT-P, KoW-C, et al.Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic"/>
   <result pre="World Health OrganizationReport of the WHO-China joint mission on coronavirus" exact="disease" post="2019 (COVID-19), 2020 Available: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf [Accessed 14 May 2020]."/>
   <result pre="14 May 2020]. 15DanisK, EpaulardO, BénetT, et al.Cluster of coronavirus" exact="disease" post="2019 (Covid-19) in the French Alps, 2020. Clin Infect"/>
   <result pre="a COVID-19 outbreak in Germany resulting from a single travel-associated" exact="primary" post="case: a case series. Lancet Infect Dis202010.1016/S1473-3099(20)30314-5 17ChanJF-W, YuanS,"/>
   <result pre="case series. Lancet Infect Dis202010.1016/S1473-3099(20)30314-5 17ChanJF-W, YuanS, KokK-H, et al.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
   <result pre="Infect Dis202010.1016/S1473-3099(20)30314-5 17ChanJF-W, YuanS, KokK-H, et al.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
   <result pre="Available: https://ourworldindata.org/grapher/total-confirmed-cases-of-covid-19-per-million-people-vs-gdp-per-capita [Accessed 1 Jul 2020]. 28collab: The Center For" exact="Disease" post="Dynamics Economics &amp;amp; PolicyModeling the spread and prevention of"/>
   <result pre="and the world. Respirology2003;8 Suppl:S2–5. 10.1046/j.1440-1843.2003.00516.x15018125 31FuruseY, SuzukiA, OshitaniHOrigin of" exact="measles" post="virus: divergence from rinderpest virus between the 11th and"/>
   <result pre="protective immunity. Lancet2020;395:1527–9. 10.1016/S0140-6736(20)30985-532353328 38PanumPLObservations made during the epidemic of" exact="measles" post="on the Faroe Islands in the year 1846. New"/>
   <result pre="York: Delta Omega Society, 1940. 39RhodesCJ, AndersonRMA scaling analysis of" exact="measles" post="epidemics in a small population. Philos Trans R Soc"/>
   <result pre="WatmoughJReproduction numbers and sub-threshold endemic equilibria for compartmental models of" exact="disease" post="transmission. Math Biosci2002;180:29–48. 10.1016/S0025-5564(02)00108-612387915 45FineP, EamesK, HeymannDL&quot;Herd Immunity&quot;: A"/>
   <result pre="Biosci2002;180:29–48. 10.1016/S0025-5564(02)00108-612387915 45FineP, EamesK, HeymannDL&quot;Herd Immunity&quot;: A Rough Guide. Clinical" exact="Infectious" post="Diseases2011;52:911–6. 10.1093/cid/cir00721427399 46LoutanL, PaillardSMeasles in a West African nomadic"/>
   <result pre="Guide. Clinical Infectious Diseases2011;52:911–6. 10.1093/cid/cir00721427399 46LoutanL, PaillardSMeasles in a West" exact="African" post="nomadic community. Bull World Health Organ1992;70:741–4.1486670 47Z-WY, YuanS, YuenK-S,"/>
   <result pre="herd immunity. To beat COVID-19, we’ll ultimately need it. National" exact="Geographic" post="2020 20 March, 2020 Available: https://www.nationalgeographic.com/science/2020/03/uk-backed-off-on-herd-immunity-to-beat-coronavirus-we-need-it/ [Accessed 30 May"/>
   <result pre="et al.The potential effects of widespread community transmission of SARS-CoV-2" exact="infection" post="in the world Health organization African region: a predictive"/>
   <result pre="community transmission of SARS-CoV-2 infection in the world Health organization" exact="African" post="region: a predictive model. BMJ Glob Health2020;5:e002647. 10.1136/bmjgh-2020-002647 68Van"/>
   <result pre="December 2019. Int J Antimicrob Agents2020;55:10600610.1016/j.ijantimicag.2020.10600632371096 71collab: World Health OrganizationCoronavirus" exact="disease" post="2019 (COVID-19) - Situation Report – 12; 1 February"/>
   <result pre="Apr 2020]. 72HamblinJA Historic Quarantine: China’s attempt to curb a" exact="viral" post="outbreak is a radical experiment in authoritarian medicine. Atlantic2020."/>
   <result pre="radical experiment in authoritarian medicine. Atlantic2020. 73collab: World Health OrganizationCoronavirus" exact="disease" post="2019 (COVID-19) - Situation Report – 41, 2020 Available:"/>
   <result pre="2003 Available: https://www.who.int/csr/don/2003_07_04/en/ [Accessed 17 Apr 2020]. 77collab: Centers for" exact="Disease" post="Control and PreventionSevere Acute Respiratory Syndrome - Singapore, 2003,"/>
   <result pre="17 Apr 2020]. 77collab: Centers for Disease Control and PreventionSevere" exact="Acute" post="Respiratory Syndrome - Singapore, 2003, 2003 Available: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5218a1.htm 78collab:"/>
   <result pre="Apr 2020]. 77collab: Centers for Disease Control and PreventionSevere Acute" exact="Respiratory" post="Syndrome - Singapore, 2003, 2003 Available: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5218a1.htm 78collab: World"/>
   <result pre="2020]. 77collab: Centers for Disease Control and PreventionSevere Acute Respiratory" exact="Syndrome" post="- Singapore, 2003, 2003 Available: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5218a1.htm 78collab: World Health"/>
   <result pre="Apr 2020]. 81collab: World Health OrganizationWHO Risk Assessment of Human" exact="infections" post="with avian influenza A(H7N9) virus, 2015 Available: https://www.who.int/influenza/human_animal_interface/influenza_h7n9/RiskAssessment_H7N9_23Feb20115.pdf?ua=1 [Accessed"/>
   <result pre="81collab: World Health OrganizationWHO Risk Assessment of Human infections with" exact="avian influenza" post="A(H7N9) virus, 2015 Available: https://www.who.int/influenza/human_animal_interface/influenza_h7n9/RiskAssessment_H7N9_23Feb20115.pdf?ua=1 [Accessed 17 Apr 2020]."/>
   <result pre="Available: https://www.who.int/influenza/human_animal_interface/influenza_h7n9/RiskAssessment_H7N9_23Feb20115.pdf?ua=1 [Accessed 17 Apr 2020]. 82collab: World Health OrganizationHuman" exact="infection" post="with avian influenza A(H5N1) virus - update (9 January"/>
   <result pre="[Accessed 17 Apr 2020]. 82collab: World Health OrganizationHuman infection with" exact="avian influenza" post="A(H5N1) virus - update (9 January 2014), 2014 Available:"/>
   <result pre="ChotpitayasunondhT, et al.Clinical aspects of pandemic 2009 influenza A (H1N1)" exact="virus infection." post="N Engl J Med2010;362:1708–19. 10.1056/NEJMra100044920445182 88collab: World Health OrganizationH1N1"/>
   <result pre="90VerityR, OkellLC, DorigattiI, et al.Estimates of the severity of coronavirus" exact="disease" post="2019: a model-based analysis. Lancet Infect Dis2020;20:669–77. 10.1016/S1473-3099(20)30243-732240634 91collab:"/>
   <result pre="Lancet Infect Dis2020;20:669–77. 10.1016/S1473-3099(20)30243-732240634 91collab: Epidemiology Working Group for NCIP" exact="Epidemic" post="Response - Chinese Center for Disease Control and PreventionEpidemiological"/>
   <result pre="Working Group for NCIP Epidemic Response - Chinese Center for" exact="Disease" post="Control and PreventionEpidemiological analysis of new coronavirus pneumonia. Zhonghua"/>
   <result pre="[Chinese]2020;41:145–51. 92WuZ, McGooganJMCharacteristics of and important lessons from the coronavirus" exact="disease" post="2019 (Covid-19) outbreak in China: summary of a report"/>
   <result pre="a report of 72 314 cases from the Chinese center for" exact="disease" post="control and prevention. JAMA2020. [Epub ahead of print: 24"/>
   <result pre="93MizumotoK, KagayaK, ZarebskiA, et al.Estimating the asymptomatic proportion of coronavirus" exact="disease" post="2019 (COVID-19) cases on board the diamond Princess cruise"/>
   <result pre="SHIP, Yokohama, Japan, 2020. Euro Surveill2020;2510.2807/1560-7917.ES.2020.25.10.2000180 94collab: National Institute of" exact="Infectious" post="Diseases (NIID)Field Briefing: diamond Princess COVID-19 cases, 2020 Available:"/>
   <result pre="Yokohama, Japan, 2020. Euro Surveill2020;2510.2807/1560-7917.ES.2020.25.10.2000180 94collab: National Institute of Infectious" exact="Diseases" post="(NIID)Field Briefing: diamond Princess COVID-19 cases, 2020 Available: https://www.niid.go.jp/niid/en/2019-ncov-e/9417-covid-dp-fe-02.html"/>
   <result pre="MiyamaT, et al.Estimation of the asymptomatic ratio of novel coronavirus" exact="infections" post="(COVID-19). Int J Infect Dis2020;94:154–5. 10.1016/j.ijid.2020.03.02032179137 96HeneghanC, BrasseyJ, JeffersonT,"/>
   <result pre="BrasseyJ, JeffersonT, collab: Centre for Evidence-Based Medicine, Nuffield Department of" exact="Primary" post="Care Health Sciences, University of OxfordCOVID-19: What proportion are"/>
   <result pre="Engl J Med2020;382:1268–9. 10.1056/NEJMe200238732109011 98RussellTW, HellewellJ, JarvisCI, et al.Estimating the" exact="infection" post="and case fatality ratio for coronavirus disease (COVID-19) using"/>
   <result pre="et al.Estimating the infection and case fatality ratio for coronavirus" exact="disease" post="(COVID-19) using age-adjusted data from the outbreak on the"/>
   <result pre="Mar 310.1053/j.gastro.2020.02.054 109XuY, LiX, ZhuB, et al.Characteristics of pediatric SARS-CoV-2" exact="infection" post="and potential evidence for persistent fecal viral shedding. Nat"/>
   <result pre="of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal" exact="viral" post="shedding. Nat Med2020;26:502–5. 10.1038/s41591-020-0817-432284613 110MedemaG, HeijnenL, ElsingaG, et al.Presence"/>
   <result pre="for the wastewater surveillance of COVID-19 in the community. Sci" exact="Total" post="Environ2020;728:138764. 10.1016/j.scitotenv.2020.13876432387778 112LodderW, de Roda HusmanAMSARS-CoV-2 in wastewater: potential"/>
   <result pre="contact tracing. Science2020;368:eabb693610.1126/science.abb693632234805 115HeX, LauEHY, WuP, et al.Temporal dynamics in" exact="viral" post="shedding and transmissibility of COVID-19. Nat Med2020;26:672–5. 10.1038/s41591-020-0869-532296168 116AraujoMB,"/>
   <result pre="119MartellettiL, MartellettiPAir pollution and the novel Covid-19 disease: a putative" exact="disease" post="risk factor. SN Compr Clin Med2020:1–5. 10.1007/s42399-020-00274-4 120GuoL, RenL,"/>
   <result pre="YangS, et al.Profiling early humoral response to diagnose novel coronavirus" exact="disease" post="(COVID-19). Clin Infect Dis2020;2410.1093/cid/ciaa310 121BaoL, DengW, GaoH, et al.Reinfection"/>
   <result pre="of early SARS-CoV-2 serosurveys. medRxiv2020. 125OkbaNMA, MüllerMA, LiW, et al.Severe" exact="acute" post="respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease"/>
   <result pre="early SARS-CoV-2 serosurveys. medRxiv2020. 125OkbaNMA, MüllerMA, LiW, et al.Severe acute" exact="respiratory" post="syndrome coronavirus 2-specific antibody responses in coronavirus disease patients."/>
   <result pre="SARS-CoV-2 serosurveys. medRxiv2020. 125OkbaNMA, MüllerMA, LiW, et al.Severe acute respiratory" exact="syndrome" post="coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg"/>
   <result pre="al.Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus" exact="disease" post="patients. Emerg Infect Dis2020;26:1478–88. 10.3201/eid2607.20084132267220 126GorseGJ, PatelGB, VitaleJN, et"/>
   <result pre="VitaleJN, et al.Prevalence of antibodies to four human coronaviruses is" exact="lower" post="in nasal secretions than in serum. CVI2010;17:1875–80. 10.1128/CVI.00278-1020943876 127TheelES,"/>
   <result pre="TrapmanP, BallFGThe disease-induced herd immunity level for Covid-19 is substantially" exact="lower" post="than the classical herd immunity level. medRxiv2020. 130GomesMGM, CorderRM,"/>
   <result pre="COVID-19. JAMA2020;323:1406–7. 10.1001/jama.2020.2565 141RotheC, SchunkM, SothmannP, et al.Transmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in Germany. N Engl J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7395586/results/search/disease/results.xml">
   <result pre="Research pmcid: 7395586S0025-6196(20)30544-9 doi: 10.1016/j.mayocp.2020.05.028 : Article Indoor Environment and" exact="Viral" post="Infections ClementsNicholasPhDabBinnickerMatthew J.PhDcRogerVéronique L.MD, MPHroger.veronique@mayo.eduade∗[a], [b], [c], [d], [e],"/>
   <result pre="pmcid: 7395586S0025-6196(20)30544-9 doi: 10.1016/j.mayocp.2020.05.028 : Article Indoor Environment and Viral" exact="Infections" post="ClementsNicholasPhDabBinnickerMatthew J.PhDcRogerVéronique L.MD, MPHroger.veronique@mayo.eduade∗[a], [b], [c], [d], [e], ∗Correspondence:"/>
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="COVID-19 resource centre remains active. The global pandemic of severe" exact="acute" post="respiratory coronavirus 2 (SARS-CoV-2) (ie, the cause of COVID-19)"/>
   <result pre="resource centre remains active. The global pandemic of severe acute" exact="respiratory" post="coronavirus 2 (SARS-CoV-2) (ie, the cause of COVID-19) has"/>
   <result pre="a major impact on overall health. It affects risk of" exact="disease" post="through multiple factors,including indoor air pollutants; surface contamination with"/>
   <result pre="science, differ markedly according to the pathogen of interest. For" exact="viral" post="transmission, the role of temperature and humidity has received"/>
   <result pre="received particular attention. These relationships are critically important for predicting" exact="infection" post="growth rates and to counsel people on possible home"/>
   <result pre="on possible home interventions that could be deployed to mitigate" exact="viral" post="transmission. The purpose of this perspective is to discuss"/>
   <result pre="implications for current practice and future research. Environmental Factors and" exact="Viral" post="Transmission Environmental factors—such as temperature, humidity, and ventilation—play a"/>
   <result pre="viruses and can alter human defense mechanisms that protect against" exact="respiratory" post="pathogens.5 Animal experiments have demonstrated a link between temperature"/>
   <result pre="have demonstrated a link between temperature and relative humidity and" exact="viral" post="transmission, with a greater persistence and infectivity of influenza"/>
   <result pre="been evoked including reduction of mucociliary clearance by desiccation of" exact="upper" post="airways, increased stability of viruses with a lipid envelope"/>
   <result pre="humidity are also believed to increase the transmission of other" exact="respiratory" post="viruses, including respiratory syncytial virus (RSV), human rhinovirus, and"/>
   <result pre="believed to increase the transmission of other respiratory viruses, including" exact="respiratory" post="syncytial virus (RSV), human rhinovirus, and avian influenza virus.7"/>
   <result pre="respiratory viruses, including respiratory syncytial virus (RSV), human rhinovirus, and" exact="avian influenza" post="virus.7 A recent systematic analysis of 37,335 studies reported"/>
   <result pre="In contrast, RSV activity was higher when the temperature was" exact="lower" post="than average. This important work illustrates the complexity of"/>
   <result pre="This important work illustrates the complexity of the mechanisms of" exact="viral" post="persistence and transmission and the importance of considering the"/>
   <result pre="considering the impact of environmental factors on a virus-by-virus basis.7" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus"/>
   <result pre="the impact of environmental factors on a virus-by-virus basis.7 Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that"/>
   <result pre="impact of environmental factors on a virus-by-virus basis.7 Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes"/>
   <result pre="of environmental factors on a virus-by-virus basis.7 Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19."/>
   <result pre="currently a topic of growing interest.9,10 The virus may remain" exact="infectious" post="in aerosols for hours and on surfaces up to"/>
   <result pre="A recent study used weather data and global reports of" exact="infection" post="to model COVID-19 growth rate before any intervention. This"/>
   <result pre="to the assumption of a substantial seasonal reprieve of the" exact="infection" post="rates. Practical Recommendations Interventions on environmental factors to mitigate"/>
   <result pre="infection rates. Practical Recommendations Interventions on environmental factors to mitigate" exact="viral" post="transmission must be grounded in science. Indoor humidity and"/>
   <result pre="than 5% and therefore adequate for typical residential use. The" exact="American" post="Society of Heating, Refrigeration, and Air-Conditioning Engineers (ASHRAE) recommends"/>
   <result pre="21st centuryAm J Public Health93920031489149312948968 2BrookR.D.RajagopalanS.PopeC.A.3rdParticulate matter air pollution and" exact="cardiovascular" post="disease: an update to the scientific statement from the"/>
   <result pre="cardiovascular disease: an update to the scientific statement from the" exact="American" post="Heart AssociationCirculation1212120102331237820458016 3HuangJ.SongY.ChuM.Cardiorespiratory responses to low-level ozone exposure: the"/>
   <result pre="disease: an update to the scientific statement from the American" exact="Heart" post="AssociationCirculation1212120102331237820458016 3HuangJ.SongY.ChuM.Cardiorespiratory responses to low-level ozone exposure: the inDoor"/>
   <result pre="in COPD patients and healthy elderly adultsIndoor Air292201919220130427075 5MoriyamaM.HugentoblerW.J.IwasakiA.Seasonality of" exact="respiratory" post="viral infectionsAnnu Rev Virol202010.1146/annurev-virology-012420-022445 6LowenA.C.MubarekaS.SteelJ.PaleseP.Influenza virus transmission is dependent"/>
   <result pre="COPD patients and healthy elderly adultsIndoor Air292201919220130427075 5MoriyamaM.HugentoblerW.J.IwasakiA.Seasonality of respiratory" exact="viral" post="infectionsAnnu Rev Virol202010.1146/annurev-virology-012420-022445 6LowenA.C.MubarekaS.SteelJ.PaleseP.Influenza virus transmission is dependent on"/>
   <result pre="Environ Health2213201837639029398406 8LiY.ReevesR.M.WangX.Global patterns in monthly activity of influenza virus," exact="respiratory" post="syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysisLancet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7402518/results/search/disease/results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Bunyaviruses:" exact="Rift Valley fever" post="virus : Biology and life sciences : Microbiology :"/>
   <result pre="sciences : Microbiology : Medical microbiology : Microbial pathogens :" exact="Viral" post="pathogens : Bunyaviruses: Rift Valley fever virus : Medicine"/>
   <result pre="Medical microbiology : Microbial pathogens : Viral pathogens : Bunyaviruses:" exact="Rift Valley fever" post="virus : Medicine and health sciences : Pathology and"/>
   <result pre="Pathology and laboratory medicine : Pathogens : Microbial pathogens :" exact="Viral" post="pathogens : Bunyaviruses: Rift Valley fever virus : Biology"/>
   <result pre=": Pathogens : Microbial pathogens : Viral pathogens : Bunyaviruses:" exact="Rift Valley fever" post="virus : Biology and life sciences : Organisms :"/>
   <result pre=": Biology and life sciences : Organisms : Viruses :" exact="Viral" post="pathogens : Bunyaviruses: Rift Valley fever virus : Biology"/>
   <result pre="sciences : Organisms : Viruses : Viral pathogens : Bunyaviruses:" exact="Rift Valley fever" post="virus : Biology and life sciences : Organisms :"/>
   <result pre="Sciences : Microbiology : Medical Microbiology : Microbial Pathogens :" exact="Viral" post="Pathogens : Togaviruses : Alphaviruses: Chikungunya Virus : Medicine"/>
   <result pre="Pathology and Laboratory Medicine : Pathogens : Microbial Pathogens :" exact="Viral" post="Pathogens : Togaviruses : Alphaviruses: Chikungunya Virus : Biology"/>
   <result pre=": Biology and Life Sciences : Organisms : Viruses :" exact="Viral" post="Pathogens : Togaviruses : Alphaviruses: Chikungunya Virus : Biology"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Sciences : Microbiology : Medical Microbiology : Microbial Pathogens :" exact="Viral" post="Pathogens : Flaviviruses: Dengue Virus : Medicine and Health"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre="Pathology and Laboratory Medicine : Pathogens : Microbial Pathogens :" exact="Viral" post="Pathogens : Flaviviruses: Dengue Virus : Biology and Life"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre=": Biology and Life Sciences : Organisms : Viruses :" exact="Viral" post="Pathogens : Flaviviruses: Dengue Virus : People and Places"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : People and Places : Geographical Locations :"/>
   <result pre=": Medicine and Health Sciences : Medical Conditions : Tropical" exact="Diseases" post=": Neglected Tropical Diseases: Chikungunya Infection : Medicine and"/>
   <result pre="Medical Conditions : Tropical Diseases : Neglected Tropical Diseases: Chikungunya" exact="Infection" post=": Medicine and Health Sciences : Medical Conditions :"/>
   <result pre="Infection : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases : Viral Diseases: Chikungunya Infection : Medicine and"/>
   <result pre=": Medicine and Health Sciences : Medical Conditions : Infectious" exact="Diseases" post=": Viral Diseases: Chikungunya Infection : Medicine and Health"/>
   <result pre="and Health Sciences : Medical Conditions : Infectious Diseases :" exact="Viral" post="Diseases: Chikungunya Infection : Medicine and Health Sciences :"/>
   <result pre=": Medical Conditions : Infectious Diseases : Viral Diseases: Chikungunya" exact="Infection" post=": Medicine and Health Sciences : Medical Conditions :"/>
   <result pre="Infection : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases : Viral Diseases: Arboviral Infections : Biology and"/>
   <result pre=": Medicine and Health Sciences : Medical Conditions : Infectious" exact="Diseases" post=": Viral Diseases: Arboviral Infections : Biology and Life"/>
   <result pre="and Health Sciences : Medical Conditions : Infectious Diseases :" exact="Viral" post="Diseases: Arboviral Infections : Biology and Life Sciences :"/>
   <result pre=": Medical Conditions : Infectious Diseases : Viral Diseases: Arboviral" exact="Infections" post=": Biology and Life Sciences : Agriculture : Animal"/>
   <result pre=": Animal Management: Livestock : Research and Analysis Methods :" exact="Immunologic" post="Techniques : Immunoassays: Enzyme-Linked Immunoassays Serological evidence of exposure"/>
   <result pre="Immunoassays: Enzyme-Linked Immunoassays Serological evidence of exposure to Rift Valley," exact="Dengue" post="and Chikungunya Viruses among agropastoral communities in Manyara and"/>
   <result pre="in Tanzania: A community survey Serological evidence of Rift Valley," exact="Dengue" post="and Chikungunya Viruses in Tanzania BudodoRule M.InvestigationMethodologyWriting – review"/>
   <result pre="and Research, Lugalo Military College of Medical Sciences (MCMS) and" exact="General" post="Military Hospital (GMH), Dar es Salaam, Tanzania[3], Department of"/>
   <result pre="Tanzania[5], Tanzania Veterinary Laboratory Agency (TVLA), Kibaha, TanzaniaAlthouseBenjaminEditor[], Institute for" exact="Disease" post="Modeling, UNITED STATES The authors have declared that no"/>
   <result pre="of Dar es Salaam and Tanga. Chikungunya and Rift Valley" exact="Fever" post="outbreaks have also been recorded in the past decade."/>
   <result pre="decade. Little is known on the burden of the arboviral" exact="disease" post="causing viruses (Dengue, Rift Valley and Chikungunya) endemically in"/>
   <result pre="at determining the prevalence of the dengue, rift valley and" exact="chikungunya" post="among humans in two geo ecologically distinct sites. The"/>
   <result pre="socio-demographic information. Data analysis was performed by using SPSSv22. A" exact="total" post="of 191 individuals from both sites participated in the"/>
   <result pre="All samples were negative by RVFV and CHIKV qPCR. Neither" exact="infection" post="nor exposure to DENV was observed in participants from"/>
   <result pre="CHIKV among Wami-Dakawa residents during the dry season and an" exact="absence of" post="exposure of the viruses among humans in Magugu site."/>
   <result pre="in Magugu site. In both sites, neither DENV exposure nor" exact="infection" post="was detected. Author summary Dengue (DENV), Chikungunya (CHIKV), Rift"/>
   <result pre="sites, neither DENV exposure nor infection was detected. Author summary" exact="Dengue" post="(DENV), Chikungunya (CHIKV), Rift Valley (RVFV) viruses and other"/>
   <result pre="in Tanzania, DENV outbreaks have been more frequent since 2010." exact="CHIKV infection" post="is an important but largely unrecognized illness in Tanzania."/>
   <result pre="Tanzania, DENV outbreaks have been more frequent since 2010. CHIKV" exact="infection" post="is an important but largely unrecognized illness in Tanzania."/>
   <result pre="we aimed to generate baseline data on the exposure and" exact="infection" post="status of DENV, RVFV and CHIKV by detecting antibodies"/>
   <result pre="viruses in human subjects in two geo-ecologically distinct sites. Neither" exact="infection" post="nor exposure to the viruses was in observed in"/>
   <result pre="to undertake active surveillance for RVFV, DENV, CHIKV and other" exact="viral" post="agents in Tanzania. Funding International Center for Genetic Engineering"/>
   <result pre="Center for Genetic Engineering and Biotechnology (ICGEB)[https://www.icgeb.org]CRP/TZA18-04http://orcid.org/0000-0003-2997-6747ChilongolaJaffu O. The East" exact="African" post="Consortium for Clinical Research (EACCR- 2)[https://eaccr.org]EDCTP-RegNet2015-1104TMmbagaBlandina T. This study"/>
   <result pre="and Biotechnology (ICGEB), Grant #CRP/TZA18-04 to JOC and The East" exact="African" post="Consortium for Clinical Research (EACCR-2) grant # EDCTP-RegNet2015-1104T through"/>
   <result pre="The ecological drivers of the pattern and frequency of virus" exact="infections" post="(and subsequent epidemics) in the different host species are"/>
   <result pre="health concern due to their rapid geographical spread and increasing" exact="disease" post="burden. The transmission of these viruses is complicated by"/>
   <result pre="internal displacement due to environmental and civil unrest in many" exact="African" post="countries and the triad of the modern world: urbanization,"/>
   <result pre="and its clinical presentations are similar to several flavivirus infections[9–12]." exact="Dengue" post="virus has caused major epidemics in Southeast Asia and"/>
   <result pre="virus has caused major epidemics in Southeast Asia and Southern" exact="American" post="countries in past centuries [8]. In the Americas, dengue"/>
   <result pre="at different weather conditions annually. Arboviruses are primarily maintained by" exact="horizontal" post="transmission (HT) between arthropod vectors and vertebrate hosts in"/>
   <result pre="are transmitted vertically in the vector population from an infected" exact="female" post="to the offspring, which is a proposed maintenance mechanism"/>
   <result pre="further impact on the distribution of vector-borne diseases, such as" exact="Rift Valley fever" post="and dengue, which are highly sensitive to climatic conditions"/>
   <result pre="This study was therefore, carried out to establish exposure and" exact="infection" post="status of RVFV, DENV and CHIKV in two geo-ecologically"/>
   <result pre="CHIKV in two geo-ecologically distinct sites in North Eastern and" exact="Central" post="Eastern Tanzania during the dry season to generate baseline"/>
   <result pre="annual rainfall is about 650mm. There are two rainy seasons," exact="short" post="rainy season from October to December and long rainy"/>
   <result pre="climate with an average annual rainfall of 800 mm. The" exact="short" post="rains start in November and end in January followed"/>
   <result pre="is crop production and livestock keeping. Participants This study included" exact="adult" post="residents (≥18 years), males and females of the two"/>
   <result pre="to participate in the interviews. Salaried and other individuals whose" exact="primary" post="occupation was not either agriculture or livestock keeping were"/>
   <result pre="or livestock keeping were excluded from participating in the study." exact="Blood" post="samples collection, processing and storage of specimens From each"/>
   <result pre="against RVFV using a competitive ELISA (ID Screen Rift Valley" exact="Fever" post="Competition Multi Species, ID-vet, Grables, France), which detects both"/>
   <result pre="Ribonucleic acid extraction and RT-PCR procedures For DENV and CHIKV," exact="Blood" post="samples kept in EDTA tubes were centrifuging at 1,000"/>
   <result pre="RVFV detection, RNA was extracted from sera using a QIAamp" exact="viral" post="RNA mini kit (QIAGEN, Germany) as per manufacturer’s instructions."/>
   <result pre="from the multivariate model were reported. Results Descriptive statistics A" exact="total" post="of 191 samples were collected, 122 from Wami-Dakawa and"/>
   <result pre="travelled having travelled to an urban destination (Table 1). A" exact="total" post="of 60 (49.2%) participants had herd sizes made of"/>
   <result pre="1 Demographic characteristics of participants. Family Characteristics Number Percent Sex" exact="Female" post="49 40.2 Male 73 59.8 Age in years (mean"/>
   <result pre="where Rural 15 31.25 Urban 33 68.75 Highest education received" exact="Primary" post="School or Higher 43 35.3 No formal education 79"/>
   <result pre="linked immunosorbent assay results for IgM/IgG antibodies to Rift Valley" exact="Fever" post="Virus and Chikungunya viruses. Total tested Rift Valley Fever"/>
   <result pre="IgM/IgG antibodies to Rift Valley Fever Virus and Chikungunya viruses." exact="Total" post="tested Rift Valley Fever IgG/IgM seropositivity Chikungunya IgM/IgG seropositivity"/>
   <result pre="Valley Fever Virus and Chikungunya viruses. Total tested Rift Valley" exact="Fever" post="IgG/IgM seropositivity Chikungunya IgM/IgG seropositivity +ve % 95% C.I."/>
   <result pre="Fever IgG/IgM seropositivity Chikungunya IgM/IgG seropositivity +ve % 95% C.I." exact="Total" post="tested +ve % 95% C.I. Low Up Low Up"/>
   <result pre="122 12 9.83 4.9 15.7 Risk factors for Rift Valley" exact="Fever" post="Virus IgG/IgM seropositivity Compared to participants aged 30 years"/>
   <result pre="of people &amp;lt;5 1 ≥5 2.15 0.038 2.43 5.10 Education" exact="Primary" post="school or higher 1 No formal education 1.90 0.029"/>
   <result pre="of people &amp;lt;5 1 ≥5 3.5 0.033 1.6 4.84 Education" exact="Primary" post="school or higher 1 No formal education 2.85 0.041"/>
   <result pre="humans. The study also pursued to identify potential predictors of" exact="infection" post="by the viruses and seropositivity to the viruses during"/>
   <result pre="recurrence of RVF in Tanzania has been documented whereby the" exact="disease" post="has been recurring in approximately ten-year cycles with three"/>
   <result pre="unknown. Classically, the RVFV cycle involves domestic animals (livestock) as" exact="viral" post="amplifying hosts before transmission to humans, as has previously"/>
   <result pre="transmission to humans, as has previously been shown in many" exact="African" post="countries[25]. The ecology of the Wami-Dakawa area and life"/>
   <result pre="target for the control of RVF and other vector borne" exact="viral" post="infections. We detected none of the studied viruses by"/>
   <result pre="none of the studied viruses by PCR, and observed an" exact="absence of" post="seropositive individuals to any of the viruses in the"/>
   <result pre="the relative &quot;sterility&quot; of the Magugu site to mosquito borne" exact="infections" post="warrants an epidemiological explanation owing to the otherwise conducive"/>
   <result pre="reasons could explain this observation in our study, including the" exact="absence of" post="mosquito species composition in the area and the limited"/>
   <result pre="absence of mosquito species composition in the area and the" exact="limited" post="sample size. Previous studies on mosquito borne infections in"/>
   <result pre="and the limited sample size. Previous studies on mosquito borne" exact="infections" post="in Magugu had reported a similar state of sterility"/>
   <result pre="had reported a similar state of sterility for mosquito borne" exact="infections" post="for the past decade[26–30]. Recent epidemiological data on CHIKV"/>
   <result pre="that involves a rich day to day human interactions. The" exact="absence of" post="data on presence or abundancy of Aedes mosquitoes in"/>
   <result pre="seasons of the year to get an insight of how" exact="infection" post="and seroconversion may vary as a means of RVFV,"/>
   <result pre="a means of RVFV, DENV and CHIKV maintenance in the" exact="absence of" post="outbreaks. Certain factors were associated with higher rates of"/>
   <result pre="outbreaks. Certain factors were associated with higher rates of RVFV" exact="infection" post="as determined by IgM/IgG competitive ELISA, including household size"/>
   <result pre="and having no formal education. RVFV is a mosquito borne," exact="viral" post="zoonotic infection whose transmission involves both vector mosquitoes and"/>
   <result pre="no formal education. RVFV is a mosquito borne, viral zoonotic" exact="infection" post="whose transmission involves both vector mosquitoes and intimate contact"/>
   <result pre="this study were mainly rural area, justifying the possibility of" exact="absence of" post="conducive conditions for transmission of the viruses as evidenced"/>
   <result pre="conditions for transmission of the viruses as evidenced by the" exact="absence of" post="any active DENV and CHIKV case. Although our study"/>
   <result pre="any active DENV and CHIKV case. Although our study is" exact="limited" post="by the small sample size due to convenience and"/>
   <result pre="RVFV, DENV and CHIKV in the studied areas. While the" exact="absence of" post="entomological data in this report may be a limitation,"/>
   <result pre="DENV. Magugu site was found to be free from both" exact="infection" post="and exposure to RVFV, CHIKV and DENV. Larger numbers"/>
   <result pre="undertake active surveillance measures for RVFV, DENV, CHIKV and other" exact="viral" post="agents in endemic countries. In addition, since our study"/>
   <result pre="CroppBC, et al.Sylvatic transmission of arboviruses among Bornean orangutans. The" exact="American" post="journal of tropical medicine and hygiene2001; 64(5):310–316.11463123 2GlDauphin, SpZientara,"/>
   <result pre="current situation in animals and humans. Comparative immunology, microbiology and" exact="infectious" post="diseases2004; 27(5):343–355. 10.1016/j.cimid.2004.03.00915225984 3NanyingiMO, MunyuaP, KiamaSG, MuchemiGM, ThumbiSM, BitekAO,"/>
   <result pre="MuchemiGM, ThumbiSM, BitekAO, et al.A systematic review of Rift Valley" exact="Fever" post="epidemiology 1931ΓÇô2014. Infection ecology &amp;amp; epidemiology2015; 5(1):28024.26234531 4NanyingiMO, MuchemiGM,"/>
   <result pre="et al.A systematic review of Rift Valley Fever epidemiology 1931ΓÇô2014." exact="Infection" post="ecology &amp;amp; epidemiology2015; 5(1):28024.26234531 4NanyingiMO, MuchemiGM, ThumbiSM, AdeF, OnyangoCO,"/>
   <result pre="MuchemiGM, ThumbiSM, AdeF, OnyangoCO, KiamaSG, et al. Seroepidemiological survey of" exact="Rift Valley fever" post="virus in ruminants in Garissa, Kenya. Vector-Borne and Zoonotic"/>
   <result pre="ZakiSR, ShiehWJ, PaweskaJ, et al.Epidemiologic and clinical aspects of a" exact="Rift Valley fever" post="outbreak in humans in Tanzania, 2007. The American journal"/>
   <result pre="Rift Valley fever outbreak in humans in Tanzania, 2007. The" exact="American" post="journal of tropical medicine and hygiene2010; 83(2_Suppl):22–27.20682902 10LequimeS, PaulRE,"/>
   <result pre="al.Early appearance of neutralizing immunoglobulin G3 antibodies is associated with" exact="chikungunya" post="virus clearance and long-term clinical protection. Journal of Infectious"/>
   <result pre="with chikungunya virus clearance and long-term clinical protection. Journal of" exact="Infectious" post="Diseases2012; 205(7):1147–1154. 10.1093/infdis/jis03322389226 12ChipwazaB, MugasaJP, SelemaniM, AmuriM, MoshaF, NgatungaSD,"/>
   <result pre="10.1093/infdis/jis03322389226 12ChipwazaB, MugasaJP, SelemaniM, AmuriM, MoshaF, NgatungaSD, et al.Dengue and" exact="Chikungunya fever" post="among viral diseases in outpatient febrile children in Kilosa"/>
   <result pre="SelemaniM, AmuriM, MoshaF, NgatungaSD, et al.Dengue and Chikungunya fever among" exact="viral" post="diseases in outpatient febrile children in Kilosa district hospital,"/>
   <result pre="hemorrhagic fever: the emergence of a global health problem. Emerging" exact="infectious" post="diseases1995; 1(2):5510.3201/eid0102.9520048903160 14Louren+ºoJ, ReckerM. Viral and epidemiological determinants of"/>
   <result pre="a global health problem. Emerging infectious diseases1995; 1(2):5510.3201/eid0102.9520048903160 14Louren+ºoJ, ReckerM." exact="Viral" post="and epidemiological determinants of the invasion dynamics of novel"/>
   <result pre="WeyerJ, le RouxC, MandlazeA, Jos+¬ ArF, et al.Serological evidence of" exact="Rift Valley fever" post="virus among acute febrile patients in Southern Mozambique during"/>
   <result pre="ArF, et al.Serological evidence of Rift Valley fever virus among" exact="acute" post="febrile patients in Southern Mozambique during and after the"/>
   <result pre="impact of climate change on the epidemiology and control of" exact="Rift Valley fever." post="Revue Scientifique et Technique-Officeinternational des +¬pizooties2008; 27(2):413–426. 17KajegukaDC, KaayaRD,"/>
   <result pre="KaayaRD, MwakalingaS, NdossiR, NdaroA, ChilongolaJO, et al.Prevalence of dengue and" exact="chikungunya" post="virus infections in north-eastern Tanzania: a cross sectional study"/>
   <result pre="NdossiR, NdaroA, ChilongolaJO, et al.Prevalence of dengue and chikungunya virus" exact="infections" post="in north-eastern Tanzania: a cross sectional study among participants"/>
   <result pre="cross sectional study among participants presenting with malaria-like symptoms. BMC" exact="infectious" post="diseases2016; 16(1):183.27112553 18WensmanJJ, LindahlJ, WachtmeisterN, TorssonE, GwakisaP, KasangaC, et"/>
   <result pre="18WensmanJJ, LindahlJ, WachtmeisterN, TorssonE, GwakisaP, KasangaC, et al.A study of" exact="Rift Valley fever" post="virus in Morogoro and Arusha regions of TanzaniaΓÇôserology and"/>
   <result pre="in Morogoro and Arusha regions of TanzaniaΓÇôserology and farmersΓÇÖ perceptions." exact="Infection" post="ecology &amp;amp; epidemiology2015; 5(1):30025.26584830 19DerksenS, KeselmanHJ. Backward, forward and"/>
   <result pre="characteristics of dengue outbreak, Dar es Salaam, Tanzania, 2014. Emerging" exact="infectious" post="diseases2016; 22(5):89510.3201/eid2205.15146227088845 23SwaiES, SchoonmanL. Prevalence of Rift Valley fever"/>
   <result pre="Tanzania, 2014. Emerging infectious diseases2016; 22(5):89510.3201/eid2205.15146227088845 23SwaiES, SchoonmanL. Prevalence of" exact="Rift Valley fever" post="immunoglobulin G antibody in various occupational groups before the"/>
   <result pre="Tanzania journal of health research2011; 13(5). 25CoetzerJA. The pathology of" exact="Rift Valley fever." post="II. Lesions occurring in field cases in adult cattle,"/>
   <result pre="Rift Valley fever. II. Lesions occurring in field cases in" exact="adult" post="cattle, calves and aborted foetuses. 1982. 26ChilongolaJ, KombeS, HorumpendeP,"/>
   <result pre="SabuniE, NdaroA, et al.Prevalence of Plasmodium falciparum and Salmonella typhi" exact="Infection" post="and Coinfection and Their Association With Fever in Northern"/>
   <result pre="and Salmonella typhi Infection and Coinfection and Their Association With" exact="Fever" post="in Northern Tanzania. EA Health Research Journal2018; 2(2):147–155. 27DaouM,"/>
   <result pre="MoshaF, van der VenA, et al.+¦-Thalassaemia trait is associated with" exact="Antibody" post="prevalence against Malaria Antigens AMA-1 and MSP-1. Journal of"/>
   <result pre="VenA, et al.+¦-Thalassaemia trait is associated with Antibody prevalence against" exact="Malaria" post="Antigens AMA-1 and MSP-1. Journal of tropical pediatrics2015; 61(2):139–142."/>
   <result pre="tropical pediatrics2015; 61(2):139–142. 10.1093/tropej/fmu07725604491 28FaustineNL, SabuniEJ, NdaroAJ, PaulE, ChilongolaJO. Chikungunya," exact="Dengue" post="and West Nile Virus Infections in Northern Tanzania. Journal"/>
   <result pre="SabuniEJ, NdaroAJ, PaulE, ChilongolaJO. Chikungunya, Dengue and West Nile Virus" exact="Infections" post="in Northern Tanzania. Journal of Advances in Medicine and"/>
   <result pre="Medical Research2017:1–7. 29MwanzivaC, ManjuranoA, MbugiE, MweyaC, MkaliH, KivuyoMP, et al.Defining" exact="malaria" post="burden from morbidity and mortality records, self treatment practices"/>
   <result pre="30MwanzivaCE, KitauJ, TunguPK, MweyaCN, MkaliH, NdegeCM, et al.Transmission intensity and" exact="malaria" post="vector population structure in Magugu, Babati District in northern"/>
   <result pre="31LaBeaudADe, MuiruriS, SutherlandLJ, DahirS, GildengorinG, MorrillJ, et al.Postepidemic analysis of" exact="Rift Valley fever" post="virus transmission in northeastern Kenya: a village cohort study."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7402651/results/search/disease/results.xml">
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="the spread of HIV could be prevented and potentially, the" exact="HIV/AIDS" post="epidemic could be ended.3 However, progress towards the HIV/AIDS"/>
   <result pre="the HIV/AIDS epidemic could be ended.3 However, progress towards the" exact="HIV/AIDS" post="90-90-90 targets has not been equally distributed across subpopulations,"/>
   <result pre="1 year period, the authors introduced a UTT intervention in" exact="adult" post="correctional facilities and tracked time to ART initiation and"/>
   <result pre="adult correctional facilities and tracked time to ART initiation and" exact="viral" post="load suppression at 6 months and 12 months follow-up"/>
   <result pre="the 6 month follow-up analysis who had at least one" exact="viral" post="load result documented, 262 (97%) had achieved viral suppression"/>
   <result pre="least one viral load result documented, 262 (97%) had achieved" exact="viral" post="suppression (&amp;lt;1000 copies per mL) at 6 months. Through"/>
   <result pre="in care, the proportion of the prison cohort who achieved" exact="viral" post="load suppression was similar to that observed in other"/>
   <result pre="viral load suppression was similar to that observed in other" exact="African" post="community-based trials for treatment-as-prevention (up to 88% of individuals"/>
   <result pre="the coronavirus epidemic in the community are developed—aggressive testing of" exact="symptomatic" post="and asymptomatic people with contact tracing—the same standard of"/>
   <result pre="can the role of prisons and jails as reservoirs of" exact="viral infection" post="be minimised. Failure to control and prevent the spread"/>
   <result pre="the role of prisons and jails as reservoirs of viral" exact="infection" post="be minimised. Failure to control and prevent the spread"/>
   <result pre="prisons and jails as reservoirs of viral infection be minimised." exact="Failure" post="to control and prevent the spread of viruses within"/>
   <result pre="result in health-care costs similar to that observed with COVID-19" exact="disease" post="in the past 3–4 months and the ongoing HIV"/>
   <result pre="of health for all must be adopted universally to prevent" exact="disease" post="and to uphold human rights to health and dignity"/>
   <result pre="outside of prison walls. References References 1DolanKWirtzALMoazenBGlobal burden of HIV," exact="viral hepatitis," post="and tuberculosis in prisoners and detaineesLancet38820161089110227427453 2collab: UNAIDSGlobal AIDS"/>
   <result pre="walls. References References 1DolanKWirtzALMoazenBGlobal burden of HIV, viral hepatitis, and" exact="tuberculosis" post="in prisoners and detaineesLancet38820161089110227427453 2collab: UNAIDSGlobal AIDS update 2018:"/>
   <result pre="HIV: time for reformLancet38820161033103527427447 5HerceMEHoffmannCJFieldingKUniversal test-and-treat in Zambian and South" exact="African" post="correctional facilities: a multisite prospective cohort studyLancet HIV2020published online"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7402669/results/search/disease/results.xml">
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="people on treatment, and 90% of people on treatment with" exact="viral" post="suppression. With the ultimate aim of interrupting transmission in"/>
   <result pre="are on treatment, and 88% of people on treatment have" exact="viral" post="suppression. This means that globally 59% of people with"/>
   <result pre="disparities. Successes include eSwatini and Switzerland, which have achieved 85%" exact="viral" post="suppression among people living with HIV, the target under"/>
   <result pre="earlier in 2010, a decline largely driven by reductions in" exact="infections" post="in girls and young women in eastern and southern"/>
   <result pre="southern Africa. Boys and men now account for most new" exact="infections" post="(52% of infections worldwide). Outside of western Europe and"/>
   <result pre="and men now account for most new infections (52% of" exact="infections" post="worldwide). Outside of western Europe and North America, men"/>
   <result pre="west Africa where just 49% of men with HIV have" exact="viral" post="suppression compared with 67% of women. Worldwide, 62% of"/>
   <result pre="suppression compared with 67% of women. Worldwide, 62% of new" exact="infections" post="were among key populations, which include sex workers, people"/>
   <result pre="prisoners, transgender people, and men who have sex with men." exact="Failure" post="to achieve targets of treatment and prevention mean that"/>
   <result pre="2015 there have been an excess of 3·5 million new" exact="infections" post="and 820 000 deaths. Against this backdrop of an HIV"/>
   <result pre="of disruptions to prevention and treatment for HIV, tuberculosis, and" exact="malaria" post="in low-income and middle-income settings. The researchers predict that"/>
   <result pre="COVID-19 pandemic. Given advances in prevention, testing, and treatment, every" exact="HIV infection" post="and death in 2020 is preventable. Nonetheless, we find"/>
   <result pre="pandemic. Given advances in prevention, testing, and treatment, every HIV" exact="infection" post="and death in 2020 is preventable. Nonetheless, we find"/>
   <result pre="in 2020 is preventable. Nonetheless, we find ourselves falling far" exact="short" post="of global targets for treatment and prevention, and in"/>
   <result pre="and eSwatini can succeed, then targets can be met elsewhere." exact="Local" post="and national governments worldwide must not lose sight of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7404095/results/search/disease/results.xml">
   <result pre="essential. Convincing evidence shows that this and every other important" exact="viral" post="epidemic emerging in the recent past and predictably into"/>
   <result pre="national health organizations have obscured the upstream causes of emerging" exact="viral" post="epidemics. These organizations have suffered cutbacks in public funding"/>
   <result pre="that emphasize the downstream effects rather than upstream causes of" exact="infectious diseases." post="Conflicts of interest also have impacted public health policies."/>
   <result pre="us rely: the World Health Organization (WHO), U.S. Centers for" exact="Disease" post="Control and Prevention (CDC), U.S. National Institute of Allergy"/>
   <result pre="Control and Prevention (CDC), U.S. National Institute of Allergy and" exact="Infectious" post="Diseases, Pan American Health Organization, Gates Foundation, and so"/>
   <result pre="(CDC), U.S. National Institute of Allergy and Infectious Diseases, Pan" exact="American" post="Health Organization, Gates Foundation, and so forth. Identifying the"/>
   <result pre="the pathologist Rudolf Virchow did his path-breaking investigation of the" exact="typhus" post="epidemic in Upper Silesia. Due to the current pandemic’s"/>
   <result pre="Causes in Agriculture This pandemic and every other important emerging" exact="viral" post="epidemic in the recent past and predictably into the"/>
   <result pre="effects we now are confronting every day.1–6 In addition to" exact="viral" post="epidemics, these and similar agricultural practices also deepen the"/>
   <result pre="similar agricultural practices also deepen the parallel crises of multi-drug-resistant" exact="bacterial infections" post="(through overuse of antibiotics in industrial meat and fish"/>
   <result pre="agricultural practices also deepen the parallel crises of multi-drug-resistant bacterial" exact="infections" post="(through overuse of antibiotics in industrial meat and fish"/>
   <result pre="have happened in China with the previous coronavirus in severe" exact="acute" post="respiratory syndrome (SARS); Ebola in Africa; Zika in Africa,"/>
   <result pre="happened in China with the previous coronavirus in severe acute" exact="respiratory" post="syndrome (SARS); Ebola in Africa; Zika in Africa, Latin"/>
   <result pre="in China with the previous coronavirus in severe acute respiratory" exact="syndrome" post="(SARS); Ebola in Africa; Zika in Africa, Latin America,"/>
   <result pre="large, oligopolistic, multinational corporations dominate factory farming. As a result," exact="viral" post="contamination and mutations to more virulent organisms in unsanitary"/>
   <result pre="organisms in unsanitary factory conditions have led to epidemics of" exact="swine flu," post="avian flu, and a variety of emerging influenza viruses.2–5"/>
   <result pre="unsanitary factory conditions have led to epidemics of swine flu," exact="avian flu," post="and a variety of emerging influenza viruses.2–5 Deemphasis on"/>
   <result pre="sources like WHO, CDC, and the Gates Foundation provide a" exact="complete" post="picture? Some well-motivated people work for these agencies, and"/>
   <result pre="and their affiliates have obscured the upstream causes of emerging" exact="viral" post="epidemics not only in COVID-19 but also in all"/>
   <result pre="epidemics. An especially disheartening example (I was involved) was the" exact="swine flu" post="epidemic of 2009, which began within 1 mile of"/>
   <result pre="public health authorities and investigators reported this epidemiological association between" exact="swine flu" post="and capitalist industrial agriculture, CDC, WHO, and all other"/>
   <result pre="became even more startling. Less than a decade after the" exact="swine flu" post="epidemic, a Hong Kong-based investment corporation, WH Group Ltd,"/>
   <result pre="epidemic, a Hong Kong-based investment corporation, WH Group Ltd, had" exact="acquired" post="Smithfield Foods. In 2018 Smithfield executives based at U.S."/>
   <result pre="U.S. headquarters in Smithfield, Virginia, welcomed the ongoing epidemic of" exact="African" post="swine fever because a reduced global supply of pork"/>
   <result pre="COVID-19 hotspots in the United States. Rapid spread of the" exact="infection" post="to workers because of similarly unsanitary working conditions threatened"/>
   <result pre="Foundation. Leaders of these agencies are fully aware that emerging" exact="viral" post="epidemics come from capitalist industrial agriculture. They showed this"/>
   <result pre="and Monthly Review Essays, 2020). References References 1WallaceRChavesLFBergmannL, et al.Clear-Cutting" exact="Disease" post="Control: Capital-Led Deforestation, Public Health Austerity, and Vector-Borne Infection."/>
   <result pre="NY: Monthly Review Press; 2018:224–238. 3WallaceRGWallaceR, eds. Neoliberal Ebola: Modeling" exact="Disease" post="Emergence From Finance to Forest and Farm. New York,"/>
   <result pre="NY: Springer; 2016. 4WallaceR.Big Farms Make Big Flu: Dispatches on" exact="Infectious" post="Disease, Agribusiness, and the Nature of Science. New York,"/>
   <result pre="CEO looks ahead to 2019: Ken Sullivan sees spread of" exact="African" post="swine fever and trade deals as positive for the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7409732/results/search/disease/results.xml">
   <result pre="Masson SAS. pmcid: 7409732S1879-7296(20)30138-1 doi: 10.1016/j.anorl.2020.05.014 : Article Viruses and" exact="viral" post="epidemics in the metabolic theory of evolution JankowskiR.r.jankowski@chru-nancy.frabc*[a], [b],"/>
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="transmission from one host to another. By breaking down the" exact="viral" post="particle, the host cell appears to resurrect the metabolic"/>
   <result pre="acid, which synthesises its components without any form of control." exact="Viral" post="products undergo self-assembly and are exported by either exocytosis"/>
   <result pre="and are exported by either exocytosis or cytolysis. In the" exact="absence of" post="cells, viruses appear to be inert. However, intracellular contamination"/>
   <result pre="of a virus does not always result in replication: the" exact="viral" post="genome can disappear, remain latent, wake up, remain embedded"/>
   <result pre="their possible role in evolution. Keywords COVID-19 Protists Prokaryotes Cell" exact="Infection" post="1 Introduction The current COVID-19 pandemic, characterised by acute"/>
   <result pre="Cell Infection 1 Introduction The current COVID-19 pandemic, characterised by" exact="acute" post="inflammatory damage to the human respiratory tract (mild to"/>
   <result pre="COVID-19 pandemic, characterised by acute inflammatory damage to the human" exact="respiratory" post="tract (mild to severe and life-threatening), is caused by"/>
   <result pre="(mild to severe and life-threatening), is caused by a so-called" exact="viral" post="particle of matter called SARS-CoV-2, which is transmitted from"/>
   <result pre="from one individual to another by droplets of saliva or" exact="respiratory" post="mucus projected into the air physiologically by breathing, speaking"/>
   <result pre="unit of every living organism (http://www.universalis.fr/encyclopedie/theorie-cellulaire). Despite their organic nature," exact="viral" post="particles therefore do not seem to be the origin"/>
   <result pre="organisms? The data concerning the structure and passive replication of" exact="viral" post="particles reported here are unanimously accepted, but often presented"/>
   <result pre="accepted, but often presented as if it were certain that" exact="viral" post="particles were living organisms. The description of viruses, detached"/>
   <result pre="[2], Nobel Prize in Medicine in 1965. 2 Structure of" exact="viral" post="particles Viruses, like living cells, associate nucleic acids with"/>
   <result pre="such as mimiviruses (contraction of microbe mimicking viruses) (which are" exact="viral" post="entities that can be infected by other viruses called"/>
   <result pre="measures 10 nanometres and its genome contains only one gene:" exact="hepatitis delta" post="virus (which, moreover, is considered to be a satellite"/>
   <result pre="moreover, is considered to be a satellite virus of the" exact="hepatitis" post="B virus, as it can only replicate in a"/>
   <result pre="it can only replicate in a patient already infected with" exact="hepatitis" post="B virus or in the presence of simultaneous contamination"/>
   <result pre="B virus or in the presence of simultaneous contamination with" exact="hepatitis" post="B virus and hepatitis D virus) [5]. One of"/>
   <result pre="the presence of simultaneous contamination with hepatitis B virus and" exact="hepatitis D" post="virus) [5]. One of the largest known viruses, mimivirus,"/>
   <result pre="by a protein shell called a capsid, which gives the" exact="viral" post="particle its characteristic morphology. The genome and capsid complex"/>
   <result pre="nasopharyngeal (in which the main site of replication is the" exact="respiratory" post="epithelium), conjunctival or gastrointestinal (for enteric strains with faeco-oral"/>
   <result pre="for many tissues and, in immunocompetent subjects, are responsible for" exact="respiratory" post="tract (sore throat, rhinopharyngitis, pneumonia), ophthalmological (conjunctivitis, keratoconjunctivitis) and"/>
   <result pre="of some viruses may be surrounded by an envelope. These" exact="viral" post="particles belong to the group of enveloped viruses. The"/>
   <result pre="the host cell membrane system, but it is encrusted with" exact="viral" post="proteins. Enveloped viruses leave the host cell by budding,"/>
   <result pre="of the host cell cytoplasmic membrane, which consequently supplies the" exact="viral" post="envelope. Herpesviridae assemble the genome and capsid in the"/>
   <result pre="which would explain certain differences in the lipid composition of" exact="viral" post="envelopes (in contrast, release of naked viruses is secondary"/>
   <result pre="of viral envelopes (in contrast, release of naked viruses is" exact="secondary" post="to rupture of the host cell membrane). Viral proteins"/>
   <result pre="viruses is secondary to rupture of the host cell membrane)." exact="Viral" post="proteins may be inserted into the lipid bilayer immediately"/>
   <result pre="the host's lipid membrane are then expelled and replaced by" exact="viral" post="proteins. In certain viruses, such as the hepatitis B"/>
   <result pre="replaced by viral proteins. In certain viruses, such as the" exact="hepatitis" post="B virus, the fraction of viral proteins inserted into"/>
   <result pre="viruses, such as the hepatitis B virus, the fraction of" exact="viral" post="proteins inserted into the lipid envelope is so abundant"/>
   <result pre="the lipid membrane, which makes the virus highly resistant to" exact="external" post="influences and detergents. The higher the proportion of lipids"/>
   <result pre="and detergents. The higher the proportion of lipids in the" exact="viral" post="envelope (e.g. SARS-CoV-2), the easier it is to destroy"/>
   <result pre="the virus by hydroalcoholic solution or soap. In reality, the" exact="viral" post="envelope makes the virus more fragile by making it"/>
   <result pre="host cell cytoplasmic membrane, allows passive intracellular penetration of the" exact="viral" post="particle. We can therefore see signs of a possible"/>
   <result pre="see signs of a possible evolution of the structure of" exact="viral" post="particles, from a simple nucleic acid to an enveloped"/>
   <result pre="viral particles, from a simple nucleic acid to an enveloped" exact="viral" post="particle, via the naked viral particle. Viral particles actually"/>
   <result pre="nucleic acid to an enveloped viral particle, via the naked" exact="viral" post="particle. Viral particles actually appear to be completely passive"/>
   <result pre="to an enveloped viral particle, via the naked viral particle." exact="Viral" post="particles actually appear to be completely passive in the"/>
   <result pre="the phenomenon of their own replication. 3 Passive replication of" exact="viral" post="particles &quot;Viruses are viruses&quot; (André Lwoff). The process of"/>
   <result pre="multiplication of virus particles inside cells is called replication: the" exact="viral" post="particle is initially broken down, then reconstructed (with possible"/>
   <result pre="various components that the cell manufactures in multiple copies. A" exact="viral" post="particle never descends directly from another viral particle. Attachment"/>
   <result pre="multiple copies. A viral particle never descends directly from another" exact="viral" post="particle. Attachment of the viral particle to the cell"/>
   <result pre="never descends directly from another viral particle. Attachment of the" exact="viral" post="particle to the cell membrane is passive, and results"/>
   <result pre="membrane receptor (protein or glycoprotein) involved in recognition of the" exact="external" post="environment. Some viruses can infect many different cell types,"/>
   <result pre="that binds to the human CD4 molecule. Penetration of the" exact="viral" post="particle can be either a passive or active process."/>
   <result pre="poxviruses, carry an uncoating enzyme in their genome). The released" exact="viral" post="genome is then in direct contact with the cytoplasmic"/>
   <result pre="then in direct contact with the cytoplasmic metabolic machinery. Positive-sense" exact="viral" post="RNA behaves like messenger RNA to produce capsid proteins"/>
   <result pre="to produce capsid proteins and to replicate (however, replication of" exact="viral" post="mRNA is a complex process that will not be"/>
   <result pre="a complex process that will not be discussed here). Negative-sense" exact="viral" post="RNA is transcribed into a single strand of complementary"/>
   <result pre="which is then translated by ribosomes, but only when the" exact="viral" post="genome contains a transcriptase (which is an RNA-dependent RNA"/>
   <result pre="DNA (or reverse transcriptase) that must be present in the" exact="viral" post="genome; the resulting DNA is then inserted into the"/>
   <result pre="of an integrase, often associated with reverse transcriptase in the" exact="viral" post="genome; the retrovirus genome then becomes an integral part"/>
   <result pre="are either host cell enzymes or enzymes included in the" exact="viral" post="genome. The natural physicochemical affinity between the various components"/>
   <result pre="components of the nucleocapsid allows the self-assembly of countless new" exact="viral" post="particles. However, self-assembly can be modulated by cellular enzymes"/>
   <result pre="modulated by cellular enzymes that can alter the structure of" exact="viral" post="proteins by modifying chemical groups, for example, by adding"/>
   <result pre="from one of the membrane compartments of the cell. The" exact="viral" post="particles released therefore exponentially contaminate the other healthy cells."/>
   <result pre="The immune system usually keeps a memory of the expelled" exact="viral" post="particle after replication, which can then be eliminated before"/>
   <result pre="event of subsequent mucosal contamination. However, intracellular contamination by a" exact="viral" post="particle does not always lead to viral replication. The"/>
   <result pre="contamination by a viral particle does not always lead to" exact="viral" post="replication. The intracellular viral genome may disappear after a"/>
   <result pre="particle does not always lead to viral replication. The intracellular" exact="viral" post="genome may disappear after a variable interval or may"/>
   <result pre="the cell. It can then sometimes wake up, like the" exact="herpes" post="virus. In the case of oncogenic viruses, certain viral"/>
   <result pre="the herpes virus. In the case of oncogenic viruses, certain" exact="viral" post="proteins or viral genome insertions into the chromosomes of"/>
   <result pre="In the case of oncogenic viruses, certain viral proteins or" exact="viral" post="genome insertions into the chromosomes of the host cell"/>
   <result pre="is no longer recognised by the immune system, resulting in" exact="autoimmune diseases." post="More surprisingly, retroviruses have been found in the genomes"/>
   <result pre="contain about half a million of these viruses [7], [8]." exact="Viral" post="replication therefore appears to be a passive viral phenomenon"/>
   <result pre="[7], [8]. Viral replication therefore appears to be a passive" exact="viral" post="phenomenon different from the process of reproduction that characterises"/>
   <result pre="it is the host cell that is the agent of" exact="viral" post="replication. Moreover, not all viral particles necessarily behave like"/>
   <result pre="that is the agent of viral replication. Moreover, not all" exact="viral" post="particles necessarily behave like infectious particles. So, what is"/>
   <result pre="viral replication. Moreover, not all viral particles necessarily behave like" exact="infectious" post="particles. So, what is a viral infection? 4 Response"/>
   <result pre="particles necessarily behave like infectious particles. So, what is a" exact="viral infection?" post="4 Response to the concept of virus and viral"/>
   <result pre="viral infection? 4 Response to the concept of virus and" exact="viral infection" post="An infection can be defined by &quot;penetration into a"/>
   <result pre="infection? 4 Response to the concept of virus and viral" exact="infection" post="An infection can be defined by &quot;penetration into a"/>
   <result pre="Response to the concept of virus and viral infection An" exact="infection" post="can be defined by &quot;penetration into a living organism"/>
   <result pre="known to man since ancient times [2]. The Chinese identified" exact="smallpox" post="2500 years ago and knew that it was transmitted"/>
   <result pre="it was transmitted between humans, without, of course, attributing the" exact="disease" post="to a virus. Sexual transmission of syphilis had been"/>
   <result pre="course, attributing the disease to a virus. Sexual transmission of" exact="syphilis" post="had been known since the 15th century, but Treponema"/>
   <result pre="been known since the 15th century, but Treponema pallidum, the" exact="bacterial" post="species responsible for syphilis, was not identified until 1905."/>
   <result pre="The work by Pasteur (1822–1895) established the microbial origin of" exact="infectious diseases." post="All microbes, whether bacteria, protists or fungi, were called"/>
   <result pre="Roux easily demonstrated, even without identifying the causative agent, that" exact="rabies" post="was a specific infectious disease probably caused by a"/>
   <result pre="without identifying the causative agent, that rabies was a specific" exact="infectious disease" post="probably caused by a microbe too small to be"/>
   <result pre="identifying the causative agent, that rabies was a specific infectious" exact="disease" post="probably caused by a microbe too small to be"/>
   <result pre="that the juice of tobacco plants affected by tobacco mosaic" exact="disease" post="remained contagious even after ultrafiltration. Many invisible but ultrafiltrable"/>
   <result pre="disease remained contagious even after ultrafiltration. Many invisible but ultrafiltrable" exact="infectious" post="agents were therefore suspected and were called viruses. At"/>
   <result pre="At the same time, the term &quot;microbe&quot; was reserved for" exact="infectious" post="agents that could be observed visually. Almost all viruses"/>
   <result pre="Lwoff highlighted the ambivalence of the concepts of viruses and" exact="viral infection" post="as early as 1957: are viruses living organisms, because"/>
   <result pre="highlighted the ambivalence of the concepts of viruses and viral" exact="infection" post="as early as 1957: are viruses living organisms, because"/>
   <result pre="interpretation from that of a parasite. The hypothesis of a" exact="deficiency" post="of the host cell's intrinsic defences towards an organic"/>
   <result pre="glial cells, neutrophils etc. Take, for example, contamination of the" exact="respiratory" post="epithelium of the nasal cavities by naked adenoviruses present"/>
   <result pre="for example, contamination of the respiratory epithelium of the nasal" exact="cavities" post="by naked adenoviruses present in a spray of respiratory"/>
   <result pre="nasal cavities by naked adenoviruses present in a spray of" exact="respiratory" post="mucus, carried by mucociliary transport allowing viral particles to"/>
   <result pre="a spray of respiratory mucus, carried by mucociliary transport allowing" exact="viral" post="particles to attach to the cytoplasmic membrane of epithelial"/>
   <result pre="allowing viral particles to attach to the cytoplasmic membrane of" exact="epithelial" post="cells simply by selective physicochemical forces. One or several"/>
   <result pre="epithelial cells simply by selective physicochemical forces. One or several" exact="viral" post="particles, for a variety of reasons, may not be"/>
   <result pre="body on the epithelium may lead to phagocytosis of the" exact="viral" post="particle by the epithelial cell. However, the digestive capacities"/>
   <result pre="may lead to phagocytosis of the viral particle by the" exact="epithelial" post="cell. However, the digestive capacities of the lysosomes of"/>
   <result pre="epithelial cell. However, the digestive capacities of the lysosomes of" exact="epithelial" post="cells that have become specialised in mucociliary clearance (which,"/>
   <result pre="mechanisms of intranuclear transport of adenoviruses have been demonstrated. Several" exact="viral" post="particles may also be phagocytosed by the same epithelial"/>
   <result pre="Several viral particles may also be phagocytosed by the same" exact="epithelial" post="cell and viral DNA then persists in the cytoplasm."/>
   <result pre="may also be phagocytosed by the same epithelial cell and" exact="viral" post="DNA then persists in the cytoplasm. A single intranuclear"/>
   <result pre="then persists in the cytoplasm. A single intranuclear molecule of" exact="viral" post="DNA may actually be sufficient to trigger the production"/>
   <result pre="RNA, leading to the synthesis of both capsid proteins and" exact="viral" post="DNA in the cytoplasm, where, as we have seen,"/>
   <result pre="adenoviruses, which are naked viruses, and exponential contamination of new" exact="epithelial" post="cells. At the same time, immune cells develop specific"/>
   <result pre="the same time, immune cells develop specific immunity to this" exact="viral" post="particle. In the case of enveloped viruses, such as"/>
   <result pre="replacement of the intrinsic proteins of the cell membrane by" exact="viral" post="proteins, resulting in the viral envelope structure, may be"/>
   <result pre="of the cell membrane by viral proteins, resulting in the" exact="viral" post="envelope structure, may be simply due to the abundance"/>
   <result pre="nucleic acid units, i.e. readable, transcriptable and translatable, results in" exact="uncontrolled" post="functioning of the cell's metabolism. The main difficulty in"/>
   <result pre="(a single gene, as in the case of the satellite" exact="hepatitis D" post="virus) or hundreds or thousands of functional units assembled"/>
   <result pre="and on objects? We have seen that intracellular penetration of" exact="viral" post="particles may be necessary and sufficient to recreate the"/>
   <result pre="the conditions of their activity. Life on Earth is not" exact="limited" post="to plants, animals, fungi and the small number of"/>
   <result pre="of this method is much easier in the context of" exact="acute" post="diseases than in chronic diseases. To date, this method"/>
   <result pre="much easier in the context of acute diseases than in" exact="chronic" post="diseases. To date, this method has only been able"/>
   <result pre="only one to three people in a million develop a" exact="malignant" post="Merckel tumour each year, often in the context of"/>
   <result pre="epidemic, as viruses appear to be identified only by the" exact="infectious diseases" post="that they cause. These diseases are always contagious. Epidemics"/>
   <result pre="contagious. Epidemics therefore appear to be an essential phenomenon for" exact="viral" post="replication. As soon as the chain of transmission is"/>
   <result pre="of the virus, may entirely depend on the rapidity of" exact="complete" post="interruption of the chain of transmission between hosts. Disclosure"/>
   <result pre="tous les savoirs – La vie2002Odile Jacob 4BaltimoreD.Viruses, polymerases, and" exact="cancer" post="(Nobel lecture)Science192197663263657644 5RizzettoM.Hepatitis D: thirty years afterJ Hepatol5020091043105019285743 6La"/>
   <result pre="analysis of the human genomeNature409200182092111236995 8De ParsevalN.HeidmannT.Human endogenous retroviruses: from" exact="infectious" post="elements to human genesCytogenet Genome Res110200531833216093684 9RoingeardP.Détection des virus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7413401/results/search/disease/results.xml">
   <result pre="Article : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases : Viral Diseases: Influenza : Biology and Life"/>
   <result pre=": Medicine and Health Sciences : Medical Conditions : Infectious" exact="Diseases" post=": Viral Diseases: Influenza : Biology and Life Sciences"/>
   <result pre="and Health Sciences : Medical Conditions : Infectious Diseases :" exact="Viral" post="Diseases: Influenza : Biology and Life Sciences : Molecular"/>
   <result pre="Reaction : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases: Nosocomial Infections : Biology and life sciences :"/>
   <result pre="and Health Sciences : Medical Conditions : Infectious Diseases: Nosocomial" exact="Infections" post=": Biology and life sciences : Organisms : Viruses"/>
   <result pre="sciences : Microbiology : Medical microbiology : Microbial pathogens :" exact="Viral" post="pathogens : Orthomyxoviruses : Influenza viruses: Influenza A virus"/>
   <result pre="Pathology and laboratory medicine : Pathogens : Microbial pathogens :" exact="Viral" post="pathogens : Orthomyxoviruses : Influenza viruses: Influenza A virus"/>
   <result pre=": Biology and life sciences : Organisms : Viruses :" exact="Viral" post="pathogens : Orthomyxoviruses : Influenza viruses: Influenza A virus"/>
   <result pre="Physicians : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases: Respiratory Infections : Medicine and Health Sciences :"/>
   <result pre="Medicine and Health Sciences : Medical Conditions : Infectious Diseases:" exact="Respiratory" post="Infections : Medicine and Health Sciences : Medical Conditions"/>
   <result pre="and Health Sciences : Medical Conditions : Infectious Diseases: Respiratory" exact="Infections" post=": Medicine and Health Sciences : Medical Conditions :"/>
   <result pre="Infections : Medicine and Health Sciences : Medical Conditions :" exact="Respiratory" post="Disorders: Respiratory Infections : Medicine and Health Sciences :"/>
   <result pre="Medicine and Health Sciences : Medical Conditions : Respiratory Disorders:" exact="Respiratory" post="Infections : Medicine and Health Sciences : Pulmonology :"/>
   <result pre="and Health Sciences : Medical Conditions : Respiratory Disorders: Respiratory" exact="Infections" post=": Medicine and Health Sciences : Pulmonology : Respiratory"/>
   <result pre="Respiratory Infections : Medicine and Health Sciences : Pulmonology :" exact="Respiratory" post="Disorders: Respiratory Infections : Medicine and Health Sciences: Critical"/>
   <result pre=": Medicine and Health Sciences : Pulmonology : Respiratory Disorders:" exact="Respiratory" post="Infections : Medicine and Health Sciences: Critical Care and"/>
   <result pre="Medicine and Health Sciences : Pulmonology : Respiratory Disorders: Respiratory" exact="Infections" post=": Medicine and Health Sciences: Critical Care and Emergency"/>
   <result pre="Paris, France[3], AP-HP, University Hospital Bichat-Claude Bernard, Virology, Paris, France[4]," exact="Infectious" post="Disease Department, AP-HP, University Hospital Bichat-Claude Bernard, Paris, France[5],"/>
   <result pre="France[3], AP-HP, University Hospital Bichat-Claude Bernard, Virology, Paris, France[4], Infectious" exact="Disease" post="Department, AP-HP, University Hospital Bichat-Claude Bernard, Paris, France[5], Clinical"/>
   <result pre="Clinical Investigation Center, AP-HP, University Hospital Bichat-Claude Bernard, Paris, France[6]," exact="Infection" post="Control Unit, AP-HP, University Hospital Bichat-Claude, Paris, FranceSealeHollyEditor[], University"/>
   <result pre="organisational issues related to patients’ isolation and the risk of" exact="viral" post="nosocomial transmission in the context of limited availability of"/>
   <result pre="the risk of viral nosocomial transmission in the context of" exact="limited" post="availability of single rooms. A study assessing the relationship"/>
   <result pre="to a single room among patients positive for influenza or" exact="respiratory" post="syncytial virus was higher, although not significantly, in those"/>
   <result pre="objective was to assess the association of influenza PCR and" exact="disease" post="severity on single-room assignment, during the first 48 hours"/>
   <result pre="PCR turnaround time, ward of admission, and room assignment. The" exact="primary" post="outcome was the single- or double-room assignment at 48"/>
   <result pre="variables. Logistic regression was used to identify factors influencing the" exact="primary" post="outcome in the multivariable analysis including: age, PCR results,"/>
   <result pre="results and room assignment. All tests were performed with a" exact="type I" post="error of 0.05. The data management and statistical analysis"/>
   <result pre="first, second, and third epidemic period, respectively (Fig 1). A" exact="total" post="of 278 patients (20.9%) tested positive for influenza with"/>
   <result pre="the second and third periods (p &amp;lt; 0.001); only influenza" exact="type A" post="virus was identified during the second period, while both"/>
   <result pre="the 221 most severe patients (16.6%) with either hemodynamic or" exact="respiratory" post="failure was not statistically significant among the three periods"/>
   <result pre="studies have shown that single-room assignment is efficient in reducing" exact="nosocomial infections," post="specifically influenza [17,18], but the availability of single rooms"/>
   <result pre="of single rooms [20], the placement of patients with high-risk" exact="respiratory" post="viral infection, notably influenza infection, remains a challenge. In"/>
   <result pre="single rooms [20], the placement of patients with high-risk respiratory" exact="viral infection," post="notably influenza infection, remains a challenge. In addition, the"/>
   <result pre="infection, remains a challenge. In addition, the proportion of influenza" exact="infections" post="is usually low among patients presenting an ILI during"/>
   <result pre="laboratory and PCR delay. Due to these delays and the" exact="limited" post="opening hours of the laboratory, the median time to"/>
   <result pre="PCR improved the proportion of patients isolated with a confirmed" exact="respiratory" post="virus infection (17 vs 9%, p = 0.02) and"/>
   <result pre="improved the proportion of patients isolated with a confirmed respiratory" exact="virus infection" post="(17 vs 9%, p = 0.02) and reduced the"/>
   <result pre="the proportion of patients isolated with a confirmed respiratory virus" exact="infection" post="(17 vs 9%, p = 0.02) and reduced the"/>
   <result pre="the first to assess factors leading to single-room assignment in" exact="adult" post="patients presenting an ILI. Due to the study’s retrospective"/>
   <result pre="The observed poor accuracy of the RIDT might explain the" exact="lower" post="frequency of single-room assignment of patients with a positive"/>
   <result pre="test References References 1Up to 650 000 people die of" exact="respiratory" post="diseases linked to seasonal flu each year. http://www.who.int/news-room/detail/14-12-2017-up-to-650-000-people-die-of-respiratory-diseases-linked-to-seasonal-flu-each-year. Accessed"/>
   <result pre="4VanhemsP, VoirinN, RocheS, et al.Risk of influenza-like illness in an" exact="acute" post="health care setting during community influenza epidemics in 2004–2005,"/>
   <result pre="RT-PCR, and other Molecular Assays for Diagnosis of Influenza Virus" exact="Infection" post="| Seasonal Influenza (Flu) | CDC. 2018. https://www.cdc.gov/flu/professionals/diagnosis/molecular-assays.htm. Accessed"/>
   <result pre="12:e018209110.1371/journal.pone.018209128750092 11BrendishNJ, MalachiraAK, ArmstrongL, et al.Routine molecular point-of-care testing for" exact="respiratory" post="viruses in adults presenting to hospital with acute respiratory"/>
   <result pre="testing for respiratory viruses in adults presenting to hospital with" exact="acute" post="respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial."/>
   <result pre="for respiratory viruses in adults presenting to hospital with acute" exact="respiratory" post="illness (ResPOC): a pragmatic, open-label, randomised controlled trial. Lancet"/>
   <result pre="5:401–411. 10.1016/S2213-2600(17)30120-028392237 12RoganDT, KocharMS, YangS, QuinnJV. Impact of Rapid Molecular" exact="Respiratory" post="Virus Testing on Real-Time Decision Making in a Pediatric"/>
   <result pre="Molecular Respiratory Virus Testing on Real-Time Decision Making in a" exact="Pediatric" post="Emergency Department. J Mol Diagn2017; 19:460–467. 10.1016/j.jmoldx.2017.01.00928341587 13LacroixS, VrignaudB,"/>
   <result pre="al.Impact of rapid influenza diagnostic test on physician estimation of" exact="viral infection" post="probability in paediatric emergency department during epidemic period. J"/>
   <result pre="of rapid influenza diagnostic test on physician estimation of viral" exact="infection" post="probability in paediatric emergency department during epidemic period. J"/>
   <result pre="MahmoodA, ValenteM. Advantages and Disadvantages of Single-Versus Multiple-Occupancy Rooms in" exact="Acute" post="Care Environments: A Review and Analysis of the Literature."/>
   <result pre="Resist Infect Control2017; 6:11710.1186/s13756-017-0275-z29177048 19BaierC, LinderkampC, BeilkenA, et al.Influenza and" exact="respiratory" post="syncytial virus screening for the detection of asymptomatically infected"/>
   <result pre="Impact of turnaround time on outcome with point-of-care testing for" exact="respiratory" post="viruses: a post hoc analysis from a randomised controlled"/>
   <result pre="a post hoc analysis from a randomised controlled trial. European" exact="Respiratory" post="Journal2018; 52:180055510.1183/13993003.00555-201829946003 24Hernández RuipérezT, Leal CostaC, de G Adánez"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7414693/results/search/disease/results.xml">
   <result pre="italic;} Infect Dis Clin North AmInfect. Dis. Clin. North AmInfectious" exact="Disease" post="Clinics of North America0891-55201557-9824Elsevier Inc. pmcid: 7414693S0891-5520(20)30049-0 doi: 10.1016/j.idc.2020.06.015"/>
   <result pre=": Article Lessons Learned from the Response to the Human" exact="Immunodeficiency" post="Virus Epidemic that Can Inform Addressing the Opioid Epidemic"/>
   <result pre="Lessons Learned from the Response to the Human Immunodeficiency Virus" exact="Epidemic" post="that Can Inform Addressing the Opioid Epidemic SpringerSandra A.MDSandra.springer@yale.edua∗RioCarlos"/>
   <result pre="Human Immunodeficiency Virus Epidemic that Can Inform Addressing the Opioid" exact="Epidemic" post="SpringerSandra A.MDSandra.springer@yale.edua∗RioCarlos delMDb[a], [b], ∗Corresponding author. Sandra.springer@yale.edu pmc-release: 2020-8-8ppub:"/>
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="active. The lessons learned from the response to the human" exact="immunodeficiency" post="virus (HIV) epidemic are important to quell the opioid"/>
   <result pre="human immunodeficiency virus (HIV) epidemic are important to quell the" exact="opioid use disorder" post="epidemic in the United States. This article identifies similar"/>
   <result pre="immunodeficiency virus (HIV) epidemic are important to quell the opioid" exact="use disorder" post="epidemic in the United States. This article identifies similar"/>
   <result pre="1990s that are currently being experienced by persons living with" exact="opioid use disorder." post="In addition, this article reviews the ways in which"/>
   <result pre="that are currently being experienced by persons living with opioid" exact="use disorder." post="In addition, this article reviews the ways in which"/>
   <result pre="highlights similar strategies that can also help persons living with" exact="opioid use disorder" post="in this country. Keywords HIV Opioid use disorder Epidemic"/>
   <result pre="similar strategies that can also help persons living with opioid" exact="use disorder" post="in this country. Keywords HIV Opioid use disorder Epidemic"/>
   <result pre="with opioid use disorder in this country. Keywords HIV Opioid" exact="use disorder" post="Epidemic Medication treatment of opioid use disorder MOUD HCV"/>
   <result pre="use disorder in this country. Keywords HIV Opioid use disorder" exact="Epidemic" post="Medication treatment of opioid use disorder MOUD HCV Infectious"/>
   <result pre="country. Keywords HIV Opioid use disorder Epidemic Medication treatment of" exact="opioid use disorder" post="MOUD HCV Infectious disease Stigma Key points •The opioid"/>
   <result pre="Keywords HIV Opioid use disorder Epidemic Medication treatment of opioid" exact="use disorder" post="MOUD HCV Infectious disease Stigma Key points •The opioid"/>
   <result pre="disorder Epidemic Medication treatment of opioid use disorder MOUD HCV" exact="Infectious" post="disease Stigma Key points •The opioid epidemic is fueling"/>
   <result pre="Epidemic Medication treatment of opioid use disorder MOUD HCV Infectious" exact="disease" post="Stigma Key points •The opioid epidemic is fueling new"/>
   <result pre="disease Stigma Key points •The opioid epidemic is fueling new" exact="infectious disease" post="epidemics, including human immunodeficiency virus (HIV), hepatitis C virus,"/>
   <result pre="Stigma Key points •The opioid epidemic is fueling new infectious" exact="disease" post="epidemics, including human immunodeficiency virus (HIV), hepatitis C virus,"/>
   <result pre="opioid epidemic is fueling new infectious disease epidemics, including human" exact="immunodeficiency" post="virus (HIV), hepatitis C virus, and serious bacterial infections"/>
   <result pre="fueling new infectious disease epidemics, including human immunodeficiency virus (HIV)," exact="hepatitis C" post="virus, and serious bacterial infections such as infective endocarditis,"/>
   <result pre="including human immunodeficiency virus (HIV), hepatitis C virus, and serious" exact="bacterial infections" post="such as infective endocarditis, across the United States among"/>
   <result pre="human immunodeficiency virus (HIV), hepatitis C virus, and serious bacterial" exact="infections" post="such as infective endocarditis, across the United States among"/>
   <result pre="(HIV), hepatitis C virus, and serious bacterial infections such as" exact="infective endocarditis," post="across the United States among persons who use drugs."/>
   <result pre="be used to combat the current opioid epidemic and intertwined" exact="infectious disease" post="epidemics in the United States. Introduction When people typically"/>
   <result pre="used to combat the current opioid epidemic and intertwined infectious" exact="disease" post="epidemics in the United States. Introduction When people typically"/>
   <result pre="days, they envision influenza, Ebola, or now the novel Coronavirus" exact="Infectious" post="Disease of 2019 (COVID-19) caused by SARS-CoV-2. According to"/>
   <result pre="they envision influenza, Ebola, or now the novel Coronavirus Infectious" exact="Disease" post="of 2019 (COVID-19) caused by SARS-CoV-2. According to Wikipedia,"/>
   <result pre="to Wikipedia, an epidemic is &quot;the rapid spread of an" exact="infectious disease" post="to a large number of people in a given"/>
   <result pre="Wikipedia, an epidemic is &quot;the rapid spread of an infectious" exact="disease" post="to a large number of people in a given"/>
   <result pre="large number of people in a given population within a" exact="short" post="period of time.&quot; Although OUD is not an infectious"/>
   <result pre="a short period of time.&quot; Although OUD is not an" exact="infectious disease," post="its &quot;transmission&quot; mimics infectious diseases and it is directly"/>
   <result pre="Although OUD is not an infectious disease, its &quot;transmission&quot; mimics" exact="infectious diseases" post="and it is directly related to a surge in"/>
   <result pre="diseases and it is directly related to a surge in" exact="infectious diseases" post="such as human immunodeficiency virus (HIV), hepatitis C virus"/>
   <result pre="related to a surge in infectious diseases such as human" exact="immunodeficiency" post="virus (HIV), hepatitis C virus (HCV), and serious bacterial"/>
   <result pre="surge in infectious diseases such as human immunodeficiency virus (HIV)," exact="hepatitis C" post="virus (HCV), and serious bacterial infections such as infective"/>
   <result pre="human immunodeficiency virus (HIV), hepatitis C virus (HCV), and serious" exact="bacterial infections" post="such as infective endocarditis. &quot;Access to life-saving interventions must"/>
   <result pre="immunodeficiency virus (HIV), hepatitis C virus (HCV), and serious bacterial" exact="infections" post="such as infective endocarditis. &quot;Access to life-saving interventions must"/>
   <result pre="hepatitis C virus (HCV), and serious bacterial infections such as" exact="infective endocarditis." post="&quot;Access to life-saving interventions must be improved in all"/>
   <result pre="early HIV epidemic, the US government funded the AIDS (acquired" exact="immunodeficiency" post="syndrome) Service Demonstration Grants through the Health Resources and"/>
   <result pre="advances in prevention and care that have reduced mortality from" exact="HIV/AIDS" post="by more than 80% since it peaked in 1995"/>
   <result pre="80% since it peaked in 1995 and have decreased new" exact="infections" post="by 8% since 2010, there are still approximately 38,500"/>
   <result pre="who use drugs (PWUD). There seems to be a collective" exact="amnesia" post="about this earlier HIV epidemic and the well-documented relationship"/>
   <result pre="opioid epidemic and intertwined HIV, HCV, as well as invasive" exact="bacterial" post="and fungal infectious disease epidemics in this country. Background"/>
   <result pre="and intertwined HIV, HCV, as well as invasive bacterial and" exact="fungal infectious disease" post="epidemics in this country. Background Current State of the"/>
   <result pre="intertwined HIV, HCV, as well as invasive bacterial and fungal" exact="infectious disease" post="epidemics in this country. Background Current State of the"/>
   <result pre="HIV, HCV, as well as invasive bacterial and fungal infectious" exact="disease" post="epidemics in this country. Background Current State of the"/>
   <result pre="vehicle accidents and gun deaths.5 According to the Centers for" exact="Disease" post="Control and Prevention (CDC), it is estimated that every"/>
   <result pre="levels, the opioid epidemic has resulted in an increase in" exact="infections" post="among PWUD,10, 11, 12, 13, 14, 15 magnifying the"/>
   <result pre="mortality associated with illicit opioid and other substance use. Such" exact="infections" post="that are increasing related to illicit opioid and other"/>
   <result pre="related to illicit opioid and other drug use include HCV;" exact="hepatitis" post="B virus; HIV; and invasive bacterial and fungal infections,"/>
   <result pre="drug use include HCV; hepatitis B virus; HIV; and invasive" exact="bacterial" post="and fungal infections, including Staphylococcus aureus bacteremia, endocarditis, skin"/>
   <result pre="by persistent or untreated infections. This population with co-occurring IDU-related" exact="infections" post="represents the most severely ill patients with OUD, and"/>
   <result pre="patients’ outcomes and to reduce the public health risk of" exact="infectious disease" post="transmission. Further, OUD affects everyone: people from urban, suburban,"/>
   <result pre="outcomes and to reduce the public health risk of infectious" exact="disease" post="transmission. Further, OUD affects everyone: people from urban, suburban,"/>
   <result pre="younger persons being affected substantially; and persons with mental illness.20" exact="Infectious" post="disease physicians as well as other physicians and nonphysician"/>
   <result pre="persons being affected substantially; and persons with mental illness.20 Infectious" exact="disease" post="physicians as well as other physicians and nonphysician clinicians"/>
   <result pre="nonphysician clinicians are at the forefront of these coalescing epidemics." exact="Infectious" post="disease clinicians are most likely to have learned lessons"/>
   <result pre="clinicians are at the forefront of these coalescing epidemics. Infectious" exact="disease" post="clinicians are most likely to have learned lessons from"/>
   <result pre="epidemic to help to defeat the opioid epidemic. The Human" exact="Immunodeficiency" post="Virus Epidemic in 1980s to 1990s in the United"/>
   <result pre="help to defeat the opioid epidemic. The Human Immunodeficiency Virus" exact="Epidemic" post="in 1980s to 1990s in the United States In"/>
   <result pre="affected persons predominantly living in urban centers and afflicting mainly" exact="African" post="American and Hispanic men and women.22,23 In the beginning"/>
   <result pre="persons predominantly living in urban centers and afflicting mainly African" exact="American" post="and Hispanic men and women.22,23 In the beginning of"/>
   <result pre="stigma,24 not only in the community but among providers, including" exact="infectious disease" post="physicians who were at the forefront of the epidemic;"/>
   <result pre="not only in the community but among providers, including infectious" exact="disease" post="physicians who were at the forefront of the epidemic;"/>
   <result pre="the United States back then and was predominantly affecting urban" exact="African" post="Americans.28 Very little public outcry was heard and, in"/>
   <result pre="country’s mass incarceration of predominantly PWUD, who were predominantly young" exact="African" post="American men. In comparison, the current opioid epidemic is"/>
   <result pre="mass incarceration of predominantly PWUD, who were predominantly young African" exact="American" post="men. In comparison, the current opioid epidemic is affecting"/>
   <result pre="methamphetamine, which is causing even more overdose deaths and more" exact="infectious disease" post="outbreaks without any evidence of abating.9,29 The reason the"/>
   <result pre="which is causing even more overdose deaths and more infectious" exact="disease" post="outbreaks without any evidence of abating.9,29 The reason the"/>
   <result pre="manufactured fentanyl.28,30 Although it is not surprising, it is still" exact="heart" post="breaking for clinicians who cared then and care now"/>
   <result pre="the United States, with specific goals to reduce new HIV" exact="infections" post="by 75% by 2025 and by 90% by 2030.36"/>
   <result pre="an all-hands-on-deck approach is required. What Helped in the Human" exact="Immunodeficiency" post="Virus Epidemic? There were several things that happened to"/>
   <result pre="local community-based programs to offer a comprehensive system of HIV" exact="primary" post="care, case-management support services, housing assistance, substance use disorder"/>
   <result pre="system of HIV primary care, case-management support services, housing assistance," exact="substance use disorder" post="(SUD) treatment, psychosocial behavioral health, wraparound services, and ART.38"/>
   <result pre="of HIV primary care, case-management support services, housing assistance, substance" exact="use disorder" post="(SUD) treatment, psychosocial behavioral health, wraparound services, and ART.38"/>
   <result pre="Act. As a result of addressing HIV from diagnosis to" exact="viral" post="suppression, the HIV care continuum has been defined with"/>
   <result pre="and, most importantly and the goal of ART treatment, HIV" exact="viral" post="suppression.39 In particular, it is well known that HIV"/>
   <result pre="viral suppression.39 In particular, it is well known that HIV" exact="viral" post="suppression not only reduces morbidity and mortality related to"/>
   <result pre="in this country. Programs that received Ryan White funding improved" exact="viral" post="suppression rates among PWH from 69.5% to 85.9% from"/>
   <result pre="racial/ethnic minorities,41 and there was a reduction in new HIV" exact="infections" post="of 8% from 2010 to 2018, from 41,000 to"/>
   <result pre="from HIV as well as a reduction in new HIV" exact="infections" post="in the United States. In addition to these actions,"/>
   <result pre="expand HIV care and reduce stigma.47 Similarities of the Human" exact="Immunodeficiency" post="Virus Epidemic to the Opioid Epidemic The opioid epidemic"/>
   <result pre="care and reduce stigma.47 Similarities of the Human Immunodeficiency Virus" exact="Epidemic" post="to the Opioid Epidemic The opioid epidemic parallels the"/>
   <result pre="Similarities of the Human Immunodeficiency Virus Epidemic to the Opioid" exact="Epidemic" post="The opioid epidemic parallels the early HIV epidemic in"/>
   <result pre="OUD being seen as a character flaw rather than a" exact="medical disorder." post="However, many clinicians view OUD and other SUDs as"/>
   <result pre="choices by the individual rather than what it is: a" exact="medical disorder" post="that is responsive to effective evidence-based treatment. Further, routine"/>
   <result pre="of HIV and HCV33,52; buprenorphine and XR-NTX also improve HIV" exact="viral" post="suppression in PLWH,53, 54, 55 the gold standard of"/>
   <result pre="and thus increased risk of overdose death or acquisition of" exact="infectious diseases;" post="inadequate training of medical professionals and lack of providers"/>
   <result pre="treatment and how to quell the coalescing substance use and" exact="infectious disease" post="epidemics. A recent National Academy of Sciences, Engineering, and"/>
   <result pre="and how to quell the coalescing substance use and infectious" exact="disease" post="epidemics. A recent National Academy of Sciences, Engineering, and"/>
   <result pre="conducting interviews of programs across the country that were integrating" exact="infectious disease" post="and OUD prevention and treatment services.48,58 In addition, the"/>
   <result pre="interviews of programs across the country that were integrating infectious" exact="disease" post="and OUD prevention and treatment services.48,58 In addition, the"/>
   <result pre="disease and OUD prevention and treatment services.48,58 In addition, the" exact="Infectious" post="Disease Society of America (IDSA) and HIV Medicine Association"/>
   <result pre="and OUD prevention and treatment services.48,58 In addition, the Infectious" exact="Disease" post="Society of America (IDSA) and HIV Medicine Association (HIVMA)"/>
   <result pre="directly end both the opioid and associated HIV and other" exact="infectious disease" post="epidemics.59 Such parallels of the opioid epidemic to the"/>
   <result pre="end both the opioid and associated HIV and other infectious" exact="disease" post="epidemics.59 Such parallels of the opioid epidemic to the"/>
   <result pre="epidemics, as well as to prevent new HIV and other" exact="infectious disease" post="epidemics from occurring in this country, as identified earlier."/>
   <result pre="as well as to prevent new HIV and other infectious" exact="disease" post="epidemics from occurring in this country, as identified earlier."/>
   <result pre="Wkly Rep68201938839531048676 10RonanM.V.HerzigS.J.Hospitalizations related to opioid abuse/dependence and associated serious" exact="infections" post="increased sharply, 2002-12Health Aff (Millwood)35201683283727140989 11FleischauerA.T.RuhlL.RheaS.Hospitalizations for endocarditis and"/>
   <result pre="associated serious infections increased sharply, 2002-12Health Aff (Millwood)35201683283727140989 11FleischauerA.T.RuhlL.RheaS.Hospitalizations for" exact="endocarditis" post="and associated health care costs among persons with diagnosed"/>
   <result pre="endocarditis and associated health care costs among persons with diagnosed" exact="drug dependence" post="- North Carolina, 2010-2015MMWR Morb Mortal Wkly Rep66201756957328594786 12JacksonK.A.BohmM.K.BrooksJ.T.Invasive"/>
   <result pre="Carolina, 2010-2015MMWR Morb Mortal Wkly Rep66201756957328594786 12JacksonK.A.BohmM.K.BrooksJ.T.Invasive methicillin-resistant staphylococcus aureus" exact="infections" post="among persons who inject drugs - six sites, 2005-2016MMWR"/>
   <result pre="six sites, 2005-2016MMWR Morb Mortal Wkly Rep67201862562829879096 13ConradC.BradleyH.M.BrozD.Community Outbreak of" exact="HIV infection" post="linked to injection drug use of oxymorphone--Indiana, 2015MMWR Morb"/>
   <result pre="sites, 2005-2016MMWR Morb Mortal Wkly Rep67201862562829879096 13ConradC.BradleyH.M.BrozD.Community Outbreak of HIV" exact="infection" post="linked to injection drug use of oxymorphone--Indiana, 2015MMWR Morb"/>
   <result pre="Northeastern Massachusetts, 2015-2018MMWR Morb Mortal Wkly Rep68201925325430870405 15GoldenM.R.LechtenbergR.GlickS.N.Outbreak of Human" exact="Immunodeficiency" post="Virus Infection Among Heterosexual Persons Who Are Living Homeless"/>
   <result pre="2015-2018MMWR Morb Mortal Wkly Rep68201925325430870405 15GoldenM.R.LechtenbergR.GlickS.N.Outbreak of Human Immunodeficiency Virus" exact="Infection" post="Among Heterosexual Persons Who Are Living Homeless and Inject"/>
   <result pre="- Seattle, Washington, 2018MMWR Morb Mortal Wkly Rep68201934434930998671 16ZibbellJ.E.AsherA.K.PatelR.C.Increases in" exact="acute" post="hepatitis C virus infection related to a growing opioid"/>
   <result pre="Seattle, Washington, 2018MMWR Morb Mortal Wkly Rep68201934434930998671 16ZibbellJ.E.AsherA.K.PatelR.C.Increases in acute" exact="hepatitis C" post="virus infection related to a growing opioid epidemic and"/>
   <result pre="2018MMWR Morb Mortal Wkly Rep68201934434930998671 16ZibbellJ.E.AsherA.K.PatelR.C.Increases in acute hepatitis C" exact="virus infection" post="related to a growing opioid epidemic and associated injection"/>
   <result pre="Morb Mortal Wkly Rep68201934434930998671 16ZibbellJ.E.AsherA.K.PatelR.C.Increases in acute hepatitis C virus" exact="infection" post="related to a growing opioid epidemic and associated injection"/>
   <result pre="2004 to 2014Am J Public Health108201817518129267061 17SchranzA.J.FleischauerA.ChuV.H.Trends in drug use-associated" exact="infective endocarditis" post="and heart valve surgery, 2007 to 2017: a study"/>
   <result pre="to 2014Am J Public Health108201817518129267061 17SchranzA.J.FleischauerA.ChuV.H.Trends in drug use-associated infective" exact="endocarditis" post="and heart valve surgery, 2007 to 2017: a study"/>
   <result pre="2014Am J Public Health108201817518129267061 17SchranzA.J.FleischauerA.ChuV.H.Trends in drug use-associated infective endocarditis" exact="and heart" post="valve surgery, 2007 to 2017: a study of statewide"/>
   <result pre="J Public Health108201817518129267061 17SchranzA.J.FleischauerA.ChuV.H.Trends in drug use-associated infective endocarditis and" exact="heart" post="valve surgery, 2007 to 2017: a study of statewide"/>
   <result pre="2017: a study of statewide discharge dataAnn Intern Med17012018314030508432 18WurcelA.G.AndersonJ.E.ChuiK.K.Increasing" exact="infectious" post="endocarditis admissions among young people who inject drugsOpen Forum"/>
   <result pre="a study of statewide discharge dataAnn Intern Med17012018314030508432 18WurcelA.G.AndersonJ.E.ChuiK.K.Increasing infectious" exact="endocarditis" post="admissions among young people who inject drugsOpen Forum Infect"/>
   <result pre="as fast as those involving opioids, 1999–2016Health Aff38201912161224 20Centers for" exact="Disease" post="Control (CDC). Risk Factors for Prescription Painkiller Abuse and"/>
   <result pre="Factors for Prescription Painkiller Abuse and Overdose. 2015. 21CurranJ.W.JaffeH.W.Centers for" exact="Disease" post="C, PreventionAIDS: the early years and CDC's responseMMWR Suppl602011646921976168"/>
   <result pre="PreventionAIDS: the early years and CDC's responseMMWR Suppl602011646921976168 22Des JarlaisD.C.KerrT.CarrieriP.HIV" exact="infection" post="among persons who inject drugs: ending old epidemics and"/>
   <result pre="drugs: ending old epidemics and addressing new outbreaksAIDS30201681582626836787 23Des JarlaisD.C.CarrieriP.HIV" exact="infection" post="among persons who inject drugs: ending old epidemics and"/>
   <result pre="epidemics and addressing new outbreaks: authors' replyAIDS3020161858185927351930 24MahajanA.P.SaylesJ.N.PatelV.A.Stigma in the" exact="HIV/AIDS" post="epidemic: a review of the literature and recommendations for"/>
   <result pre="and recommendations for the way forwardAIDS22Suppl 22008S67S79 25FoxD.M.AIDS and the" exact="American" post="Health Polity: the history and prospects of a crisis"/>
   <result pre="Q8342005126 26DeWeerdtS.Tracing the US opioid crisis to its rootsNature5732019S10S1231511672 27PetersP.J.PontonesP.HooverK.W.HIV" exact="infection" post="linked to injection use of oxymorphone in Indiana, 2014-2015N"/>
   <result pre="the US opioid overdose crisisInt J Drug Policy71201918318830718120 31Des JarlaisD.C.FriedmanS.R.NovickD.M.HIV-1" exact="infection" post="among intravenous drug users in Manhattan, New York City,"/>
   <result pre="32Des JarlaisD.C.FeelemyerJ.P.ModiS.N.Are females who inject drugs at higher risk for" exact="HIV infection" post="than males who inject drugs: an international systematic review"/>
   <result pre="JarlaisD.C.FeelemyerJ.P.ModiS.N.Are females who inject drugs at higher risk for HIV" exact="infection" post="than males who inject drugs: an international systematic review"/>
   <result pre="12015S1S425727257 35Abdul-QuaderA.S.FeelemyerJ.ModiS.Effectiveness of structural-level needle/syringe programs to reduce HCV and" exact="HIV infection" post="among people who inject drugs: a systematic reviewAIDS Behav17920132878289223975473"/>
   <result pre="35Abdul-QuaderA.S.FeelemyerJ.ModiS.Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV" exact="infection" post="among people who inject drugs: a systematic reviewAIDS Behav17920132878289223975473"/>
   <result pre="for America'? 2019. Available at: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview. 37Congress US. Ryan White" exact="HIV/AIDS" post="Program Legislation. 1990. Available at: https://hab.hrsa.gov/about-ryan-white-hivaids-program/ryan-white-hivaids-program-legislation. 38KayE.S.BateyD.S.MugaveroM.J.The ryan white"/>
   <result pre="HIV/AIDS Program Legislation. 1990. Available at: https://hab.hrsa.gov/about-ryan-white-hivaids-program/ryan-white-hivaids-program-legislation. 38KayE.S.BateyD.S.MugaveroM.J.The ryan white" exact="HIV/AIDS" post="program: supplementary service provision post-affordable care actAIDS Patient Care"/>
   <result pre="provision post-affordable care actAIDS Patient Care STDS32201826527129985648 39ColasantiJ.KellyJ.PennisiE.Continuous Retention and" exact="Viral" post="Suppression Provide Further Insights Into the HIV Care Continuum"/>
   <result pre="the Cross-sectional HIV Care CascadeClin Infect Dis62201664865426567263 40CohenM.S.ChenY.Q.McCauleyM.Prevention of HIV-1" exact="infection" post="with early antiretroviral therapyN Engl J Med365201149350521767103 41collab: Health"/>
   <result pre="J Med365201149350521767103 41collab: Health Resources and Services Administration (HRSA)Ryan White" exact="HIV/AIDS" post="program annual client-level data report 2017Administration HRaS2018Health Resources and"/>
   <result pre="HRaS2018Health Resources and Services Administration ( HRSA)Washington, DC 42Centers for" exact="Disease" post="Control and Prevention (CDC)Diagnoses of HIV infection in the"/>
   <result pre="HRSA)Washington, DC 42Centers for Disease Control and Prevention (CDC)Diagnoses of" exact="HIV infection" post="in the United States and dependent areas, 20182018(CDC)Atlanta (GA)"/>
   <result pre="DC 42Centers for Disease Control and Prevention (CDC)Diagnoses of HIV" exact="infection" post="in the United States and dependent areas, 20182018(CDC)Atlanta (GA)"/>
   <result pre="the United States and dependent areas, 20182018(CDC)Atlanta (GA) 43Centers for" exact="Disease" post="Control and Prevention (CDC)Preexposure Prophylaxis for the prevention of"/>
   <result pre="Disease Control and Prevention (CDC)Preexposure Prophylaxis for the prevention of" exact="HIV infection" post="in the United States-2014: a Clinical Practice Guideline2014DHHS) United"/>
   <result pre="Control and Prevention (CDC)Preexposure Prophylaxis for the prevention of HIV" exact="infection" post="in the United States-2014: a Clinical Practice Guideline2014DHHS) United"/>
   <result pre="of Health and Human Services (DHHS)Bethesda (MD) 44collab: Centers for" exact="Disease" post="Control and PreventionRevised recommendations for HIv testing of adults,"/>
   <result pre="Soc1220091519660113 48National Academies of Sciences, Engineering, and MedicineOpportunities to improve" exact="opioid use disorder" post="and infectious disease services: Integrating responses to a dual"/>
   <result pre="48National Academies of Sciences, Engineering, and MedicineOpportunities to improve opioid" exact="use disorder" post="and infectious disease services: Integrating responses to a dual"/>
   <result pre="Sciences, Engineering, and MedicineOpportunities to improve opioid use disorder and" exact="infectious disease" post="services: Integrating responses to a dual epidemicThe National Academies"/>
   <result pre="Engineering, and MedicineOpportunities to improve opioid use disorder and infectious" exact="disease" post="services: Integrating responses to a dual epidemicThe National Academies"/>
   <result pre="Correct Health Care212015122625559628 50SevalN.EatonE.SpringerS.A.Beyond antibiotics: a practical guide for the" exact="infectious disease" post="physician to treat opioid use disorder in the setting"/>
   <result pre="Health Care212015122625559628 50SevalN.EatonE.SpringerS.A.Beyond antibiotics: a practical guide for the infectious" exact="disease" post="physician to treat opioid use disorder in the setting"/>
   <result pre="a practical guide for the infectious disease physician to treat" exact="opioid use disorder" post="in the setting of associated infectious diseasesOpen Forum Infect"/>
   <result pre="practical guide for the infectious disease physician to treat opioid" exact="use disorder" post="in the setting of associated infectious diseasesOpen Forum Infect"/>
   <result pre="to treat opioid use disorder in the setting of associated" exact="infectious" post="diseasesOpen Forum Infect Dis72020ofz53931993454 51SevalN.EatonE.SpringerS.A.Inpatient Opioid Use Disorder (OUD)"/>
   <result pre="of associated infectious diseasesOpen Forum Infect Dis72020ofz53931993454 51SevalN.EatonE.SpringerS.A.Inpatient Opioid Use" exact="Disorder" post="(OUD) treatment for the infectious disease physicianNortonB.The opioid epidemic"/>
   <result pre="Infect Dis72020ofz53931993454 51SevalN.EatonE.SpringerS.A.Inpatient Opioid Use Disorder (OUD) treatment for the" exact="infectious disease" post="physicianNortonB.The opioid epidemic and infectious diseases1st edition2020Elsevier Inc.New York"/>
   <result pre="Dis72020ofz53931993454 51SevalN.EatonE.SpringerS.A.Inpatient Opioid Use Disorder (OUD) treatment for the infectious" exact="disease" post="physicianNortonB.The opioid epidemic and infectious diseases1st edition2020Elsevier Inc.New York"/>
   <result pre="(OUD) treatment for the infectious disease physicianNortonB.The opioid epidemic and" exact="infectious" post="diseases1st edition2020Elsevier Inc.New York 52GowingL.FarrellM.F.BornemannR.Oral substitution treatment of injecting"/>
   <result pre="prevention of HIV infectionCochrane Database Syst Rev82011CD004145 53SpringerS.A.ChenS.AlticeF.L.Improved HIV and" exact="substance abuse" post="treatment outcomes for released HIV-infected prisoners: the impact of"/>
   <result pre="impact of buprenorphine treatmentJ Urban Health87201059260220177974 54SpringerS.A.Di PaolaA.AzarM.M.Extended-release naltrexone improves" exact="viral" post="suppression among incarcerated persons living with HIV with opioid"/>
   <result pre="55SpringerS.A.QiuJ.Saber-TehraniA.S.Retention on buprenorphine is associated with high levels of maximal" exact="viral" post="suppression among HIV-infected opioid dependent released prisonersPLoS One72012e3833522719814 56SpringerS.A.KorthuisP.T.Del"/>
   <result pre="released prisonersPLoS One72012e3833522719814 56SpringerS.A.KorthuisP.T.Del RioC.Integrating treatment at the intersection of" exact="opioid use disorder" post="and infectious disease epidemics in medical settings: a call"/>
   <result pre="prisonersPLoS One72012e3833522719814 56SpringerS.A.KorthuisP.T.Del RioC.Integrating treatment at the intersection of opioid" exact="use disorder" post="and infectious disease epidemics in medical settings: a call"/>
   <result pre="RioC.Integrating treatment at the intersection of opioid use disorder and" exact="infectious disease" post="epidemics in medical settings: a call for action after"/>
   <result pre="treatment at the intersection of opioid use disorder and infectious" exact="disease" post="epidemics in medical settings: a call for action after"/>
   <result pre="Engineering, and MedicineIntegrating responses at the Intersection of Opioid Use" exact="Disorder" post="and Infectious Disease Epidemics: Proceedings of a WorkshopNational Academies"/>
   <result pre="MedicineIntegrating responses at the Intersection of Opioid Use Disorder and" exact="Infectious" post="Disease Epidemics: Proceedings of a WorkshopNational Academies of Sciences,"/>
   <result pre="responses at the Intersection of Opioid Use Disorder and Infectious" exact="Disease" post="Epidemics: Proceedings of a WorkshopNational Academies of Sciences, Engineering,"/>
   <result pre="DCAvailable at: http://www.nationalacademies.org/hmd/Reports/2018/integrating-responses-at-the-intersection-of-opioid-use-disorder-and-infectious-disease-epidemics-proceedings.aspx. 58SpringerS.A.MerluzziA.P.Del RioC.Integrating Responses to the Opioid Use" exact="Disorder" post="and Infectious Disease Epidemics: A Report From the National"/>
   <result pre="http://www.nationalacademies.org/hmd/Reports/2018/integrating-responses-at-the-intersection-of-opioid-use-disorder-and-infectious-disease-epidemics-proceedings.aspx. 58SpringerS.A.MerluzziA.P.Del RioC.Integrating Responses to the Opioid Use Disorder and" exact="Infectious" post="Disease Epidemics: A Report From the National Academies of"/>
   <result pre="58SpringerS.A.MerluzziA.P.Del RioC.Integrating Responses to the Opioid Use Disorder and Infectious" exact="Disease" post="Epidemics: A Report From the National Academies of Sciences,"/>
   <result pre="Academies of Sciences, Engineering, and MedicineJAMA2020Available at: https://www.ncbi.nlm.nih.gov/pubmed/32159771 59Reducing the" exact="Infectious" post="Consequences of Substance Use Disorders: An Urgent Call to"/>
   <result pre="Substance Use Disorders: An Urgent Call to Action from the" exact="Infectious" post="Disease Society of America (IDSA) and HIV Medicine Association"/>
   <result pre="Use Disorders: An Urgent Call to Action from the Infectious" exact="Disease" post="Society of America (IDSA) and HIV Medicine Association (HIVMA)."/>
   <result pre="of America (IDSA) and HIV Medicine Association (HIVMA). Journal Of" exact="Infectious" post="Disease. September 2020. In Press. Disclosure S.A. Springer has"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7414935/results/search/disease/results.xml">
   <result pre="humans, thereby posing a threat to global public health. CoV" exact="infection" post="mostly occurs during winter and spring in temperate countries;"/>
   <result pre="the virus has high transmission efficiency and may have severe" exact="infection" post="outcomes. The recent SARS-CoV-2 outbreak exhibited transboundary transmission due"/>
   <result pre="while livestock, poultry and other warm-blooded animals may act as" exact="intermediate" post="hosts for CoVs. This paper outlines the biological and"/>
   <result pre="CoVs, while only a few CoVs can infect humans through" exact="intermediate" post="hosts. Human infections result in diverse symptoms and diseases"/>
   <result pre="a few CoVs can infect humans through intermediate hosts. Human" exact="infections" post="result in diverse symptoms and diseases of the respiratory"/>
   <result pre="Human infections result in diverse symptoms and diseases of the" exact="respiratory" post="tract, digestive tract, and nervous system. For example, the"/>
   <result pre="digestive tract, and nervous system. For example, the Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) caused Middle East respiratory syndrome after"/>
   <result pre="tract, and nervous system. For example, the Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) caused Middle East respiratory syndrome after infecting"/>
   <result pre="the Middle East respiratory syndrome coronavirus (MERS-CoV) caused Middle East" exact="respiratory" post="syndrome after infecting dromedary camels. Currently, there are seven"/>
   <result pre="Middle East respiratory syndrome coronavirus (MERS-CoV) caused Middle East respiratory" exact="syndrome" post="after infecting dromedary camels. Currently, there are seven known"/>
   <result pre="SARS-CoV, MERS-CoV, and the newly discovered SARS-CoV-2 that causes coronavirus" exact="disease" post="2019 (COVID-19).3 CoVs usually cause self-limiting and mild respiratory"/>
   <result pre="coronavirus disease 2019 (COVID-19).3 CoVs usually cause self-limiting and mild" exact="respiratory" post="tract infections; the main symptoms include fever, coughing, runny"/>
   <result pre="mild respiratory tract infections; the main symptoms include fever, coughing," exact="runny nose," post="and wheezing. Therefore, these infections are often misdiagnosed as"/>
   <result pre="symptoms include fever, coughing, runny nose, and wheezing. Therefore, these" exact="infections" post="are often misdiagnosed as pneumonia.4,5 SARS-CoV, MERS-CoV, and SARS-CoV-2"/>
   <result pre="of deaths. SARS-CoV and SARS-CoV-2 are designated as category B" exact="infectious diseases" post="by the National Health Commission, and prevention and control"/>
   <result pre="are carried out according to measures used for category a" exact="infectious" post="diseases.6 CoV outbreaks mostly occur during winter and spring"/>
   <result pre="Other species of livestock, poultry and warm-blooded animals may be" exact="intermediate" post="hosts for CoVs.7 Currently, CoVs with high mortality rate"/>
   <result pre="Currently, CoVs with high mortality rate mainly infect humans through" exact="intermediate" post="hosts and &quot;host jumps.&quot; In addition, there is no"/>
   <result pre="specific drug or vaccine available for CoVs, and thus only" exact="symptomatic" post="treatments are used. Increasing movement of people and international"/>
   <result pre="amount of nucleocapsid protein (N protein) is attached to the" exact="viral" post="RNA, and the surface of the virus particle contains"/>
   <result pre="of polymerization; it can induce cellular immunity and bind to" exact="viral" post="RNA to form the nucleocapsid.13 The S protein recognizes"/>
   <result pre="recognizes specific receptors (N-acetyl-neuraminic acid) on the cell surface during" exact="infection" post="to penetrate and lyse the cell membrane so that"/>
   <result pre="infection to penetrate and lyse the cell membrane so that" exact="viral" post="nucleic acid can be injected into cells and induce"/>
   <result pre="and triggers virus particle assembly and the formation of new" exact="viral" post="envelopes.15 The E protein is smaller and is mainly"/>
   <result pre="UTRs are extremely important for the translation and replication of" exact="viral" post="RNA in the host. The remaining middle sequence contains"/>
   <result pre="rate that mainly involves nucleic acid changes.23 MERS-CoV is still" exact="infectious" post="after 60 minutes of aerosolization at 25°C and 79%"/>
   <result pre="and other lipid solvents are associated with effective virus destruction.27" exact="Infection" post="Process The main target cells of CoVs include macrophages,"/>
   <result pre="of subgenomic mRNA, and replication of virus genomic gRNA.32 After" exact="virus infection" post="of host cells, dendritic cells (DC) will recognize these"/>
   <result pre="subgenomic mRNA, and replication of virus genomic gRNA.32 After virus" exact="infection" post="of host cells, dendritic cells (DC) will recognize these"/>
   <result pre="cells, dendritic cells (DC) will recognize these cells and secrete" exact="type I" post="interferons (IFN-α and IFN-β) and inflammatory factors such as"/>
   <result pre="CoVs can inhibit signaling pathways related to the secretion of" exact="type I" post="interferons and chemokines and can impair the function of"/>
   <result pre="which CoVs evade immune responses.38 Epidemiological Characteristics of Coronavirus CoV" exact="infections" post="are distributed globally but show regional differences. Humans are"/>
   <result pre="regional differences. Humans are generally susceptible and can develop self-limiting" exact="acute" post="or chronic persistent infections and can suffer repeated infection"/>
   <result pre="differences. Humans are generally susceptible and can develop self-limiting acute" exact="or chronic" post="persistent infections and can suffer repeated infection and coinfection"/>
   <result pre="Humans are generally susceptible and can develop self-limiting acute or" exact="chronic" post="persistent infections and can suffer repeated infection and coinfection"/>
   <result pre="generally susceptible and can develop self-limiting acute or chronic persistent" exact="infections" post="and can suffer repeated infection and coinfection by multiple"/>
   <result pre="self-limiting acute or chronic persistent infections and can suffer repeated" exact="infection" post="and coinfection by multiple respiratory viruses. CoV infections mainly"/>
   <result pre="infections and can suffer repeated infection and coinfection by multiple" exact="respiratory" post="viruses. CoV infections mainly occur during winter and spring."/>
   <result pre="suffer repeated infection and coinfection by multiple respiratory viruses. CoV" exact="infections" post="mainly occur during winter and spring. HCoV-229E and HCoV-OC43"/>
   <result pre="years during winter and spring, but pandemics are rare. The" exact="infection" post="rate of HCoV-HKU1 is 0.3–4.4%. HCoV-NL63 mainly cause epidemics"/>
   <result pre="although infants, elderly people, immunosuppressed patients, and patients with underlying" exact="disease" post="are most susceptible. The incidence is around 2%, while"/>
   <result pre="infected with HCoV-229E, HCoV-NL63, or HCoV-OC43 in childhood. However, repeated" exact="infections" post="may occur throughout life due to reduction in antibody"/>
   <result pre="occur throughout life due to reduction in antibody titers and" exact="viral" post="mutation.39,40 Although human CoV infections often cause mild upper"/>
   <result pre="reduction in antibody titers and viral mutation.39,40 Although human CoV" exact="infections" post="often cause mild upper respiratory tract infections, deaths still"/>
   <result pre="and viral mutation.39,40 Although human CoV infections often cause mild" exact="upper" post="respiratory tract infections, deaths still occur when patients suffer"/>
   <result pre="viral mutation.39,40 Although human CoV infections often cause mild upper" exact="respiratory" post="tract infections, deaths still occur when patients suffer from"/>
   <result pre="the rest of the world. Ultimately, SARS-CoV resulted in 8096" exact="infections" post="and 774 deaths in 32 countries, with a mortality"/>
   <result pre="or territories and more than 13876441 confirmed cases of coronavirus" exact="disease" post="2019 (COVID-19) caused by SARS-CoV-2, where the virus infects"/>
   <result pre="14.8%, respectively. The mortality rate is higher in patients with" exact="cardiovascular disease," post="diabetes, chronic respiratory diseases, or hypertension.3 Clinical Symptoms and"/>
   <result pre="mortality rate is higher in patients with cardiovascular disease, diabetes," exact="chronic" post="respiratory diseases, or hypertension.3 Clinical Symptoms and Diagnosis of"/>
   <result pre="rate is higher in patients with cardiovascular disease, diabetes, chronic" exact="respiratory" post="diseases, or hypertension.3 Clinical Symptoms and Diagnosis of Coronavirus"/>
   <result pre="respiratory diseases, or hypertension.3 Clinical Symptoms and Diagnosis of Coronavirus" exact="Pneumonia" post="Symptoms of Coronavirus Infection The incubation period of human"/>
   <result pre="Clinical Symptoms and Diagnosis of Coronavirus Pneumonia Symptoms of Coronavirus" exact="Infection" post="The incubation period of human CoV infection41 is around"/>
   <result pre="of human CoV infection41 is around 2–5 days, and the" exact="disease" post="course is 6–7 days. CoV infection mainly causes fever,"/>
   <result pre="2–5 days, and the disease course is 6–7 days. CoV" exact="infection" post="mainly causes fever, runny nose, cough, and headaches, while"/>
   <result pre="disease course is 6–7 days. CoV infection mainly causes fever," exact="runny nose," post="cough, and headaches, while gastrointestinal symptoms occur in some"/>
   <result pre="cases. However, symptoms are normally mild. Bronchitis, pneumonia, or severe" exact="respiratory" post="diseases may result in infants, elderly people, and immunocompromised"/>
   <result pre="people, and immunocompromised people. HCoV-229E has a higher proportion of" exact="runny nose" post="symptoms compared with other common respiratory diseases. HCoV-OC43 often"/>
   <result pre="higher proportion of runny nose symptoms compared with other common" exact="respiratory" post="diseases. HCoV-OC43 often causes more severe symptoms than HCoV-229E,"/>
   <result pre="HCoV-OC43 often causes more severe symptoms than HCoV-229E, but asymptomatic" exact="infections" post="and occasional severe lower respiratory tract infections may be"/>
   <result pre="severe symptoms than HCoV-229E, but asymptomatic infections and occasional severe" exact="lower" post="respiratory tract infections may be present. HCoV-HKU1 does not"/>
   <result pre="symptoms than HCoV-229E, but asymptomatic infections and occasional severe lower" exact="respiratory" post="tract infections may be present. HCoV-HKU1 does not have"/>
   <result pre="HCoV-229E, but asymptomatic infections and occasional severe lower respiratory tract" exact="infections" post="may be present. HCoV-HKU1 does not have specific characteristic"/>
   <result pre="not have specific characteristic symptoms and is often diagnosed as" exact="bronchiolitis" post="or pneumonia, but infants tend to develop convulsions and"/>
   <result pre="bronchiolitis or pneumonia, but infants tend to develop convulsions and" exact="febrile seizures." post="HCoV-NL63 may cause severe cold symptoms and acute respiratory"/>
   <result pre="and febrile seizures. HCoV-NL63 may cause severe cold symptoms and" exact="acute" post="respiratory symptoms in infants and immunocompromised adults. The incubation"/>
   <result pre="febrile seizures. HCoV-NL63 may cause severe cold symptoms and acute" exact="respiratory" post="symptoms in infants and immunocompromised adults. The incubation period"/>
   <result pre="2–14 days, of which 3–5 days is the most common." exact="Fever" post="is the first symptom to occur, with a temperature"/>
   <result pre="with a temperature of more than 38°C accompanied by headaches," exact="muscle" post="aches, malaise, and diarrhea. Subsequently, pneumonia, frequent coughing, and"/>
   <result pre="and/or shortness of breath, diarrhea, and other gastrointestinal symptoms. The" exact="disease" post="rapidly progresses to severe pneumonia and causes respiratory failure,"/>
   <result pre="and other gastrointestinal symptoms. The disease rapidly progresses to severe" exact="pneumonia" post="and causes respiratory failure, thrombocytopenia, and coagulation disorder. MERS-CoV"/>
   <result pre="symptoms. The disease rapidly progresses to severe pneumonia and causes" exact="respiratory" post="failure, thrombocytopenia, and coagulation disorder. MERS-CoV infection tends to"/>
   <result pre="pneumonia and causes respiratory failure, thrombocytopenia, and coagulation disorder. MERS-CoV" exact="infection" post="tends to lead to renal failure or septic shock"/>
   <result pre="thrombocytopenia, and coagulation disorder. MERS-CoV infection tends to lead to" exact="renal failure" post="or septic shock in immunocompromised people. The incubation period"/>
   <result pre="disorder. MERS-CoV infection tends to lead to renal failure or" exact="septic shock" post="in immunocompromised people. The incubation period of SARS-CoV-23 infection"/>
   <result pre="septic shock in immunocompromised people. The incubation period of SARS-CoV-23" exact="infection" post="is 1–14 days, of which 3–7 days is the"/>
   <result pre="the most common incubation period. The main symptoms of SARS-CoV-2" exact="infection" post="include fever, fatigue, and dry cough along with ground-glass"/>
   <result pre="in both lungs. A minority of patients develop nasal congestion," exact="runny nose," post="sore throat, and diarrhea. Severely affected patients will experience"/>
   <result pre="will experience dyspnea and/or hypoxemia, and critical patients will develop" exact="acute" post="respiratory distress syndrome, septic shock, refractory metabolic acidosis, and"/>
   <result pre="experience dyspnea and/or hypoxemia, and critical patients will develop acute" exact="respiratory" post="distress syndrome, septic shock, refractory metabolic acidosis, and coagulation"/>
   <result pre="hypoxemia, and critical patients will develop acute respiratory distress syndrome," exact="septic shock," post="refractory metabolic acidosis, and coagulation disorders. Some SARS-CoV, MERS-CoV,"/>
   <result pre="patients will develop acute respiratory distress syndrome, septic shock, refractory" exact="metabolic acidosis," post="and coagulation disorders. Some SARS-CoV, MERS-CoV, and SARS-CoV-2 patients"/>
   <result pre="for integrated analysis, and a clinical diagnosis should be made." exact="Respiratory" post="tract samples or blood samples should be used for"/>
   <result pre="density and widespread distribution of bats provide opportunities for pathogen" exact="infection" post="and rapid transmission. When there is frequent contact between"/>
   <result pre="human diet, has climbed during these decades. For example, SARS," exact="Marburg hemorrhagic fever," post="and Ebola hemorrhagic fever are associated with human consumption"/>
   <result pre="hemorrhagic fever, and Ebola hemorrhagic fever are associated with human" exact="consumption" post="of wildlife. And Public Health England (PHE) also indicated"/>
   <result pre="England (PHE) also indicated that 60% to 80% of emerging" exact="infections" post="are derived from an animal source. And &quot;Bush meat&quot;"/>
   <result pre="emerging infections.49 One study suggested that pangolins may be an" exact="intermediate" post="host for SARS-CoV-2.50 Consumption of pangolins, illegal but frequent,"/>
   <result pre="frequent, is present throughout the world that might be an" exact="infection" post="pathway of COVID-19. In addition, excessive emphasis on food"/>
   <result pre="in the prevalence of cold foods, raw foods and other" exact="consumption" post="methods. However, most bacteria and viruses (eg Ebola virus,"/>
   <result pre="strong infectivity under room temperature and refrigeration conditions, causing possible" exact="food poisoning" post="or foodborne infections in humans and providing conditions for"/>
   <result pre="temperature and refrigeration conditions, causing possible food poisoning or foodborne" exact="infections" post="in humans and providing conditions for viral and bacterial"/>
   <result pre="poisoning or foodborne infections in humans and providing conditions for" exact="viral" post="and bacterial outbreaks in human societies. Therefore, China has"/>
   <result pre="foodborne infections in humans and providing conditions for viral and" exact="bacterial" post="outbreaks in human societies. Therefore, China has revised the"/>
   <result pre="the list of &quot;animal sources of epidemics&quot; to ban the" exact="consumption" post="of wildlife. Evidently, CoVs can infect humans, and positive"/>
   <result pre="camels, and birds. Therefore, it is a high risk of" exact="infection" post="from uncooked animal-source foods such as milk and meat."/>
   <result pre="rates of intestinal and stool samples are higher than for" exact="respiratory" post="tract or urine samples, indicating that before entering the"/>
   <result pre="means potential but no evidence of transmission. Although there are" exact="limited" post="intermediate hosts for CoV transmission from bats to humans,"/>
   <result pre="potential but no evidence of transmission. Although there are limited" exact="intermediate" post="hosts for CoV transmission from bats to humans, certain"/>
   <result pre="factories and meat markets are known to be hotbeds for" exact="disease" post="for deadly pathogens like the ones behind COVID-19, SARS,"/>
   <result pre="disease for deadly pathogens like the ones behind COVID-19, SARS," exact="bird flu," post="and more (PHE).49 Due to the risk of virus"/>
   <result pre="in processing companies and the foodborne transmission nature of CoVs," exact="residual" post="viruses may be present in raw materials, intermediate products,"/>
   <result pre="of CoVs, residual viruses may be present in raw materials," exact="intermediate" post="products, and finished products. And coronavirus’ apparent ability to"/>
   <result pre="And coronavirus’ apparent ability to thrive in cold, humid air," exact="infection" post="control should be strengthened in the processing of animal-source"/>
   <result pre="large number of people staying in close quarters and sharing" exact="limited" post="space, measures should be adopted to prevent infection in"/>
   <result pre="and sharing limited space, measures should be adopted to prevent" exact="infection" post="in company staff. Routine Control Measures in Foodstuff Manufacturing"/>
   <result pre="after a health certificate has been obtained. Staff with dysentery," exact="hepatitis" post="A and other digestive tract diseases, pulmonary tuberculosis, or"/>
   <result pre="Staff with dysentery, hepatitis A and other digestive tract diseases," exact="pulmonary" post="tuberculosis, or exudative or purulent skin diseases should not"/>
   <result pre="hepatitis A and other digestive tract diseases, pulmonary tuberculosis, or" exact="exudative" post="or purulent skin diseases should not be employed.60 During"/>
   <result pre="other digestive tract diseases, pulmonary tuberculosis, or exudative or purulent" exact="skin diseases" post="should not be employed.60 During CoV epidemics, foodstuff companies"/>
   <result pre="steps to protect workers. For instance, the federal Centers for" exact="Disease" post="Control (CDC) and the Occupational Health and Safety Administration"/>
   <result pre="so that workers can remain six feet apart and providing" exact="short" post="breaks to allow workers to wash their hands more"/>
   <result pre="for normal slaughter. When animals that have died due to" exact="disease" post="are discovered, they should be processed according to the"/>
   <result pre="include CoV testing staff, basic medical staff, company directors, and" exact="disease" post="prevention and control center monitors who will test and"/>
   <result pre="and must be disposed of and reported to the local" exact="disease" post="prevention and control center and the National Medical Products"/>
   <result pre="be quarantine and stricter disinfections should be taken. If an" exact="intermediate" post="product or finished product tests positive, the local disease"/>
   <result pre="an intermediate product or finished product tests positive, the local" exact="disease" post="prevention and control center must be notified, the product"/>
   <result pre="foods. At the same time, human hunting of wildlife and" exact="consumption" post="of raw animal-source foods has continued to increase, resulting"/>
   <result pre="are currently no effective vaccines or drugs for CoVs, deviant" exact="consumption" post="mentality should be curbed. Meat is an indispensable nutrient"/>
   <result pre="doi:10.1136/bmj.1.5448.146714288084 2.DrexlerJF, Gloza-RauschF, GlendeJ, et al. Genomic characterization of severe" exact="acute" post="respiratory syndrome-related coronavirus in European bats and classification of"/>
   <result pre="2.DrexlerJF, Gloza-RauschF, GlendeJ, et al. Genomic characterization of severe acute" exact="respiratory" post="syndrome-related coronavirus in European bats and classification of coronaviruses"/>
   <result pre="coronavirus in European bats and classification of coronaviruses based on" exact="partial" post="RNA-dependent RNA polymerase gene sequences. J Virol. 2010;84:11336–11349. doi:10.1128/JVI.00650-1020686038"/>
   <result pre="Accessed 724, 2020. 4.WooPC, LauSK, ChuCM, et al. Characterization and" exact="complete" post="genome sequence of a novel coronavirus, coronavirus HKU1, from"/>
   <result pre="J Virol. 2005;79:884–895. doi:10.1128/JVI.79.2.884-895.200515613317 5.WooPC, YuenKY, LauSK. Epidemiology of coronavirus-associated" exact="respiratory" post="tract infections and the role of rapid diagnostic tests:"/>
   <result pre="2005;79:884–895. doi:10.1128/JVI.79.2.884-895.200515613317 5.WooPC, YuenKY, LauSK. Epidemiology of coronavirus-associated respiratory tract" exact="infections" post="and the role of rapid diagnostic tests: a prospective"/>
   <result pre="by the novel coronavirus is placed under the control of" exact="infectious disease" post="statutory. National Health Commission of the People’s Republic of"/>
   <result pre="the novel coronavirus is placed under the control of infectious" exact="disease" post="statutory. National Health Commission of the People’s Republic of"/>
   <result pre="pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181–192. doi:10.1038/s41579-018-0118-930531947 10.JohnsonBA, GrahamRL, MenacheryVD." exact="Viral" post="metagenomics, protein structure, and reverse genetics: key strategies for"/>
   <result pre="and functional regions of the human coronavirus OC43 nucleocapsid protein." exact="Protein" post="Sci. 2009;18:2209–2218. doi:10.1002/pro.22519691129 14.SanchezCM, IzetaA, Sanchez-morgadoJM, et al. Target"/>
   <result pre="et al. Target recombination demonstrates the spike gene of transmissible" exact="gastroenteritis" post="coronavirus is a determination of its tropism and virulence."/>
   <result pre="al. The membrane M protein carboxy terminal bind to transmissible" exact="gastroenteritis" post="coronavirus core and contribute to core stability. J Virol."/>
   <result pre="contribute to core stability. J Virol. 2001;75:1312–1324. doi:10.1128/JVI.75.3.1312-1324.200111152504 16.CorseE, MachamerCE." exact="Infectious" post="bronchitis virus E protein is targeted to the golgi"/>
   <result pre="to core stability. J Virol. 2001;75:1312–1324. doi:10.1128/JVI.75.3.1312-1324.200111152504 16.CorseE, MachamerCE. Infectious" exact="bronchitis" post="virus E protein is targeted to the golgi complex"/>
   <result pre="19.IzetaA, SmerdouC, AlonsoS, et al. Replication and packaging of transmissible" exact="gastroenteritis" post="coronavirus-derived synthetic minigenomes. J Virol. 1999;73:1535–1545. doi:10.1128/JVI.73.2.1535-1545.19999882359 20.SpaanWJM, DeliusH,"/>
   <result pre="2001;88:183–204. doi:10.1016/S0168-1656(01)00281-4 23.KhanRM, Al-DorziHM, Al JohaniS, et al. Middle East" exact="respiratory" post="syndrome coronavirus on inanimate surfaces: a risk for health"/>
   <result pre="doi:10.1016/S0168-1656(01)00281-4 23.KhanRM, Al-DorziHM, Al JohaniS, et al. Middle East respiratory" exact="syndrome" post="coronavirus on inanimate surfaces: a risk for health care"/>
   <result pre="BatejatC, BurguiereAM, et al. Heat inactivation of the Middle East" exact="respiratory" post="syndrome coronavirus. Influenza Other Respir. 2014;8:585–586. doi:10.1111/irv.12261 27.ZhangC, WangG,"/>
   <result pre="BurguiereAM, et al. Heat inactivation of the Middle East respiratory" exact="syndrome" post="coronavirus. Influenza Other Respir. 2014;8:585–586. doi:10.1111/irv.12261 27.ZhangC, WangG, YaoY."/>
   <result pre="syndrome coronavirus. Influenza Other Respir. 2014;8:585–586. doi:10.1111/irv.12261 27.ZhangC, WangG, YaoY." exact="Resistance" post="and stability capacity of SARS-CoV against physicochemical factors in"/>
   <result pre="coronavirus. Nature. 2003;426:450–454. doi:10.1038/nature0214514647384 31.WilliamsRK, JiangGD, HolmesKM. Receptor for mouse" exact="hepatitis" post="virus is a member of the carcinoembryonic antigen family"/>
   <result pre="entry pathway of coronavirus. Chin J Virol. 2019;35:964–971. 33.StetsonDB, MedzhitovR." exact="Type I" post="interferons in host defense. Immunity. 2006;25:373–381. doi:10.1016/j.immuni.2006.08.00716979569 34.FensterlV, SenGC."/>
   <result pre="in host defense. Immunity. 2006;25:373–381. doi:10.1016/j.immuni.2006.08.00716979569 34.FensterlV, SenGC. Interferons and" exact="viral" post="infections. Biofactors. 2009;35:14–20. doi:10.1002/biof.619319841 35.SherryB, Tekamp-OlsonP, GallegosC, et al."/>
   <result pre="Immunol. 2017;33:488–493. 38.DominguezSR, TravantyEA, QianZ, et al. Human coronavirus HKU1" exact="infection" post="of primary human type II alveolar epithelial cells: cytopathic"/>
   <result pre="38.DominguezSR, TravantyEA, QianZ, et al. Human coronavirus HKU1 infection of" exact="primary" post="human type II alveolar epithelial cells: cytopathic effects and"/>
   <result pre="QianZ, et al. Human coronavirus HKU1 infection of primary human" exact="type II" post="alveolar epithelial cells: cytopathic effects and innate immune response."/>
   <result pre="Human coronavirus HKU1 infection of primary human type II alveolar" exact="epithelial" post="cells: cytopathic effects and innate immune response. PLoS One."/>
   <result pre="ZhangD, WangW, et al. A novel coronavirus from patients with" exact="pneumonia" post="in China. N Engl J Med. 2020;382:727–733. doi:10.1056/NEJMoa200101731978945 46.ForniD,"/>
   <result pre="diversity of bat viruses and the bat origin of emerging" exact="infectious diseases." post="ISME J. 2016;10:609–620. doi:10.1038/ismej.2015.13826262818 48.RodhainE. Bats and viruses: complex"/>
   <result pre="Gen Virol. 2017;98:2297–2309. doi:10.1099/jgv.0.00089828840816 52.AlloacatiN, PetrucciAG, GiovanniPD, et al. Bat-man" exact="disease" post="transmission: zoonotic pathogens from wildlife reservoirs to human populations."/>
   <result pre="2005;11:446–448. doi:10.3201/eid1103.04082415757562 58.Vergara-AlertJ, van de BrandJMA, WidagdoW, et al. Livestock" exact="susceptibility to" post="infection with Middle East respiratory syndrome coronavirus. Emerg Infect"/>
   <result pre="58.Vergara-AlertJ, van de BrandJMA, WidagdoW, et al. Livestock susceptibility to" exact="infection" post="with Middle East respiratory syndrome coronavirus. Emerg Infect Dis."/>
   <result pre="WidagdoW, et al. Livestock susceptibility to infection with Middle East" exact="respiratory" post="syndrome coronavirus. Emerg Infect Dis. 2017;23:232–240. doi:10.3201/eid2302.16123927901465 59.SabirJSM, LamTT,"/>
   <result pre="et al. Livestock susceptibility to infection with Middle East respiratory" exact="syndrome" post="coronavirus. Emerg Infect Dis. 2017;23:232–240. doi:10.3201/eid2302.16123927901465 59.SabirJSM, LamTT, AhmedMM,"/>
   <result pre="2016;351:81–84. doi:10.1126/science.aac860826678874 60.Standardization Administration.GB 14881-2013 National Standard for Food Safety:" exact="General" post="Hygienic Standard for Food Production. China standard press; 2014."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7416915/results/search/disease/results.xml">
   <result pre="sciences : Microbiology : Medical microbiology : Microbial pathogens :" exact="Viral" post="pathogens : Coronaviruses : SARS coronavirus: SARS CoV 2"/>
   <result pre="Pathology and laboratory medicine : Pathogens : Microbial pathogens :" exact="Viral" post="pathogens : Coronaviruses : SARS coronavirus: SARS CoV 2"/>
   <result pre=": Biology and life sciences : Organisms : Viruses :" exact="Viral" post="pathogens : Coronaviruses : SARS coronavirus: SARS CoV 2"/>
   <result pre="2 : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases : Infectious Disease Control: Social Distancing : Medicine"/>
   <result pre=": Medicine and Health Sciences : Medical Conditions : Infectious" exact="Diseases" post=": Infectious Disease Control: Social Distancing : Medicine and"/>
   <result pre="and Health Sciences : Medical Conditions : Infectious Diseases :" exact="Infectious" post="Disease Control: Social Distancing : Medicine and Health Sciences"/>
   <result pre="Health Sciences : Medical Conditions : Infectious Diseases : Infectious" exact="Disease" post="Control: Social Distancing : Medicine and Health Sciences :"/>
   <result pre="Distancing : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases: Respiratory Infections : Medicine and Health Sciences :"/>
   <result pre="Medicine and Health Sciences : Medical Conditions : Infectious Diseases:" exact="Respiratory" post="Infections : Medicine and Health Sciences : Medical Conditions"/>
   <result pre="and Health Sciences : Medical Conditions : Infectious Diseases: Respiratory" exact="Infections" post=": Medicine and Health Sciences : Medical Conditions :"/>
   <result pre="Infections : Medicine and Health Sciences : Medical Conditions :" exact="Respiratory" post="Disorders: Respiratory Infections : Medicine and Health Sciences :"/>
   <result pre="Medicine and Health Sciences : Medical Conditions : Respiratory Disorders:" exact="Respiratory" post="Infections : Medicine and Health Sciences : Pulmonology :"/>
   <result pre="and Health Sciences : Medical Conditions : Respiratory Disorders: Respiratory" exact="Infections" post=": Medicine and Health Sciences : Pulmonology : Respiratory"/>
   <result pre="Respiratory Infections : Medicine and Health Sciences : Pulmonology :" exact="Respiratory" post="Disorders: Respiratory Infections : People and places : Geographical"/>
   <result pre=": Medicine and Health Sciences : Pulmonology : Respiratory Disorders:" exact="Respiratory" post="Infections : People and places : Geographical locations :"/>
   <result pre="Medicine and Health Sciences : Pulmonology : Respiratory Disorders: Respiratory" exact="Infections" post=": People and places : Geographical locations : North"/>
   <result pre=": Epidemiology: Social Epidemiology Modeling the role of asymptomatics in" exact="infection" post="spread with application to SARS-CoV-2 Asymptomatics in SARS-CoV-2 http://orcid.org/0000-0003-3592-6770DobrovolnyHana"/>
   <result pre="original author and source are credited.pone.0236976.pdf Abstract SARS-CoV-2 started causing" exact="infections" post="in humans in late 2019 and has spread rapidly"/>
   <result pre="this study, we use a compartmental mathematical model of a" exact="viral" post="epidemic that includes asymptomatic infection to examine the role"/>
   <result pre="compartmental mathematical model of a viral epidemic that includes asymptomatic" exact="infection" post="to examine the role of asymptomatic individuals in the"/>
   <result pre="in California, Florida, New York, and Texas, finding that asymptomatic" exact="infections" post="far outnumber reported symptomatic infections at the peak of"/>
   <result pre="York, and Texas, finding that asymptomatic infections far outnumber reported" exact="symptomatic" post="infections at the peak of the epidemic in all"/>
   <result pre="and Texas, finding that asymptomatic infections far outnumber reported symptomatic" exact="infections" post="at the peak of the epidemic in all four"/>
   <result pre="widely around the world. The virus can cause a severe" exact="respiratory" post="illness, known as COVID-19, characterized by fever and cough"/>
   <result pre="COVID-19, characterized by fever and cough that can lead to" exact="respiratory" post="failure and death [3, 4]. The virus appears to"/>
   <result pre="cases. One study estimated that the asymptomatic proportion of SARS-CoV-2" exact="infections" post="on the Diamond Princess cruise ship docked outside Tokyo"/>
   <result pre="Japanese evacuees from Wuhan, China estimated the proportion of asymptomatic" exact="infections" post="at ∼30% [11]. A similar study of German nationals"/>
   <result pre="that ∼5% of patients testing positive for SARS-CoV-2 had asymptomatic" exact="infections" post="[15]. While the exact proportion of asymptomatic infections is"/>
   <result pre="had asymptomatic infections [15]. While the exact proportion of asymptomatic" exact="infections" post="is still unclear, these studies indicate that asymptomatic infections"/>
   <result pre="asymptomatic infections is still unclear, these studies indicate that asymptomatic" exact="infections" post="with SARS-CoV-2 are not uncommon. However, it is not"/>
   <result pre="are not uncommon. However, it is not enough that asymptomatic" exact="infections" post="exist. In order for asymptomatic individuals to spread the"/>
   <result pre="indicate this might in fact be the case for asymptomatic" exact="infections" post="with SARS-CoV-2. Zhang et al. [16] report on a"/>
   <result pre="infections with SARS-CoV-2. Zhang et al. [16] report on a" exact="familial" post="cluster of COVID patients initiated by an asymptomatic individual."/>
   <result pre="other members of his family [17]. A series of SARS-CoV-2" exact="infections" post="among business associates in Germany was traced to a"/>
   <result pre="study of transmission in China that suggests that ∼86% of" exact="infections" post="were caused by asymptomatic or unreported cases [9]. These"/>
   <result pre="asymptomatics during an epidemic have previously been done for other" exact="infectious diseases" post="[19–26]. These models have estimated the proportion of asymptomatic"/>
   <result pre="the current SARS-CoV-2 pandemic, isolation and social distancing are the" exact="primary" post="weapons in stopping the spread of the infection. In"/>
   <result pre="paper, we study a compartmental epidemic model that includes asymptomatic" exact="infections" post="to determine the role that asymptomatic individuals might play"/>
   <result pre="New York, and Texas, finding that a large number of" exact="infections" post="in these states are unreported and that relaxing social"/>
   <result pre="distancing measures too early will cause a rapid spike in" exact="infections" post="driven in part by these hidden infections. Materials and"/>
   <result pre="Mathematical model We use a compartmental model that includes asymptomatic" exact="infections" post="with assumptions geared towards modeling the current SARS-CoV-2 pandemic,"/>
   <result pre="died. We assume that the course of the epidemic is" exact="short" post="compared to the human lifespan and do not include"/>
   <result pre="births or deaths from other causes, instead assuming that the" exact="total" post="population, N = S + A + I +"/>
   <result pre="the asymptomatics can infect susceptible individuals, but with a different" exact="infection" post="rate, determined by the proportionality constant r. We assume"/>
   <result pre="File. We assume that the epidemic starts with a single" exact="symptomatic" post="individual, I(0) = 1 and that there are no"/>
   <result pre="time of the infection. We fix the death rate of" exact="symptomatic" post="individuals to δ = 0.056/d based on mean time"/>
   <result pre="cumulative infected individuals. Early in the pandemic, testing was primarily" exact="limited" post="to individuals who displayed symptoms, so the case count"/>
   <result pre="case count in this data set should primarily consist of" exact="symptomatic" post="individuals. We simultaneously fit both the infected and dead"/>
   <result pre="through bootstrapping with 1000 replicates. Results Effect of asymptomatics on" exact="infection" post="size and deaths We explored the effect of asymptomatics"/>
   <result pre="explored the effect of asymptomatics on the course of the" exact="infection" post="using a base set of parameters given in Table"/>
   <result pre="and used estimates for the remaining parameters from the literature." exact="Infections" post="are initiated with a single symptomatic infected individual. The"/>
   <result pre="parameters from the literature. Infections are initiated with a single" exact="symptomatic" post="infected individual. The infection rate was taken from a"/>
   <result pre="Infections are initiated with a single symptomatic infected individual. The" exact="infection" post="rate was taken from a model fit to data"/>
   <result pre="was taken from a model fit to data of coronavirus" exact="infections" post="from China [9]; they estimate infection rates before and"/>
   <result pre="to data of coronavirus infections from China [9]; they estimate" exact="infection" post="rates before and after travel bans and social distancing"/>
   <result pre="is defined as the number of dead divided by the" exact="total" post="number infected. The size of the epidemic is measured"/>
   <result pre="the epidemic is measured here as the proportion of the" exact="total" post="population who become infected, either symptomatically or asymptomatically. Results"/>
   <result pre="1 for both high (left column) and low (right column)" exact="infection" post="rates. We see that the relative infectivity (r) of"/>
   <result pre="of r except when p is near one. In the" exact="upper" post="left corner, there is a pocket where the mortality"/>
   <result pre="the mortality is zero; this is particularly evident for the" exact="lower" post="infection rate. This pocket is more clearly defined for"/>
   <result pre="mortality is zero; this is particularly evident for the lower" exact="infection" post="rate. This pocket is more clearly defined for the"/>
   <result pre="time of peak are fairly constant until we approach the" exact="upper" post="left hand corner where there is a rapid decrease"/>
   <result pre="p ) β α + δ represents spread due to" exact="symptomatic" post="individuals. Fig 1 Effect of asymptomatic individuals on case-fatality"/>
   <result pre="(bottom row). The left column shows results for a high" exact="infection" post="rate and the right column shows results for a"/>
   <result pre="rate and the right column shows results for a low" exact="infection" post="rate. The relative infectivity of asymptomatics (r) has little"/>
   <result pre="interesting to understand the trade-off between the proportion of asymptomatic" exact="infections" post="and the relative infectivity in contributing to a particular"/>
   <result pre="(Fig 2 (left)) and low (Fig 2 (right)) values of" exact="infection" post="rate. Solving for p in the R0 equation gives"/>
   <result pre="+ δ ) - k β . (3) When the" exact="infection" post="rate is high, a high proportion of asymptomatics and"/>
   <result pre="higher values of r for a particular R0. When the" exact="infection" post="rate is low, we see a slightly different relationship"/>
   <result pre="for high R0—when R0 = 3, increasing r values require" exact="lower" post="values of p for a particular R0. This change"/>
   <result pre="to achieve a particular basic reproduction number for a high" exact="infection" post="rate (left) and low infection rate (right). In the"/>
   <result pre="reproduction number for a high infection rate (left) and low" exact="infection" post="rate (right). In the current COVID pandemic, public health"/>
   <result pre="current COVID pandemic, public health authorities have been attempting to" exact="lower" post="the infection rate through social distancing measures, so we"/>
   <result pre="pandemic, public health authorities have been attempting to lower the" exact="infection" post="rate through social distancing measures, so we more closely"/>
   <result pre="more closely examined the dependence of the epidemic threshold on" exact="infection" post="rate. Fig 3 shows the R0 = 1 (the"/>
   <result pre="1 (the epidemic threshold value) curves for different values of" exact="infection" post="rate (β). R0 &amp;lt; 1 is to the left"/>
   <result pre="the left of each curve. We see that as the" exact="infection" post="rate is lowered, there are more combinations of r"/>
   <result pre="p that result in no epidemic. That is, the general" exact="infection" post="rate is just not high enough to support spread"/>
   <result pre="is just not high enough to support spread of the" exact="infection" post="no matter what the proportion of asymptomatic individuals or"/>
   <result pre="asymptomatic individuals or their relative infectivity. Fig 3 Effect of" exact="infection" post="rate on epidemic threshold. The contours indicate the points"/>
   <result pre="between 2 and 4.25 [29–31], typically falling below 1 when" exact="complete" post="lockdowns are imposed [28]. The R0 values found here"/>
   <result pre="in all four states, indicating that the spread of the" exact="infection" post="is largely driven by asymptomatic individuals, at least in"/>
   <result pre="estimated in China [9] and might be indicative of the" exact="limited" post="testing availability in the United States early in the"/>
   <result pre="the United States early in the pandemic. The undercounting of" exact="symptomatic" post="infections is particularly problematic since each symptomatic person incorrectly"/>
   <result pre="United States early in the pandemic. The undercounting of symptomatic" exact="infections" post="is particularly problematic since each symptomatic person incorrectly classified"/>
   <result pre="The undercounting of symptomatic infections is particularly problematic since each" exact="symptomatic" post="person incorrectly classified as asymptomatic because they weren’t tested"/>
   <result pre="pre-symptomatic phase in this model; recent studies have shown that" exact="symptomatic" post="people can infect others during the pre-symptomatic phase [32–34]"/>
   <result pre="Fig 5 shows the time course of asymptomatic individuals and" exact="symptomatic" post="individuals for epidemics in all four states. In all"/>
   <result pre="of the epidemic, there are far more asymptomatic individuals than" exact="symptomatic" post="individuals. This is due not only to the high"/>
   <result pre="This is due not only to the high proportion of" exact="infections" post="that are asymptomatic, but is also caused by a"/>
   <result pre="asymptomatic, but is also caused by a faster removal of" exact="symptomatic" post="individuals as compared to asymptomatic individuals. While it might"/>
   <result pre="might seem unusual that asymptomatic individuals are recovering slower than" exact="symptomatic" post="individuals, given the heightened awareness of transmission of infectious"/>
   <result pre="than symptomatic individuals, given the heightened awareness of transmission of" exact="infectious diseases" post="as well as the stay-at-home orders in these states,"/>
   <result pre="diseases as well as the stay-at-home orders in these states," exact="symptomatic" post="individuals are likely to isolate themselves upon symptom onset,"/>
   <result pre="not true recovery, from the standpoint of the model, these" exact="symptomatic" post="people are classified as recovered. Therefore, asymptomatic individuals participate"/>
   <result pre="classified as recovered. Therefore, asymptomatic individuals participate in transmitting the" exact="infection" post="for a longer period of time and in greater"/>
   <result pre="individuals. It is also notable that the peak in asymptomatic" exact="infections" post="occurs slightly after the peak in symptomatic infections. This"/>
   <result pre="peak in asymptomatic infections occurs slightly after the peak in" exact="symptomatic" post="infections. This could have repercussions for decisions on when"/>
   <result pre="social distancing measures since we will observe a decline in" exact="infections" post="while asymptomatic infections are still increasing. Fig 5 Estimated"/>
   <result pre="since we will observe a decline in infections while asymptomatic" exact="infections" post="are still increasing. Fig 5 Estimated asymptomatic dynamics during"/>
   <result pre="the time at which the initial infected individual initiated the" exact="infection" post="in each state. Using our estimates of Td, we"/>
   <result pre="as early as January 15, while for Florida the estimated" exact="infection" post="start date is January 14. New York has the"/>
   <result pre="the latest is in Texas on January 24. Changing the" exact="infection" post="rate Strict stay-at-home measures have severe economic implications and"/>
   <result pre="fact that the asymptomatic peak is slightly later than the" exact="symptomatic" post="peak, we decided to investigate model predictions of what"/>
   <result pre="previous modeling study, we assume that stay-at-home orders cut the" exact="infection" post="rate β in half [9], so double the infection"/>
   <result pre="the infection rate β in half [9], so double the" exact="infection" post="rate at two week intervals starting on the last"/>
   <result pre="We see that there is an immediate spike in both" exact="symptomatic" post="and asymptomatic infections upon reopening and that the spike"/>
   <result pre="there is an immediate spike in both symptomatic and asymptomatic" exact="infections" post="upon reopening and that the spike becomes smaller as"/>
   <result pre="different times, we found the final death toll and the" exact="total" post="size of the epidemic for each reopening scenario. Results"/>
   <result pre="illness and deaths. For California, Florida, and Texas, both the" exact="total" post="epidemic size and the number of fatalities increase with"/>
   <result pre="2020). Discussion We analyzed a compartmental model that includes asymptomatic" exact="infections" post="finding that the relative infectiousness of asymptomatic individuals plays"/>
   <result pre="and size of the epidemic while the proportion of asymptomatic" exact="infections" post="plays a larger role in determining mortality. Yet testing"/>
   <result pre="role in determining mortality. Yet testing in many countries is" exact="limited" post="to people who are symptomatic, meaning that there is"/>
   <result pre="developed, previous studies have shown that the number of asymptomatic" exact="infections" post="also alters the effectiveness of vaccination strategies [20, 21]."/>
   <result pre="we found that there were far more asymptomatic individuals than" exact="symptomatic" post="individuals at the peak of the epidemic in all"/>
   <result pre="individuals can rise to high numbers. If the proportion of" exact="infections" post="that become asymptomatic is high (p close to 1),"/>
   <result pre="high (p close to 1), then as the number of" exact="infections" post="rise, more of these will be asymptomatic. It is"/>
   <result pre="also possible to accumulate large numbers of asymptomatic individuals if" exact="symptomatic" post="infections are removed from the epidemic, either through death,"/>
   <result pre="possible to accumulate large numbers of asymptomatic individuals if symptomatic" exact="infections" post="are removed from the epidemic, either through death, recovery,"/>
   <result pre="faster than asymptomatic infections. This might be the case if" exact="symptomatic" post="individuals are quickly tested and then isolated thereby being"/>
   <result pre="then isolated thereby being removed from further participation in the" exact="infection" post="as might be the case for these four states"/>
   <result pre="these states at the time this data was taken, was" exact="limited" post="to symptomatic individuals. This also points to a limitation"/>
   <result pre="at the time this data was taken, was limited to" exact="symptomatic" post="individuals. This also points to a limitation of this"/>
   <result pre="the number of asymptomatic cases and likely an undercount of" exact="symptomatic" post="cases. Thus the asymptomatic compartment in this application of"/>
   <result pre="the asymptomatic compartment in this application of the model includes" exact="symptomatic" post="patients who were unable to get tested. Our model"/>
   <result pre="pre-symptomatic phase, which also lumps people who likely have different" exact="infection" post="rates into one compartment. This mixing of individuals who"/>
   <result pre="in separate compartments as well as the inadequate counting of" exact="symptomatic" post="infections leads to error in our parameter estimates and"/>
   <result pre="separate compartments as well as the inadequate counting of symptomatic" exact="infections" post="leads to error in our parameter estimates and an"/>
   <result pre="four data sets used. Adequate testing protocols that capture both" exact="symptomatic" post="and asymptomatic infections will allow better parameterization of the"/>
   <result pre="used. Adequate testing protocols that capture both symptomatic and asymptomatic" exact="infections" post="will allow better parameterization of the model. Additional data,"/>
   <result pre="number of recovered, this number is really only reflective of" exact="symptomatic" post="patients who have been hospitalized and released. Symptomatic patients"/>
   <result pre="around 2 for all four states. This is at the" exact="lower" post="end of SARS-CoV R0 estimates in the absence of"/>
   <result pre="at the lower end of SARS-CoV R0 estimates in the" exact="absence of" post="any behavioral changes [29–31]. These low values of R0"/>
   <result pre="to 2.5, contact tracing only needs to capture 70% of" exact="infections" post="to be effective. Conclusion While the epidemiological model used"/>
   <result pre="key aspect of SARS-CoV-2 transmission. Our model shows that asymptomatic" exact="infections" post="can change the size and lethality of an epidemic"/>
   <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. 10.1016/S0140-6736(20)30211-732007143"/>
   <result pre="ChenYM, WangW, SongZG, et al.A new coronavirus associated with human" exact="respiratory" post="disease in China. Nature. 2020;579(7798):265–271. 10.1038/s41586-020-2008-332015508 3GoyalP, ChoiJJ, PinheiroLC,"/>
   <result pre="WangW, SongZG, et al.A new coronavirus associated with human respiratory" exact="disease" post="in China. Nature. 2020;579(7798):265–271. 10.1038/s41586-020-2008-332015508 3GoyalP, ChoiJJ, PinheiroLC, SchenckEJ,"/>
   <result pre="CaiY, CheungCW, XiaZ. Review of the Clinical Characteristics of Coronavirus" exact="Disease" post="2019 (COVID-19). J Gen Intern Med. 2020;35:1545–1549. 10.1007/s11606-020-05762-w32133578 5GhinaiI,"/>
   <result pre="KirkingHL, ChristiansenD, JoshiK, et al.First known person-to-person transmission of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet."/>
   <result pre="ChristiansenD, JoshiK, et al.First known person-to-person transmission of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet. 2020;395(10230):1137–1144."/>
   <result pre="JoshiK, et al.First known person-to-person transmission of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) in the USA. Lancet. 2020;395(10230):1137–1144. 10.1016/S0140-6736(20)30607-332178768"/>
   <result pre="2020;395(10230):1137–1144. 10.1016/S0140-6736(20)30607-332178768 6ChanJFW, YuanS, KokKH, ToKKW, ChuH, YangJ, et al.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
   <result pre="YuanS, KokKH, ToKKW, ChuH, YangJ, et al.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
   <result pre="10.1111/irv.12743 9LiR, PeiS, ChenB, SongY, ZhangT, YangW, et al.Substantial undocumented" exact="infection" post="facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science."/>
   <result pre="10MizumotoK, KagayaK, ZarebskiA, ChowellG. Estimating the asymptomatic proportion of coronavirus" exact="disease" post="2019 (COVID-19) cases on board the Diamond Princess cruise"/>
   <result pre="KinoshitaR, et al.Estimation of the asymptomatic ratio of novel coronavirus" exact="infections" post="(COVID-19). Int J Inf Dis. 2020;94:154–155. 10.1016/j.ijid.2020.03.02032179137 12HoehlS, RabenauH,"/>
   <result pre="12HoehlS, RabenauH, BergerA, KortenbuschM, CinatlJ, BojkovaD, et al.Evidence of SARS-CoV-2" exact="Infection" post="in Returning Travelers from Wuhan, China. N Engl J"/>
   <result pre="HatfieldKM, AronsM, JamesA, TaylorJ, SpicerK, et al.Asymptomatic and Presymptomatic SARS-CoV-2" exact="Infections" post="in Residents of a Long-Term Care Skilled Nursing Facility—King"/>
   <result pre="15TianS, HuN, LouJ, ChenK, KangX, XiangZ, et al.Characteristics of COVID-19" exact="infection" post="in Beijing. J Infect. 2020;80(4):401–406. 10.1016/j.jinf.2020.02.01832112886 16ZhangJ, TianS, LouJ,"/>
   <result pre="in Beijing. J Infect. 2020;80(4):401–406. 10.1016/j.jinf.2020.02.01832112886 16ZhangJ, TianS, LouJ, ChenY." exact="Familial" post="cluster of COVID-19 infection from an asymptomatic. Crit Care."/>
   <result pre="2020;80(4):401–406. 10.1016/j.jinf.2020.02.01832112886 16ZhangJ, TianS, LouJ, ChenY. Familial cluster of COVID-19" exact="infection" post="from an asymptomatic. Crit Care. 2020;24(1):11910.1186/s13054-020-2817-732220236 17HuZ, SongC, XuC,"/>
   <result pre="Yaling ChenGJ, XuX, MaH, et al.Clinical characteristics of 24 asymptomatic" exact="infections" post="with COVID-19 screened among close contacts in Nanjing, China."/>
   <result pre="18RotheC, SchunkM, SothmannP, BretzelG, FroeschlG, WallrauchC, et al.Transmission of 2019-nCoV" exact="Infection" post="from an Asymptomatic Contact in Germany. N Engl J"/>
   <result pre="CampbellPT, WuY, TongSYC, McVernonJ, GeardN. Implications of asymptomatic carriers for" exact="infectious disease" post="transmission and control. Royal Soc Open Sci. 2018;5(2):17234110.1098/rsos.172341 20WangJ,"/>
   <result pre="WuY, TongSYC, McVernonJ, GeardN. Implications of asymptomatic carriers for infectious" exact="disease" post="transmission and control. Royal Soc Open Sci. 2018;5(2):17234110.1098/rsos.172341 20WangJ,"/>
   <result pre="20WangJ, WuD, SunH. Analysis of an SVIC model with age-dependent" exact="infection" post="and asymptomatic carriers. Appl Anal. 2018;97(9):1467–1495. 10.1080/00036811.2017.1313409 21ManyombeMLM, MbangJ,"/>
   <result pre="MbangJ, LubumaJ, TsanouB. Global dynamics of a vaccination model for" exact="infectious diseases" post="with asymptomatic carriers. Math Biosci Eng. 2016;13(4):813–840. 10.3934/mbe.201601927775386 22KucharskiAJ,"/>
   <result pre="Dis. 2016;10(5):e0004726. 23FraserC, RileyS, AndersonRM, NeilMF. Factors that make an" exact="infectious disease" post="outbreak controllable. Proc Natl Acad Sci USA. 2004;101(16):6146–6151. 10.1073/pnas.030750610115071187"/>
   <result pre="2016;10(5):e0004726. 23FraserC, RileyS, AndersonRM, NeilMF. Factors that make an infectious" exact="disease" post="outbreak controllable. Proc Natl Acad Sci USA. 2004;101(16):6146–6151. 10.1073/pnas.030750610115071187"/>
   <result pre="USA. 2004;101(16):6146–6151. 10.1073/pnas.030750610115071187 24LeungKY, TrapmanP, BrittonT. Who is the infector?" exact="Epidemic" post="models with symptomatic and asymptomatic cases. Math Biosci. 2018;301:190–198."/>
   <result pre="24LeungKY, TrapmanP, BrittonT. Who is the infector? Epidemic models with" exact="symptomatic" post="and asymptomatic cases. Math Biosci. 2018;301:190–198. 10.1016/j.mbs.2018.04.00229654792 25DeanNE, HalloranME,"/>
   <result pre="of Ebola Virus: A Systematic Review and Meta-analysis of Household" exact="Secondary" post="Attack Rate and Asymptomatic Infection. Clin Infect Dis. 2016;62(10):1277–1286."/>
   <result pre="Ebola Virus: A Systematic Review and Meta-analysis of Household Secondary" exact="Attack" post="Rate and Asymptomatic Infection. Clin Infect Dis. 2016;62(10):1277–1286. 10.1093/cid/ciw11426932131"/>
   <result pre="Biological Model for Influenza Transmission: Pandemic Planning Implications of Asymptomatic" exact="Infection" post="and Immunity. Plos One. 2007;2(11):e122010.1371/journal.pone.000122018043733 27DengY, LiuW, LiuK, FangYY,"/>
   <result pre="et al.Clinical characteristics of fatal and recovered cases of coronavirus" exact="disease" post="2019 (COVID-19) in Wuhan, China: a retrospective study. Chin"/>
   <result pre="epidemiological and clinical features of the emerging 2019 novel coronavirus" exact="pneumonia" post="(COVID-19) implicate special control measures. J Med Virol. 2020;92(6):568–576."/>
   <result pre="One. 2013;8(4):e6150410.1371/journal.pone.006150423585906 37BendavidE, MulaneyB, SoodN, ShahS, LingE, Bromley-DulfanoR, et al.COVID-19" exact="Antibody" post="Seroprevalence in Santa Clara County, California. medRxiv. 2020. 38SoodN,"/>
   <result pre="MCMC. Int J Biomath. 2013;6(7):135000810.1142/S1793524513500083 41ThompsonRN, GilliganCA, CunniffeNJ. Detecting Presymptomatic" exact="Infection" post="Is Necessary to Forecast Major Epidemics in the Earliest"/>
   <result pre="Necessary to Forecast Major Epidemics in the Earliest Stages of" exact="Infectious" post="Disease Outbreaks. PLoS Comput Biol. 2016;12(4):e100483610.1371/journal.pcbi.100483627046030 42RoosaK, ChowellG. Assessing"/>
   <result pre="to Forecast Major Epidemics in the Earliest Stages of Infectious" exact="Disease" post="Outbreaks. PLoS Comput Biol. 2016;12(4):e100483610.1371/journal.pcbi.100483627046030 42RoosaK, ChowellG. Assessing parameter"/>
   <result pre="in compartmental dynamic models using a computational approach: application to" exact="infectious disease" post="transmission models. Theor Biol Med Model. 2019;16:110.1186/s12976-018-0097-630642334 43HellewellJ, AbbottS,"/>
   <result pre="compartmental dynamic models using a computational approach: application to infectious" exact="disease" post="transmission models. Theor Biol Med Model. 2019;16:110.1186/s12976-018-0097-630642334 43HellewellJ, AbbottS,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7419580/results/search/disease/results.xml">
   <result pre="Media S.A. pmcid: 7419580 doi: 10.3389/fmed.2020.00420 : Medicine: Mini Review" exact="Secondary" post="Bacterial Infections in Patients With Viral Pneumonia ManoharPrasanth12LohBelinda1NachimuthuRamesh3HuaXiaoting45WelburnSusan C.16LeptihnSebastian146*[],"/>
   <result pre="S.A. pmcid: 7419580 doi: 10.3389/fmed.2020.00420 : Medicine: Mini Review Secondary" exact="Bacterial Infections" post="in Patients With Viral Pneumonia ManoharPrasanth12LohBelinda1NachimuthuRamesh3HuaXiaoting45WelburnSusan C.16LeptihnSebastian146*[], 1Zhejiang University-University"/>
   <result pre="pmcid: 7419580 doi: 10.3389/fmed.2020.00420 : Medicine: Mini Review Secondary Bacterial" exact="Infections" post="in Patients With Viral Pneumonia ManoharPrasanth12LohBelinda1NachimuthuRamesh3HuaXiaoting45WelburnSusan C.16LeptihnSebastian146*[], 1Zhejiang University-University"/>
   <result pre=": Medicine: Mini Review Secondary Bacterial Infections in Patients With" exact="Viral" post="Pneumonia ManoharPrasanth12LohBelinda1NachimuthuRamesh3HuaXiaoting45WelburnSusan C.16LeptihnSebastian146*[], 1Zhejiang University-University of Edinburgh (ZJU-UoE) Institute,"/>
   <result pre="Medicine: Mini Review Secondary Bacterial Infections in Patients With Viral" exact="Pneumonia" post="ManoharPrasanth12LohBelinda1NachimuthuRamesh3HuaXiaoting45WelburnSusan C.16LeptihnSebastian146*[], 1Zhejiang University-University of Edinburgh (ZJU-UoE) Institute, Zhejiang"/>
   <result pre="of Medicine, The Second Affiliated Hospital Zhejiang University (SAHZU)HangzhouChina[], 3Antibiotic" exact="Resistance" post="and Phage Therapy Laboratory, School of Bio Sciences and"/>
   <result pre="Sciences and Technology, Vellore Institute of Technology (VIT)VelloreIndia[], 4Department of" exact="Infectious" post="Diseases, Sir Run Run Shaw Hospital, Zhejiang University School"/>
   <result pre="Mexico *Correspondence: Sebastian Leptihn Leptihn@intl.zju.edu.cn This article was submitted to" exact="Infectious" post="Diseases - Surveillance, Prevention and Treatment, a section of"/>
   <result pre="*Correspondence: Sebastian Leptihn Leptihn@intl.zju.edu.cn This article was submitted to Infectious" exact="Diseases" post="- Surveillance, Prevention and Treatment, a section of the"/>
   <result pre="is permitted which does not comply with these terms. Abstract" exact="Pulmonary" post="diseases of viral origin are often followed by the"/>
   <result pre="does not comply with these terms. Abstract Pulmonary diseases of" exact="viral" post="origin are often followed by the manifestation of secondary"/>
   <result pre="of viral origin are often followed by the manifestation of" exact="secondary" post="infections, leading to further clinical complications and negative disease"/>
   <result pre="of secondary infections, leading to further clinical complications and negative" exact="disease" post="outcomes. Thus, research on secondary infections is essential. Here,"/>
   <result pre="further clinical complications and negative disease outcomes. Thus, research on" exact="secondary" post="infections is essential. Here, we review clinical data of"/>
   <result pre="clinical complications and negative disease outcomes. Thus, research on secondary" exact="infections" post="is essential. Here, we review clinical data of secondary"/>
   <result pre="secondary infections is essential. Here, we review clinical data of" exact="secondary" post="bacterial infections developed after the onset of pulmonary viral"/>
   <result pre="infections is essential. Here, we review clinical data of secondary" exact="bacterial infections" post="developed after the onset of pulmonary viral infections. We"/>
   <result pre="is essential. Here, we review clinical data of secondary bacterial" exact="infections" post="developed after the onset of pulmonary viral infections. We"/>
   <result pre="data of secondary bacterial infections developed after the onset of" exact="pulmonary" post="viral infections. We review the most recent clinical data"/>
   <result pre="of secondary bacterial infections developed after the onset of pulmonary" exact="viral" post="infections. We review the most recent clinical data and"/>
   <result pre="review the most recent clinical data and current knowledge of" exact="secondary" post="bacterial infections and their treatment in SARS-CoV-2 positive patients;"/>
   <result pre="the most recent clinical data and current knowledge of secondary" exact="bacterial infections" post="and their treatment in SARS-CoV-2 positive patients; case reports"/>
   <result pre="most recent clinical data and current knowledge of secondary bacterial" exact="infections" post="and their treatment in SARS-CoV-2 positive patients; case reports"/>
   <result pre="patients; case reports from SARS-CoV, MERS-CoV, SARS-CoV2 and the best-studied" exact="respiratory" post="virus, influenza, are described. We outline treatments used or"/>
   <result pre="described. We outline treatments used or prophylactic measures employed for" exact="secondary" post="bacterial infections. This evaluation includes recent clinical reports of"/>
   <result pre="We outline treatments used or prophylactic measures employed for secondary" exact="bacterial infections." post="This evaluation includes recent clinical reports of pulmonary viral"/>
   <result pre="secondary bacterial infections. This evaluation includes recent clinical reports of" exact="pulmonary" post="viral infections, including those by COVID-19, that reference secondary"/>
   <result pre="bacterial infections. This evaluation includes recent clinical reports of pulmonary" exact="viral" post="infections, including those by COVID-19, that reference secondary infections."/>
   <result pre="of pulmonary viral infections, including those by COVID-19, that reference" exact="secondary" post="infections. Where data was provided for COVID-19 patients, a"/>
   <result pre="for COVID-19 patients, a mortality rate of 15.2% due to" exact="secondary" post="bacterial infections was observed for patients with pneumonia (41"/>
   <result pre="COVID-19 patients, a mortality rate of 15.2% due to secondary" exact="bacterial infections" post="was observed for patients with pneumonia (41 of 268)."/>
   <result pre="patients, a mortality rate of 15.2% due to secondary bacterial" exact="infections" post="was observed for patients with pneumonia (41 of 268)."/>
   <result pre="due to secondary bacterial infections was observed for patients with" exact="pneumonia" post="(41 of 268). Most clinicians treated patients with SARS-CoV-2"/>
   <result pre="pneumonia (41 of 268). Most clinicians treated patients with SARS-CoV-2" exact="infections" post="with prophylactic antibiotics (63.7%, n = 1,901), compared to"/>
   <result pre="to 73.5% (n = 3,072) in all clinical reports of" exact="viral pneumonia" post="included in this review. For all cases of viral"/>
   <result pre="73.5% (n = 3,072) in all clinical reports of viral" exact="pneumonia" post="included in this review. For all cases of viral"/>
   <result pre="viral pneumonia included in this review. For all cases of" exact="viral pneumonia," post="a mortality rate of 10.9% due to secondary infections"/>
   <result pre="of viral pneumonia, a mortality rate of 10.9% due to" exact="secondary" post="infections was observed (53 of 482). Most commonly, quinolones,"/>
   <result pre="viral pneumonia, a mortality rate of 10.9% due to secondary" exact="infections" post="was observed (53 of 482). Most commonly, quinolones, cephalosporins"/>
   <result pre="and macrolides were administered, but also the glycopeptide vancomycin. Several" exact="bacterial" post="pathogens appear to be prevalent as causative agents of"/>
   <result pre="bacterial pathogens appear to be prevalent as causative agents of" exact="secondary" post="infections, including antibiotic-resistant strains of Staphylococcus aureus and Klebsiella"/>
   <result pre="infections, including antibiotic-resistant strains of Staphylococcus aureus and Klebsiella pneumoniae." exact="secondary" post="bacterial infection pulmonary viruses viral pneumonia SARS-CoV-2 COVID-19 influenza"/>
   <result pre="including antibiotic-resistant strains of Staphylococcus aureus and Klebsiella pneumoniae. secondary" exact="bacterial infection" post="pulmonary viruses viral pneumonia SARS-CoV-2 COVID-19 influenza SARS antibiotic"/>
   <result pre="antibiotic-resistant strains of Staphylococcus aureus and Klebsiella pneumoniae. secondary bacterial" exact="infection" post="pulmonary viruses viral pneumonia SARS-CoV-2 COVID-19 influenza SARS antibiotic"/>
   <result pre="strains of Staphylococcus aureus and Klebsiella pneumoniae. secondary bacterial infection" exact="pulmonary" post="viruses viral pneumonia SARS-CoV-2 COVID-19 influenza SARS antibiotic resistance"/>
   <result pre="Staphylococcus aureus and Klebsiella pneumoniae. secondary bacterial infection pulmonary viruses" exact="viral pneumonia" post="SARS-CoV-2 COVID-19 influenza SARS antibiotic resistance fig-count: table-count: equation-count:"/>
   <result pre="aureus and Klebsiella pneumoniae. secondary bacterial infection pulmonary viruses viral" exact="pneumonia" post="SARS-CoV-2 COVID-19 influenza SARS antibiotic resistance fig-count: table-count: equation-count:"/>
   <result pre="resistance fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Viruses causing" exact="respiratory" post="tract infections have been the cause of high morbidities"/>
   <result pre="table-count: equation-count: ref-count: page-count: word-count: Introduction Viruses causing respiratory tract" exact="infections" post="have been the cause of high morbidities and mortality"/>
   <result pre="20 years, the world has experienced six major outbreaks of" exact="infectious" post="agents (SARS-CoV: 2002-2004; H1N1 Influenza: 2009–2010; MERS-CoV: 2012–2020; Ebola"/>
   <result pre="MERS-CoV: 2012–2020; Ebola virus: 2013–2016; Zika virus: 2015–2016; SARS-CoV-2: 2019-present)," exact="infection" post="with four of which (SARS-CoV, H1N1 Influenza, MERS-CoV, SARS-CoV-2)"/>
   <result pre="virus: 2015–2016; SARS-CoV-2: 2019-present), infection with four of which (SARS-CoV," exact="H1N1 Influenza," post="MERS-CoV, SARS-CoV-2) result in respiratory tract infections. During the"/>
   <result pre="four of which (SARS-CoV, H1N1 Influenza, MERS-CoV, SARS-CoV-2) result in" exact="respiratory" post="tract infections. During the emergency of a viral disease,"/>
   <result pre="result in respiratory tract infections. During the emergency of a" exact="viral" post="disease, attention is initially focussed on clinical management of"/>
   <result pre="disease, attention is initially focussed on clinical management of the" exact="primary" post="infection, but it is imperative to consider secondary bacterial"/>
   <result pre="of the primary infection, but it is imperative to consider" exact="secondary" post="bacterial infections that develop in patients during or following"/>
   <result pre="the primary infection, but it is imperative to consider secondary" exact="bacterial infections" post="that develop in patients during or following initial infection."/>
   <result pre="primary infection, but it is imperative to consider secondary bacterial" exact="infections" post="that develop in patients during or following initial infection."/>
   <result pre="or following initial infection. In addition, co-infections - the simultaneous" exact="infection" post="with a second pathogen of viral or bacterial origin-"/>
   <result pre="co-infections - the simultaneous infection with a second pathogen of" exact="viral" post="or bacterial origin- can also occur and ultimately result"/>
   <result pre="the simultaneous infection with a second pathogen of viral or" exact="bacterial" post="origin- can also occur and ultimately result in the"/>
   <result pre="by two different pathogens (2, 3). One major complication of" exact="viral" post="infections, especially pulmonary viruses, is colonization of the viral"/>
   <result pre="pathogens (2, 3). One major complication of viral infections, especially" exact="pulmonary" post="viruses, is colonization of the viral affected organs by"/>
   <result pre="of viral infections, especially pulmonary viruses, is colonization of the" exact="viral" post="affected organs by bacteria which is associated with high"/>
   <result pre="immune response and/or opportunistic and accessible routes of entry for" exact="bacterial" post="pathogen(s) (4). While secondary bacterial infections or superinfections are"/>
   <result pre="and accessible routes of entry for bacterial pathogen(s) (4). While" exact="secondary" post="bacterial infections or superinfections are largely a consequence of"/>
   <result pre="accessible routes of entry for bacterial pathogen(s) (4). While secondary" exact="bacterial infections" post="or superinfections are largely a consequence of immune susceptibility"/>
   <result pre="routes of entry for bacterial pathogen(s) (4). While secondary bacterial" exact="infections" post="or superinfections are largely a consequence of immune susceptibility"/>
   <result pre="are largely a consequence of immune susceptibility caused by the" exact="primary" post="viral infection, co-infections are multiple infections (viral/bacterial/yeast) that occur"/>
   <result pre="largely a consequence of immune susceptibility caused by the primary" exact="viral infection," post="co-infections are multiple infections (viral/bacterial/yeast) that occur simultaneously. Co-infections,"/>
   <result pre="susceptibility caused by the primary viral infection, co-infections are multiple" exact="infections" post="(viral/bacterial/yeast) that occur simultaneously. Co-infections, secondary infections or &quot;superinfections&quot;"/>
   <result pre="infection, co-infections are multiple infections (viral/bacterial/yeast) that occur simultaneously. Co-infections," exact="secondary" post="infections or &quot;superinfections&quot; are common during viral pandemics. The"/>
   <result pre="co-infections are multiple infections (viral/bacterial/yeast) that occur simultaneously. Co-infections, secondary" exact="infections" post="or &quot;superinfections&quot; are common during viral pandemics. The 1918"/>
   <result pre="occur simultaneously. Co-infections, secondary infections or &quot;superinfections&quot; are common during" exact="viral" post="pandemics. The 1918 Spanish Flu pandemic saw around 50"/>
   <result pre="Spanish Flu pandemic saw around 50 million deaths ascribed to" exact="bacterial" post="co-infections and during the 2009 H1N1 Influenza pandemic up"/>
   <result pre="million deaths ascribed to bacterial co-infections and during the 2009" exact="H1N1 Influenza" post="pandemic up to 34% of all deaths were a"/>
   <result pre="up to 34% of all deaths were a result of" exact="bacterial" post="co-infections (5). These complications are often neglected in the"/>
   <result pre="clinical record (Figure 1B) (6, 7). Figure 1 (A) Possible" exact="disease" post="progression after infection with a respiratory virus. (B) Overview"/>
   <result pre="1B) (6, 7). Figure 1 (A) Possible disease progression after" exact="infection" post="with a respiratory virus. (B) Overview of case reports"/>
   <result pre="Figure 1 (A) Possible disease progression after infection with a" exact="respiratory" post="virus. (B) Overview of case reports of all respiratory"/>
   <result pre="a respiratory virus. (B) Overview of case reports of all" exact="respiratory" post="virus infection data reviewed in this study, including rate"/>
   <result pre="respiratory virus. (B) Overview of case reports of all respiratory" exact="virus infection" post="data reviewed in this study, including rate of secondary"/>
   <result pre="virus. (B) Overview of case reports of all respiratory virus" exact="infection" post="data reviewed in this study, including rate of secondary"/>
   <result pre="virus infection data reviewed in this study, including rate of" exact="secondary" post="bacterial infections, antibiotic use and pathogenic bacteria identified. While"/>
   <result pre="infection data reviewed in this study, including rate of secondary" exact="bacterial infections," post="antibiotic use and pathogenic bacteria identified. While the precise"/>
   <result pre="use and pathogenic bacteria identified. While the precise mechanism for" exact="susceptibility to" post="secondary infections is poorly understood, it is likely that"/>
   <result pre="pathogenic bacteria identified. While the precise mechanism for susceptibility to" exact="secondary" post="infections is poorly understood, it is likely that virus-mediated"/>
   <result pre="bacteria identified. While the precise mechanism for susceptibility to secondary" exact="infections" post="is poorly understood, it is likely that virus-mediated immunosuppression"/>
   <result pre="response to one pathogen may alter the immunity to other" exact="infectious" post="agent(s), resulting in increased prevalence of viral-induced secondary bacterial"/>
   <result pre="to other infectious agent(s), resulting in increased prevalence of viral-induced" exact="secondary" post="bacterial infections (10). Mammalian cells are more susceptible to"/>
   <result pre="other infectious agent(s), resulting in increased prevalence of viral-induced secondary" exact="bacterial infections" post="(10). Mammalian cells are more susceptible to bacterial attachment"/>
   <result pre="infectious agent(s), resulting in increased prevalence of viral-induced secondary bacterial" exact="infections" post="(10). Mammalian cells are more susceptible to bacterial attachment"/>
   <result pre="secondary bacterial infections (10). Mammalian cells are more susceptible to" exact="bacterial" post="attachment and colonization when infected by a virus (11,"/>
   <result pre="attachment and colonization when infected by a virus (11, 12);" exact="infection" post="with respiratory syncytial virus (RSV), rhinovirus and influenza virus"/>
   <result pre="colonization when infected by a virus (11, 12); infection with" exact="respiratory" post="syncytial virus (RSV), rhinovirus and influenza virus (all of"/>
   <result pre="virus (all of which damage the mucosal layer), lead to" exact="bacterial" post="adherence of Streptococcus pneumoniae, Pseudomonas aeruginosa, and Haemophilus influenzae,"/>
   <result pre="the linings of the airways (13). Common bacteria isolated during" exact="secondary" post="infections include Staphylococcus aureus, S. pneumoniae, Neisseria meningitides, H."/>
   <result pre="linings of the airways (13). Common bacteria isolated during secondary" exact="infections" post="include Staphylococcus aureus, S. pneumoniae, Neisseria meningitides, H. influenzae,"/>
   <result pre="of the Proteus, Enterobacter and Citrobacter spp. (14). During active" exact="viral" post="infections, the route of infection, proximity of infection as"/>
   <result pre="During active viral infections, the route of infection, proximity of" exact="infection" post="as well as virulence factors varies between bacterial strains"/>
   <result pre="proximity of infection as well as virulence factors varies between" exact="bacterial" post="strains resulting in different outcomes. Effective treatment of both"/>
   <result pre="strains resulting in different outcomes. Effective treatment of both the" exact="viral" post="and the secondary bacterial infection(s) is of critical importance."/>
   <result pre="different outcomes. Effective treatment of both the viral and the" exact="secondary" post="bacterial infection(s) is of critical importance. Antiviral treatments deployed"/>
   <result pre="outcomes. Effective treatment of both the viral and the secondary" exact="bacterial" post="infection(s) is of critical importance. Antiviral treatments deployed initially"/>
   <result pre="of critical importance. Antiviral treatments deployed initially do not treat" exact="secondary" post="bacterial infections (15). The preferred treatment for bacterial infections"/>
   <result pre="critical importance. Antiviral treatments deployed initially do not treat secondary" exact="bacterial infections" post="(15). The preferred treatment for bacterial infections is generally"/>
   <result pre="importance. Antiviral treatments deployed initially do not treat secondary bacterial" exact="infections" post="(15). The preferred treatment for bacterial infections is generally"/>
   <result pre="not treat secondary bacterial infections (15). The preferred treatment for" exact="bacterial infections" post="is generally broad-spectrum antibiotics, but this can result in"/>
   <result pre="treat secondary bacterial infections (15). The preferred treatment for bacterial" exact="infections" post="is generally broad-spectrum antibiotics, but this can result in"/>
   <result pre="a population can be protected from risk of some common" exact="bacterial" post="pathogens that are also capable to cause secondary infections,"/>
   <result pre="some common bacterial pathogens that are also capable to cause" exact="secondary" post="infections, for example pneumonia, if vaccines are available; furthermore,"/>
   <result pre="available; furthermore, the immune system is often capable of fighting" exact="bacterial infections" post="alone, while during a virus-bacterial infection, the complex immune"/>
   <result pre="furthermore, the immune system is often capable of fighting bacterial" exact="infections" post="alone, while during a virus-bacterial infection, the complex immune"/>
   <result pre="the complex immune responses might be inapt to eliminate bacterial-induced" exact="disease" post="complications (19). To reduce severe disease progression or lethal"/>
   <result pre="inapt to eliminate bacterial-induced disease complications (19). To reduce severe" exact="disease" post="progression or lethal outcomes, alternative ways to alleviate complications"/>
   <result pre="or lethal outcomes, alternative ways to alleviate complications due to" exact="secondary" post="bacterial infections and to eliminate bacterial pathogens while preserving"/>
   <result pre="lethal outcomes, alternative ways to alleviate complications due to secondary" exact="bacterial infections" post="and to eliminate bacterial pathogens while preserving host immunity"/>
   <result pre="outcomes, alternative ways to alleviate complications due to secondary bacterial" exact="infections" post="and to eliminate bacterial pathogens while preserving host immunity"/>
   <result pre="alleviate complications due to secondary bacterial infections and to eliminate" exact="bacterial" post="pathogens while preserving host immunity might be necessary. Secondary"/>
   <result pre="eliminate bacterial pathogens while preserving host immunity might be necessary." exact="Secondary" post="infections can also be acquired from the patient's environment"/>
   <result pre="bacterial pathogens while preserving host immunity might be necessary. Secondary" exact="infections" post="can also be acquired from the patient's environment i.e.,"/>
   <result pre="host immunity might be necessary. Secondary infections can also be" exact="acquired" post="from the patient's environment i.e., hospital-acquired or nosocomial infections."/>
   <result pre="also be acquired from the patient's environment i.e., hospital-acquired or" exact="nosocomial infections." post="Nosocomial pathogens are often resistant to a wide range"/>
   <result pre="Carbapenem-resistant Enterobacteriaceae (CRE), Colistin-resistant Klebsiella, Carbapenem-resistant Pseudomonas aeruginosa, and Carbapenem-resistant" exact="Acinetobacter" post="baumannii (20). If a patient with a viral infection"/>
   <result pre="and Carbapenem-resistant Acinetobacter baumannii (20). If a patient with a" exact="viral infection" post="is unfortunate to become infected by MDR bacteria, no"/>
   <result pre="Carbapenem-resistant Acinetobacter baumannii (20). If a patient with a viral" exact="infection" post="is unfortunate to become infected by MDR bacteria, no"/>
   <result pre="more detail below; almost 50% (10 of 21) patients developed" exact="secondary" post="bacterial infections in the lung caused by Klebsiella pneumoniae,"/>
   <result pre="detail below; almost 50% (10 of 21) patients developed secondary" exact="bacterial infections" post="in the lung caused by Klebsiella pneumoniae, Staphylococcus, Acinetobacter"/>
   <result pre="below; almost 50% (10 of 21) patients developed secondary bacterial" exact="infections" post="in the lung caused by Klebsiella pneumoniae, Staphylococcus, Acinetobacter"/>
   <result pre="bacterial infections in the lung caused by Klebsiella pneumoniae, Staphylococcus," exact="Acinetobacter" post="baumannii, and E. coli, ultimately leading to their death,"/>
   <result pre="This evaluation of all the COVID-19 reports available that reference" exact="secondary" post="infections showed that most clinicians prescribed meropenem and linezolid"/>
   <result pre="evaluation of all the COVID-19 reports available that reference secondary" exact="infections" post="showed that most clinicians prescribed meropenem and linezolid to"/>
   <result pre="study, we have assimilated the most recent clinical data on" exact="bacterial" post="secondary infections associated with pneumonias, caused by pulmonary viruses,"/>
   <result pre="we have assimilated the most recent clinical data on bacterial" exact="secondary" post="infections associated with pneumonias, caused by pulmonary viruses, including"/>
   <result pre="have assimilated the most recent clinical data on bacterial secondary" exact="infections" post="associated with pneumonias, caused by pulmonary viruses, including for"/>
   <result pre="data on bacterial secondary infections associated with pneumonias, caused by" exact="pulmonary" post="viruses, including for SARS-CoV-2. We outline treatments used or"/>
   <result pre="SARS-CoV-2. We outline treatments used or prophylactic measures employed for" exact="secondary" post="bacterial infections. This review focuses on secondary bacterial infections"/>
   <result pre="We outline treatments used or prophylactic measures employed for secondary" exact="bacterial infections." post="This review focuses on secondary bacterial infections that occur"/>
   <result pre="measures employed for secondary bacterial infections. This review focuses on" exact="secondary" post="bacterial infections that occur in the respiratory tissue of"/>
   <result pre="employed for secondary bacterial infections. This review focuses on secondary" exact="bacterial infections" post="that occur in the respiratory tissue of patients suffering"/>
   <result pre="for secondary bacterial infections. This review focuses on secondary bacterial" exact="infections" post="that occur in the respiratory tissue of patients suffering"/>
   <result pre="review focuses on secondary bacterial infections that occur in the" exact="respiratory" post="tissue of patients suffering from a viral infection, as"/>
   <result pre="occur in the respiratory tissue of patients suffering from a" exact="viral infection," post="as most lung infections by secondary bacterial pathogens remain"/>
   <result pre="of patients suffering from a viral infection, as most lung" exact="infections" post="by secondary bacterial pathogens remain localized in the respiratory"/>
   <result pre="suffering from a viral infection, as most lung infections by" exact="secondary" post="bacterial pathogens remain localized in the respiratory tract, while"/>
   <result pre="from a viral infection, as most lung infections by secondary" exact="bacterial" post="pathogens remain localized in the respiratory tract, while a"/>
   <result pre="infection, as most lung infections by secondary bacterial pathogens remain" exact="localized" post="in the respiratory tract, while a small percentage leads"/>
   <result pre="lung infections by secondary bacterial pathogens remain localized in the" exact="respiratory" post="tract, while a small percentage leads to infections that"/>
   <result pre="in the respiratory tract, while a small percentage leads to" exact="infections" post="that spread systematically. COVID-19 Related Secondary Bacterial Infections and"/>
   <result pre="small percentage leads to infections that spread systematically. COVID-19 Related" exact="Secondary" post="Bacterial Infections and Treatment SARS-CoV-2 is an enveloped, positive-sense,"/>
   <result pre="percentage leads to infections that spread systematically. COVID-19 Related Secondary" exact="Bacterial Infections" post="and Treatment SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA"/>
   <result pre="leads to infections that spread systematically. COVID-19 Related Secondary Bacterial" exact="Infections" post="and Treatment SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA"/>
   <result pre="Coronaviridae. The virus emerged in 2019 and is responsible for" exact="respiratory" post="illnesses Coronavirus Disease 2019 (COVID-19) that results in respiratory"/>
   <result pre="emerged in 2019 and is responsible for respiratory illnesses Coronavirus" exact="Disease" post="2019 (COVID-19) that results in respiratory tract infections and"/>
   <result pre="for respiratory illnesses Coronavirus Disease 2019 (COVID-19) that results in" exact="respiratory" post="tract infections and causes severe lung damage in most"/>
   <result pre="illnesses Coronavirus Disease 2019 (COVID-19) that results in respiratory tract" exact="infections" post="and causes severe lung damage in most fatal cases."/>
   <result pre="COVID-19 requiring hospitalization and critical care. Early stages of SARS-CoV-2" exact="infection" post="typically include symptoms of mild fever and shortness of"/>
   <result pre="shortness of breath (25). As the virus replicates in the" exact="respiratory" post="tract, the symptoms worsen and once the virus reaches"/>
   <result pre="may result in pneumonia. In almost all severe cases, SARS-CoV-2" exact="infection" post="results in pneumonia and the inflamed fluid-filled alveolar tissue"/>
   <result pre="pneumonia. In almost all severe cases, SARS-CoV-2 infection results in" exact="pneumonia" post="and the inflamed fluid-filled alveolar tissue now is an"/>
   <result pre="inflamed fluid-filled alveolar tissue now is an ideal habitat for" exact="bacterial" post="growth for pathogens including P. aeruginosa and S. aureus."/>
   <result pre="and S. aureus. The causative agent resulting in a severe" exact="disease" post="progression may be bacteria, virus or fungi (26). The"/>
   <result pre="may be bacteria, virus or fungi (26). The presence of" exact="secondary" post="bacterial infections in those infected with SARS-CoV-2 complicates treatment"/>
   <result pre="be bacteria, virus or fungi (26). The presence of secondary" exact="bacterial infections" post="in those infected with SARS-CoV-2 complicates treatment (26, 27)."/>
   <result pre="bacteria, virus or fungi (26). The presence of secondary bacterial" exact="infections" post="in those infected with SARS-CoV-2 complicates treatment (26, 27)."/>
   <result pre="Information, where we have analyzed 15 case studies reporting SARS-CoV-2" exact="infection" post="(Supplemental Data Sheet 1). In particular for data obtained"/>
   <result pre="(azithromycin, moxifloxacin, ceftriaxone, vancomycin, cefepime) to reduce the risk of" exact="nosocomial infections," post="a prophylactic strategy. Should a bacterial infection occur despite"/>
   <result pre="the risk of nosocomial infections, a prophylactic strategy. Should a" exact="bacterial infection" post="occur despite the prophylactic use of antibiotics, caused by"/>
   <result pre="risk of nosocomial infections, a prophylactic strategy. Should a bacterial" exact="infection" post="occur despite the prophylactic use of antibiotics, caused by"/>
   <result pre="in COVID-19 Patients Fifteen clinical reports, for which data for" exact="secondary" post="infections were available, mainly from hospitals in China, were"/>
   <result pre="COVID-19 Patients Fifteen clinical reports, for which data for secondary" exact="infections" post="were available, mainly from hospitals in China, were examined"/>
   <result pre="information of the occurrence, treatment of or prophylactic measures for" exact="bacterial" post="secondary infections during the course of COVID-19 infections (Supplementary"/>
   <result pre="of the occurrence, treatment of or prophylactic measures for bacterial" exact="secondary" post="infections during the course of COVID-19 infections (Supplementary File)."/>
   <result pre="the occurrence, treatment of or prophylactic measures for bacterial secondary" exact="infections" post="during the course of COVID-19 infections (Supplementary File). A"/>
   <result pre="measures for bacterial secondary infections during the course of COVID-19" exact="infections" post="(Supplementary File). A total of 3,133 COVID-19 patient cases"/>
   <result pre="infections during the course of COVID-19 infections (Supplementary File). A" exact="total" post="of 3,133 COVID-19 patient cases were detailed in the"/>
   <result pre="carbapenems, tigecycline, doxycycline, and cefoperazone. In total, 10 studies reported" exact="secondary" post="bacterial infections, with 273 of the 997 patients (27.3%)"/>
   <result pre="tigecycline, doxycycline, and cefoperazone. In total, 10 studies reported secondary" exact="bacterial infections," post="with 273 of the 997 patients (27.3%) being infected."/>
   <result pre="SARS-CoV-2 virus (28, 30, 34, 35, 37). The most common" exact="bacterial infections" post="were caused by the Gram-positive pathogen Staphylococcus aureus or"/>
   <result pre="virus (28, 30, 34, 35, 37). The most common bacterial" exact="infections" post="were caused by the Gram-positive pathogen Staphylococcus aureus or"/>
   <result pre="strains of the Gram-negative bacterium Klebsiella pneumoniae. Five studies reported" exact="infections" post="that were confirmed by tests in a microbiology laboratory,"/>
   <result pre="in 92 of 146 patients (63%), which were administered as" exact="secondary" post="bacterial infections were observed (29, 35, 39). Four studies"/>
   <result pre="92 of 146 patients (63%), which were administered as secondary" exact="bacterial infections" post="were observed (29, 35, 39). Four studies reported complications"/>
   <result pre="of 146 patients (63%), which were administered as secondary bacterial" exact="infections" post="were observed (29, 35, 39). Four studies reported complications"/>
   <result pre="39). Four studies reported complications with fatal outcome due to" exact="bacterial infections" post="that included 41 of 268 patients (15.2%) (26, 27,"/>
   <result pre="Four studies reported complications with fatal outcome due to bacterial" exact="infections" post="that included 41 of 268 patients (15.2%) (26, 27,"/>
   <result pre="and challenges faced in treating SARS-CoV-2 infected patients. Patients with" exact="pneumonia" post="caused by other respiratory viruses or SARS-CoV-2 pneumonia patients"/>
   <result pre="treating SARS-CoV-2 infected patients. Patients with pneumonia caused by other" exact="respiratory" post="viruses or SARS-CoV-2 pneumonia patients were often prophylactically treated"/>
   <result pre="Patients with pneumonia caused by other respiratory viruses or SARS-CoV-2" exact="pneumonia" post="patients were often prophylactically treated with broad-spectrum antibiotics, in"/>
   <result pre="broad-spectrum antibiotics, in an attempt to reduce the risk of" exact="bacterial" post="superinfections. Complications were observed in patients that were not"/>
   <result pre="with antibiotics. Antibiotic-resistant infections, in particular, nosocomial - hospital-acquired -" exact="infections" post="were common for more than one third of ICU"/>
   <result pre="than one third of ICU patients, posing a threat to" exact="disease" post="progression, often resulting in the death of the affected"/>
   <result pre="in the death of the affected individual (26, 40). SARS-related" exact="Secondary" post="Bacterial Infections and Treatment Severe Acute Respiratory Syndrome-related Coronavirus"/>
   <result pre="the death of the affected individual (26, 40). SARS-related Secondary" exact="Bacterial Infections" post="and Treatment Severe Acute Respiratory Syndrome-related Coronavirus (SARS) Co-V,"/>
   <result pre="death of the affected individual (26, 40). SARS-related Secondary Bacterial" exact="Infections" post="and Treatment Severe Acute Respiratory Syndrome-related Coronavirus (SARS) Co-V,"/>
   <result pre="affected individual (26, 40). SARS-related Secondary Bacterial Infections and Treatment" exact="Severe" post="Acute Respiratory Syndrome-related Coronavirus (SARS) Co-V, was first report"/>
   <result pre="individual (26, 40). SARS-related Secondary Bacterial Infections and Treatment Severe" exact="Acute" post="Respiratory Syndrome-related Coronavirus (SARS) Co-V, was first report in"/>
   <result pre="(26, 40). SARS-related Secondary Bacterial Infections and Treatment Severe Acute" exact="Respiratory" post="Syndrome-related Coronavirus (SARS) Co-V, was first report in Guangdong"/>
   <result pre="April 2004 (42). The case studies showed the occurrence of" exact="bacterial" post="co-infections in the large number of patients. These include"/>
   <result pre="bacterial co-infections in the large number of patients. These include" exact="infections" post="by MRSA, Klebsiella spp., P. aeruginosa and Streptococcus (43)."/>
   <result pre="of the SARS patients may be due to the underlining" exact="bacterial infections" post="(43). The use of broad-spectrum antibiotics to cover the"/>
   <result pre="the SARS patients may be due to the underlining bacterial" exact="infections" post="(43). The use of broad-spectrum antibiotics to cover the"/>
   <result pre="infections (43). The use of broad-spectrum antibiotics to cover the" exact="secondary" post="bacterial infections is one of the supportive cares during"/>
   <result pre="(43). The use of broad-spectrum antibiotics to cover the secondary" exact="bacterial infections" post="is one of the supportive cares during SARS outbreak"/>
   <result pre="The use of broad-spectrum antibiotics to cover the secondary bacterial" exact="infections" post="is one of the supportive cares during SARS outbreak"/>
   <result pre="(Supplementary File). The case studies (n = 7) reported the" exact="disease" post="progression of a total of 534 SARS-CoV patients (45–51)"/>
   <result pre="studies (n = 7) reported the disease progression of a" exact="total" post="of 534 SARS-CoV patients (45–51) (Supplementary File). Details about"/>
   <result pre="(n = 206, 74.6%). Of the four studies that reported" exact="secondary" post="bacterial infections, 35 of 306 patients (11.4%) became infected."/>
   <result pre="= 206, 74.6%). Of the four studies that reported secondary" exact="bacterial infections," post="35 of 306 patients (11.4%) became infected. The pathogens"/>
   <result pre="306 patients (11.4%) became infected. The pathogens that caused the" exact="infections" post="included P. aeruginosa, MRSA, S. pneumoniae, K. pneumoniae, Enterococci,"/>
   <result pre="infections included P. aeruginosa, MRSA, S. pneumoniae, K. pneumoniae, Enterococci," exact="Acinetobacter" post="baumannii, Enterobacter, H. influenza, S. maltophilia, and Serratia (45,"/>
   <result pre="studies who provided the respective information) had complications due to" exact="secondary" post="bacterial infections (47, 51). During the 2002 outbreak, most"/>
   <result pre="who provided the respective information) had complications due to secondary" exact="bacterial infections" post="(47, 51). During the 2002 outbreak, most SARS patients"/>
   <result pre="provided the respective information) had complications due to secondary bacterial" exact="infections" post="(47, 51). During the 2002 outbreak, most SARS patients"/>
   <result pre="however the use of antibiotics as a precaution in many" exact="viral" post="infections and their potential overuse may have contributed to"/>
   <result pre="the use of antibiotics as a precaution in many viral" exact="infections" post="and their potential overuse may have contributed to the"/>
   <result pre="overuse may have contributed to the current antibiotic crisis. MERS-related" exact="Secondary" post="Bacterial Infections and Treatment The first cases of the"/>
   <result pre="may have contributed to the current antibiotic crisis. MERS-related Secondary" exact="Bacterial Infections" post="and Treatment The first cases of the Middle East"/>
   <result pre="have contributed to the current antibiotic crisis. MERS-related Secondary Bacterial" exact="Infections" post="and Treatment The first cases of the Middle East"/>
   <result pre="Infections and Treatment The first cases of the Middle East" exact="respiratory" post="syndrome (MERS) CoV epidemic occurred in June 2012 in"/>
   <result pre="and Treatment The first cases of the Middle East respiratory" exact="syndrome" post="(MERS) CoV epidemic occurred in June 2012 in Saudi"/>
   <result pre="= 866), the highest among all coronavirus diseases (52). The" exact="infection" post="often starts as a mild viral respiratory illness but"/>
   <result pre="coronavirus diseases (52). The infection often starts as a mild" exact="viral" post="respiratory illness but can rapidly progress to a fatal"/>
   <result pre="diseases (52). The infection often starts as a mild viral" exact="respiratory" post="illness but can rapidly progress to a fatal viral"/>
   <result pre="viral respiratory illness but can rapidly progress to a fatal" exact="viral pneumonia" post="mostly complicated by ARDS (acute respiratory distress syndrome) and"/>
   <result pre="respiratory illness but can rapidly progress to a fatal viral" exact="pneumonia" post="mostly complicated by ARDS (acute respiratory distress syndrome) and"/>
   <result pre="to a fatal viral pneumonia mostly complicated by ARDS (acute" exact="respiratory" post="distress syndrome) and ARF (acute renal failure) (53). Due"/>
   <result pre="rate of MERS infections, the impact of the occurrence of" exact="bacterial infections" post="remains unclear as death occurs due to hypoxemia and"/>
   <result pre="of MERS infections, the impact of the occurrence of bacterial" exact="infections" post="remains unclear as death occurs due to hypoxemia and"/>
   <result pre="infections remains unclear as death occurs due to hypoxemia and" exact="bilateral" post="interstitial infiltrates in most cases, or ARDS. Nosocomial bacterial"/>
   <result pre="and bilateral interstitial infiltrates in most cases, or ARDS. Nosocomial" exact="bacterial pneumonia" post="is however common among MERS patients with ventilator support."/>
   <result pre="bilateral interstitial infiltrates in most cases, or ARDS. Nosocomial bacterial" exact="pneumonia" post="is however common among MERS patients with ventilator support."/>
   <result pre="with ventilator support. Therefore, antibiotic therapy was commonly deployed with" exact="secondary" post="bacterial infections rarely occurring under this treatment regime (53–55)."/>
   <result pre="ventilator support. Therefore, antibiotic therapy was commonly deployed with secondary" exact="bacterial infections" post="rarely occurring under this treatment regime (53–55). Here, we"/>
   <result pre="support. Therefore, antibiotic therapy was commonly deployed with secondary bacterial" exact="infections" post="rarely occurring under this treatment regime (53–55). Here, we"/>
   <result pre="Here, we review MERS-related case studies, outlining antibiotic therapies and" exact="bacterial infections." post="A total of 138 MERS-CoV infected patients were reported"/>
   <result pre="MERS-related case studies, outlining antibiotic therapies and bacterial infections. A" exact="total" post="of 138 MERS-CoV infected patients were reported (55–59) (Supplementary"/>
   <result pre="other broad-spectrum antibiotics (55, 56, 58, 59). The development of" exact="secondary" post="bacterial infection was reported in two studies, with 32"/>
   <result pre="broad-spectrum antibiotics (55, 56, 58, 59). The development of secondary" exact="bacterial infection" post="was reported in two studies, with 32 of 82"/>
   <result pre="antibiotics (55, 56, 58, 59). The development of secondary bacterial" exact="infection" post="was reported in two studies, with 32 of 82"/>
   <result pre="studies, with 32 of 82 patients experiencing complications due to" exact="bacterial" post="pathogens (55, 57). The most common bacteria were MRSA,"/>
   <result pre="The most common bacteria were MRSA, while others included carbapenem-resistant" exact="Acinetobacter" post="baumannii, VRE and S. pneumoniae. No detailed report was"/>
   <result pre="one study reported (patients n = 15) complications due to" exact="bacterial infections" post="in intensive care units (55). Influenza Viruses and Secondary"/>
   <result pre="study reported (patients n = 15) complications due to bacterial" exact="infections" post="in intensive care units (55). Influenza Viruses and Secondary"/>
   <result pre="bacterial infections in intensive care units (55). Influenza Viruses and" exact="Secondary" post="Bacterial Infections Influenza viruses are known to cause seasonal"/>
   <result pre="infections in intensive care units (55). Influenza Viruses and Secondary" exact="Bacterial Infections" post="Influenza viruses are known to cause seasonal flu every"/>
   <result pre="in intensive care units (55). Influenza Viruses and Secondary Bacterial" exact="Infections" post="Influenza viruses are known to cause seasonal flu every"/>
   <result pre="seasonal flu every year and of the four influenza types," exact="type A" post="and B are known to cause seasonal epidemics (60)."/>
   <result pre="0.25 and 0.5 million people according to the WHO (61)." exact="Secondary" post="bacterial infections are one of the leading causes for"/>
   <result pre="and 0.5 million people according to the WHO (61). Secondary" exact="bacterial infections" post="are one of the leading causes for influenza associated"/>
   <result pre="0.5 million people according to the WHO (61). Secondary bacterial" exact="infections" post="are one of the leading causes for influenza associated"/>
   <result pre="for influenza associated deaths (62). According to the Center for" exact="Disease" post="Control and Prevention (CDC), during the 2009 H1N1 influenza"/>
   <result pre="pandemic between 29 and 55% of mortalities were due to" exact="secondary" post="bacterial infections (63). The lethal synergism between influenza virus"/>
   <result pre="between 29 and 55% of mortalities were due to secondary" exact="bacterial infections" post="(63). The lethal synergism between influenza virus and Pneumococcus"/>
   <result pre="29 and 55% of mortalities were due to secondary bacterial" exact="infections" post="(63). The lethal synergism between influenza virus and Pneumococcus"/>
   <result pre="summarize case studies that are related to influenza viruses and" exact="secondary" post="bacterial infections (Supplementary File). Details on treatment and disease"/>
   <result pre="case studies that are related to influenza viruses and secondary" exact="bacterial infections" post="(Supplementary File). Details on treatment and disease progression of"/>
   <result pre="studies that are related to influenza viruses and secondary bacterial" exact="infections" post="(Supplementary File). Details on treatment and disease progression of"/>
   <result pre="and secondary bacterial infections (Supplementary File). Details on treatment and" exact="disease" post="progression of a total of 910 patients that were"/>
   <result pre="(Supplementary File). Details on treatment and disease progression of a" exact="total" post="of 910 patients that were infected with influenza were"/>
   <result pre="and dicloxacillin. In total, 223 patients of 910 (24.5%) developed" exact="secondary" post="bacterial infections. The infective agents were S. pneumoniae, MRSA,"/>
   <result pre="dicloxacillin. In total, 223 patients of 910 (24.5%) developed secondary" exact="bacterial infections." post="The infective agents were S. pneumoniae, MRSA, P. aeruginosa,"/>
   <result pre="223 patients of 910 (24.5%) developed secondary bacterial infections. The" exact="infective" post="agents were S. pneumoniae, MRSA, P. aeruginosa, S. viridians,"/>
   <result pre="hominis, Enterococci, H. influenza, S. pyogenes, S. mitis, S. agalactiae," exact="Acinetobacter" post="baumannii, E. coli, Chlamydophila pneumoniae, and Moraxella catarrhalis. To"/>
   <result pre="all eight case studies reported the treatment complications due to" exact="secondary" post="bacterial infections. Discussion The lack of detailed clinical data"/>
   <result pre="eight case studies reported the treatment complications due to secondary" exact="bacterial infections." post="Discussion The lack of detailed clinical data regarding secondary"/>
   <result pre="bacterial infections. Discussion The lack of detailed clinical data regarding" exact="secondary" post="bacterial infections following COVID-19, SARS, MERS and influenza is"/>
   <result pre="infections. Discussion The lack of detailed clinical data regarding secondary" exact="bacterial infections" post="following COVID-19, SARS, MERS and influenza is surprising. In"/>
   <result pre="Discussion The lack of detailed clinical data regarding secondary bacterial" exact="infections" post="following COVID-19, SARS, MERS and influenza is surprising. In"/>
   <result pre="addition, precise numbers of clinical cases of COVID-19 or other" exact="respiratory" post="virus infections with antibiotic-resistant secondary bacterial infections are not"/>
   <result pre="numbers of clinical cases of COVID-19 or other respiratory virus" exact="infections" post="with antibiotic-resistant secondary bacterial infections are not available. As"/>
   <result pre="cases of COVID-19 or other respiratory virus infections with antibiotic-resistant" exact="secondary" post="bacterial infections are not available. As globally mortality rates"/>
   <result pre="of COVID-19 or other respiratory virus infections with antibiotic-resistant secondary" exact="bacterial infections" post="are not available. As globally mortality rates from antibiotic-resistant"/>
   <result pre="COVID-19 or other respiratory virus infections with antibiotic-resistant secondary bacterial" exact="infections" post="are not available. As globally mortality rates from antibiotic-resistant"/>
   <result pre="infections are not available. As globally mortality rates from antibiotic-resistant" exact="bacterial infections" post="are increasing, providing such data of secondary infection is"/>
   <result pre="are not available. As globally mortality rates from antibiotic-resistant bacterial" exact="infections" post="are increasing, providing such data of secondary infection is"/>
   <result pre="from antibiotic-resistant bacterial infections are increasing, providing such data of" exact="secondary" post="infection is important, almost critical. Clinical reports are a"/>
   <result pre="antibiotic-resistant bacterial infections are increasing, providing such data of secondary" exact="infection" post="is important, almost critical. Clinical reports are a valuable"/>
   <result pre="pathogenic bacterium. Such data are essential for the study of" exact="secondary" post="infections in human patients; the scientific community and ultimately"/>
   <result pre="bacterium. Such data are essential for the study of secondary" exact="infections" post="in human patients; the scientific community and ultimately the"/>
   <result pre="and ultimately the patient will benefit when clinicians and non-clinical" exact="disease" post="experts work close together. The information from such collaborative"/>
   <result pre="is evident. Reviewing the available information, it becomes clear that" exact="secondary" post="bacterial infections play a critical role in the morbidity"/>
   <result pre="evident. Reviewing the available information, it becomes clear that secondary" exact="bacterial infections" post="play a critical role in the morbidity and mortality"/>
   <result pre="Reviewing the available information, it becomes clear that secondary bacterial" exact="infections" post="play a critical role in the morbidity and mortality"/>
   <result pre="morbidity and mortality rates of patients initially falling ill with" exact="pulmonary" post="viral diseases. Similar to epidemics caused by influenza viruses,"/>
   <result pre="and mortality rates of patients initially falling ill with pulmonary" exact="viral" post="diseases. Similar to epidemics caused by influenza viruses, during"/>
   <result pre="caused by influenza viruses, during the current SARS-CoV-2 pandemic, antibiotic-resistant" exact="bacterial infections" post="are a significant threat to the well-being of hospitalized"/>
   <result pre="by influenza viruses, during the current SARS-CoV-2 pandemic, antibiotic-resistant bacterial" exact="infections" post="are a significant threat to the well-being of hospitalized"/>
   <result pre="significant threat to the well-being of hospitalized COVID-19 patients. Nosocomial" exact="infections" post="including ventilator-associated infections are often unavoidable and especially so"/>
   <result pre="the well-being of hospitalized COVID-19 patients. Nosocomial infections including ventilator-associated" exact="infections" post="are often unavoidable and especially so during a pandemic."/>
   <result pre="this date unavailable preventive measures are in place at hospitals," exact="secondary" post="infections will remain unavoidable due to the nature of"/>
   <result pre="date unavailable preventive measures are in place at hospitals, secondary" exact="infections" post="will remain unavoidable due to the nature of nosocomial"/>
   <result pre="populations until a vaccine is deployed, globally. To prepare for" exact="recurrent" post="waves of COVID-19 disease and the inevitable next new"/>
   <result pre="is deployed, globally. To prepare for recurrent waves of COVID-19" exact="disease" post="and the inevitable next new pandemic, new antibiotics or"/>
   <result pre="next new pandemic, new antibiotics or alternative treatments targeted against" exact="secondary" post="bacterial infections are needed. Alternative therapies such as Antimicrobial"/>
   <result pre="new pandemic, new antibiotics or alternative treatments targeted against secondary" exact="bacterial infections" post="are needed. Alternative therapies such as Antimicrobial Peptides or"/>
   <result pre="pandemic, new antibiotics or alternative treatments targeted against secondary bacterial" exact="infections" post="are needed. Alternative therapies such as Antimicrobial Peptides or"/>
   <result pre="show promise. Most antimicrobial peptides perturb the structure of the" exact="bacterial" post="cell envelope while not affecting the eukaryotic cell membrane;"/>
   <result pre="cell membrane; eventually creating a leaky lipid bilayer and the" exact="collapse" post="of the proton-motif-force, ultimately resulting in bacterial cell death"/>
   <result pre="bilayer and the collapse of the proton-motif-force, ultimately resulting in" exact="bacterial" post="cell death (73–76). Phage therapy makes use of bacterial"/>
   <result pre="in bacterial cell death (73–76). Phage therapy makes use of" exact="bacterial" post="viruses (or bacteriophages) that specifically infect bacterial pathogens for"/>
   <result pre="makes use of bacterial viruses (or bacteriophages) that specifically infect" exact="bacterial" post="pathogens for viral replication, which leads to the lysis"/>
   <result pre="bacterial viruses (or bacteriophages) that specifically infect bacterial pathogens for" exact="viral" post="replication, which leads to the lysis of the host"/>
   <result pre="that do not kill or arrest the growth of a" exact="bacterial" post="pathogen, but rather target pathogen-intrinsic components important for the"/>
   <result pre="bacterial pathogen, but rather target pathogen-intrinsic components important for the" exact="infection" post="process. These include bacterial components such as exo- and"/>
   <result pre="target pathogen-intrinsic components important for the infection process. These include" exact="bacterial" post="components such as exo- and endotoxins, i.e., actively secreted"/>
   <result pre="demonstrated to prevent or reduce the severity of symptoms of" exact="acute" post="infections (84, 85). Pulmonary coronaviruses will likely be a"/>
   <result pre="to prevent or reduce the severity of symptoms of acute" exact="infections" post="(84, 85). Pulmonary coronaviruses will likely be a clinical"/>
   <result pre="reduce the severity of symptoms of acute infections (84, 85)." exact="Pulmonary" post="coronaviruses will likely be a clinical challenge for many"/>
   <result pre="likely be a clinical challenge for many years to come." exact="Viral" post="pandemics from coronaviruses and emerging pathogens are inevitable in"/>
   <result pre="the next pandemic, exploring and establishing new avenues to treat" exact="bacterial" post="pathogens commonly observed in secondary infections to avert a"/>
   <result pre="establishing new avenues to treat bacterial pathogens commonly observed in" exact="secondary" post="infections to avert a healthcare crisis due to antibiotic-resistance."/>
   <result pre="new avenues to treat bacterial pathogens commonly observed in secondary" exact="infections" post="to avert a healthcare crisis due to antibiotic-resistance. Author"/>
   <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
   <result pre="https://www.frontiersin.org/articles/10.3389/fmed.2020.00420/full#supplementary-material Supplementary Figure 1 Overview of case reports of SARS-CoV-2" exact="infection" post="data reviewed in this study, including rate of secondary"/>
   <result pre="SARS-CoV-2 infection data reviewed in this study, including rate of" exact="secondary" post="bacterial infections, antibiotic use and pathogenic bacteria identified. LINK"/>
   <result pre="infection data reviewed in this study, including rate of secondary" exact="bacterial infections," post="antibiotic use and pathogenic bacteria identified. LINK Click here"/>
   <result pre="file. Supplementary File Tables summarizing case reports of patients with" exact="pulmonary" post="virus infections and clinical interventions to prevent or cure"/>
   <result pre="File Tables summarizing case reports of patients with pulmonary virus" exact="infections" post="and clinical interventions to prevent or cure secondary bacterial"/>
   <result pre="pulmonary virus infections and clinical interventions to prevent or cure" exact="secondary" post="bacterial infections. LINK Click here for additional data file."/>
   <result pre="virus infections and clinical interventions to prevent or cure secondary" exact="bacterial infections." post="LINK Click here for additional data file. Supplemental Data"/>
   <result pre="file. Supplemental Data Sheet 1 Case reports of patients with" exact="secondary" post="bacterial infections. LINK Click here for additional data file."/>
   <result pre="Supplemental Data Sheet 1 Case reports of patients with secondary" exact="bacterial infections." post="LINK Click here for additional data file. References References"/>
   <result pre="Click here for additional data file. References References 1.BradleyBTBryanA. Emerging" exact="respiratory" post="Infections: The infectious disease pathology of SARS, MERS, pandemic"/>
   <result pre="additional data file. References References 1.BradleyBTBryanA. Emerging respiratory Infections: The" exact="infectious disease" post="pathology of SARS, MERS, pandemic influenza, and Legionella. Semin"/>
   <result pre="data file. References References 1.BradleyBTBryanA. Emerging respiratory Infections: The infectious" exact="disease" post="pathology of SARS, MERS, pandemic influenza, and Legionella. Semin"/>
   <result pre="influenza, and Legionella. Semin Diagn Pathol. (2019) 36:152–9. 10.1053/j.semdp.2019.04.00631054790 2.MorrisDEClearyDWClarkeSC." exact="Secondary" post="bacterial infections associated with influenza pandemics. Front Microbiol. (2017)"/>
   <result pre="and Legionella. Semin Diagn Pathol. (2019) 36:152–9. 10.1053/j.semdp.2019.04.00631054790 2.MorrisDEClearyDWClarkeSC. Secondary" exact="bacterial infections" post="associated with influenza pandemics. Front Microbiol. (2017) 8:1041. 10.3389/fmicb.2017.0104128690590"/>
   <result pre="Legionella. Semin Diagn Pathol. (2019) 36:152–9. 10.1053/j.semdp.2019.04.00631054790 2.MorrisDEClearyDWClarkeSC. Secondary bacterial" exact="infections" post="associated with influenza pandemics. Front Microbiol. (2017) 8:1041. 10.3389/fmicb.2017.0104128690590"/>
   <result pre="influenza pandemics. Front Microbiol. (2017) 8:1041. 10.3389/fmicb.2017.0104128690590 3.WangHAnthonyDSelemidisSVlahosRBozinovskiS. Resolving viral-induced" exact="secondary" post="bacterial infection in COPD: a concise review. Front Immunol."/>
   <result pre="pandemics. Front Microbiol. (2017) 8:1041. 10.3389/fmicb.2017.0104128690590 3.WangHAnthonyDSelemidisSVlahosRBozinovskiS. Resolving viral-induced secondary" exact="bacterial infection" post="in COPD: a concise review. Front Immunol. (2018) 9:2345."/>
   <result pre="Front Microbiol. (2017) 8:1041. 10.3389/fmicb.2017.0104128690590 3.WangHAnthonyDSelemidisSVlahosRBozinovskiS. Resolving viral-induced secondary bacterial" exact="infection" post="in COPD: a concise review. Front Immunol. (2018) 9:2345."/>
   <result pre="concise review. Front Immunol. (2018) 9:2345. 10.3389/fimmu.2018.0234530459754 4.MalliaPFootittJSoteroRJepsonAContoliMTrujillo-TorralboMBet al.. Rhinovirus" exact="infection" post="induces degradation of antimicrobial peptides and secondary bacterial infection"/>
   <result pre="4.MalliaPFootittJSoteroRJepsonAContoliMTrujillo-TorralboMBet al.. Rhinovirus infection induces degradation of antimicrobial peptides and" exact="secondary" post="bacterial infection in chronic obstructive pulmonary disease. Am J"/>
   <result pre="al.. Rhinovirus infection induces degradation of antimicrobial peptides and secondary" exact="bacterial infection" post="in chronic obstructive pulmonary disease. Am J Respir Crit"/>
   <result pre="Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial" exact="infection" post="in chronic obstructive pulmonary disease. Am J Respir Crit"/>
   <result pre="induces degradation of antimicrobial peptides and secondary bacterial infection in" exact="chronic" post="obstructive pulmonary disease. Am J Respir Crit Care Med."/>
   <result pre="of antimicrobial peptides and secondary bacterial infection in chronic obstructive" exact="pulmonary" post="disease. Am J Respir Crit Care Med. (2012) 186:1117–24."/>
   <result pre="influenza: a grand rounds review. JAMA. (2013) 309:275–82. 10.1001/jama.2012.19413923321766 6.KashJCTaubenbergerJKInfectious" exact="disease" post="theme issue the role of viral, host, and secondary"/>
   <result pre="6.KashJCTaubenbergerJKInfectious disease theme issue the role of viral, host, and" exact="secondary" post="bacterial factors in influenza pathogenesis. Am J Pathol. (2015)"/>
   <result pre="disease theme issue the role of viral, host, and secondary" exact="bacterial" post="factors in influenza pathogenesis. Am J Pathol. (2015) 185:1528–36."/>
   <result pre="J Pathol. (2015) 185:1528–36. 10.1016/j.ajpath.2014.08.03025747532 7.MacIntyreCRChughtaiAABarnesMRiddaISealeHTomsRet al.. The role of" exact="pneumonia" post="and secondary bacterial infection in fatal and serious outcomes"/>
   <result pre="(2015) 185:1528–36. 10.1016/j.ajpath.2014.08.03025747532 7.MacIntyreCRChughtaiAABarnesMRiddaISealeHTomsRet al.. The role of pneumonia and" exact="secondary" post="bacterial infection in fatal and serious outcomes of pandemic"/>
   <result pre="185:1528–36. 10.1016/j.ajpath.2014.08.03025747532 7.MacIntyreCRChughtaiAABarnesMRiddaISealeHTomsRet al.. The role of pneumonia and secondary" exact="bacterial infection" post="in fatal and serious outcomes of pandemic influenza a"/>
   <result pre="10.1016/j.ajpath.2014.08.03025747532 7.MacIntyreCRChughtaiAABarnesMRiddaISealeHTomsRet al.. The role of pneumonia and secondary bacterial" exact="infection" post="in fatal and serious outcomes of pandemic influenza a"/>
   <result pre="(H1N1) pdm09. BMC Infect Dis. (2018) 18:637. 10.1186/s12879-018-3548-030526505 8.KimYGParkJHReimerTBakerDPKawaiTKumarHet al.." exact="Viral" post="infection augments Nod1/2 signaling to potentiate lethality associated with"/>
   <result pre="pdm09. BMC Infect Dis. (2018) 18:637. 10.1186/s12879-018-3548-030526505 8.KimYGParkJHReimerTBakerDPKawaiTKumarHet al.. Viral" exact="infection" post="augments Nod1/2 signaling to potentiate lethality associated with secondary"/>
   <result pre="Viral infection augments Nod1/2 signaling to potentiate lethality associated with" exact="secondary" post="bacterial infections. Cell Host Microbe. (2011) 9:496–507. 10.1016/j.chom.2011.05.00621669398 9.JamiesonAMYuSAnnicelliCHMedzhitovR."/>
   <result pre="infection augments Nod1/2 signaling to potentiate lethality associated with secondary" exact="bacterial infections." post="Cell Host Microbe. (2011) 9:496–507. 10.1016/j.chom.2011.05.00621669398 9.JamiesonAMYuSAnnicelliCHMedzhitovR. Article influenza"/>
   <result pre="Article influenza virus-induced glucocorticoids compromise innate host defense against a" exact="secondary" post="bacterial infection. Cell Host Microbe. (2010) 7:103–14. 10.1016/j.chom.2010.01.01020159617 10.HendausMAJomhaFAAlhammadiAH."/>
   <result pre="influenza virus-induced glucocorticoids compromise innate host defense against a secondary" exact="bacterial infection." post="Cell Host Microbe. (2010) 7:103–14. 10.1016/j.chom.2010.01.01020159617 10.HendausMAJomhaFAAlhammadiAH. Virus-induced secondary"/>
   <result pre="bacterial infection. Cell Host Microbe. (2010) 7:103–14. 10.1016/j.chom.2010.01.01020159617 10.HendausMAJomhaFAAlhammadiAH. Virus-induced" exact="secondary" post="bacterial infection: a concise review. Ther Clin Risk Manag."/>
   <result pre="infection. Cell Host Microbe. (2010) 7:103–14. 10.1016/j.chom.2010.01.01020159617 10.HendausMAJomhaFAAlhammadiAH. Virus-induced secondary" exact="bacterial" post="infection: a concise review. Ther Clin Risk Manag. (2015)"/>
   <result pre="review. Ther Clin Risk Manag. (2015) 11:1265–71. 10.2147/TCRM.S8778926345407 11.NyangachaRMOdongoDOyiekeFOchwotoMKorirRNgetichRKet al.." exact="Secondary" post="bacterial infections and antibiotic resistance among tungiasis patients in"/>
   <result pre="Ther Clin Risk Manag. (2015) 11:1265–71. 10.2147/TCRM.S8778926345407 11.NyangachaRMOdongoDOyiekeFOchwotoMKorirRNgetichRKet al.. Secondary" exact="bacterial infections" post="and antibiotic resistance among tungiasis patients in Western, Kenya."/>
   <result pre="Clin Risk Manag. (2015) 11:1265–71. 10.2147/TCRM.S8778926345407 11.NyangachaRMOdongoDOyiekeFOchwotoMKorirRNgetichRKet al.. Secondary bacterial" exact="infections" post="and antibiotic resistance among tungiasis patients in Western, Kenya."/>
   <result pre="10.2147/TCRM.S8778926345407 11.NyangachaRMOdongoDOyiekeFOchwotoMKorirRNgetichRKet al.. Secondary bacterial infections and antibiotic resistance among" exact="tungiasis" post="patients in Western, Kenya. PLoS Neglect Trop D. (2017)"/>
   <result pre="Kenya. PLoS Neglect Trop D. (2017) 11:e0005901. 10.1371/journal.pntd.000590128886013 12.PittetLAHall-StoodleyLRutkowskiMRHarmsenAG. Influenza" exact="virus infection" post="decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae."/>
   <result pre="PLoS Neglect Trop D. (2017) 11:e0005901. 10.1371/journal.pntd.000590128886013 12.PittetLAHall-StoodleyLRutkowskiMRHarmsenAG. Influenza virus" exact="infection" post="decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae."/>
   <result pre="Resp Cell Mol. (2010) 42:450–60. 10.1165/rcmb.2007-0417OC19520922 13.MorrisDP. Bacterial biofilm in" exact="upper" post="respiratory tract infections. Curr Infect Dis Rep. (2007) 9:186–92."/>
   <result pre="Cell Mol. (2010) 42:450–60. 10.1165/rcmb.2007-0417OC19520922 13.MorrisDP. Bacterial biofilm in upper" exact="respiratory" post="tract infections. Curr Infect Dis Rep. (2007) 9:186–92. 10.1007/s11908-007-0030-317430699"/>
   <result pre="14.HandelALonginiIMAntiaR. Intervention strategies for an influenza pandemic taking into account" exact="secondary" post="bacterial infections. Epidem. (2009) 1:185–95. 10.1016/j.epidem.2009.09.00120161493 15.McCullersJA. Preventing and"/>
   <result pre="Intervention strategies for an influenza pandemic taking into account secondary" exact="bacterial infections." post="Epidem. (2009) 1:185–95. 10.1016/j.epidem.2009.09.00120161493 15.McCullersJA. Preventing and treating secondary"/>
   <result pre="bacterial infections. Epidem. (2009) 1:185–95. 10.1016/j.epidem.2009.09.00120161493 15.McCullersJA. Preventing and treating" exact="secondary" post="bacterial infections with antiviral agents. Antivir Ther. (2011) 16:123–35."/>
   <result pre="infections. Epidem. (2009) 1:185–95. 10.1016/j.epidem.2009.09.00120161493 15.McCullersJA. Preventing and treating secondary" exact="bacterial infections" post="with antiviral agents. Antivir Ther. (2011) 16:123–35. 10.3851/IMP173021447860 16.BrookI."/>
   <result pre="Epidem. (2009) 1:185–95. 10.1016/j.epidem.2009.09.00120161493 15.McCullersJA. Preventing and treating secondary bacterial" exact="infections" post="with antiviral agents. Antivir Ther. (2011) 16:123–35. 10.3851/IMP173021447860 16.BrookI."/>
   <result pre="infections with antiviral agents. Antivir Ther. (2011) 16:123–35. 10.3851/IMP173021447860 16.BrookI." exact="Secondary" post="bacterial infections complicating skin lesions. J Med Microbiol. (2002)"/>
   <result pre="with antiviral agents. Antivir Ther. (2011) 16:123–35. 10.3851/IMP173021447860 16.BrookI. Secondary" exact="bacterial infections" post="complicating skin lesions. J Med Microbiol. (2002) 51:808–12. 10.1099/0022-1317-51-10-80812435058"/>
   <result pre="antiviral agents. Antivir Ther. (2011) 16:123–35. 10.3851/IMP173021447860 16.BrookI. Secondary bacterial" exact="infections" post="complicating skin lesions. J Med Microbiol. (2002) 51:808–12. 10.1099/0022-1317-51-10-80812435058"/>
   <result pre="lesions. J Med Microbiol. (2002) 51:808–12. 10.1099/0022-1317-51-10-80812435058 17.BrookI. Microbiology of" exact="secondary" post="bacterial infection in scabies lesions. J Clin Microbiol. (1995)"/>
   <result pre="J Med Microbiol. (2002) 51:808–12. 10.1099/0022-1317-51-10-80812435058 17.BrookI. Microbiology of secondary" exact="bacterial infection" post="in scabies lesions. J Clin Microbiol. (1995) 33:2139–40. 10.1128/JCM.33.8.2139-2140.19957559963"/>
   <result pre="Med Microbiol. (2002) 51:808–12. 10.1099/0022-1317-51-10-80812435058 17.BrookI. Microbiology of secondary bacterial" exact="infection" post="in scabies lesions. J Clin Microbiol. (1995) 33:2139–40. 10.1128/JCM.33.8.2139-2140.19957559963"/>
   <result pre="(2002) 51:808–12. 10.1099/0022-1317-51-10-80812435058 17.BrookI. Microbiology of secondary bacterial infection in" exact="scabies" post="lesions. J Clin Microbiol. (1995) 33:2139–40. 10.1128/JCM.33.8.2139-2140.19957559963 18.MaharPDWasiakJClelandHPaulEGinDWattersDAet al.."/>
   <result pre="scabies lesions. J Clin Microbiol. (1995) 33:2139–40. 10.1128/JCM.33.8.2139-2140.19957559963 18.MaharPDWasiakJClelandHPaulEGinDWattersDAet al.." exact="Secondary" post="bacterial infection and empirical antibiotic use in toxic epidermal"/>
   <result pre="lesions. J Clin Microbiol. (1995) 33:2139–40. 10.1128/JCM.33.8.2139-2140.19957559963 18.MaharPDWasiakJClelandHPaulEGinDWattersDAet al.. Secondary" exact="bacterial infection" post="and empirical antibiotic use in toxic epidermal necrolysis patients."/>
   <result pre="J Clin Microbiol. (1995) 33:2139–40. 10.1128/JCM.33.8.2139-2140.19957559963 18.MaharPDWasiakJClelandHPaulEGinDWattersDAet al.. Secondary bacterial" exact="infection" post="and empirical antibiotic use in toxic epidermal necrolysis patients."/>
   <result pre="18.MaharPDWasiakJClelandHPaulEGinDWattersDAet al.. Secondary bacterial infection and empirical antibiotic use in" exact="toxic epidermal necrolysis" post="patients. J Burn Care Res. (2014) 35:518–24. 10.1097/BCR.000000000000006224988228 19.SmithAMMcCullersJASecondary"/>
   <result pre="necrolysis patients. J Burn Care Res. (2014) 35:518–24. 10.1097/BCR.000000000000006224988228 19.SmithAMMcCullersJASecondary" exact="bacterial infections" post="in influenza virus infection pathogenesis in influenza pathogenesis and"/>
   <result pre="patients. J Burn Care Res. (2014) 35:518–24. 10.1097/BCR.000000000000006224988228 19.SmithAMMcCullersJASecondary bacterial" exact="infections" post="in influenza virus infection pathogenesis in influenza pathogenesis and"/>
   <result pre="Care Res. (2014) 35:518–24. 10.1097/BCR.000000000000006224988228 19.SmithAMMcCullersJASecondary bacterial infections in influenza" exact="virus infection" post="pathogenesis in influenza pathogenesis and control. Curr Top Microbiol"/>
   <result pre="Res. (2014) 35:518–24. 10.1097/BCR.000000000000006224988228 19.SmithAMMcCullersJASecondary bacterial infections in influenza virus" exact="infection" post="pathogenesis in influenza pathogenesis and control. Curr Top Microbiol"/>
   <result pre="antibiotics. In: Arora G, Sajid A, Kalia VC, editors. Drug" exact="Resistance" post="in Bacteria, Fungi, Malaria, and Cancer. Cham: Springer (2017)."/>
   <result pre="a multidisciplinary future of phage therapy to combat multi-drug resistant" exact="bacterial infections." post="Infect Microb Dis. (2020) 2:1–2. 10.1097/IM9.0000000000000018 23.DuRHLiangLRYangCQWangWCaoTZLiMet al.. Predictors"/>
   <result pre="10.1097/IM9.0000000000000018 23.DuRHLiangLRYangCQWangWCaoTZLiMet al.. Predictors of mortality for patients with COVID-19" exact="pneumonia" post="caused by SARS-CoV-2: a prospective cohort study. Eur Respir"/>
   <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13."/>
   <result pre="Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study. Lancet"/>
   <result pre="27.ZhouFYuTDuRFanGLiuYLiuZet al.. Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
   <result pre="Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected" exact="pneumonia" post="in Wuhan, China. JAMA. (2020) 323:1061–9. 10.1001/jama.2020.158532031570 29.HolshueMLDeBoltCLindquistSLofyKHWiesmanJBruceHet al.First"/>
   <result pre="J Med. (2020) 382:929–36. 10.1056/NEJMoa200119132004427 30.GuanWJNiZYHuYLiangWHOuCQHeJXet al.Clinical characteristics of coronavirus" exact="disease" post="2019 in China. N Engl J Med. (2020) 382:1708–20."/>
   <result pre="Med. (2020) 3:1–3. 10.1007/s00134-020-06028-z 32.WuCChenXCaiYZhouXXuSHuangHet al.. Risk factors associated with" exact="acute" post="respiratory distress syndrome and death in patients with coronavirus"/>
   <result pre="(2020) 3:1–3. 10.1007/s00134-020-06028-z 32.WuCChenXCaiYZhouXXuSHuangHet al.. Risk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
   <result pre="10.1007/s00134-020-06028-z 32.WuCChenXCaiYZhouXXuSHuangHet al.. Risk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
   <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019 pneumonia in Wuhan, China. JAMA Intern Med. (2020)"/>
   <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in Wuhan, China. JAMA Intern Med. (2020) 180:1–11. 10.1001/jamainternmed.2020.099432167524"/>
   <result pre="patients assessed for COVID-19 infection; experience from a UK regional" exact="infectious disease" post="unit. Influenza Other Respir Viruses. (2020) 14:374–9. 10.1111/irv.1273932223012 37.ChenTWuDChenHYanWYangDChenGet"/>
   <result pre="assessed for COVID-19 infection; experience from a UK regional infectious" exact="disease" post="unit. Influenza Other Respir Viruses. (2020) 14:374–9. 10.1111/irv.1273932223012 37.ChenTWuDChenHYanWYangDChenGet"/>
   <result pre="37.ChenTWuDChenHYanWYangDChenGet al.. Clinical characteristics of 113 deceased patients with coronavirus" exact="disease" post="2019: retrospective study. BMJ. (2020) 368:m1295. 10.1136/bmj.m129532234718 38.WangZYangBLiQWenLZhangRClinical features"/>
   <result pre="(2020) 368:m1295. 10.1136/bmj.m129532234718 38.WangZYangBLiQWenLZhangRClinical features of 69 cases with coronavirus" exact="disease" post="2019 in Wuhan, China. Clin Infect Dis. (2020) ciaa27210.1093/cid/ciaa272."/>
   <result pre="China. Int J Infect Dis. (2020) 95:421–8. 10.1016/j.ijid.2020.03.07032289565 40.RichardsMJEdwardsJRCulverDHGaynesRP. Nosocomial" exact="infections" post="in medical intensive care units in the United States."/>
   <result pre="http://www.who.int/csr/sars/country/table2004_04_21/en/ 42.Available, online at: http://www.who.int/csr/don/archive/disease/severe_acute_respiratory_syndrome/en/index.html 43.GuJKortewegCPathology and pathogenesis of severe" exact="acute" post="respiratory syndrome. Am J Pathol. (2007) 170:1136–47. 10.2353/ajpath.2007.06108817392154 44.ChengVCChanJFToKKYuenKY."/>
   <result pre="42.Available, online at: http://www.who.int/csr/don/archive/disease/severe_acute_respiratory_syndrome/en/index.html 43.GuJKortewegCPathology and pathogenesis of severe acute" exact="respiratory" post="syndrome. Am J Pathol. (2007) 170:1136–47. 10.2353/ajpath.2007.06108817392154 44.ChengVCChanJFToKKYuenKY. Clinical"/>
   <result pre="Am J Pathol. (2007) 170:1136–47. 10.2353/ajpath.2007.06108817392154 44.ChengVCChanJFToKKYuenKY. Clinical management and" exact="infection" post="control of SARS: lessons learned. Antiviral Res. (2013) 100:407–19."/>
   <result pre="100:407–19. 10.1016/j.antiviral.2013.08.01623994190 45.ChongPYChuiPLingAEFranksTJTaiDYLeoYSet al.. Analysis of deaths during the severe" exact="acute" post="respiratory syndrome (SARS) epidemic in Singapore: challenges in determining"/>
   <result pre="10.1016/j.antiviral.2013.08.01623994190 45.ChongPYChuiPLingAEFranksTJTaiDYLeoYSet al.. Analysis of deaths during the severe acute" exact="respiratory" post="syndrome (SARS) epidemic in Singapore: challenges in determining a"/>
   <result pre="45.ChongPYChuiPLingAEFranksTJTaiDYLeoYSet al.. Analysis of deaths during the severe acute respiratory" exact="syndrome" post="(SARS) epidemic in Singapore: challenges in determining a SARS"/>
   <result pre="46.SoLKLauACYamLYCheungTMPoonEYungRWet al.. Development of a standard treatment protocol for severe" exact="acute" post="respiratory syndrome. Lancet. (2003) 361:1615–7. 10.1016/S0140-6736(03)13265-512747883 47.LeeNHuiDWuAChanPCameronPJoyntGMet al.. A"/>
   <result pre="al.. Development of a standard treatment protocol for severe acute" exact="respiratory" post="syndrome. Lancet. (2003) 361:1615–7. 10.1016/S0140-6736(03)13265-512747883 47.LeeNHuiDWuAChanPCameronPJoyntGMet al.. A major"/>
   <result pre="(2003) 361:1615–7. 10.1016/S0140-6736(03)13265-512747883 47.LeeNHuiDWuAChanPCameronPJoyntGMet al.. A major outbreak of severe" exact="acute" post="respiratory syndrome in Hong Kong. N Engl J Med."/>
   <result pre="361:1615–7. 10.1016/S0140-6736(03)13265-512747883 47.LeeNHuiDWuAChanPCameronPJoyntGMet al.. A major outbreak of severe acute" exact="respiratory" post="syndrome in Hong Kong. N Engl J Med. (2003)"/>
   <result pre="10.1016/S0140-6736(03)13265-512747883 47.LeeNHuiDWuAChanPCameronPJoyntGMet al.. A major outbreak of severe acute respiratory" exact="syndrome" post="in Hong Kong. N Engl J Med. (2003) 348:1986–94."/>
   <result pre="348:1986–94. 10.1056/NEJMoa03068512682352 48.TsangKWHoPLOoiGCYeeWKWangTChan-YeungMet al.. A cluster of cases of severe" exact="acute" post="respiratory syndrome in Hong Kong. N Engl J Med."/>
   <result pre="10.1056/NEJMoa03068512682352 48.TsangKWHoPLOoiGCYeeWKWangTChan-YeungMet al.. A cluster of cases of severe acute" exact="respiratory" post="syndrome in Hong Kong. N Engl J Med. (2003)"/>
   <result pre="48.TsangKWHoPLOoiGCYeeWKWangTChan-YeungMet al.. A cluster of cases of severe acute respiratory" exact="syndrome" post="in Hong Kong. N Engl J Med. (2003) 348:1977–85."/>
   <result pre="J Med. (2003) 348:1977–85. 10.1056/NEJMoa03066612671062 49.PeirisJSChuCMChengVCChanKSHungIFPoonLLet al.. Clinical progression and" exact="viral" post="load in a community outbreak of coronavirus-associated SARS pneumonia:"/>
   <result pre="Description and clinical treatment of an early outbreak of severe" exact="acute" post="respiratory syndrome (SARS) in Guangzhou, PR China. J Med"/>
   <result pre="and clinical treatment of an early outbreak of severe acute" exact="respiratory" post="syndrome (SARS) in Guangzhou, PR China. J Med Microbiol."/>
   <result pre="clinical treatment of an early outbreak of severe acute respiratory" exact="syndrome" post="(SARS) in Guangzhou, PR China. J Med Microbiol. (2003)"/>
   <result pre="Dis. (2004) 10:818–24. 10.3201/eid1005.03064015200814 52.Available, online at: https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/ 53.CunhaCBOpalSMMiddle east" exact="respiratory" post="syndrome (MERS) A new zoonotic viral pneumonia. Virulence. (2014)"/>
   <result pre="(2004) 10:818–24. 10.3201/eid1005.03064015200814 52.Available, online at: https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/ 53.CunhaCBOpalSMMiddle east respiratory" exact="syndrome" post="(MERS) A new zoonotic viral pneumonia. Virulence. (2014) 5:650–4."/>
   <result pre="at: https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/ 53.CunhaCBOpalSMMiddle east respiratory syndrome (MERS) A new zoonotic" exact="viral pneumonia." post="Virulence. (2014) 5:650–4. 10.4161/viru.3207725089913 54.MemishZACottenMWatsonSJKellamPZumlaAAlhakeemRFet al.. Community case clusters"/>
   <result pre="5:650–4. 10.4161/viru.3207725089913 54.MemishZACottenMWatsonSJKellamPZumlaAAlhakeemRFet al.. Community case clusters of middle east" exact="respiratory" post="syndrome coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia:"/>
   <result pre="10.4161/viru.3207725089913 54.MemishZACottenMWatsonSJKellamPZumlaAAlhakeemRFet al.. Community case clusters of middle east respiratory" exact="syndrome" post="coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: a"/>
   <result pre="course and outcomes of critically ill patients with middle east" exact="respiratory" post="syndrome coronavirus infection. Ann Intern Med. (2014) 160:389–97. 10.7326/M13-248624474051"/>
   <result pre="and outcomes of critically ill patients with middle east respiratory" exact="syndrome" post="coronavirus infection. Ann Intern Med. (2014) 160:389–97. 10.7326/M13-248624474051 56.Al-TawfiqJAMomattinHDibJMemishZA."/>
   <result pre="and interferon therapy in patients infected with the middle east" exact="respiratory" post="syndrome coronavirus: an observational study. Int J Infect Dis."/>
   <result pre="interferon therapy in patients infected with the middle east respiratory" exact="syndrome" post="coronavirus: an observational study. Int J Infect Dis. (2014)"/>
   <result pre="Clinical aspects and outcomes of 70 patients with middle east" exact="respiratory" post="syndrome coronavirus infection: a single-center experience in Saudi Arabia."/>
   <result pre="aspects and outcomes of 70 patients with middle east respiratory" exact="syndrome" post="coronavirus infection: a single-center experience in Saudi Arabia. Int"/>
   <result pre="demographic, and clinical characteristics of 47 cases of middle east" exact="respiratory" post="syndrome coronavirus disease from Saudi Arabia: a descriptive study."/>
   <result pre="and clinical characteristics of 47 cases of middle east respiratory" exact="syndrome" post="coronavirus disease from Saudi Arabia: a descriptive study. Lancet"/>
   <result pre="characteristics of 47 cases of middle east respiratory syndrome coronavirus" exact="disease" post="from Saudi Arabia: a descriptive study. Lancet Infect Dis."/>
   <result pre="Dis. (2013) 13:752–61. 10.1016/S1473-3099(13)70204-423891402 59.MemishZAZumlaAIAl-HakeemRFAl-RabeeahAAStephensGM. Family cluster of middle east" exact="respiratory" post="syndrome coronavirus infections. N Engl J Med. (2013) 368:2487–94."/>
   <result pre="(2013) 13:752–61. 10.1016/S1473-3099(13)70204-423891402 59.MemishZAZumlaAIAl-HakeemRFAl-RabeeahAAStephensGM. Family cluster of middle east respiratory" exact="syndrome" post="coronavirus infections. N Engl J Med. (2013) 368:2487–94. 10.1056/NEJMoa130372923718156"/>
   <result pre="61.https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/ 62.McCullersJA. Effect of antiviral treatment on the outcome of" exact="secondary" post="bacterial pneumonia after influenza. J Infect Dis. (2004) 190:519–26."/>
   <result pre="62.McCullersJA. Effect of antiviral treatment on the outcome of secondary" exact="bacterial pneumonia" post="after influenza. J Infect Dis. (2004) 190:519–26. 10.1086/42152515243927 63.collab:"/>
   <result pre="Effect of antiviral treatment on the outcome of secondary bacterial" exact="pneumonia" post="after influenza. J Infect Dis. (2004) 190:519–26. 10.1086/42152515243927 63.collab:"/>
   <result pre="influenza. J Infect Dis. (2004) 190:519–26. 10.1086/42152515243927 63.collab: Center for" exact="Disease" post="Control and Prevention (CDC) (2012) Available online at: https://www.cdc.gov/flu/spotlights/pandemic-global-estimates.htm"/>
   <result pre="Impact of antibacterials on subsequent resistance and clinical outcomes in" exact="adult" post="patients with viral pneumonia: an opportunity for stewardship. Critical"/>
   <result pre="on subsequent resistance and clinical outcomes in adult patients with" exact="viral" post="pneumonia: an opportunity for stewardship. Critical Care. (2015) 19:404."/>
   <result pre="stewardship. Critical Care. (2015) 19:404. 10.1186/s13054-015-1120-526577540 68.Abelenda-AlonsoGRombautsAGudiolCMeijeYOrtegaLClementeMet al.. Influenza and" exact="bacterial" post="coinfection in adults with community-acquired pneumonia admitted to conventional"/>
   <result pre="68.Abelenda-AlonsoGRombautsAGudiolCMeijeYOrtegaLClementeMet al.. Influenza and bacterial coinfection in adults with community-acquired" exact="pneumonia" post="admitted to conventional wards: risk factors, clinical features, and"/>
   <result pre="and immunohistochemical findings of 20 autopsy cases with (2009). H1N1" exact="virus infection." post="Modern Pathol. (2012) 25:1–3. 10.1038/modpathol.2011.18021874012 72.Perez-PadillaRDe La Rosa-ZamboniDPonce de"/>
   <result pre="Pathol. (2012) 25:1–3. 10.1038/modpathol.2011.18021874012 72.Perez-PadillaRDe La Rosa-ZamboniDPonce de LeonSHernandezMQuiñones-FalconiFBautistaEet al.." exact="Pneumonia" post="and respiratory failure from swine-origin influenza A (H1N1) in"/>
   <result pre="25:1–3. 10.1038/modpathol.2011.18021874012 72.Perez-PadillaRDe La Rosa-ZamboniDPonce de LeonSHernandezMQuiñones-FalconiFBautistaEet al.. Pneumonia and" exact="respiratory" post="failure from swine-origin influenza A (H1N1) in Mexico. N"/>
   <result pre="future. Front Microbiol. (2017) 8:981. 10.3389/fmicb.2017.0098128663740 81.CisekAADabrowskaIGregorczykKPWyzewskiZ. Phage therapy in" exact="bacterial infections" post="treatment: one hundred years after the discovery of bacteriophages."/>
   <result pre="Front Microbiol. (2017) 8:981. 10.3389/fmicb.2017.0098128663740 81.CisekAADabrowskaIGregorczykKPWyzewskiZ. Phage therapy in bacterial" exact="infections" post="treatment: one hundred years after the discovery of bacteriophages."/>
   <result pre="phage therapy. Infect Microb Dis. (2019) 1:34–42. 10.1097/IM9.0000000000000013 83.ManoharPLohBAthiraSNachimuthuRHuaXWelburnSCet al.." exact="Secondary" post="bacterial infections during pulmonary viral disease: phage therapeutics as"/>
   <result pre="therapy. Infect Microb Dis. (2019) 1:34–42. 10.1097/IM9.0000000000000013 83.ManoharPLohBAthiraSNachimuthuRHuaXWelburnSCet al.. Secondary" exact="bacterial infections" post="during pulmonary viral disease: phage therapeutics as alternatives to"/>
   <result pre="Infect Microb Dis. (2019) 1:34–42. 10.1097/IM9.0000000000000013 83.ManoharPLohBAthiraSNachimuthuRHuaXWelburnSCet al.. Secondary bacterial" exact="infections" post="during pulmonary viral disease: phage therapeutics as alternatives to"/>
   <result pre="Dis. (2019) 1:34–42. 10.1097/IM9.0000000000000013 83.ManoharPLohBAthiraSNachimuthuRHuaXWelburnSCet al.. Secondary bacterial infections during" exact="pulmonary" post="viral disease: phage therapeutics as alternatives to antibiotics?Front Microbiol."/>
   <result pre="(2019) 1:34–42. 10.1097/IM9.0000000000000013 83.ManoharPLohBAthiraSNachimuthuRHuaXWelburnSCet al.. Secondary bacterial infections during pulmonary" exact="viral" post="disease: phage therapeutics as alternatives to antibiotics?Front Microbiol. (2020)"/>
   <result pre="antibiotics?Front Microbiol. (2020) 11:1434. 10.3389/fmicb.2020.0143432733404 84.JohnsonBKAbramovitchRB. Small molecules that sabotage" exact="bacterial" post="virulence. Trends Pharmacol Sci. (2017) 38:339–62. 10.1016/j.tips.2017.01.00428209403 85.StarkeyMLepineFMauraDBandyopadhayaALesicBHeJet al.."/>
   <result pre="85.StarkeyMLepineFMauraDBandyopadhayaALesicBHeJet al.. Identification of anti-virulence compounds that disrupt quorum-sensing regulated" exact="acute" post="and persistent pathogenicity. PLoS Pathog. (2014) 10:e1004321. 10.1371/journal.ppat.100432125144274"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7423094/results/search/disease/results.xml">
   <result pre="and Life Sciences : Anatomy : Body Fluids : Blood:" exact="Blood" post="Plasma : Medicine and Health Sciences : Anatomy :"/>
   <result pre="and Health Sciences : Anatomy : Body Fluids : Blood:" exact="Blood" post="Plasma : Biology and Life Sciences : Physiology :"/>
   <result pre="and Life Sciences : Physiology : Body Fluids : Blood:" exact="Blood" post="Plasma : Medicine and Health Sciences : Medical Conditions"/>
   <result pre="Plasma : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases : Viral Diseases: Covid 19 : Biology and"/>
   <result pre=": Medicine and Health Sciences : Medical Conditions : Infectious" exact="Diseases" post=": Viral Diseases: Covid 19 : Biology and Life"/>
   <result pre="and Health Sciences : Medical Conditions : Infectious Diseases :" exact="Viral" post="Diseases: Covid 19 : Biology and Life Sciences :"/>
   <result pre="Proteins: Antibodies : Medicine and Health Sciences : Oncology :" exact="Cancer" post="Treatment: Antibody Therapy : Medicine and Health Sciences :"/>
   <result pre=": Medicine and Health Sciences : Oncology : Cancer Treatment:" exact="Antibody" post="Therapy : Medicine and Health Sciences : Clinical Medicine"/>
   <result pre="Medicine and Health Sciences : Clinical Medicine : Clinical Immunology:" exact="Antibody" post="Therapy : Biology and Life Sciences : Immunology :"/>
   <result pre=": Biology and Life Sciences : Immunology : Clinical Immunology:" exact="Antibody" post="Therapy : Medicine and Health Sciences : Immunology :"/>
   <result pre=": Medicine and Health Sciences : Immunology : Clinical Immunology:" exact="Antibody" post="Therapy : Medicine and Health Sciences : Medical Conditions"/>
   <result pre="Therapy : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases: Respiratory Infections : Medicine and Health Sciences :"/>
   <result pre="Medicine and Health Sciences : Medical Conditions : Infectious Diseases:" exact="Respiratory" post="Infections : Medicine and Health Sciences : Medical Conditions"/>
   <result pre="and Health Sciences : Medical Conditions : Infectious Diseases: Respiratory" exact="Infections" post=": Medicine and Health Sciences : Medical Conditions :"/>
   <result pre="Infections : Medicine and Health Sciences : Medical Conditions :" exact="Respiratory" post="Disorders: Respiratory Infections : Medicine and Health Sciences :"/>
   <result pre="Medicine and Health Sciences : Medical Conditions : Respiratory Disorders:" exact="Respiratory" post="Infections : Medicine and Health Sciences : Pulmonology :"/>
   <result pre="and Health Sciences : Medical Conditions : Respiratory Disorders: Respiratory" exact="Infections" post=": Medicine and Health Sciences : Pulmonology : Respiratory"/>
   <result pre="Respiratory Infections : Medicine and Health Sciences : Pulmonology :" exact="Respiratory" post="Disorders: Respiratory Infections : Medicine and Health Sciences :"/>
   <result pre=": Medicine and Health Sciences : Pulmonology : Respiratory Disorders:" exact="Respiratory" post="Infections : Medicine and Health Sciences : Medical Conditions"/>
   <result pre="Medicine and Health Sciences : Pulmonology : Respiratory Disorders: Respiratory" exact="Infections" post=": Medicine and Health Sciences : Medical Conditions :"/>
   <result pre="Infections : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases : Viral Diseases: SARS : Medicine and Health"/>
   <result pre=": Medicine and Health Sciences : Medical Conditions : Infectious" exact="Diseases" post=": Viral Diseases: SARS : Medicine and Health Sciences"/>
   <result pre="and Health Sciences : Medical Conditions : Infectious Diseases :" exact="Viral" post="Diseases: SARS : Medicine and Health Sciences : Diagnostic"/>
   <result pre=": Diagnostic Medicine : Clinical Laboratory Sciences : Transfusion Medicine:" exact="Blood" post="Transfusion : Medicine and Health Sciences : Hematology :"/>
   <result pre=": Medicine and Health Sciences : Hematology : Transfusion Medicine:" exact="Blood" post="Transfusion : Medicine and Health Sciences : Pharmacology :"/>
   <result pre="for COVID-19: A 19th century remedy for a 21st century" exact="disease" post="http://orcid.org/0000-0001-6079-4277Montelongo-JaureguiDaniel1*http://orcid.org/0000-0001-5600-4367VilaTaissa1http://orcid.org/0000-0001-5286-4562SultanAhmed S.1Jabra-RizkMary Ann12[1], Department of Oncology and Diagnostic Sciences,"/>
   <result pre="publication was supported by the National Institute of Allergy and" exact="Infectious" post="Diseases of the NIH under award number R01AI130170 (NIAID)."/>
   <result pre="was supported by the National Institute of Allergy and Infectious" exact="Diseases" post="of the NIH under award number R01AI130170 (NIAID). The"/>
   <result pre="table-count: page-count: Bridging the gap between now and then Coronavirus" exact="disease" post="2019 (COVID-19) is a viral respiratory disease that mysteriously"/>
   <result pre="between now and then Coronavirus disease 2019 (COVID-19) is a" exact="viral" post="respiratory disease that mysteriously emerged in late December 2019"/>
   <result pre="now and then Coronavirus disease 2019 (COVID-19) is a viral" exact="respiratory" post="disease that mysteriously emerged in late December 2019 in"/>
   <result pre="and then Coronavirus disease 2019 (COVID-19) is a viral respiratory" exact="disease" post="that mysteriously emerged in late December 2019 in Wuhan"/>
   <result pre="coronavirus was identified as the etiologic agent and named severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), the seventh coronavirus to"/>
   <result pre="was identified as the etiologic agent and named severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), the seventh coronavirus to infect"/>
   <result pre="identified as the etiologic agent and named severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), the seventh coronavirus to infect humans"/>
   <result pre="as remdesivir, are available to help prevent or treat this" exact="disease" post="[5], therefore, convalescent plasma therapy, a century-old medical remedy"/>
   <result pre="viable and immediate option for mitigating the impact of this" exact="disease" post="[6]. Convalescent plasma therapy is a type of passive"/>
   <result pre="recuperated from an infection, and administered to patients with the" exact="infection" post="in order to improve clinical outcome [6]. Although the"/>
   <result pre="COVID-19 and the mainstay of current clinical treatment consisting of" exact="symptomatic" post="management and mechanical ventilation, administering convalescent plasma for treatment"/>
   <result pre="factors) therapy was widely used to treat a range of" exact="infectious diseases" post="such as scarlet fever and pneumococcal pneumonia. In 1890,"/>
   <result pre="a range of infectious diseases such as scarlet fever and" exact="pneumococcal pneumonia." post="In 1890, the physiologists von Behring and Kitasato used"/>
   <result pre="and Kitasato used blood serum from immunized animals to treat" exact="diphtheria" post="and tetanus [13]; subsequently, serum from recovered animals was"/>
   <result pre="used blood serum from immunized animals to treat diphtheria and" exact="tetanus" post="[13]; subsequently, serum from recovered animals was identified as"/>
   <result pre="of convalescent serum gained global recognition and revolutionized the way" exact="infectious diseases" post="were treated, and in 1901, Emil von Behring was"/>
   <result pre="degree of success to treat an array of diseases, including" exact="rheumatic" post="fever [16], scarlet fever [17], mumps [18], measles [18,"/>
   <result pre="array of diseases, including rheumatic fever [16], scarlet fever [17]," exact="mumps" post="[18], measles [18, 19], chickenpox [18], and pneumococcal and"/>
   <result pre="diseases, including rheumatic fever [16], scarlet fever [17], mumps [18]," exact="measles" post="[18, 19], chickenpox [18], and pneumococcal and meningococcal infections"/>
   <result pre="[18], measles [18, 19], chickenpox [18], and pneumococcal and meningococcal" exact="infections" post="[20] (Fig 1). Most notable use was during the"/>
   <result pre="convalescent plasma containing anti-EBOV antibodies. Similarly, in 1979, patients with" exact="Argentine hemorrhagic fever" post="virus treated with convalescent plasma had a lower mortality"/>
   <result pre="Argentine hemorrhagic fever virus treated with convalescent plasma had a" exact="lower" post="mortality rate compared with subjects treated with normal plasma,"/>
   <result pre="and similar results were reported for subsequent epidemics of the" exact="disease" post="[21]. Over the following decades, convalescent plasma therapy was"/>
   <result pre="decades, convalescent plasma therapy was successfully employed during the H1N1" exact="swine influenza" post="pandemic (2009), the H5N1 avian flu epidemic (2003), as"/>
   <result pre="employed during the H1N1 swine influenza pandemic (2009), the H5N1" exact="avian flu" post="epidemic (2003), as well as during the EBOV outbreak"/>
   <result pre="use of convalescent plasma during 2 previous coronavirus epidemics: severe" exact="acute" post="respiratory syndrome (SARS) in 2003, and Middle East respiratory"/>
   <result pre="of convalescent plasma during 2 previous coronavirus epidemics: severe acute" exact="respiratory" post="syndrome (SARS) in 2003, and Middle East respiratory syndrome"/>
   <result pre="convalescent plasma during 2 previous coronavirus epidemics: severe acute respiratory" exact="syndrome" post="(SARS) in 2003, and Middle East respiratory syndrome (MERS)"/>
   <result pre="severe acute respiratory syndrome (SARS) in 2003, and Middle East" exact="respiratory" post="syndrome (MERS) in 2012 [21]. The high degree of"/>
   <result pre="acute respiratory syndrome (SARS) in 2003, and Middle East respiratory" exact="syndrome" post="(MERS) in 2012 [21]. The high degree of success"/>
   <result pre="21–23]. Fig 1 Notable historic uses of antibody therapy against" exact="infectious diseases." post="COVID-19, coronavirus disease 2019; MERS, Middle East respiratory syndrome;"/>
   <result pre="historic uses of antibody therapy against infectious diseases. COVID-19, coronavirus" exact="disease" post="2019; MERS, Middle East respiratory syndrome; SARS, severe acute"/>
   <result pre="against infectious diseases. COVID-19, coronavirus disease 2019; MERS, Middle East" exact="respiratory" post="syndrome; SARS, severe acute respiratory syndrome. Buying time with"/>
   <result pre="coronavirus disease 2019; MERS, Middle East respiratory syndrome; SARS, severe" exact="acute" post="respiratory syndrome. Buying time with the help of the"/>
   <result pre="disease 2019; MERS, Middle East respiratory syndrome; SARS, severe acute" exact="respiratory" post="syndrome. Buying time with the help of the convalescent"/>
   <result pre="antibodies from the blood of someone who recovered from an" exact="infection" post="can be administered to protect or treat another person"/>
   <result pre="is the same as vaccines, making antibodies against a specific" exact="infectious" post="agent readily available. For instance, a vaccine relies on"/>
   <result pre="against SARS-CoV-2 and lacks the presence of other types of" exact="infections" post="[21, 27]. Additionally, only plasma with high anti-SARS-CoV-2 titers"/>
   <result pre="case of prophylaxis, a subject considered at high risk for" exact="infection" post="(because of age or underlying medical conditions or who"/>
   <result pre="can be administered to treat subjects who have contracted the" exact="infection" post="but have not made sufficient antibodies against the virus"/>
   <result pre="virus yet in order to augment their immune response, improve" exact="disease" post="course, and enhance recovery [21]. However, it is important"/>
   <result pre="who recovered from COVID-19 can be administered prophylactically to prevent" exact="infection" post="in vulnerable individuals and those with known exposure to"/>
   <result pre="improve the clinical outcome (Treatment). CP, convalescent plasma; COVID-19, coronavirus" exact="disease" post="2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. Convalescent"/>
   <result pre="(Treatment). CP, convalescent plasma; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe" exact="acute" post="respiratory syndrome coronavirus 2. Convalescent plasma with neutralizing antibodies"/>
   <result pre="CP, convalescent plasma; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute" exact="respiratory" post="syndrome coronavirus 2. Convalescent plasma with neutralizing antibodies is"/>
   <result pre="convalescent plasma; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory" exact="syndrome" post="coronavirus 2. Convalescent plasma with neutralizing antibodies is currently"/>
   <result pre="transfusion to rescue a group of 10 patients with severe" exact="disease" post="showed that 1 dose (200 mL) of convalescent plasma"/>
   <result pre="One theoretical complication that may arise is an antibody-mediated proinflammatory" exact="disease" post="enhancement known as antibody-dependent enhancement (ADE), whereby antibodies that"/>
   <result pre="antibody-dependent enhancement (ADE), whereby antibodies that developed during a prior" exact="infection" post="exacerbate severity of the disease [12, 28]. The transfer"/>
   <result pre="that developed during a prior infection exacerbate severity of the" exact="disease" post="[12, 28]. The transfer of these antibodies may aberrantly"/>
   <result pre="recruitment of proinflammatory cytokines and chemokines to the site of" exact="infection" post="and causing severe tissue damage [29–31]. Additionally, the presence"/>
   <result pre="damage [29–31]. Additionally, the presence of non-neutralizing antibodies may exacerbate" exact="viral" post="endocytosis or phagocytosis into host cells via Fc receptors,"/>
   <result pre="endocytosis or phagocytosis into host cells via Fc receptors, potentializing" exact="viral" post="replication [29, 32]. However, although this phenomenon is well"/>
   <result pre="[29, 32]. However, although this phenomenon is well known with" exact="Dengue" post="and other viral diseases, there have not been any"/>
   <result pre="although this phenomenon is well known with Dengue and other" exact="viral" post="diseases, there have not been any reported ADE cases"/>
   <result pre="challenges, the substantial evidence of benefit with use for prior" exact="viral" post="infections offers strong precedent for convalescent plasma as a"/>
   <result pre="the substantial evidence of benefit with use for prior viral" exact="infections" post="offers strong precedent for convalescent plasma as a therapeutic"/>
   <result pre="only on evaluation of the feasibility of plasma treatment for" exact="infectious diseases" post="but also ensure that use of convalescent plasma therapy"/>
   <result pre="Marburg201310.17192/eb2013.0165 15KaufmannSH. Remembering Emil von Behring: from Tetanus Treatment to" exact="Antibody" post="Cooperation with Phagocytes. mBio. 2017;8(1). Epub 2017/03/02. 10.1128/mBio.00117-1728246359 16MooreJJ."/>
   <result pre="Action of Vaccines and of Concentrated Antistreptococcus Serum in Experimental" exact="Streptococcal" post="Arthritis. J Infect Dis. 1914;15(1):215–26. 17Smith DD. Serum treatment"/>
   <result pre="use of convalescent serum in the treatment of measles, chickenpox," exact="mumps" post="and whooping cough, including the prophylactic value of parental"/>
   <result pre="convalescent serum in the treatment of measles, chickenpox, mumps and" exact="whooping cough," post="including the prophylactic value of parental blood: J. M."/>
   <result pre="10.1016/S0097-0522(33)90316-0 PubMed PMID: S0097052233903160. 19KohnJL, KleinIF, SchwarzH. Treatment of preeruptive" exact="measles" post="with convalescent serum. JAMA. 1938;111(26):2361–4. 10.1001/jama.1938.02790520017004 20CasadevallA, ScharffMD. Serum"/>
   <result pre="1938;111(26):2361–4. 10.1001/jama.1938.02790520017004 20CasadevallA, ScharffMD. Serum therapy revisited: animal models of" exact="infection" post="and development of passive antibody therapy. Antimicrob Agents Chemother."/>
   <result pre="mortality in patients with severe pandemic influenza A (H1N1) 2009" exact="virus infection." post="Clin Infect Dis. 2011;52(4):447–56. Epub 2011/01/21. 10.1093/cid/ciq106 .21248066 23HungIFN,"/>
   <result pre="CfDCa. Principles of Vaccination. In: Epidemiology and Prevention of Vaccine-Preventable" exact="Diseases" post="[Internet]. Washington, D.C.: Public Health Foundation. 13th. [cited 2020"/>
   <result pre="Pharmacol. 2009;157(2):220–33. Epub 2009/05/23. 10.1111/j.1476-5381.2009.00190.x19459844 26LaiCC, ShihTP, KoWC, TangHJ, HsuehPR." exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019"/>
   <result pre="2009;157(2):220–33. Epub 2009/05/23. 10.1111/j.1476-5381.2009.00190.x19459844 26LaiCC, ShihTP, KoWC, TangHJ, HsuehPR. Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):"/>
   <result pre="Epub 2009/05/23. 10.1111/j.1476-5381.2009.00190.x19459844 26LaiCC, ShihTP, KoWC, TangHJ, HsuehPR. Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The"/>
   <result pre="2009/05/23. 10.1111/j.1476-5381.2009.00190.x19459844 26LaiCC, ShihTP, KoWC, TangHJ, HsuehPR. Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic"/>
   <result pre="LiPH, CheungCY, DutryI, LiD, et al.Antibody-dependent enhancement of SARS coronavirus" exact="infection" post="and its role in the pathogenesis of SARS. Hong"/>
   <result pre="Epub 2016/07/09. .27390007 33KatzelnickLC, HarrisE, Participants in the Summit on" exact="Dengue" post="Immune Correlates of P. Immune correlates of protection for"/>
   <result pre="from other coronaviruses?Microbes Infect. 2020;22(2):72–3. Epub 2020/02/25. 10.1016/j.micinf.2020.02.00632092539 35HalsteadSB, O'RourkeEJ." exact="Dengue" post="viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing"/>
   <result pre="2020/02/25. 10.1016/j.micinf.2020.02.00632092539 35HalsteadSB, O'RourkeEJ. Dengue viruses and mononuclear phagocytes. I." exact="Infection" post="enhancement by non-neutralizing antibody. J Exp Med. 1977;146(1):201–17. Epub"/>
   <result pre="al.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study. Lancet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7423499/results/search/disease/results.xml">
   <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
   <result pre="of COVID-19 as a global pandemic. Abstract Outbreaks of emerging" exact="infectious diseases" post="are occurring with increasing frequency and consequences, including wildlife"/>
   <result pre="direct and indirect effects on ecosystems. The intensifying emergence of" exact="infectious" post="pathogens has many underlying reasons, all driven by the"/>
   <result pre="manage the planet as a whole. Keywords Covid-19 Zoonoses Pandemics" exact="Disease" post="pyramid Ecosystem health Introduction In 2020, the global public"/>
   <result pre="and their geographic spread are increasing. For example, the simian" exact="immunodeficiency" post="virus (SIV) has been regularly infecting individual humans in"/>
   <result pre="immunodeficiency virus (SIV) has been regularly infecting individual humans in" exact="Central" post="and Eastern Africa for hundreds of years without establishing"/>
   <result pre="hundreds of years without establishing itself as the transmissible human" exact="disease" post="we now know as Acquired Immune Deficiency Syndrome (AIDS)."/>
   <result pre="itself as the transmissible human disease we now know as" exact="Acquired" post="Immune Deficiency Syndrome (AIDS). Sustained human-to-human transmission only occurred"/>
   <result pre="the transmissible human disease we now know as Acquired Immune" exact="Deficiency Syndrome" post="(AIDS). Sustained human-to-human transmission only occurred in the second"/>
   <result pre="transmissible human disease we now know as Acquired Immune Deficiency" exact="Syndrome" post="(AIDS). Sustained human-to-human transmission only occurred in the second"/>
   <result pre="three times, resulting in as many distinct lineages of Human" exact="Immunodeficiency" post="Virus (HIV) today (Sharp and Hahn 2011). Perhaps the"/>
   <result pre="their other colonies in Latin America, protecting the colonizers from" exact="malaria" post="as they pushed into the interior from all along"/>
   <result pre="the interior from all along the coast (Rutz 2018). Endemic" exact="malaria" post="has stopped many invasions in their tracks and ancient"/>
   <result pre="large mammals. These examples show that the outbreak of a" exact="disease" post="is linked to manifold interactions between hosts, pathogens, and"/>
   <result pre="manifold interactions between hosts, pathogens, and the environment, forming a" exact="disease" post="triangle. A fourth player, which only recently became a"/>
   <result pre="focus of scientific studies, is the host microbiome, making the" exact="disease" post="triangle a pyramid (Bernardo-Cravo et al. 2020; Fig. 1)."/>
   <result pre="their interactions with each other. The four-way interaction of the" exact="disease" post="pyramid determines the intensity and severity of the disease"/>
   <result pre="the disease pyramid determines the intensity and severity of the" exact="disease" post="outcome from asymptomatic at the periphery to high mortality"/>
   <result pre="of the bubble (Bernardo-Cravo et al. 2020; Fig. 1). The" exact="disease" post="pyramid illustrates the complexity of the relationship between ecosystem"/>
   <result pre="risks, we need to understand the four-way interactions of the" exact="disease" post="pyramid, including also various anthropogenic impacts, such as pollution,"/>
   <result pre="intensification), upon them (Schmeller et al. 2018). Fig. 1 The" exact="disease" post="pyramid depicting the four-way interaction between host, host microbiome,"/>
   <result pre="four-way interactions feed towards the centre of the pyramid, affecting" exact="disease" post="outcome from asymptomatic in the periphery to high mortality"/>
   <result pre="et al. (2020) We know that the intensifying emergence of" exact="infectious" post="pathogens has manifold reasons, all driven by the growing"/>
   <result pre="of which modify interactions between the four components of the" exact="disease" post="pyramid. We are profoundly changing our environment, imposing an"/>
   <result pre="wild animals to humans, so a constant stream of new" exact="viral" post="pathogens has emerged steadily over recent decades (Woolhouse et"/>
   <result pre="Dentinger 2013). It is no wonder then, that zoonotic emerging" exact="infectious disease" post="risk is elevated in high biodiversity regions experiencing anthropogenic"/>
   <result pre="2013). It is no wonder then, that zoonotic emerging infectious" exact="disease" post="risk is elevated in high biodiversity regions experiencing anthropogenic"/>
   <result pre="the H1N1, H5N1 and Nipah virus originated from wild animal" exact="infections" post="of chicken and pigs in extremely dense and physiologically"/>
   <result pre="Globalization and introductions of invasive species, for example translocation of" exact="disease" post="vectors like Aedes aegypti and A. albopictus mosquitoes, the"/>
   <result pre="from the Korean Peninsula (O’Hanlon et al. 2018), with subsequent" exact="infection" post="of the American bullfrog, an invasive amphibian species now"/>
   <result pre="Peninsula (O’Hanlon et al. 2018), with subsequent infection of the" exact="American" post="bullfrog, an invasive amphibian species now threatening indigenous amphibian"/>
   <result pre="show no sign of saturation yet (Seebens et al. 2017)." exact="Invasive" post="pathogenic microorganisms comprise only a small fraction of all"/>
   <result pre="2017; Sherman 2011; Travis et al. 2011). Following from the" exact="disease" post="pyramid, all these impacts can fragilize ecosystems and can"/>
   <result pre="revaluation of trade rules is therefore needed considering the current" exact="incomplete" post="knowledge of the countless pathogenic viruses, bacteria and fungi"/>
   <result pre="(Pachetti et al. 2020), which accelerates as we allow the" exact="viral" post="population to grow in size, only adds to the"/>
   <result pre="worse the current Covid-19 pandemic could be. Despite the far" exact="lower" post="infection fatality rate of just over 1% (Verity et"/>
   <result pre="the current Covid-19 pandemic could be. Despite the far lower" exact="infection" post="fatality rate of just over 1% (Verity et al."/>
   <result pre="spread of pathogens. All these factors increase the probability of" exact="disease" post="severity both in wildlife as well as in the"/>
   <result pre="value but also protracted human conflict, associated entrenched poverty, endemic" exact="infectious disease" post="burden and perpetual threat of emerging infections. The misfortunes"/>
   <result pre="but also protracted human conflict, associated entrenched poverty, endemic infectious" exact="disease" post="burden and perpetual threat of emerging infections. The misfortunes"/>
   <result pre="food insecure. Since January 2019, there have been outbreaks of" exact="cholera" post="(15,331 cases, 287 deaths), measles (161,397 cases, 3,117 deaths)"/>
   <result pre="there have been outbreaks of cholera (15,331 cases, 287 deaths)," exact="measles" post="(161,397 cases, 3,117 deaths) and malaria, the leading cause"/>
   <result pre="than 48,000 people every year&quot; (WHO 2019). After decades of" exact="chronic" post="and brutal conflict, including dozens of attacks on Ebola"/>
   <result pre="need to be more restrictive in regard to wildlife food" exact="consumption" post="(Yang et al. 2020), wildlife transportation and trade, deforestation,"/>
   <result pre="Congo: getting the job doneLancet202039592210.1016/S0140-6736(20)30645-0 AnthonySJEpsteinJHMurrayKANavarrete-MaciasIZambrana-TorrelioCMSolovyovAOjeda-FloresRArrigoNCIslamAKhanSAHosseiniPBogichTLOlivalKJSanchez-LeonMDKareshWBGoldsteinTLubySPMorseSSMazetJAKDaszakPLipkinWIA strategy to estimate unknown" exact="viral" post="diversity in mammalsMBio20134e00598e151310.1128/mBio.00598-1324003179 AuliyaMGarcía-MorenoJSchmidtBRSchmellerDSHoogmoedMSFisherMCPasmansFHenleKBickfordDMartelAThe global amphibian trade flows through"/>
   <result pre="an emerging fungal pathogen?Science200932322710.1126/science.116387418974316 BrayRSArmies of pestilence: the impact of" exact="disease" post="on history2004CambridgeJames Clarke &amp;amp; Co. BridgewaterPLoyauASchmellerDSThe seventh plenary of"/>
   <result pre="human-type receptor specificityPLoS Pathog201713100639010.1371/journal.ppat.1006390 DespommierDEllisBWilcoxBThe role of ecotones in emerging" exact="infectious" post="diseasesEcoHealth2006328128910.1007/s10393-006-0063-3 Destoumieux-GarzónDMavinguiPBoetschGBoissierJDarrietFDubozPFritschCGiraudouxPLe RouxFMorandSPaillardCPontierDSueurCVoituronYThe one health concept: 10 years old"/>
   <result pre="must account for pandemic riskProc Natl Acad Sci USA20201173888389210.1073/pnas.200165511732060123 DuffusACunninghamAAMajor" exact="disease" post="threats to European amphibiansHerpetol J201020117127 FisherMCGarnerTWJWalkerSFGlobal emergence of Batrachochytrium"/>
   <result pre="relax UK import rule on fungiNature201349616916910.1038/496169b23579669 JonesKEPatelNGLevyMAStoreygardABalkDGittlemanJLDaszakPGlobal trends in emerging" exact="infectious" post="diseasesNature200845199099310.1038/nature0653618288193 JoseBNipah: The deadly menaceJ Acad Clin Microbiol201820667310.4103/jacm.jacm_34_18 LamTT-YShumMH-HZhuH-CTongY-GNiX-BLiaoY-SWeiWCheungWY-MLiW-JLiL-FLeungGMHolmesECHuY-LGuanYIdentifying"/>
   <result pre="SARS-CoV-2 related coronaviruses in Malayan pangolinsNature202010.1038/s41586-020-2169-032555460 collab: MGE NetworkInsights into" exact="malaria" post="susceptibility using genome-wide data on 17,000 individuals from Africa,"/>
   <result pre="pathogenic landscapes: two hypotheses on how land use change drives" exact="viral" post="emergenceCurr Opin Virol20133798310.1016/j.coviro.2013.01.00623415415 MussoDGublerDJZika virus: following the path of"/>
   <result pre="excelsior) dieback–a conservation biology challengeBiol Conserv2013158374910.1016/j.biocon.2012.08.026 PengJYangHJiangHLinY-xLuCDXuY-wZengJThe origin of novel" exact="avian influenza" post="A (H7N9) and mutation dynamics for its human-to-human transmissible"/>
   <result pre="of the sickle cell gene and geographical confirmation of the" exact="malaria" post="hypothesisNat Commun201011710.1038/ncomms110420975674 PyšekPHulmePESimberloffDBacherSBlackburnTMCarltonJTDawsonWEsslFFoxcroftLCGenovesiPScientists' warning on invasive alien speciesBiol Rev202010.1111/brv.1262732588508"/>
   <result pre="Commun201011710.1038/ncomms110420975674 PyšekPHulmePESimberloffDBacherSBlackburnTMCarltonJTDawsonWEsslFFoxcroftLCGenovesiPScientists' warning on invasive alien speciesBiol Rev202010.1111/brv.1262732588508 RohrJRBarrettCBCivitelloDJCraftMEDeliusBDeLeoGAHudsonPJJouanardNNguyenKHOstfeldRSRemaisJVRiveauGSokolowSHTilmanDEmerging human" exact="infectious diseases" post="and the links to global food productionNat Sustain2019244545610.1038/s41893-019-0293-332219187 Rutz"/>
   <result pre="(2018) King Leopold's Congo and the &quot;scramble for Africa&quot;: a" exact="short" post="history with documents. Hackett Publishing, Indianapolis SchieffelinJSShafferJGGobaAGbakieMGireSKColubriASealfonRSKannehLMoigboiAMomohMClinical illness and"/>
   <result pre="pollution and pathogens: global change impacts in mountain freshwater ecosystemsSci" exact="Total" post="Environ2018622–62375676310.1016/j.scitotenv.2017.12.00629223902 SeebensHBlackburnTMDyerEEGenovesiPHulmePEJeschkeJMPagadSPyšekPWinterMArianoutsouMNo saturation in the accumulation of alien species"/>
   <result pre="and avian fluCurr Opin Infect Dis20152834936110.1097/QCO.000000000000018326098498 TaylorLHLathamSMWoolhouseMEJRisk factors for human" exact="disease" post="emergencePhil Trans R Soc Lond B200135698398910.1098/rstb.2001.088811516376 TravisDWatsonRTauerAThe spread of"/>
   <result pre="trade in wildlifeRevue Scientifique et Technique-OIE20113021910.20506/rst.30.1.2035 VerhagenJHFouchierRAMunsterVJEcology of avian virusesStud" exact="Viral" post="Ecol2011236539410.1002/9781118025710.ch14 VerityROkellLCDorigattiIWinskillPWhittakerCImaiNCuomo-DannenburgGThompsonHWalkerPGFuHEstimates of the severity of coronavirus disease 2019:"/>
   <result pre="avian virusesStud Viral Ecol2011236539410.1002/9781118025710.ch14 VerityROkellLCDorigattiIWinskillPWhittakerCImaiNCuomo-DannenburgGThompsonHWalkerPGFuHEstimates of the severity of coronavirus" exact="disease" post="2019: a model-based analysisLancet Infect Dis202010.1016/S1473-3099(20)30243-732473660 WhiteRJRazgourOEmerging zoonotic diseases"/>
   <result pre="(2020) WHO Director-General’s Statement on IHR Emergency Committee on Ebola" exact="Virus Disease" post="in the Democratic Republic of the Congo. https://www.who.int/news-room/detail/14-04-2020-who-director-general-s-statement-on-ihr-emergency-committee-on-ebola-virus-disease-in-the-democratic-republic-of-the-congo. Accessed"/>
   <result pre="WHO Director-General’s Statement on IHR Emergency Committee on Ebola Virus" exact="Disease" post="in the Democratic Republic of the Congo. https://www.who.int/news-room/detail/14-04-2020-who-director-general-s-statement-on-ihr-emergency-committee-on-ebola-virus-disease-in-the-democratic-republic-of-the-congo. Accessed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7427094/results/search/disease/results.xml">
   <result pre="Biology Faculty, Havana University, [6], grid.8761.80000 0000 9919 9582Department of" exact="Infectious" post="Diseases/Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg,"/>
   <result pre="Coxsackievirus A24 variant (CVA24v) is a major causative agent of" exact="acute" post="hemorrhagic conjunctivitis outbreaks worldwide, yet the evolutionary and transmission"/>
   <result pre="variant (CVA24v) is a major causative agent of acute hemorrhagic" exact="conjunctivitis" post="outbreaks worldwide, yet the evolutionary and transmission dynamics of"/>
   <result pre="To address this, we analyzed and compared the 3C and" exact="partial" post="VP1 gene regions of CVA24v isolates obtained from five"/>
   <result pre="The two genotypes co-evolved with a population size that is" exact="stable" post="over time. However, nucleotide substitution rates peaked during pandemics"/>
   <result pre="VP1 region, respectively. The phylogeographic analysis identified 25 and 19" exact="viral" post="transmission routes based on 3C and VP1 regions, respectively."/>
   <result pre="of this virus and possibly other pandemic viruses. Subject terms" exact="Viral" post="infection Phylogenetics Funding Wood-Whelan Research Fellowships 2007 Funding VLIR-UOS"/>
   <result pre="this virus and possibly other pandemic viruses. Subject terms Viral" exact="infection" post="Phylogenetics Funding Wood-Whelan Research Fellowships 2007 Funding VLIR-UOS project"/>
   <result pre="five to 63 different types, with no cross neutralization, i.e." exact="infection" post="with one type does not infer immunity against another"/>
   <result pre="species Enterovirus C), was first isolated from an outbreak of" exact="acute" post="hemorrhagic conjunctivitis (AHC) in Singapore in 1970. Afterwards, CVA24v"/>
   <result pre="C), was first isolated from an outbreak of acute hemorrhagic" exact="conjunctivitis" post="(AHC) in Singapore in 1970. Afterwards, CVA24v has been"/>
   <result pre="there were numerous outbreaks caused by CVA24v in several Latin" exact="American" post="countries, as Antigua/Barbuda, Bahamas, British Virgin Islands, St. Christopher/Nevis,"/>
   <result pre="five AHC epidemics in Cuba were used to determine the" exact="viral" post="phylodynamics and the phylogenetic relationships between strains involved in"/>
   <result pre="the world during the same periods. Results Identity analysis A" exact="total" post="of 157 partial 3C sequences (507 nt) and 149"/>
   <result pre="the same periods. Results Identity analysis A total of 157" exact="partial" post="3C sequences (507 nt) and 149 partial VP1 sequences"/>
   <result pre="total of 157 partial 3C sequences (507 nt) and 149" exact="partial" post="VP1 sequences (234 nt) were obtained from 159 strains"/>
   <result pre="of CVA24v isolates could be attributed to the degradation of" exact="viral" post="RNA due to prolonged storage or multiple freeze–thaw cycles."/>
   <result pre="in 54 Cuban 3C sequences that were compared with 83" exact="partial" post="3C sequences from strains isolated in 17 countries. Likewise,"/>
   <result pre="least one intratypic recombination event, which was verified by testing" exact="complete" post="sequences of some CVA24v and other Enterovirus C strains"/>
   <result pre="isolated in 2003 and CVA24v strains that had caused the" exact="Brazilian" post="AHC outbreaks during 2003–2005 (97.4–99.6% nucleotide identity). The analyses"/>
   <result pre="&quot;ladder-like&quot; shape, characterized by a sequential replacement of the existing" exact="viral" post="populations by other emergent ones on a global scale,"/>
   <result pre="by other emergent ones on a global scale, and a" exact="limited" post="genetic diversity observed through time. Additionally, short terminal branches"/>
   <result pre="scale, and a limited genetic diversity observed through time. Additionally," exact="short" post="terminal branches with low support values were observed, which"/>
   <result pre="showed that the effective population size of the virus is" exact="stable" post="over time with slight increases, coinciding with the pandemic"/>
   <result pre="for 3C and to 2.79 for VP1, coinciding with the" exact="limited" post="CVA24v circulation in the Southeast Asia and Indian regions"/>
   <result pre="the beginning of the 1990s and after 199614–17. Finally, the" exact="viral" post="population size increased exponentially between 2002 and 2003 (3C"/>
   <result pre="or decreases during particular periods. Thus, effective population size is" exact="stable" post="over time when both the 3C and the VP1"/>
   <result pre="stable over time when both the 3C and the VP1" exact="partial" post="regions were analysed (Fig. 4). The greatest uncertainty is"/>
   <result pre="by Chu et al., based on Bayesian sequence analysis of" exact="partial" post="3C and VP1 regions. CV-A24v genotypes TMRCAs (95% HPD)/(N"/>
   <result pre="into Cuba by the frequent travelling between Cuba and Latin" exact="American" post="countries. Taken together, these results provide insight into the"/>
   <result pre="with previous reports, suggesting a genomic barrier for recombination when" exact="complete" post="3C and VP1 of CVA24 were analysed28,40. However, intratypic"/>
   <result pre="laboratory surveillance. We envisage three possible scenarios to explain the" exact="viral" post="circulation during inter epidemics periods, (1) CVA24v circulate at"/>
   <result pre="at low levels and escape the surveillance system since asymptomatic" exact="infection" post="is the most common outcome, (2) the virus cause"/>
   <result pre="nearly escape the humoral immune response. In support of this," exact="recurrent" post="AHC epidemics have been associated with a decline in"/>
   <result pre="countries by using the 3C and VP1 coding regions or" exact="complete" post="genome6,23,38,40,50,51. Many of these studies have used different definitions"/>
   <result pre="of the world was shown by the analysis of the" exact="viral" post="sequences in this study. This may indicate that there"/>
   <result pre="Asia causing new outbreaks and pandemics. This circle with global" exact="viral" post="transmissions may take 3 to 7 years as shown"/>
   <result pre="the CVA24v strains (2) the analysis was performed only on" exact="partial" post="and not complete genomes; (3) the few availability of"/>
   <result pre="(2) the analysis was performed only on partial and not" exact="complete" post="genomes; (3) the few availability of the CVA24v sequences"/>
   <result pre="(23) Feces (16) 2005 59 November 5 5 Conjunctival swabs" exact="Total" post="159 159 Conjunctival swabs (125) Feces (32), Nasal swab"/>
   <result pre="using the ElimDupes tool from the Alamos HIV database (https://www.hiv.lanl.gov)." exact="Multiple" post="sequence alignments were performed by MAFFT v7 by using"/>
   <result pre="from the filtering of duplex sequences. The nucleotide sequences of" exact="partial" post="3C and VP1 regions of Cuban and world-wide CVA24v"/>
   <result pre="of the most recent common ancestor (TMRCA) with 95% highest" exact="posterior" post="density (HPD). It was also used to reconstruct the"/>
   <result pre="It was also used to reconstruct the history of the" exact="viral" post="population and spatiotemporal dynamic by using both alignments, 3C"/>
   <result pre="countries with positive transmission routes (BF &amp;gt; 3) in order to detect" exact="viral" post="transmission networks of CVA24v32. Ethics statement All procedures performed"/>
   <result pre="The authors gratefully acknowledge the Department of Virology, Institute for" exact="Infectious" post="Disease Control (SMI), Solna, Sweden, for their valuable technical"/>
   <result pre="authors gratefully acknowledge the Department of Virology, Institute for Infectious" exact="Disease" post="Control (SMI), Solna, Sweden, for their valuable technical assistance"/>
   <result pre="original idea of the study, conceived and designed the study," exact="acquired" post="data, wrote and edited the manuscript. She is the"/>
   <result pre="3.ChangCHLinKHSheuMMHuangWLWangHZChenCWThe change of etiological agents and clinical signs of epidemic" exact="viral conjunctivitis" post="over an 18-year period in southern TaiwanGraefes Arch. Clin."/>
   <result pre="change of etiological agents and clinical signs of epidemic viral" exact="conjunctivitis" post="over an 18-year period in southern TaiwanGraefes Arch. Clin."/>
   <result pre="southern TaiwanGraefes Arch. Clin. Exp. Ophthalmol.2003241755456010.1007/s00417-003-0680-212768288 4.LevequeNet al.Rapid diagnosis of" exact="acute" post="hemorrhagic conjunctivitis due to coxsackievirus A24 variant by real-time"/>
   <result pre="Arch. Clin. Exp. Ophthalmol.2003241755456010.1007/s00417-003-0680-212768288 4.LevequeNet al.Rapid diagnosis of acute hemorrhagic" exact="conjunctivitis" post="due to coxsackievirus A24 variant by real-time one-step RT-PCRJ."/>
   <result pre="circulating in JapanArch. Virol.199212617919310.1007/BF013096941326259 7.ChuPYet al.Molecular epidemiology of coxsackie A" exact="type 24" post="variant in Taiwan, 2000–2007J. Clin. Virol.20094528529110.1016/j.jcv19473877 8.TavaresFNet al.Molecular characterization"/>
   <result pre="characterization and phylogenetic study of coxsackievirus A24v causing outbreaks of" exact="acute" post="hemorrhagic conjunctivitis (AHC) in BrazilPLoS ONE20116e2320610.1371/journal.pone21858030 9.EnfissiaAJMDelaunebDDelpeyrouxbFRoussetaDBessaudbMCoxsackievirus A24 variant"/>
   <result pre="phylogenetic study of coxsackievirus A24v causing outbreaks of acute hemorrhagic" exact="conjunctivitis" post="(AHC) in BrazilPLoS ONE20116e2320610.1371/journal.pone21858030 9.EnfissiaAJMDelaunebDDelpeyrouxbFRoussetaDBessaudbMCoxsackievirus A24 variant associated with"/>
   <result pre="conjunctivitis (AHC) in BrazilPLoS ONE20116e2320610.1371/journal.pone21858030 9.EnfissiaAJMDelaunebDDelpeyrouxbFRoussetaDBessaudbMCoxsackievirus A24 variant associated with" exact="acute" post="haemorrhagic conjunctivitis cases, French Guiana, 2017Intervirology20186027127510.1159/000489339 10.SousaIPJret al.Re-emergence of"/>
   <result pre="in BrazilPLoS ONE20116e2320610.1371/journal.pone21858030 9.EnfissiaAJMDelaunebDDelpeyrouxbFRoussetaDBessaudbMCoxsackievirus A24 variant associated with acute haemorrhagic" exact="conjunctivitis" post="cases, French Guiana, 2017Intervirology20186027127510.1159/000489339 10.SousaIPJret al.Re-emergence of a coxsackievirus"/>
   <result pre="Guiana, 2017Intervirology20186027127510.1159/000489339 10.SousaIPJret al.Re-emergence of a coxsackievirus A24 variant causing" exact="acute" post="hemorrhagic conjunctivitis in Brazil from 2017 to 2018Arch. Virol.20191641181118510.1007/s00705-019-04157-530725183"/>
   <result pre="10.SousaIPJret al.Re-emergence of a coxsackievirus A24 variant causing acute hemorrhagic" exact="conjunctivitis" post="in Brazil from 2017 to 2018Arch. Virol.20191641181118510.1007/s00705-019-04157-530725183 11.Fragoso-FonsecaDEet al.Complete"/>
   <result pre="of a coxsackievirus type A24 variant causing an outbreak of" exact="acute" post="haemorrhagic conjunctivitis in southeastern Mexico in 2017Arch. Virol.20201651015101810.1007/s00705-020-04552-332052193 12.Ministerio"/>
   <result pre="coxsackievirus type A24 variant causing an outbreak of acute haemorrhagic" exact="conjunctivitis" post="in southeastern Mexico in 2017Arch. Virol.20201651015101810.1007/s00705-020-04552-332052193 12.Ministerio de Salud"/>
   <result pre="of a variant of coxsackievirus A24J. Med. Virol.20016426927410.1002/jmv.104611424114 15.KosrirukvongsPKanyokRSitritantikornSWasiCAcute hemorrhagic" exact="conjunctivitis" post="outbreak in Thailand, 1992Southeast Asian J. Trop. Med. Public"/>
   <result pre="of coxsackie A 24 variant isolated from an epidemic of" exact="acute" post="haemorrhagic conjunctivitis in north India by RT-PCR using a"/>
   <result pre="A 24 variant isolated from an epidemic of acute haemorrhagic" exact="conjunctivitis" post="in north India by RT-PCR using a novel primer"/>
   <result pre="a novel primer pairIndian J. Med. Res.200211517618312362556 17.collab: Centers for" exact="Disease" post="Control and PreventionAcute hemorrhagic conjunctivitis—St. Croix, U.S. Virgin Islands,"/>
   <result pre="Islands, September–October 1998MMWR Morb. Mortal. Wkly. Rep.199847428999019810014 18.collab: Centers for" exact="Disease" post="Control and PreventionAcute hemorrhagic conjunctivitis outbreak caused by coxsackievirus"/>
   <result pre="Wkly. Rep.199847428999019810014 18.collab: Centers for Disease Control and PreventionAcute hemorrhagic" exact="conjunctivitis" post="outbreak caused by coxsackievirus A24—Puerto Rico, 2003MMWR Morb. Mortal."/>
   <result pre="Rico, 2003MMWR Morb. Mortal. Wkly. Rep.20045363263415269699 19.MengRQiuYYanLStudy on etiology of" exact="acute" post="hemorrhagic conjunctivitis in Qingdao during 1997Zhonghua shiyan he linchuang"/>
   <result pre="Morb. Mortal. Wkly. Rep.20045363263415269699 19.MengRQiuYYanLStudy on etiology of acute hemorrhagic" exact="conjunctivitis" post="in Qingdao during 1997Zhonghua shiyan he linchuang bingduxue zazhi"/>
   <result pre="bingduxue zazhi Chin. J. Exp. Clin. Virol.1999132186187 20.MadhavanHNMalathyJPriyaKAn outbreak of" exact="acute" post="conjunctivitis caused by coxsackie virus A 24Indian J. Ophthalmol.200048215911116516"/>
   <result pre="zazhi Chin. J. Exp. Clin. Virol.1999132186187 20.MadhavanHNMalathyJPriyaKAn outbreak of acute" exact="conjunctivitis" post="caused by coxsackie virus A 24Indian J. Ophthalmol.200048215911116516 21.FonsecaMCet"/>
   <result pre="21.FonsecaMCet al.Isolation of coxsackievirus A24 variant from patients with hemorrhagic" exact="conjunctivitis" post="in Cuba, 2008–2009J. Clin. Virol.2012531778110.1016/j.jcv.2011.10.00622074932 22.PAHO/OPS. Conjuntivitis hemorrágica aguda:"/>
   <result pre="al.Molecular and immunocytochemical identification of coxsackievirus A-24 variant from the" exact="acute" post="haemorrhagic conjunctivitis outbreak in Taiwan in 2007Eye20102413113610.1038/eye.200919218990 24.WuBet al.Genetic"/>
   <result pre="immunocytochemical identification of coxsackievirus A-24 variant from the acute haemorrhagic" exact="conjunctivitis" post="outbreak in Taiwan in 2007Eye20102413113610.1038/eye.200919218990 24.WuBet al.Genetic characteristics of"/>
   <result pre="al.Genetic characteristics of the coxsackievirus A24 variant causing outbreaks of" exact="acute" post="hemorrhagic conjunctivitis in Jiangsu, China, 2010PLoS ONE20149e8688310.1371/journal.pone.008688324475191 25.ShuklaDKumarASrivastavaSDholeTNMolecular identification"/>
   <result pre="of the coxsackievirus A24 variant causing outbreaks of acute hemorrhagic" exact="conjunctivitis" post="in Jiangsu, China, 2010PLoS ONE20149e8688310.1371/journal.pone.008688324475191 25.ShuklaDKumarASrivastavaSDholeTNMolecular identification and phylogenetic"/>
   <result pre="study of coxsackievirus A24 variant isolated from an outbreak of" exact="acute" post="hemorrhagic conjunctivitis in India in 2010Arch. Virol201315867968410.1007/s00705-012-1520-723124888 26.DarribaDTaboadaGLDoalloRPosadaDjModelTest 2:"/>
   <result pre="coxsackievirus A24 variant isolated from an outbreak of acute hemorrhagic" exact="conjunctivitis" post="in India in 2010Arch. Virol201315867968410.1007/s00705-012-1520-723124888 26.DarribaDTaboadaGLDoalloRPosadaDjModelTest 2: more models,"/>
   <result pre="clades of enterovirus 68J. Gen. Virol.201293Pt 91952195810.1099/vir.0.043935-022694903 35.DussartPet al.Outbreak of" exact="acute" post="hemorrhagic conjunctivitis in French Guiana and West Indies caused"/>
   <result pre="enterovirus 68J. Gen. Virol.201293Pt 91952195810.1099/vir.0.043935-022694903 35.DussartPet al.Outbreak of acute hemorrhagic" exact="conjunctivitis" post="in French Guiana and West Indies caused by coxsackievirus"/>
   <result pre="analysis reveals Asian importJ. Med. Virol.20057555956510.1002/jmv.2030415714481 36.ChansaenrojJet al.Epidemic outbreak of" exact="acute" post="haemorrhagic conjunctivitis caused by coxsackievirus A24 in Thailand, 2014Epidemiol."/>
   <result pre="Asian importJ. Med. Virol.20057555956510.1002/jmv.2030415714481 36.ChansaenrojJet al.Epidemic outbreak of acute haemorrhagic" exact="conjunctivitis" post="caused by coxsackievirus A24 in Thailand, 2014Epidemiol. Infect.20151433087309310.1017/S095026881500064325824006 37.LaxmivandanaRYergolkarPRajeshwariMChitambarSDGenomic"/>
   <result pre="Infect.20151433087309310.1017/S095026881500064325824006 37.LaxmivandanaRYergolkarPRajeshwariMChitambarSDGenomic characterization of coxsackievirus type A24 strains associated with" exact="acute" post="flaccid paralysis and rarely identified Hopkins syndromeArch. Virol.20141593125312910.1007/s00705-014-2129-925081118 38.DeWet"/>
   <result pre="molecular characterization of coxsackievirus A24 variant isolates from a 2010" exact="acute" post="hemorrhagic conjunctivitis outbreak in Guangdong, ChinaVirol. J.201294110.1186/1743-422X-9-4122336176 39.CabrerizoMEchevarriaJEOteroALucasPTralleroGMolecular characterization"/>
   <result pre="of coxsackievirus A24 variant isolates from a 2010 acute hemorrhagic" exact="conjunctivitis" post="outbreak in Guangdong, ChinaVirol. J.201294110.1186/1743-422X-9-4122336176 39.CabrerizoMEchevarriaJEOteroALucasPTralleroGMolecular characterization of a"/>
   <result pre="of a coxsackievirus A24 variant that caused an outbreak of" exact="acute" post="haemorrhagic conjunctivitis in Spain, 2004J. Clin. Virol.200843332332710.1016/j.jcv.2008.07.01718786853 40.NidairaMet al.Molecular"/>
   <result pre="coxsackievirus A24 variant that caused an outbreak of acute haemorrhagic" exact="conjunctivitis" post="in Spain, 2004J. Clin. Virol.200843332332710.1016/j.jcv.2008.07.01718786853 40.NidairaMet al.Molecular evolution of"/>
   <result pre="VP1, 3C(pro) and 3D(pol) coding regions in coxsackievirus group A" exact="type 24" post="variant isolates from acute hemorrhagic conjunctivitis in 2011 Okinawa,"/>
   <result pre="regions in coxsackievirus group A type 24 variant isolates from" exact="acute" post="hemorrhagic conjunctivitis in 2011 Okinawa, JapanMicrobiol. Immunol.20145822723810.1111/1348-0421.1214124517637 41.BessaudMJoffretMLBlondelBDelpeyrouxFExchanges of"/>
   <result pre="coxsackievirus group A type 24 variant isolates from acute hemorrhagic" exact="conjunctivitis" post="in 2011 Okinawa, JapanMicrobiol. Immunol.20145822723810.1111/1348-0421.1214124517637 41.BessaudMJoffretMLBlondelBDelpeyrouxFExchanges of genomic domains"/>
   <result pre="high degree of plasticitySci. Rep.20166388310.1038/srep38831 42.NikolaidisMet al.Large-scale genomic analysis reveals" exact="recurrent" post="patterns of intertypic recombination in human enterovirusesVirology2019526728010.1016/j.virol.2018.10.00630366300 43.PallanschMObersteMSWhittonLKnipeDMHowleyPMEnteroviruses: polioviruses,"/>
   <result pre="&amp;amp; Wilkins490529 44.Yin-MurphyMSimple tests for the diagnosis of picornavirus epidemic" exact="conjunctivitis" post="(acute haemorrhagic conjunctivitis)Bull. World Health Organ.19765466756791088513 45.ChristopherSTheogarajSGodboleSJohnTJAn epidemic of"/>
   <result pre="conjunctivitis (acute haemorrhagic conjunctivitis)Bull. World Health Organ.19765466756791088513 45.ChristopherSTheogarajSGodboleSJohnTJAn epidemic of" exact="acute" post="hemorrhagic conjunctivitis due to coxsackievirus A24J. Infect. Dis.19821461161910.1093/infdis/146.1.166282991 46.GohKTOoiPLMiyamuraKOginoTYamazakiSAcute"/>
   <result pre="haemorrhagic conjunctivitis)Bull. World Health Organ.19765466756791088513 45.ChristopherSTheogarajSGodboleSJohnTJAn epidemic of acute hemorrhagic" exact="conjunctivitis" post="due to coxsackievirus A24J. Infect. Dis.19821461161910.1093/infdis/146.1.166282991 46.GohKTOoiPLMiyamuraKOginoTYamazakiSAcute haemorrhagic conjunctivitis:"/>
   <result pre="47.LangfordMPAndersEABurchMAAcute hemorrhagic conjunctivitis: anti-coxsackievirus A24 variant secretory immunoglobulin A in" exact="acute" post="and convalescent tearClin. Ophthalmol.201591665167310.2147/OPTH.S8535826392747 48.ComellasMMásPGoyenecheaAVarcárcelMEstudio de un brote de"/>
   <result pre="de conjuntivitis hemorrágica, Cuba 1986Rev. Cub. Hig. Epidemiol.1989277179 49.RedonIALagoPJPerezLRPuentesPCorredorMBOutbreak of" exact="acute" post="haemorrhagic conjunctivitis in CubaMem. Inst. Oswaldo Cruz.199994446746810.1590/S0074-0276199900040000610446002 50.YanDet al.Molecular"/>
   <result pre="hemorrágica, Cuba 1986Rev. Cub. Hig. Epidemiol.1989277179 49.RedonIALagoPJPerezLRPuentesPCorredorMBOutbreak of acute haemorrhagic" exact="conjunctivitis" post="in CubaMem. Inst. Oswaldo Cruz.199994446746810.1590/S0074-0276199900040000610446002 50.YanDet al.Molecular identification and"/>
   <result pre="and phylogenetic analyses of coxsackievirus A24v causing an outbreak of" exact="acute" post="hemorrhagic conjunctivitis in Jiangxi, China, in 2010Bing Du Xue"/>
   <result pre="analyses of coxsackievirus A24v causing an outbreak of acute hemorrhagic" exact="conjunctivitis" post="in Jiangxi, China, in 2010Bing Du Xue Bao201531325125726470530 51.ZhangLet"/>
   <result pre="China, in 2010Bing Du Xue Bao201531325125726470530 51.ZhangLet al.Molecular epidemiology of" exact="acute" post="hemorrhagic conjunctivitis caused by coxsackie A type 24 variant"/>
   <result pre="2010Bing Du Xue Bao201531325125726470530 51.ZhangLet al.Molecular epidemiology of acute hemorrhagic" exact="conjunctivitis" post="caused by coxsackie A type 24 variant in China,"/>
   <result pre="al.Molecular epidemiology of acute hemorrhagic conjunctivitis caused by coxsackie A" exact="type 24" post="variant in China, 2004–2014Sci. Rep.201774520210.1038/srep4520228332617 52.MásPLComellasMMGoyenecheaAJacoboMPalomeraRBeltránJDiagnóstico etiológico de un"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7427313/results/search/disease/results.xml">
   <result pre="License Abstract In the near future, the overlap of Coronavirus" exact="disease" post="2019 (COVID-19) and dengue epidemics is a concrete threat"/>
   <result pre="and dengue patients. Among 32 COVID-19 positive sera, no positive" exact="Dengue" post="virus (DENV) IgG/IgM results were observed. On the other"/>
   <result pre="words: COVID-19 SARS-CoV-2 dengue antibodies ref-count: Since December 2019, Coronavirus" exact="disease" post="2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus"/>
   <result pre="Since December 2019, Coronavirus disease 2019 (COVID-19), caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in the international"/>
   <result pre="December 2019, Coronavirus disease 2019 (COVID-19), caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), emerged in the international scene"/>
   <result pre="2019, Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), emerged in the international scene as"/>
   <result pre="time, a large outbreak of dengue is ongoing in Latin" exact="American" post="countries, with several deaths being recorded.2 In the near"/>
   <result pre="rapid diagnostic test (RDT) for dengue in patients with SARS-CoV-2" exact="infection" post="were reported from Singapore.6 If serological cross-reactivity between patients"/>
   <result pre="on sera from well-characterised COVID-19- and dengue-positive patients, respectively. A" exact="total" post="of 32 anonymised sera, obtained from symptomatic patients with"/>
   <result pre="patients, respectively. A total of 32 anonymised sera, obtained from" exact="symptomatic" post="patients with COVID-19 diagnosed by positive anti-SARS-CoV-2 IgM/IgG (32/32,"/>
   <result pre="RT-PCR for SARS-CoV-2 on nasopharyngeal swab (26/32), were tested by" exact="Dengue" post="Enzyme Linked Immune Assay (ELISA) DENV IgG-IgM (VIRCELL, Granada,"/>
   <result pre="was unlikely. Moreover, 44 anonymised DENV-positive sera, from cases of" exact="acute" post="dengue (27 of whom confirmed by NS1 antigen positivity,"/>
   <result pre="cross-reactivity issues in areas were multiple Flavivirus, such as Zika," exact="Yellow fever" post="or Japanese encephalitis virus are circulating. The risk of"/>
   <result pre="areas were multiple Flavivirus, such as Zika, Yellow fever or" exact="Japanese encephalitis" post="virus are circulating. The risk of false-positive results is"/>
   <result pre="were multiple Flavivirus, such as Zika, Yellow fever or Japanese" exact="encephalitis" post="virus are circulating. The risk of false-positive results is"/>
   <result pre="antibodies.9 Of course, this is a preliminary study on a" exact="limited" post="number of samples, which need to be validated on"/>
   <result pre="Experimental and Clinical Medicine). References REFERENCES 1collab: World Health OrganizationCoronavirus" exact="disease" post="(COVID-2019) situation reports2020https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ 2collab: PAHO/WHO - Pan American Health"/>
   <result pre="Health OrganizationCoronavirus disease (COVID-2019) situation reports2020https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ 2collab: PAHO/WHO - Pan" exact="American" post="Health Organization/World Health OrganizationEpidemiological update: arbovirus. Washington,2020DCPAHO/WHO 3NavarroJCArrivillaga-HenríquezJSalazar-LoorJRodriguez-MoralesAJCOVID-19 and"/>
   <result pre="care systems over the edgeTravel Med Infect Dis2020 4LorenzCAzevedoTSChiaravalloti-NetoFCOVID-19 and" exact="dengue fever" post="a dangerous combination for the health system in BrazilTravel"/>
   <result pre="system in BrazilTravel Med Infect Dis20203510165910165932278756 5LamLTMChuaYXTanDHYRoles and challenges of" exact="primary" post="care physicians facing a dual outbreak of COVID-19 and"/>
   <result pre="and false-positive dengue serology in SingaporeLancet Infect Dis202020553653632145189 7LiRPeiSChenBSongYZhangTYangWSubstantial undocumented" exact="infection" post="facilitates the rapid dissemination of novel coronavirus (SARS-CoV2)Science2020368649048949332179701 8MullerDADepelsenaireACYoungPRClinical"/>
   <result pre="diagnostic tests for SARS-CoV-2.JAMA2020 10BokhariSMMAMahmoodFBokhariSMSACase report diagnosis of novel Coronavirus" exact="disease" post="(COVID-19) versus tropical diseases in PakistanAm J Trop Med"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7428060/results/search/disease/results.xml">
   <result pre="Viewpoints : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases : Viral Diseases: Covid 19 : Medicine and"/>
   <result pre=": Medicine and Health Sciences : Medical Conditions : Infectious" exact="Diseases" post=": Viral Diseases: Covid 19 : Medicine and Health"/>
   <result pre="and Health Sciences : Medical Conditions : Infectious Diseases :" exact="Viral" post="Diseases: Covid 19 : Medicine and Health Sciences :"/>
   <result pre=": Medicine and Health Sciences : Medical Conditions : Tropical" exact="Diseases" post=": Neglected Tropical Diseases: Dengue Fever : Medicine and"/>
   <result pre=": Medical Conditions : Tropical Diseases : Neglected Tropical Diseases:" exact="Dengue" post="Fever : Medicine and Health Sciences : Medical Conditions"/>
   <result pre="Medical Conditions : Tropical Diseases : Neglected Tropical Diseases: Dengue" exact="Fever" post=": Medicine and Health Sciences : Medical Conditions :"/>
   <result pre="Fever : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases : Viral Diseases: Dengue Fever : Biology and"/>
   <result pre=": Medicine and Health Sciences : Medical Conditions : Infectious" exact="Diseases" post=": Viral Diseases: Dengue Fever : Biology and life"/>
   <result pre="and Health Sciences : Medical Conditions : Infectious Diseases :" exact="Viral" post="Diseases: Dengue Fever : Biology and life sciences :"/>
   <result pre="Sciences : Medical Conditions : Infectious Diseases : Viral Diseases:" exact="Dengue" post="Fever : Biology and life sciences : Organisms :"/>
   <result pre=": Medical Conditions : Infectious Diseases : Viral Diseases: Dengue" exact="Fever" post=": Biology and life sciences : Organisms : Viruses"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Sciences : Microbiology : Medical Microbiology : Microbial Pathogens :" exact="Viral" post="Pathogens : Flaviviruses: Dengue Virus : Medicine and Health"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre="Pathology and Laboratory Medicine : Pathogens : Microbial Pathogens :" exact="Viral" post="Pathogens : Flaviviruses: Dengue Virus : Biology and Life"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre=": Biology and Life Sciences : Organisms : Viruses :" exact="Viral" post="Pathogens : Flaviviruses: Dengue Virus : Medicine and Health"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Medical Conditions"/>
   <result pre="Virus : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases : Infectious Disease Control: Social Distancing : Medicine"/>
   <result pre=": Medicine and Health Sciences : Medical Conditions : Infectious" exact="Diseases" post=": Infectious Disease Control: Social Distancing : Medicine and"/>
   <result pre="and Health Sciences : Medical Conditions : Infectious Diseases :" exact="Infectious" post="Disease Control: Social Distancing : Medicine and Health Sciences:"/>
   <result pre="Health Sciences : Medical Conditions : Infectious Diseases : Infectious" exact="Disease" post="Control: Social Distancing : Medicine and Health Sciences: Diagnostic"/>
   <result pre="Brazil : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases: Co-Infections : Medicine and Health Sciences : Epidemiology:"/>
   <result pre="Risk Factors Simultaneous dengue and COVID-19 epidemics: Difficult days ahead?" exact="Dengue" post="and COVID-19 simultaneous epidemics http://orcid.org/0000-0001-9397-3204NacherMathieu12*http://orcid.org/0000-0003-4616-6690DouineMaylis1GailletMélanie3FlamandClaude4http://orcid.org/0000-0002-1473-3147RoussetDominique5RousseauCyril6MahdaouiChedli7CarrollStanley8http://orcid.org/0000-0002-4622-0282ValdesAudrey9PassardNathalie10http://orcid.org/0000-0002-7975-0132CarlesGabriel11DjossouFélix12DemarMagalie21314http://orcid.org/0000-0002-3481-5991EpelboinLoïc12[1], Centre d’Investigation Clinique Antilles"/>
   <result pre="for this work. fig-count: table-count: page-count: Introduction As the coronavirus" exact="disease" post="2019 (COVID-19) pandemic reaches South America, researchers have already"/>
   <result pre="In Singapore, 2 clinical cases consisted of dengue-like syndromes with" exact="thrombocytopenia" post="and false immunoglobulin M (IgM) positives with 2 different"/>
   <result pre="Guiana and the Amazonian region of Brazil, the coinfection between" exact="malaria" post="and dengue is not exceptional [8,9]. Arboviral infections (Tonate,"/>
   <result pre="coinfection between malaria and dengue is not exceptional [8,9]. Arboviral" exact="infections" post="(Tonate, Mayaro) [10], Q fever [11], leptospirosis, influenza, Amazonian"/>
   <result pre="dengue is not exceptional [8,9]. Arboviral infections (Tonate, Mayaro) [10]," exact="Q fever" post="[11], leptospirosis, influenza, Amazonian toxoplasmosis, and primary HIV infection"/>
   <result pre="Mayaro) [10], Q fever [11], leptospirosis, influenza, Amazonian toxoplasmosis, and" exact="primary" post="HIV infection can be potential differential diagnoses during a"/>
   <result pre="[10], Q fever [11], leptospirosis, influenza, Amazonian toxoplasmosis, and primary" exact="HIV infection" post="can be potential differential diagnoses during a dengue epidemic"/>
   <result pre="Q fever [11], leptospirosis, influenza, Amazonian toxoplasmosis, and primary HIV" exact="infection" post="can be potential differential diagnoses during a dengue epidemic"/>
   <result pre="2020, 7 years after the last epidemic, the Committee for" exact="Infectious" post="and Emergent Diseases officially declared a dengue epidemic (dengue"/>
   <result pre="after the last epidemic, the Committee for Infectious and Emergent" exact="Diseases" post="officially declared a dengue epidemic (dengue virus 1 [DENV-1]"/>
   <result pre="of joint epidemics has several complex collateral consequences. Fig 1" exact="Dengue" post="and COVID-19 data: French Guiana, January–April 2020. COVID-19, coronavirus"/>
   <result pre="Dengue and COVID-19 data: French Guiana, January–April 2020. COVID-19, coronavirus" exact="disease" post="2019. Is it COVID-19 or dengue? Contextual elements are"/>
   <result pre="patients with confirmed dengue having a cough and 20% with" exact="upper" post="respiratory tract symptoms [14]. Similarly, COVID-19 may manifest itself"/>
   <result pre="with confirmed dengue having a cough and 20% with upper" exact="respiratory" post="tract symptoms [14]. Similarly, COVID-19 may manifest itself as"/>
   <result pre="symptoms [14]. Similarly, COVID-19 may manifest itself as fever with" exact="muscle" post="and joint pains without respiratory symptoms, especially in infants"/>
   <result pre="manifest itself as fever with muscle and joint pains without" exact="respiratory" post="symptoms, especially in infants [15–17]. Thus, most patients must"/>
   <result pre="must be explored for both diseases. 10.1371/journal.pntd.0008426.t001Table 1 COVID-19 and" exact="dengue fever" post="similarities and differences. COVID-19 Dengue Symptoms and biological findings"/>
   <result pre="10.1371/journal.pntd.0008426.t001Table 1 COVID-19 and dengue fever similarities and differences. COVID-19" exact="Dengue" post="Symptoms and biological findings Fever +++ +++ Headache ++"/>
   <result pre="fever similarities and differences. COVID-19 Dengue Symptoms and biological findings" exact="Fever" post="+++ +++ Headache ++ +++ Retro-orbital paina ++ Asthenia"/>
   <result pre="++ Rhinorrheab + Sneezingb + Anosmia, ageusiab +++ ± (dysgueusia)" exact="Diarrhea" post="+ + Nausea/vomiting + + Persistent vomitinga +* Abdominal"/>
   <result pre="criteria DENGUE. bIndicates more discriminating criteria COVID-19. *Prognostic value. #The" exact="American" post="College of Cardiology recommends not to prescribe it unless"/>
   <result pre="ALAT, alanine amino transferase; ASAT, aspartate amino transferase; COVID-19, coronavirus" exact="disease" post="2019; CRP, C-reactive protein; LDH, lactate dehydrogenase However, given"/>
   <result pre="a loss of chance for patients with dengue, as this" exact="disease" post="may be potentially lethal as well [19,20]. For nonfebrile"/>
   <result pre="a combined diagnosis (COVID-19–dengue) for ambulatory patients and at least" exact="complete" post="blood count, liver enzymes, C-reactive protein, serum protein, creatinine,"/>
   <result pre="needed. Telemedicine or normal consultation? Given the potential risks of" exact="infectious diseases" post="in pregnancy, and the difficulties to evaluate small children,"/>
   <result pre="in French Guiana are as follows: In a context of" exact="respiratory" post="signs and symptoms, Q fever, usual respiratory pathogens such"/>
   <result pre="as follows: In a context of respiratory signs and symptoms," exact="Q fever," post="usual respiratory pathogens such as Streptococcus pneumoniae and Mycoplasma"/>
   <result pre="a context of respiratory signs and symptoms, Q fever, usual" exact="respiratory" post="pathogens such as Streptococcus pneumoniae and Mycoplasma pneumoniae, influenza,"/>
   <result pre="virus and Mayaro virus (French Guiana reports no case of" exact="chikungunya" post="virus infection from early 2016 and no case of"/>
   <result pre="and Mayaro virus (French Guiana reports no case of chikungunya" exact="virus infection" post="from early 2016 and no case of Zika virus"/>
   <result pre="Mayaro virus (French Guiana reports no case of chikungunya virus" exact="infection" post="from early 2016 and no case of Zika virus"/>
   <result pre="virus infection from early 2016 and no case of Zika" exact="virus infection" post="from early 2017) [22], malaria, Q fever, leptospirosis, salmonellosis,"/>
   <result pre="infection from early 2016 and no case of Zika virus" exact="infection" post="from early 2017) [22], malaria, Q fever, leptospirosis, salmonellosis,"/>
   <result pre="case of Zika virus infection from early 2017) [22], malaria," exact="Q fever," post="leptospirosis, salmonellosis, and HIV primary infection [10,12,23,24]. This list"/>
   <result pre="early 2017) [22], malaria, Q fever, leptospirosis, salmonellosis, and HIV" exact="primary" post="infection [10,12,23,24]. This list will vary between regions. The"/>
   <result pre="2017) [22], malaria, Q fever, leptospirosis, salmonellosis, and HIV primary" exact="infection" post="[10,12,23,24]. This list will vary between regions. The objectives"/>
   <result pre="to the context and clinical presentation, physicians may prescribe a" exact="malaria" post="test, blood and urine cultures, serologies, or molecular diagnosis"/>
   <result pre="arguably has the potential to give an edge to the" exact="dengue fever" post="vectors, Aedes aegypti. Population movements and the frequency of"/>
   <result pre="distancing. Transmission depends on the frequency of mosquito bites, and" exact="infection" post="incidence in the human and mosquito populations is almost"/>
   <result pre="of contacts [27]. Mosquitoes are locally mobile but only travel" exact="short" post="distances, usually far less than infected humans who can"/>
   <result pre="human movement enhances the rescue effect. Thus, modeling suggests that" exact="infection" post="hubs and reservoirs can be locations people visit frequently,"/>
   <result pre="the lockdown, people stay home, and the risk of dengue" exact="infection" post="may increase as A. aegypti, the vector of dengue"/>
   <result pre="or health professionals have COVID-19. In French Guiana, despite a" exact="limited" post="number of cases (97 on April 21, 2020), the"/>
   <result pre="potential vector breeding places and protect themselves from mosquito bites." exact="Local" post="authorities should be very vigilant and activate strategic services"/>
   <result pre="to accommodate a surge of COVID-19 patients, should plan for" exact="severe dengue" post="beds. Patients should remain under mosquito nets, to avoid"/>
   <result pre="of most air traffic. Most initial cases were imported with" exact="secondary" post="transmission clusters around imported cases. However, as social distancing"/>
   <result pre="of illegal goldminers from Brazil in French Guiana. As the" exact="Brazilian" post="president resists social distancing, there are risks of importing"/>
   <result pre="PeñaJ, MackM, TalaricoLB, et al.Influenza and dengue virus co-infection impairs" exact="monocyte" post="recruitment to the lung, increases dengue virus titers, and"/>
   <result pre="8EpelboinL, HanfM, DussartP, Ouar-EpelboinS, DjossouF, NacherM, et al.Is dengue and" exact="malaria" post="co-infection more severe than single infections? A retrospective matched-pair"/>
   <result pre="14210.1186/1475-2875-11-14222549018 9MagalhãesBML, SiqueiraAM, AlexandreMAA, SouzaMS, GimaqueJB, BastosMS, et al.P. vivax" exact="malaria" post="and dengue fever co-infection: a cross-sectional study in the"/>
   <result pre="SiqueiraAM, AlexandreMAA, SouzaMS, GimaqueJB, BastosMS, et al.P. vivax malaria and" exact="dengue fever" post="co-infection: a cross-sectional study in the Brazilian Amazon. PLoS"/>
   <result pre="malaria and dengue fever co-infection: a cross-sectional study in the" exact="Brazilian" post="Amazon. PLoS Negl Trop Dis. 2014;8: e323910.1371/journal.pntd.000323925340346 10MutricyR, DjossouF,"/>
   <result pre="MatheusS, Lorenzi-MartinezE, De LavalF, DemarM, et al.Discriminating Tonate Virus from" exact="Dengue" post="Virus Infection: A Matched Case–Control Study in French Guiana,"/>
   <result pre="10.4269/ajtmh.19-015631769401 11EpelboinL, ChesnaisC, BoulléC, DrogoulA-S, RaoultD, DjossouF, et al.Q fever" exact="pneumonia" post="in French Guiana: prevalence, risk factors, and prognostic score."/>
   <result pre="from: https://www.guyane.ars.sante.fr/system/files/2020-04/2020_04_PE_dengue_Guyane.pdf. 14EpelboinL, BoulléC, Ouar-EpelboinS, HanfM, DussartP, DjossouF, et al.Discriminating" exact="malaria" post="from dengue fever in endemic areas: clinical and biological"/>
   <result pre="14EpelboinL, BoulléC, Ouar-EpelboinS, HanfM, DussartP, DjossouF, et al.Discriminating malaria from" exact="dengue fever" post="in endemic areas: clinical and biological criteria, prognostic score"/>
   <result pre="ShiH, WangW, et al.Digestive Symptoms in COVID-19 Patients With Mild" exact="Disease" post="Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes."/>
   <result pre="in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool" exact="Viral" post="RNA Testing, and Outcomes. Am J Gastroenterol. 202010.14309/ajg.000000000000066432301761 18WangX,"/>
   <result pre="VesinG, BidaudB, BlanchetD, DjossouF. Caractéristiques clinico-biologiques et score prédictif de" exact="chikungunya" post="vs. dengue. Médecine Mal Infect. 2017;47: S58–S59. 24FlamandC, BaillyS,"/>
   <result pre="al.Impact of Zika Virus Emergence in French Guiana: A Large" exact="General" post="Population Seroprevalence Survey. J Infect Dis. 2019;220: 1915–1925. 10.1093/infdis/jiz39631418012"/>
   <result pre="bites mosquito: understanding the contribution of human movement to vector-borne" exact="disease" post="dynamics. PLoS ONE. 2009;4: e676310.1371/journal.pone.000676319707544 28SPF. Situation épidémiologique de"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7431640/results/search/disease/results.xml">
   <result pre="italic;} Influenza Other Respir VirusesInfluenza Other Respir Viruses10.1111/(ISSN)1750-2659IRVInfluenza and Other" exact="Respiratory" post="Viruses1750-26401750-2659John Wiley and Sons Inc.Hoboken pmcid: 7431640 doi: 10.1111/irv.12744IRV12744"/>
   <result pre="al. Paz–BaileyGabriela1gmb5@cdc.govQuandelacyTalia M.1AdamsLaura E.1OlsenSonja J.2BlantonLenee2Munoz-JordanJorge L.1LozierMatthew1AlvaradoLuisa I.3JohanssonMichael A.1[1], Centers for" exact="Disease" post="Control and PreventionSan JuanPuerto Rico[2], Centers for Disease Control"/>
   <result pre="Centers for Disease Control and PreventionSan JuanPuerto Rico[2], Centers for" exact="Disease" post="Control and PreventionAtlantaGeorgia[3], Saint Luke’s Episcopal Hospital and Ponce"/>
   <result pre="Ponce Health Sciences UniversityPoncePuerto Rico *Correspondence Gabriela Paz–Bailey, Centers for" exact="Disease" post="Control and Prevention, 1324 Calle Canada, San Juan 00920,"/>
   <result pre="Abstract Abstract Background We used data from the Sentinel Enhanced" exact="Dengue" post="Surveillance System (SEDSS) to describe influenza trends in southern"/>
   <result pre="World Health Organization (WHO) Collaborating Laboratories System and the National" exact="Respiratory" post="and Enteric Virus Surveillance System (NREVSS). We compared influenza"/>
   <result pre="Virus Surveillance System (NREVSS). We compared influenza A and B" exact="infections" post="identified from SEDSS and WHO/NREVSS laboratories reported by US"/>
   <result pre="virus in HHS regions. In Puerto Rico, coherence was much" exact="lower" post="in the early years but increased to similar levels"/>
   <result pre="trends United States Funding National Center for Emerging and Zoonotic" exact="Infectious" post="Diseases 10.13039/100006088 fig-count: table-count: page-count: word-count: Paz–BaileyG, QuandelacyTM, AdamsLE,"/>
   <result pre="United States Funding National Center for Emerging and Zoonotic Infectious" exact="Diseases" post="10.13039/100006088 fig-count: table-count: page-count: word-count: Paz–BaileyG, QuandelacyTM, AdamsLE, et"/>
   <result pre="significant public health problem globally. Seasonal influenza has a high" exact="disease" post="burden, reducing school attendance, increasing worker absenteeism and impacting"/>
   <result pre="United States (US).2 Though antivirals treat infection, vaccination remains the" exact="primary" post="tool to prevent influenza‐associated morbidity and mortality.3 The US"/>
   <result pre="who do not have contraindications.4 Influenza immunization programmes must consider" exact="disease" post="seasonality to most effectively use immunization.5 As a US"/>
   <result pre="mitigation measures on the island. We analysed data from enhanced" exact="acute" post="febrile illness (AFI) surveillance sites in southern Puerto Rico"/>
   <result pre="METHODS 2.1 Sentinel enhanced dengue surveillance system The Sentinel Enhanced" exact="Dengue" post="Surveillance System (SEDSS)12 recruits febrile patients presenting at emergency"/>
   <result pre="Ponce and Mayaguez (~500 000 residents) Health Districts. The Outpatient" exact="Acute" post="Care Clinic (2016‐present) services ~20 000 patients/year. Guayama Menonita"/>
   <result pre="~20 000 patients/year. Guayama Menonita Hospital (2013‐2015) is a 161‐bed" exact="secondary" post="care hospital site that receives ~35 000 patients per"/>
   <result pre="collected from enrolled patients, and diagnostic testing was performed. Upper" exact="respiratory" post="tract specimens were tested for influenza A and B"/>
   <result pre="specimens were tested for influenza A and B viruses, adenovirus," exact="respiratory" post="syncytial virus (RSV), coronavirus, parainfluenza viruses and human metapneumovirus"/>
   <result pre="chain reaction (RT–PCR) as previously described.13, 14, 15 For each" exact="respiratory" post="pathogen, a positive result was defined as nucleic acid"/>
   <result pre="The Ponce Medical School Foundation and the US Centers for" exact="Disease" post="Control and Prevention (CDC) ethics committees reviewed and approved"/>
   <result pre="reviewed and approved the SEDSS study protocol. 2.2 US influenza" exact="viral" post="surveillance Virologic surveillance data from the 40th week of"/>
   <result pre="US World Health Organization (WHO) Collaborating Laboratories and the National" exact="Respiratory" post="and Enteric Virus Surveillance System (NREVSS). The WHO Collaborating"/>
   <result pre="Division and the NREVSS is maintained by CDC’s Division of" exact="Viral" post="Diseases. The data included the total number of respiratory"/>
   <result pre="by CDC’s Division of Viral Diseases. The data included the" exact="total" post="number of respiratory specimens tested, and the number positive"/>
   <result pre="of Viral Diseases. The data included the total number of" exact="respiratory" post="specimens tested, and the number positive for influenza types"/>
   <result pre="Utah, and Wyoming. Region 9 includes: Arizona, California, Hawaii, Nevada," exact="American" post="Samoa, Common wealth of the Northern Mariana Islands, Federated"/>
   <result pre="temperature and precipitation) from 2012 to 2018 from the North" exact="American" post="Regional Reanalysis data set from the National Oceanic and"/>
   <result pre="treatment, 16% had hospital admittance. From 2012‐2013, 20% of the" exact="total" post="enrollees were recruited, 20% in 2014‐2015, 43% in 2016‐2017"/>
   <result pre="1 Characteristics of participants by year of recruitment, Sentinel Enhanced" exact="Dengue" post="Surveillance System, Ponce, Puerto Rico, 2012‐2018 Participant Characteristics Overall"/>
   <result pre="% N % N % N % N % Gender" exact="Female" post="11 924 51.6 2282 49.6 2383 50.0 5264 53.5"/>
   <result pre="167 0.7 6 0.1 5 0.1 94 1.0 62 1.6" exact="Total" post="23 124 100 4602 100 4771 100 9842 100"/>
   <result pre="of participants with Influenza A and Influenza B, Sentinel Enhanced" exact="Dengue" post="Surveillance System, Ponce, Puerto Rico, 2012‐2018 Participant Characteristics Total"/>
   <result pre="Enhanced Dengue Surveillance System, Ponce, Puerto Rico, 2012‐2018 Participant Characteristics" exact="Total" post="All Influenza Influenza A Influenza B N n %"/>
   <result pre="Influenza B N n % n % n % Gender" exact="Female" post="11 924 1619 13.6 1051 8.8 568 4.8 Male"/>
   <result pre=". . Other 167 18 10.8 10 6.0 8 4.8" exact="Total" post="23 124 3214 13.9 2036 8.8 1178 5.1 (C)"/>
   <result pre="and 2018 (Figure 1A). Specifically, influenza A virus had an" exact="atypical" post="summer peak in 2013, but had subsequent peaks in"/>
   <result pre="cases overall (1A‐C) and by type in the Sentinel Enhanced" exact="Dengue" post="Surveillance System (SEDSS), Southern Puerto Rico (PR) and US"/>
   <result pre="North Carolina, South Carolina, and Tennessee), but this region had" exact="lower" post="coherence with Puerto Rico (0.52), suggesting they do not"/>
   <result pre="regions by as much as 12‐18 weeks. However, this pattern" exact="inverted" post="in 2016, after which the seasonal patterns in SEDSS"/>
   <result pre="different in Puerto Rico. Influenza A virus coherence was much" exact="lower" post="in the early years, but by the 2017‐2018 season,"/>
   <result pre="had higher coherence during the most recent influenza seasons. The" exact="absence of" post="high coherence between influenza peaks and temperature and humidity"/>
   <result pre="virus survival and aerosolized transmission19, 20 and epidemiological studies showed" exact="lower" post="humidity is associated with the onset of influenza epidemics"/>
   <result pre="with the onset of influenza epidemics in the United States.21" exact="Increased" post="proximity between susceptible and infected hosts associated with cold"/>
   <result pre="by other factors23 including travel and global and US influenza" exact="viral" post="introductions into Puerto Rico. For instance, a previous study"/>
   <result pre="Puerto Rico, and other tropical areas, such as Hawaii or" exact="American" post="Samoa. The annual coherence of influenza B increased from"/>
   <result pre="is subject to several limitations. First, the patient population was" exact="limited" post="to two sentinel hospitals and one outpatient clinic in"/>
   <result pre="by different hospitals, the observed percentages of patients with a" exact="respiratory" post="virus may not be representative of all Puerto Rican"/>
   <result pre="not account for vaccine effects. While Puerto Rico generally has" exact="lower" post="influenza vaccination rates compared with US states,29 we did"/>
   <result pre="of age and older, and possibly under‐estimating the number of" exact="infections" post="in Puerto Rico.29 Our study highlights the poorly understood"/>
   <result pre="not necessarily represent the official position of the Centers for" exact="Disease" post="Control and Prevention. Supporting information FigS1‐S5 LINK Click here"/>
   <result pre="file. ACKNOWLEDGEMENTS We acknowledge funding provided by the Centers for" exact="Disease" post="Control and Prevention. We would like to thank the"/>
   <result pre="and tropical regions. Environ Health Perspect. 2011;119:439‐445.21097384 2collab: Centers for" exact="Disease" post="Control and Prevention . Disease burden of influenza [Internet]."/>
   <result pre="Perspect. 2011;119:439‐445.21097384 2collab: Centers for Disease Control and Prevention ." exact="Disease" post="burden of influenza [Internet]. 2019 [cited 2019 Mar. 18];"/>
   <result pre="et al. Timing of influenza epidemics and vaccines in the" exact="American" post="tropics, 2002–2008, 2011–2014. Influenza Other Respir Viruses. 2016;10:170‐175.26701079 12TomashekKM,"/>
   <result pre="12TomashekKM, RiveraA, Torres‐VelasquezB, et al. Enhanced surveillance for fatal dengue‐like" exact="acute" post="febrile illness in Puerto Rico, 2010–2012. PLoS Negl Trop"/>
   <result pre="Dis. 2016;10:e0005025.27727271 13PaulinoRDS, BenegaMA, SantosKCDO, et al. Differential diagnosis of" exact="respiratory" post="viruses by using real time RT‐PCR methodology. Rev Inst"/>
   <result pre="by real time RT‐PCR is not affected by delays in" exact="respiratory" post="specimen processing. J Med Virol. 2016;88:1891‐1895.27089468 15collab: World Health"/>
   <result pre="USA. 2009;106:3243‐3248.19204283 22ChewFT, DoraisinghamS, LingAE, KumarasingheG, LeeBW. Seasonal trends of" exact="viral" post="respiratory tract infections in the tropics. Epidemiol Infect. 1998;121:121‐128.9747763"/>
   <result pre="2009;106:3243‐3248.19204283 22ChewFT, DoraisinghamS, LingAE, KumarasingheG, LeeBW. Seasonal trends of viral" exact="respiratory" post="tract infections in the tropics. Epidemiol Infect. 1998;121:121‐128.9747763 23CauchemezS,"/>
   <result pre="DoraisinghamS, LingAE, KumarasingheG, LeeBW. Seasonal trends of viral respiratory tract" exact="infections" post="in the tropics. Epidemiol Infect. 1998;121:121‐128.9747763 23CauchemezS, ValleronAJ, BoellePY,"/>
   <result pre="data. Nature. 2008;452:750‐754.18401408 24AlthouseBM, FlascheS, ThiemVD, et al. Seasonality of" exact="respiratory" post="viruses causing hospitalizations for acute respiratory infections in children"/>
   <result pre="ThiemVD, et al. Seasonality of respiratory viruses causing hospitalizations for" exact="acute" post="respiratory infections in children in Nha Trang, Vietnam. Int"/>
   <result pre="et al. Seasonality of respiratory viruses causing hospitalizations for acute" exact="respiratory" post="infections in children in Nha Trang, Vietnam. Int J"/>
   <result pre="al. Seasonality of respiratory viruses causing hospitalizations for acute respiratory" exact="infections" post="in children in Nha Trang, Vietnam. Int J Infect"/>
   <result pre="Natl Acad Sci U S A. 2020;117:619‐628.31843889 28collab: Centers for" exact="Disease" post="Control and Prevention . National, regional, and state level"/>
   <result pre="Prevention . National, regional, and state level outpatient illness and" exact="viral" post="surveillance [Internet]. 2016–17. [cited 2020 Mar. 26]; Available from:"/>
   <result pre="[cited 2020 Mar. 26]; Available from: https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html 29collab: Centers for" exact="Disease" post="Control and Prevention . 2013–14 influenza season vaccination coverage"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7435559/results/search/disease/results.xml">
   <result pre=", This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
   <result pre="developing economies of Africa. We conclude that digital connectedness enabled" exact="African" post="countries to access; share and implement globally suggested mechanisms"/>
   <result pre="spread of the COVID‐19 epidemic. Future, studies should examine how" exact="African" post="economies use digital connectedness to increase individual and organizational"/>
   <result pre="health management. fig-count: table-count: page-count: word-count: 1 INTRODUCTION The severe" exact="acute" post="respiratory syndrome (SARS); a viral respiratory disease outbreak in"/>
   <result pre="management. fig-count: table-count: page-count: word-count: 1 INTRODUCTION The severe acute" exact="respiratory" post="syndrome (SARS); a viral respiratory disease outbreak in Southern"/>
   <result pre="fig-count: table-count: page-count: word-count: 1 INTRODUCTION The severe acute respiratory" exact="syndrome" post="(SARS); a viral respiratory disease outbreak in Southern China"/>
   <result pre="word-count: 1 INTRODUCTION The severe acute respiratory syndrome (SARS); a" exact="viral" post="respiratory disease outbreak in Southern China (between November 2002"/>
   <result pre="1 INTRODUCTION The severe acute respiratory syndrome (SARS); a viral" exact="respiratory" post="disease outbreak in Southern China (between November 2002 and"/>
   <result pre="INTRODUCTION The severe acute respiratory syndrome (SARS); a viral respiratory" exact="disease" post="outbreak in Southern China (between November 2002 and July"/>
   <result pre="how countries respond to health epidemics such as the coronavirus" exact="formerly" post="known as 2019‐nCoV (Dodds &amp;amp; Zolfagharifard, 2020; World Health"/>
   <result pre="Organization to digitally share its interim guidance on the COVID‐19" exact="infection" post="prevention and needed health care when the novel coronavirus"/>
   <result pre="infection prevention and needed health care when the novel coronavirus" exact="infection" post="was suspected (World Health Organization [WHO/2019‐nCoV/IPC/v20202.2], 2020). For instance,"/>
   <result pre="Ebola viruses. For instance, the &quot;African swine fever (ASF) a" exact="viral" post="hemorrhagic disease, caused by a large double‐stranded DNA virus"/>
   <result pre="viruses. For instance, the &quot;African swine fever (ASF) a viral" exact="hemorrhagic disease," post="caused by a large double‐stranded DNA virus with an"/>
   <result pre="a large double‐stranded DNA virus with an icosahedral symmetry, many" exact="African" post="nations reacted to it during its infancy level. Since"/>
   <result pre="its infancy level. Since its first description in Kenya, the" exact="disease" post="was reported in various countries around the world such"/>
   <result pre="I., Arinaitwe, E., …, Ojok, L. (2013). Epidemiological Overview of" exact="African" post="Swine Fever in Uganda (2001–2012). Journal of Veterinary Medicine,"/>
   <result pre="E., …, Ojok, L. (2013). Epidemiological Overview of African Swine" exact="Fever" post="in Uganda (2001–2012). Journal of Veterinary Medicine, 2013, 1–9."/>
   <result pre="J., Ndekezi, C., &amp;amp; Sylvester, O. (2019). Molecular characterization of" exact="African" post="swine fever viruses from outbreaks in Peri‐urban Kampala, Uganda."/>
   <result pre="G., Oura, C., Vosloo, W., …, Dixon, L. K. (2008)." exact="African" post="Swine Fever Virus Isolate, Georgia, 2007. Emerging Infectious Diseases,"/>
   <result pre="C., Vosloo, W., …, Dixon, L. K. (2008). African Swine" exact="Fever" post="Virus Isolate, Georgia, 2007. Emerging Infectious Diseases, 14(12), 1870–1874."/>
   <result pre="K. (2008). African Swine Fever Virus Isolate, Georgia, 2007. Emerging" exact="Infectious" post="Diseases, 14(12), 1870–1874. 10.3201/eid1412.08059119046509 Sánchez‐Cordón, P., Montoya, M., Reis,"/>
   <result pre="Sánchez‐Cordón, P., Montoya, M., Reis, A., &amp;amp; Dixon, L. (2018)." exact="African" post="swine fever: A re‐emerging viral disease threatening the global"/>
   <result pre="A., &amp;amp; Dixon, L. (2018). African swine fever: A re‐emerging" exact="viral" post="disease threatening the global pig industry. The Veterinary Journal,"/>
   <result pre="&amp;amp; Dixon, L. (2018). African swine fever: A re‐emerging viral" exact="disease" post="threatening the global pig industry. The Veterinary Journal, 233,"/>
   <result pre="41–48.29486878 collab: World Health Organization [WHO/2019‐nCoV/IPC/v20202.2] . (2020, January 25)." exact="Infection" post="prevention and control during health care when novel coronavirus"/>
   <result pre="prevention and control during health care when novel coronavirus (nCoV)" exact="infection" post="is suspected. World Health Organization Retrieved from https://www.who.int/publications‐detail/infection‐prevention‐and‐control‐during‐health‐care‐when‐novel‐coronavirus‐(ncov)o‐infection‐is‐suspected‐20200125"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7440033/results/search/disease/results.xml">
   <result pre="Department of Microbiology, Faculty of Natural and Applied Sciences and" exact="African" post="Centre for Infection and Biomolecular Sciences (ACIBS), Nasarawa State"/>
   <result pre="Faculty of Natural and Applied Sciences and African Centre for" exact="Infection" post="and Biomolecular Sciences (ACIBS), Nasarawa State University, Keffi, Nigeria"/>
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="tirées pour un confinement plus rapide et plus sévère. Le" exact="syndrome" post="respiratoire aigu coronavirus 2 (Sars-CoV-2), la cause virale du"/>
   <result pre="à une phase exponentielle, 47 pays africains ayant déclaré un" exact="total" post="de 766.803 cas, 13.191 décès et 486.925 récupérations au"/>
   <result pre="ou pandémies de toute maladie infectieuse en Afrique. The coronavirus" exact="disease" post="2019 (COVID-19) will continue to have a significant impact"/>
   <result pre="vaccine. Unfortunately, this will not be the last pandemic of" exact="infectious diseases" post="the world will experience, and the next one may"/>
   <result pre="are learnt now for more rapid and robust containment measures." exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the viral cause"/>
   <result pre="learnt now for more rapid and robust containment measures. Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), the viral cause of"/>
   <result pre="now for more rapid and robust containment measures. Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), the viral cause of COVID-19,"/>
   <result pre="for more rapid and robust containment measures. Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), the viral cause of COVID-19, is"/>
   <result pre="containment measures. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the" exact="viral" post="cause of COVID-19, is thought to have been introduced"/>
   <result pre="Europe and America. In a pandemic with Africa having relatively" exact="lower" post="morbidity and mortality, it is alarming that in about"/>
   <result pre="case of COVID-19 in Egypt on February 14th, 2020, the" exact="infection" post="rate remains at an exponential phase with forty-seven African"/>
   <result pre="the infection rate remains at an exponential phase with forty-seven" exact="African" post="countries reporting a total of 766,803 cases, 13,191 deaths"/>
   <result pre="at an exponential phase with forty-seven African countries reporting a" exact="total" post="of 766,803 cases, 13,191 deaths and 486,925 recoveries as"/>
   <result pre="for containment of future outbreaks, epidemics or pandemics of any" exact="infectious disease" post="in Africa. Keywords Africa Coronavirus disease 2019 (COVID-19) Health"/>
   <result pre="containment of future outbreaks, epidemics or pandemics of any infectious" exact="disease" post="in Africa. Keywords Africa Coronavirus disease 2019 (COVID-19) Health"/>
   <result pre="pandemics of any infectious disease in Africa. Keywords Africa Coronavirus" exact="disease" post="2019 (COVID-19) Health System Preparedness Nigeria SARS-CoV-2 Mots-clés Afrique"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7441048/results/search/disease/results.xml">
   <result pre="italic;} Int J Infect DisInt. J. Infect. DisInternational Journal of" exact="Infectious" post="Diseases1201-97121878-3511The Author(s). Published by Elsevier Ltd on behalf of"/>
   <result pre="Published by Elsevier Ltd on behalf of International Society for" exact="Infectious" post="Diseases. pmcid: 7441048S1201-9712(20)30671-8 doi: 10.1016/j.ijid.2020.08.041 : Short Communication Current"/>
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="strategies of testing and sampling sites were examined at different" exact="disease" post="stages. •The choice of test depends on technical characteristics,"/>
   <result pre="characteristics, clinical scenarios and requirements. Abstract The outbreak of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), which began in Wuhan,"/>
   <result pre="clinical scenarios and requirements. Abstract The outbreak of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), which began in Wuhan, Hubei"/>
   <result pre="scenarios and requirements. Abstract The outbreak of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), which began in Wuhan, Hubei Province,"/>
   <result pre="spread of SARS-CoV-2. There are currently several diagnostic techniques (e.g." exact="viral" post="culture and nucleic acid amplification test) being used to"/>
   <result pre="of the currently available laboratory diagnostic assays for detecting SARS-CoV-2" exact="infection" post="and summarized the selection strategies of testing and sampling"/>
   <result pre="the selection strategies of testing and sampling sites at different" exact="disease" post="stages to improve the diagnostic accuracy of Coronavirus Disease"/>
   <result pre="different disease stages to improve the diagnostic accuracy of Coronavirus" exact="Disease" post="2019 (COVID-19). Keywords Novel coronavirus SARS-CoV-2 COVID-19 Laboratory testing"/>
   <result pre="SARS-CoV-2 COVID-19 Laboratory testing Laboratory diagnosis An outbreak of coronavirus" exact="disease" post="2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus"/>
   <result pre="An outbreak of coronavirus disease 2019 (COVID-19) caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) was discovered in Wuhan,"/>
   <result pre="outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) was discovered in Wuhan, China,"/>
   <result pre="of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) was discovered in Wuhan, China, in"/>
   <result pre="into a global pandemic. As of 29 May 2020 a" exact="total" post="of 5,701,337 laboratory-confirmed COVID-19 cases had been reported worldwide,"/>
   <result pre="in the community, early and reliable laboratory confirmation of SARS-CoV-2" exact="infection" post="is of crucial importance. This review summarized advances made"/>
   <result pre="advances made in technologies for rapid diagnosis and confirmation of" exact="respiratory" post="infections caused by SARS-CoV-2, as well as the selection"/>
   <result pre="made in technologies for rapid diagnosis and confirmation of respiratory" exact="infections" post="caused by SARS-CoV-2, as well as the selection strategies"/>
   <result pre="sampling sites in SARS-CoV-2 detection. Since the initial cases of" exact="pneumonia" post="of unknown cause were first reported, viral culture and"/>
   <result pre="initial cases of pneumonia of unknown cause were first reported," exact="viral" post="culture and genetic sequencing of isolates obtained from these"/>
   <result pre="10 days in January 2020. This benefitted understanding of the" exact="disease" post="occurrence and transmission, as well as diagnostic test development"/>
   <result pre="well as diagnostic test development (Zhu et al., 2020). Although" exact="viral" post="culture is relatively time-consuming and labor-intensive, it is much"/>
   <result pre="Table 1 Testing type Specimen type Characteristics Testing time Limitation" exact="Viral" post="culture Respiratory sample Gold standard for virus diagnosis and"/>
   <result pre="Testing type Specimen type Characteristics Testing time Limitation Viral culture" exact="Respiratory" post="sample Gold standard for virus diagnosis and useful in"/>
   <result pre="be widely used in clinical settings NAAT, whole genome sequencing" exact="Respiratory" post="sample and blood Detects all pathogens in a given"/>
   <result pre="pathogens in a given specimen, including SARS-CoV-2, as well as" exact="viral" post="genome mutations 20 h Time-consuming, specialized instruments with high"/>
   <result pre="with high technical thresholds, and high cost NAAT, real-time RT-PCR" exact="Respiratory" post="sample, stool and blood Most widely used for laboratory"/>
   <result pre="and blood Most widely used for laboratory confirmation of SARS-CoV-2" exact="infection" post="1.5–3 h Time-consuming procedure, requires biosafety conditions, expensive equipment,"/>
   <result pre="personnel, and can have false negative results NAAT, isothermal amplification" exact="Respiratory" post="sample, stool and blood Requires only a single temperature"/>
   <result pre="and blood Less time required, simple to operate, useful in" exact="disease" post="surveillance and epidemiologic research 15–45 min Cross-reaction with other"/>
   <result pre="15–45 min Cross-reaction with other subtypes of coronaviruses Point-of-care test" exact="Respiratory" post="sample Provides rapid actionable information with good sensitivity and"/>
   <result pre="reverse transcription polymerase chain reaction (RT-PCR) is routinely used in" exact="acute" post="respiratory infection to detect causative viruses from respiratory specimens."/>
   <result pre="transcription polymerase chain reaction (RT-PCR) is routinely used in acute" exact="respiratory" post="infection to detect causative viruses from respiratory specimens. The"/>
   <result pre="polymerase chain reaction (RT-PCR) is routinely used in acute respiratory" exact="infection" post="to detect causative viruses from respiratory specimens. The World"/>
   <result pre="used in acute respiratory infection to detect causative viruses from" exact="respiratory" post="specimens. The World Health Organization (WHO) recommends that patients"/>
   <result pre="detecting SARS-CoV-2 RNA have been developed worldwide, with different targeted" exact="viral" post="genes or regions (Table S1). To date, 13 and"/>
   <result pre="to the selection of sampling locations, poor sample quality, low" exact="viral" post="load of the specimen, incorrect storage and transportation, as"/>
   <result pre="asymptomatic infections. The entire test could be completed in a" exact="short" post="time, and be independent of specific equipment or places."/>
   <result pre="and 90.63% in blood samples, respectively (Li et al., 2020b)." exact="Combined" post="IgM–IgG tests provided better sensitivity than tests for only"/>
   <result pre="et al., 2020). Besides, serological testing is critically useful in" exact="disease" post="surveillance and epidemiologic research. A community seroprevalence study of"/>
   <result pre="have an immediate impact on patient management and control of" exact="infectious disease" post="epidemics (Kozel and Burnham-Marusich, 2017). At the time of"/>
   <result pre="an immediate impact on patient management and control of infectious" exact="disease" post="epidemics (Kozel and Burnham-Marusich, 2017). At the time of"/>
   <result pre="of SARS-CoV-2 (Table 2). To prevent misdiagnosis caused by insufficient" exact="viral" post="load, bronchoalveolar lavage fluid (BALF) is the most preferred"/>
   <result pre="lavage fluid (BALF) is the most preferred specimen, as the" exact="viral" post="loads of respiratory tract specimens are highest in BALF,"/>
   <result pre="is the most preferred specimen, as the viral loads of" exact="respiratory" post="tract specimens are highest in BALF, followed by sputum,"/>
   <result pre="et al., 2020). Due to the prolonged presence of SARS-CoV-2" exact="viral" post="RNA in fecal samples and potential fecal-oral transmission, fecal"/>
   <result pre="SARS-CoV-2 is highly recommended when there is virus negativity in" exact="respiratory" post="tract specimens (Wu et al., 2020). In addition, sampling"/>
   <result pre="Specimen type Positive ratea Priority of specimen Early stage/initial diagnosis" exact="Advanced" post="stage Recovery/follow-up Remarks Oropharyngeal swab 32–48% ⋆ Recommended Recommended"/>
   <result pre="stage Recovery/follow-up Remarks Oropharyngeal swab 32–48% ⋆ Recommended Recommended Recommended" exact="Viral" post="loads in the upper respiratory tract peak soon within"/>
   <result pre="swab 32–48% ⋆ Recommended Recommended Recommended Viral loads in the" exact="upper" post="respiratory tract peak soon within one week after symptom"/>
   <result pre="32–48% ⋆ Recommended Recommended Recommended Viral loads in the upper" exact="respiratory" post="tract peak soon within one week after symptom onset"/>
   <result pre="Highly recommended Highly recommended Nasopharyngeal swab samples generally show higher" exact="viral" post="loads and positive rates than oropharyngeal swab samples. Bronchoalveolar"/>
   <result pre="BALF could be collected from patients presenting with more severe" exact="disease" post="or undergoing mechanical ventilation. Sputum 72–76% Highly recommended Highly"/>
   <result pre="Highly recommend Fecal testing for SARS-CoV-2 is highly recommended after" exact="viral" post="clearance in the respiratory samples. aAll patients were confirmed"/>
   <result pre="for SARS-CoV-2 is highly recommended after viral clearance in the" exact="respiratory" post="samples. aAll patients were confirmed by SARS-CoV-2 detection (Wang"/>
   <result pre="into full consideration. Moreover, to improve the detection accuracy of" exact="infectious diseases" post="with COVID-19, proper collection of specimens is of great"/>
   <result pre="April 202032306853 GuoL.RenL.YangS.XiaoM.ChangYangF.Profiling early humoral response to diagnose novel coronavirus" exact="disease" post="(COVID-19)Clin Infect Dis2020PubMed PMID: 32198501. Pubmed Central PMCID: PMC7184472."/>
   <result pre="diagnose novel coronavirus disease (COVID-19)Clin Infect Dis2020PubMed PMID: 32198501. Pubmed" exact="Central" post="PMCID: PMC7184472. Epub 22 March 2020 KozelT.R.Burnham-MarusichA.R.Point-of-care testing for"/>
   <result pre="Central PMCID: PMC7184472. Epub 22 March 2020 KozelT.R.Burnham-MarusichA.R.Point-of-care testing for" exact="infectious" post="diseases: past, present, and futureJ Clin Microbiol558201723132320PubMed PMID: 28539345."/>
   <result pre="diseases: past, present, and futureJ Clin Microbiol558201723132320PubMed PMID: 28539345. Pubmed" exact="Central" post="PMCID: PMC5527409. Epub 26 May 201728539345 LiY.YaoL.LiJ.ChenL.SongY.CaiZ.Stability issues of"/>
   <result pre="patients clinically diagnosed with COVID-19J Med Virol2020PubMed PMID: 32219885. Pubmed" exact="Central" post="PMCID: PMC7228231. Epub 29 March 2020 LiZ.YiY.LuoX.XiongN.LiuY.LiS.Development and clinical"/>
   <result pre="application of a rapid IgM-IgG combined antibody test for SARS-CoV-2" exact="infection" post="diagnosisJ Med Virol2020PubMed PMID: 32104917. Pubmed Central PMCID: PMC7228300."/>
   <result pre="test for SARS-CoV-2 infection diagnosisJ Med Virol2020PubMed PMID: 32104917. Pubmed" exact="Central" post="PMCID: PMC7228300. Epub 28 February 2020 SoodN.SimonP.EbnerP.EichnerD.ReynoldsJ.BendavidE.Seroprevalence of SARS-CoV-2-specific"/>
   <result pre="Angeles County, California, on April 10–11, 2020JAMA2020PubMed PMID: 32421144. Pubmed" exact="Central" post="PMCID: PMC7235907. Epub 19 May 2020 WangW.XuY.GaoR.LuR.HanK.WuG.Detection of SARS-CoV-2"/>
   <result pre="SARS-CoV-2 in different types of clinical specimensJAMA2020PubMed PMID: 32159775. Pubmed" exact="Central" post="PMCID: PMC7066521. Epub 12 March 2020 WuY.GuoC.TangL.HongZ.ZhouJ.DongX.Prolonged presence of"/>
   <result pre="PMCID: PMC7066521. Epub 12 March 2020 WuY.GuoC.TangL.HongZ.ZhouJ.DongX.Prolonged presence of SARS-CoV-2" exact="viral" post="RNA in faecal samplesLancet Gastroenterol Hepatol552020434435PubMed PMID: 32199469. Pubmed"/>
   <result pre="viral RNA in faecal samplesLancet Gastroenterol Hepatol552020434435PubMed PMID: 32199469. Pubmed" exact="Central" post="PMCID: PMC7158584. Epub 23 March 202032199469 XiaoA.T.TongY.X.ZhangS.False-negative of RT-PCR"/>
   <result pre="in COVID-19: rather than recurrenceJ Med Virol2020PubMed PMID: 32270882. Pubmed" exact="Central" post="PMCID: PMC7262304. Epub 10 April 2020 XieX.ZhongZ.ZhaoW.ZhengC.WangF.LiuJ.Chest CT for"/>
   <result pre="2019-nCoV pneumonia: relationship to negative RT-PCR testingRadiology2020200343PubMed PMID: 32049601. Pubmed" exact="Central" post="PMCID: PMC7233363. Epub 13 February 2020 YanC.CuiJ.HuangL.DuB.ChenL.XueG.Rapid and visual"/>
   <result pre="Pubmed Central PMCID: PMC7233363. Epub 13 February 2020 YanC.CuiJ.HuangL.DuB.ChenL.XueG.Rapid and" exact="visual" post="detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse"/>
   <result pre="transcription loop-mediated isothermal amplification assayClin Microbiol Infect2662020773779PubMed PMID: 32276116. Pubmed" exact="Central" post="PMCID: PMC7144850. Epub 11 April 202032276116 YangY.YangM.ShenC.WangF.YuanJ.LiJ.Evaluating the accuracy"/>
   <result pre="PMC7144850. Epub 11 April 202032276116 YangY.YangM.ShenC.WangF.YuanJ.LiJ.Evaluating the accuracy of different" exact="respiratory" post="specimens in the laboratory diagnosis and monitoring the viral"/>
   <result pre="different respiratory specimens in the laboratory diagnosis and monitoring the" exact="viral" post="shedding of 2019-nCoV infectionsmedRxiv20202020.02.11.20021493 ZhuN.ZhangD.WangW.LiX.YangB.SongJ.A novel coronavirus from patients"/>
   <result pre="shedding of 2019-nCoV infectionsmedRxiv20202020.02.11.20021493 ZhuN.ZhangD.WangW.LiX.YangB.SongJ.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019New Engl J Med2020PubMed PMID: 31978945 Appendix"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7445369/results/search/disease/results.xml">
   <result pre="12 34, karger@karger.com pmcid: 7445369 doi: 10.1159/000508991ned-0001 : Review COVID-19" exact="Infection" post="and Neurological Complications: Present Findings and Future Predictions BeghiEttorea*FeiginValerybCasoValeriacSantaluciaPaoladLogroscinoGiancarloe[],"/>
   <result pre="caused by SARS-CoV-2, an influenza virus with neurotropic potential, presents" exact="with neurological manifestations" post="in a large proportion of the affected individuals. Disorders"/>
   <result pre="neurological manifestations in a large proportion of the affected individuals." exact="Disorders" post="of the central and peripheral nervous system are all"/>
   <result pre="proportion of the affected individuals. Disorders of the central and" exact="peripheral" post="nervous system are all present, while stroke, ataxia, seizures,"/>
   <result pre="severe complications are most likely elderly with medical comorbidities, especially" exact="hypertension" post="and other vascular risk factors. However, postinfectious complications are"/>
   <result pre="most likely elderly with medical comorbidities, especially hypertension and other" exact="vascular" post="risk factors. However, postinfectious complications are also expected. Neurological"/>
   <result pre="past and include symptoms, signs, and diseases occurring during the" exact="acute" post="phase and, not rarely, during follow-up. Postinfectious neurological complications"/>
   <result pre="and can explain the insurgence of immune-mediated diseases, including the" exact="Guillain-Barré syndrome" post="and other diseases of the central and peripheral nervous"/>
   <result pre="can explain the insurgence of immune-mediated diseases, including the Guillain-Barré" exact="syndrome" post="and other diseases of the central and peripheral nervous"/>
   <result pre="the Guillain-Barré syndrome and other diseases of the central and" exact="peripheral" post="nervous system that in the past occurred as complications"/>
   <result pre="nervous system that in the past occurred as complications of" exact="viral" post="infections and occasionally with vaccines. For these reasons, the"/>
   <result pre="system that in the past occurred as complications of viral" exact="infections" post="and occasionally with vaccines. For these reasons, the present"/>
   <result pre="with several millions of inhabitants. The public health system, mainly" exact="primary" post="care, needs to be strengthened to ensure that research"/>
   <result pre="treat, and prevent future epidemics. Keywords Coronavirus Neurological disorders Outbreak" exact="Infection" post="ref-count: page-count: Introduction An unexpected infection caused by a"/>
   <result pre="Coronavirus Neurological disorders Outbreak Infection ref-count: page-count: Introduction An unexpected" exact="infection" post="caused by a coronavirus, SARS-CoV-2, is devastating the health"/>
   <result pre="the world population and, consequently, the global economy. Although the" exact="primary" post="manifestation of COVID-19 infection is pneumonia, there is increasing"/>
   <result pre="consequently, the global economy. Although the primary manifestation of COVID-19" exact="infection" post="is pneumonia, there is increasing evidence that suggests the"/>
   <result pre="that suggests the spread to key organs other than the" exact="respiratory" post="system, among them the central and peripheral nervous system."/>
   <result pre="other than the respiratory system, among them the central and" exact="peripheral" post="nervous system. A growing body of evidence shows that"/>
   <result pre="mechanisms. While the first action can be verified during the" exact="acute" post="phase of the disease, the second can be apparent"/>
   <result pre="apparent only after days, weeks, or even months following the" exact="acute" post="phase. Many viral infections can damage the structure and"/>
   <result pre="days, weeks, or even months following the acute phase. Many" exact="viral" post="infections can damage the structure and function of the"/>
   <result pre="weeks, or even months following the acute phase. Many viral" exact="infections" post="can damage the structure and function of the nervous"/>
   <result pre="structure and function of the nervous system, manifesting as encephalitis," exact="toxic encephalopathy," post="and postinfectious demyelinating disease [2]. Coronaviruses can invade the"/>
   <result pre="the nervous system, manifesting as encephalitis, toxic encephalopathy, and postinfectious" exact="demyelinating disease" post="[2]. Coronaviruses can invade the nervous tissues involving immune-functioning"/>
   <result pre="nervous system, manifesting as encephalitis, toxic encephalopathy, and postinfectious demyelinating" exact="disease" post="[2]. Coronaviruses can invade the nervous tissues involving immune-functioning"/>
   <result pre="tissues involving immune-functioning macrophages, microglia, or astrocytes [3] and cause" exact="nerve" post="damage through direct infection pathways (circulatory and neuronal), hypoxia,"/>
   <result pre="microglia, or astrocytes [3] and cause nerve damage through direct" exact="infection" post="pathways (circulatory and neuronal), hypoxia, immune injury, attack to"/>
   <result pre="long-term neurological complications. Present Findings on the Association between COVID-19" exact="Infection" post="and the Occurrence of Neurological Disorders In one of"/>
   <result pre="the Association between COVID-19 Infection and the Occurrence of Neurological" exact="Disorders" post="In one of the first reports on neurological findings"/>
   <result pre="present in 78/214 patients (36.4%) and fell into 3 categories:" exact="central nervous system" post="(dizziness, headache, impaired consciousness, acute cerebrovascular disease, ataxia, and"/>
   <result pre="into 3 categories: central nervous system (dizziness, headache, impaired consciousness," exact="acute" post="cerebrovascular disease, ataxia, and seizure), peripheral nervous system (taste"/>
   <result pre="3 categories: central nervous system (dizziness, headache, impaired consciousness, acute" exact="cerebrovascular disease," post="ataxia, and seizure), peripheral nervous system (taste impairment, smell"/>
   <result pre="(dizziness, headache, impaired consciousness, acute cerebrovascular disease, ataxia, and seizure)," exact="peripheral" post="nervous system (taste impairment, smell impairment, vision impairment, and"/>
   <result pre="ataxia, and seizure), peripheral nervous system (taste impairment, smell impairment," exact="vision impairment," post="and nerve pain), and muscular-skeletal [5]. Stroke, ataxia, seizures,"/>
   <result pre="peripheral nervous system (taste impairment, smell impairment, vision impairment, and" exact="nerve" post="pain), and muscular-skeletal [5]. Stroke, ataxia, seizures, and depressed"/>
   <result pre="a single center in Wuhan, 11/221 patients with COVID-19 developed" exact="acute" post="ischemic stroke, 1 cerebral venous sinus thrombosis, and 1"/>
   <result pre="Wuhan, 11/221 patients with COVID-19 developed acute ischemic stroke, 1" exact="cerebral" post="venous sinus thrombosis, and 1 cerebral hemorrhage. However, patients"/>
   <result pre="acute ischemic stroke, 1 cerebral venous sinus thrombosis, and 1" exact="cerebral hemorrhage." post="However, patients with these severe complications are more likely"/>
   <result pre="more likely to be elderly and present medical comorbidities, especially" exact="vascular" post="risk factors such as hypertension [6]. Hypoxic encephalopathy has"/>
   <result pre="and present medical comorbidities, especially vascular risk factors such as" exact="hypertension" post="[6]. Hypoxic encephalopathy has been diagnosed in 20% of"/>
   <result pre="comorbidities, especially vascular risk factors such as hypertension [6]. Hypoxic" exact="encephalopathy" post="has been diagnosed in 20% of 113 deceased patients"/>
   <result pre="31% incidence of thrombotic complications in ICU patients with COVID-19" exact="infection" post="has been documented in 184 ICU patients with proven"/>
   <result pre="In a meta-analysis of 6 studies in patients with COVID-19," exact="cerebrovascular disease" post="was identified as a risk factor along with hypertension,"/>
   <result pre="a meta-analysis of 6 studies in patients with COVID-19, cerebrovascular" exact="disease" post="was identified as a risk factor along with hypertension,"/>
   <result pre="was identified as a risk factor along with hypertension, diabetes," exact="chronic" post="obstructive pulmonary disease, and cardiovascular disease [9]. Other neurological"/>
   <result pre="as a risk factor along with hypertension, diabetes, chronic obstructive" exact="pulmonary" post="disease, and cardiovascular disease [9]. Other neurological features were"/>
   <result pre="factor along with hypertension, diabetes, chronic obstructive pulmonary disease, and" exact="cardiovascular disease" post="[9]. Other neurological features were observed in severe cases,"/>
   <result pre="along with hypertension, diabetes, chronic obstructive pulmonary disease, and cardiovascular" exact="disease" post="[9]. Other neurological features were observed in severe cases,"/>
   <result pre="Other neurological features were observed in severe cases, including confusion," exact="diffuse" post="corticospinal tract signs, and dysexecutive syndrome [10]. A complete"/>
   <result pre="severe cases, including confusion, diffuse corticospinal tract signs, and dysexecutive" exact="syndrome" post="[10]. A complete assessment of neurological signs is often"/>
   <result pre="confusion, diffuse corticospinal tract signs, and dysexecutive syndrome [10]. A" exact="complete" post="assessment of neurological signs is often difficult because of"/>
   <result pre="often difficult because of drug-induced neuromuscular blockade or early death." exact="Acute" post="inflammatory demyelinating polyneuropathy [11] and Miller-Fisher syndrome [12] were"/>
   <result pre="because of drug-induced neuromuscular blockade or early death. Acute inflammatory" exact="demyelinating" post="polyneuropathy [11] and Miller-Fisher syndrome [12] were also observed."/>
   <result pre="of drug-induced neuromuscular blockade or early death. Acute inflammatory demyelinating" exact="polyneuropathy" post="[11] and Miller-Fisher syndrome [12] were also observed. The"/>
   <result pre="blockade or early death. Acute inflammatory demyelinating polyneuropathy [11] and" exact="Miller-Fisher syndrome" post="[12] were also observed. The occurrence of cerebrovascular events"/>
   <result pre="or early death. Acute inflammatory demyelinating polyneuropathy [11] and Miller-Fisher" exact="syndrome" post="[12] were also observed. The occurrence of cerebrovascular events"/>
   <result pre="also observed. The occurrence of cerebrovascular events in patients with" exact="arterial hypertension" post="and cardiovascular disease might be related to a direct"/>
   <result pre="observed. The occurrence of cerebrovascular events in patients with arterial" exact="hypertension" post="and cardiovascular disease might be related to a direct"/>
   <result pre="occurrence of cerebrovascular events in patients with arterial hypertension and" exact="cardiovascular disease" post="might be related to a direct effect of the"/>
   <result pre="of cerebrovascular events in patients with arterial hypertension and cardiovascular" exact="disease" post="might be related to a direct effect of the"/>
   <result pre="disease might be related to a direct effect of the" exact="infection" post="itself or an inappropriate host response. However, in case"/>
   <result pre="Lessons from the Past Neurological complications as sequelae of influenza" exact="infection" post="have been documented for over a century. In an"/>
   <result pre="the pandemic and postulated that influenza &quot;attacked more particularly the" exact="nerve" post="centres&quot; based on the &quot;very pronounced nerve sequelae observed.&quot;"/>
   <result pre="more particularly the nerve centres&quot; based on the &quot;very pronounced" exact="nerve" post="sequelae observed.&quot; In the discussion, the authors argued that"/>
   <result pre="(meningitis), poliomyelitis, and polio-encephalitis was more than coincidence. Most importantly," exact="encephalitis" post="lethargica and postencephalitic Parkinsonism have been closely associated with"/>
   <result pre="was more than coincidence. Most importantly, encephalitis lethargica and postencephalitic" exact="Parkinsonism" post="have been closely associated with the 1918 flu pandemic."/>
   <result pre="flu pandemic. Several other viruses have been then associated with" exact="secondary" post="Parkinsonisms. These include Coksackievirus; Japanese encephalitis B, St. Louis,"/>
   <result pre="have been then associated with secondary Parkinsonisms. These include Coksackievirus;" exact="Japanese encephalitis" post="B, St. Louis, and West Nile viruses; and HIV"/>
   <result pre="been then associated with secondary Parkinsonisms. These include Coksackievirus; Japanese" exact="encephalitis" post="B, St. Louis, and West Nile viruses; and HIV"/>
   <result pre="B, St. Louis, and West Nile viruses; and HIV [15]." exact="Viral" post="Infections and Neurological Complications Coronaviruses are not the only"/>
   <result pre="St. Louis, and West Nile viruses; and HIV [15]. Viral" exact="Infections" post="and Neurological Complications Coronaviruses are not the only viruses"/>
   <result pre="to Zika virus, serious neurological complications were observed, including microcephaly," exact="Guillain-Barré syndrome" post="(GBS), and eye infections [16]. Less frequently reported neurological"/>
   <result pre="Zika virus, serious neurological complications were observed, including microcephaly, Guillain-Barré" exact="syndrome" post="(GBS), and eye infections [16]. Less frequently reported neurological"/>
   <result pre="complications were observed, including microcephaly, Guillain-Barré syndrome (GBS), and eye" exact="infections" post="[16]. Less frequently reported neurological complications include encephalitis/meningoencephalitis, acute"/>
   <result pre="eye infections [16]. Less frequently reported neurological complications include encephalitis/meningoencephalitis," exact="acute" post="disseminated encephalomyelitis, myelitis, cerebrovascular diseases (ischemic infarction and vasculopathy),"/>
   <result pre="acute disseminated encephalomyelitis, myelitis, cerebrovascular diseases (ischemic infarction and vasculopathy)," exact="seizures" post="and encephalopathy, sensory polyneuropathy, and neuronopathy [17]. H1N1 2009"/>
   <result pre="and young adults being the most susceptible age-groups [18]. In" exact="Central" post="America and the Dominican Republic, H1N1 pandemic was lethal"/>
   <result pre="spread [20]. Many neurological symptoms have been described during the" exact="acute" post="phase, including altered mental status, seizures, and meningoencephalitis, among"/>
   <result pre="concerns. These include EV-A71, which has caused epidemics of hand-foot-and-mouth" exact="disease" post="(HFMD) in Southeast Asia, and EV-D68, which recently caused"/>
   <result pre="and EV-D68, which recently caused a large outbreak of severe" exact="lower" post="respiratory tract disease in North America [23]. HFMD is"/>
   <result pre="EV-D68, which recently caused a large outbreak of severe lower" exact="respiratory" post="tract disease in North America [23]. HFMD is associated"/>
   <result pre="recently caused a large outbreak of severe lower respiratory tract" exact="disease" post="in North America [23]. HFMD is associated with acute"/>
   <result pre="tract disease in North America [23]. HFMD is associated with" exact="acute" post="neurological disease in children and a substantial burden of"/>
   <result pre="disease in North America [23]. HFMD is associated with acute" exact="neurological disease" post="in children and a substantial burden of long-term neurological"/>
   <result pre="in North America [23]. HFMD is associated with acute neurological" exact="disease" post="in children and a substantial burden of long-term neurological"/>
   <result pre="children and a substantial burden of long-term neurological sequelae [24]." exact="Infections" post="due to these viruses are associated with severe neurological"/>
   <result pre="associated with severe neurological complications, including, in addition to HFMD," exact="aseptic meningitis," post="encephalitis, acute flaccid paralysis, and acute flaccid myelitis. Other"/>
   <result pre="neurological complications, including, in addition to HFMD, aseptic meningitis, encephalitis," exact="acute" post="flaccid paralysis, and acute flaccid myelitis. Other Coronaviruses and"/>
   <result pre="addition to HFMD, aseptic meningitis, encephalitis, acute flaccid paralysis, and" exact="acute" post="flaccid myelitis. Other Coronaviruses and Neurological Disorders Severe acute"/>
   <result pre="flaccid paralysis, and acute flaccid myelitis. Other Coronaviruses and Neurological" exact="Disorders" post="Severe acute respiratory syndrome (SARS) is a zoonotic respiratory"/>
   <result pre="paralysis, and acute flaccid myelitis. Other Coronaviruses and Neurological Disorders" exact="Severe" post="acute respiratory syndrome (SARS) is a zoonotic respiratory disease"/>
   <result pre="and acute flaccid myelitis. Other Coronaviruses and Neurological Disorders Severe" exact="acute" post="respiratory syndrome (SARS) is a zoonotic respiratory disease caused"/>
   <result pre="acute flaccid myelitis. Other Coronaviruses and Neurological Disorders Severe acute" exact="respiratory" post="syndrome (SARS) is a zoonotic respiratory disease caused by"/>
   <result pre="flaccid myelitis. Other Coronaviruses and Neurological Disorders Severe acute respiratory" exact="syndrome" post="(SARS) is a zoonotic respiratory disease caused by a"/>
   <result pre="Neurological Disorders Severe acute respiratory syndrome (SARS) is a zoonotic" exact="respiratory" post="disease caused by a coronavirus (SARS-CoV) starting in Southeast"/>
   <result pre="Disorders Severe acute respiratory syndrome (SARS) is a zoonotic respiratory" exact="disease" post="caused by a coronavirus (SARS-CoV) starting in Southeast Asia"/>
   <result pre="induce several neurological diseases, including polyneuropathy, encephalitis, and aortic ischemic" exact="stroke" post="[25]. Autopsy studies demonstrated that signs of cerebral edema"/>
   <result pre="aortic ischemic stroke [25]. Autopsy studies demonstrated that signs of" exact="cerebral edema" post="and meningeal vasodilation could be detected in most cases"/>
   <result pre="in the vessel wall, ischemic changes of neurons, demyelination of" exact="nerve" post="fibers, and SARS-CoV particles and genome sequences could be"/>
   <result pre="SARS-CoV particles and genome sequences could be detected in the" exact="brain" post="[26]. Another zoonotic disease is the Middle East respiratory"/>
   <result pre="sequences could be detected in the brain [26]. Another zoonotic" exact="disease" post="is the Middle East respiratory syndrome (MERS) that in"/>
   <result pre="the brain [26]. Another zoonotic disease is the Middle East" exact="respiratory" post="syndrome (MERS) that in 2012 marked the introduction of"/>
   <result pre="brain [26]. Another zoonotic disease is the Middle East respiratory" exact="syndrome" post="(MERS) that in 2012 marked the introduction of MERS-CoV,"/>
   <result pre="neuroinvasive, with 25.7% of patients developing insanity and 8.6% experiencing" exact="seizures" post="[27]. Neurological symptoms occurring during the infection process also"/>
   <result pre="and 8.6% experiencing seizures [27]. Neurological symptoms occurring during the" exact="infection" post="process also included disturbance of consciousness, paralysis, ischemic stroke,"/>
   <result pre="of consciousness, paralysis, ischemic stroke, GBS, and other poisoning or" exact="infectious" post="neuropathies [28]. Seropositivity for coronaviruses has been reported in"/>
   <result pre="has been reported in a variety of neurological disorders, including" exact="encephalitis" post="[29], optic neuritis [30], multiple sclerosis [31], and Parkinson's"/>
   <result pre="reported in a variety of neurological disorders, including encephalitis [29]," exact="optic neuritis" post="[30], multiple sclerosis [31], and Parkinson's disease [32]. Neurological"/>
   <result pre="in a variety of neurological disorders, including encephalitis [29], optic" exact="neuritis" post="[30], multiple sclerosis [31], and Parkinson's disease [32]. Neurological"/>
   <result pre="variety of neurological disorders, including encephalitis [29], optic neuritis [30]," exact="multiple sclerosis" post="[31], and Parkinson's disease [32]. Neurological Complications: Direct Viral"/>
   <result pre="including encephalitis [29], optic neuritis [30], multiple sclerosis [31], and" exact="Parkinson's disease" post="[32]. Neurological Complications: Direct Viral Effects versus Adverse Effects"/>
   <result pre="encephalitis [29], optic neuritis [30], multiple sclerosis [31], and Parkinson's" exact="disease" post="[32]. Neurological Complications: Direct Viral Effects versus Adverse Effects"/>
   <result pre="multiple sclerosis [31], and Parkinson's disease [32]. Neurological Complications: Direct" exact="Viral" post="Effects versus Adverse Effects of Vaccines A significantly increased"/>
   <result pre="Effects of Vaccines A significantly increased incidence of GBS after" exact="swine flu" post="vaccination in the USA in 1976 led to a"/>
   <result pre="influenza vaccine antigens may induce cross-reactive anti-ganglioside antibodies, eventually causing" exact="peripheral" post="nerve damage. During the influenza pandemic in 2009, the"/>
   <result pre="vaccine antigens may induce cross-reactive anti-ganglioside antibodies, eventually causing peripheral" exact="nerve" post="damage. During the influenza pandemic in 2009, the possible"/>
   <result pre="Complications or Stochastic Findings? The increased incidence of GBS after" exact="swine flu" post="vaccination raised several claims that the vaccine was the"/>
   <result pre="claims that the vaccine was the cause of several other" exact="infectious" post="or immune-mediated diseases, including postvaccinal encephalopathy, myelopathy, and peripheral"/>
   <result pre="other infectious or immune-mediated diseases, including postvaccinal encephalopathy, myelopathy, and" exact="peripheral" post="nerve lesions [37]. These claims led the US government"/>
   <result pre="infectious or immune-mediated diseases, including postvaccinal encephalopathy, myelopathy, and peripheral" exact="nerve" post="lesions [37]. These claims led the US government to"/>
   <result pre="provide reference data on the incidence of a number of" exact="infectious" post="and immune-mediated inflammatory neurological diseases, including encephalitis and aseptic"/>
   <result pre="a number of infectious and immune-mediated inflammatory neurological diseases, including" exact="encephalitis" post="and aseptic meningitis [38], acute transverse myelitis [39], brachial"/>
   <result pre="of infectious and immune-mediated inflammatory neurological diseases, including encephalitis and" exact="aseptic meningitis" post="[38], acute transverse myelitis [39], brachial plexus neuropathy [40],"/>
   <result pre="infectious and immune-mediated inflammatory neurological diseases, including encephalitis and aseptic" exact="meningitis" post="[38], acute transverse myelitis [39], brachial plexus neuropathy [40],"/>
   <result pre="immune-mediated inflammatory neurological diseases, including encephalitis and aseptic meningitis [38]," exact="acute" post="transverse myelitis [39], brachial plexus neuropathy [40], and GBS"/>
   <result pre="neurological diseases, including encephalitis and aseptic meningitis [38], acute transverse" exact="myelitis" post="[39], brachial plexus neuropathy [40], and GBS [41], and"/>
   <result pre="including encephalitis and aseptic meningitis [38], acute transverse myelitis [39]," exact="brachial plexus neuropathy" post="[40], and GBS [41], and calculate the excess number"/>
   <result pre="and aseptic meningitis [38], acute transverse myelitis [39], brachial plexus" exact="neuropathy" post="[40], and GBS [41], and calculate the excess number"/>
   <result pre="an etiological agent (in our case, the COVID-19) and a" exact="neurological disease." post="Problems Arising When Assessing a Cause-Effect Relationship between the"/>
   <result pre="Arising When Assessing a Cause-Effect Relationship between the Virus and" exact="Acute" post="and Long-Term Complications The unexpected clinical manifestations of the"/>
   <result pre="cause-effect relationship between the extent of contagion, development of symptoms," exact="disease" post="severity and complications, and outcome. These measures included, among"/>
   <result pre="transports, amusement places, healthcare facilities, nursing homes, etc.); (2) the" exact="uncontrolled" post="use of RT-PCR-based assays on respiratory specimens, some of"/>
   <result pre="homes, etc.); (2) the uncontrolled use of RT-PCR-based assays on" exact="respiratory" post="specimens, some of them with still unproven validity and"/>
   <result pre="be contrasted with the intrinsic heterogeneity of the interaction of" exact="viral infection" post="and host reaction, which includes (1) the reproductive number;"/>
   <result pre="contrasted with the intrinsic heterogeneity of the interaction of viral" exact="infection" post="and host reaction, which includes (1) the reproductive number;"/>
   <result pre="of treatments and treatment categories. Thus, the insurgence of a" exact="neurological disease" post="in the acute phase of the infection must be"/>
   <result pre="treatments and treatment categories. Thus, the insurgence of a neurological" exact="disease" post="in the acute phase of the infection must be"/>
   <result pre="categories. Thus, the insurgence of a neurological disease in the" exact="acute" post="phase of the infection must be assessed in the"/>
   <result pre="of a neurological disease in the acute phase of the" exact="infection" post="must be assessed in the light of this complex"/>
   <result pre="of this complex scenario, in order to verify whether the" exact="disease" post="is the direct effect of the viral aggression (meningitis,"/>
   <result pre="verify whether the disease is the direct effect of the" exact="viral" post="aggression (meningitis, encephalitis, or acute encephalopathy) or an indirect,"/>
   <result pre="the direct effect of the viral aggression (meningitis, encephalitis, or" exact="acute" post="encephalopathy) or an indirect, immune-mediated, effect. Compared to the"/>
   <result pre="in the area due to the incidence of that same" exact="disease" post="in the general population. Preventive Measures and Treatments The"/>
   <result pre="and proper treatment. This might have occurred for people with" exact="stroke" post="[42, 43] and can be expected for other conditions"/>
   <result pre="contagion or who presented with general or neurological manifestations of" exact="infection" post="had perhaps a negative impact on the introduction of"/>
   <result pre="others, the measurement of D-dimer at the onset of the" exact="infection" post="to prevent thrombosis [44]. Last, the uncontrolled use of"/>
   <result pre="of D-dimer at the onset of the infection to prevent" exact="thrombosis" post="[44]. Last, the uncontrolled use of several drugs without"/>
   <result pre="onset of the infection to prevent thrombosis [44]. Last, the" exact="uncontrolled" post="use of several drugs without waiting for the results"/>
   <result pre="COVID-19 is entirely based on clinical series that, in the" exact="absence of" post="controls and a population base, give us only a"/>
   <result pre="one of these disorders considering that the incidence of the" exact="disease" post="has been calculated in several countries in all continents"/>
   <result pre="Health Metrics and Evaluation, site of the Global Burden of" exact="Disease" post="(GBD) Collaboration, has developed projections of resource utilization in"/>
   <result pre="at risk of incurring the most severe complications of the" exact="infectious disease," post="and, conversely, the infection itself might be a source"/>
   <result pre="most severe complications of the infectious disease, and, conversely, the" exact="infection" post="itself might be a source of neurological complications. These"/>
   <result pre="complications. These observations have profound reflections on the management of" exact="acute" post="neurological conditions like stroke and chronic conditions like multiple"/>
   <result pre="profound reflections on the management of acute neurological conditions like" exact="stroke" post="and chronic conditions like multiple sclerosis, neurodegenerative disorders, and"/>
   <result pre="on the management of acute neurological conditions like stroke and" exact="chronic" post="conditions like multiple sclerosis, neurodegenerative disorders, and myasthenia gravis."/>
   <result pre="of acute neurological conditions like stroke and chronic conditions like" exact="multiple sclerosis," post="neurodegenerative disorders, and myasthenia gravis. Furthermore, the implementation of"/>
   <result pre="stroke and chronic conditions like multiple sclerosis, neurodegenerative disorders, and" exact="myasthenia gravis." post="Furthermore, the implementation of social distancing and interruption of"/>
   <result pre="have induced significant problems in the clinical care of several" exact="chronic" post="neurological conditions. The likely worsening of the outcomes of"/>
   <result pre="to medical care is part of the impact of COVID-19" exact="infection" post="that should be measured [48]. Curbing the impact of"/>
   <result pre="that should be measured [48]. Curbing the impact of future" exact="viral" post="epidemics, or comparable diseases, requires increased long-term investments in"/>
   <result pre="neuroinvasive potential of SARS-CoV2 may play a role in the" exact="respiratory" post="failure of COVID-19 patientsJ Med Virol2020Feb 27 2MichalicováABhideKBhideMKováčAHow viruses"/>
   <result pre="infiltrate the central nervous systemActa Virol201761(04)39340029186956 3Al-ObaidiMMJBahadoranAWangSMManikamRRajuCSSekaranSDDisruption of the blood" exact="brain" post="barrier is vital property of neurotropic viral infection of"/>
   <result pre="of the blood brain barrier is vital property of neurotropic" exact="viral infection" post="of the central nervous systemActa Virol201862(1)162729521099 4WuYXuXChenZDuanJHashimotoKYangLet al.Nervous system"/>
   <result pre="the blood brain barrier is vital property of neurotropic viral" exact="infection" post="of the central nervous systemActa Virol201862(1)162729521099 4WuYXuXChenZDuanJHashimotoKYangLet al.Nervous system"/>
   <result pre="the central nervous systemActa Virol201862(1)162729521099 4WuYXuXChenZDuanJHashimotoKYangLet al.Nervous system involvement after" exact="infection" post="with COVID-19 and other coronavirusesBrain Behav Immun2020Mar 30S0889-1591(20)303573 5MaoLJinHWangMHuYChenSHeQet"/>
   <result pre="Immun2020Mar 30S0889-1591(20)303573 5MaoLJinHWangMHuYChenSHeQet al.Neurologic manifestations of hospitalized patients with coronavirus" exact="disease" post="2019 in Wuhan, ChinaJAMA Neurol2020Apr 10e201127 6GuanWJNiZYHuYLiangWHOuCQHeJXet al.Clinical characteristics"/>
   <result pre="in Wuhan, ChinaJAMA Neurol2020Apr 10e201127 6GuanWJNiZYHuYLiangWHOuCQHeJXet al.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl J Med2020Apr 30382(18)17082032109013 7ChenTWuDChenHYanWYangDChenGet al.Clinical"/>
   <result pre="30382(18)17082032109013 7ChenTWuDChenHYanWYangDChenGet al.Clinical characteristics of 113 deceased patients with coronavirus" exact="disease" post="2019: retrospective studyBMJ2020Mar 26368m109132217556 8KlokFKruipMvan der MeerNArbousMGommersDKantKet al.Incidence of"/>
   <result pre="features in severe SARS-CoV-2 infectionN Engl J Med202064382(23)226870 11ToscanoGPalmeriniFRavagliaSRuizLInvernizziPCuzzoniMGet al.Guillain-Barré" exact="syndrome" post="associated with SARS-CoV-2N Engl J Med2020Apr 17 12Gutiérrez-OrtizCMéndezARodrigo-ReySSan Pedro-MurilloEBermejo-GuerreroLGordo-MañasRet"/>
   <result pre="associated with SARS-CoV-2N Engl J Med2020Apr 17 12Gutiérrez-OrtizCMéndezARodrigo-ReySSan Pedro-MurilloEBermejo-GuerreroLGordo-MañasRet al.Miller" exact="Fisher syndrome" post="and polyneuritis cranialis in COVID-19Neurology2020Apr 1710.1212/WNL.0000000000009619. doi: 10.1212/WNL. 0000000000009619."/>
   <result pre="with SARS-CoV-2N Engl J Med2020Apr 17 12Gutiérrez-OrtizCMéndezARodrigo-ReySSan Pedro-MurilloEBermejo-GuerreroLGordo-MañasRet al.Miller Fisher" exact="syndrome" post="and polyneuritis cranialis in COVID-19Neurology2020Apr 1710.1212/WNL.0000000000009619. doi: 10.1212/WNL. 0000000000009619."/>
   <result pre="COVID-19Neurology2020Apr 1710.1212/WNL.0000000000009619. doi: 10.1212/WNL. 0000000000009619. Epub ahead of print 13ZhaoHShenDZhouHLiuJChenSGuillain-Barré" exact="syndrome" post="associated with SARS-CoV-2 infection: causality or coincidence?Lancet Neurol202019(5)383432246917 14HenryJSmeyneRJJangHMillerBOkunMSParkinsonism"/>
   <result pre="clinical characteristics of deaths associated with influenza A(H1N1) pdm09 in" exact="Central" post="America and Dominican Republic 2009–2010BMC Public Health20151573426227404 20ColtartCELindseyBGhinaiIJohnsonAMHeymannDLThe Ebola"/>
   <result pre="virus diseaseCurr Infect Dis Rep201719(5)1928391498 22WongGQiuXBiYFormentyPSprecherAJacobsMet al.More challenges from Ebola:" exact="infection" post="of the central nervous systemJ Infect Dis2016214(Suppl 3)S294627707893 23BaggenJThibautHStratingJvan"/>
   <result pre="review and meta-analysisEur J Paediatr Neurol201822(5)7637329778429 25TsaiLHsiehSChangYNeurological manifestations in severe" exact="acute" post="respiratory syndromeActa Neurol Taiwan200514(3)113916252612 26GuJGongEZhangBZhengJGaoZZhongYet al.Multiple organ infection and"/>
   <result pre="and meta-analysisEur J Paediatr Neurol201822(5)7637329778429 25TsaiLHsiehSChangYNeurological manifestations in severe acute" exact="respiratory" post="syndromeActa Neurol Taiwan200514(3)113916252612 26GuJGongEZhangBZhengJGaoZZhongYet al.Multiple organ infection and the"/>
   <result pre="in severe acute respiratory syndromeActa Neurol Taiwan200514(3)113916252612 26GuJGongEZhangBZhengJGaoZZhongYet al.Multiple organ" exact="infection" post="and the pathogenesis of SARSJ Exp Med2005202(3)4152416043521 27SaadMOmraniASBaigKBahloulAElzeinFMatinMAet al.Clinical"/>
   <result pre="al.Clinical aspects and outcomes of 70 patients with Middle East" exact="respiratory" post="syndrome coronavirus infection: a single-center experience in Saudi ArabiaInt"/>
   <result pre="aspects and outcomes of 70 patients with Middle East respiratory" exact="syndrome" post="coronavirus infection: a single-center experience in Saudi ArabiaInt J"/>
   <result pre="Infect Dis201429301625303830 28KimJEHeoJHKimHOSongSHParkSSParkTHet al.Neurological complications during treatment of Middle East" exact="respiratory" post="syndromeJ Clin Neurol201713(3)2273328748673 29LiYLiHFanRWenBZhangJCaoXet al.Coronavirus infections in the central"/>
   <result pre="treatment of Middle East respiratory syndromeJ Clin Neurol201713(3)2273328748673 29LiYLiHFanRWenBZhangJCaoXet al.Coronavirus" exact="infections" post="in the central nervous system and respiratory tract show"/>
   <result pre="East respiratory syndromeJ Clin Neurol201713(3)2273328748673 29LiYLiHFanRWenBZhangJCaoXet al.Coronavirus infections in the" exact="central nervous system" post="and respiratory tract show distinct features in hospitalized childrenIntervirology201659(3)163928103598"/>
   <result pre="Neurol201713(3)2273328748673 29LiYLiHFanRWenBZhangJCaoXet al.Coronavirus infections in the central nervous system and" exact="respiratory" post="tract show distinct features in hospitalized childrenIntervirology201659(3)163928103598 30DessauRLisbyGFrederiksenJCoronaviruses in"/>
   <result pre="in hospitalized childrenIntervirology201659(3)163928103598 30DessauRLisbyGFrederiksenJCoronaviruses in spinal fluid of patients with" exact="acute" post="monosymptomatic optic neuritisActa Neurol Scand1999100(2)889110442448 31SalmiAZiolaBHoviTReunanenMAntibodies to coronaviruses OC43"/>
   <result pre="neuritisActa Neurol Scand1999100(2)889110442448 31SalmiAZiolaBHoviTReunanenMAntibodies to coronaviruses OC43 and 229E in" exact="multiple sclerosis" post="patientsNeurology198232(3)29256278362 32FazziniEFlemingJFahnSCerebrospinal fluid antibodies to coronavirus in patients with"/>
   <result pre="to coronavirus in patients with Parkinson's diseaseMov Disord19927(2)15381316552 33SchonbergerLBBregmanDJSullivan-BolyaiJZKeenlysideRAZieglerDWRetailliauHFet al.Guillain-Barre" exact="syndrome" post="following vaccination in the National Influenza Immunization Program, United"/>
   <result pre="Immunization Program, United States, 1976–1977Am J Epidemiol1979110(2)10523463869 34GaleottiFMassariMD'AlessandroRBeghiEChiòALogroscinoGet al.Risk of" exact="Guillain-Barré syndrome" post="after 2010–2011 influenza vaccinationEur J Epidemiol201328(5)4334423543123 35SejvarJJBaughmanALWiseMMorganOWPopulation incidence of"/>
   <result pre="Program, United States, 1976–1977Am J Epidemiol1979110(2)10523463869 34GaleottiFMassariMD'AlessandroRBeghiEChiòALogroscinoGet al.Risk of Guillain-Barré" exact="syndrome" post="after 2010–2011 influenza vaccinationEur J Epidemiol201328(5)4334423543123 35SejvarJJBaughmanALWiseMMorganOWPopulation incidence of"/>
   <result pre="syndrome after 2010–2011 influenza vaccinationEur J Epidemiol201328(5)4334423543123 35SejvarJJBaughmanALWiseMMorganOWPopulation incidence of" exact="Guillain-Barré" post="syndrome: a systematic review and meta-analysisNeuroepidemiology201136(2)1233321422765 36NachamkinIShadomySVMoranAPCoxNFitzgeraldCUngHet al.Anti-ganglioside antibody"/>
   <result pre="by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated" exact="Guillain-Barré" post="syndromeJ Infect Dis2008198(2)2263318522505 37PoserCNeurological complications of swine influenza vaccinationActa"/>
   <result pre="insights into vaccine-associated Guillain-Barré syndromeJ Infect Dis2008198(2)2263318522505 37PoserCNeurological complications of" exact="swine influenza" post="vaccinationActa Neurol Scand198266(4)413316128862 38BeghiENicolosiAKurlandLTMulderDWHauserWAShusterLEncephalitis and aseptic meningitis, Olmsted County,"/>
   <result pre="37PoserCNeurological complications of swine influenza vaccinationActa Neurol Scand198266(4)413316128862 38BeghiENicolosiAKurlandLTMulderDWHauserWAShusterLEncephalitis and" exact="aseptic meningitis," post="Olmsted County, Minnesota, 1950–1981: I. EpidemiologyAnn Neurol198416(3)283946148911 39BeghiEKurlandLTMulderDWIncidence of"/>
   <result pre="meningitis, Olmsted County, Minnesota, 1950–1981: I. EpidemiologyAnn Neurol198416(3)283946148911 39BeghiEKurlandLTMulderDWIncidence of" exact="acute" post="transverse myelitis in rochester, Minnesota, 1970–1980, and implications with"/>
   <result pre="County, Minnesota, 1950–1981: I. EpidemiologyAnn Neurol198416(3)283946148911 39BeghiEKurlandLTMulderDWIncidence of acute transverse" exact="myelitis" post="in rochester, Minnesota, 1970–1980, and implications with respect to"/>
   <result pre="1970–1980, and implications with respect to influenza vaccineNeuroepidemiology19821(3)17688 40BeghiEKurlandLTMulderDWNicolosiABrachial plexus" exact="neuropathy" post="in the population of Rochester, Minnesota, 1970–1981Ann Neurol198518(3)32032996415 41BeghiEKurlandLTMulderDWWiederholtWCGuillain-Barré"/>
   <result pre="transmission dynamics of SARS-CoV-2 through the postpandemic periodScience2020May 22368(6493)860832291278 46SejvarJJPfeiferDSchonbergerLBGuillain-barré" exact="syndrome" post="following influenza vaccination: causal or coincidental?Curr Infect Dis Rep201113(4)3879821681501"/>
   <result pre="MEDRXIV/2020/074732 48CapozzoRZoccolellaSMusioMBaroneRAccogliMLogroscinoGTelemedicine is a useful tool to deliver care to" exact="Amyotrophic Lateral Sclerosis" post="patients during COVID-19 pandemic: results from Southern ItalyALS &amp;amp;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7448857/results/search/disease/results.xml">
   <result pre="inhibit novel coronavirus (SARS-CoV-2) in cell culture Emerging Microbes &amp;amp;" exact="Infections" post="Y.-N. Zhang et al. ZhangYa-Nanae*ZhangQiu-Yanbc*LiXiao-Danad*XiongJinaXiaoShu-QiaWangZhenfZhangZhe-RuiaeDengCheng-LinaYangXing-LouaWeiHong-Pingahttps://orcid.org/0000-0002-3234-9616YuanZhi-MingaYeHan-Qingahttps://orcid.org/0000-0002-8895-3679ZhangBoabcf[a], Key Laboratory of Special"/>
   <result pre="Biosafety Mega-Science, Chinese Academy of SciencesWuhanPeople’s Republic of China[b], The" exact="Joint" post="Center of Translational Precision Medicine, Guangzhou Institute of Pediatrics,"/>
   <result pre="Guangzhou Women and Children’s Medical CenterGuangzhouPeople’s Republic of China[c], The" exact="Joint" post="Center of Translational Precision Medicine, Wuhan Institute of Virology,"/>
   <result pre="Academy of SciencesWuhanPeople’s Republic of China[d], School of Medicine, Hunan" exact="Normal" post="UniversityChangshaPeople’s Republic of China[e], University of Chinese Academy of"/>
   <result pre="Academy of SciencesBeijingPeople’s Republic of China[f], Drug Discovery Center for" exact="Infectious" post="Disease, Nankai UniversityTianjinPeople’s Republic of China CONTACT Han-Qing Ye"/>
   <result pre="work is properly cited. http://creativecommons.org/licenses/by/4.0/TEMI_9_1772676.pdf Abstract ABSTRACT The emerging SARS-CoV-2" exact="infection" post="associated with the outbreak of viral pneumonia in China"/>
   <result pre="ABSTRACT The emerging SARS-CoV-2 infection associated with the outbreak of" exact="viral pneumonia" post="in China is ongoing worldwide. There are no approved"/>
   <result pre="The emerging SARS-CoV-2 infection associated with the outbreak of viral" exact="pneumonia" post="in China is ongoing worldwide. There are no approved"/>
   <result pre="worldwide. There are no approved antiviral therapies to treat this" exact="viral" post="disease. Here we examined the antiviral abilities of three"/>
   <result pre="cell culture. We found that all three tested compounds inhibited" exact="viral" post="replication in Vero-E6 cells at noncytotoxic concentrations. The antiviral"/>
   <result pre="screening of antiviral compounds against newly emerging viruses to control" exact="viral infection." post="KEYWORDS Novel coronavirus alkaloid broad-spectrum antiviral 2019-nCoV SARS-CoV-2 fig-count:"/>
   <result pre="ref-count: page-count: Since the late 2019 when a cluster of" exact="pneumonia" post="associated with the emerging novel coronavirus, SARS-CoV-2 was reported"/>
   <result pre="to develop some antiviral compounds for the treatment of SARS-CoV-2" exact="infection" post="because of its high infectivity and morbidity and its"/>
   <result pre="tested antiviral activity of gemcitabine, lycorine and oxysophoridine against SARS-CoV-2" exact="infection" post="in cell culture, and chloroquine was used as a"/>
   <result pre="cells infected with SARS-CoV-2 (WIV04) [2] at a multiplicity of" exact="infection" post="(MOI) of 0.005 were treated with increased concentrations of"/>
   <result pre="of 0.005 were treated with increased concentrations of compounds. The" exact="viral" post="RNAs in cell culture media were quantified with quantitative"/>
   <result pre="0.18 and 1.36 μM, respectively. To confirm that the inhibition of" exact="viral" post="replication was not due to compound-mediated cytotoxicity, a cell"/>
   <result pre="30, respectively. We then performed indirect immunofluorescence assay (IFA) for" exact="viral" post="protein expression using anti-NP antibody to further verify the"/>
   <result pre="compounds for 24 hours. Real-time RT-PCR was used to quantify" exact="viral" post="RNA copy numbers in culture media. The cytotoxicity of"/>
   <result pre="blue, respectively. The EC50 and CC50 are displayed in the" exact="upper" post="right corner for each compound. At least three independent"/>
   <result pre="of compounds were fixed and subjected to IFA using the" exact="primary" post="antibody against NP protein of SARS-CoV-2. (C) Characterization of"/>
   <result pre="treated with increasing concentration of compounds for 72 hours, and" exact="viral" post="RNA copy numbers in culture media were quantified through"/>
   <result pre="antiviral agent against multiple RNA viruses which include Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV)"/>
   <result pre="agent against multiple RNA viruses which include Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV) [4],"/>
   <result pre="viruses which include Middle East respiratory syndrome coronavirus (MERS-CoV), severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) [4], Zika virus [5], influenza"/>
   <result pre="which include Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) [4], Zika virus [5], influenza virus"/>
   <result pre="include Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) [4], Zika virus [5], influenza virus [6]"/>
   <result pre="been demonstrated in the mice models of enterovirus and human" exact="immunodeficiency" post="virus (HIV) [7]. Additionally, the mean peak plasma concentration"/>
   <result pre="concentration of gemcitabine observed in patients with advanced non-small cell" exact="lung cancer" post="(NSCLC) could reach 17 µM after bronchial artery infusion or"/>
   <result pre="of gemcitabine observed in patients with advanced non-small cell lung" exact="cancer" post="(NSCLC) could reach 17 µM after bronchial artery infusion or"/>
   <result pre="vivo evaluation about the antiviral activity of gemcitabine against SARS-CoV-2" exact="infection" post="is going to be carried out in the near"/>
   <result pre="has various pharmacological activities, including suppression of the growth of" exact="hepatocellular carcinoma" post="[10] and colorectal cancer cells [11] by regulating apoptosis"/>
   <result pre="various pharmacological activities, including suppression of the growth of hepatocellular" exact="carcinoma" post="[10] and colorectal cancer cells [11] by regulating apoptosis"/>
   <result pre="including suppression of the growth of hepatocellular carcinoma [10] and" exact="colorectal cancer" post="cells [11] by regulating apoptosis associated with the Bcl-2/Bax/caspase-3"/>
   <result pre="suppression of the growth of hepatocellular carcinoma [10] and colorectal" exact="cancer" post="cells [11] by regulating apoptosis associated with the Bcl-2/Bax/caspase-3"/>
   <result pre="apoptosis associated with the Bcl-2/Bax/caspase-3 signalling pathway, and alleviation of" exact="spinal cord injury" post="via anti-inflammatory, anti-oxidative stress and anti-apoptosis effects [12]. In"/>
   <result pre="a new indication for oxysophoridine as a compound inhibiting SARS-CoV-2" exact="infection" post="in cell culture. To our knowledge, this is the"/>
   <result pre="in Amaryllidaceae with a wide range of biological functions for" exact="cancer" post="and infectious diseases treatment [13]. Unlike oxysophoridine, lycorine has"/>
   <result pre="with a wide range of biological functions for cancer and" exact="infectious diseases" post="treatment [13]. Unlike oxysophoridine, lycorine has been well known"/>
   <result pre="to exhibit antiviral activities against enterovirus, flaviviruses, HIV-1, SARS-CoV and" exact="hepatitis C" post="virus. Regarding the exact antiviral mechanism of lycorine, however,"/>
   <result pre="drug resistant mutations of lycorine have been identified within the" exact="viral" post="protease of enterovirus or nonstructural protein 2 K of West"/>
   <result pre="and (ii) downregulate autophagy [15] or block the elongation of" exact="viral" post="RNA translation during EV71 infection [13] to suppress viral"/>
   <result pre="or block the elongation of viral RNA translation during EV71" exact="infection" post="[13] to suppress viral replication. Altogether, we speculate that"/>
   <result pre="of viral RNA translation during EV71 infection [13] to suppress" exact="viral" post="replication. Altogether, we speculate that the mechanism behind the"/>
   <result pre="probably attributed to modulating host factors instead of directly targeting" exact="viral" post="factors. Overall, more information is needed regarding anti-SARS-CoV-2 issues"/>
   <result pre="ZhengXS, ZhaoK, ChenQJ, DengF, LiuLL, YanB, ZhanFX, WangYY, XiaoGF, ShiZL.2020A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
   <result pre="FriemanMB.2014Repurposing of clinically developed drugs for treatment of Middle East" exact="respiratory" post="syndrome coronavirus infection. Antimicrob Agents Chemother58:4885-93. doi: 10.1128/AAC.03036-1424841273 5KuivanenS,"/>
   <result pre="of clinically developed drugs for treatment of Middle East respiratory" exact="syndrome" post="coronavirus infection. Antimicrob Agents Chemother58:4885-93. doi: 10.1128/AAC.03036-1424841273 5KuivanenS, BespalovMM,"/>
   <result pre="5KuivanenS, BespalovMM, NandaniaJ, et al.Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika" exact="virus infection" post="in vitro and differentially affect cellular signaling, transcription and"/>
   <result pre="BespalovMM, NandaniaJ, et al.Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus" exact="infection" post="in vitro and differentially affect cellular signaling, transcription and"/>
   <result pre="KakkolaL, FengL, et al.Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a" exact="virus infection." post="J Biol Chem. 2012;287:35324–32. doi: 10.1074/jbc.M112.39214222910914 7LeeK, KimDE, JangKS,"/>
   <result pre="KimDE, JangKS, et al.Gemcitabine, a broad-spectrum antiviral drug, suppresses enterovirus" exact="infections" post="through innate immunity induced by the inhibition of pyrimidine"/>
   <result pre="8AlharbiAF, KratzkeRA, D’CunhaJ, et al.Gemcitabine and metabolite pharmacokinetics in advanced" exact="NSCLC" post="patients after bronchial artery infusion and intravenous infusion. Cancer"/>
   <result pre="advanced NSCLC patients after bronchial artery infusion and intravenous infusion." exact="Cancer" post="Chemother Pharmacol. 2019;83:387–391. doi: 10.1007/s00280-018-3757-730542769 9QiFH, WangZX, CaiPP, et"/>
   <result pre="and related active compounds: a review of their role on" exact="hepatitis" post="B virus infection. Drug Discov Ther. 2013;7:212–24. doi: 10.5582/ddt.2013.v7.6.21224423652"/>
   <result pre="active compounds: a review of their role on hepatitis B" exact="virus infection." post="Drug Discov Ther. 2013;7:212–24. doi: 10.5582/ddt.2013.v7.6.21224423652 10YaoXQ, ZhangYH, LongW,"/>
   <result pre="10.5582/ddt.2013.v7.6.21224423652 10YaoXQ, ZhangYH, LongW, et al.Oxysophoridine suppresses the growth of" exact="hepatocellular carcinoma" post="in mice: in vivo and cDNA microarray studies. Chin"/>
   <result pre="10YaoXQ, ZhangYH, LongW, et al.Oxysophoridine suppresses the growth of hepatocellular" exact="carcinoma" post="in mice: in vivo and cDNA microarray studies. Chin"/>
   <result pre="in vitro induction of the apoptotic effects of oxysophoridine on" exact="colorectal cancer" post="cells via the Bcl-2/Bax/caspase-3 signaling pathway. Oncol Lett. 2017;14:8000–8006.29344242"/>
   <result pre="vitro induction of the apoptotic effects of oxysophoridine on colorectal" exact="cancer" post="cells via the Bcl-2/Bax/caspase-3 signaling pathway. Oncol Lett. 2017;14:8000–8006.29344242"/>
   <result pre="pathway. Oncol Lett. 2017;14:8000–8006.29344242 12CaoZ, ChenL, LiuY, et al.Oxysophoridine rescues" exact="spinal cord injury" post="via antiinflammatory, antioxidative stress and antiapoptosis effects. Mol Med"/>
   <result pre="inhibit nuclear-to-cytoplasmic export of ribonucleoprotein (RNP) complex of highly pathogenic" exact="avian influenza" post="virus H5N1. Infl Other Respir Viruses. 2013;7:922–31. doi: 10.1111/irv.12035"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7454301/results/search/disease/results.xml">
   <result pre="Europe PMC, consistent with existing copyright protections.bbaa170.pdf Abstract Abstract Coronavirus" exact="Disease" post="2019 (COVID-19) is a sudden viral contagion that appeared"/>
   <result pre="protections.bbaa170.pdf Abstract Abstract Coronavirus Disease 2019 (COVID-19) is a sudden" exact="viral" post="contagion that appeared at the end of last year"/>
   <result pre="to worldwide health. Also in the last two decades, several" exact="viral" post="epidemics have been listed like the severe acute respiratory"/>
   <result pre="decades, several viral epidemics have been listed like the severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) in 2002/2003, the influenza H1N1"/>
   <result pre="several viral epidemics have been listed like the severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) in 2002/2003, the influenza H1N1 in"/>
   <result pre="viral epidemics have been listed like the severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) in 2002/2003, the influenza H1N1 in 2009"/>
   <result pre="the influenza H1N1 in 2009 and recently the Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) which appeared in Saudi Arabia in"/>
   <result pre="influenza H1N1 in 2009 and recently the Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) which appeared in Saudi Arabia in 2012."/>
   <result pre="to facilitate the diagnosis process and increase the accuracy of" exact="disease" post="detection in less time. The selected database contains 76"/>
   <result pre="(++RNA) viruses that hit humans and animals. It includes four" exact="primary" post="proteins which are the envelope, nucleocapsid, membrane and spike"/>
   <result pre="consideration that 229E-CoV, NL63-CoV, OC43-CoV and HKU1-CoV result in simple" exact="respiratory" post="marks like that in common cold, SARS-CoV and MERS-CoV"/>
   <result pre="in common cold, SARS-CoV and MERS-CoV cause dangerous and deadly" exact="respiratory" post="tract infections [8]. In 2002 and 2012, the flare-up"/>
   <result pre="cold, SARS-CoV and MERS-CoV cause dangerous and deadly respiratory tract" exact="infections" post="[8]. In 2002 and 2012, the flare-up of SARS"/>
   <result pre="2020. Secondly, the WHO organization named it formally as Coronavirus" exact="Disease" post="2019 (COVID-19) on 11 February 2020. At the same"/>
   <result pre="At the same time, the ICTV committee named it severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) [6, 10]. The danger"/>
   <result pre="the same time, the ICTV committee named it severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) [6, 10]. The danger of"/>
   <result pre="same time, the ICTV committee named it severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) [6, 10]. The danger of COVID-19"/>
   <result pre="quick and terrifying shape. As of 14 May 2020, a" exact="total" post="of 4 442 466 COVID-19 cases have been recorded"/>
   <result pre="by implication for the development of RBD protein as a" exact="viral" post="attachment inhibitor and vaccine. Zhou et al. [3] showed"/>
   <result pre="SARS patients. Al-Tawfiq et al. [18] discussed the asymptomatic coronavirus" exact="infection" post="through a comparison between MERS-CoV and COVID-19. Gorbalenya et"/>
   <result pre="is 99.6%. Basu et al. [23] determined characteristic features from" exact="chest" post="X-ray images and used domain extension transfer learning (DETL)"/>
   <result pre="was measured as 95.3% ± 0.02. Ozturk et al. [24] used raw" exact="chest" post="X-ray images and the DarkCovidNet model as a classifier"/>
   <result pre="et al. [25] employed both X-ray and CT images for" exact="bacterial pneumonia," post="coronavirus, COVID-19 and normal cases and used different deep"/>
   <result pre="system with high-accuracy results that can detect the type of" exact="disease" post="using its genome which leads to a rapid diagnosis"/>
   <result pre="These databases are called GenBank [28]. In this work, 76" exact="complete" post="genomes for each epidemic (COVID-19, SARS-CoV and MERS-CoV) are"/>
   <result pre="nucleotides. RNA was extracted for whole genome sequencing of the" exact="viral" post="isolate. Briefly, RNA was extracted from clarified cell culture"/>
   <result pre="Abdominal CT images: 16 × 16 − Grey-level co-occurrence matrix (GLCM) −" exact="Local" post="directional pattern (LDP) − Grey-level run length matrix (GLRLM)"/>
   <result pre="learning (ML)Deep learning (DL) 95.3% ± 0.02 Ozturk et al. [24] Raw" exact="chest" post="X-ray images: DarkCovidNet model Deep learning (DL) 98.08 −"/>
   <result pre="For the classification process, the training data consists of 46" exact="complete" post="genomes, and the testing data consists of 30 complete"/>
   <result pre="46 complete genomes, and the testing data consists of 30" exact="complete" post="genomes for each epidemic. In this step, three classification"/>
   <result pre="to set apart between COVID-19 and MERS-CoV; thirdly, building a" exact="complete" post="system to differentiate between the three pandemics; and finally,"/>
   <result pre="overall classification system. In the comparison case, getting higher ACC," exact="lower" post="error rate, higher F1 score and higher MCC is"/>
   <result pre="analyze and plan, hoping to reach medicine for this terrifying" exact="disease" post="quickly. As a result, some researchers began to compare"/>
   <result pre="to achieve new objectives in COVID-19 researches. Key Points Coronavirus" exact="Disease" post="2019 (COVID-19) is a sudden viral contagion that appeared"/>
   <result pre="researches. Key Points Coronavirus Disease 2019 (COVID-19) is a sudden" exact="viral" post="contagion that appeared at the end of last year"/>
   <result pre="novel coronavirus: implication for development of RBD protein as a" exact="viral" post="attachment inhibitor and vaccine. Cell Mol Immunol2020https://www.nature.com/articles/s41423-020-0400-4#citeas. 2.CascellaM, RajnikM,"/>
   <result pre="https://www.ncbi.nlm.nih.gov/books/NBK554776/(updated Mar 20, 2020), 2020. 3.ZhouP, YangX, WangX, et al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
   <result pre="HongZ, et al.The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreak—an update on the status. Military Med"/>
   <result pre="9.WuF, ZhaoS, YuB, et al.A new coronavirus associated with human" exact="respiratory" post="disease in China. Nature2020;579:265–9. doi: 10.1038/s41586-020-2008-3.32015508 10.PanL, MuM, YangP,"/>
   <result pre="ZhaoS, YuB, et al.A new coronavirus associated with human respiratory" exact="disease" post="in China. Nature2020;579:265–9. doi: 10.1038/s41586-020-2008-3.32015508 10.PanL, MuM, YangP, et"/>
   <result pre="Dis2020;35(101608):1–9. doi: 10.1016/j.tmaid.2020.101608. 19.GorbalenyaAE, BakerSC, BaricRS, et al.The species severe" exact="acute" post="respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2."/>
   <result pre="doi: 10.1016/j.tmaid.2020.101608. 19.GorbalenyaAE, BakerSC, BaricRS, et al.The species severe acute" exact="respiratory" post="syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat"/>
   <result pre="arXiv:2020:2003:09424, preprint. 23.BasuS, MitraS, SahaNDeep learning for screening COVID-19 using" exact="chest" post="X-ray images. arXiv:2020:2004:10507. preprint. 24.OzturkT, TaloM, et al.Automated detection"/>
   <result pre="Struct Dyn2020;1–12. doi: 10.1080/07391102.2020.1767212. 26.UdugamaB, KadhiresanP, et al.Diagnosing COVID-19: the" exact="disease" post="and tools for detection. ACS Nano2020;4:3822–55. doi: 10.1021/acsnano.0c02624. 27.TahamtanA,"/>
   <result pre="et al.Metagenomic nanopore sequencing of influenza virus direct from clinical" exact="respiratory" post="samples. J Clin Microbiol2019;58:e00963–19.31666364 30.KafetzopoulouLE, EfthymiadisK, LewandowskiK, et al.Assessment"/>
   <result pre="nanopore and illumina sequencing for recovering whole genome sequences of" exact="chikungunya" post="and dengue viruses directly from clinical samples. Euro Surveill2018;23:1800228."/>
   <result pre="−19 in Australia. Med J Aust2020;212(10):459–62.32237278 32.DasJ, BarmanSBayesian fusion in" exact="cancer" post="gene prediction. Int J Comput Appl2014;1:5–10. 33.TradCH, FangQ, CosicIProtein"/>
   <result pre="FangQ, CosicIProtein sequence comparison based on the wavelet transform approach." exact="Protein" post="Eng2002;15(3):193–203. doi: 10.1093/protein/15.3.193.11932490 34.GhoshA, BarmanSPrediction of prostate cancer cells"/>
   <result pre="wavelet transform approach. Protein Eng2002;15(3):193–203. doi: 10.1093/protein/15.3.193.11932490 34.GhoshA, BarmanSPrediction of" exact="prostate cancer" post="cells based on principal component analysis technique In: Procedia"/>
   <result pre="transform approach. Protein Eng2002;15(3):193–203. doi: 10.1093/protein/15.3.193.11932490 34.GhoshA, BarmanSPrediction of prostate" exact="cancer" post="cells based on principal component analysis technique In: Procedia"/>
   <result pre="47.Al BatainehAA comparative analysis of nonlinear machine learning algorithms for" exact="breast cancer" post="detection. Int J Mach Learn Comput2019;9(3):248–54. 48.FogliattoFS, AnzanelloMJ, SoaresF,"/>
   <result pre="BatainehAA comparative analysis of nonlinear machine learning algorithms for breast" exact="cancer" post="detection. Int J Mach Learn Comput2019;9(3):248–54. 48.FogliattoFS, AnzanelloMJ, SoaresF,"/>
   <result pre="Mach Learn Comput2019;9(3):248–54. 48.FogliattoFS, AnzanelloMJ, SoaresF, et al.Decision support for" exact="breast cancer" post="detection: classification improvement through feature selection. Cancer Control2019;26(1):1–8. doi:"/>
   <result pre="Learn Comput2019;9(3):248–54. 48.FogliattoFS, AnzanelloMJ, SoaresF, et al.Decision support for breast" exact="cancer" post="detection: classification improvement through feature selection. Cancer Control2019;26(1):1–8. doi:"/>
   <result pre="support for breast cancer detection: classification improvement through feature selection." exact="Cancer" post="Control2019;26(1):1–8. doi: 10.1177/1073274819876598. 49.MedjahedSA, SaadiTA, BenyettouABreast cancer diagnosis by"/>
   <result pre="through feature selection. Cancer Control2019;26(1):1–8. doi: 10.1177/1073274819876598. 49.MedjahedSA, SaadiTA, BenyettouABreast" exact="cancer" post="diagnosis by using k-nearest neighbor with different distances and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7454384/results/search/disease/results.xml">
   <result pre="courier ; font-style : italic;} Clin Infect DisClin. Infect. DiscidClinical" exact="Infectious" post="Diseases: An Official Publication of the Infectious Diseases Society"/>
   <result pre="DisClin. Infect. DiscidClinical Infectious Diseases: An Official Publication of the" exact="Infectious" post="Diseases Society of America1058-48381537-6591Oxford University PressUS pmcid: 7454384 pmid:"/>
   <result pre="Infect. DiscidClinical Infectious Diseases: An Official Publication of the Infectious" exact="Diseases" post="Society of America1058-48381537-6591Oxford University PressUS pmcid: 7454384 pmid: 32687168"/>
   <result pre="doi: 10.1093/cid/ciaa1028ciaa1028 : Major Article: AcademicSubjects/MED00290 Pan-Family Assays for Rapid" exact="Viral" post="Screening: Reducing Delays in Public Health Responses During Pandemics"/>
   <result pre="stages of pandemics. Here we describe a strategy utilizing pan-family" exact="viral" post="assays to improve early accessibility of large-scale nucleic acid"/>
   <result pre="were used as a case-study for assessing utility of pan-family" exact="viral" post="assays during the early stages of a novel pandemic."/>
   <result pre="asymptomatic adults, but up to 30% of immunocompromised patients with" exact="respiratory" post="disease. Half of reported Pan-CoV assays identify SARS-CoV-2 and"/>
   <result pre="of novel diseases prior to the availability of species-specific assays." exact="Viral" post="Screening Pan-Family Assays SARS-CoV-2"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7454771/results/search/disease/results.xml">
   <result pre="predictive biomarker, suggesting a need for additional biomarkers to reveal" exact="intermediate" post="hosts or tissues. The hunt for the zoonotic origin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7458341/results/search/disease/results.xml">
   <result pre=": Medicine and Health Sciences : Medical Conditions : Tropical" exact="Diseases" post=": Neglected Tropical Diseases: Dengue Fever : Medicine and"/>
   <result pre=": Medical Conditions : Tropical Diseases : Neglected Tropical Diseases:" exact="Dengue" post="Fever : Medicine and Health Sciences : Medical Conditions"/>
   <result pre="Medical Conditions : Tropical Diseases : Neglected Tropical Diseases: Dengue" exact="Fever" post=": Medicine and Health Sciences : Medical Conditions :"/>
   <result pre="Fever : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases : Viral Diseases: Dengue Fever : Medicine and"/>
   <result pre=": Medicine and Health Sciences : Medical Conditions : Infectious" exact="Diseases" post=": Viral Diseases: Dengue Fever : Medicine and Health"/>
   <result pre="and Health Sciences : Medical Conditions : Infectious Diseases :" exact="Viral" post="Diseases: Dengue Fever : Medicine and Health Sciences: Epidemiology"/>
   <result pre="Sciences : Medical Conditions : Infectious Diseases : Viral Diseases:" exact="Dengue" post="Fever : Medicine and Health Sciences: Epidemiology : Medicine"/>
   <result pre=": Medical Conditions : Infectious Diseases : Viral Diseases: Dengue" exact="Fever" post=": Medicine and Health Sciences: Epidemiology : Medicine and"/>
   <result pre="Sciences: Epidemiology : Medicine and Health Sciences : Epidemiology :" exact="Disease" post="Surveillance: Infectious Disease Surveillance : Medicine and Health Sciences"/>
   <result pre=": Medicine and Health Sciences : Epidemiology : Disease Surveillance:" exact="Infectious" post="Disease Surveillance : Medicine and Health Sciences : Medical"/>
   <result pre="Medicine and Health Sciences : Epidemiology : Disease Surveillance: Infectious" exact="Disease" post="Surveillance : Medicine and Health Sciences : Medical Conditions"/>
   <result pre="Surveillance : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases : Infectious Disease Control: Infectious Disease Surveillance :"/>
   <result pre=": Medicine and Health Sciences : Medical Conditions : Infectious" exact="Diseases" post=": Infectious Disease Control: Infectious Disease Surveillance : Biology"/>
   <result pre="and Health Sciences : Medical Conditions : Infectious Diseases :" exact="Infectious" post="Disease Control: Infectious Disease Surveillance : Biology and life"/>
   <result pre="Health Sciences : Medical Conditions : Infectious Diseases : Infectious" exact="Disease" post="Control: Infectious Disease Surveillance : Biology and life sciences"/>
   <result pre=": Medical Conditions : Infectious Diseases : Infectious Disease Control:" exact="Infectious" post="Disease Surveillance : Biology and life sciences : Organisms"/>
   <result pre="Medical Conditions : Infectious Diseases : Infectious Disease Control: Infectious" exact="Disease" post="Surveillance : Biology and life sciences : Organisms :"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Sciences : Microbiology : Medical Microbiology : Microbial Pathogens :" exact="Viral" post="Pathogens : Flaviviruses: Dengue Virus : Medicine and Health"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre="Pathology and Laboratory Medicine : Pathogens : Microbial Pathogens :" exact="Viral" post="Pathogens : Flaviviruses: Dengue Virus : Biology and Life"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre=": Biology and Life Sciences : Organisms : Viruses :" exact="Viral" post="Pathogens : Flaviviruses: Dengue Virus : People and places"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : People and places : Geographical locations :"/>
   <result pre="People and places : Geographical locations : North America :" exact="Central" post="America: Guatemala : People and Places : Population Groupings:"/>
   <result pre="Public and Occupational Health : Research and Analysis Methods :" exact="Immunologic" post="Techniques : Immunoassays: Enzyme-Linked Immunoassays Epidemiology of dengue fever"/>
   <result pre="Methods : Immunologic Techniques : Immunoassays: Enzyme-Linked Immunoassays Epidemiology of" exact="dengue fever" post="in Guatemala Dengue in Guatemala Castillo SignorLeticia del CarmenConceptualizationData"/>
   <result pre=": Immunoassays: Enzyme-Linked Immunoassays Epidemiology of dengue fever in Guatemala" exact="Dengue" post="in Guatemala Castillo SignorLeticia del CarmenConceptualizationData curationFunding acquisitionInvestigationProject administrationValidationWriting"/>
   <result pre="Liverpool School of Tropical Medicine, Liverpool, United KingdomAlthouseBenjaminEditor[], Institute for" exact="Disease" post="Modeling, UNITED STATES The authors have declared that no"/>
   <result pre="medium, provided the original author and source are credited.pntd.0008535.pdf Abstract" exact="Dengue" post="fever occurs worldwide and about 1% of cases progress"/>
   <result pre="about 1% of cases progress to severe haemorrhage and shock." exact="Dengue" post="is endemic in Guatemala and its surveillance system could"/>
   <result pre="serotype adjusted by age and gender. 91,554 samples were tested." exact="Dengue" post="was confirmed by RT-qPCR, culture or NS1-ELISA in 7097"/>
   <result pre="the 2010 DENV2 and 2003 DENV3 outbreaks. Adults had a" exact="lower" post="incidence immediately after epidemics, which is likely linked to"/>
   <result pre="epidemics, which is likely linked to increased immunity. Author summary" exact="Dengue" post="is the most common mosquito-borne virus, and a major"/>
   <result pre="a major cause of fever, with an estimated 390 million" exact="infections" post="annually. Guatemala, in Central America, has had ongoing dengue"/>
   <result pre="fever, with an estimated 390 million infections annually. Guatemala, in" exact="Central" post="America, has had ongoing dengue transmission since the 1990s."/>
   <result pre="Its national surveillance system monitors outbreaks and seasonal trends of" exact="infections" post="to inform public health responses. We have analysed 17"/>
   <result pre="This is important, as it increases the likelihood of dengue" exact="infections" post="being followed by a new infection with a different"/>
   <result pre="the likelihood of dengue infections being followed by a new" exact="infection" post="with a different serotype, which can lead to severe"/>
   <result pre="new infection with a different serotype, which can lead to" exact="severe dengue." post="We also report that adults in Guatemala have a"/>
   <result pre="dengue. We also report that adults in Guatemala have a" exact="lower" post="likelihood of infection the year after an epidemic, which"/>
   <result pre="report that adults in Guatemala have a lower likelihood of" exact="infection" post="the year after an epidemic, which might be linked"/>
   <result pre="emailing Dr Julia Martin, Head of Information Services (Julia.Martin@lstmed.ac.uk). Introduction" exact="Dengue" post="is widespread across the tropics with up to 3.97"/>
   <result pre="at risk of transmission [1], with an estimated 390 million" exact="infections" post="occurring each year [2]. Its extensive geographical range and"/>
   <result pre="changing yearly patterns and fluctuating levels of serotype-specific immunity [12]." exact="Infection" post="with one serotype provides serotype-specific immunity without significant cross"/>
   <result pre="without significant cross protection for other serotypes and a follow-on" exact="infection" post="with a different DENV serotype carries an increased risk"/>
   <result pre="with a different DENV serotype carries an increased risk of" exact="disease" post="severity through antibody mediated enhancement [13]. Surveillance of the"/>
   <result pre="serotypes and outbreaks is essential to forecast the risk of" exact="disease" post="burden and to enable reactive measures such as vector"/>
   <result pre="are similar and serological diagnostics of flaviviruses cross react [16]." exact="Dengue" post="had a low incidence and was not considered a"/>
   <result pre="the twentieth century, possibly as a by-product of the national" exact="malaria" post="and yellow fever eradication campaigns [17]. However dengue viruses"/>
   <result pre="century, possibly as a by-product of the national malaria and" exact="yellow fever" post="eradication campaigns [17]. However dengue viruses were reported since"/>
   <result pre="serotypes in the country. Methods Ethics statement This analysis used" exact="secondary" post="sources of data collected for surveillance purposes and ethical"/>
   <result pre="were anonymised prior to analysis. National surveillance Surveillance of arboviral" exact="infections" post="in Guatemala is conducted by the National Epidemiology Centre"/>
   <result pre="of the Ministry of Health. The surveillance network comprises 340" exact="primary" post="care centres and 44 hospitals situated in the 29"/>
   <result pre="cases. The laboratory has the capacity to test for dengue," exact="chikungunya" post="and Zika infections, with the aim of testing samples"/>
   <result pre="three viruses, except during outbreaks, when the most likely causative" exact="infection" post="is prioritised. The LNS reports surveillance data to the"/>
   <result pre="and serious cases are in turn reported to the Pan" exact="American" post="Health Organisation, along with monthly reports of passive surveillance"/>
   <result pre="displacement to receive health services. Diagnostic algorithms and case definitions" exact="Dengue" post="case definitions have changed with the advent of new"/>
   <result pre="detect DENV antigens in serum, and since 2010 testing of" exact="acute" post="cases has utilised the Centers for Disease Control (CDC)"/>
   <result pre="2010 testing of acute cases has utilised the Centers for" exact="Disease" post="Control (CDC) DENV 1–4 RT-qPCR assay that serotypes the"/>
   <result pre="this assay are reported here as &quot;probable cases&quot;. Results A" exact="total" post="of 91,554 samples were received by the LNS from"/>
   <result pre="number of samples received varied over the years (Fig 1)." exact="Dengue" post="infection was confirmed by RT-qPCR, viral culture or NS1"/>
   <result pre="of samples received varied over the years (Fig 1). Dengue" exact="infection" post="was confirmed by RT-qPCR, viral culture or NS1 ELISA"/>
   <result pre="the years (Fig 1). Dengue infection was confirmed by RT-qPCR," exact="viral" post="culture or NS1 ELISA in 7097 (7.8%) samples and"/>
   <result pre="by NS1 ELISA but not serotyped are designated DENV unknown." exact="Dengue" post="affected populations of all ages, with an average of"/>
   <result pre="and subsequent year (DENV 2 versus all DENV) Age Group" exact="Epidemic" post="year vs subsequent year Incidence Ratio (95% CI*), p-value"/>
   <result pre="2011 1.93 (0.57;6.46), 0.8034 * Confidence Interval ** Significant, DENV:" exact="Dengue" post="virus. Some Departments (districts) provided health services to neighbouring"/>
   <result pre="being highest in Zacapa. In contrast, the Departments in the" exact="Central" post="Highlands of the country, such as Sololá, Chimaltenango, Retalhuleu,"/>
   <result pre="high proportion of samples were dengue-positive (Fig 5). Fig 5" exact="Geographic" post="distribution of dengue in Guatemala (2000–2016). A. Number of"/>
   <result pre="data from Wikipedia: Departments of Guatemala, 2011 population estimate). Discussion" exact="Central" post="America has a considerable burden of dengue, with an"/>
   <result pre="and 586.3 cases per 100,000 inhabitants in South America [22]." exact="Dengue" post="is hyperendemic, and seasonal in Guatemala with simultaneous circulation"/>
   <result pre="simultaneous circulation of all DENV serotypes [23]. In Guatemala, most" exact="infections" post="were caused by DENV1 and DENV2, followed by DENV3"/>
   <result pre="by DENV3 and DENV4, which mirrors reports from other Pan" exact="American" post="Health Organization regions. The co-circulation of all four DENV"/>
   <result pre="of all four DENV serotypes increases the risk of second" exact="infections" post="[24] with a different serotype, which leads to a"/>
   <result pre="a different serotype, which leads to a higher risk of" exact="severe dengue" post="[25]. Whilst previous DENV exposure can lead to the"/>
   <result pre="[27], which have been shown to increase dengue transmission in" exact="Central" post="America [28]. The understanding of the seasonality of dengue"/>
   <result pre="epidemic in Guatemala coincided with simultaneous DENV2 outbreaks across other" exact="Central" post="and South American countries, with over 1.6 million reported"/>
   <result pre="coincided with simultaneous DENV2 outbreaks across other Central and South" exact="American" post="countries, with over 1.6 million reported cases [17]. Neighbouring"/>
   <result pre="to DENV2 [17]. The 2010 epidemic was followed by a" exact="lower" post="incidence in the 5–20 and 20–60 age groups. The"/>
   <result pre="[26] is thought to reflect herd immunity afforded by previous" exact="infection" post="with the same serotype. Although it is widely believed"/>
   <result pre="with the same serotype. Although it is widely believed that" exact="infection" post="by a serotype confers lifelong immunity thanks to the"/>
   <result pre="heterologous neutralising antibodies, recent studies describing homotypic re-infections in the" exact="short" post="and long term have challenged this concept [32],[33]. This"/>
   <result pre="term have challenged this concept [32],[33]. This suggests mechanisms facilitating" exact="viral" post="evasion of the host immune system, escaping recognition or"/>
   <result pre="notably high in 2015 and 2016, coinciding with the large" exact="chikungunya" post="[35] and zika [36] epidemics in the country. These"/>
   <result pre="common causes of fever compatible with dengue in the Latin" exact="American" post="region include leptospirosis, typhoid fever, influenza, Rickettsiosis and less"/>
   <result pre="compatible with dengue in the Latin American region include leptospirosis," exact="typhoid fever," post="influenza, Rickettsiosis and less common arboviruses such as Oropouche"/>
   <result pre="as potential dengue cases in surveillance laboratories. Testing samples using" exact="syndromic" post="panels that include a wider range of pathogens is"/>
   <result pre="and parallel epidemics are well documented. For example, dengue and" exact="chikungunya" post="co-circulated in Guatemala, with a report indicating that both"/>
   <result pre="Trioplex [20] has simplified testing algorithms and improved detection of" exact="acute" post="co-infections. However, serological tests still struggle to differentiate between"/>
   <result pre="tests still struggle to differentiate between DENV and Zika virus" exact="infections" post="[39], which may have inflated the number of probable"/>
   <result pre="the cost of implementing active case detection strategies for a" exact="disease" post="with no specific treatment and limited vaccine uptake. Passive"/>
   <result pre="detection strategies for a disease with no specific treatment and" exact="limited" post="vaccine uptake. Passive surveillance for dengue in Latin America"/>
   <result pre="and hospital services, adding bias to epidemiological data, particularly regarding" exact="disease" post="severity and patient outcomes. It has been estimated that"/>
   <result pre="varied case definitions used to select the samples for screening." exact="Dengue" post="is the most prevalent mosquito-transmitted infection worldwide and causes"/>
   <result pre="the samples for screening. Dengue is the most prevalent mosquito-transmitted" exact="infection" post="worldwide and causes important economic and human costs [45]."/>
   <result pre="provide insights into the present and past epidemiology of the" exact="disease" post="at a country level [31, 46], and is essential"/>
   <result pre="numbers of monthly cases during the period 2000–2016. Minimum expected:" exact="lower" post="limit of values from the confidence intervals of the"/>
   <result pre="burden of dengue: an analysis from the Global Burden of" exact="Disease" post="Study 2013. Lancet Infect Dis. 2016; 16(6):712–23. 10.1016/S1473-3099(16)00026-826874619 4ShepardDS,"/>
   <result pre="ArmengaudA, Peloux-PetiotF, DelaunayP, DespresP, et al.First two autochthonous dengue virus" exact="infections" post="in metropolitan France, September 2010. Euro Surveill. 2010;15(39):1967620929659 8Gjenero-MarganI,"/>
   <result pre="Surveill. 2010;15(39):1967620929659 8Gjenero-MarganI, AlerajB, KrajcarD, LesnikarV, KlobucarA, Pem-NovoselI, et al.Autochthonous" exact="dengue fever" post="in Croatia, August-September 2010. Euro surveill. 2011;16(9). 9RadkeEG, GregoryCJ,"/>
   <result pre="EngleRE, St. ClaireM, PurcellRH, LaiC-J. Monoclonal antibody-mediated enhancement of dengue" exact="virus infection" post="in vitro and in vivo and strategies for prevention."/>
   <result pre="St. ClaireM, PurcellRH, LaiC-J. Monoclonal antibody-mediated enhancement of dengue virus" exact="infection" post="in vitro and in vivo and strategies for prevention."/>
   <result pre="Int J Infect Dis. 2016;44:44–9. 10.1016/j.ijid.2016.01.01526836763 15PaixãoES, TeixeiraMG, RodriguesLC. Zika," exact="chikungunya" post="and dengue: the causes and threats of new and"/>
   <result pre="Am J Trop Med Hyg. 2012;87(4):584–93. 10.4269/ajtmh.2012.11-077023042846 18WilsonME, ChenL. H." exact="Dengue" post="in the Americas. Dengue Bulletin. 2002;26:44–61. 19SantiagoGA, VergneE, QuilesY,"/>
   <result pre="Hyg. 2012;87(4):584–93. 10.4269/ajtmh.2012.11-077023042846 18WilsonME, ChenL. H. Dengue in the Americas." exact="Dengue" post="Bulletin. 2002;26:44–61. 19SantiagoGA, VergneE, QuilesY, CosmeJ, VazquezJ, MedinaJF, et"/>
   <result pre="Trioplex real-time RT-PCR assay for detection of Zika, dengue, and" exact="chikungunya" post="viruses. Nat Comms. 2018;9(1):1391. 21HunspergerEA, YoksanS, BuchyP, NguyenVC, SekaranSD,"/>
   <result pre="virus IgM antibody. PLoS Neglect Trop Dis. 2014;8(10):e3171. 22collab: Pan" exact="American" post="Health Organisation. PLISA Health Information Platform for the Americas."/>
   <result pre="23Ramos-CastañedaJ, Barreto dos SantosF, Martínez-VegaR, Galvão de AraujoJM, JointG, SartiE." exact="Dengue" post="in Latin America: systematic review of molecular epidemiological trends."/>
   <result pre="et al.Co-circulation of all four dengue virus serotypes with concurrent" exact="infections" post="in a single dengue season. Int J Infect Dis."/>
   <result pre="dengue season. Int J Infect Dis. 2016;45:446. 25GuzmanMG, AlvarezM, HalsteadSB." exact="Secondary" post="infection as a risk factor for dengue hemorrhagic fever/dengue"/>
   <result pre="season. Int J Infect Dis. 2016;45:446. 25GuzmanMG, AlvarezM, HalsteadSB. Secondary" exact="infection" post="as a risk factor for dengue hemorrhagic fever/dengue shock"/>
   <result pre="distribution of the association between El Nino South Oscillation and" exact="dengue fever" post="in the Americas: a continental analysis using geographical information"/>
   <result pre="health. 2014;9(1):141–51. 28AnyambaA, ChretienJ-P, BritchSC, SoebiyantoRP, SmallJL, JepsenR, et al.Global" exact="disease" post="outbreaks associated with the 2015–2016 El Niño event. Sci"/>
   <result pre="10.1038/s41598-018-38034-z30760757 29SippyR, HerreraD, GausD, GangnonRE, PatzJA, OsorioJE. Seasonal patterns of" exact="dengue fever" post="in rural Ecuador: 2009–2016. PLoS Neglect Trop Dis. 2019;13(5):e0007360."/>
   <result pre="OlkowskiS, MorrisonAC, EspinozaA, LongKC, et al.Incomplete protection against dengue virus" exact="type 2" post="re-infection in Peru. PLoS Neglect Trop Dis. 2016;10(2):e0004398. 34UnoN,"/>
   <result pre="re-infection in Peru. PLoS Neglect Trop Dis. 2016;10(2):e0004398. 34UnoN, RossTM." exact="Dengue" post="virus and the host innate immune response. Emerg Microb"/>
   <result pre="Infect. 2018;7(1):167. 35EdwardsT, SignorLD, WilliamsC, DonisE, CuevasLE, AdamsER. Co-infections with" exact="chikungunya" post="and dengue viruses, Guatemala, 2015. Emerg Infect Dis. 2016;22(11):2003–5."/>
   <result pre="Wkly Rep. 2016;65(3):55–8. 10.15585/mmwr.mm6503e126820163 37MoreiraJ, BressanCS, BrasilP, SiqueiraAM. Epidemiology of" exact="acute" post="febrile illness in Latin America. Clin Microbiol Infect. 2018;24(8):827–35."/>
   <result pre="ChangG-JJ. Comprehensive Evaluation of Differential Serodiagnosis between Zika and dengue" exact="viral" post="infections. J Clin Microbiol. 2019;57(3):e01506–18. 10.1128/JCM.01506-1830541932 40GibbonsCL, MangenM-JJ, PlassD,"/>
   <result pre="PlassD, HavelaarAH, BrookeRJ, KramarzP, et al.Measuring underreporting and under-ascertainment in" exact="infectious disease" post="datasets: a comparison of methods. BMC public health. 2014;14:14710.1186/1471-2458-14-14724517715"/>
   <result pre="HavelaarAH, BrookeRJ, KramarzP, et al.Measuring underreporting and under-ascertainment in infectious" exact="disease" post="datasets: a comparison of methods. BMC public health. 2014;14:14710.1186/1471-2458-14-14724517715"/>
   <result pre="2011;84(2):200–7. 10.4269/ajtmh.2011.10-050321292885 42LasernaA, Barahona-CorreaJ, BaqueroL, Castañeda-CardonaC, RosselliD. Economic impact of" exact="dengue fever" post="in Latin America and the Caribbean: a systematic review."/>
   <result pre="review. Rev Panam Salud Publica. 2018;42:e11110.26633/RPSP.2018.11131093139 43Runge‐RanzingerS, McCallPJ, KroegerA, HorstickO." exact="Dengue" post="disease surveillance: an updated systematic literature review. Trop Med"/>
   <result pre="Rev Panam Salud Publica. 2018;42:e11110.26633/RPSP.2018.11131093139 43Runge‐RanzingerS, McCallPJ, KroegerA, HorstickO. Dengue" exact="disease" post="surveillance: an updated systematic literature review. Trop Med Int"/>
   <result pre="review. PloS one. 2019;14(2):e021140110.1371/journal.pone.021140130785894 46RaclozV, RamseyR, TongS, HuW. Surveillance of" exact="dengue fever" post="virus: a review of epidemiological models and early warning"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7459150/results/search/disease/results.xml">
   <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7461001/results/search/disease/results.xml">
   <result pre="doi: 10.1002/pa.2306PA2306 : Academic Paper: Academic Papers Mathematical modeling for" exact="infectious" post="viral disease: The COVID‐19 perspective Adekola et al. AdekolaHafeez"/>
   <result pre="10.1002/pa.2306PA2306 : Academic Paper: Academic Papers Mathematical modeling for infectious" exact="viral" post="disease: The COVID‐19 perspective Adekola et al. AdekolaHafeez Aderinsayo1*AdekunleIbrahim"/>
   <result pre=", This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
   <result pre="of COVID‐19 transmission mechanisms, structures, and features. Considering that the" exact="disease" post="has spread sporadically around the world, causing large scale"/>
   <result pre="actively engaged in finding ways to reduce the rate of" exact="infection" post="until a cure or vaccination procedure is established. We"/>
   <result pre="understanding the transmission dynamics and other significant factors of the" exact="disease" post="that would aid policymakers to make accurate decisions and"/>
   <result pre="page-count: word-count: AdekolaHA, AdekunleIA, EgberongbeHO, OnitiloSA, AbdullahiIN. Mathematical modeling for" exact="infectious" post="viral disease: The COVID‐19 perspective. J Public Affairs. 2020;e230610.1002/pa.2306"/>
   <result pre="word-count: AdekolaHA, AdekunleIA, EgberongbeHO, OnitiloSA, AbdullahiIN. Mathematical modeling for infectious" exact="viral" post="disease: The COVID‐19 perspective. J Public Affairs. 2020;e230610.1002/pa.2306 1"/>
   <result pre="disease: The COVID‐19 perspective. J Public Affairs. 2020;e230610.1002/pa.2306 1 INTRODUCTION" exact="Severe" post="Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2), a novel β‐coronavirus is"/>
   <result pre="The COVID‐19 perspective. J Public Affairs. 2020;e230610.1002/pa.2306 1 INTRODUCTION Severe" exact="Acute" post="Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2), a novel β‐coronavirus is the"/>
   <result pre="COVID‐19 perspective. J Public Affairs. 2020;e230610.1002/pa.2306 1 INTRODUCTION Severe Acute" exact="Respiratory" post="Syndrome Coronavirus‐2 (SARS‐CoV‐2), a novel β‐coronavirus is the pathogen"/>
   <result pre="perspective. J Public Affairs. 2020;e230610.1002/pa.2306 1 INTRODUCTION Severe Acute Respiratory" exact="Syndrome" post="Coronavirus‐2 (SARS‐CoV‐2), a novel β‐coronavirus is the pathogen responsible"/>
   <result pre="a novel β‐coronavirus is the pathogen responsible for the coronavirus" exact="disease" post="2019 (COVID‐19; Li, Geng, Peng, Meng, &amp;amp; Lu, 2020)."/>
   <result pre="confirmed cases with about 189,582 attributable deaths. In the Eastern" exact="Mediterranean" post="region, cases have soared to 817,458 with fatalities around"/>
   <result pre="about 200,586 cases with about 7,239 attributable deaths. Across the" exact="African" post="region, the number of confirmed cases stood at 187,625"/>
   <result pre="considerable uncertainties among many other deep‐rooted issues (Sameni, 2020). The" exact="viral" post="genome sequence of the SARS‐CoV‐2 suggests the close relatedness"/>
   <result pre="specific language to explain and predict the behavior of the" exact="infectious" post="viral disease. These models could be deterministic, non‐deterministic, or"/>
   <result pre="language to explain and predict the behavior of the infectious" exact="viral" post="disease. These models could be deterministic, non‐deterministic, or could"/>
   <result pre="could contain branching processes that aid the prediction of the" exact="infectious disease." post="2 MATHEMATICAL MODELS Mathematical models help to make mental"/>
   <result pre="model prediction (Jewell et al., 2020). 2.1 Models for airborne" exact="viral" post="diseases 2.1.1 Susceptible–infectious–recovered The underlying mathematical model which has"/>
   <result pre="three groups as in Shil (2016); the susceptible (S), the" exact="infectious" post="(I), and the recovered (R). It was developed by"/>
   <result pre="a mean transmission rate β. At the end of the" exact="infectious" post="period, individuals who recover from the infections are referred"/>
   <result pre="end of the infectious period, individuals who recover from the" exact="infections" post="are referred to as the recovered (R) member of"/>
   <result pre="I(t) represents the number of individuals in the susceptible and" exact="infectious" post="states respectively at any time t, while the rates"/>
   <result pre="also the epidemic declines, as more individuals recover from the" exact="disease" post="(Shil, 2016). Basic reproduction number is a phenomenon where"/>
   <result pre="reproduction number is a phenomenon where the average number of" exact="secondary" post="infections generated by one infectious individual when introduced into"/>
   <result pre="number is a phenomenon where the average number of secondary" exact="infections" post="generated by one infectious individual when introduced into a"/>
   <result pre="where the average number of secondary infections generated by one" exact="infectious" post="individual when introduced into a fully susceptible population is"/>
   <result pre="been used to explain the transmission and repeated outbreaks of" exact="measles" post="in New York between 1930 and 1962. The SIR"/>
   <result pre="and weather/seasonal variations. Modified SIR has been used to explain" exact="viral" post="epidemics such as Influenza justifying its applicability to the"/>
   <result pre="justifying its applicability to the COVID‐19 context. 2.1.2 Susceptible–exposed–infectious–recovered Certain" exact="infectious diseases" post="have an incubation period or exposed state in an"/>
   <result pre="an incubation period or exposed state in an individual following" exact="infection" post="until the symptoms are observed. In other words, the"/>
   <result pre="which the virus is incubated but does not transmit the" exact="infection" post="to anyone, so with the onset of symptoms the"/>
   <result pre="onset of symptoms the individual makes a transition to the" exact="infectious" post="state. Considering the constant population size (6) N ="/>
   <result pre="+ r ∝ 1 + r k where the mean" exact="infective" post="period is 1/α while the mean incubation period is"/>
   <result pre="model with suitable adaptations has been widely applied for various" exact="disease" post="epidemics such as chickenpox and SARS, and its relevance"/>
   <result pre="this context. 2.1.3 Susceptible–exposed–infectious–asymptomatic–recovered This is a simple model for" exact="viral" post="epidemics involving asymptomatic individuals in the population in a"/>
   <result pre="Individuals testing positive in serological tests or blood tests for" exact="disease" post="without symptoms is referred to as asymptomatic and is"/>
   <result pre="t + A t + R t This indicates the" exact="total" post="population was susceptible, and there was no transmission from"/>
   <result pre="latent state and a fraction of the proceeds to the" exact="infectious" post="state. In contrast, other fractions (I − p) proceed to the"/>
   <result pre="model was used to explain the transmission dynamics of the" exact="swine flu" post="outbreak in 2009 at a residential school in Maharashtra,"/>
   <result pre="at a residential school in Maharashtra, India (Shil, 2016). 2.1.4" exact="Complex" post="SEIAR (hospitalization) This model describes the incorporation of the"/>
   <result pre="describes the incorporation of the hospitalization of a fraction of" exact="infectious" post="individuals. Here the population is classified into SEIAR with"/>
   <result pre="and D(t) denoting the hospitalized and dead respectively. Considering the" exact="total" post="population is constant at any time, (16) N ="/>
   <result pre="of birth and natural death, while the cumulative number of" exact="infections" post="is represented by C(t). Epidemic data of the Spanish"/>
   <result pre="while the cumulative number of infections is represented by C(t)." exact="Epidemic" post="data of the Spanish Flu pandemic in Geneva was"/>
   <result pre="the Spanish Flu pandemic in Geneva was obtained using the" exact="Complex" post="SEIAR model, and all parameters of the model were"/>
   <result pre="the COVID‐19 Pandemic. Several countries have been on full or" exact="partial" post="lockdown while adhering to social distancing measures as they"/>
   <result pre="modeled by various researchers with the aim of stimulating the" exact="infections" post="within the population (Shaikh, Shaikh, &amp;amp; Nisar, 2020). Most"/>
   <result pre="a given community, these compartments are based on each individual's" exact="infectious" post="state, and related population sizes with respect to time"/>
   <result pre="for COVID‐19, this model effectively catches the timeline of the" exact="disease" post="epidemic while Chen et al. (2020) examined a model"/>
   <result pre="= κI + υA − ηQ ,where N represents the" exact="total" post="population and is further divided into five subclasses which"/>
   <result pre="describe the transmission dynamics and forecast the spread of the" exact="disease" post="using reported data between December 31, 2019, to January"/>
   <result pre="used to study the effectiveness of non‐pharmaceutical interventions in three" exact="African" post="countries (Van Zandvoort et al., 2020). Most African countries"/>
   <result pre="in three African countries (Van Zandvoort et al., 2020). Most" exact="African" post="countries have resource‐limited settings and have fewer means to"/>
   <result pre="individuals is the most effective way of reducing transmission in" exact="African" post="countries (Van Zandvoort et al., 2020). All these studies"/>
   <result pre="an SEIR model that describes multiple transmission pathways in the" exact="infection" post="dynamics. It also emphasized the role of the environmental"/>
   <result pre="bodies of deceased individuals should be well treated to prevent" exact="viral" post="transmission (Li, Wang, et al., 2020). Kim et al."/>
   <result pre="for various interventions that would be reliable in combating the" exact="disease" post="(Jewell et al., 2020). Models are very useful tools"/>
   <result pre="et al., 2020). Models are very useful tools particularly for" exact="short" post="term accurate predictions, and it helps policymakers to make"/>
   <result pre="helps policymakers to make decisions and allocate adequate resources toward" exact="disease" post="control through predictions of disease spread and infected population"/>
   <result pre="and allocate adequate resources toward disease control through predictions of" exact="disease" post="spread and infected population (Kucharski et al., 2020; Revathi"/>
   <result pre="models can be used to understand how and where the" exact="disease" post="is most likely to spread while avoiding so many"/>
   <result pre="are potent tools for understanding the transmission dynamics of an" exact="infectious" post="viral disease. In other climes, there is no gainsaying"/>
   <result pre="potent tools for understanding the transmission dynamics of an infectious" exact="viral" post="disease. In other climes, there is no gainsaying to"/>
   <result pre="structures, containment and risk analysis of the virus transmission. Since" exact="infectious diseases" post="have an incubation period or exposed state in an"/>
   <result pre="an incubation period or exposed state in an individual following" exact="infection" post="until the symptoms are observed, the SEIR account for"/>
   <result pre="Science core collections and Scopus such as Science of The" exact="Total" post="Environment, Journal of Public Affairs, Heliyon, Economic Annals, Iranian"/>
   <result pre="&amp;amp; Ogunbanjo, O. W. (2020). Modelling spatial variations of coronavirus" exact="disease" post="(COVID‐19) in Africa. Science of The Total Environment, 729,"/>
   <result pre="variations of coronavirus disease (COVID‐19) in Africa. Science of The" exact="Total" post="Environment, 729, 13899810.1016/j.scitotenv.2020.13899832361455 Bauer, F. (2017). Mathematical epidemiology: Past,"/>
   <result pre="13899810.1016/j.scitotenv.2020.13899832361455 Bauer, F. (2017). Mathematical epidemiology: Past, present, and future." exact="Infectious" post="Disease Modelling, 2(2), 113–127. 10.1016/j.idm.2017.02.00129928732 Chen, T.‐M., Rui, J.,"/>
   <result pre="Bauer, F. (2017). Mathematical epidemiology: Past, present, and future. Infectious" exact="Disease" post="Modelling, 2(2), 113–127. 10.1016/j.idm.2017.02.00129928732 Chen, T.‐M., Rui, J., Wang,"/>
   <result pre="model for simulating the phase‐based transmissibility of a novel coronavirus." exact="Infectious" post="Diseases of Poverty, 9(1), 2410.1186/s40249-020-00640-332111262 Delamater, P. L., Street,"/>
   <result pre="for simulating the phase‐based transmissibility of a novel coronavirus. Infectious" exact="Diseases" post="of Poverty, 9(1), 2410.1186/s40249-020-00640-332111262 Delamater, P. L., Street, E."/>
   <result pre="Complexity of the basic reproduction number (R 0 ). Emerging" exact="Infectious" post="Diseases, 25(1), 1–4. 10.3201/eid2501.171901 Freiberger, M. (2014). Fighting epidemics"/>
   <result pre="Y. (2020). The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID‐19) outbreak – An update on the status."/>
   <result pre="M. (2020). Mathematical modeling of the spread of the coronavirus" exact="disease" post="2019 (COVID‐19) taking into account the undetected infections. The"/>
   <result pre="transmission and control of COVID‐19: A mathematical modelling study. Lancet" exact="Infectious" post="Diseases, 20, 553–558. 10.1016/S1473-3099(20)30144-432171059 Li, X., Geng, M., Peng,"/>
   <result pre="COVID‐19 and its significance to epidemic prevention and. Annals of" exact="Infectious" post="Disease and Epidemiology, 5(1), 1052. Lin, Q., Zhao, S.,"/>
   <result pre="and its significance to epidemic prevention and. Annals of Infectious" exact="Disease" post="and Epidemiology, 5(1), 1052. Lin, Q., Zhao, S., Gao,"/>
   <result pre="… He, D. (2020). A conceptual model for the coronavirus" exact="disease" post="2019 (COVID‐19) outbreak in Wuhan, China with individual reaction"/>
   <result pre="China with individual reaction and governmental action. International Journal of" exact="Infectious" post="Diseases, 93, 211–216. 10.1016/j.ijid.2020.02.05832145465 Nandal, U. (2020). Mathematical modeling"/>
   <result pre="Preprint, 20200401, 1–21. 10.20944/preprints202004.0140.v1 Shil, P. (2016). Mathematical modeling of" exact="viral" post="epidemics: A review. Biomedical Research Journal, 3(2), 19510.4103/2349-3666.240612 Sinha,"/>
   <result pre="… Liu, Y. (2020). Response strategies for COVID‐19 epidemics in" exact="African" post="settings: A mathematical modelling study. London: Centre for Mathematical"/>
   <result pre="A mathematical modelling study. London: Centre for Mathematical Modelling of" exact="Infectious" post="Diseases. collab: WHO . (2020). Coronavirus disease 2019 (COVID‐19)"/>
   <result pre="Mathematical Modelling of Infectious Diseases. collab: WHO . (2020). Coronavirus" exact="disease" post="2019 (COVID‐19) situation Report‐68. Geneva: World Health Organization. Wu,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7461190/results/search/disease/results.xml">
   <result pre=", This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
   <result pre="that the COVID‐19 epidemic has changed the use of the" exact="Pediatric" post="Emergency Room, and the access to healthcare facilities in"/>
   <result pre="confirm our report: the epidemic led to a reduction in" exact="Pediatric" post="Emergency Room access. The causes of this phenomenon are"/>
   <result pre="schools led to a reduction in the number of paediatric" exact="infectious" post="diseases.3 Instead, the prohibition of movements reduced the amount"/>
   <result pre="1ManzoniP, MilitelloMA, FioricaL, ManzionnaM, CappielloA. Impact of Covid‐19 epidemics in" exact="Pediatric" post="Morbidity and utilization of Hospital Pediatric Services in Italy."/>
   <result pre="of Covid‐19 epidemics in Pediatric Morbidity and utilization of Hospital" exact="Pediatric" post="Services in Italy. Acta Paediatr. 202010.1111/apa.15435 2PataD, GattoA, BuonsensoD,"/>
   <result pre="closure and national lockdown on pediatric visits and admissions for" exact="viral" post="and non‐viral infections, a time series analysis. Clin Infect"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7462751/results/search/disease/results.xml">
   <result pre="italic;} Travel Med Infect DisTravel Med Infect DisTravel Medicine and" exact="Infectious" post="Disease1477-89391873-0442Elsevier Ltd. pmcid: 7462751S1477-8939(20)30366-5 doi: 10.1016/j.tmaid.2020.101870101870 : Correspondence Microbial"/>
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="on the presence of viruses (specifically, the authors searched for" exact="viral" post="RNA [1]). The emergence of novel coronavirus SARS-CoV-2 in"/>
   <result pre="2019 and its high transmissibility, resulting in a rapid coronavirus" exact="disease" post="(Covid-19) outbreak globally, has led the scientific community to"/>
   <result pre="globally, has led the scientific community to look for undetected" exact="infection" post="pathways [1]. The SARS-CoV-2 has been shown to spread"/>
   <result pre="epidemics and pandemics [1]. The growing number of reports regarding" exact="bacterial" post="contamination of MPs is contradicted by a paucity of"/>
   <result pre="further research is warranted, focusing both on the identification of" exact="viral" post="material on the surface of MPs and on the"/>
   <result pre="4Cicciarella ModicaD.MauriciM.D’AlòG.L.MozzettiC.MessinaA.DistefanoA.PicaF.De FilippisP.Taking screenshots of the invisible: a study on" exact="bacterial" post="contamination of mobile phones from university students of healthcare"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7466926/results/search/disease/results.xml">
   <result pre="7466926628 doi: 10.1007/s13337-020-00628-5 : Review Article A brief outline of" exact="respiratory" post="viral disease outbreaks: 1889–till date on the public health"/>
   <result pre="doi: 10.1007/s13337-020-00628-5 : Review Article A brief outline of respiratory" exact="viral" post="disease outbreaks: 1889–till date on the public health perspectives"/>
   <result pre="10.1007/s13337-020-00628-5 : Review Article A brief outline of respiratory viral" exact="disease" post="outbreaks: 1889–till date on the public health perspectives http://orcid.org/0000-0003-4837-221XNoorRashedrashednoor@iub.edu.bdManihaSyeda"/>
   <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
   <result pre="Organization (WHO) declaration of COVID-19 as a global pandemic. Abstract" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently causing"/>
   <result pre="(WHO) declaration of COVID-19 as a global pandemic. Abstract Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently causing the"/>
   <result pre="declaration of COVID-19 as a global pandemic. Abstract Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) is currently causing the respiratory"/>
   <result pre="of COVID-19 as a global pandemic. Abstract Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) is currently causing the respiratory illness"/>
   <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently causing the" exact="respiratory" post="illness termed as the coronavirus disease 2019 or the"/>
   <result pre="is currently causing the respiratory illness termed as the coronavirus" exact="disease" post="2019 or the COVID-19 pandemic. Indeed, the significant increase"/>
   <result pre="trial basis, (2) the biochemical and genetic aspects underlying the" exact="viral" post="pathogenicity, (3) the viral epidemiology, and on (4) the"/>
   <result pre="biochemical and genetic aspects underlying the viral pathogenicity, (3) the" exact="viral" post="epidemiology, and on (4) the protective immunity against the"/>
   <result pre="to increase the protective awareness among the general people. The" exact="viral" post="reassortments during the initiation of pandemics have also been"/>
   <result pre="literatures. Keywords Influenza viruses COVID-19 Pandemic History Public health Introduction" exact="Disease" post="outbreaks, epidemics and pandemics (like the ongoing COVID-19 pandemic"/>
   <result pre="pandemics (like the ongoing COVID-19 pandemic caused by the severe" exact="acute" post="respiratory syndrome coronavirus 2 or the SARS-CoV-2; and the"/>
   <result pre="(like the ongoing COVID-19 pandemic caused by the severe acute" exact="respiratory" post="syndrome coronavirus 2 or the SARS-CoV-2; and the Spanish"/>
   <result pre="the ongoing COVID-19 pandemic caused by the severe acute respiratory" exact="syndrome" post="coronavirus 2 or the SARS-CoV-2; and the Spanish influenza"/>
   <result pre="well as for the other health professionals [1, 2]. A" exact="disease" post="outbreak, both regional and seasonal, is known to take"/>
   <result pre="regional and seasonal, is known to take place when a" exact="disease" post="propagates into a relatively large numbers of people within"/>
   <result pre="an outbreak, an epidemic is known to occur when an" exact="infectious disease" post="tends to spread more quickly among a huge number"/>
   <result pre="outbreak, an epidemic is known to occur when an infectious" exact="disease" post="tends to spread more quickly among a huge number"/>
   <result pre="huge number of populations, as can be exemplified by the" exact="acute" post="respiratory syndrome (SARS) epidemic in 2003, causing 774 deaths"/>
   <result pre="number of populations, as can be exemplified by the acute" exact="respiratory" post="syndrome (SARS) epidemic in 2003, causing 774 deaths worldwide"/>
   <result pre="of populations, as can be exemplified by the acute respiratory" exact="syndrome" post="(SARS) epidemic in 2003, causing 774 deaths worldwide [2]."/>
   <result pre="deaths worldwide [2]. A pandemic is simply known as global" exact="disease" post="like the Spanish influenza H1N1 (causing around 50 million"/>
   <result pre="H2N2 (causing nearly 2 million deaths in 1957–1958), or the" exact="Russian" post="influenza H2N2 (causing more than 1 million deaths in"/>
   <result pre="[4]. COVID-19 is already well known as the life threatening" exact="infectious" post="respiratory disease which actually shares the same routes and"/>
   <result pre="COVID-19 is already well known as the life threatening infectious" exact="respiratory" post="disease which actually shares the same routes and means"/>
   <result pre="is already well known as the life threatening infectious respiratory" exact="disease" post="which actually shares the same routes and means of"/>
   <result pre="as influenza; and hence influenza can be correlated with COVID-19" exact="disease" post="which has been further confirmed by the case of"/>
   <result pre="virus [6]. Therefore, measures taken for the influenza (and other" exact="infectious" post="respiratory diseases) prevention and control may also serve effectively"/>
   <result pre="[6]. Therefore, measures taken for the influenza (and other infectious" exact="respiratory" post="diseases) prevention and control may also serve effectively to"/>
   <result pre="regulatory bodies, scientists usually concentrate on the transmission of viruses," exact="viral" post="pathogenesis, the associated host immunity, effectual diagnosis of the"/>
   <result pre="focuses primarily on the biomedical research advances along with the" exact="disease" post="mitigation possibilities, the control of any pandemic largely requires"/>
   <result pre="level of emergency is of prime significance to limit the" exact="viral" post="transmission and eventually to maintain the global public health"/>
   <result pre="and vaccine development, research on the host immune responses during" exact="viral" post="pathogenesis and the evolution of virus, detecting virus transmission,"/>
   <result pre="the common knowledge to be safe during a pandemic situation." exact="Russian" post="influenza (La Grippe) H2N2 (1889–1892) Russian Flu, the first"/>
   <result pre="during a pandemic situation. Russian influenza (La Grippe) H2N2 (1889–1892)" exact="Russian" post="Flu, the first true epidemic cases observed in May"/>
   <result pre="H1N1 subtype) if they had been previously infected by the" exact="Russian" post="flu (1889–1890) [12]. Viral reassortment and pathogenicity Interestingly, it"/>
   <result pre="had been previously infected by the Russian flu (1889–1890) [12]." exact="Viral" post="reassortment and pathogenicity Interestingly, it has been recently inferred"/>
   <result pre="has been recently inferred that the causative virus of the" exact="Russian" post="influenza could be of the H3Nx subtype which circulated"/>
   <result pre="the reassortment events as stated above, another interpretation on the" exact="viral" post="pathogenecity underlies the point mutations within the set of"/>
   <result pre="which are already known as the antigenic cluster of the" exact="viral" post="subtype [15]. Such an event leads to parallel replacement"/>
   <result pre="ancestral forms which go a long way to impart the" exact="viral" post="adaptation and survival within the host inactivating the protective"/>
   <result pre="inactivating the protective immunity [15]. A simple illustration of the" exact="viral" post="reassortment between the influenza viruses is shown in Fig."/>
   <result pre="the influenza viruses is shown in Fig. 1. Fig. 1" exact="Simple" post="illustration of viral reassortment between the influenza viruses. After"/>
   <result pre="is shown in Fig. 1. Fig. 1 Simple illustration of" exact="viral" post="reassortment between the influenza viruses. After the 1918–1920 Spanish"/>
   <result pre="the matrix protein, M1 and M2, grossly required for the" exact="viral" post="pathogenecity) and was co-circulated with H3N2 viruses till 2009"/>
   <result pre="viruses yy[20, 36–38]. This is to be noted that such" exact="viral" post="reaasortments have not been shown between the SARS or"/>
   <result pre="and cap stealing mechanism; PA polymerase acidic protein, involved in" exact="viral" post="RNA transcription and replication; NP nuceloprotein, involved in the"/>
   <result pre="and replication; NP nuceloprotein, involved in the encapsulation of the" exact="viral" post="genome for RNA transcription, replication and packaging; M matrix"/>
   <result pre="packaging; M matrix protein, involved in the formation of the" exact="viral" post="envelope; NS non-structural protein, involved in the inhibition of"/>
   <result pre="is integral to its infectivity, and is involved in the" exact="viral" post="attachment and acts as a membrane fusion protein.; NA"/>
   <result pre="individual genetic makeup like the single-nucleotide polymorphisms (SNPs), co-infections with" exact="bacterial" post="pathogens, and with the measles and malaria causing agents;"/>
   <result pre="single-nucleotide polymorphisms (SNPs), co-infections with bacterial pathogens, and with the" exact="measles" post="and malaria causing agents; and finally the malnutrition or"/>
   <result pre="(SNPs), co-infections with bacterial pathogens, and with the measles and" exact="malaria" post="causing agents; and finally the malnutrition or obesity has"/>
   <result pre="with the measles and malaria causing agents; and finally the" exact="malnutrition" post="or obesity has been found to contribute to the"/>
   <result pre="measles and malaria causing agents; and finally the malnutrition or" exact="obesity" post="has been found to contribute to the high mortality"/>
   <result pre="contribute to the high mortality due to the 1918 H1N1" exact="virus infection" post="[9]. Though the 1918 influenza pandemic is known as"/>
   <result pre="to the high mortality due to the 1918 H1N1 virus" exact="infection" post="[9]. Though the 1918 influenza pandemic is known as"/>
   <result pre="United States of America and then France, from where the" exact="viral" post="transmission spread throughout Europe and within the rest of"/>
   <result pre="origins of the 1918 virus remained obscure, and eventually the" exact="viral" post="vector (animal reservoir) became controversial. Being a segmented virus,"/>
   <result pre="1968 influenza pandemics [9, 19]. Demolition of protective immunity during" exact="viral" post="pathogenesis Some of the viral factors including haemagglutinin (HA)"/>
   <result pre="Demolition of protective immunity during viral pathogenesis Some of the" exact="viral" post="factors including haemagglutinin (HA) and the polymerase gene segments"/>
   <result pre="(IFN)-inducible protein (IP-10), macrophage inflammatory protein 1α (MIP1α), MIP1β and" exact="monocyte" post="chemoattractant protein-1 (MCP1), tumor necrosis factor alpha (TNF-α), etc."/>
   <result pre="inflammatory protein 1α (MIP1α), MIP1β and monocyte chemoattractant protein-1 (MCP1)," exact="tumor" post="necrosis factor alpha (TNF-α), etc. in course of the"/>
   <result pre="tumor necrosis factor alpha (TNF-α), etc. in course of the" exact="viral" post="pathogenesis during a pandemic outbreak [9]. However, a dysregulated"/>
   <result pre="among the young population was another prime factor for the" exact="viral" post="pathogenecity [9, 21]. This is to be noted that"/>
   <result pre="encoding H2 hemagglutinin and N2 neuraminidase) that originated from an" exact="avian influenza" post="A virus emerged in East Asia, which triggered another"/>
   <result pre="July of that year, the pandemic reached Europe and South" exact="American" post="countries of the Pacific coast, New Zealand, and South"/>
   <result pre="The study revealed that only 5.6% of the adults having" exact="symptomatic" post="influenza A, developed the infection earlier during the pandemic,"/>
   <result pre="5.6% of the adults having symptomatic influenza A, developed the" exact="infection" post="earlier during the pandemic, despite living in households with"/>
   <result pre="living in households with participants who had influenza; whereas the" exact="infection" post="frequency was much higher (55.2%) in the children having"/>
   <result pre="frequency was much higher (55.2%) in the children having the" exact="symptomatic" post="influenza A. This finding clearly showed the accumulation of"/>
   <result pre="feature of antigenic drift, consisted of two genes from an" exact="avian influenza" post="A virus: a new H3 hemagglutinin (HA), and the"/>
   <result pre="host, which in turn results in the alteration in the" exact="viral" post="antigenicity; i.e., the antigenic drift which is very likely"/>
   <result pre="which is very likely to reduce NA-antibody-based protection against the" exact="viral infection" post="as revealed from the in vivo studies [30]. It"/>
   <result pre="is very likely to reduce NA-antibody-based protection against the viral" exact="infection" post="as revealed from the in vivo studies [30]. It"/>
   <result pre="antigenicity to optimize the influenza vaccines has been suggested [30]." exact="Severe" post="acute respiratory syndrome (SARS) in 2002–2003 SARS, the severe"/>
   <result pre="to optimize the influenza vaccines has been suggested [30]. Severe" exact="acute" post="respiratory syndrome (SARS) in 2002–2003 SARS, the severe acute"/>
   <result pre="optimize the influenza vaccines has been suggested [30]. Severe acute" exact="respiratory" post="syndrome (SARS) in 2002–2003 SARS, the severe acute respiratory"/>
   <result pre="the influenza vaccines has been suggested [30]. Severe acute respiratory" exact="syndrome" post="(SARS) in 2002–2003 SARS, the severe acute respiratory syndrome,"/>
   <result pre="Severe acute respiratory syndrome (SARS) in 2002–2003 SARS, the severe" exact="acute" post="respiratory syndrome, caused by a novel coronavirus (termed as"/>
   <result pre="acute respiratory syndrome (SARS) in 2002–2003 SARS, the severe acute" exact="respiratory" post="syndrome, caused by a novel coronavirus (termed as SARS-CoV,"/>
   <result pre="774 deaths out of 8000 infected cases), is another highly" exact="infectious" post="and lethal atypical form of pneumonia, originating in China"/>
   <result pre="of 8000 infected cases), is another highly infectious and lethal" exact="atypical" post="form of pneumonia, originating in China too; and spreading"/>
   <result pre="from them to humans [33]. Since the mutations of the" exact="viral" post="receptor genes (more specifically, the point mutations and recombination"/>
   <result pre="pandemics is thought be the unique model of an emerging" exact="disease" post="[32–34]. In 2012, some incidences of novel coronavirus infection"/>
   <result pre="emerging disease [32–34]. In 2012, some incidences of novel coronavirus" exact="infection" post="were reported in Arabian Peninsula with pneumonia and acute"/>
   <result pre="of novel coronavirus infection were reported in Arabian Peninsula with" exact="pneumonia" post="and acute kidney injury; and the virus was named"/>
   <result pre="coronavirus infection were reported in Arabian Peninsula with pneumonia and" exact="acute" post="kidney injury; and the virus was named Middle East"/>
   <result pre="infection were reported in Arabian Peninsula with pneumonia and acute" exact="kidney injury;" post="and the virus was named Middle East respiratory syndrome"/>
   <result pre="acute kidney injury; and the virus was named Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) which was thought to be propagated"/>
   <result pre="kidney injury; and the virus was named Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) which was thought to be propagated from"/>
   <result pre="(HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1) appeared to be endemic (i.e., an" exact="infectious" post="microorganism that is restricted to a specific locality or"/>
   <result pre="or region) so far and mainly associated with the mild" exact="respiratory" post="illnesses; whereas the other two coronaviruses: SARS-CoV and the"/>
   <result pre="coronaviruses: SARS-CoV and the MERS-CoV) are widely known as emerging" exact="infections" post="triggering severe respiratory syndrome worldwide [32, 33]. Indeed, the"/>
   <result pre="the MERS-CoV) are widely known as emerging infections triggering severe" exact="respiratory" post="syndrome worldwide [32, 33]. Indeed, the current COVID-19 pandemic"/>
   <result pre="MERS-CoV) are widely known as emerging infections triggering severe respiratory" exact="syndrome" post="worldwide [32, 33]. Indeed, the current COVID-19 pandemic is"/>
   <result pre="in 2012 [32–34]. SARS patients were found to suffer from" exact="acute" post="renal impairment and proteinuria together with hematological abnormalities like"/>
   <result pre="SARS patients were found to suffer from acute renal impairment" exact="and proteinuria" post="together with hematological abnormalities like thrombocytopenia and lymphopenia [34–36]."/>
   <result pre="acute renal impairment and proteinuria together with hematological abnormalities like" exact="thrombocytopenia" post="and lymphopenia [34–36]. In contrast the SARS-CoV-2 is principally"/>
   <result pre="impairment and proteinuria together with hematological abnormalities like thrombocytopenia and" exact="lymphopenia" post="[34–36]. In contrast the SARS-CoV-2 is principally causing headache,"/>
   <result pre="the SARS-CoV-2 is principally causing headache, fever, sore throat, cough," exact="acute" post="respiratory distress syndrome, acute cardiac injury, upper airway congestion,"/>
   <result pre="SARS-CoV-2 is principally causing headache, fever, sore throat, cough, acute" exact="respiratory" post="distress syndrome, acute cardiac injury, upper airway congestion, pharyngalgia,"/>
   <result pre="causing headache, fever, sore throat, cough, acute respiratory distress syndrome," exact="acute" post="cardiac injury, upper airway congestion, pharyngalgia, myalgia, and diarrhea,"/>
   <result pre="sore throat, cough, acute respiratory distress syndrome, acute cardiac injury," exact="upper" post="airway congestion, pharyngalgia, myalgia, and diarrhea, anemia, and even"/>
   <result pre="airway congestion, pharyngalgia, myalgia, and diarrhea, anemia, and even the" exact="secondary" post="infections [37]. However, the onset of acute respiratory distress"/>
   <result pre="congestion, pharyngalgia, myalgia, and diarrhea, anemia, and even the secondary" exact="infections" post="[37]. However, the onset of acute respiratory distress syndrome"/>
   <result pre="and even the secondary infections [37]. However, the onset of" exact="acute" post="respiratory distress syndrome (ARDS) by three β-coronaviruses: SARS-CoV-2, SARS-CoV"/>
   <result pre="even the secondary infections [37]. However, the onset of acute" exact="respiratory" post="distress syndrome (ARDS) by three β-coronaviruses: SARS-CoV-2, SARS-CoV and"/>
   <result pre="secondary infections [37]. However, the onset of acute respiratory distress" exact="syndrome" post="(ARDS) by three β-coronaviruses: SARS-CoV-2, SARS-CoV and MERS-CoV is"/>
   <result pre="17]. It is to be pondered that both the ongoing" exact="infection" post="SARS-CoV-2 and the previous SARS-CoV infections are associated with"/>
   <result pre="that both the ongoing infection SARS-CoV-2 and the previous SARS-CoV" exact="infections" post="are associated with the elevation of the pro-inflammatory cytokines"/>
   <result pre="is based on its interferon (IFN) antagonist proteins [32]. Coronavirus" exact="disease" post="in 2019–2020 (COVID-19) by SARS-CoV-2 The pandemic of the"/>
   <result pre="in 2019–2020 (COVID-19) by SARS-CoV-2 The pandemic of the Coronavirus" exact="Disease" post="2019 (COVID-19) resulting in novel coronavirus-infected pneumonia (NCIP) is"/>
   <result pre="of the Coronavirus Disease 2019 (COVID-19) resulting in novel coronavirus-infected" exact="pneumonia" post="(NCIP) is the ongoing pandemics around the world which"/>
   <result pre="UK and Iran [39, 40]. A significant genomic similarity with" exact="Severe" post="Acute Respiratory Syndrome (SARS, a pandemics occurred in 2002)"/>
   <result pre="and Iran [39, 40]. A significant genomic similarity with Severe" exact="Acute" post="Respiratory Syndrome (SARS, a pandemics occurred in 2002) was"/>
   <result pre="Iran [39, 40]. A significant genomic similarity with Severe Acute" exact="Respiratory" post="Syndrome (SARS, a pandemics occurred in 2002) was noticed"/>
   <result pre="[39, 40]. A significant genomic similarity with Severe Acute Respiratory" exact="Syndrome" post="(SARS, a pandemics occurred in 2002) was noticed [32,"/>
   <result pre="inadequate water, sanitation, and hygiene (WASH) tools may provoke the" exact="viral" post="fatality [41]. Coronaviruses are already known as the enveloped"/>
   <result pre="those as seen during the common cold or more severe" exact="respiratory" post="syndromes [42]. Besides the running pandemic outbreak by the"/>
   <result pre="along the last two decades: SARS and MERS (Middle East" exact="respiratory" post="syndrome coronavirus) [43]. Together with an array of published"/>
   <result pre="the last two decades: SARS and MERS (Middle East respiratory" exact="syndrome" post="coronavirus) [43]. Together with an array of published articles"/>
   <result pre="of published articles on coronaviruses, the China CDC (Centers for" exact="Disease" post="Control and Prevention) published a guideline for the public"/>
   <result pre="guideline for the public awareness on combating COVID-19 pandemic [38]." exact="Viral" post="pathogenesis and the host immunity escaping strategies Dissemination of"/>
   <result pre="or sneeze droplets or direct contact within human-to-human [37]. The" exact="viral" post="particles are thought to bind to the angiotensin-converting enzyme"/>
   <result pre="in humans thereby rendering the infected individual prone to the" exact="respiratory" post="disorders [31]. The coronavirus pneumonia develops within maximum 7"/>
   <result pre="infected individual prone to the respiratory disorders [31]. The coronavirus" exact="pneumonia" post="develops within maximum 7 days with the early symptoms"/>
   <result pre="symptoms of fever, headache, cough, congestion, pharyngalgia, etc.[38–42]. The sequential" exact="secondary" post="bacterial infections are not surprising during the viral infections."/>
   <result pre="of fever, headache, cough, congestion, pharyngalgia, etc.[38–42]. The sequential secondary" exact="bacterial infections" post="are not surprising during the viral infections. Suppression of"/>
   <result pre="fever, headache, cough, congestion, pharyngalgia, etc.[38–42]. The sequential secondary bacterial" exact="infections" post="are not surprising during the viral infections. Suppression of"/>
   <result pre="The sequential secondary bacterial infections are not surprising during the" exact="viral" post="infections. Suppression of the intricate innate antiviral responses induces"/>
   <result pre="infections. Suppression of the intricate innate antiviral responses induces the" exact="viral infection." post="The SARS-CoV-2 RNA encodes at least two proteases possessing"/>
   <result pre="to form specific replication organelles which protect the recognition of" exact="viral" post="RNA by the innate immune sensors [38, 40]. The"/>
   <result pre="viral RNA by the innate immune sensors [38, 40]. The" exact="viral" post="endoribonuclease (RNase) activity is another means of excaping the"/>
   <result pre="immune cells [35, 39]. Moreover, the receptor-binding domain (RBD) of" exact="viral" post="spike can mediate the viral entry. Interestingly, a monoclonal"/>
   <result pre="the receptor-binding domain (RBD) of viral spike can mediate the" exact="viral" post="entry. Interestingly, a monoclonal antibody (MAb) can bind to"/>
   <result pre="immunolglobulin G (IgG) Fc receptor which in turn mediates the" exact="viral" post="entry into the host as also happens during the"/>
   <result pre="entry into the host as also happens during the MERS-CoV" exact="infection" post="[32, 38, 40]. Indeed, using the spike (S) protein,"/>
   <result pre="while in case of SARS-CoV, the neutralizing antibodies block the" exact="viral" post="entry whereas the MERS-CoV entry principally depends on the"/>
   <result pre="caused by H3N2 subtype in 1968. An integrated interplay between" exact="viral" post="genome, host immunity including the dysregulated pro-inflammatory response, and"/>
   <result pre="influenza virus was due to the proteins encoded by the" exact="viral" post="haemagglutinin (HA) and polymerase gene segments [9, 19]. Lack"/>
   <result pre="immunity can be another promoting factor for the onset of" exact="viral infection" post="[20]. Thus the anti-HA antibody, anti-NA antibody, and cell-mediated"/>
   <result pre="can be another promoting factor for the onset of viral" exact="infection" post="[20]. Thus the anti-HA antibody, anti-NA antibody, and cell-mediated"/>
   <result pre="such as single-nucleotide polymorphisms (SNPs), (2) the co-infections with other" exact="bacterial" post="pathogens, (3) malnutrition, (4) obesity, (5) population demographics, (6)"/>
   <result pre="climate change, etc. may influence the dreadfulness of influenza virus" exact="infections" post="[11]. Quick identification of suspect cases is the major"/>
   <result pre="molecular biological tools like the sequencing and annotation of the" exact="viral" post="genome as well as the development of rapid diagnostic"/>
   <result pre="safety [3, 41]. In the current time, the diagnosis of" exact="viral" post="strains responsible for influenza has spectacularly improved both in"/>
   <result pre="pandemic viruses has also improved through the screening of the" exact="viral" post="genome within the infected individuals. Monitoring the possible mutations"/>
   <result pre="within the infected individuals. Monitoring the possible mutations within the" exact="viral" post="genome is also possible. The Public Health Emergency of"/>
   <result pre="the World Health Organization (WHO) and the CDC (Centers for" exact="Disease" post="Control and Prevention) is already working on the pandemic"/>
   <result pre="with set goals to maintain the global public health sustainability." exact="Respiratory" post="hygiene (maintained by hand hygiene, safe cough practice, and"/>
   <result pre="health intercession as a preventive strategy against the spread of" exact="respiratory" post="viruses [41]. During the SARS pandemic in 2003 the"/>
   <result pre="sequence evolved which is major breakthrough in the diagnosis of" exact="viral" post="infections [35]. Also, a forceful home quarantine strategy was"/>
   <result pre="evolved which is major breakthrough in the diagnosis of viral" exact="infections" post="[35]. Also, a forceful home quarantine strategy was launched"/>
   <result pre="appropriate vaccine has been developed till date to circumvent these" exact="respiratory" post="viruses. Rather, proper medical nursing seemed to be useful"/>
   <result pre="useful for gaining general knowledge and the protective against the" exact="viral" post="fatality by a broad range of population. For the"/>
   <result pre="on the published epidemiological and medical reports) especially regarding the" exact="viral" post="transmission, the time wave pattern of viral infection, the"/>
   <result pre="especially regarding the viral transmission, the time wave pattern of" exact="viral infection," post="the possible failures in developing the appropriate vaccines and"/>
   <result pre="by the viruses (through the antigenic drift and/ or the" exact="viral" post="reassortment) could be of great importance for outbreak predictions,"/>
   <result pre="the centenary of the 1918–1919 Spanish influenza pandemic: mechanisms of" exact="psychosis" post="riskFront Psychiatry2020117210.3389/fpsyt.2020.0007232174851 2.Ksiazek TG, Erdman D, Goldsmith CS, Zaki"/>
   <result pre="LJ, SARS Working Group. A novel coronavirus associated with severe" exact="acute" post="respiratory syndrome. N Engl J Med. 2003; 348(20):1953–66. 10.1056/nejmoa030781"/>
   <result pre="SARS Working Group. A novel coronavirus associated with severe acute" exact="respiratory" post="syndrome. N Engl J Med. 2003; 348(20):1953–66. 10.1056/nejmoa030781 3.LeungYToMLamTYauSLeungOChuangSEpidemiology"/>
   <result pre="J Med. 2003; 348(20):1953–66. 10.1056/nejmoa030781 3.LeungYToMLamTYauSLeungOChuangSEpidemiology of human influenza A(H7N9)" exact="infection" post="in Hong KongJ Microbiol Immunol Infect201750218318810.1016/j.jmii.2015.06.00426220305 4.LinQZhaoSGaoDLouYYangSMusaSSWangMHCaiYWangWYangLHeDA conceptual model"/>
   <result pre="KongJ Microbiol Immunol Infect201750218318810.1016/j.jmii.2015.06.00426220305 4.LinQZhaoSGaoDLouYYangSMusaSSWangMHCaiYWangWYangLHeDA conceptual model for the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in Wuhan, China with individual reaction"/>
   <result pre="reaction and governmental actionInt J Infect Dis20209321121610.1016/j.ijid.2020.02.05832145465 5.CDC (Centers for" exact="Disease" post="Control and Prevention). 1918 Pandemic influenza: three waves. https://www.cdc.gov/flu/pandemic-resources/1918-commemoration/three-waves.htm"/>
   <result pre="on May 30, 2020. 6.WuDLuJMaXLiuQWangDGuYLiYHeWCoinfection of influenza virus and severe" exact="acute" post="respiratory syndrome Coronavirus 2 (SARS-COV-2)Ped Infect Dis J202010.1097/INF.0000000000002688 7.VogelOAManicassamyBBroadly"/>
   <result pre="May 30, 2020. 6.WuDLuJMaXLiuQWangDGuYLiYHeWCoinfection of influenza virus and severe acute" exact="respiratory" post="syndrome Coronavirus 2 (SARS-COV-2)Ped Infect Dis J202010.1097/INF.0000000000002688 7.VogelOAManicassamyBBroadly protective"/>
   <result pre="30, 2020. 6.WuDLuJMaXLiuQWangDGuYLiYHeWCoinfection of influenza virus and severe acute respiratory" exact="syndrome" post="Coronavirus 2 (SARS-COV-2)Ped Infect Dis J202010.1097/INF.0000000000002688 7.VogelOAManicassamyBBroadly protective strategies"/>
   <result pre="influenza viruses: universal vaccines and therapeuticsFront Microbiol202071113510.3389/fmicb.2020.00135 8.EwingETLa Grippe or" exact="Russian" post="influenza: mortality statistics during the 1890 epidemic in IndianaInfluenza"/>
   <result pre="measures on influenza preventionInt J Infect Dis2020S1201–971220302253023310.1016/j.ijid.2020.04.009 11.CDC (Centers for" exact="Disease" post="Control and Prevention). 1957–1958 Pandemic (H2N2 virus). https://www.cdc.gov/flu/pandemic-resources/1968-pandemic.html. Accessed"/>
   <result pre="a quantitative analysisLancet200636895542211221810.1016/s0140-6736(06)69895-417189032 17.CollinsSDAge and sex incidence of influenza and" exact="pneumonia" post="morbidity and mortality in the epidemic of 1928–29 with"/>
   <result pre="the haemagglutinin of the 1918 pandemic virusNature2004431700970370710.1038/nature0295115470432 21.AhmedROldstoneMBAPalesePProtective immunity and" exact="susceptibility to" post="infectious diseases: lessons from the 1918 influenza pandemicNat Immunol20078111188119310.1038/ni153017952044"/>
   <result pre="of the 1918 pandemic virusNature2004431700970370710.1038/nature0295115470432 21.AhmedROldstoneMBAPalesePProtective immunity and susceptibility to" exact="infectious" post="diseases: lessons from the 1918 influenza pandemicNat Immunol20078111188119310.1038/ni153017952044 22.ReedCKatzJMSerological"/>
   <result pre="of the 1957–1959 influenza pandemicJ Infect Dis2016213573874510.1093/infdis/jiv53426908781 28.EpsteinSLPrior H1N1 influenza" exact="infection" post="and susceptibility of Cleveland Family Study participants during the"/>
   <result pre="epidemic in ChinaJ Autoimmun2003202010243410.1016/j.jaut.2020.102434 35.ChuKHTsangWKTangCSLamMFLaiFMToKFFungKSTangHLYanWWChanHWHLaiTSTTongKLLaiKNAcute renal impairment in coronavirus-associated severe" exact="acute" post="respiratory syndromeKidney Int200567269870510.1111/j.1523-1755.2005.67130.x15673319 36.BoothCMClinical features and short-term outcomes of"/>
   <result pre="in ChinaJ Autoimmun2003202010243410.1016/j.jaut.2020.102434 35.ChuKHTsangWKTangCSLamMFLaiFMToKFFungKSTangHLYanWWChanHWHLaiTSTTongKLLaiKNAcute renal impairment in coronavirus-associated severe acute" exact="respiratory" post="syndromeKidney Int200567269870510.1111/j.1523-1755.2005.67130.x15673319 36.BoothCMClinical features and short-term outcomes of 144"/>
   <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet20203951022350751310.1016/s0140-6736(20)30211-732007143 38.ChafekarAFieldingBCMERS-CoV: understanding the"/>
   <result pre="ORF 4a, ORF 4b, and ORF 5 of Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) are potent interferon antagonistsProtein Cell201341295196110.1007/s13238-013-3096-824318862 41.PooleDNEscuderoDJGostinLOLeblangDTalbotEAResponding"/>
   <result pre="4a, ORF 4b, and ORF 5 of Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) are potent interferon antagonistsProtein Cell201341295196110.1007/s13238-013-3096-824318862 41.PooleDNEscuderoDJGostinLOLeblangDTalbotEAResponding to"/>
   <result pre="causes, clinical manifestation and diagnosis, prevention and control of coronavirus" exact="disease" post="(COVID-19) during the early outbreak period: a scoping reviewInfect"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7467230/results/search/disease/results.xml">
   <result pre="font-style : italic;} J Infect DisJ. Infect. DisjidThe Journal of" exact="Infectious" post="Diseases0022-18991537-6613Oxford University PressUS pmcid: 7467230 doi: 10.1093/infdis/jiz673jiz673 : Supplement"/>
   <result pre="Introduction: AcademicSubjects/MED00860AcademicSubjects/MED00290 Federal and State Action Needed to End the" exact="Infectious" post="Complications of Illicit Drug Use in the United States:"/>
   <result pre="HIVMA’s Advocacy Agenda SpringerSandra A1BarocasJoshua A2WurcelAlysse3NijhawanAnk4ThakararKinna56LynfieldRuth7HurleyHermione8SnowdenJessica9ThorntonAlice10del RioCarlos11on behalf of the" exact="Infectious" post="Diseases Society of America and HIV Medicine Association’s Infectious"/>
   <result pre="Advocacy Agenda SpringerSandra A1BarocasJoshua A2WurcelAlysse3NijhawanAnk4ThakararKinna56LynfieldRuth7HurleyHermione8SnowdenJessica9ThorntonAlice10del RioCarlos11on behalf of the Infectious" exact="Diseases" post="Society of America and HIV Medicine Association’s Infectious Diseases"/>
   <result pre="the Infectious Diseases Society of America and HIV Medicine Association’s" exact="Infectious" post="Diseases and Opioid Use Disorder Working Group[1], Yale School"/>
   <result pre="Infectious Diseases Society of America and HIV Medicine Association’s Infectious" exact="Diseases" post="and Opioid Use Disorder Working Group[1], Yale School of"/>
   <result pre="America and HIV Medicine Association’s Infectious Diseases and Opioid Use" exact="Disorder" post="Working Group[1], Yale School of MedicineUSA[2], Boston UniversityUSA[3], Tufts"/>
   <result pre="New Haven, CT 06510 (sandra.springer@yale.edu). ppub: 2020-10-10epub: 2020-9-9pmc-release: 2020-9-9222Suppl 5Infectious" exact="Diseases" post="and Injection Drug Use: Public Health Burden and ResponseS230S238(C)"/>
   <result pre="and human rights-based response to illicit drug use and associated" exact="infectious diseases." post="Infectious diseases and HIV physicians have an opportunity to"/>
   <result pre="rights-based response to illicit drug use and associated infectious diseases." exact="Infectious" post="diseases and HIV physicians have an opportunity to intervene,"/>
   <result pre="further dissemination. This paper reviews (1) programs most relevant to" exact="infectious diseases" post="in the 2018 SUPPORT Act; (2) opportunities offered by"/>
   <result pre="tools and improving integrated prevention and treatment services for the" exact="infectious diseases" post="and substance use disorder care continuum. By strengthening collaborations"/>
   <result pre="integrated prevention and treatment services for the infectious diseases and" exact="substance use disorder" post="care continuum. By strengthening collaborations between infectious diseases and"/>
   <result pre="prevention and treatment services for the infectious diseases and substance" exact="use disorder" post="care continuum. By strengthening collaborations between infectious diseases and"/>
   <result pre="and substance use disorder care continuum. By strengthening collaborations between" exact="infectious diseases" post="and addiction specialists, including increasing training in substance use"/>
   <result pre="between infectious diseases and addiction specialists, including increasing training in" exact="substance use disorder" post="treatment among infectious diseases and addiction specialists, we can"/>
   <result pre="infectious diseases and addiction specialists, including increasing training in substance" exact="use disorder" post="treatment among infectious diseases and addiction specialists, we can"/>
   <result pre="specialists, including increasing training in substance use disorder treatment among" exact="infectious diseases" post="and addiction specialists, we can decrease morbidity and mortality"/>
   <result pre="epidemics. injection drug use opioid epidemic medications for treatment of" exact="opioid use disorder" post="Funding National Institute on Drug Abuse10.13039/100000026 K02 DA032322 National"/>
   <result pre="injection drug use opioid epidemic medications for treatment of opioid" exact="use disorder" post="Funding National Institute on Drug Abuse10.13039/100000026 K02 DA032322 National"/>
   <result pre="As a result, the incidence of injection drug use (IDU)-related" exact="infections" post="such as human immunodeficiency virus (HIV), hepatitis C virus"/>
   <result pre="incidence of injection drug use (IDU)-related infections such as human" exact="immunodeficiency" post="virus (HIV), hepatitis C virus (HCV), hepatitis B virus"/>
   <result pre="drug use (IDU)-related infections such as human immunodeficiency virus (HIV)," exact="hepatitis C" post="virus (HCV), hepatitis B virus (HBV), and invasive bacterial"/>
   <result pre="such as human immunodeficiency virus (HIV), hepatitis C virus (HCV)," exact="hepatitis" post="B virus (HBV), and invasive bacterial and fungal infections,"/>
   <result pre="hepatitis C virus (HCV), hepatitis B virus (HBV), and invasive" exact="bacterial" post="and fungal infections, including Staphylococcus aureus bacteremia, endocarditis, and"/>
   <result pre="throughout the country [4, 10–12]. In addition to HIV, both" exact="acute" post="HCV and HBV infection incidence has mirrored the rise"/>
   <result pre="10–12]. In addition to HIV, both acute HCV and HBV" exact="infection" post="incidence has mirrored the rise in injection opioids [5,"/>
   <result pre="in injection opioids [5, 13] and hospitalizations for injection opioid-related" exact="endocarditis" post="have increased more than 12-fold in recent years [6,"/>
   <result pre="in the United States. This plan seeks to reduce new" exact="infections" post="by 75% in the next 5 years and by"/>
   <result pre="the HIV epidemic as well as HCV and other IDU-related" exact="infections" post="also requires a focus on the opioid and co-occurring"/>
   <result pre="improve patients’ outcomes and reduce the public health risk of" exact="infectious disease" post="transmission. Nevertheless, a number of barriers to care in"/>
   <result pre="patients’ outcomes and reduce the public health risk of infectious" exact="disease" post="transmission. Nevertheless, a number of barriers to care in"/>
   <result pre="in the United States as well as reduce the other" exact="infectious disease" post="health outcomes. To address these barriers we recommend expanding"/>
   <result pre="the United States as well as reduce the other infectious" exact="disease" post="health outcomes. To address these barriers we recommend expanding"/>
   <result pre="paper are members of a working group created by the" exact="Infectious" post="Diseases Society of America (IDSA) and the HIV Medicine"/>
   <result pre="are members of a working group created by the Infectious" exact="Diseases" post="Society of America (IDSA) and the HIV Medicine Association"/>
   <result pre="on the urgent need to better prevent and treat serious" exact="infections" post="linked to the opioid and stimulant epidemics and underlying"/>
   <result pre="working group developed a policy agenda reflecting issues raised by" exact="infectious diseases" post="and HIV physicians and health care professionals working at"/>
   <result pre="physicians and health care professionals working at the intersection of" exact="infectious diseases" post="and opioid use disorder (OUD) and other SUD epidemics"/>
   <result pre="care professionals working at the intersection of infectious diseases and" exact="opioid use disorder" post="(OUD) and other SUD epidemics more broadly. In this"/>
   <result pre="professionals working at the intersection of infectious diseases and opioid" exact="use disorder" post="(OUD) and other SUD epidemics more broadly. In this"/>
   <result pre="are likely to positively impact the OUD, stimulant epidemics, and" exact="infectious diseases" post="epidemics, and that have been reviewed and approved by"/>
   <result pre="HIVMA Board of Directors as a call to action for" exact="infectious diseases" post="and HIV practitioners. WHAT DOES TREATMENT FOR OUD ENTAIL"/>
   <result pre="IT MATTER TO INFECTIOUS DISEASES CLINICIANS? Medications for treatment of" exact="opioid use disorder" post="(MOUDs, which is now the preferred term to medication-assisted"/>
   <result pre="MATTER TO INFECTIOUS DISEASES CLINICIANS? Medications for treatment of opioid" exact="use disorder" post="(MOUDs, which is now the preferred term to medication-assisted"/>
   <result pre="Methadone is a full opioid agonist and buprenorphine is a" exact="partial" post="opioid agonist, while XR-NTX is an opioid antagonist. All"/>
   <result pre="transmission [14, 15]; and buprenorphine and XR-NTX also improve HIV" exact="viral" post="suppression in people living with HIV, the gold standard"/>
   <result pre="Of the 3 MOUDs, access to methadone and buprenorphine are" exact="limited" post="by regulations. Prescribing requires special training outside postgraduate programs"/>
   <result pre="leave the hospital, readmissions after OUD relapse, and, if concomitant" exact="infection" post="is present, lack of antibiotic adherence and reinfection. Ultimately,"/>
   <result pre="poor clinical outcomes, high health care costs, and excess deaths." exact="Infectious" post="disease specialists are at the frontlines in many hospitals"/>
   <result pre="clinical outcomes, high health care costs, and excess deaths. Infectious" exact="disease" post="specialists are at the frontlines in many hospitals treating"/>
   <result pre="disease specialists are at the frontlines in many hospitals treating" exact="infectious diseases" post="in people who use drugs and have an opportunity"/>
   <result pre="to heighten the response to the opioid epidemic and its" exact="infectious diseases" post="complications. On 24 October 2018, President Trump signed into"/>
   <result pre="October 2018, President Trump signed into law the Substance Use" exact="Disorder" post="Prevention that Promotes Opioid Recovery and Treatment (SUPPORT Act)."/>
   <result pre="pilot studies to identify effective care models for comanagement of" exact="infectious diseases" post="and SUD. 6. Increase funding for national and regional warmlines"/>
   <result pre="10. Develop a national surveillance system to report and track IDU-related" exact="infections" post="to predict and respond to emerging epidemics. 11. Integrate"/>
   <result pre="to the community. 15. Fund research to evaluate non-HIV/ HCV related" exact="infections" post="secondary to OUD/ SUD such as skin and soft"/>
   <result pre="the community. 15. Fund research to evaluate non-HIV/ HCV related infections" exact="secondary" post="to OUD/ SUD such as skin and soft tissue"/>
   <result pre="secondary to OUD/ SUD such as skin and soft tissue" exact="infections" post="and risk of endocarditis with a specific focus on"/>
   <result pre="such as skin and soft tissue infections and risk of" exact="endocarditis" post="with a specific focus on criminal justice involved populations."/>
   <result pre="a specific focus on criminal justice involved populations. Abbreviations: HCV," exact="hepatitis C" post="virus; HIV, human immunodeficiency virus; IDU, injection drug use;"/>
   <result pre="justice involved populations. Abbreviations: HCV, hepatitis C virus; HIV, human" exact="immunodeficiency" post="virus; IDU, injection drug use; MOUD, medication for treatment"/>
   <result pre="virus; IDU, injection drug use; MOUD, medication for treatment of" exact="opioid use disorder;" post="OUD, opioid use disorder; SSPs, syringe services program; SUD,"/>
   <result pre="IDU, injection drug use; MOUD, medication for treatment of opioid" exact="use disorder;" post="OUD, opioid use disorder; SSPs, syringe services program; SUD,"/>
   <result pre="use; MOUD, medication for treatment of opioid use disorder; OUD," exact="opioid use disorder;" post="SSPs, syringe services program; SUD, substance use disorder. IDSA"/>
   <result pre="MOUD, medication for treatment of opioid use disorder; OUD, opioid" exact="use disorder;" post="SSPs, syringe services program; SUD, substance use disorder. IDSA"/>
   <result pre="disorder; OUD, opioid use disorder; SSPs, syringe services program; SUD," exact="substance use disorder." post="IDSA and HIVMA supported the SUPPORT Act, including provisions"/>
   <result pre="OUD, opioid use disorder; SSPs, syringe services program; SUD, substance" exact="use disorder." post="IDSA and HIVMA supported the SUPPORT Act, including provisions"/>
   <result pre="and HIVMA were provisions authorizing funding for the Centers for" exact="Disease" post="Control and Prevention (CDC) to eliminate opioid related infections"/>
   <result pre="for Disease Control and Prevention (CDC) to eliminate opioid related" exact="infections" post="through improved surveillance and prevention for infections linked to"/>
   <result pre="eliminate opioid related infections through improved surveillance and prevention for" exact="infections" post="linked to IDU and funding for the Health Resources"/>
   <result pre="for fiscal year 2019 for the CDC Eliminate Opioid Related" exact="Infections" post="funding provision. The fiscal year 2020 appropriations bills were"/>
   <result pre="and included $10 million for the CDC’s Eliminate Opioid Related" exact="Infections" post="program and $12 million for the new substance use"/>
   <result pre="Opioid Related Infections program and $12 million for the new" exact="substance use disorder" post="loan forgiveness program [21]. Other legislative proposals supported by"/>
   <result pre="Related Infections program and $12 million for the new substance" exact="use disorder" post="loan forgiveness program [21]. Other legislative proposals supported by"/>
   <result pre="Resources Emergency Act modeled after the highly successful Ryan White" exact="HIV/AIDS" post="Program and that would provide funding to states to"/>
   <result pre="a significant barrier to expanding access to SSP services [25]." exact="Increased" post="state and federal funding are needed to expand SSP"/>
   <result pre="and other harm reduction services, including access to MOUD and" exact="infectious diseases" post="treatment services in order to decrease HCV, HIV, IDU-related"/>
   <result pre="34%, respectively [28]. SSPs also can facilitate vaccine uptake for" exact="hepatitis" post="A virus (HAV), HBV, influenza, and invasive pneumococcal disease,"/>
   <result pre="reluctant to seek nonemergent care for skin and soft tissue" exact="infections" post="and postpone medical evaluation until the need is more"/>
   <result pre="is more urgent. Providing care for skin and soft tissue" exact="infections" post="in a supported setting may reduce progression to serious"/>
   <result pre="infections in a supported setting may reduce progression to serious" exact="infections" post="and reduce complications like wound botulism or partial drainage"/>
   <result pre="may reduce progression to serious infections and reduce complications like" exact="wound botulism" post="or partial drainage of abscesses. Given the increased incidence"/>
   <result pre="reduce progression to serious infections and reduce complications like wound" exact="botulism" post="or partial drainage of abscesses. Given the increased incidence"/>
   <result pre="to serious infections and reduce complications like wound botulism or" exact="partial" post="drainage of abscesses. Given the increased incidence of IDU-associated"/>
   <result pre="partial drainage of abscesses. Given the increased incidence of IDU-associated" exact="infections" post="and overdose deaths [1, 2], there is a need"/>
   <result pre="documented need for these programs and their potential to reduce" exact="infectious diseases" post="[34, 35]. Additionally, drug paraphernalia laws, which prohibit possession"/>
   <result pre="who inject drugs having an adequate supply of sterile syringes." exact="Secondary" post="exchange, or the distribution of sterile syringes from 1"/>
   <result pre="the United States. Improving the Care Continuum for Individuals With" exact="Infectious" post="Diseases and Substance Use Disorders Significant work needs to"/>
   <result pre="United States. Improving the Care Continuum for Individuals With Infectious" exact="Diseases" post="and Substance Use Disorders Significant work needs to be"/>
   <result pre="Care Continuum for Individuals With Infectious Diseases and Substance Use" exact="Disorders" post="Significant work needs to be done to improve the"/>
   <result pre="be done to improve the care continuum for people with" exact="infectious diseases" post="and co-occurring SUD. The first step needs to be"/>
   <result pre="treatment programs that integrate substance use care and treatment for" exact="infectious" post="complications in order to improve outcomes are needed. Treatment"/>
   <result pre="outcomes are needed. Treatment of both the SUD and associated" exact="infections" post="(eg, HIV, HCV) can be cost-effective and is associated"/>
   <result pre="HIV, HCV) can be cost-effective and is associated with improved" exact="infection" post="and SUD outcomes [44]. Previous studies have shown that"/>
   <result pre="with either HIV or HCV who receive MOUDs have improved" exact="viral" post="suppression (HIV) [16, 17], achieve sustained virologic response/cure (HCV)"/>
   <result pre="needed to evaluate novel approaches to antimicrobial treatment for IDU-associated" exact="infections" post="such as the role of long-acting glycopeptides. Increased funding"/>
   <result pre="for IDU-associated infections such as the role of long-acting glycopeptides." exact="Increased" post="funding is necessary for other demonstration projects and pilot"/>
   <result pre="pilot studies to identify effective care models for comanagement of" exact="infectious diseases" post="and OUD as well as other SUDs. Additionally, we"/>
   <result pre="need to expand the network of providers prescribing MOUD. Most" exact="infectious diseases" post="and HIV physicians receive little to no formal training"/>
   <result pre="physician assistant schools, residency programs, and within hospitals. While all" exact="infectious diseases" post="and HIV physicians should become familiar with harm reduction"/>
   <result pre="national support for physicians to comanage OUD, SUDs, and co-occurring" exact="infectious diseases." post="Lack of confidence has been identified as a major"/>
   <result pre="to provide support on a number of clinical aspects of" exact="disease" post="management (Table 2) [44]. Increasing funding for national and"/>
   <result pre="substance use treatment. Table 2. Clinical Tools and Resources for" exact="Infectious" post="Disease and HIV Clinicians Buprenorphine practitioner locator https://www.samhsa.gov/medication-assisted-treatment/practitioner-program-data/treatment-practitioner-locator Buprenorphine"/>
   <result pre="use treatment. Table 2. Clinical Tools and Resources for Infectious" exact="Disease" post="and HIV Clinicians Buprenorphine practitioner locator https://www.samhsa.gov/medication-assisted-treatment/practitioner-program-data/treatment-practitioner-locator Buprenorphine waiver"/>
   <result pre="https://pcssnow.org State-targeted response technical assistance consortium https://opioidresponsenetwork.org/ Support for hospital" exact="opioid use disorder" post="treatment https://www.projectshout.org In addition, a reorganization of the buprenorphine"/>
   <result pre="State-targeted response technical assistance consortium https://opioidresponsenetwork.org/ Support for hospital opioid" exact="use disorder" post="treatment https://www.projectshout.org In addition, a reorganization of the buprenorphine"/>
   <result pre="management and other support services to clinics that prescribe MOUDs." exact="Increased" post="funding and reimbursement are also needed for low-barrier care"/>
   <result pre="innovative programs, which have already begun to be tested in" exact="infectious" post="diseases/OUD comanagement [50], have the potential to increase medication"/>
   <result pre="and collaborative decisions on complex patients, such as those with" exact="recurrent" post="endocarditis following valve repair. Evaluation of the impact of"/>
   <result pre="collaborative decisions on complex patients, such as those with recurrent" exact="endocarditis" post="following valve repair. Evaluation of the impact of these"/>
   <result pre="of child-bearing age and in prenatal care to prevent infant" exact="infection" post="[55–57]. Persons experiencing homelessness and unstable housing are similarly"/>
   <result pre="homelessness and unstable housing are similarly at increased risk for" exact="infections" post="associated with SUD. This is, in part, due to"/>
   <result pre="in part, due to the high prevalence of concomitant untreated" exact="mental illness" post="and SUD among these individuals and sanitation issues [58,"/>
   <result pre="our inability to implement effective management strategies for SUD and" exact="infections" post="in this vulnerable population. In addition to ensuring persons"/>
   <result pre="to ensuring persons who experience homelessness receive treatment of their" exact="infectious diseases" post="and SUD through low-barrier and street-based medicine programs, expanding"/>
   <result pre="SUD through low-barrier and street-based medicine programs, expanding access to" exact="stable" post="housing would also improve short- and long-term outcomes and"/>
   <result pre="for HCV infection, there is no national database of IDU-related" exact="infections" post="for surveillance, prevention activities, and program evaluation. This makes"/>
   <result pre="makes it difficult—if not impossible—to identify, predict, and prevent new" exact="infectious disease" post="epidemics related to substance use in the United States."/>
   <result pre="it difficult—if not impossible—to identify, predict, and prevent new infectious" exact="disease" post="epidemics related to substance use in the United States."/>
   <result pre="treatment and HIV resultant from IDU, but not toward the" exact="bacterial" post="and fungal infection complications, partly due to lack of"/>
   <result pre="HIV resultant from IDU, but not toward the bacterial and" exact="fungal infection" post="complications, partly due to lack of integrated surveillance systems"/>
   <result pre="resultant from IDU, but not toward the bacterial and fungal" exact="infection" post="complications, partly due to lack of integrated surveillance systems"/>
   <result pre="increasing National Institutes of Health funding for research into other" exact="infectious diseases" post="related to the worsening SUD epidemics in this country"/>
   <result pre="epidemics in this country are urgently needed. Addressing Substance Use" exact="Disorders" post="in Criminal Justice-Involved Individuals Over half of the criminal"/>
   <result pre="with a 10-fold higher prevalence than found in the general" exact="adult" post="population [62]. As such, employing and enforcing evidence-based treatment"/>
   <result pre="evidence-based treatment guidelines that address the overlap of SUD and" exact="infectious diseases" post="in the criminal justice system has the potential to"/>
   <result pre="care coordination, seamless referral to outpatient care for SUD and" exact="chronic" post="infections, and uninterrupted insurance coverage for CJIP. Intertwined with"/>
   <result pre="OUD leading to fatal overdose, progression of HIV, and HBV/HCV-induced" exact="liver disease" post="[66–68]. Additionally, overall infectious disease testing rates and rates"/>
   <result pre="leading to fatal overdose, progression of HIV, and HBV/HCV-induced liver" exact="disease" post="[66–68]. Additionally, overall infectious disease testing rates and rates"/>
   <result pre="progression of HIV, and HBV/HCV-induced liver disease [66–68]. Additionally, overall" exact="infectious disease" post="testing rates and rates of vaccination against HAV and"/>
   <result pre="of HIV, and HBV/HCV-induced liver disease [66–68]. Additionally, overall infectious" exact="disease" post="testing rates and rates of vaccination against HAV and"/>
   <result pre="against HAV and HBV are low [69, 70]. Integration of" exact="infectious disease" post="management with treatment for OUD in CJIP is an"/>
   <result pre="HAV and HBV are low [69, 70]. Integration of infectious" exact="disease" post="management with treatment for OUD in CJIP is an"/>
   <result pre="reducing these health inequities that will likely lead to improved" exact="infectious disease" post="outcomes and facilitates linkage to care postrelease [16, 17,"/>
   <result pre="these health inequities that will likely lead to improved infectious" exact="disease" post="outcomes and facilitates linkage to care postrelease [16, 17,"/>
   <result pre="also decreases postrelease mortality [72, 73] and increases postrelease HIV" exact="viral" post="suppression [16, 17]. Clearly, prevention and treatment for OUD"/>
   <result pre="[16, 17]. Clearly, prevention and treatment for OUD and associated" exact="infections" post="in this population can improve both individual outcomes and"/>
   <result pre="integrated into jails and prisons to improve substance use and" exact="infectious diseases" post="outcomes. In addition to testing and treatment, access to"/>
   <result pre="testing and treatment, access to harm reduction tools to prevent" exact="infection" post="needs to be prioritized in the CJIP. Harm reduction"/>
   <result pre="drug use but also associated with suboptimal postrelease management of" exact="chronic" post="conditions like liver disease [82]. Increased flexibility of Medicaid,"/>
   <result pre="also associated with suboptimal postrelease management of chronic conditions like" exact="liver disease" post="[82]. Increased flexibility of Medicaid, allowing initiation of insurance"/>
   <result pre="associated with suboptimal postrelease management of chronic conditions like liver" exact="disease" post="[82]. Increased flexibility of Medicaid, allowing initiation of insurance"/>
   <result pre="suboptimal postrelease management of chronic conditions like liver disease [82]." exact="Increased" post="flexibility of Medicaid, allowing initiation of insurance before release"/>
   <result pre="is needed to develop and evaluate strategies to manage non-HIV/HCV–related" exact="infections" post="secondary to IDU, such as skin and soft tissue"/>
   <result pre="needed to develop and evaluate strategies to manage non-HIV/HCV–related infections" exact="secondary" post="to IDU, such as skin and soft tissue infections"/>
   <result pre="infections secondary to IDU, such as skin and soft tissue" exact="infections" post="or infective endocarditis. Despite increasing frequency of endocarditis in"/>
   <result pre="to IDU, such as skin and soft tissue infections or" exact="infective endocarditis." post="Despite increasing frequency of endocarditis in people with OUD/SUD"/>
   <result pre="soft tissue infections or infective endocarditis. Despite increasing frequency of" exact="endocarditis" post="in people with OUD/SUD [7], and high rates of"/>
   <result pre="of history of incarceration in people with skin and soft-tissue" exact="infections" post="[7], there are limited data on the epidemiology of"/>
   <result pre="in people with skin and soft-tissue infections [7], there are" exact="limited" post="data on the epidemiology of disseminated bacterial and fungal"/>
   <result pre="[7], there are limited data on the epidemiology of disseminated" exact="bacterial" post="and fungal infections in CJIP. CONCLUSION Since the time"/>
   <result pre="limited data on the epidemiology of disseminated bacterial and fungal" exact="infections" post="in CJIP. CONCLUSION Since the time this manuscript was"/>
   <result pre="HCV, and other IDU-related infections. As a result, we as" exact="infectious disease" post="specialists need a paradigm shift in our clinical approach,"/>
   <result pre="and other IDU-related infections. As a result, we as infectious" exact="disease" post="specialists need a paradigm shift in our clinical approach,"/>
   <result pre="and aggressive policy changes to support that shift. Throughout history," exact="infectious diseases" post="clinicians have risen to the challenge. In 1998, Dr"/>
   <result pre="Supplement sponsorship. This supplement is sponsored by the Centers for" exact="Disease" post="Control and Prevention. Potential conflict of interests. S. A."/>
   <result pre="submitted work. R. L. reports royalties for a book on" exact="Infectious" post="Disease Surveillance donated to Minnesota Department of Health. All"/>
   <result pre="work. R. L. reports royalties for a book on Infectious" exact="Disease" post="Surveillance donated to Minnesota Department of Health. All other"/>
   <result pre="65:1445–52.28033313 2.RonanMV, HerzigSJHospitalizations related to opioid abuse/dependence and associated serious" exact="infections" post="increased sharply, 2002-12. Health Aff (Millwood)2016; 35:832–7.27140989 3.RuhmCJNonopioid overdose"/>
   <result pre="(Millwood)2019; 38:1216–24.31260365 4.ConradC, BradleyHM, BrozD, et al.; collab: Centers for" exact="Disease" post="Control and Prevention (CDC)Community outbreak of HIV infection linked"/>
   <result pre="collab: Centers for Disease Control and Prevention (CDC)Community outbreak of" exact="HIV infection" post="linked to injection drug use of oxymorphone–Indiana, 2015. MMWR"/>
   <result pre="Centers for Disease Control and Prevention (CDC)Community outbreak of HIV" exact="infection" post="linked to injection drug use of oxymorphone–Indiana, 2015. MMWR"/>
   <result pre="Mortal Wkly Rep2015; 64:443–4.25928470 5.ZibbellJE, AsherAK, PatelRC, et al.Increases in" exact="acute" post="hepatitis C virus infection related to a growing opioid"/>
   <result pre="Wkly Rep2015; 64:443–4.25928470 5.ZibbellJE, AsherAK, PatelRC, et al.Increases in acute" exact="hepatitis C" post="virus infection related to a growing opioid epidemic and"/>
   <result pre="64:443–4.25928470 5.ZibbellJE, AsherAK, PatelRC, et al.Increases in acute hepatitis C" exact="virus infection" post="related to a growing opioid epidemic and associated injection"/>
   <result pre="5.ZibbellJE, AsherAK, PatelRC, et al.Increases in acute hepatitis C virus" exact="infection" post="related to a growing opioid epidemic and associated injection"/>
   <result pre="Health2018; 108:175–81.29267061 6.SchranzAJ, FleischauerA, ChuVH, WuLT, RosenDLTrends in drug use-associated" exact="infective endocarditis" post="and heart valve surgery, 2007 to 2017: a study"/>
   <result pre="108:175–81.29267061 6.SchranzAJ, FleischauerA, ChuVH, WuLT, RosenDLTrends in drug use-associated infective" exact="endocarditis" post="and heart valve surgery, 2007 to 2017: a study"/>
   <result pre="6.SchranzAJ, FleischauerA, ChuVH, WuLT, RosenDLTrends in drug use-associated infective endocarditis" exact="and heart" post="valve surgery, 2007 to 2017: a study of statewide"/>
   <result pre="FleischauerA, ChuVH, WuLT, RosenDLTrends in drug use-associated infective endocarditis and" exact="heart" post="valve surgery, 2007 to 2017: a study of statewide"/>
   <result pre="data. Ann Intern Med2018; 170:31–40.30508432 7.WurcelAG, AndersonJE, ChuiKK, et al.Increasing" exact="infectious" post="endocarditis admissions among young people who inject drugs. Open"/>
   <result pre="Ann Intern Med2018; 170:31–40.30508432 7.WurcelAG, AndersonJE, ChuiKK, et al.Increasing infectious" exact="endocarditis" post="admissions among young people who inject drugs. Open Forum"/>
   <result pre="Open Forum Infect Dis2016; 3:ofw157.27800528 8.FleischauerAT, RuhlL, RheaS, BarnesEHospitalizations for" exact="endocarditis" post="and associated health care costs among persons with diagnosed"/>
   <result pre="Rep2017; 66:569–73.28594786 9.JacksonKA, BohmMK, BrooksJT, et al.Invasive methicillin-resistant Staphylococcus aureus" exact="infections" post="among persons who inject drugs—six sites, 2005–2016. MMWR Morb"/>
   <result pre="Wkly Rep2019; 68:253–4.30870405 11.GoldenMR, LechtenbergR, GlickSN, et al.Outbreak of human" exact="immunodeficiency" post="virus infection among heterosexual persons who are living homeless"/>
   <result pre="Rep2019; 68:253–4.30870405 11.GoldenMR, LechtenbergR, GlickSN, et al.Outbreak of human immunodeficiency" exact="virus infection" post="among heterosexual persons who are living homeless and inject"/>
   <result pre="68:253–4.30870405 11.GoldenMR, LechtenbergR, GlickSN, et al.Outbreak of human immunodeficiency virus" exact="infection" post="among heterosexual persons who are living homeless and inject"/>
   <result pre="Rep2019; 68:344–9.30998671 12.EvansME, LabudaSM, HoganV, et al.Notes from the field:" exact="HIV infection" post="investigation in a rural area—West Virginia, 2017. MMWR Morb"/>
   <result pre="68:344–9.30998671 12.EvansME, LabudaSM, HoganV, et al.Notes from the field: HIV" exact="infection" post="investigation in a rural area—West Virginia, 2017. MMWR Morb"/>
   <result pre="Mortal Wkly Rep2017; 67:257–8. 13.HarrisAM, IqbalK, SchillieS, et al.Increases in" exact="acute" post="hepatitis B virus infections—Kentucky, Tennessee, and West Virginia, 2006–2013."/>
   <result pre="Wkly Rep2017; 67:257–8. 13.HarrisAM, IqbalK, SchillieS, et al.Increases in acute" exact="hepatitis" post="B virus infections—Kentucky, Tennessee, and West Virginia, 2006–2013. MMWR"/>
   <result pre="AliROral substitution treatment of injecting opioid users for prevention of" exact="HIV infection." post="Cochrane Database Syst Rev2011; (8):CD004145. 16.SpringerSA, QiuJ, Saber-TehraniAS, AlticeFLRetention"/>
   <result pre="AlticeFLRetention on buprenorphine is associated with high levels of maximal" exact="viral" post="suppression among HIV-infected opioid dependent released prisoners. PLoS One2012;"/>
   <result pre="One2012; 7:e38335.22719814 17.SpringerSA, Di PaolaA, AzarMM, et al.Extended-release naltrexone improves" exact="viral" post="suppression among incarcerated persons living with HIV with opioid"/>
   <result pre="Sciences, Engineering, and Medicine. Integrating responses at the intersection of" exact="opioid use disorder" post="and infectious disease epidemics: proceedings of a workshop. Washington,"/>
   <result pre="Engineering, and Medicine. Integrating responses at the intersection of opioid" exact="use disorder" post="and infectious disease epidemics: proceedings of a workshop. Washington,"/>
   <result pre="Integrating responses at the intersection of opioid use disorder and" exact="infectious disease" post="epidemics: proceedings of a workshop. Washington, DC: National Academies"/>
   <result pre="responses at the intersection of opioid use disorder and infectious" exact="disease" post="epidemics: proceedings of a workshop. Washington, DC: National Academies"/>
   <result pre="2018. 27.SpringerSA, KorthuisPT, Del RioCintegrating treatment at the intersection of" exact="opioid use disorder" post="and infectious disease epidemics in medical settings: a call"/>
   <result pre="27.SpringerSA, KorthuisPT, Del RioCintegrating treatment at the intersection of opioid" exact="use disorder" post="and infectious disease epidemics in medical settings: a call"/>
   <result pre="RioCintegrating treatment at the intersection of opioid use disorder and" exact="infectious disease" post="epidemics in medical settings: a call for action after"/>
   <result pre="treatment at the intersection of opioid use disorder and infectious" exact="disease" post="epidemics in medical settings: a call for action after"/>
   <result pre="and meta-analysis. Addiction2018; 113:545–63.28891267 29.PeakCM, StousSS, HealyJM, et al.Homelessness and" exact="hepatitis" post="A—San Diego County, 2016–2018 [published online ahead of print"/>
   <result pre="and safety of people who inject drugs during transition from" exact="acute" post="to outpatient care: narrative review with clinical checklist. Postgrad"/>
   <result pre="35.MacArthurGJ, van VelzenE, PalmateerN, et al.Interventions to prevent HIV and" exact="hepatitis C" post="in people who inject drugs: a review of reviews"/>
   <result pre="60:177–97.29990675 42.SalonerB, LandisR, SteinBD, BarryCLThe Affordable Care Act in the" exact="heart" post="of the opioid crisis: evidence from West Virginia. Health"/>
   <result pre="enrollment in Affordable Care Act qualified health plans’ association with" exact="viral" post="suppression [published online ahead of print 18 November 2019]."/>
   <result pre="DurkinMJAddiction medicine consultations reduce readmission rates for patients with serious" exact="infections" post="from opioid use disorder. Clin Infect Dis2019; 68:1935–7.30357363 45.AkiyamaMJ,"/>
   <result pre="consultations reduce readmission rates for patients with serious infections from" exact="opioid use disorder." post="Clin Infect Dis2019; 68:1935–7.30357363 45.AkiyamaMJ, NortonBL, ArnstenJH, AgyemangL, HeoM,"/>
   <result pre="reduce readmission rates for patients with serious infections from opioid" exact="use disorder." post="Clin Infect Dis2019; 68:1935–7.30357363 45.AkiyamaMJ, NortonBL, ArnstenJH, AgyemangL, HeoM,"/>
   <result pre="Dis2019; 68:1935–7.30357363 45.AkiyamaMJ, NortonBL, ArnstenJH, AgyemangL, HeoM, LitwinAHIntensive models of" exact="hepatitis C" post="care for people who inject drugs receiving opioid agonist"/>
   <result pre="trial. Ann Intern Med2019; 170:594–603.30959528 46.AkiyamaM, LipseyD, MoonseongH, et al.Low" exact="hepatitis" post="reinfection following direct acting antiviral therapy among people who"/>
   <result pre="WalshSL, ThorntonAC, NuzzoPA, LofwallMROutpatient parenteral antimicrobial therapy plus buprenorphine for" exact="opioid use disorder" post="and severe injection-related infections [published online ahead of print"/>
   <result pre="ThorntonAC, NuzzoPA, LofwallMROutpatient parenteral antimicrobial therapy plus buprenorphine for opioid" exact="use disorder" post="and severe injection-related infections [published online ahead of print"/>
   <result pre="therapy plus buprenorphine for opioid use disorder and severe injection-related" exact="infections" post="[published online ahead of print 26 July 2019]. Clin"/>
   <result pre="50.TalalAH, AndrewsP, McleodA, et al.Integrated, co-located, telemedicine-based treatment approaches for" exact="hepatitis C" post="virus management in opioid use disorder patients on methadone."/>
   <result pre="co-located, telemedicine-based treatment approaches for hepatitis C virus management in" exact="opioid use disorder" post="patients on methadone. Clin Infect Dis2019; 69:323–31.30329042 51.KroelingerCD, RiceME,"/>
   <result pre="telemedicine-based treatment approaches for hepatitis C virus management in opioid" exact="use disorder" post="patients on methadone. Clin Infect Dis2019; 69:323–31.30329042 51.KroelingerCD, RiceME,"/>
   <result pre="Dis2019; 69:323–31.30329042 51.KroelingerCD, RiceME, CoxS, et al.State strategies to address" exact="opioid use disorder" post="among pregnant and postpartum women and infants prenatally exposed"/>
   <result pre="69:323–31.30329042 51.KroelingerCD, RiceME, CoxS, et al.State strategies to address opioid" exact="use disorder" post="among pregnant and postpartum women and infants prenatally exposed"/>
   <result pre="al.State strategies to address opioid use disorder among pregnant and" exact="postpartum" post="women and infants prenatally exposed to substances, including infants"/>
   <result pre="women and infants prenatally exposed to substances, including infants with" exact="neonatal abstinence syndrome." post="MMWR Morb Mortal Wkly Rep2019; 68:777–83.31513558 52.collab: American College"/>
   <result pre="and infants prenatally exposed to substances, including infants with neonatal" exact="abstinence syndrome." post="MMWR Morb Mortal Wkly Rep2019; 68:777–83.31513558 52.collab: American College"/>
   <result pre="neonatal abstinence syndrome. MMWR Morb Mortal Wkly Rep2019; 68:777–83.31513558 52.collab:" exact="American" post="College of Obstetricians and Gynecologists. Routine tests during pregnancy."/>
   <result pre="2019. 53.collab: US Preventive Services Task Force. Draft recommendation statement" exact="hepatitis C" post="virus infection in adolescents and adults: screening. Rockville, MD:"/>
   <result pre="US Preventive Services Task Force. Draft recommendation statement hepatitis C" exact="virus infection" post="in adolescents and adults: screening. Rockville, MD: USPSTF, 2019."/>
   <result pre="Preventive Services Task Force. Draft recommendation statement hepatitis C virus" exact="infection" post="in adolescents and adults: screening. Rockville, MD: USPSTF, 2019."/>
   <result pre="Rockville, MD: USPSTF, 2019. 54.ZibbellJE, AsherAK, PatelRC, et al.Increases in" exact="acute" post="hepatitis C virus infection related to a growing opioid"/>
   <result pre="MD: USPSTF, 2019. 54.ZibbellJE, AsherAK, PatelRC, et al.Increases in acute" exact="hepatitis C" post="virus infection related to a growing opioid epidemic and"/>
   <result pre="2019. 54.ZibbellJE, AsherAK, PatelRC, et al.Increases in acute hepatitis C" exact="virus infection" post="related to a growing opioid epidemic and associated injection"/>
   <result pre="54.ZibbellJE, AsherAK, PatelRC, et al.Increases in acute hepatitis C virus" exact="infection" post="related to a growing opioid epidemic and associated injection"/>
   <result pre="Public Health2018; 108:175–81.29267061 55.LyKN, JilesRB, TeshaleEH, FosterMA, PesanoRL, HolmbergSDHepatitis C" exact="virus infection" post="among reproductive-aged women and children in the United States,"/>
   <result pre="Health2018; 108:175–81.29267061 55.LyKN, JilesRB, TeshaleEH, FosterMA, PesanoRL, HolmbergSDHepatitis C virus" exact="infection" post="among reproductive-aged women and children in the United States,"/>
   <result pre="56.CottrellEB, ChouR, WassonN, RahmanB, GuiseJMReducing risk for mother-to-infant transmission of" exact="hepatitis C" post="virus: a systematic review for the U.S. Preventive Services"/>
   <result pre="38:1289–97. 59.BarocasJA, BeiserM, LeónC, GaetaJM, O’ConnellJJ, LinasBPExperience and outcomes of" exact="hepatitis C" post="treatment in a cohort of homeless and marginally housed"/>
   <result pre="72:129–37.30962036 61.BangsbergDR, HechtFM, CharleboisED, et al.Adherence to protease inhibitors, HIV-1" exact="viral" post="load, and development of drug resistance in an indigent"/>
   <result pre="of Justice, 2017. 63.HennesseyKA, KimAA, GriffinV, CollinsNT, WeinbaumCM, SabinKPrevalence of" exact="infection" post="with hepatitis B and C viruses and co-infection with"/>
   <result pre="2017. 63.HennesseyKA, KimAA, GriffinV, CollinsNT, WeinbaumCM, SabinKPrevalence of infection with" exact="hepatitis" post="B and C viruses and co-infection with HIV in"/>
   <result pre="and co-infection with HIV in three jails: a case for" exact="viral hepatitis" post="prevention in jails in the United States. J Urban"/>
   <result pre="co-infection with HIV in three jails: a case for viral" exact="hepatitis" post="prevention in jails in the United States. J Urban"/>
   <result pre="States. J Urban Health2009; 86:93–105. 64.ZallerN, Brinkley-RubinsteinLIncarceration, drug use, and" exact="infectious" post="diseases: a syndemic still not addressed. Lancet Infect Dis2018;"/>
   <result pre="Public Health Rep2001; 116:203–9. 71.AkiyamaMJ, ColumbusD, MacDonaldR, et al.Linkage to" exact="hepatitis C" post="care after incarceration in jail: a prospective, single arm"/>
   <result pre="pre-exposure prophylaxis for people involved in criminal justice systems. Curr" exact="HIV/AIDS" post="Rep2018; 15:93–5.29516265 77.SanderG, Shirley-BeavanS, StoneKThe global state of harm"/>
   <result pre="Infect Dis doi: 10.1093/cid/ciz383. 79.HeT, LiK, RobertsMS, et al.Prevention of" exact="hepatitis C" post="by screening and treatment in U.S. prisons. Ann Intern"/>
   <result pre="BrockmannBW, VohrF, SpauldingA, MontagueBTA budget impact analysis of newly available" exact="hepatitis C" post="therapeutics and the financial burden on a state correctional"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7467512/results/search/disease/results.xml">
   <result pre="The current COVID-19 pandemic has resulted in high rates of" exact="infection" post="and death, as well as widespread social disruption and"/>
   <result pre="in place to curb the pandemic, will impact people with" exact="mental disorders." post="We aim to study the effect of pandemics and"/>
   <result pre="and epidemics on mental health outcomes for people with premorbid" exact="mental disorders." post="Methods and analysis With our predefined search strategy, we"/>
   <result pre="studies reporting on mental health outcomes in people with pre-existing" exact="mental disorders" post="during pandemic and epidemic settings. Search dates are planned"/>
   <result pre="reviewers. Studies involving non-clinical populations or patients diagnosed with a" exact="mental disorder" post="during a pandemic/epidemic will be excluded. We will include"/>
   <result pre="the impact of pandemics and epidemics on those with pre-existing" exact="mental disorders." post="Knowledge generated may inform future intervention studies as well"/>
   <result pre="Systematic review registration PROSPERO registration number: CRD42020179611. psychiatry public health" exact="depression" post="&amp;amp; mood disorders anxiety disorders adult psychiatry COVID-19 Strengths"/>
   <result pre="registration PROSPERO registration number: CRD42020179611. psychiatry public health depression &amp;amp;" exact="mood disorders" post="anxiety disorders adult psychiatry COVID-19 Strengths and limitations of"/>
   <result pre="registration number: CRD42020179611. psychiatry public health depression &amp;amp; mood disorders" exact="anxiety" post="disorders adult psychiatry COVID-19 Strengths and limitations of this"/>
   <result pre="CRD42020179611. psychiatry public health depression &amp;amp; mood disorders anxiety disorders" exact="adult" post="psychiatry COVID-19 Strengths and limitations of this study A"/>
   <result pre="review is the lack of data pertaining to individuals with" exact="mental disorders" post="during pandemic or epidemic settings; limited data may prevent"/>
   <result pre="to individuals with mental disorders during pandemic or epidemic settings;" exact="limited" post="data may prevent us from conducting subgroup meta-analyses, as"/>
   <result pre="populations.3–5 Indeed, the 2003 SARS epidemic was associated with increased" exact="emotional" post="distress and with completed suicides.6 7 Further, during the"/>
   <result pre="to stress (eg, substance use), and perhaps, the onset of" exact="mental disorders," post="as a result of the COVID-19 pandemic.9 Governing bodies"/>
   <result pre="isolation and loneliness are strong risk factors for depressive symptomatology," exact="anxiety" post="and substance use, as well as suicidal ideation and"/>
   <result pre="of mood disturbance and had an increased vulnerability to clinical" exact="mental disorders" post="during pandemic settings. In a recent study, Italian physicians"/>
   <result pre="COVID-19-positive patients were more likely to suffer from symptoms of" exact="anxiety" post="and depression than those who visited fewer of these"/>
   <result pre="were more likely to suffer from symptoms of anxiety and" exact="depression" post="than those who visited fewer of these patients.16 Interestingly,"/>
   <result pre="outbreak in Singapore were also at heightened risk for developing" exact="mood disorders," post="anxiety disorders and post-traumatic stress disorder.17 Emerging literature certainly"/>
   <result pre="Singapore were also at heightened risk for developing mood disorders," exact="anxiety" post="disorders and post-traumatic stress disorder.17 Emerging literature certainly suggests"/>
   <result pre="during COVID-19 will be at a higher risk for developing" exact="mental disorders." post="Importantly, the stress of pandemics and epidemics often disproportionately"/>
   <result pre="low-income workers facing job insecurity are more likely to experience" exact="anxiety" post="during quarantine measures.20 Evidence suggests that people with pre-existing"/>
   <result pre="anxiety during quarantine measures.20 Evidence suggests that people with pre-existing" exact="mental disorders" post="are more susceptible to the effects of major life"/>
   <result pre="of 1700 people who were quarantined during the Middle East" exact="respiratory" post="syndrome (MERS) Korean outbreak in 2015. After controlling for"/>
   <result pre="1700 people who were quarantined during the Middle East respiratory" exact="syndrome" post="(MERS) Korean outbreak in 2015. After controlling for sex"/>
   <result pre="2015. After controlling for sex and age, having a premorbid" exact="mental disorder" post="increased the likelihood of persistent anxiety and anger at"/>
   <result pre="having a premorbid mental disorder increased the likelihood of persistent" exact="anxiety" post="and anger at 4–6 months post-quarantine.21 The disruption in"/>
   <result pre="COVID-19 pandemic may contribute to worsened outcomes for people with" exact="mental disorders." post="A number of mental health experts have expressed concern"/>
   <result pre="in the UK, and 70% reported having lived experience with" exact="mental disorders." post="Stakeholders were most often concerned about the effects of"/>
   <result pre="such as the impact of loneliness on people with pre-existing" exact="mental disorders." post="Other prevailing concerns included lack of access to mental"/>
   <result pre="access to mental health supports and services, exacerbation of pre-existing" exact="mental disorders," post="and increased anxiety and depressive symptomatology.9 In addition to"/>
   <result pre="supports and services, exacerbation of pre-existing mental disorders, and increased" exact="anxiety" post="and depressive symptomatology.9 In addition to the social consequences"/>
   <result pre="the social consequences related to COVID-19, viruses can also induce" exact="neurotoxicity" post="and lead to permanent damage to the central nervous"/>
   <result pre="like SARS-CoV-2 to exacerbate pre-existing neuropsychiatric symptoms, individuals with premorbid" exact="mental disorders" post="may be disproportionately impacted by pandemics and epidemics through"/>
   <result pre="patients and society on how to best support patients with" exact="mental disorders" post="during epidemics/pandemics. We seek to answer the following: For"/>
   <result pre="We seek to answer the following: For people with pre-existing" exact="mental disorders," post="what is the impact of pandemics and epidemics on"/>
   <result pre="these patients? What has been beneficial in supporting patients with" exact="mental illness" post="during past health crises? Objectives Our primary objective seeks"/>
   <result pre="patients with mental illness during past health crises? Objectives Our" exact="primary" post="objective seeks to determine the impact of pandemics and"/>
   <result pre="and epidemics on the mental health of people with pre-existing" exact="mental disorders." post="The majority of recent reviews published on COVID-19 and"/>
   <result pre="in this context; however, this review only examined persons with" exact="psychosis" post="and excluded participants with other mental disorders.30 Further, the"/>
   <result pre="the previously mentioned review included studies reporting on patients whose" exact="psychosis" post="presented during an epidemic/pandemic. In contrast, our planned review"/>
   <result pre="the effects of pandemics or epidemics on individuals with any" exact="mental disorder," post="not limited to individuals affected by psychosis, and will"/>
   <result pre="pandemics or epidemics on individuals with any mental disorder, not" exact="limited" post="to individuals affected by psychosis, and will not report"/>
   <result pre="the impact of pandemics and epidemics on people with premorbid" exact="mental disorders." post="We will also conduct subgroup analyses if an adequate"/>
   <result pre="a hypothesis. Proposed subgroup analyses are as follows: Type of" exact="mental disorder." post="Identity factors (age, sex, gender, ethnicity, sexual orientation): We"/>
   <result pre="years), seniors, women, females, ethnic minorities, LGBTQ+ community members) with" exact="mental disorders" post="will experience worse mental health outcomes during pandemics and"/>
   <result pre="strongest association with adverse psychiatric outcomes in people with pre-existing" exact="mental disorders." post="While data on those with pre-existing mental disorders may"/>
   <result pre="with pre-existing mental disorders. While data on those with pre-existing" exact="mental disorders" post="may be scant, data from the general population suggest"/>
   <result pre="diseases.2 11 12 We have two additional objectives as follows:" exact="Secondary" post="objective: Assimilate and examine the current evidence for neuropsychiatric"/>
   <result pre="manifestations of SARS-CoV-2 and the impact on patients with pre-existing" exact="mental disorders." post="For this particular objective, we will only report on"/>
   <result pre="Types of participants Our population of interest is people with" exact="mental disorders" post="whose diagnosis predated the onset of a pandemic or"/>
   <result pre="Studies exploring mental health outcomes in the general population, or" exact="mental disorders" post="diagnosed during a pandemic or epidemic, will not be"/>
   <result pre="on specific diseases and their impact on people with pre-existing" exact="mental disorders," post="such as HIV/AIDS, we will conduct subgroup analyses (eg,"/>
   <result pre="epidemic. Outcomes We will examine the following mental health outcomes:" exact="anxiety" post="and depressive symptomatology, substance use, relapse rate, suicidal behaviour"/>
   <result pre="use, and suicidal ideation and behaviour, such as the Beck" exact="Depression" post="Inventory or Alcohol Use Disorders Identification Test. We expect"/>
   <result pre="behaviour, such as the Beck Depression Inventory or Alcohol Use" exact="Disorders" post="Identification Test. We expect that other studies could report"/>
   <result pre="studies cannot identify outcomes with any degree of certainty. Our" exact="secondary" post="objective is to synthesise the literature on the neuropsychiatric"/>
   <result pre="the novel SARS-CoV-2 can present neuropsychiatrically in people with pre-existing" exact="mental disorders," post="and also exacerbate these pre-existing conditions, is exceptionally important"/>
   <result pre="explore measures that have been beneficial in supporting patients with" exact="mental disorders" post="during past health crises. These resources will be identified"/>
   <result pre="search to identify virtual healthcare tools. Outcomes and prioritisation The" exact="primary" post="outcomes are as follows: anxiety and depressive symptomatology, substance"/>
   <result pre="tools. Outcomes and prioritisation The primary outcomes are as follows:" exact="anxiety" post="and depressive symptomatology, substance use, relapse rate (a change"/>
   <result pre="crisis intervention uptake and mental health-related family physician visits. Our" exact="secondary" post="outcomes are neuropsychiatric signs and symptoms of COVID-19, including,"/>
   <result pre="are neuropsychiatric signs and symptoms of COVID-19, including, but not" exact="limited" post="to confusion, apathy and delirium. Our third outcome is"/>
   <result pre="were identified by a combination of search terms relating to" exact="mental disorders" post="and pandemics (refer to table 1). In addition to"/>
   <result pre="Wuhan.mp.)3 ('COVID-19' or '2019-nCov' or 'SARS-CoV-2').mp. or exp Coronavirus Infections/4" exact="Severe" post="Acute Respiratory Syndrome/5 severe acute respiratory syndrom*.ti, ab, kf.6"/>
   <result pre="('COVID-19' or '2019-nCov' or 'SARS-CoV-2').mp. or exp Coronavirus Infections/4 Severe" exact="Acute" post="Respiratory Syndrome/5 severe acute respiratory syndrom*.ti, ab, kf.6 (sars"/>
   <result pre="or '2019-nCov' or 'SARS-CoV-2').mp. or exp Coronavirus Infections/4 Severe Acute" exact="Respiratory" post="Syndrome/5 severe acute respiratory syndrom*.ti, ab, kf.6 (sars or"/>
   <result pre="'SARS-CoV-2').mp. or exp Coronavirus Infections/4 Severe Acute Respiratory Syndrome/5 severe" exact="acute" post="respiratory syndrom*.ti, ab, kf.6 (sars or sars-cov).ti, ab, kf.7"/>
   <result pre="or exp Coronavirus Infections/4 Severe Acute Respiratory Syndrome/5 severe acute" exact="respiratory" post="syndrom*.ti, ab, kf.6 (sars or sars-cov).ti, ab, kf.7 disease"/>
   <result pre="acute respiratory syndrom*.ti, ab, kf.6 (sars or sars-cov).ti, ab, kf.7" exact="disease" post="outbreaks/ or exp epidemics/8 (disease outbreak* or pandemic* or"/>
   <result pre="epidemic*).ti, ab, kf.9 (mers virus or mers-cov or middle east*" exact="respiratory" post="syndrom*).ti, ab, kf.10 Influenza Pandemic, 1918–1919/11 Influenza A Virus,"/>
   <result pre="spanish flu or h1n1).ti, ab, kf.13 exp HIV Infections/ or" exact="Acquired" post="Immunodeficiency Syndrome/14 (HIV or AIDS or human immunodeficienc* syndrome*"/>
   <result pre="flu or h1n1).ti, ab, kf.13 exp HIV Infections/ or Acquired" exact="Immunodeficiency" post="Syndrome/14 (HIV or AIDS or human immunodeficienc* syndrome* or"/>
   <result pre="Immunodeficiency Syndrome/14 (HIV or AIDS or human immunodeficienc* syndrome* or" exact="acquired" post="immunodeficiency syndrome*).ti, ab, kf.15 Zika Virus Infection/ or Zika"/>
   <result pre="Syndrome/14 (HIV or AIDS or human immunodeficienc* syndrome* or acquired" exact="immunodeficiency" post="syndrome*).ti, ab, kf.15 Zika Virus Infection/ or Zika Virus/16"/>
   <result pre="kf.15 Zika Virus Infection/ or Zika Virus/16 zika.ti, ab, kf.17" exact="Hemorrhagic" post="Fever, Ebola/18 ebola.ti, ab, kf.19 1 or 2 or"/>
   <result pre="2527 (mental illness* or mental disorder* or mental health or" exact="anxiety" post="or anxious or schizophren* or posttraumatic stress disorder* or"/>
   <result pre="traumatic stress disorder* or bipolar or major depressi* disorder* or" exact="depression" post="or major depressive episode* or postpartum depression or ADHD"/>
   <result pre="major depressi* disorder* or depression or major depressive episode* or" exact="postpartum" post="depression or ADHD or attention deficit disorder or attention"/>
   <result pre="depressi* disorder* or depression or major depressive episode* or postpartum" exact="depression" post="or ADHD or attention deficit disorder or attention deficit"/>
   <result pre="or major depressive episode* or postpartum depression or ADHD or" exact="attention deficit disorder" post="or attention deficit hyperactivity disorder* or panic disorder* or"/>
   <result pre="psychos?s or addiction* or neurobehavioural or emotions or psychiatr* or" exact="mood disorder" post="or adjustment disorder or somatic or somatoform or delusional"/>
   <result pre="or neurobehavioural or emotions or psychiatr* or mood disorder or" exact="adjustment disorder" post="or somatic or somatoform or delusional disorder or mani*"/>
   <result pre="mood disorder or adjustment disorder or somatic or somatoform or" exact="delusional disorder" post="or mani* or affective or suicid* or mental status"/>
   <result pre="or affective or depress* or anxi* or obsessive compulsive or" exact="panic disorder" post="or post-trauma* or posttrauma* or PTSD or neurosis or"/>
   <result pre="or panic disorder or post-trauma* or posttrauma* or PTSD or" exact="neurosis" post="or neurotic or bipolar or mania or manic or"/>
   <result pre="mania or manic or schizophreni* or intelligence quotient or IQ" exact="or mental retardation" post="or intellectual disability or learning disability or autis* or"/>
   <result pre="or manic or schizophreni* or intelligence quotient or IQ or" exact="mental retardation" post="or intellectual disability or learning disability or autis* or"/>
   <result pre="schizophreni* or intelligence quotient or IQ or mental retardation or" exact="intellectual disability" post="or learning disability or autis* or asperger* or attention"/>
   <result pre="quotient or IQ or mental retardation or intellectual disability or" exact="learning disability" post="or autis* or asperger* or attention deficit or ADHD"/>
   <result pre="exp disorders of excessive somnolence/ or exp parasomnias/ or exp" exact="psychomotor" post="disorders/ or exp dementia/ or exp neurocognitive disorders/ or"/>
   <result pre="exp hallucinations/ or exp delusions/ or exp apathy/ or exp" exact="psychomotor" post="agitation/ or exp euphoria/ or exp aggression/ or exp"/>
   <result pre="amnesia/ or exp catatonia/ or exp personality disorders/ or exp" exact="schizophrenia" post="spectrum/) and other psychotic disorders/) or exp mental disorders/"/>
   <result pre="mood disorders/ or exp depression/ or exp anxiety/ or exp" exact="anxiety" post="disorders/ or exp obsessive-compulsive disorder/ or exp panic disorder/"/>
   <result pre="or exp pneumonia/) and Wuhan.mp.)3 ('COVID-19' or '2019-nCov' or 'SARS-CoV-2').mp.4" exact="Severe" post="Acute Respiratory Syndrome/5 severe acute respiratory syndrom*.ti, ab.6 (sars"/>
   <result pre="exp pneumonia/) and Wuhan.mp.)3 ('COVID-19' or '2019-nCov' or 'SARS-CoV-2').mp.4 Severe" exact="Acute" post="Respiratory Syndrome/5 severe acute respiratory syndrom*.ti, ab.6 (sars or"/>
   <result pre="pneumonia/) and Wuhan.mp.)3 ('COVID-19' or '2019-nCov' or 'SARS-CoV-2').mp.4 Severe Acute" exact="Respiratory" post="Syndrome/5 severe acute respiratory syndrom*.ti, ab.6 (sars or sars-cov).ti,"/>
   <result pre="('COVID-19' or '2019-nCov' or 'SARS-CoV-2').mp.4 Severe Acute Respiratory Syndrome/5 severe" exact="acute" post="respiratory syndrom*.ti, ab.6 (sars or sars-cov).ti, ab.7 disease outbreaks/"/>
   <result pre="or '2019-nCov' or 'SARS-CoV-2').mp.4 Severe Acute Respiratory Syndrome/5 severe acute" exact="respiratory" post="syndrom*.ti, ab.6 (sars or sars-cov).ti, ab.7 disease outbreaks/ or"/>
   <result pre="Syndrome/5 severe acute respiratory syndrom*.ti, ab.6 (sars or sars-cov).ti, ab.7" exact="disease" post="outbreaks/ or exp epidemics/8 (disease outbreak* or pandemic* or"/>
   <result pre="or epidemic*).ti, ab.9 (mers virus or mers-cov or middle east*" exact="respiratory" post="syndrom*).ti, ab.10 Influenza Pandemic, 1918–1919/11 Influenza A Virus, H1N1"/>
   <result pre="or spanish flu or h1n1).ti, ab.13 exp HIV Infections/ or" exact="Acquired" post="Immunodeficiency Syndrome/14 exp HIV/15 (HIV or AIDS or human"/>
   <result pre="spanish flu or h1n1).ti, ab.13 exp HIV Infections/ or Acquired" exact="Immunodeficiency" post="Syndrome/14 exp HIV/15 (HIV or AIDS or human immunodeficienc*"/>
   <result pre="exp HIV/15 (HIV or AIDS or human immunodeficienc* syndrome* or" exact="acquired" post="immunodeficiency syndrome*).ti, ab.16 exp Infectious Disorders/ or exp Viral"/>
   <result pre="HIV/15 (HIV or AIDS or human immunodeficienc* syndrome* or acquired" exact="immunodeficiency" post="syndrome*).ti, ab.16 exp Infectious Disorders/ or exp Viral Disorders/17"/>
   <result pre="or human immunodeficienc* syndrome* or acquired immunodeficiency syndrome*).ti, ab.16 exp" exact="Infectious" post="Disorders/ or exp Viral Disorders/17 zika.ti, ab.18 Hemorrhagic Fever,"/>
   <result pre="or acquired immunodeficiency syndrome*).ti, ab.16 exp Infectious Disorders/ or exp" exact="Viral" post="Disorders/17 zika.ti, ab.18 Hemorrhagic Fever, Ebola/19 ebola.ti, ab.20 1"/>
   <result pre="ab.16 exp Infectious Disorders/ or exp Viral Disorders/17 zika.ti, ab.18" exact="Hemorrhagic" post="Fever, Ebola/19 ebola.ti, ab.20 1 or 2 or 3"/>
   <result pre="Disorders/30 (mental illness* or mental disorder* or mental health or" exact="anxiety" post="or anxious or schizophren* or posttraumatic stress disorder* or"/>
   <result pre="traumatic stress disorder* or bipolar or major depressi* disorder* or" exact="depression" post="or major depressive episode* or postpartum depression or ADHD"/>
   <result pre="major depressi* disorder* or depression or major depressive episode* or" exact="postpartum" post="depression or ADHD or attention deficit disorder or attention"/>
   <result pre="depressi* disorder* or depression or major depressive episode* or postpartum" exact="depression" post="or ADHD or attention deficit disorder or attention deficit"/>
   <result pre="or major depressive episode* or postpartum depression or ADHD or" exact="attention deficit disorder" post="or attention deficit hyperactivity disorder* or panic disorder* or"/>
   <result pre="psychos?s or addiction* or neurobehavioural or emotions or psychiatr* or" exact="mood disorder" post="or adjustment disorder or somatic or somatoform or delusional"/>
   <result pre="or neurobehavioural or emotions or psychiatr* or mood disorder or" exact="adjustment disorder" post="or somatic or somatoform or delusional disorder or mani*"/>
   <result pre="mood disorder or adjustment disorder or somatic or somatoform or" exact="delusional disorder" post="or mani* or affective or suicid* or mental status"/>
   <result pre="or affective or depress* or anxi* or obsessive compulsive or" exact="panic disorder" post="or post-trauma* or posttrauma* or PTSD or neurosis or"/>
   <result pre="or panic disorder or post-trauma* or posttrauma* or PTSD or" exact="neurosis" post="or neurotic or bipolar or mania or manic or"/>
   <result pre="mania or manic or schizophreni* or intelligence quotient or IQ" exact="or mental retardation" post="or intellectual disability or learning disability or autis* or"/>
   <result pre="or manic or schizophreni* or intelligence quotient or IQ or" exact="mental retardation" post="or intellectual disability or learning disability or autis* or"/>
   <result pre="schizophreni* or intelligence quotient or IQ or mental retardation or" exact="intellectual disability" post="or learning disability or autis* or asperger* or attention"/>
   <result pre="quotient or IQ or mental retardation or intellectual disability or" exact="learning disability" post="or autis* or asperger* or attention deficit or ADHD"/>
   <result pre="exp disorders of excessive somnolence/ or exp parasomnias/ or exp" exact="psychomotor" post="disorders/ or exp dementia/ or exp neurocognitive disorders/ or"/>
   <result pre="exp hallucinations/ or exp delusions/ or exp apathy/ or exp" exact="psychomotor" post="agitation/ or exp euphoria/ or exp aggression/ or exp"/>
   <result pre="amnesia/ or exp catatonia/ or exp personality disorders/ or exp" exact="schizophrenia" post="spectrum/) and other psychotic disorders/) or exp mental disorders/"/>
   <result pre="mood disorders/ or exp depression/ or exp anxiety/ or exp" exact="anxiety" post="disorders/ or exp obsessive-compulsive disorder/ or exp panic disorder/"/>
   <result pre="(MH &quot;Coronavirus+&quot;) OR &quot;coronavirus&quot; OR (MH &quot;Coronavirus Infections+&quot;)2 (MH &quot;Severe" exact="Acute" post="Respiratory Syndrome&quot;) OR (MH &quot;SARS Virus&quot;) OR (MH&quot;Respiratory Distress"/>
   <result pre="&quot;Coronavirus+&quot;) OR &quot;coronavirus&quot; OR (MH &quot;Coronavirus Infections+&quot;)2 (MH &quot;Severe Acute" exact="Respiratory" post="Syndrome&quot;) OR (MH &quot;SARS Virus&quot;) OR (MH&quot;Respiratory Distress Syndrome,"/>
   <result pre="(MH &quot;SARS Virus&quot;) OR (MH&quot;Respiratory Distress Syndrome, Acute&quot;) OR &quot;Severe" exact="Acute" post="Respiratory Syndrome/&quot;OR (MH &quot;Respiratory Distress Syndrome&quot;)3 AB severe acute"/>
   <result pre="&quot;SARS Virus&quot;) OR (MH&quot;Respiratory Distress Syndrome, Acute&quot;) OR &quot;Severe Acute" exact="Respiratory" post="Syndrome/&quot;OR (MH &quot;Respiratory Distress Syndrome&quot;)3 AB severe acute respiratory"/>
   <result pre="&quot;Severe Acute Respiratory Syndrome/&quot;OR (MH &quot;Respiratory Distress Syndrome&quot;)3 AB severe" exact="acute" post="respiratory syndrom*4 (MH &quot;Disease Outbreaks&quot;) OR &quot;disease outbreaks&quot;5 &quot;pandemic&quot;6"/>
   <result pre="Acute Respiratory Syndrome/&quot;OR (MH &quot;Respiratory Distress Syndrome&quot;)3 AB severe acute" exact="respiratory" post="syndrom*4 (MH &quot;Disease Outbreaks&quot;) OR &quot;disease outbreaks&quot;5 &quot;pandemic&quot;6 &quot;epidemic&quot;7"/>
   <result pre="&quot;Disease Outbreaks&quot;) OR &quot;disease outbreaks&quot;5 &quot;pandemic&quot;6 &quot;epidemic&quot;7 (MH &quot;Middle East" exact="Respiratory" post="SyndromeCoronavirus&quot;) OR (MH &quot;Middle EastRespiratory Syndrome&quot;) OR &quot;mers&quot;8 (MH"/>
   <result pre="(MH &quot;Hemorrhagic Fever, Ebola&quot;) OR &quot;Hemorrhagic Fever, Ebola&quot; OR (MH&quot;Hemorrhagic" exact="Fever" post="with Renal Syndrome&quot;) OR (MH &quot;Hemorrhagic Fevers, Viral&quot;)OR (MH"/>
   <result pre="Fever, Ebola&quot;) OR &quot;Hemorrhagic Fever, Ebola&quot; OR (MH&quot;Hemorrhagic Fever with" exact="Renal" post="Syndrome&quot;) OR (MH &quot;Hemorrhagic Fevers, Viral&quot;)OR (MH &quot;Dengue Hemorrhagic"/>
   <result pre="with Renal Syndrome&quot;) OR (MH &quot;Hemorrhagic Fevers, Viral&quot;)OR (MH &quot;Dengue" exact="Hemorrhagic" post="Fever&quot;) OR (MH &quot;Intracranial Hemorrhage&quot;)16 &quot;zika&quot;17 &quot;ebola&quot;18 1 OR"/>
   <result pre="illness&quot;43 &quot;(mental illness* or mental disorder* or mental health or" exact="anxiety" post="or anxious orschizophren* or posttraumatic stress disorder* or posttraumatic"/>
   <result pre="or posttraumatic stress disorder* orbipolar or major depressi* disorder* or" exact="depression" post="or major depressive episode* orpostpartum depression or ADHD or"/>
   <result pre="major depressi* disorder* or depression or major depressive episode* orpostpartum" exact="depression" post="or ADHD or attention deficit disorder or attention deficithyperactivity"/>
   <result pre="depression or major depressive episode* orpostpartum depression or ADHD or" exact="attention deficit disorder" post="or attention deficithyperactivity disorder* or panic disorder* or borderline"/>
   <result pre="or psychos?s or addiction* or neurobehavioural or emotions orpsychiatr* or" exact="mood disorder" post="or adjustment disorder or somatic or somatoform ordelusional disorder"/>
   <result pre="addiction* or neurobehavioural or emotions orpsychiatr* or mood disorder or" exact="adjustment disorder" post="or somatic or somatoform ordelusional disorder or mani* or"/>
   <result pre="mood or affective or depress* or anxi* or obsessivecompulsive or" exact="panic disorder" post="or post-trauma* or posttrauma* or PTSD or neurosis or"/>
   <result pre="or panic disorder or post-trauma* or posttrauma* or PTSD or" exact="neurosis" post="or neurotic or bipolar ormania or manic or schizophreni*"/>
   <result pre="ormania or manic or schizophreni* or intelligence quotient or IQ" exact="or mental retardation" post="or intellectualdisability or learning disability or autis* or asperger*"/>
   <result pre="or manic or schizophreni* or intelligence quotient or IQ or" exact="mental retardation" post="or intellectualdisability or learning disability or autis* or asperger*"/>
   <result pre="intelligence quotient or IQ or mental retardation or intellectualdisability or" exact="learning disability" post="or autis* or asperger* or attention deficit or ADHD"/>
   <result pre="or exp disorders of excessivesomnolence/ or exp parasomnias/ or exp" exact="psychomotor" post="disorders/ or exp dementia/ or exp neurocognitivedisorders/ or exp"/>
   <result pre="exp hallucinations/ or exp delusions/ or exp apathy/ or exp" exact="psychomotor" post="agitation/ or expeuphoria/ or exp aggression/ or exp amnesia/"/>
   <result pre="exp mood disorders/or exp depression/ or exp anxiety/ or exp" exact="anxiety" post="disorders/ or exp obsessive-compulsive disorder/ orexp panic disorder/ or"/>
   <result pre="('COVID-19' or '2019-nCov' or 'SARS-CoV-2').mp. or exp Coronavirus Infections/ (44182)4" exact="Severe" post="Acute Respiratory Syndrome/ (8984)5 severe acute respiratory syndrom*.ti, ab."/>
   <result pre="or '2019-nCov' or 'SARS-CoV-2').mp. or exp Coronavirus Infections/ (44182)4 Severe" exact="Acute" post="Respiratory Syndrome/ (8984)5 severe acute respiratory syndrom*.ti, ab. (8235)6"/>
   <result pre="'2019-nCov' or 'SARS-CoV-2').mp. or exp Coronavirus Infections/ (44182)4 Severe Acute" exact="Respiratory" post="Syndrome/ (8984)5 severe acute respiratory syndrom*.ti, ab. (8235)6 (sars"/>
   <result pre="exp Coronavirus Infections/ (44182)4 Severe Acute Respiratory Syndrome/ (8984)5 severe" exact="acute" post="respiratory syndrom*.ti, ab. (8235)6 (sars or sars-cov).ti, ab. (18161)7"/>
   <result pre="Coronavirus Infections/ (44182)4 Severe Acute Respiratory Syndrome/ (8984)5 severe acute" exact="respiratory" post="syndrom*.ti, ab. (8235)6 (sars or sars-cov).ti, ab. (18161)7 disease"/>
   <result pre="acute respiratory syndrom*.ti, ab. (8235)6 (sars or sars-cov).ti, ab. (18161)7" exact="disease" post="outbreaks/ or exp epidemics/ (106717)8 (disease outbreak* or pandemic*"/>
   <result pre="epidemic*).ti, ab. (155507)9 (mers virus or mers-cov or middle east*" exact="respiratory" post="syndrom*).ti, ab. (2864)10 Influenza Pandemic, 1918–1919/ (518)11 Influenza A"/>
   <result pre="spanish flu or h1n1).ti, ab. (23160)13 exp HIV Infections/ or" exact="Acquired" post="Immunodeficiency Syndrome/ (376955)14 (HIV or AIDS or human immunodeficienc*"/>
   <result pre="flu or h1n1).ti, ab. (23160)13 exp HIV Infections/ or Acquired" exact="Immunodeficiency" post="Syndrome/ (376955)14 (HIV or AIDS or human immunodeficienc* syndrome*"/>
   <result pre="Syndrome/ (376955)14 (HIV or AIDS or human immunodeficienc* syndrome* or" exact="acquired" post="immunodeficiency syndrome*).ti, ab. (490688)15 Zika Virus Infection/ or Zika"/>
   <result pre="(376955)14 (HIV or AIDS or human immunodeficienc* syndrome* or acquired" exact="immunodeficiency" post="syndrome*).ti, ab. (490688)15 Zika Virus Infection/ or Zika Virus/"/>
   <result pre="(1819862)27 (mental illness* or mental disorder* or mental health or" exact="anxiety" post="or anxious or schizophren* or posttraumatic stress disorder* or"/>
   <result pre="traumatic stress disorder* or bipolar or major depressi* disorder* or" exact="depression" post="or major depressive episode* or postpartum depression or ADHD"/>
   <result pre="major depressi* disorder* or depression or major depressive episode* or" exact="postpartum" post="depression or ADHD or attention deficit disorder or attention"/>
   <result pre="depressi* disorder* or depression or major depressive episode* or postpartum" exact="depression" post="or ADHD or attention deficit disorder or attention deficit"/>
   <result pre="or major depressive episode* or postpartum depression or ADHD or" exact="attention deficit disorder" post="or attention deficit hyperactivity disorder* or panic disorder* or"/>
   <result pre="psychos?s or addiction* or neurobehavioural or emotions or psychiatr* or" exact="mood disorder" post="or adjustment disorder or somatic or somatoform or delusional"/>
   <result pre="or neurobehavioural or emotions or psychiatr* or mood disorder or" exact="adjustment disorder" post="or somatic or somatoform or delusional disorder or mani*"/>
   <result pre="mood disorder or adjustment disorder or somatic or somatoform or" exact="delusional disorder" post="or mani* or affective or suicid* or mental status"/>
   <result pre="or affective or depress* or anxi* or obsessive compulsive or" exact="panic disorder" post="or post-trauma* or posttrauma* or PTSD or neurosis or"/>
   <result pre="or panic disorder or post-trauma* or posttrauma* or PTSD or" exact="neurosis" post="or neurotic or bipolar or mania or manic or"/>
   <result pre="mania or manic or schizophreni* or intelligence quotient or IQ" exact="or mental retardation" post="or intellectual disability or learning disability or autis* or"/>
   <result pre="or manic or schizophreni* or intelligence quotient or IQ or" exact="mental retardation" post="or intellectual disability or learning disability or autis* or"/>
   <result pre="schizophreni* or intelligence quotient or IQ or mental retardation or" exact="intellectual disability" post="or learning disability or autis* or asperger* or attention"/>
   <result pre="quotient or IQ or mental retardation or intellectual disability or" exact="learning disability" post="or autis* or asperger* or attention deficit or ADHD"/>
   <result pre="exp disorders of excessive somnolence/ or exp parasomnias/ or exp" exact="psychomotor" post="disorders/ or exp dementia/ or exp neurocognitive disorders/ or"/>
   <result pre="exp hallucinations/ or exp delusions/ or exp apathy/ or exp" exact="psychomotor" post="agitation/ or exp euphoria/ or exp aggression/ or exp"/>
   <result pre="amnesia/ or exp catatonia/ or exp personality disorders/ or exp" exact="schizophrenia" post="spectrum/) and other psychotic disorders/) or exp mental disorders/"/>
   <result pre="mood disorders/ or exp depression/ or exp anxiety/ or exp" exact="anxiety" post="disorders/ or exp obsessive-compulsive disorder/ or exp panic disorder/"/>
   <result pre="including study methodology and design, population demographics and sample size," exact="mental disorder" post="diagnosis, symptomatology measure (if applicable), study outcomes and findings,"/>
   <result pre="papers that reported on psychiatric outcomes in patients with pre-existing" exact="mental disorders." post="It will be noted qualitatively if we find insufficient"/>
   <result pre="team collaborated with a patient with recent lived experience with" exact="mental illness" post="and suicidality throughout the conception of this project. This"/>
   <result pre="this project. This team member was instrumental in designing the" exact="primary" post="research question in particular. We have arranged for regular"/>
   <result pre="crises, including the current COVID-19 pandemic, impact individuals with pre-existing" exact="mental disorders." post="The effects of the COVID-19 pandemic are expected to"/>
   <result pre="innovations and policy changes that can effectively support people with" exact="mental disorders" post="during and after this pandemic. In the interim, widespread"/>
   <result pre="interim, widespread education and implementation of services for individuals with" exact="mental disorders" post="is crucial in order to prevent undue suffering. As"/>
   <result pre="substantial contributions to future researchers, policy makers, clinicians, people with" exact="mental disorders" post="and overarchingly, to the national and international response to"/>
   <result pre="for the urgent implementation of support services for individuals with" exact="mental disorders." post="As a result of ‘non-essential closures’, people with mental"/>
   <result pre="mental disorders. As a result of ‘non-essential closures’, people with" exact="mental disorders" post="around the world have been left without access to"/>
   <result pre="4CheungYT, ChauPH, YipPSFA revisit on older adults suicides and severe" exact="acute" post="respiratory syndrome (SARS) epidemic in Hong Kong. Int J"/>
   <result pre="ChauPH, YipPSFA revisit on older adults suicides and severe acute" exact="respiratory" post="syndrome (SARS) epidemic in Hong Kong. Int J Geriatr"/>
   <result pre="YipPSFA revisit on older adults suicides and severe acute respiratory" exact="syndrome" post="(SARS) epidemic in Hong Kong. Int J Geriatr Psychiatry2008;23:1231–8."/>
   <result pre="10.2307/267629511198566 15PappaS, NtellaV, GiannakasT, et al.Prevalence of depression, anxiety, and" exact="insomnia" post="among healthcare workers during the COVID-19 pandemic: a systematic"/>
   <result pre="workers during the COVID-19 pandemic: a systematic review and meta-analysis." exact="Brain" post="Behav Immun2020;88:901–7. 10.1016/j.bbi.2020.05.02632437915 16AmerioA, BianchiD, SantiF, et al.Covid-19 pandemic"/>
   <result pre="al.Mental health status of people isolated due to middle East" exact="respiratory" post="syndrome. Epidemiol Health2016;38:e2016048:1–7. 10.4178/epih.e201604828196409 22DrussBGAddressing the COVID-19 pandemic in"/>
   <result pre="Health2016;38:e2016048:1–7. 10.4178/epih.e201604828196409 22DrussBGAddressing the COVID-19 pandemic in populations with serious" exact="mental illness." post="JAMA Psychiatry2020:jamapsychiatry.2020.0894. 10.1001/jamapsychiatry.2020.0894 23YaoH, ChenJ-H, XuY-FPatients with mental health"/>
   <result pre="COVID-19 outbreak. Lancet Psychiatry2020;7:e19. 10.1016/S2215-0366(20)30079-132085843 25SwansonPA, McGavernDBViral diseases of the" exact="central nervous system." post="Curr Opin Virol2015;11:44–54. 10.1016/j.coviro.2014.12.00925681709 26MaoL, JinH, WangM, et al.Neurologic"/>
   <result pre="JinH, WangM, et al.Neurologic manifestations of hospitalized patients with coronavirus" exact="disease" post="2019 in Wuhan, China. JAMA Neurol2020:1127. 10.1001/jamaneurol.2020.1127 27McCallS, VilenskyJA,"/>
   <result pre="JAMA Neurol2020:1127. 10.1001/jamaneurol.2020.1127 27McCallS, VilenskyJA, GilmanS, et al.The relationship between" exact="encephalitis" post="lethargica and influenza: a critical analysis. J Neurovirol2008;14:177–85. 10.1080/1355028080199544518569452"/>
   <result pre="CooganAN, FaltracoF, et al.COVID-19 paranoia in a patient suffering from" exact="schizophrenic" post="psychosis - a case report. Psychiatry Res2020;288:113001. 10.1016/j.psychres.2020.11300132315884 33collab:"/>
   <result pre="FaltracoF, et al.COVID-19 paranoia in a patient suffering from schizophrenic" exact="psychosis" post="- a case report. Psychiatry Res2020;288:113001. 10.1016/j.psychres.2020.11300132315884 33collab: Cochrane&quot;What"/>
   <result pre="Available: https://handbook-5-1.cochrane.org/chapter_9/9_6_2_what_are_subgroup_analyses.htm [Accessed 26 Jul 2020]. 34QuinnSC, KumarSHealth inequalities and" exact="infectious disease" post="epidemics: a challenge for global health security. Biosecur Bioterror2014;12:263–73."/>
   <result pre="https://handbook-5-1.cochrane.org/chapter_9/9_6_2_what_are_subgroup_analyses.htm [Accessed 26 Jul 2020]. 34QuinnSC, KumarSHealth inequalities and infectious" exact="disease" post="epidemics: a challenge for global health security. Biosecur Bioterror2014;12:263–73."/>
   <result pre="neuropsychiatric sequelae of COVID-19? neuropsychiatric symptoms and potential immunologic mechanisms." exact="Brain" post="Behav Immun2020;87:34–9. 10.1016/j.bbi.2020.04.02732298803 39collab: CovidenceCovidence systematic review software, Veritas"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7469891/results/search/disease/results.xml">
   <result pre="reopening SARS-CoV-2 schools transmission page-count: The unknown correlates of severe" exact="acute" post="respiratory syndrome coronavirus 2 transmission One of the key"/>
   <result pre="SARS-CoV-2 schools transmission page-count: The unknown correlates of severe acute" exact="respiratory" post="syndrome coronavirus 2 transmission One of the key characteristics"/>
   <result pre="schools transmission page-count: The unknown correlates of severe acute respiratory" exact="syndrome" post="coronavirus 2 transmission One of the key characteristics of"/>
   <result pre="coronavirus 2 transmission One of the key characteristics of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) is high transmissibility which,"/>
   <result pre="2 transmission One of the key characteristics of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) is high transmissibility which, fueled"/>
   <result pre="transmission One of the key characteristics of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) is high transmissibility which, fueled by"/>
   <result pre="[1]. Within a period of four months, the resulting coronavirus" exact="disease" post="of 2019 (COVID-19) was declared a pandemic by the"/>
   <result pre="coronaviruses that can be fatal for humans, the first severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV-1) of 2002–2003 and the Middle"/>
   <result pre="that can be fatal for humans, the first severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV-1) of 2002–2003 and the Middle East"/>
   <result pre="can be fatal for humans, the first severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV-1) of 2002–2003 and the Middle East respiratory"/>
   <result pre="respiratory syndrome coronavirus (SARS-CoV-1) of 2002–2003 and the Middle East" exact="respiratory" post="syndrome coronavirus of 2012, the origin of SARS-CoV-2 is"/>
   <result pre="syndrome coronavirus (SARS-CoV-1) of 2002–2003 and the Middle East respiratory" exact="syndrome" post="coronavirus of 2012, the origin of SARS-CoV-2 is thought"/>
   <result pre="Syrian hamsters, with some of these animal species (rhesus macaques," exact="juvenile" post="cats and hamsters) displaying mild-to-moderate clinical disease [7–13]. In"/>
   <result pre="species (rhesus macaques, juvenile cats and hamsters) displaying mild-to-moderate clinical" exact="disease" post="[7–13]. In addition to these experimental infections, there have"/>
   <result pre="SARS-CoV-2 was thought to be spreading from person-to-person principally through" exact="respiratory" post="droplets generated during coughing and sneezing by infected individuals"/>
   <result pre="SARS-CoV-1, SARS-CoV-2 is transmitted before the onset of symptoms by" exact="symptomatic" post="persons and even by asymptomatic individuals [18,19]. Droplets of"/>
   <result pre="Droplets of saliva and other secretions are expelled from the" exact="respiratory" post="tract (the mouth and nose) not only during such"/>
   <result pre="trajectories of the epidemic in countries like Italy and Spain." exact="Respiratory" post="exhalations do not solely consist of mucosalivary droplets that"/>
   <result pre="agencies transmission model originally proposed by William F Wells for" exact="tuberculosis" post="in the 1930s had suggested. Instead, according to the"/>
   <result pre="1930s had suggested. Instead, according to the new model for" exact="respiratory" post="emissions, exhalations consist of clusters of varying in size"/>
   <result pre="School closures that are commonly suggested for mitigating epidemics of" exact="respiratory" post="infection were among the first social distancing measures implemented"/>
   <result pre="closures that are commonly suggested for mitigating epidemics of respiratory" exact="infection" post="were among the first social distancing measures implemented during"/>
   <result pre="the early phases of the outbreak, it became apparent that" exact="adult" post="pathogenesis varies with age and gender since older men"/>
   <result pre="with age and gender since older men with comorbidities (e.g.," exact="diabetes" post="or cardiovascular disease) were at higher risk for severe"/>
   <result pre="and gender since older men with comorbidities (e.g., diabetes or" exact="cardiovascular" post="disease) were at higher risk for severe illness from"/>
   <result pre="other end of the spectrum, children generally experience less severe" exact="disease" post="and have better prognosis after infection with SARS-CoV-2 [27],"/>
   <result pre="generally experience less severe disease and have better prognosis after" exact="infection" post="with SARS-CoV-2 [27], although a multisystem inflammatory syndrome (MIS-C)"/>
   <result pre="prognosis after infection with SARS-CoV-2 [27], although a multisystem inflammatory" exact="syndrome" post="(MIS-C) resembling Kawasaki Disease and toxic shock syndrome-like conditions"/>
   <result pre="SARS-CoV-2 [27], although a multisystem inflammatory syndrome (MIS-C) resembling Kawasaki" exact="Disease" post="and toxic shock syndrome-like conditions has been observed in"/>
   <result pre="although a multisystem inflammatory syndrome (MIS-C) resembling Kawasaki Disease and" exact="toxic shock" post="syndrome-like conditions has been observed in pediatric patients [28]."/>
   <result pre="mortality in children, including fewer underlying medical conditions and healthier" exact="respiratory" post="tracts because of less exposure to cigarette smoke and"/>
   <result pre="innate immune responses [31]. An alternative explanation for the generally" exact="benign" post="disease course in pediatric cases pertains to the less"/>
   <result pre="immune responses [31]. An alternative explanation for the generally benign" exact="disease" post="course in pediatric cases pertains to the less mature,"/>
   <result pre="cells. In agreement with this reasoning, data suggest that SARS-CoV-2" exact="infections" post="in children involve the upper rather than the lower"/>
   <result pre="reasoning, data suggest that SARS-CoV-2 infections in children involve the" exact="upper" post="rather than the lower respiratory tract, the typical site"/>
   <result pre="SARS-CoV-2 infections in children involve the upper rather than the" exact="lower" post="respiratory tract, the typical site of severe COVID-19 disease"/>
   <result pre="infections in children involve the upper rather than the lower" exact="respiratory" post="tract, the typical site of severe COVID-19 disease where"/>
   <result pre="the lower respiratory tract, the typical site of severe COVID-19" exact="disease" post="where ACE2 receptors are more abundant [29]. The role"/>
   <result pre="Singapore, Canada and South Korea, Davies et al. estimated that" exact="susceptibility to" post="infection in individuals under 20 years of age was"/>
   <result pre="and South Korea, Davies et al. estimated that susceptibility to" exact="infection" post="in individuals under 20 years of age was approximately"/>
   <result pre="SARS-CoV-2 transmission, particularly in settings where the transmissibility of subclinical" exact="infections" post="is low [33]. Studies from Israel and Greece that"/>
   <result pre="examined the dynamics of COVID-19 transmission within families showed significantly" exact="lower" post="infection rates in children compared with adults residing in"/>
   <result pre="the dynamics of COVID-19 transmission within families showed significantly lower" exact="infection" post="rates in children compared with adults residing in the"/>
   <result pre="a study of young children from northern France [36], SARS-CoV-2" exact="infection" post="was found to be largely mild or asymptomatic and"/>
   <result pre="line with previous studies from Australia, Ireland and France [37–39]." exact="Primary" post="or elementary school children aged 6–11 years were less"/>
   <result pre="group in Germany using two different PCR systems to assess" exact="viral" post="load, determined that children under the age of 19"/>
   <result pre="age of 19 produce virtually the same average levels of" exact="viral" post="RNA as adults [41]. Another study from Chicago showed"/>
   <result pre="5 years had tenfold to 100-fold greater amount of SARS-CoV-2" exact="viral" post="RNA, which correlates with infectious virus [42], in their"/>
   <result pre="100-fold greater amount of SARS-CoV-2 viral RNA, which correlates with" exact="infectious" post="virus [42], in their upper respiratory tracts compared with"/>
   <result pre="viral RNA, which correlates with infectious virus [42], in their" exact="upper" post="respiratory tracts compared with older children aged 5–17 years"/>
   <result pre="RNA, which correlates with infectious virus [42], in their upper" exact="respiratory" post="tracts compared with older children aged 5–17 years or"/>
   <result pre="[43]. Sampling bias due to the increased possibility of asymptomatic" exact="infection" post="in children that reduces the chances of being tested"/>
   <result pre="children that reduces the chances of being tested early in" exact="infection" post="when virus levels in the nasopharynx are high, could"/>
   <result pre="could explain the disparity in results from different studies. Since" exact="viral" post="RNA levels in the feces remain high for more"/>
   <result pre="three weeks after the onset of symptoms in contrast to" exact="viral" post="RNA in the nose and saliva that decline drastically"/>
   <result pre="1–2 weeks, analyzing stool samples for transmissible virus from mildly" exact="symptomatic" post="and asymptomatic children could provide the experimental data to"/>
   <result pre="could provide the experimental data to validate this argument [44]." exact="Viral" post="replication in the GI tract and prolonged fecal shedding"/>
   <result pre="to SARS-CoV-2, will help determine the incidence of novel coronavirus" exact="infection" post="in children in the USA and whether rates differ"/>
   <result pre="the USA and whether rates differ between children who have" exact="asthma" post="or other allergic conditions and children who do not"/>
   <result pre="of schools in the fall The new US Centers for" exact="Disease" post="Control and Prevention (CDC) guidelines on education and child"/>
   <result pre="to be infected than adults (at least based on nasopharyngeal" exact="viral" post="RNA detection as discussed in the previous subsection), and"/>
   <result pre="be considered carefully, with continuous monitoring of possible resurgence in" exact="infections" post="through frequent testing and isolation of infected – and"/>
   <result pre="and isolation of infected – and perhaps more importantly of" exact="infectious" post="– students, educators and other staff, for their safety"/>
   <result pre="safety and wellbeing of their families. The current Centers for" exact="Disease" post="Control and Prevention guidelines do not recommend universal screenings"/>
   <result pre="caregivers to monitor their children every day for ‘signs of" exact="infectious" post="illness’, most likely referring to symptoms that, if present"/>
   <result pre="distancing considering the recent advances in the biophysics of host-to-host" exact="respiratory" post="disease transmission, respiratory etiquette and masks for older children."/>
   <result pre="considering the recent advances in the biophysics of host-to-host respiratory" exact="disease" post="transmission, respiratory etiquette and masks for older children. Such"/>
   <result pre="recent advances in the biophysics of host-to-host respiratory disease transmission," exact="respiratory" post="etiquette and masks for older children. Such mitigation measures"/>
   <result pre="older children. Such mitigation measures would also help contain other" exact="respiratory" post="infections in the community. Alternative plans for virtual learning"/>
   <result pre="children. Such mitigation measures would also help contain other respiratory" exact="infections" post="in the community. Alternative plans for virtual learning should"/>
   <result pre="direct and indirect benefit given that children may contribute to" exact="adult" post="infections and develop life-threatening disease themselves, is that vaccine"/>
   <result pre="and indirect benefit given that children may contribute to adult" exact="infections" post="and develop life-threatening disease themselves, is that vaccine development"/>
   <result pre="that children may contribute to adult infections and develop life-threatening" exact="disease" post="themselves, is that vaccine development efforts for COVID-19 should"/>
   <result pre="Med.382(13), 1199–1207 (2020).31995857 2.collab: The World Heath Organization (WHO). Coronavirus" exact="disease" post="2019 (COVID-19): situation report, 51. https://apps.who.int/iris/handle/10665/331475 3.BosmanJW.H.O. warns of"/>
   <result pre="York Times (2020). http://www.nytimes.com/2020/06/19/us/coronavirus-new-dangerous-phase.html 4.ZhouP , YangXL , WangXGet al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
   <result pre="YuanSet al.Simulation of the clinical and pathological manifestations of coronavirus" exact="disease" post="2019 (COVID-19) in golden Syrian hamster model: implications for"/>
   <result pre="disease 2019 (COVID-19) in golden Syrian hamster model: implications for" exact="disease" post="pathogenesis and transmissibility. Clin. Infect. Dis. (2020) (Epub ahead"/>
   <result pre="(Epub ahead of print). 12.MunsterVJ , FeldmannF , WilliamsonBNet al.Respiratory" exact="disease" post="in rhesus macaques inoculated with SARS-CoV-2. Nature (2020) (Epub"/>
   <result pre="hamsters. Nature583, 834–838 (2020).32408338 14.OreshkovaN , MolenaarRJ , VremanSet al.SARS-CoV-2" exact="infection" post="in farmed minks, The Netherlands, April and May 2020."/>
   <result pre="(2020) (Epub ahead of print). 16.collab: Advisory Board on Cat" exact="Diseases" post="(ABCD). European advisory board on cat diseases. SARS-coronavirus (CoV)-2"/>
   <result pre="1200–1204 (2020).32555424 19.HeX , LauEHY , WuPet al.Temporal dynamics in" exact="viral" post="shedding and transmissibility of COVID-19. Nat. Med.26(5), 672–675 (2020).32296168"/>
   <result pre="of COVID-19. Nat. Med.26(5), 672–675 (2020).32296168 20.BourouibaLTurbulent gas clouds and" exact="respiratory" post="pathogen emissions: potential implications for reducing transmission of COVID-19."/>
   <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive study. Lancet395(10223), 507–513 (2020).32007143"/>
   <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, China. JAMA323(11), 1061–1069 (2020). 27.LudvigssonJFSystematic review of"/>
   <result pre="1088–1095 (2020).32202343 28.NakraNA , BlumbergDA , Herrera-GuerraA , LakshminrusimhaSMulti-system inflammatory" exact="syndrome" post="in children (MIS-C) following SARS-CoV-2 infection: review of clinical"/>
   <result pre="J. Med. Virol. (2020). 36.FontanetA , GrantR , TondeurLet al.SARS-CoV-2" exact="infection" post="in primary schools in northern France: a retrospective cohort"/>
   <result pre="Virol. (2020). 36.FontanetA , GrantR , TondeurLet al.SARS-CoV-2 infection in" exact="primary" post="schools in northern France: a retrospective cohort study in"/>
   <result pre=", CaseyG , KellyC , KellyD , McDarbyGNo evidence of" exact="secondary" post="transmission of COVID-19 from children attending school in Ireland,"/>
   <result pre="2000903 (2020). 38.DanisK , EpaulardO , BenetTet al.Cluster of coronavirus" exact="disease" post="2019 (Covid-19) in the French Alps, 2020. Clin. Infect."/>
   <result pre="http://ncirs.org.au/sites/default/files/2020-04/NCIRS%20NSW%20Schools%20COVID_Summary_FINAL%20public_26%20April%202020.pdf 40.ParkYJ , ChoeYJ , ParkOet al.Contact tracing during coronavirus" exact="disease" post="outbreak, South Korea, 2020. Emerg. Infect. Dis.26(10), (2020). 41.JonesTC"/>
   <result pre="(2020). 41.JonesTC , MühlemannB , VeithTet al.An analysis of SARS-CoV-2" exact="viral" post="load by patient age. medRxiv.2020.2006.2008.20125484 (2020) (Epub ahead of"/>
   <result pre=", PignyF , KaiserL , EckerleICulture-competent SARS-CoV-2 in nasopharynx of" exact="symptomatic" post="neonates, children, and adolescents. Emerg. Infect. Dis.26(10), (2020). 43.Heald-SargentT"/>
   <result pre=", RippeJ , PatelAB , KociolekLKAge-related differences in nasopharyngeal severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) levels in patients with"/>
   <result pre="RippeJ , PatelAB , KociolekLKAge-related differences in nasopharyngeal severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) levels in patients with mild"/>
   <result pre=", PatelAB , KociolekLKAge-related differences in nasopharyngeal severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) levels in patients with mild to"/>
   <result pre="2 (SARS-CoV-2) levels in patients with mild to moderate coronavirus" exact="disease" post="2019 (COVID-19). JAMA Pediatr. (2020) (Epub ahead of print)."/>
   <result pre="44.HanMS , SeongMW , KimNet al.Viral RNA load in mildly" exact="symptomatic" post="and asymptomatic children with COVID-19, Seoul. Emerg. Infect. Dis.26(10),"/>
   <result pre="Infect. Dis.26(10), (2020). 45.collab: The National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID). COVID-19: Human Epidemiology and Response to SARS-CoV-2"/>
   <result pre="Dis.26(10), (2020). 45.collab: The National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID). COVID-19: Human Epidemiology and Response to SARS-CoV-2 (HEROS)."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7470771/results/search/disease/results.xml">
   <result pre="#stayhome to contain Covid-19: Neuro-SIR – Neurodynamical epidemic modeling of" exact="infection" post="patterns in social networks LymperopoulosIlias N.[], pmc-release: 2020-9-9ppub: 2021-3-3epub:"/>
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="are mechanistically modeled as analogous to the activity propagation in" exact="neuronal" post="populations. The workings of infection transmission from individual to"/>
   <result pre="to the activity propagation in neuronal populations. The workings of" exact="infection" post="transmission from individual to individual through a network of"/>
   <result pre="evolving landscape of the susceptibility of a population to a" exact="disease" post="is formed. In this context, epidemics with varying velocities"/>
   <result pre="recovery, enable the modeling of the Susceptible–Infected–Recovered–Susceptible (SIRS) process of" exact="recurrent" post="epidemics. Neuro-SIR by supporting an impressive level of heterogeneities"/>
   <result pre="the description of a population, contagiousness of a disease, and" exact="external" post="factors, allows a more insightful investigation of epidemic spreading"/>
   <result pre="is applicable in designing and assessing epidemic control strategies. Keywords" exact="Epidemic" post="modeling Spreading of diseases SIR epidemic models Leaky integrate-and-fire"/>
   <result pre="and more than 342,540 persons had died of Covid-19,1 the" exact="disease" post="caused by the new coronavirus. While the Covid-19 pandemic"/>
   <result pre="not only the global development, but also the transmission of" exact="infections" post="from individual to individual and from country to country."/>
   <result pre="dynamics of spreading diseases should be studied and modeled. The" exact="bubonic plague" post="(Black Death), caused by bacillus pestis, a microorganism originating"/>
   <result pre="of spreading diseases should be studied and modeled. The bubonic" exact="plague" post="(Black Death), caused by bacillus pestis, a microorganism originating"/>
   <result pre="1 4 t h century. Nevertheless, at that time, the" exact="bubonic plague" post="was spreading up through Europe at a speed of"/>
   <result pre="4 t h century. Nevertheless, at that time, the bubonic" exact="plague" post="was spreading up through Europe at a speed of"/>
   <result pre="the tremendous impact of interconnectedness on the transmission velocity of" exact="communicable diseases." post="Meanwhile, other factors, such as age, general health condition,"/>
   <result pre="condition, length of incubation period, infectiveness, strength of immune system," exact="external" post="conditions (e.g. weather, pollution, sanitary conditions), and length of"/>
   <result pre="the underlying transmission network and the heterogeneities in the individuals’" exact="susceptibility to" post="a contagious disease, is of paramount importance for designing"/>
   <result pre="equipment (PPE) (Chu et al., 2020, Leclerc et al., 2020);" exact="infection" post="transmission through asymptomatic individuals (Huang et al., 2020, Nishiura"/>
   <result pre="(Lauer et al., 2020, Yu et al., 2020); susceptibility and" exact="disease" post="severity relative to age and health condition (Ludvigsson, 2020,"/>
   <result pre="modeling of the spreading dynamics of Covid-19, and of other" exact="infectious diseases," post="entails an approach, capable of accommodating the aforementioned factors"/>
   <result pre="process, through an isomorphism between the activity propagation in a" exact="neuronal" post="population, and the spreading of a pathogen in a"/>
   <result pre="transmission of action potentials through synaptic connections among neurons. The" exact="infection" post="mechanism is represented by the activation dynamics of leaky"/>
   <result pre="described in recent epidemiological studies pertaining to the propagation of" exact="tuberculosis" post="(Ackley et al., 2019, Lee et al., 2016). The"/>
   <result pre="(Ackley et al., 2019, Lee et al., 2016). The heterogeneous" exact="susceptibility to" post="a disease is analogous to varying activation thresholds in"/>
   <result pre="2019, Lee et al., 2016). The heterogeneous susceptibility to a" exact="disease" post="is analogous to varying activation thresholds in leaky integrate-and-fire"/>
   <result pre="in leaky integrate-and-fire neurons, and the incubation period of a" exact="disease" post="can be represented by the transmission delays of action"/>
   <result pre="can be represented by the transmission delays of action potentials." exact="Viral" post="loads, social distancing, contact network, and usage of personal"/>
   <result pre="affecting the spreading dynamics of a disease, are represented by" exact="external" post="signals, supplied to a neural network. Viral transmission through"/>
   <result pre="are represented by external signals, supplied to a neural network." exact="Viral" post="transmission through asymptomatic infected individuals, can be represented by"/>
   <result pre="the transmission dynamics of pathogens, and the description of the" exact="infection" post="mechanism. Also, they cannot support a high level of"/>
   <result pre="epidemic spreading in a social network. As a result, a" exact="limited" post="exploration of the evolution of epidemic processes can be"/>
   <result pre="Recently, many models aiming at predicting the trend of Covid-19" exact="infections" post="in various countries, were based on SIR modeling approaches"/>
   <result pre="a view to generating forecasts about the evolution of the" exact="total" post="number of Covid-19 infections (Anastassopoulou et al., 2020, Fanelli"/>
   <result pre="forecasts about the evolution of the total number of Covid-19" exact="infections" post="(Anastassopoulou et al., 2020, Fanelli and Piazza, 2020, Hamzah"/>
   <result pre="Sun et al., 2020, Zhou, Ma et al., 2020). The" exact="limited" post="capacity of existing SIR models to incorporate many of"/>
   <result pre="the transmission of Covid-19, suggests that a considerable amount of" exact="symptomatic" post="infections in a population of individuals, are caused through"/>
   <result pre="transmission of Covid-19, suggests that a considerable amount of symptomatic" exact="infections" post="in a population of individuals, are caused through contacts"/>
   <result pre="people throughout an epidemic wave, thus giving rise to new" exact="symptomatic" post="infections in the part of the population, who develop"/>
   <result pre="throughout an epidemic wave, thus giving rise to new symptomatic" exact="infections" post="in the part of the population, who develop symptoms"/>
   <result pre="density to the layer of the individuals, who can become" exact="symptomatic" post="when infected. The layer of asymptomatic individuals creates spikes"/>
   <result pre="process, thus simulating the random contacts between individuals of the" exact="symptomatic" post="layer and individuals of the asymptomatic layer. In this"/>
   <result pre="length of a simulation process, affects the evolution of the" exact="symptomatic" post="development of an epidemic. Section 5.3 deals with a"/>
   <result pre="of social distancing, usage of personal protective equipment, transmission of" exact="viral" post="load and severity of illness, on the spreading of"/>
   <result pre="contagious disease, through the configuration of the distribution of the" exact="infection" post="thresholds of a simulated population of individuals, susceptible to"/>
   <result pre="impact of the length of the incubation period of a" exact="disease" post="on the evolution of an epidemic, through the configuration"/>
   <result pre="on the spreading of a disease, through the configuration of" exact="external" post="signals increasing or decreasing the individuals’ susceptibility to a"/>
   <result pre="the configuration of external signals increasing or decreasing the individuals’" exact="susceptibility to" post="a disease. •Investigation of the impact of varying immunity"/>
   <result pre="disease, through the configuration of the refractory periods of a" exact="neuronal" post="population representing individuals. •Investigation of the impact of the"/>
   <result pre="•Investigation of the impact of the asymptomatic transmission of a" exact="disease" post="on the epidemic spreading pattern, through the configuration of"/>
   <result pre="epidemic spreading pattern, through the configuration of an additional asymptomatic" exact="infection" post="propagation layer interacting with the layer of the symptomatic"/>
   <result pre="asymptomatic infection propagation layer interacting with the layer of the" exact="symptomatic" post="progression of a disease. The versatility of Neuro-SIR enables"/>
   <result pre="strategies aiming at the prevention and containment of outbreaks of" exact="infectious diseases." post="In the experimental part of this study we demonstrate"/>
   <result pre="of a network decreases, so does the rate of new" exact="infections" post="and the speed of epidemic spreading. Reducing the density"/>
   <result pre="network below a certain value inhibits the penetration of a" exact="disease" post="to a large part of a population. Furthermore, we"/>
   <result pre="illustrate the ability of Neuro-SIR to capture the dynamics of" exact="recurrent" post="epidemics, where the recovery from a disease does not"/>
   <result pre="the dynamics of recurrent epidemics, where the recovery from a" exact="disease" post="does not confer permanent immunity. In this regard, we"/>
   <result pre="in a population, in relation to the individuals’ dynamically evolving" exact="susceptibility to" post="a disease. Through the simulation of recurrent epidemics, it"/>
   <result pre="dynamically evolving susceptibility to a disease. Through the simulation of" exact="recurrent" post="epidemics, it is shown that Neuro-SIR can be easily"/>
   <result pre="presents the concluding remarks of this study. 2 Related work" exact="Epidemic" post="modeling constitutes a well established scientific field, and a"/>
   <result pre="additional classes, such as Exposed (E), Quarantined (Q), Vaccinated (V)," exact="Isolated" post="(W), or Dead (D) (Del Valle et al., 2005,"/>
   <result pre="various topological and transmission parameters, in the propagation of a" exact="disease" post="in a population of networked individuals (Barthélemy et al.,"/>
   <result pre="scale-free networks is characterized by critical behavior, such as the" exact="absence of" post="epidemic threshold, that is, the spreading rate value, beyond"/>
   <result pre="threshold, that is, the spreading rate value, beyond which, a" exact="disease" post="becomes prevalent (Boguná et al., 2003, Moreno et al.,"/>
   <result pre="2002, Pastor-Satorras and Vespignani, 2001). Also, the fast propagation of" exact="infections" post="in heterogeneous complex networks (Barthélemy et al., 2004, Barthélemy"/>
   <result pre="for further developing the modeling of epidemics. The prediction of" exact="disease" post="propagation patterns, and the formation of proper prevention strategies,"/>
   <result pre="to providing reliable tools for analyzing the spreading dynamics of" exact="infectious diseases," post="and assisting their prediction and control. To this end,"/>
   <result pre="process in a social network composed of N individuals, whose" exact="susceptibility to" post="a disease obeys the dynamics of the membrane potential"/>
   <result pre="social network composed of N individuals, whose susceptibility to a" exact="disease" post="obeys the dynamics of the membrane potential of leaky"/>
   <result pre="of leaky Integrate-and-Fire neurons. Susceptible (S) individuals can contract an" exact="infectious disease" post="D, through contacts with infected individuals (I). Removed (R)"/>
   <result pre="leaky Integrate-and-Fire neurons. Susceptible (S) individuals can contract an infectious" exact="disease" post="D, through contacts with infected individuals (I). Removed (R)"/>
   <result pre="individuals (I). Removed (R) individuals have either recovered from the" exact="disease" post="D with permanent immunity, or died due to an"/>
   <result pre="of which a pathogen p (e.g. virus, bacterium) causing a" exact="disease" post="D, might be transmitted. In the present model formulation,"/>
   <result pre="S , is in the susceptible state (S). As the" exact="disease" post="propagates in the population P, susceptible (S) individuals become"/>
   <result pre="C R ( i ) evolve over time as the" exact="disease" post="spreading unfolds, however at any time t, C I"/>
   <result pre="of the graph G. An individual’s Susceptibility (S) to the" exact="disease" post="D, evolves dynamically according to the mechanism regulating the"/>
   <result pre="the membrane potential of a leaky Integrate-and-Fire neuron. In the" exact="absence of" post="any contact with infected individuals, one’s susceptibility remains at"/>
   <result pre="susceptible (S) individual i carries a dynamically evolving amount of" exact="infectious" post="agents, obtained through i’s contacts with infected individuals in"/>
   <result pre="t ) ∕ τ constitutes a drift term driving i’s" exact="susceptibility to" post="the resting value S r e s t ."/>
   <result pre="r e s t . The exponential relaxation of i’s" exact="susceptibility to" post="the resting value S r e s t with"/>
   <result pre="time constant τ, represents i’s immunity mechanism defying the invading" exact="infective" post="agents, thereby protecting the susceptible individual i from developing"/>
   <result pre="agents, thereby protecting the susceptible individual i from developing the" exact="disease" post="D. The gain term of the differential equation describing"/>
   <result pre="t ( t ) ∕ τ , which represents the" exact="infection" post="force increasing i’s susceptibility to the disease D. As"/>
   <result pre="∕ τ , which represents the infection force increasing i’s" exact="susceptibility to" post="the disease D. As a result, the transition of"/>
   <result pre="which represents the infection force increasing i’s susceptibility to the" exact="disease" post="D. As a result, the transition of an individual"/>
   <result pre="individuals, leads to the development of a critical level of" exact="infection" post="signifying the onset of the disease D in the"/>
   <result pre="a critical level of infection signifying the onset of the" exact="disease" post="D in the individual i. To enable a more"/>
   <result pre="a threshold mechanism, better describes the contagion dynamics of an" exact="infectious disease." post="In particular, case studies have shown that the infection"/>
   <result pre="infectious disease. In particular, case studies have shown that the" exact="infection" post="risk of tuberculosis increases with multiple exposures to infected"/>
   <result pre="particular, case studies have shown that the infection risk of" exact="tuberculosis" post="increases with multiple exposures to infected individuals following a"/>
   <result pre="a sigmoidal pattern, whereby a sudden transition to a high" exact="infection" post="risk occurs after a certain number of contacts with"/>
   <result pre="leaky integrate-and-fire neurons, more precisely captures the contagion dynamics of" exact="communicable diseases," post="as it incorporates the epidemiological empirical evidence of the"/>
   <result pre="the epidemiological empirical evidence of the phase transition in the" exact="infection" post="risk, as the number of contacts with infected individuals"/>
   <result pre="period (defined later), no longer affects the dynamics of the" exact="disease" post="propagation, since he/she either retreats to his/her home or"/>
   <result pre="to the Removed (R) state, either through recovery from a" exact="disease" post="with permanent immunity, or because of death. Obviously, the"/>
   <result pre="we examine the behavior of Neuro-SIR with both endless and" exact="limited" post="refractory periods. In the former case, Neuro-SIR simulates the"/>
   <result pre="epidemic process, whereby the immunity after the recovery from a" exact="disease" post="is not permanent, and therefore a Recovered individual becomes"/>
   <result pre="a Recovered individual becomes Susceptible again, thus giving rise to" exact="recurrent" post="epidemics. To accommodate the entire state transition dynamics into"/>
   <result pre="describing the state transition mechanism of Neuro-SIR for endless and" exact="limited" post="immunity periods ( I m P e r i"/>
   <result pre="transmits pathogens to his/her connection only once, since after the" exact="infection" post="the individual j moves permanently to the Removed (R)"/>
   <result pre="infected individual, and the potential development of symptoms of the" exact="disease" post="D caused by pathogen P, we include a transmission"/>
   <result pre="fully invading an individual’s organism through a proper doorway (e.g." exact="respiratory" post="gates, eyes), and also due to the response of"/>
   <result pre="I i n e t ( t ) driving one’s" exact="susceptibility to" post="the threshold value S i T h r e"/>
   <result pre="to his/her contacts only once. However, by setting up a" exact="limited" post="immunity period I m P e r i o"/>
   <result pre="are analogous to the equations describing the dynamics of the" exact="presynaptic" post="current that a leaky integrate-and-fire neuron receives from activated"/>
   <result pre="j. It is analogous to the momentary value of the" exact="presynaptic" post="current received by a leaky integrate-and-fire neuron τ Time"/>
   <result pre="F i e x t ( t ) Strength of" exact="external" post="factors influencing an individuals’ susceptibility to a disease. It"/>
   <result pre="( t ) Strength of external factors influencing an individuals’" exact="susceptibility to" post="a disease. It is analogous to external signals received"/>
   <result pre="an individuals’ susceptibility to a disease. It is analogous to" exact="external" post="signals received by sensory neurons G The graph consisting"/>
   <result pre="introduction, Neuro-SIR has the capacity to capture the impact of" exact="external" post="factors on the dynamics of epidemic spreading in a"/>
   <result pre="such as weather, pollution, sanitary conditions can significantly affect one’s" exact="susceptibility to" post="a disease, and therefore they influence the epidemic spreading"/>
   <result pre="spreading patterns. To take into consideration, the effect of the" exact="external" post="environment on the propagation dynamics of an infectious disease,"/>
   <result pre="of the external environment on the propagation dynamics of an" exact="infectious disease," post="we incorporate an additional term into the differential equation"/>
   <result pre="of the membrane potential of sensory neurons, which apart from" exact="presynaptic" post="current, they also receive signals from external sources. As"/>
   <result pre="which apart from presynaptic current, they also receive signals from" exact="external" post="sources. As a result, Eq. (6) combined with the"/>
   <result pre="of the Neuro-SIR model to an epidemic spreading process with" exact="external" post="influencing factors. In the experimental part of this study,"/>
   <result pre="Eq. (1), or Eq. (6) in the case of adding" exact="external" post="factors influencing the epidemic spreading. (b) A set of"/>
   <result pre="⋅ ( N − 1 ) 2 Considering that the" exact="total" post="number of undirected links in a random graph is"/>
   <result pre="is indeed a highly effective strategy for slowing down the" exact="infection" post="rate, and preventing the spreading of the disease. In"/>
   <result pre="k 〉 〈 k 〉 k k ! Fig. 1" exact="Infection" post="rate in a random network with density 0.03. Table"/>
   <result pre="pathogenic load per link, and even then the strength of" exact="external" post="factors influencing the spread of a disease. Consequently, Neuro-SIR"/>
   <result pre="providing insights into the dynamics of the propagation of a" exact="disease" post="in a highly flexible way surpassing existing methods. Considering"/>
   <result pre="network dynamical system, we proceeded to our experiments using a" exact="limited" post="level of heterogeneity among the individuals of the synthetic"/>
   <result pre="the epidemic spreading, the variability in the sensitivity to an" exact="infection" post="in a population due to factors, such as age,"/>
   <result pre="which a susceptible individual gets infected. Furthermore, we record the" exact="infection" post="rate per 2 ms, that is, the number of"/>
   <result pre="illustrating various patterns of the epidemic spreading process. Fig. 2" exact="Infection" post="rate in a random network with density 0.015. Fig."/>
   <result pre="rate in a random network with density 0.015. Fig. 3" exact="Infection" post="rate and evolution of the cumulative number of infected"/>
   <result pre="individuals in a random network with density 0.015. Fig. 4" exact="Infection" post="rate in a random network with density 0.01. Fig."/>
   <result pre="rate in a random network with density 0.01. Fig. 5" exact="Infection" post="rate in a random network with density 0.00825. Fig."/>
   <result pre="are connected in a random network. The experiment examines the" exact="infection" post="rate, the speed of epidemic spreading, and the evolution"/>
   <result pre="the speed of epidemic spreading, and the evolution of the" exact="total" post="number of individuals who got infected, in relation to"/>
   <result pre="model simulates an Susceptible–Infected–Removed epidemic process. Fig. 1 illustrates the" exact="infection" post="rate per 2 ms in the population of 1000"/>
   <result pre="population. It can be seen in Fig. 1 that the" exact="infection" post="rate exhibits a sharp increase, and the duration of"/>
   <result pre="of the duration of the experiment. Fig. 2 shows the" exact="infection" post="rate with the network density of the interconnected individuals"/>
   <result pre="the network density of the interconnected individuals set to a" exact="lower" post="value. In this simulation run d G is equal"/>
   <result pre="individuals’ degree distribution is approximately 15. In comparison with the" exact="infection" post="rate of the previous case ( d G ="/>
   <result pre="a significant decrease is noticed. The maximum value of the" exact="infection" post="rate is substantially lower and the epidemic lasts longer."/>
   <result pre="noticed. The maximum value of the infection rate is substantially" exact="lower" post="and the epidemic lasts longer. In Fig. 3 we"/>
   <result pre="we visualize two additional epidemic spreading patterns along with the" exact="infection" post="rate. In particular, Fig. 3 shows the evolution of"/>
   <result pre="during the epidemic, as well as the evolution of the" exact="total" post="number of susceptible individuals. It can be seen that"/>
   <result pre="seen that at the end of the epidemic outbreak, the" exact="disease" post="had penetrated the entire network, and therefore all the"/>
   <result pre="all the individuals got infected at some point during the" exact="disease" post="spreading process. As a result, the evolution of the"/>
   <result pre="disease spreading process. As a result, the evolution of the" exact="total" post="number of susceptibles in the population follows an inverse"/>
   <result pre="individuals, and the inverse pattern describing the evolution of the" exact="total" post="number of susceptibles, will be further analyzed later. As"/>
   <result pre="sigmoidal functions for the description of the evolution of the" exact="total" post="number of infected individuals during an epidemic. The effective"/>
   <result pre="infected individuals during an epidemic. The effective control of the" exact="infection" post="rate through the reduction of the network density, is"/>
   <result pre="distribution is approximately 10. It can be observed, that the" exact="infection" post="rate is substantially smoother and the epidemic lasts significantly"/>
   <result pre="Covid-19. By decreasing the density of a social network, the" exact="infection" post="rate becomes less bursty and the epidemic progresses at"/>
   <result pre="rate becomes less bursty and the epidemic progresses at a" exact="lower" post="speed. These effects yield valuable societal benefits, as they"/>
   <result pre="on the reduction of the death toll caused by an" exact="infectious" post="and dangerous disease like Covid-19. Fig. 5 illustrates the"/>
   <result pre="of the death toll caused by an infectious and dangerous" exact="disease" post="like Covid-19. Fig. 5 illustrates the infection rate in"/>
   <result pre="infectious and dangerous disease like Covid-19. Fig. 5 illustrates the" exact="infection" post="rate in a random network with density d G"/>
   <result pre="( d G = 0 . 01 ) , the" exact="infection" post="rate is substantially lower and smoother in comparison with"/>
   <result pre="0 . 01 ) , the infection rate is substantially" exact="lower" post="and smoother in comparison with the previous case, thus"/>
   <result pre="also obvious in Fig. 6 depicting the evolution of the" exact="total" post="number of individuals, who got infected in the aforementioned"/>
   <result pre="individuals. For network densities equal to 0.03 and 0.015, the" exact="infection" post="spreads to the entire population. However, in the case"/>
   <result pre="outbreak is sharper, when we compare the penetration of the" exact="infection" post="in the population in random networks with densities 0.01"/>
   <result pre="values are close, there is a substantial difference in the" exact="total" post="number of individuals who got infected, as well as"/>
   <result pre="the infected population. With a network density of 0.01 the" exact="disease" post="penetrates the largest part of the population, however with"/>
   <result pre="comes to implementing &quot;lockdown&quot; strategies for the containment of an" exact="infectious disease." post="The evidence obtained from the simulations that we discuss,"/>
   <result pre="in the network densities values separating the containment of a" exact="disease" post="from the widespread infection of a population. Fig. 7"/>
   <result pre="values separating the containment of a disease from the widespread" exact="infection" post="of a population. Fig. 7 Comparison of infection rates"/>
   <result pre="the widespread infection of a population. Fig. 7 Comparison of" exact="infection" post="rates for various interaction network densities. Fig. 8 Visualization"/>
   <result pre="which an individual of the networked population got infected. (a)" exact="Epidemic" post="spreading with network density 0.03, (b) Epidemic spreading with"/>
   <result pre="got infected. (a) Epidemic spreading with network density 0.03, (b)" exact="Epidemic" post="spreading with network density 0.015, (c) Epidemic spreading with"/>
   <result pre="density 0.03, (b) Epidemic spreading with network density 0.015, (c)" exact="Epidemic" post="spreading with network density 0.01, (d) Epidemic spreading with"/>
   <result pre="density 0.015, (c) Epidemic spreading with network density 0.01, (d)" exact="Epidemic" post="spreading with network density 0.00825. Fig. 7 illustrates a"/>
   <result pre="density 0.00825. Fig. 7 illustrates a comparative chart of the" exact="infection" post="rates in relation to the network density. This diagram"/>
   <result pre="networks. The denser a contact network is, the higher the" exact="infection" post="rate will be. As a result, &quot;lockdown&quot; policies constitute"/>
   <result pre="to the density of the interaction network. Nevertheless, while the" exact="short" post="duration of an epidemic might sound beneficial, one has"/>
   <result pre="an epidemic might sound beneficial, one has to consider the" exact="limited" post="capacity of health systems to adequately respond to the"/>
   <result pre="With higher network densities the epidemic spreading looks like a" exact="short" post="and forceful wave. On the contrary, when the network"/>
   <result pre="time, and features a smoother form without concentrations. 5.2 Validation" exact="Classic" post="epidemiological theory (Anderson et al., 1992, Bailey et al.,"/>
   <result pre="the logistic growth equation to describe the evolution of the" exact="total" post="number of the individuals, who get infected from a"/>
   <result pre="total number of the individuals, who get infected from a" exact="disease" post="during an epidemic. The logistic growth equation is generally"/>
   <result pre="capacity of an environment, the diffusion of innovations, and the" exact="tumor" post="expansion among others (Murray, 2007). The adaptation of the"/>
   <result pre="( x 0 ≪ 1 ) , from whom a" exact="disease" post="starts spreading in the remaining population of susceptible individuals."/>
   <result pre="enable the fitting process of Eq. (10), we normalized the" exact="total" post="number of infected individuals to 1. It can be"/>
   <result pre="role of asymptomatic transmission in the progression of a contagious" exact="disease" post="In this simulation experiment we are going to demonstrate"/>
   <result pre="infection, progresses in parallel with the transmission of a contagious" exact="disease" post="through contacts between symptomatic and susceptible individuals. To illustrate"/>
   <result pre="with the transmission of a contagious disease through contacts between" exact="symptomatic" post="and susceptible individuals. To illustrate the effects of the"/>
   <result pre="To illustrate the effects of the asymptomatic transmission of a" exact="disease" post="to the evolution of an epidemic, we are going"/>
   <result pre="asymptomatic layer randomly generates contact events with individuals from the" exact="symptomatic" post="layer, through a Poison process with a frequency of"/>
   <result pre="Hz. The density of the connections between the asymptomatic and" exact="symptomatic" post="layers is equal to 0.01. This means that each"/>
   <result pre="individual is on average connected to 10 individuals in the" exact="symptomatic" post="layer. Therefore, each time a contact event is triggered"/>
   <result pre="process for an asymptomatic individual, then this individual transmits a" exact="viral" post="load to 10 individuals on average in the symptomatic"/>
   <result pre="a viral load to 10 individuals on average in the" exact="symptomatic" post="layer. The viral load transmitted by asymptomatic individuals is"/>
   <result pre="to 10 individuals on average in the symptomatic layer. The" exact="viral" post="load transmitted by asymptomatic individuals is configured to a"/>
   <result pre="viral load transmitted by asymptomatic individuals is configured to a" exact="lower" post="value (=2.7), in relation to the viral load transmitted"/>
   <result pre="configured to a lower value (=2.7), in relation to the" exact="viral" post="load transmitted by symptomatic infected individuals (=5). This difference"/>
   <result pre="value (=2.7), in relation to the viral load transmitted by" exact="symptomatic" post="infected individuals (=5). This difference is an approximation of"/>
   <result pre="an approximation of recent epidemiological findings suggesting that the SARS-CoV-2" exact="viral" post="load transmitted by asymptomatic or milder cases of Covid-19"/>
   <result pre="transmitted by asymptomatic or milder cases of Covid-19 patients, is" exact="lower" post="than the viral load transmitted by severe cases of"/>
   <result pre="or milder cases of Covid-19 patients, is lower than the" exact="viral" post="load transmitted by severe cases of Covid-19 (Ludvigsson, 2020,"/>
   <result pre="2020, Zheng et al., 2020). Fig. 10 The evolution of" exact="infection" post="events in the symptomatic layer, with (middle) and without"/>
   <result pre="2020). Fig. 10 The evolution of infection events in the" exact="symptomatic" post="layer, with (middle) and without (upper) asymptomatic transmission. Contact"/>
   <result pre="transmission. Contact events from asymptomatic individuals are illustrated in the" exact="lower" post="part of the figure. Fig. 11 The infection rate"/>
   <result pre="in the lower part of the figure. Fig. 11 The" exact="infection" post="rate in the layer of susceptibles who can develop"/>
   <result pre="of contact events from asymptomatic individuals are illustrated in the" exact="lower" post="part of the figure. Fig. 10, in the middle,"/>
   <result pre="of the figure. Fig. 10, in the middle, shows the" exact="infection" post="events in the layer of susceptible individuals, who become"/>
   <result pre="infection events in the layer of susceptible individuals, who become" exact="symptomatic" post="when infected, in relation to the contact events with"/>
   <result pre="to the contact events with asymptomatic individuals, illustrated in the" exact="lower" post="part of Fig. 10. The upper part of Fig."/>
   <result pre="individuals, illustrated in the lower part of Fig. 10. The" exact="upper" post="part of Fig. 10 shows the evolution of the"/>
   <result pre="upper part of Fig. 10 shows the evolution of the" exact="infection" post="events without asymptomatic transmission. It can be seen that"/>
   <result pre="can be seen that when asymptomatic transmission takes place, the" exact="infection" post="events increase and occur in a shorter time interval."/>
   <result pre="after a time point do not give rise to new" exact="infection" post="events, as the remaining susceptibles have a higher infection"/>
   <result pre="new infection events, as the remaining susceptibles have a higher" exact="infection" post="threshold, which cannot be crossed through the accumulation of"/>
   <result pre="cannot be crossed through the accumulation of the relatively low" exact="viral" post="load transmitted by asymptomatic individuals. Fig. 11, in the"/>
   <result pre="by asymptomatic individuals. Fig. 11, in the middle, illustrates the" exact="infection" post="rate in the layer of susceptibles who can develop"/>
   <result pre="with asymptomatics, as well as without asymptomatic transmission, in the" exact="upper" post="part of the figure. The lower part of the"/>
   <result pre="asymptomatic transmission, in the upper part of the figure. The" exact="lower" post="part of the figure illustrates the contact rate between"/>
   <result pre="the figure illustrates the contact rate between individuals of the" exact="symptomatic" post="and asymptomatic layers. As expected, the existence of asymptomatic"/>
   <result pre="layers. As expected, the existence of asymptomatic transmission increases the" exact="infection" post="rate in the layer of susceptible-symptomatic individuals, and shortens"/>
   <result pre="evolution of the cumulative number of infected individuals in the" exact="symptomatic" post="layer with and without the presence of asymptomatic transmission."/>
   <result pre="of asymptomatic transmission. Fig. 12, illustrates the development of the" exact="total" post="number of infected individuals in the susceptible-symptomatic layer with"/>
   <result pre="can be seen that the asymptomatic transmission substantially increases the" exact="total" post="number of symptomatic infections. In the simulation experiment, 874"/>
   <result pre="that the asymptomatic transmission substantially increases the total number of" exact="symptomatic" post="infections. In the simulation experiment, 874 individuals were infected"/>
   <result pre="epidemic process, the immunity conferred after the recovery from a" exact="disease" post="is limited, and therefore individuals get reinfected, thus giving"/>
   <result pre="repetitive epidemic waves. To simulate this scenario we assign a" exact="short" post="immunity period to the individuals of the synthetic population."/>
   <result pre="other infected individuals do not drive his/her susceptibility towards the" exact="infection" post="threshold. After the expiration of the immunity period, an"/>
   <result pre="the dynamically evolving susceptibilities from the reset value to the" exact="infection" post="threshold, for all the interconnected individuals of the simulation"/>
   <result pre="are depicted in Fig. 14. It can be seen that" exact="recurrent" post="epidemics occur in waves, whereby vulnerable individuals contract the"/>
   <result pre="recurrent epidemics occur in waves, whereby vulnerable individuals contract the" exact="disease" post="through infection cascades transmitting significant pathogenic load from the"/>
   <result pre="occur in waves, whereby vulnerable individuals contract the disease through" exact="infection" post="cascades transmitting significant pathogenic load from the infected to"/>
   <result pre="in the contact network lead to stronger and more solid" exact="infection" post="bursts. Neuro-SIR models these bursts through the dynamics of"/>
   <result pre="neural networks, and other excitable media. Fig. 13 Simulation of" exact="recurrent" post="epidemic waves through Neuro-SIR by assigning short immunity periods"/>
   <result pre="13 Simulation of recurrent epidemic waves through Neuro-SIR by assigning" exact="short" post="immunity periods to the individuals of the synthetic population."/>
   <result pre="equal to 165 ms. Fig. 15 (a) Profile of the" exact="external" post="force applied on the epidemic spreading process, (b) Epidemic"/>
   <result pre="the external force applied on the epidemic spreading process, (b)" exact="Epidemic" post="spreading pattern affected by the external force, (c) Epidemic"/>
   <result pre="epidemic spreading process, (b) Epidemic spreading pattern affected by the" exact="external" post="force, (c) Epidemic spreading pattern without external factors. 5.5"/>
   <result pre="(b) Epidemic spreading pattern affected by the external force, (c)" exact="Epidemic" post="spreading pattern without external factors. 5.5 Simulation experiment 4"/>
   <result pre="affected by the external force, (c) Epidemic spreading pattern without" exact="external" post="factors. 5.5 Simulation experiment 4 – SIRS epidemic process"/>
   <result pre="factors. 5.5 Simulation experiment 4 – SIRS epidemic process with" exact="external" post="factors The fourth simulation experiment deals with a SIRS"/>
   <result pre="deals with a SIRS epidemic process, which is affected by" exact="external" post="factors. The experiment aims to demonstrate the ability of"/>
   <result pre="the ability of Neuro-SIR to model the epidemic spreading, when" exact="external" post="conditions influence the dynamics of the propagation of a"/>
   <result pre="In this regard, we examine the case in which an" exact="external" post="factor (e.g. weather) increases the individuals’ susceptibility in a"/>
   <result pre="a pathogen, thereby reinforcing the spreading of a disease. The" exact="external" post="force is modeled as a step signal with strength"/>
   <result pre="value. The difference between the epidemic spreading pattern influenced by" exact="external" post="conditions, and the respective pattern without exogenous factors is"/>
   <result pre="illustrating the latter. Fig. 15(a) shows the profile of the" exact="external" post="force applied on the epidemic process. A detailed list"/>
   <result pre="the spreading dynamics of Covid-19, as well as of other" exact="infectious diseases." post="i.Use of personal protective equipment (PPE): The impact of"/>
   <result pre="the connection density of a social network. iii.Transmission of a" exact="disease" post="through asymptomatic infected individuals: Recent research confirms that asymptomatic"/>
   <result pre="Neuro-SIR supports the study of the dynamics of a contagious" exact="disease" post="through interconnected multi-layer networks. In the implementation of the"/>
   <result pre="role of asymptomatic individuals in the propagation of a contagious" exact="disease" post="was studied through the creation of a group of"/>
   <result pre="connected to another network comprising susceptible individuals, who can become" exact="symptomatic" post="patients. The group of asymptomatic individuals comes into contact"/>
   <result pre="of susceptible individuals, who can develop symptoms. To incorporate the" exact="lower" post="risk of Covid-19 transmission through contacts between asymptomatic and"/>
   <result pre="individuals, the connection weight between them was configured with a" exact="lower" post="value in relation to the connection weights between susceptible"/>
   <result pre="associated with a different level of risk, as the transmitted" exact="viral" post="load varies in relation to the transmission mode. A"/>
   <result pre="places. The adjustment of the impact of this type of" exact="external" post="factors, could be performed in consultation with empirical studies"/>
   <result pre="disease: Neuro-SIR enables the incorporation of the incubation period of" exact="infections" post="through the adjustment of the value of the transmission"/>
   <result pre="vi.Heterogeneous susceptibility: The susceptibility of people to Covid-19 and other" exact="infectious diseases," post="as well as the severity of the illness in"/>
   <result pre="parameters, so they realistically describe the quantitative impact of the" exact="external" post="environment on the evolution of an epidemic, enables a"/>
   <result pre="a more precise simulation of the propagation of a contagious" exact="disease" post="in a population. viii.Dynamically evolving susceptibility of a population"/>
   <result pre="dynamical evolution of the susceptibility of a population to an" exact="infectious" post="agent. This dynamic susceptibility landscape, actually constitutes a map"/>
   <result pre="the reliable estimation of the community transmission risk of an" exact="infectious disease," post="thus permitting the timely organization and implementation of containment"/>
   <result pre="policies. Simulating the dynamics of the transmission of a contagious" exact="disease" post="in complex settings comprising all the aforementioned factors, is"/>
   <result pre="of various factors on how, when and in which conditions" exact="infectious diseases" post="spread faster or slower. Neuro-SIR has the capacity to"/>
   <result pre="on the calibration and adaptation of Neuro-SIR to more realistic" exact="infection" post="transmission scenarios. The implementation of such simulation experiments entails"/>
   <result pre="of the model from real epidemiological data pertaining to particular" exact="infectious diseases," post="such as Covid-19. The information collected through test-and-trace programs"/>
   <result pre="role of various transmission modes (including airborne), the role of" exact="viral" post="load causing transmission of Covid-19, as well as the"/>
   <result pre="recent research (Liu, Yan et al., 2020) suggests that the" exact="viral" post="load transmitted from severe cases of Covid-19 patients, is"/>
   <result pre="cases of Covid-19 patients, is 60 times higher than the" exact="viral" post="load passed on by Covid-19 patients in mild condition."/>
   <result pre="condition. Also, another research (Jones et al., 2020) examining the" exact="viral" post="load in relation to the age of the Covid-19"/>
   <result pre="patients suggests that there is no considerable difference between the" exact="viral" post="load transmitted by patients in the age group of"/>
   <result pre="integrate-and-fire neurons to describe the transmission process of a contagious" exact="disease" post="in a networked population, is of course an approximation"/>
   <result pre="of realistic scenarios regarding the propagation of Covid-19 or other" exact="infectious diseases," post="requires close cooperation with relevant organizations and authorities, which"/>
   <result pre="current epidemiological studies analyze: (a) The role of the SARS-CoV-2" exact="viral" post="load in the transmission of Covid-19 (Jones et al.,"/>
   <result pre="al., 2020, Leclerc et al., 2020). (c) The transmission of" exact="respiratory" post="diseases through multiple contacts with infected persons (Ackley et"/>
   <result pre="al., 2020, Wang et al., 2020). (f) The role of" exact="external" post="factors (indoor places, air-conditioning, water environments, airborne transmission, contaminated"/>
   <result pre="of Covid-19, as well as to the propagation of other" exact="infectious diseases." post="The flexibility and adaptability of Neuro-SIR to complex epidemiological"/>
   <result pre="complex epidemiological processes, enable the study of the dynamics of" exact="infectious diseases" post="in a more informative and insightful way. As a"/>
   <result pre="individuals. In this regard, we initiated the modeling of the" exact="infection" post="transmission process, through an isomorphism between disease spreading in"/>
   <result pre="modeling of the infection transmission process, through an isomorphism between" exact="disease" post="spreading in a social network, and activity propagation in"/>
   <result pre="in highly heterogeneous populations and contagiousness contexts, in terms of" exact="susceptibility to" post="a disease, pathogen infectiveness, proximity and number of contacts,"/>
   <result pre="to a disease, pathogen infectiveness, proximity and number of contacts," exact="disease" post="incubation period, immunity, and exogenous factors affecting the propagation"/>
   <result pre="contagiousness of a disease; the density of contact network; and" exact="external" post="factors, such as climate, pollution, and sanitary conditions. This"/>
   <result pre="the effectiveness of various prevention and control policies for an" exact="infectious disease," post="through simulations with real parameter values. The results of"/>
   <result pre="contact network affects the penetration speed and scope of a" exact="disease" post="in a population with inhomogeneous vulnerabilities to a pathogen."/>
   <result pre="reproduces the stylized facts pertaining to the evolution of the" exact="total" post="number of infected and susceptibles during an epidemic process"/>
   <result pre="therefore social distancing is crucial to inhibiting the progression of" exact="infections" post="in a population of individuals. However, Neuro-SIR through a"/>
   <result pre="allowing the incorporation of additional factors affecting the propagation of" exact="infectious diseases." post="The expanded modeling capacity of Neuro-SIR is in line"/>
   <result pre="recent epidemiological findings pertaining to: (a) The role of the" exact="viral" post="load on the spreading of Covid-19 (Jones et al.,"/>
   <result pre="also expanded on the ability of Neuro-SIR to capture the" exact="infection" post="mechanism through multiple exposures to infected individuals. Recent epidemiological"/>
   <result pre="a susceptible individual to infected ones, so that a contagious" exact="disease" post="can be transmitted (Ackley et al., 2019, Lee et"/>
   <result pre="transmitted (Ackley et al., 2019, Lee et al., 2016). The" exact="infection" post="threshold featured in Neuro-SIR, which is reached through contacts"/>
   <result pre="multiple exposures. As a result, Neuro-SIR models the transmission of" exact="infectious diseases" post="in a realistic way, thereby providing a modeling platform"/>
   <result pre="aspect with a significant effect on the propagation patterns of" exact="infectious diseases," post="is the influence of external factors such as weather"/>
   <result pre="the propagation patterns of infectious diseases, is the influence of" exact="external" post="factors such as weather conditions, pollution, and the hygienic"/>
   <result pre="model both the intensity, and the temporal structure of time-varying" exact="external" post="factors affecting the individuals’ vulnerability to an infection. In"/>
   <result pre="of epidemics. This is achieved by dynamically changing the individuals’" exact="susceptibility to" post="a pathogen through the integration of time-varying external signals"/>
   <result pre="individuals’ susceptibility to a pathogen through the integration of time-varying" exact="external" post="signals driving one’s susceptibility either closer to the infection"/>
   <result pre="time-varying external signals driving one’s susceptibility either closer to the" exact="infection" post="threshold, or away from it. When the individuals’ susceptibility"/>
   <result pre="from it. When the individuals’ susceptibility has increased due to" exact="external" post="conditions, then infection cascades of large size can easily"/>
   <result pre="the individuals’ susceptibility has increased due to external conditions, then" exact="infection" post="cascades of large size can easily occur, as the"/>
   <result pre="can easily occur, as the individuals’ are closer to the" exact="infection" post="threshold and few contacts with infected persons suffice to"/>
   <result pre="endogenous and exogenous factors realistically describing the dynamics of propagating" exact="infections" post="in heterogeneous populations. Consequently, Neuro-SIR can be a valuable"/>
   <result pre="transmit via expiratory particles?2020Taylor &amp;amp; Francis BaileyN.T.The mathematical theory of" exact="infectious diseases" post="and its applications1975Charles Griffin &amp;amp; Company Ltd, 5a Crendon"/>
   <result pre="Theoretical Biology2352200527528815862595 BelikV.GeiselT.BrockmannD.Natural human mobility patterns and spatial spread of" exact="infectious" post="diseasesPhysical Review X112011011001 BoccalettiS.LatoraV.MorenoY.ChavezM.HwangD.-U.Complex networks: Structure and dynamicsPhysics Reports4244–52006175308"/>
   <result pre="of excitatory and inhibitory spiking neuronsJournal of Computational Neuroscience83200018320810809012 ChanJ.F.-W.YuanS.KokK.-H.ToK.K.-W.ChuH.YangJ.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
   <result pre="inhibitory spiking neuronsJournal of Computational Neuroscience83200018320810809012 ChanJ.F.-W.YuanS.KokK.-H.ToK.K.-W.ChuH.YangJ.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
   <result pre="neural systems2001MIT press Del ValleS.HethcoteH.HymanJ.M.Castillo-ChavezC.Effects of behavioral changes in a" exact="smallpox" post="attack modelMathematical Biosciences1952200522825115913667 DickisonM.HavlinS.StanleyH.E.Epidemics on interconnected networksPhysical Review E8562012066109"/>
   <result pre="and predictionBulletin of the World Health Organization1202032 HethcoteH.W.The mathematics of" exact="infectious" post="diseasesSIAM Review4242000599653 HuangL.ZhangX.ZhangX.WeiZ.ZhangL.XuJ.Rapid asymptomatic transmission of COVID-19 during the"/>
   <result pre="a prospective contact-tracing studyJournal of Infection2020 JonesT.C.MühlemannB.VeithT.BieleG.ZuchowskiM.HoffmannJ.An analysis of SARS-CoV-2" exact="viral" post="load by patient agemedRxiv2020 KermarkM.MckendrickA.Contributions to the mathematical theory"/>
   <result pre="and Engineering Sciences11551927700721 KuniyaT.Prediction of the epidemic peak of coronavirus" exact="disease" post="in Japan, 2020Journal of Clinical Medicine932020789 KupermanM.AbramsonG.Small world effect"/>
   <result pre="concentration methods-A scoping reviewWater Research2020115899 LauerS.A.GrantzK.H.BiQ.JonesF.K.ZhengQ.MeredithH.R.The incubation period of coronavirus" exact="disease" post="2019 (COVID-19) from publicly reported confirmed cases: estimation and"/>
   <result pre="been linked to SARS-CoV-2 transmission clusters?Wellcome Open Research58320208332656368 LeeR.S.ProulxJ.-F.MenziesD.BehrM.A.Progression to" exact="tuberculosis" post="disease increases with multiple exposuresEuropean Respiratory Journal48620161682168927824599 LiuJ.LiaoX.QianS.YuanJ.WangF.LiuY.Community transmission"/>
   <result pre="linked to SARS-CoV-2 transmission clusters?Wellcome Open Research58320208332656368 LeeR.S.ProulxJ.-F.MenziesD.BehrM.A.Progression to tuberculosis" exact="disease" post="increases with multiple exposuresEuropean Respiratory Journal48620161682168927824599 LiuJ.LiaoX.QianS.YuanJ.WangF.LiuY.Community transmission of"/>
   <result pre="Open Research58320208332656368 LeeR.S.ProulxJ.-F.MenziesD.BehrM.A.Progression to tuberculosis disease increases with multiple exposuresEuropean" exact="Respiratory" post="Journal48620161682168927824599 LiuJ.LiaoX.QianS.YuanJ.WangF.LiuY.Community transmission of severe acute respiratory syndrome coronavirus"/>
   <result pre="increases with multiple exposuresEuropean Respiratory Journal48620161682168927824599 LiuJ.LiaoX.QianS.YuanJ.WangF.LiuY.Community transmission of severe" exact="acute" post="respiratory syndrome coronavirus 2, shenzhen, China, 20202020 LiuY.YanL.-M.WanL.XiangT.-X.LeA.LiuJ.-M.Viral dynamics"/>
   <result pre="with multiple exposuresEuropean Respiratory Journal48620161682168927824599 LiuJ.LiaoX.QianS.YuanJ.WangF.LiuY.Community transmission of severe acute" exact="respiratory" post="syndrome coronavirus 2, shenzhen, China, 20202020 LiuY.YanL.-M.WanL.XiangT.-X.LeA.LiuJ.-M.Viral dynamics in"/>
   <result pre="multiple exposuresEuropean Respiratory Journal48620161682168927824599 LiuJ.LiaoX.QianS.YuanJ.WangF.LiuY.Community transmission of severe acute respiratory" exact="syndrome" post="coronavirus 2, shenzhen, China, 20202020 LiuY.YanL.-M.WanL.XiangT.-X.LeA.LiuJ.-M.Viral dynamics in mild"/>
   <result pre="LiuY.YanL.-M.WanL.XiangT.-X.LeA.LiuJ.-M.Viral dynamics in mild and severe cases of COVID-19The Lancet" exact="Infectious" post="Diseases2020 LuJ.GuJ.LiK.XuC.SuW.LaiZ.COVID-19 outbreak associated with air conditioning in restaurant,"/>
   <result pre="outbreak associated with air conditioning in restaurant, Guangzhou, China, 2020Emerging" exact="Infectious" post="Diseases2672020162832240078 LudvigssonJ.F.Systematic review of COVID-19 in children shows milder"/>
   <result pre="complex adaptive systems and neural network models based on the" exact="brain" post="dynamics(Ph.D. thesis)2015 LymperopoulosI.N.Dynamic response and transfer function of social"/>
   <result pre="introduction, Vol. 172007Springer Science &amp;amp; Business Media NewmanM.E.Spread of epidemic" exact="disease" post="on networksPhysical Review E6612002016128 NewmanM.Networks2018Oxford university press NishiuraH.KobayashiT.MiyamaT.SuzukiA.JungS.-m.HayashiK.Estimation of"/>
   <result pre="university press NishiuraH.KobayashiT.MiyamaT.SuzukiA.JungS.-m.HayashiK.Estimation of the asymptomatic ratio of novel coronavirus" exact="infections" post="(COVID-19)International Journal of Infectious Diseases94202015432179137 PandeyG.ChaudharyP.GuptaR.PalS.SEIR And regression model"/>
   <result pre="the asymptomatic ratio of novel coronavirus infections (COVID-19)International Journal of" exact="Infectious" post="Diseases94202015432179137 PandeyG.ChaudharyP.GuptaR.PalS.SEIR And regression model based COVID-19 outbreak predictions"/>
   <result pre="RodaW.C.VarugheseM.B.HanD.LiM.Y.Why is it difficult to accurately predict the COVID-19 epidemic?Infectious" exact="Disease" post="Modelling2020 SakuraiA.SasakiT.KatoS.HayashiM.TsuzukiS.-i.IshiharaT.Natural history of asymptomatic SARS-CoV-2 infectionNew England Journal"/>
   <result pre="SARS-CoV-2 infectionNew England Journal of Medicine2020 SchneiderC.M.MihaljevT.HavlinS.HerrmannH.J.Suppressing epidemics with a" exact="limited" post="amount of immunization unitsPhysical Review E8462011061911 SomsenG.A.van RijnC.KooijS.BemR.A.BonnD.Small droplet"/>
   <result pre="droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmissionThe Lancet." exact="Respiratory" post="Medicine2020 StadnytskyiV.BaxC.E.BaxA.AnfinrudP.The airborne lifetime of small speech droplets and"/>
   <result pre="and predicting COVID-19 epidemic in china mainlandmedRxiv2020 ToK.K.-W.TsangO.T.-Y.LeungW.-S.TamA.R.WuT.-C.LungD.C.Temporal profiles of" exact="viral" post="load in posterior oropharyngeal saliva samples and serum antibody"/>
   <result pre="epidemic in china mainlandmedRxiv2020 ToK.K.-W.TsangO.T.-Y.LeungW.-S.TamA.R.WuT.-C.LungD.C.Temporal profiles of viral load in" exact="posterior" post="oropharyngeal saliva samples and serum antibody responses during infection"/>
   <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort studyThe Lancet Infectious Diseases2020"/>
   <result pre="responses during infection by SARS-CoV-2: an observational cohort studyThe Lancet" exact="Infectious" post="Diseases2020 TuckwellH.C.Introduction to theoretical neurobiology: volume 2, nonlinear and"/>
   <result pre="socio-technical systemsNature Physics8120123239 WangY.LiuY.LiuL.WangX.LuoN.LiL.Clinical outcomes in 55 patients with severe" exact="acute" post="respiratory syndrome coronavirus 2 who were asymptomatic at hospital"/>
   <result pre="systemsNature Physics8120123239 WangY.LiuY.LiuL.WangX.LuoN.LiL.Clinical outcomes in 55 patients with severe acute" exact="respiratory" post="syndrome coronavirus 2 who were asymptomatic at hospital admission"/>
   <result pre="Physics8120123239 WangY.LiuY.LiuL.WangX.LuoN.LiL.Clinical outcomes in 55 patients with severe acute respiratory" exact="syndrome" post="coronavirus 2 who were asymptomatic at hospital admission in"/>
   <result pre="were asymptomatic at hospital admission in shenzhen, chinaThe Journal of" exact="Infectious" post="Diseases2211120201770177432179910 WölfelR.CormanV.M.GuggemosW.SeilmaierM.ZangeS.MüllerM.A.Virological assessment of hospitalized patients with COVID-2019Nature5817809202046546932235945 WuJ.T.LeungK.BushmanM.KishoreN.NiehusR.de"/>
   <result pre="COVID-19 from the transmission dynamics in Wuhan, ChinaNature Medicine2642020506510 YuP.ZhuJ.ZhangZ.HanY.A" exact="familial" post="cluster of infection associated with the 2019 novel coronavirus"/>
   <result pre="transmission dynamics in Wuhan, ChinaNature Medicine2642020506510 YuP.ZhuJ.ZhangZ.HanY.A familial cluster of" exact="infection" post="associated with the 2019 novel coronavirus indicating possible person-to-person"/>
   <result pre="indicating possible person-to-person transmission during the incubation periodThe Journal of" exact="Infectious" post="Diseases2211120201757176132067043 ZhengS.FanJ.YuF.FengB.LouB.ZouQ.Viral load dynamics and disease severity in patients"/>
   <result pre="incubation periodThe Journal of Infectious Diseases2211120201757176132067043 ZhengS.FanJ.YuF.FengB.LouB.ZouQ.Viral load dynamics and" exact="disease" post="severity in patients infected with SARS-CoV-2 in zhejiang province,"/>
   <result pre="of COVID-19 based on logistic model and SEIR modelmedRxiv2020 ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.SARS-CoV-2" exact="Viral" post="load in upper respiratory specimens of infected patientsNew England"/>
   <result pre="on logistic model and SEIR modelmedRxiv2020 ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.SARS-CoV-2 Viral load in" exact="upper" post="respiratory specimens of infected patientsNew England Journal of Medicine3821220201177117932074444"/>
   <result pre="logistic model and SEIR modelmedRxiv2020 ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.SARS-CoV-2 Viral load in upper" exact="respiratory" post="specimens of infected patientsNew England Journal of Medicine3821220201177117932074444 Ilias"/>
   <result pre="complex adaptive systems and neural network models based on the" exact="brain" post="dynamics. His research interests focus on the study and"/>
   <result pre="prestigious journals. He has thorough managerial and technical professional experience" exact="acquired" post="from his participation with leading roles in large and"/>
   <result pre="fields such as, Web applications, Robotics, ERP systems, eCommerce, Telecommunications," exact="Transport" post="Telematics, Logistics and Banking. Acknowledgments The Author wishes to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7472381/results/search/disease/results.xml">
   <result pre="in the family Togiviridae, native to Africa, which causes human" exact="disease" post="and is transmitted by Aedes mosquitoes, primarily invasive Stegomyia."/>
   <result pre="[1,2]. Three major lineages are recognized (East, Central, and South" exact="African" post="(ECSA), Asian, and West African (WA)), with an additional"/>
   <result pre="recognized (East, Central, and South African (ECSA), Asian, and West" exact="African" post="(WA)), with an additional sublineage of ECSA (Indian Ocean"/>
   <result pre="was widespread transmission of Zika virus (ZIKV) in South and" exact="Central" post="America and the Caribbean [14]. The introduction pressure was"/>
   <result pre="wider ranges or higher transmission rates, a shorter EIP, and" exact="lower" post="turnover of the mosquito population. Under their assumptions and"/>
   <result pre="fixed rate (e.g., [20]) or increasing with temperature (e.g., [17,18,19])." exact="Adult" post="mosquito mortality in the field is complex, and is"/>
   <result pre="albopictus, CHIKV strain variation, and includes a nonlinear relationship between" exact="adult" post="mosquito mortality and temperature. We used the model to"/>
   <result pre="interaction, the human population was simplified. Human populations are relatively" exact="stable" post="over short time periods, so the human population size"/>
   <result pre="human population was simplified. Human populations are relatively stable over" exact="short" post="time periods, so the human population size was fixed"/>
   <result pre="humans was included, as this was thought to be relatively" exact="short" post="[39] and, with no human mortality, would act only"/>
   <result pre="The duration of infectiousness in humans may extend beyond the" exact="symptomatic" post="period (approximately 1 week [40]), and more recently has"/>
   <result pre="mosquito dynamics. We assumed that water availability would be the" exact="primary" post="driver of recruitment to the adult population, and that"/>
   <result pre="availability would be the primary driver of recruitment to the" exact="adult" post="population, and that both species would respond similarly. This"/>
   <result pre="(~N(qi, σi); i = [1,2] for spring, summer peaks) in" exact="adult" post="recruitment ([19], Figure S2). Abundance is specified as ρmax,j,"/>
   <result pre="Figure S2). Abundance is specified as ρmax,j, the number of" exact="adult" post="female mosquitoes of species j per human host over"/>
   <result pre="S2). Abundance is specified as ρmax,j, the number of adult" exact="female" post="mosquitoes of species j per human host over the"/>
   <result pre="species j per human host over the entire year. The" exact="total" post="number of mosquitoes of species j is then given"/>
   <result pre="− p δ 1 , j . Recruitment to the" exact="adult" post="population was thus (for each mosquito species j, j"/>
   <result pre="vector competence in Ae. albopictus affect the EIP (rate of" exact="viral" post="development) and the proportion of insects that can acquire"/>
   <result pre="structure of a linear increase with temperature and added a" exact="lower" post="bound of 10 °C, below which no development occurs."/>
   <result pre="infected, and recovered humans and susceptible, exposed (latently infected) and" exact="infectious" post="mosquitoes of each species (j): As detailed above, mosquito"/>
   <result pre="was assumed to die out and all state variables including" exact="infection" post="reset to 0. (8) d H s d t"/>
   <result pre="same LHC parameter sets with each Tempc value (for a" exact="total" post="of 750 simulation runs). For each LHC set (each"/>
   <result pre="analysis, human population size was reduced to 5000. Adaptation between" exact="viral" post="strain and mosquito species was defined as higher vector"/>
   <result pre="larval development and thus the seasonality of recruitment to the" exact="adult" post="population will be similar. However, population abundance of both"/>
   <result pre="a wide range (100–20,000 mosquitoes/species/host/year). This resulted in both the" exact="total" post="number of mosquitoes and the relative population size of"/>
   <result pre="in recruitment was the same for the two species, temperature-dependent" exact="adult" post="mortality was not (see above, [52]). Therefore, adult populations"/>
   <result pre="species, temperature-dependent adult mortality was not (see above, [52]). Therefore," exact="adult" post="populations could show differences between species in seasonal abundance."/>
   <result pre="0.5:0.5 aegypti:albopictus. The parameter values to generate these ratios were:" exact="total" post="ρmax = 5000/host/year; equal recruitment: ρmax = 2500/species; asymmetric"/>
   <result pre="to reflect shorter expected life span, but temperature sensitivity was" exact="lower" post="in Ae. aegypti as it is expected to be"/>
   <result pre="competency (10–80% transmitting virus; e.g., [4,46,55]). Some CHIKV strains have" exact="acquired" post="mutations that increase the competence of Ae. albopictus (although"/>
   <result pre="There is less information available on the rate of human" exact="infection" post="following infectious bites (βj), so the range and most"/>
   <result pre="less information available on the rate of human infection following" exact="infectious" post="bites (βj), so the range and most likely values"/>
   <result pre="virus strain variation (e.g., [56]). Notable for CHIKV is the" exact="short" post="extrinsic incubation period relative to other arboviruses (e.g., [4,46,48,55])."/>
   <result pre="in other systems (e.g., DENV, [16,43]; West Nile virus, [45])." exact="Limited" post="information available during parameter estimation suggested CHIKV development would"/>
   <result pre="respectively, for both species. The virus was introduced by one" exact="infectious" post="human, on the day specified by tcrjt, as this"/>
   <result pre="a convenient way to rank the input parameters in importance." exact="Multiple" post="regression was used to assess input parameter effects on"/>
   <result pre="most influential parameters identified as for epi. 3. Results 3.1." exact="Epidemic" post="Behavior Most simulation runs demonstrated one of three behaviors:"/>
   <result pre="single outbreak occurred that infected all susceptibles in a relatively" exact="short" post="time period (Figure 3A), or two outbreaks occurred (usually"/>
   <result pre="within these behaviors (Table 2). A few parameter sets showed" exact="intermediate" post="or alternate behaviors. Changes in Tempc alone could change"/>
   <result pre="(Table 3 and Table S1; Figure 5). When Tempc was" exact="lower" post="(=10 or 16), decreasing annual mean temperature increased the"/>
   <result pre="for biting frequency, but with a negative relationship indicating that" exact="lower" post="biting frequency of Ae. aegypti increased the likelihood of"/>
   <result pre="frequency of Ae. aegypti increased the likelihood of epidemics at" exact="lower" post="Tempc levels. The slope of the mortality rate–temperature relationship"/>
   <result pre="and duration of virus activity, as some simulations showed single," exact="short" post="outbreaks (Figure 3) while others had prolonged, lower viral"/>
   <result pre="showed single, short outbreaks (Figure 3) while others had prolonged," exact="lower" post="viral activity. The average MaxHi increased with Tempc, but"/>
   <result pre="single, short outbreaks (Figure 3) while others had prolonged, lower" exact="viral" post="activity. The average MaxHi increased with Tempc, but the"/>
   <result pre="only), a different pattern is observed. Highest outbreak sizes are" exact="lower" post="than those observed with identical species characteristics or with"/>
   <result pre="tropical mosquito and mortality is likely to be high at" exact="lower" post="temperatures. Extending the upper range of this parameter would"/>
   <result pre="is likely to be high at lower temperatures. Extending the" exact="upper" post="range of this parameter would be of interest, given"/>
   <result pre="work will consider more specific mortality relationships and broader ranges." exact="Adult" post="mosquito mortality has been identified as an important parameter"/>
   <result pre="even with constant mortality rates or simple relationships with temperature." exact="Complex" post="relationships between mortality and temperature have been observed for"/>
   <result pre="populations with low Ae. aegypti abundance. Interestingly, even with a" exact="viral" post="strain adapted to Ae. albopictus, Ae. aegypti supported higher"/>
   <result pre="identified as key factors, while virus development rates (γ) had" exact="limited" post="impacts on outcome variables, suggesting that mutations affecting transmission"/>
   <result pre="duration of the latency stage. Our central transmission rates were" exact="lower" post="than the baseline transmission rates of [20] as well,"/>
   <result pre="transmission dynamics. Extensions of the sensitivity analysis to higher and" exact="lower" post="Tmean values would be of interest to explore the"/>
   <result pre="of invasion and identify factors that most influence epidemic dynamics." exact="Adult" post="recruitment patterns were based on rainfall and modeled similarly"/>
   <result pre="may have occurred years before surveillance detectionSci. Rep.20199276010.1038/s41598-019-39406-930809003 8.TroutA.BaraccoG.RodriguezM.BarberJ.LealA.RadkeE.WeisK.StanekD.StarkL.BlackmoreC.et al.Locally" exact="acquired" post="dengue-Key West, Florida, 2009-2010J. Amer. Med. Assoc.201030324652468 9.collab: FLDOHDengue"/>
   <result pre="on 6 May 2020) 10.MessengerA.M.Serological evidence of ongoing transmission of" exact="Dengue" post="virus in permanent residents of Key West, FloridaVector. Borne."/>
   <result pre="FloridaVector. Borne. Zoon. Dis.20141478378710.1089/vbz.2014.1665 11.ReyJ.R.Dengue in Florida (USA)Insects20145991100010.3390/insects504099126462955 12.collab: FLDOHChikungunya" exact="Fever" post="(CHIK)Available online: http://www.floridahealth.gov/diseases-and-conditions/chikungunya/index.html/(accessed on 6 May 2020) 13.KendrickK.D.StanekC.BlackmoreC.Transmission of"/>
   <result pre="June-August 2016MMWR2016651032103810.15585/mmwr.mm6538e127684886 16.FocksD.A.DanielsE.HaileD.G.KeeslingJ.E.A simulation model of the epidemiology of urban" exact="Dengue" post="fever: Literature analysis, model development, preliminary validation, and samples"/>
   <result pre="of simulation resultsAm. J. Trop. Med. Hyg.19955348950610.4269/ajtmh.1995.53.4897485707 17.LordC.C.DayJ.F.Simulation studies of" exact="St. Louis encephalitis" post="in South FloridaVector. Borne. Zoon. Dis.2001129931610.1089/1530366016002592112653129 18.LordC.C.DayJ.F.Simulation studies of"/>
   <result pre="resultsAm. J. Trop. Med. Hyg.19955348950610.4269/ajtmh.1995.53.4897485707 17.LordC.C.DayJ.F.Simulation studies of St. Louis" exact="encephalitis" post="in South FloridaVector. Borne. Zoon. Dis.2001129931610.1089/1530366016002592112653129 18.LordC.C.DayJ.F.Simulation studies of"/>
   <result pre="encephalitis in South FloridaVector. Borne. Zoon. Dis.2001129931610.1089/1530366016002592112653129 18.LordC.C.DayJ.F.Simulation studies of" exact="St. Louis encephalitis" post="and West Nile viruses: The impact of bird mortalityVector."/>
   <result pre="South FloridaVector. Borne. Zoon. Dis.2001129931610.1089/1530366016002592112653129 18.LordC.C.DayJ.F.Simulation studies of St. Louis" exact="encephalitis" post="and West Nile viruses: The impact of bird mortalityVector."/>
   <result pre="of multiple vectors on arbovirus transmissionIsrael J. Ecol. Evol.20105537139210.1560/IJEE.55.3-4.371 20.ManoreC.A.HickmannK.S.XuS.WearingH.J.HymanJ.M.Comparing" exact="Dengue" post="and Chikungunya emergence and endemic transmission in A. aegypti"/>
   <result pre="aegypti and A. albopictusJ. Theor. Biol.201435617419110.1016/j.jtbi.2014.04.03324801860 21.AndraudM.HensN.MaraisC.BeutelsP.Dynamic epidemiological models for" exact="Dengue" post="transmission: A systematic review of structural approachesPLoS ONE2012710.1371/journal.pone.0049085 22.WonhamM.J.LewisM.A.RencławowiczJ.Van"/>
   <result pre="ONE2012710.1371/journal.pone.0049085 22.WonhamM.J.LewisM.A.RencławowiczJ.Van Den DriesscheP.Transmission assumptions generate conflicting predictions in host–vector" exact="disease" post="models: A case study in West Nile virusEcol. Lett.2006970672510.1111/j.1461-0248.2006.00912.x16706915"/>
   <result pre="mortality and the extrinsic incubation period in models of mosquito-borne" exact="disease" post="transmission and controlPLoS ONE2010510.1371/journal.pone.001016520405010 27.YangH.M.MacorisM.L.G.GalvaniK.C.AndrighettiM.T.M.WanderleyD.M.V.Assessing the effects of temperature"/>
   <result pre="of Aedes aegypti (Diptera: Culicidae) in Thailand and Puerto Rico:" exact="Blood" post="feeding frequencyJ. Med. Entomol.2000378910110.1603/0022-2585-37.1.8915218911 35.RichardsS.L.PonnusamyL.UnnaschT.R.HassanH.K.AppersonC.S.Host-feeding patterns of Aedes albopictus"/>
   <result pre="Infect. Dis.2016214S446S44810.1093/infdis/jiw36227920171 39.StaplesJ.E.BreimanR.F.PowersA.M.Chikungunya fever: An epidemiological review of a re-emerging" exact="infectious" post="diseaseClin. Infect. Dis.20094994294810.1086/60549619663604 40.PardigonN.The biology of Chikungunya: A brief"/>
   <result pre="43.XiaoF.-Z.ZhangY.DengY.-Q.HeS.XieH.-G.ZhouX.-N.YanY.-S.The effect of temperature on the extrinsic incubation period and" exact="infection" post="rate of dengue virus serotype 2 infection in Aedes"/>
   <result pre="incubation period and infection rate of dengue virus serotype 2" exact="infection" post="in Aedes albopictusArch. Virol.20141593053305710.1007/s00705-014-2051-124990415 44.ChanM.JohanssonM.A.The incubation periods of Dengue"/>
   <result pre="2 infection in Aedes albopictusArch. Virol.20141593053305710.1007/s00705-014-2051-124990415 44.ChanM.JohanssonM.A.The incubation periods of" exact="Dengue" post="virusesPLoS ONE2012710.1371/journal.pone.0050972 45.ReisenW.K.FangY.LothropH.D.MartinezV.M.WilsonJ.O’ConnorP.CarneyR.Cahoon-YoungB.ShafiiM.BraultA.C.Overwintering of West Nile virus in Southern"/>
   <result pre="vector competence of Aedes aegypti and Aedes albopictus from ten" exact="American" post="countries as a crucial factor of the spread of"/>
   <result pre="the spread of ChikungunyaJ. Virol.20149010.1128/JVI.00370-1424672026 47.ZouacheK.FontaineA.Vega-RuaA.MoussonL.ThibergeJ.-M.Lourenco-De-OliveiraR.CaroV.LambrechtsL.FaillouxA.-B.Three-way interactions between mosquito population," exact="viral" post="strain and temperature underlying chikungunya virus transmission potentialProc. Roy."/>
   <result pre="47.ZouacheK.FontaineA.Vega-RuaA.MoussonL.ThibergeJ.-M.Lourenco-De-OliveiraR.CaroV.LambrechtsL.FaillouxA.-B.Three-way interactions between mosquito population, viral strain and temperature underlying" exact="chikungunya" post="virus transmission potentialProc. Roy. Soc. B20142812014107810.1098/rspb.2014.107825122228 48.DubrulleM.MoussonL.MoutaillerS.VazeilleM.FaillouxA.-B.Chikungunya virus and"/>
   <result pre="Roy. Soc. B20142812014107810.1098/rspb.2014.107825122228 48.DubrulleM.MoussonL.MoutaillerS.VazeilleM.FaillouxA.-B.Chikungunya virus and Aedes mosquitoes: Saliva is" exact="infectious" post="as soon as two days after oral infectionPLoS ONE2009410.1371/journal.pone.0005895"/>
   <result pre="infectionPLoS ONE2009410.1371/journal.pone.0005895 49.BlowerS.M.DowlatabadiH.Sensitivity and uncertainty analysis of complex models of" exact="disease" post="transmission: An HIV model, as an exampleInt. Stat. Rev.19946222924310.2307/1403510"/>
   <result pre="of eggs and the coexistence of competing mosquitoesOecologia200213045846910.1007/s00442010081120871747 52.BradyO.J.JohanssonM.A.GuerraC.A.BhattS.GoldingN.PigottD.M.DelatteH.GrechM.G.LeisnhamP.T.Maciel-de-FreitasR.et al.Modelling" exact="adult" post="Aedes aegypti and Aedes albopictus survival at different temperatures"/>
   <result pre="(Diptera: Culicidae)J. Med. Entomol.20135083884610.1603/ME1214623926783 62.McMenimanC.J.LaneR.V.CassB.N.FongA.W.C.SidhuM.WangY.F.O’NeillS.L.Stable introduction of a life-shortening Wolbachia" exact="infection" post="into the mosquito Aedes aegyptiScience200932314114410.1126/science.116532619119237 63.DongY.MortonJ.C.RamirezJ.L.Souza-NetoJ.A.DimopoulosG.The entomopathogenic fungus Beauveria"/>
   <result pre="bimodal outbreaks. Top panels, number of humans in each class," exact="lower" post="panels, number of adult female mosquitoes of each species"/>
   <result pre="number of humans in each class, lower panels, number of" exact="adult" post="female mosquitoes of each species in each class. (A)"/>
   <result pre="of humans in each class, lower panels, number of adult" exact="female" post="mosquitoes of each species in each class. (A) Run"/>
   <result pre="S6. Tempc = 22 °C. Blue lines, susceptible; red lines," exact="infectious" post="humans or mosquitoes; and green lines, recovered humans. Mosquito"/>
   <result pre="Mosquito panels set to the same Y-axis scaling for comparison;" exact="infectious" post="mosquitoes not always visible at this scale. Figure 4"/>
   <result pre="outbreak, then delayed single outbreak. Blue lines, susceptible; red lines," exact="infectious" post="humans or mosquitoes; and green lines, recovered humans. Figure"/>
   <result pre="cases at the peak with species and strain specific parameters." exact="Total" post="mosquito recruitment: ρmax = 5000/host/year. Equal recruitment (aeg ="/>
   <result pre="Symbol Distribution a Range Center State variables Susceptible humans Hs" exact="Infectious" post="humans Hin Recovered humans Hr Susceptible mosquitoes, species j"/>
   <result pre="Susceptible mosquitoes, species j Sj Latent mosquitoes, species j Lj" exact="Infectious" post="mosquitoes, species j Yj Parameters Mean of temperature curve"/>
   <result pre="introduced tcrit Uni 5–360 Human recovery rate rH Fixed 0.125" exact="Total" post="(initial) number of humans Htot Fixed 50,000 Both mosquito"/>
   <result pre="Fixed 15 Width of optimal survival range W Fixed 2" exact="Central" post="point of optimal survival temperature range Tempc Set values"/>
   <result pre="γsl,alb Tri 0.004–0.02 0.015 Maximum recruitment ρmax,alb Tri 100–20,000 5000" exact="Total" post="recruitment through year Rtot,alb Calculated Aedes aegypti Transmission mosquito"/>
   <result pre="γsl,aeg Tri 0.004–0.02 0.015 Maximum recruitment ρmax,aeg Tri 100–20,000 5000" exact="Total" post="recruitment through year Rtot,aeg Calculated LHC—Latin hypercube sampling; a"/>
   <result pre="Outcome variables for sensitivity analysis at three values of Tempc." exact="Central" post="Temperature, Tempc (°C) Outcome Variable 10 16 22 #"/>
   <result pre="and ranked by p-value. Negative regression coefficients indicated by (-)." exact="Central" post="Temperature, Tempc (°C) 10 16 22 Annual mean temperature"/>
   <result pre="parameters influencing MaxHi. Includes only epidemic simulations, main effects only." exact="Central" post="Temperature, Tempc (°C) 10 16 22 Annual mean temperature"/>
   <result pre="parameters influencing lag. Includes only epidemic simulations, main effects only." exact="Central" post="Temperature, Tempc (°C) 10 16 22 Annual mean temperature"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7482569/results/search/disease/results.xml">
   <result pre="human population in the past two decades, following the severe" exact="acute" post="respiratory syndrome coronavirus SARS-CoV outbreak in 2002 and the"/>
   <result pre="population in the past two decades, following the severe acute" exact="respiratory" post="syndrome coronavirus SARS-CoV outbreak in 2002 and the Middle"/>
   <result pre="in the past two decades, following the severe acute respiratory" exact="syndrome" post="coronavirus SARS-CoV outbreak in 2002 and the Middle East"/>
   <result pre="syndrome coronavirus SARS-CoV outbreak in 2002 and the Middle East" exact="syndrome" post="coronavirus MERS-CoV outbreak in 2012. SARS-CoV-2 initially emerged in"/>
   <result pre="two coronaviruses [2]. For example, in the first case of" exact="pneumonia" post="caused by this virus reported in USA, a 35-year-old,"/>
   <result pre="a hospital four days after he experienced dry cough and" exact="low grade" post="fever; he proceeded to develop pneumonia 5 days later,"/>
   <result pre="dry cough and low grade fever; he proceeded to develop" exact="pneumonia" post="5 days later, but quickly recovered [3]. This is"/>
   <result pre="days later, but quickly recovered [3]. This is the typical" exact="disease" post="course for young persons. However, COVID-19 has a significant"/>
   <result pre="for those with a variety of underlying medical conditions, including" exact="respiratory" post="and cardiovascular diseases, as well as diabetes mellitus. For"/>
   <result pre="with a variety of underlying medical conditions, including respiratory and" exact="cardiovascular" post="diseases, as well as diabetes mellitus. For example, after"/>
   <result pre="medical conditions, including respiratory and cardiovascular diseases, as well as" exact="diabetes mellitus." post="For example, after the identification of an individual in"/>
   <result pre="virus is the high level of SARS-CoV-2 shedding in the" exact="upper" post="respiratory tract even among asymptomatic individuals [5]. As a"/>
   <result pre="is the high level of SARS-CoV-2 shedding in the upper" exact="respiratory" post="tract even among asymptomatic individuals [5]. As a result"/>
   <result pre="that a plateau will be reached, as well as the" exact="total" post="number of individuals reported to be infected at that"/>
   <result pre="in epidemiology. Also, importantly, the birational model may provide an" exact="upper" post="bound of N(t), and hence it is preferable to"/>
   <result pre="data until around the time when the maximum rate of" exact="infection" post="occurs, which will be denoted by T (the corresponding"/>
   <result pre="short-term memory (BiLSTM) network, which provides a powerful generalization of" exact="recurrent" post="neural networks. A prerequisite for the development of any"/>
   <result pre="appear to have a slow approach towards a plateau. The" exact="total" post="reported cases of the above countries as a function"/>
   <result pre="virus epidemics in Italy, Spain, France, Germany, USA and Sweden:" exact="total" post="cumulative number of individuals reported to be infected up"/>
   <result pre="In this pioneering paper, the population is divided into susceptible," exact="infectious" post="and recovered (removed) sub-populations. Then, specific ordinary differential equations"/>
   <result pre="derived in [8]). The generalization of SIR to models involving" exact="partial" post="differential equations is presented in [9]. A simple extension"/>
   <result pre="individuals reported at time t to be infected by a" exact="viral" post="epidemic. In this work, we assume that the function"/>
   <result pre="given country for the prevention of the spread of the" exact="viral infection." post="The dependence of α(t) on time reflects various time-dependent"/>
   <result pre="formula is adequate for capturing the evolution N(t) of typical" exact="viral" post="epidemics. For example, determining the three constant parameters κ,"/>
   <result pre="were obtained from the official site of the Centers for" exact="Disease" post="Control and Prevention (CDC); they are official World Health"/>
   <result pre="outbreak of Guinea in 2014: predicted versus actual for the" exact="total" post="cumulative number of individuals reported to be infected with"/>
   <result pre="underestimates N(t); in other words, the logistic model provides a" exact="lower" post="bound of the actual N(t). This raises the following"/>
   <result pre="it becomes evident that first, the logistic formula provides a" exact="lower" post="bound, and second, that the rational and birational formulae"/>
   <result pre="the data, suggesting that the birational model may provide an" exact="upper" post="bound. (ii) We established that the rational and birational"/>
   <result pre="(as noted above, the estimate for Italy may be an" exact="upper" post="bound); Spain, plateau on 17 May 2020, with 226"/>
   <result pre="Sweden and of USA. In the case of Sweden, only" exact="partial" post="restrictions were applied instead of strict lockdown measures, whereas"/>
   <result pre="(for these two countries the following numbers provide rather inaccurate" exact="lower" post="bounds: USA, plateau on 28 August 2020, with 2"/>
   <result pre="I, S with I-T, where the constant T denotes the" exact="total" post="population, one finds a Riccati equation of the form"/>
   <result pre="a constant coefficients Riccati equation in the mathematical modelling of" exact="infectious" post="processes can be found in the paper of Anderson"/>
   <result pre="model is the time T when the maximum rate of" exact="infection" post="is achieved: computing the second derivative of the right-hand"/>
   <result pre="T )   , where Nl and Nu are the" exact="upper" post="and lower values of the relevant curve. This expression"/>
   <result pre="  , where Nl and Nu are the upper and" exact="lower" post="values of the relevant curve. This expression provides the"/>
   <result pre="Optimization method We obtained the time-series data for the coronavirus" exact="disease" post="(COVID-19) for the counties studies here from the official"/>
   <result pre="here from the official site of the European Centre for" exact="Disease" post="Prevention and Control.3 We arranged the data in the"/>
   <result pre="On the other hand, this can be easily achieved using" exact="recurrent" post="neural networks (RNN), where the current state of the"/>
   <result pre="is the activation function, whh are the weights of the" exact="recurrent" post="neurons, and wxh are the weights of the input"/>
   <result pre="this case, T corresponds to the inflection point of the" exact="complete" post="dataset, namely data up to 24 May 2020. The"/>
   <result pre="occurs, was determined by fitting the logistic model in the" exact="complete" post="dataset (the other models yield similar results). For Italy,"/>
   <result pre="for USA and Sweden, which was also determined from the" exact="complete" post="set of data (up to 24 May 2020), occurred"/>
   <result pre="reported cases, since on 24 May 2020 (last day of" exact="acquired" post="data for this study) the number of reported cases"/>
   <result pre="is used in [26] to estimate the associated per day" exact="infection" post="mortality and recovery rates. (iv) In [27], by combining"/>
   <result pre="In [27], by combining a stochastic model for the SARS-CoV-2" exact="infection" post="with the knowledge of data from China during January"/>
   <result pre="in a great variety of applications, including the modelling of" exact="infectious" post="processes. The fact that α is now a function"/>
   <result pre="has the following consequences: (i) for the case that an" exact="infection" post="that has been stabilized, any of the three analytical"/>
   <result pre="mechanisms dictating the evolution of N(t). In particular, following the" exact="transient" post="stage of the epidemic, it is envisioned that α(t)"/>
   <result pre="figure 5. Figure 5. Plot of α(t) for the SARS-CoV-2" exact="virus infection" post="for Italy, Spain, France, Germany, USA and Sweden as"/>
   <result pre="5. Figure 5. Plot of α(t) for the SARS-CoV-2 virus" exact="infection" post="for Italy, Spain, France, Germany, USA and Sweden as"/>
   <result pre="represents the cumulative effect of different biological mechanisms4. An additional" exact="partial" post="explanation of the success of equation (1.1) is that"/>
   <result pre="evolution of the number of individuals infected by a given" exact="viral infection." post="On the other hand, assuming that the number of"/>
   <result pre="quite well until at least 24 May, implies that the" exact="partial" post="easing of the measures did not have any impact"/>
   <result pre="a variety of phenomena. (ii) The fact that two different" exact="viral" post="infections, namely SARS-CoV-2 and Ebola, are modelled by the"/>
   <result pre="play a generic role in the modelling of aspects of" exact="viral" post="epidemics. (iii) The celebrated Burgers' equation, which is an"/>
   <result pre="epidemics. (iii) The celebrated Burgers' equation, which is an evolution" exact="partial" post="differential equation combining the generic effects of diffusion and"/>
   <result pre="parameter γ. Data accessibility The time-series data for the coronavirus" exact="disease" post="(COVID-19) for the counties studies here were obtained from"/>
   <result pre="obtained from the official site of the European Centre for" exact="Disease" post="Prevention and Control (https://www.ecdc.europa.eu/en/publications-data/download-todays-data-geographic-distribution-covid-19-cases-worldwide). Analytic spread sheets of our"/>
   <result pre="learning network to make accurate predictions. References References 1ZhouPet al.2020A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
   <result pre="States. New England J. Med.382, 929–936. (10.1056/NEJMoa2001191)32004427 4AronsMMet al.2020Presymptomatic SARS-CoV-2" exact="infections" post="and transmission in a skilled nursing facility. N. Engl."/>
   <result pre="Modelling Natl Phenomena11, 89–104. (10.1051/mmnp/201611407) 9SchiesserWE2018A mathematical modeling approach to" exact="infectious diseases," post="cross diffusion PDE models for epidemiology. Hackensack, NJ: World"/>
   <result pre="other neural network architectures. Neural Netw.18, 602–610. (10.1016/j.neunet.2005.06.042)16112549 22SchusterM, PaliwalKK1997Bidirectional" exact="recurrent" post="neural networks. IEEE Trans. Signal Process.45, 2673–2681. (10.1109/78.650093) 23DiederikPK,"/>
   <result pre="Poverty9, 1 (10.1186/s40249-020-00640-3)31996251 25LiuTet al.2020Time-varying transmission dynamics of Novel Coronavirus" exact="Pneumonia" post="in China. BioRxiv. (10.1101/2020.01.25.919787) 26AnastassopoulouC, RussoL, TsakrisA, SiettosC2020Data-based analysis,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7494453/results/search/disease/results.xml">
   <result pre=": bold;} span.year {font-family : courier ; font-style : italic;}" exact="Brain" post="Behav Immun HealthBrain Behav Immun HealthBrain, Behavior, &amp;amp; Immunity"/>
   <result pre="10.1016/j.bbih.2020.100144100144 : Review The psychological impact of COVID-19 and other" exact="viral" post="epidemics on frontline healthcare workers and ways to address"/>
   <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
   <result pre="nurse and doctor), mental health (e.g., wellbeing and psychological), and" exact="viral" post="outbreaks (e.g., epidemic and pandemic). Only studies with greater"/>
   <result pre="in close proximity to infected patients) were included. Results A" exact="total" post="of 55 studies were included, with 53 using quantitative"/>
   <result pre="several studies demonstrating an increased risk of acquiring trauma or" exact="stress-related disorders," post="depression and anxiety. Fear of the unknown or becoming"/>
   <result pre="demonstrating an increased risk of acquiring trauma or stress-related disorders," exact="depression" post="and anxiety. Fear of the unknown or becoming infected"/>
   <result pre="of the mental challenges faced. Being a nurse and being" exact="female" post="appeared to confer greater risk. The perceived stigma from"/>
   <result pre="supports to HCWs who play a critical role during largescale" exact="disease" post="outbreaks. Psychological implications are largely negative and require greater"/>
   <result pre="HCWs who play a critical role during largescale disease outbreaks." exact="Psychological" post="implications are largely negative and require greater attention to"/>
   <result pre="groups at risk of mental health problems, especially during severe" exact="viral" post="epidemics. •Fear of uncertainty or becoming infected were at"/>
   <result pre="•Several studies demonstrated an increased risk of acquiring trauma or" exact="stress-related disorders," post="depression and anxiety. •Coping strategies varied between sociocultural settings"/>
   <result pre="demonstrated an increased risk of acquiring trauma or stress-related disorders," exact="depression" post="and anxiety. •Coping strategies varied between sociocultural settings and"/>
   <result pre="and clear dissemination of disease-related information was consistently recommended. Keywords" exact="Epidemic" post="Pandemic Mental health Psychological impact SARS COVID-19 1 Introduction"/>
   <result pre="disease-related information was consistently recommended. Keywords Epidemic Pandemic Mental health" exact="Psychological" post="impact SARS COVID-19 1 Introduction Large-scale disease epidemics pose"/>
   <result pre="Pandemic Mental health Psychological impact SARS COVID-19 1 Introduction Large-scale" exact="disease" post="epidemics pose various challenges to individuals of all ages"/>
   <result pre="challenges to individuals of all ages and cultures but the" exact="emotional" post="stress experienced by frontline health care workers (HCWs) is"/>
   <result pre="(Emergencies preparedness,) The world has faced several such bio-disasters including" exact="Severe" post="Acute Respiratory Syndrome (SARS) in China, parts of Asia"/>
   <result pre="preparedness,) The world has faced several such bio-disasters including Severe" exact="Acute" post="Respiratory Syndrome (SARS) in China, parts of Asia and"/>
   <result pre="The world has faced several such bio-disasters including Severe Acute" exact="Respiratory" post="Syndrome (SARS) in China, parts of Asia and Canada"/>
   <result pre="world has faced several such bio-disasters including Severe Acute Respiratory" exact="Syndrome" post="(SARS) in China, parts of Asia and Canada in"/>
   <result pre="2003, Ebola in West Africa in 2014 and Middle East" exact="Respiratory" post="Syndrome (MERS) in 2016. The most recent epidemic of"/>
   <result pre="Ebola in West Africa in 2014 and Middle East Respiratory" exact="Syndrome" post="(MERS) in 2016. The most recent epidemic of COVID-19"/>
   <result pre="Government bodies make plans using other countries’ data to project" exact="infection" post="rates. The high degree of uncertainty associated to novel"/>
   <result pre="uncertainty associated to novel pathogens further contributes to the communal" exact="anxiety" post="held, and makes for an overall negative experience for"/>
   <result pre="al., 2014; Unprecedented number of m, 2014) and survivors of" exact="infectious diseases" post="have higher rates of post-traumatic stress disorder (PTSD) (Hong"/>
   <result pre="2014) and survivors of infectious diseases have higher rates of" exact="post-traumatic stress disorder" post="(PTSD) (Hong et al., 2009). Recommendations around the use"/>
   <result pre="area but little is known about the psychological impact during" exact="infectious disease" post="outbreaks (Mak et al., 2009). Detrimental outcomes such as"/>
   <result pre="but little is known about the psychological impact during infectious" exact="disease" post="outbreaks (Mak et al., 2009). Detrimental outcomes such as"/>
   <result pre="Specifically, we aimed to identify original research pertaining to severe" exact="viral" post="outbreaks, from 2002 to the 21st of August 2020."/>
   <result pre="Characteristics of included studies. Table 1 Country or region Design" exact="Epidemic" post="studied Participants Duration and year Measures An et al."/>
   <result pre="days, 2003 A newly-designed SARS-related stress reaction questionnaire, composed of" exact="acute" post="stress disorder criteria from the DSM-IV Cai et al."/>
   <result pre="117 health care workers (89 nurses, 16 physicians and 12" exact="respiratory" post="specialists) 1 month, 2014 A newly-developed 72 item MERS"/>
   <result pre="staff) 11 months, 2004 to 2005 CAPS, SCID (excluding the" exact="psychosis" post="and PTSD modules) and IES, K10, the emotional exhaustion"/>
   <result pre="(excluding the psychosis and PTSD modules) and IES, K10, the" exact="emotional" post="exhaustion scale of the MBI and self-report of: smoking,"/>
   <result pre="exhaustion scale of the MBI and self-report of: smoking, drinking" exact="alcoholic" post="beverages, using non-prescription drugs, or other problem activities Lee"/>
   <result pre="al. (2020) (Li et al., 2020b) China Cross-sectional COVID-19 4,369" exact="female" post="frontline HCWs 8 days, February 2020 PHQ, GAD-7, IES-R"/>
   <result pre="24 physicians and 54 others [medical technicians, emergency attendants and" exact="respiratory" post="therapists]) 32 months, 2003 to 2005 PBI, EPQ and"/>
   <result pre="COVID-19 3,109 health care workers 10 days, April 2020 A" exact="Psychological" post="Stress and Adaptation at Work Score (PSAS) based on"/>
   <result pre="COVID-19 1,378 health care workers (472 nurses, 433 physicians, 86" exact="General" post="Practitioners, 275 other [lab technicians, physiotherapists, radiotherapists] and 112"/>
   <result pre="to March 2020 SCL-90, PSQI and CPSS AIS ​= ​Athens" exact="Insomnia" post="Scale. BAI=Beck Anxiety Inventory. BDI=Beck Depression Inventory. BDI-II= Beck"/>
   <result pre="CPSS AIS ​= ​Athens Insomnia Scale. BAI=Beck Anxiety Inventory. BDI=Beck" exact="Depression" post="Inventory. BDI-II= Beck Depression Inventory, Second Edition. CAPS=Clinician-Administered PTSD"/>
   <result pre="Insomnia Scale. BAI=Beck Anxiety Inventory. BDI=Beck Depression Inventory. BDI-II= Beck" exact="Depression" post="Inventory, Second Edition. CAPS=Clinician-Administered PTSD Scale. CD-RISC ​= ​Connor"/>
   <result pre="Questionnaire. EVD ​= ​Ebola virus disease. GAD-2 ​= ​Generalised Anxiety" exact="Disorder" post="Scale-2. GAD-7 ​= ​Generalised Anxiety Disorder Scale-7. GSS ​="/>
   <result pre="GAD-2 ​= ​Generalised Anxiety Disorder Scale-2. GAD-7 ​= ​Generalised Anxiety" exact="Disorder" post="Scale-7. GSS ​= ​General Self-Efficacy Scale. GHQ-28 ​= ​General"/>
   <result pre="Screen. GSES ​= ​General Self-Efficacy Scale. HAMA=Hamilton Anxiety Scale. HAMD=Hamilton" exact="Depression" post="Scale. IES-R ​= ​Impact of Events Scale-Revised. IES= Impact"/>
   <result pre="Scale. ISI=Insomnia Severity Index. K-6=Kessler Distress Scale. K10 ​= ​Kessler" exact="Psychological" post="Distress Scale. MBI ​= ​Maslach Burnout Inventory. MERS ​="/>
   <result pre="Scale. MBI ​= ​Maslach Burnout Inventory. MERS ​= ​Middle East" exact="respiratory" post="syndrome. MSPSS ​= ​Multidimensional Scale of Perceived Social Support."/>
   <result pre="PBI=Parental Bonding Instrument. PCL-5 ​= ​PTSD Checklist for DSM-5. PC-PTSD=The" exact="Primary" post="Care PTSD Screen for DSM-5. PHQ-2 ​= ​Patient Health"/>
   <result pre="Scale-10. SARS NSQ= SARS Nurses’ Survey Questionnaire. SARS ​= ​severe" exact="acute" post="respiratory syndrome. SAS ​= ​Zung Self-rating Anxiety Scale. SASR=Stanford"/>
   <result pre="SARS NSQ= SARS Nurses’ Survey Questionnaire. SARS ​= ​severe acute" exact="respiratory" post="syndrome. SAS ​= ​Zung Self-rating Anxiety Scale. SASR=Stanford Acute"/>
   <result pre="acute respiratory syndrome. SAS ​= ​Zung Self-rating Anxiety Scale. SASR=Stanford" exact="Acute" post="Stress Reaction Questionnaire. SCID=Structured Clinical Interview for DSM-IV. SCL-90-R"/>
   <result pre="​Symptom Checklist-90-Revised. SCL-90 ​= ​Symptom Checklist-90. SDS ​= ​Zung Self-rating" exact="Depression" post="Scale. SF-12 ​= ​Medical Outcomes Study Short Form 12"/>
   <result pre="HCWs. The most common psychiatric disorders diagnosed were post-trauma stress" exact="syndrome" post="(PTSS), depression and anxiety, as assessed in 32 studies"/>
   <result pre="most common psychiatric disorders diagnosed were post-trauma stress syndrome (PTSS)," exact="depression" post="and anxiety, as assessed in 32 studies (Ji et"/>
   <result pre="with psychological outcomes (Chew et al., 2020). Sleep disorders including" exact="insomnia" post="were also frequently identified (Wasim et al., 2020; Wańkowicz"/>
   <result pre="al., 2020; Chew et al., 2020; Cai et al., 2020b)." exact="Female" post="nurses with close contact to COVID-19 patients appeared to"/>
   <result pre="it is important to note that most studies included predominantly" exact="female" post="participants, especially nurses, with only one study suggesting higher"/>
   <result pre="stress levels amongst males (Liu et al., 2020b). Specifically, being" exact="female" post="conferred greater risks for depression, anxiety and higher levels"/>
   <result pre="al., 2020b). Specifically, being female conferred greater risks for depression," exact="anxiety" post="and higher levels of stress (Xiaoming et al., 2020;"/>
   <result pre="was identified amongst 6.5% (306 of 4,692) of HCWs with" exact="lower" post="self-perceived health status listed as an additional risk factor"/>
   <result pre="2020a). Two-weeks after Wuhan went into lockdown, the proportion of" exact="female" post="HCWs with depression, anxiety and acute stress symptoms were"/>
   <result pre="went into lockdown, the proportion of female HCWs with depression," exact="anxiety" post="and acute stress symptoms were respectively 14.2% (621 of"/>
   <result pre="lockdown, the proportion of female HCWs with depression, anxiety and" exact="acute" post="stress symptoms were respectively 14.2% (621 of 4,369), 25.2%"/>
   <result pre="at a hospital in East Taiwan met criteria for an" exact="Acute" post="Stress Disorder (ASD) during the SARS pandemic (Bai et"/>
   <result pre="a hospital in East Taiwan met criteria for an Acute" exact="Stress Disorder" post="(ASD) during the SARS pandemic (Bai et al., 2004)."/>
   <result pre="hospital in East Taiwan met criteria for an Acute Stress" exact="Disorder" post="(ASD) during the SARS pandemic (Bai et al., 2004)."/>
   <result pre="a range of psychological symptoms, such as obsession-compulsion, interpersonal sensitivity," exact="depression" post="and paranoid ideation (Ji et al., 2017). During the"/>
   <result pre="of psychological symptoms, such as obsession-compulsion, interpersonal sensitivity, depression and" exact="paranoid" post="ideation (Ji et al., 2017). During the 3-year period"/>
   <result pre="2020) also found that HCWs (613) had higher symptoms of" exact="acute" post="stress than compared with non-HCWs (164). Similarly, anxiety and"/>
   <result pre="symptoms of acute stress than compared with non-HCWs (164). Similarly," exact="anxiety" post="and insomnia were significantly higher in frontline HCWs compared"/>
   <result pre="acute stress than compared with non-HCWs (164). Similarly, anxiety and" exact="insomnia" post="were significantly higher in frontline HCWs compared to non-frontline"/>
   <result pre="those who were married, and doctors had more stress and" exact="anxiety" post="compared to nurses. Further, 27% of participants (177 of"/>
   <result pre="likely to feel fear and twice more likely to suffer" exact="anxiety" post="and depression when compared to non-clinical staff (Lu et"/>
   <result pre="feel fear and twice more likely to suffer anxiety and" exact="depression" post="when compared to non-clinical staff (Lu et al., 2020)."/>
   <result pre="1,257 HCW’s during the COVID-19 outbreak, high rates of depression," exact="anxiety" post="and insomnia were reported with over 70% reporting psychological"/>
   <result pre="during the COVID-19 outbreak, high rates of depression, anxiety and" exact="insomnia" post="were reported with over 70% reporting psychological distress. A"/>
   <result pre="province found that staff in Wuhan had higher rates of" exact="insomnia" post="and stress responses (Li et al., 2020a). One study"/>
   <result pre="(241 of 271) of HCWs experienced negative psychological symptoms. A" exact="total" post="of six studies (Tam et al., 2004; Lancee et"/>
   <result pre="their families, clients, and colleagues (Shih et al., 2007). 4.1.2.1" exact="Infection" post="related fears Participants across seventeen studies (Tam et al.,"/>
   <result pre="associated with PTSS, whereas, a colleague dying was associated to" exact="depression" post="and insomnia. A major theme was anxiety, especially across"/>
   <result pre="al., 2020a) the most important factor in HCWs with high" exact="anxiety" post="was being suspected of having COVID-19 infection when compared"/>
   <result pre="HCWs with high anxiety was being suspected of having COVID-19" exact="infection" post="when compared to those who were not suspected of"/>
   <result pre="and staff from SARS-affected institutions expressed significantly higher levels of" exact="anxiety" post="than other HCWs (Koh et al., 2005). In 466"/>
   <result pre="a major concern, with worries that they would transmit the" exact="disease" post="to their families and friends. All nurses (200) responding"/>
   <result pre="who perceived protection as insufficient rated higher levels of depression," exact="anxiety" post="and acute stress than those who perceived it to"/>
   <result pre="protection as insufficient rated higher levels of depression, anxiety and" exact="acute" post="stress than those who perceived it to be adequate"/>
   <result pre="doctors to use self-distraction (Wong et al., 2005). Amongst 657" exact="American" post="HCWs, exercise was the most commonly used coping strategy"/>
   <result pre="need for prompt and continuous psychiatric interventions in high mortality" exact="infectious disease" post="outbreaks (Lee et al., 2018; Wang et al., 2020;"/>
   <result pre="for prompt and continuous psychiatric interventions in high mortality infectious" exact="disease" post="outbreaks (Lee et al., 2018; Wang et al., 2020;"/>
   <result pre="of the extent and sources of stress among HCWs during" exact="disease" post="outbreaks (Tam et al., 2004). Moreover, hospital support systems"/>
   <result pre="to people involved in response planning for future outbreaks of" exact="infectious disease" post="(Wu et al., 2009). 4.3 Strengths of studies The"/>
   <result pre="people involved in response planning for future outbreaks of infectious" exact="disease" post="(Wu et al., 2009). 4.3 Strengths of studies The"/>
   <result pre="high number of studies during the COVID-19 pandemic within a" exact="short" post="period is impressive given the understandable difficulties in conducting"/>
   <result pre="compare studies due to heterogeneity of design and outcome measures." exact="Geographic" post="factors may have influenced results due to unique social"/>
   <result pre="During the COVID-19 pandemic, HCWs have been exposed to high" exact="infection" post="risks, death and dying, moral dilemmas in deciding who"/>
   <result pre="honorarium for consulting service for Janssen. References References AnY.Prevalence of" exact="depression" post="and its impact on quality of life among frontline"/>
   <result pre="health among health care workers during the outbreak of Corona" exact="Virus Disease" post="2019Asian J Psychiatr51202010211132361388 CaiQ.The mental health of frontline and"/>
   <result pre="among health care workers during the outbreak of Corona Virus" exact="Disease" post="2019Asian J Psychiatr51202010211132361388 CaiQ.The mental health of frontline and"/>
   <result pre="health of frontline and non-frontline medical workers during the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: a case-control studyJ. Affect."/>
   <result pre="case-control studyJ. Affect. Disord.275202021021532734910 ChanA.O.HuakC.Y.Psychological impact of the 2003 severe" exact="acute" post="respiratory syndrome outbreak on health care workers in a"/>
   <result pre="studyJ. Affect. Disord.275202021021532734910 ChanA.O.HuakC.Y.Psychological impact of the 2003 severe acute" exact="respiratory" post="syndrome outbreak on health care workers in a medium"/>
   <result pre="Affect. Disord.275202021021532734910 ChanA.O.HuakC.Y.Psychological impact of the 2003 severe acute respiratory" exact="syndrome" post="outbreak on health care workers in a medium size"/>
   <result pre="science. The Lancet Psychiatry. HongX.Posttraumatic stress disorder in convalescent severe" exact="acute" post="respiratory syndrome patients: a 4-year follow-up studyGen. Hosp. Psychiatr.3162009546554"/>
   <result pre="The Lancet Psychiatry. HongX.Posttraumatic stress disorder in convalescent severe acute" exact="respiratory" post="syndrome patients: a 4-year follow-up studyGen. Hosp. Psychiatr.3162009546554 HongS.Immediate"/>
   <result pre="Lancet Psychiatry. HongX.Posttraumatic stress disorder in convalescent severe acute respiratory" exact="syndrome" post="patients: a 4-year follow-up studyGen. Hosp. Psychiatr.3162009546554 HongS.Immediate psychological"/>
   <result pre="and nursing staff in Wuhan during the 2019 novel coronavirus" exact="disease" post="outbreak: a cross-sectional studyBrain Behav. Immun.2020 KhalidI.Healthcare workers emotions,"/>
   <result pre="care providersCrit. Care Shock2004100106 KohD.Risk perception and impact of severe" exact="acute" post="respiratory syndrome (SARS) on work and personal lives of"/>
   <result pre="providersCrit. Care Shock2004100106 KohD.Risk perception and impact of severe acute" exact="respiratory" post="syndrome (SARS) on work and personal lives of healthcare"/>
   <result pre="Care Shock2004100106 KohD.Risk perception and impact of severe acute respiratory" exact="syndrome" post="(SARS) on work and personal lives of healthcare workers"/>
   <result pre="healthcare workers in Singapore what can we learn?Med. Care200567668215970782 KorkmazS.The" exact="anxiety" post="levels, quality of sleep and life and problem-solving skills"/>
   <result pre="mental health outcomes among health care workers exposed to coronavirus" exact="disease" post="2019JAMA Network Open332020e203976-e LanceeW.J.Prevalence of psychiatric disorders among Toronto"/>
   <result pre="hemodialysis patientsCompr. Psychiatr.872018123127 LiX.Prevalence, risk factors, and clinical correlates of" exact="insomnia" post="in volunteer and at home medical staff during the"/>
   <result pre="in ChinaAm. J. Psychiatr.1777202063563632605443 LiuC.-Y.The prevalence and influencing factors in" exact="anxiety" post="in medical workers fighting COVID-19 in China: a cross-sectional"/>
   <result pre="Hosp. Psychiatr.3142009318326 MaunderR.G.Factors associated with the psychological impact of severe" exact="acute" post="respiratory syndrome on nurses and other hospital workers in"/>
   <result pre="Psychiatr.3142009318326 MaunderR.G.Factors associated with the psychological impact of severe acute" exact="respiratory" post="syndrome on nurses and other hospital workers in TorontoPsychosom."/>
   <result pre="MaunderR.G.Factors associated with the psychological impact of severe acute respiratory" exact="syndrome" post="on nurses and other hospital workers in TorontoPsychosom. Med.666200493894215564361"/>
   <result pre="psychological first aidJournal of emergency management (Weston, Mass)11120133948 PouralizadehM.Anxiety and" exact="depression" post="and the related factors in nurses of guilan university"/>
   <result pre="during COVID-19: a web-based cross-sectional studyInt J Afr Nurs Sci13202010023332837911" exact="Psychological" post="First Aid during Ebola Virus Disease Outbreaks (Provisional Version)"/>
   <result pre="studyInt J Afr Nurs Sci13202010023332837911 Psychological First Aid during Ebola" exact="Virus Disease" post="Outbreaks (Provisional Version) [online]2014World Health Organisation, CBM, World Vision"/>
   <result pre="J Afr Nurs Sci13202010023332837911 Psychological First Aid during Ebola Virus" exact="Disease" post="Outbreaks (Provisional Version) [online]2014World Health Organisation, CBM, World Vision"/>
   <result pre="among frontline and second-line health care workers during the coronavirus" exact="disease" post="2019 (COVID-19) pandemic in ItalyJAMA Network Open352020e2010185-e SandeshR.Impact of"/>
   <result pre="surviving nurses’ reflections on taking care of patients with severe" exact="acute" post="respiratory syndromeAppl. Nurs. Res.204200717118017996803 TamC.W.Severe acute respiratory syndrome (SARS)"/>
   <result pre="nurses’ reflections on taking care of patients with severe acute" exact="respiratory" post="syndromeAppl. Nurs. Res.204200717118017996803 TamC.W.Severe acute respiratory syndrome (SARS) in"/>
   <result pre="of patients with severe acute respiratory syndromeAppl. Nurs. Res.204200717118017996803 TamC.W.Severe" exact="acute" post="respiratory syndrome (SARS) in Hong Kong in 2003: stress"/>
   <result pre="patients with severe acute respiratory syndromeAppl. Nurs. Res.204200717118017996803 TamC.W.Severe acute" exact="respiratory" post="syndrome (SARS) in Hong Kong in 2003: stress and"/>
   <result pre="with severe acute respiratory syndromeAppl. Nurs. Res.204200717118017996803 TamC.W.Severe acute respiratory" exact="syndrome" post="(SARS) in Hong Kong in 2003: stress and psychological"/>
   <result pre="with Ebola [Online]2014World Health Organization;GenevaAvailable from:https://www.who.int/mediacentre/news/ebola/25-august-2014/en/ WangL.-Q.Psychological impact of coronavirus" exact="disease" post="(2019) (COVID-19) epidemic on medical staff in different posts"/>
   <result pre="Res. Publ. Health171620205849 WilsonW.Prevalence and predictors of stress, anxiety, and" exact="depression" post="among healthcare workers managing COVID-19 pandemic in India: a"/>
   <result pre="observational studyIndian J. Psychol. Med.4242020353358 WongT.W.The psychological impact of severe" exact="acute" post="respiratory syndrome outbreak on healthcare workers in emergency departments"/>
   <result pre="studyIndian J. Psychol. Med.4242020353358 WongT.W.The psychological impact of severe acute" exact="respiratory" post="syndrome outbreak on healthcare workers in emergency departments and"/>
   <result pre="J. Psychol. Med.4242020353358 WongT.W.The psychological impact of severe acute respiratory" exact="syndrome" post="outbreak on healthcare workers in emergency departments and how"/>
   <result pre="on sleep quality of medical staff treating patients with coronavirus" exact="disease" post="2019 (COVID-19) in january and february 2020 in ChinaMed."/>
   <result pre="COVID-19: a cross-sectional study in chongqingJ. Affect. Disord.2020 ZhangC.Survey of" exact="insomnia" post="and related social psychological factors among medical staff involved"/>
   <result pre="factors among medical staff involved in the 2019 novel coronavirus" exact="disease" post="outbreakFront. Psychiatr.112020306 ZhangW.R.Mental health and psychosocial problems of medical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="dict8/PMC7499620/results/search/disease/results.xml">
   <result pre="font-style : italic;} J Infect DisJ. Infect. DisjidThe Journal of" exact="Infectious" post="Diseases0022-18991537-6613Oxford University PressUS pmcid: 7499620 pmid: 32898256 doi: 10.1093/infdis/jiaa570jiaa570"/>
   <result pre="of Public Health(Shenzhen), Sun Yat-sen UniversityP.R. China[3], National Institute for" exact="Viral" post="Disease Control and Prevention, Chinese Center for Disease Control"/>
   <result pre="Public Health(Shenzhen), Sun Yat-sen UniversityP.R. China[3], National Institute for Viral" exact="Disease" post="Control and Prevention, Chinese Center for Disease Control and"/>
   <result pre="Institute for Viral Disease Control and Prevention, Chinese Center for" exact="Disease" post="Control and Prevention; Key Laboratory for Medical Virology, National"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
